,sentence_text,e1,e2,relation_type,normalized_sentence
0,"Interaction study of moxifloxacin and lomefloxacin with co-administered drugs.
",moxifloxacin,lomefloxacin,No interaction,Interaction_bf study_bf DRUG OTHER_DRUG co-administered_af drugs_af ._af
1,Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. ,Moxifloxacin,lomefloxacin,No interaction,DRUG OTHER_DRUG fluoroquinolone_af antibiotics_af used_af treating_af urinary_af respiratory_af tract_af infections_af ._af
2,Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. ,Moxifloxacin,fluoroquinolone antibiotics,No interaction,DRUG lomefloxacin_be fluoroquinolone_be antibiotics_be used_be treating_be urinary_be respiratory_be tract_be infections_be ._be
3,Moxifloxacin and lomefloxacin are fluoroquinolone antibiotics used in treating urinary and respiratory tract infections. ,lomefloxacin,fluoroquinolone antibiotics,No interaction,Moxifloxacin_bf DRUG fluoroquinolone_be antibiotics_be used_be treating_be urinary_be respiratory_be tract_be infections_be ._be
4,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",moxifloxacin,fluoroquinolones,No interaction,"Being_bf DRUG lomefloxacin_be OTHER_DRUG interaction_af study_af carried_af sucralfate_af ,_af gelusil_af ,_af erythromycin_af multi_af minerals_af ._af"
5,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",moxifloxacin,sucralfate,No interaction,"Being_bf DRUG lomefloxacin_be fluoroquinolones_be interaction_be study_be carried_be OTHER_DRUG ,_af gelusil_af ,_af erythromycin_af multi_af minerals_af ._af"
6,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",moxifloxacin,gelusil,No interaction,"Being_bf DRUG lomefloxacin_be fluoroquinolones_be interaction_be study_be carried_be sucralfate_be ,_be OTHER_DRUG ,_af erythromycin_af multi_af minerals_af ._af"
7,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",moxifloxacin,erythromycin,No interaction,"Being_bf DRUG lomefloxacin_be fluoroquinolones_be interaction_be study_be carried_be sucralfate_be ,_be gelusil_be ,_be OTHER_DRUG multi_af minerals_af ._af"
8,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",moxifloxacin,multi minerals,No interaction,"Being_bf DRUG lomefloxacin_be fluoroquinolones_be interaction_be study_be carried_be sucralfate_be ,_be gelusil_be ,_be erythromycin_be multi_be minerals_be ._be"
9,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",fluoroquinolones,sucralfate,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf DRUG interaction_be study_be carried_be OTHER_DRUG ,_af gelusil_af ,_af erythromycin_af multi_af minerals_af ._af"
10,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",fluoroquinolones,gelusil,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf DRUG interaction_be study_be carried_be sucralfate_be ,_be OTHER_DRUG ,_af erythromycin_af multi_af minerals_af ._af"
11,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",fluoroquinolones,erythromycin,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf DRUG interaction_be study_be carried_be sucralfate_be ,_be gelusil_be ,_be OTHER_DRUG multi_af minerals_af ._af"
12,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",fluoroquinolones,multi minerals,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf DRUG interaction_be study_be carried_be sucralfate_be ,_be gelusil_be ,_be erythromycin_be multi_be minerals_be ._be"
13,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",sucralfate,gelusil,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf DRUG ,_be OTHER_DRUG ,_af erythromycin_af multi_af minerals_af ._af"
14,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",sucralfate,erythromycin,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf DRUG ,_be gelusil_be ,_be OTHER_DRUG multi_af minerals_af ._af"
15,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",sucralfate,multi minerals,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf DRUG ,_be gelusil_be ,_be erythromycin_be multi_be minerals_be ._be"
16,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",gelusil,erythromycin,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf sucralfate_bf ,_bf DRUG ,_be OTHER_DRUG multi_af minerals_af ._af"
17,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",gelusil,multi minerals,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf sucralfate_bf ,_bf DRUG ,_be erythromycin_be multi_be minerals_be ._be"
18,"Being moxifloxacin and lomefloxacin fluoroquinolones the interaction study of was carried out with sucralfate, gelusil, erythromycin and multi minerals. ",erythromycin,multi minerals,No interaction,"Being_bf moxifloxacin_bf lomefloxacin_bf fluoroquinolones_bf interaction_bf study_bf carried_bf sucralfate_bf ,_bf gelusil_bf ,_bf DRUG multi_be minerals_be ._be"
19,The response of moxifloxacin and lomefloxacin after interaction with co-administered drugs at different conditions and temperature were noted using a Shimadzu HPLC system with PDA detector. ,moxifloxacin,lomefloxacin,No interaction,The_bf response_bf DRUG OTHER_DRUG interaction_af co-administered_af drugs_af different_af conditions_af temperature_af noted_af using_af Shimadzu_af HPLC_af system_af PDA_af detector_af ._af
20,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,Lomefloxacin,No interaction,DRUG OTHER_DRUG reacts_af faster_af sucralfate_af gelusil_af acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
21,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,sucralfate,mechanism,DRUG Lomefloxacin_be reacts_be faster_be OTHER_DRUG gelusil_af acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
22,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,gelusil,mechanism,DRUG Lomefloxacin_be reacts_be faster_be sucralfate_be OTHER_DRUG acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
23,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,erythromycin,mechanism,DRUG Lomefloxacin_be reacts_be faster_be sucralfate_be gelusil_be acidic_be media_be whereas_be OTHER_DRUG basic_af media_af multi-minerals_af neutral_af media_af ._af
24,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Moxifloxacin,multi-minerals,mechanism,DRUG Lomefloxacin_be reacts_be faster_be sucralfate_be gelusil_be acidic_be media_be whereas_be erythromycin_be basic_be media_be OTHER_DRUG neutral_af media_af ._af
25,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,sucralfate,mechanism,Moxifloxacin_bf DRUG reacts_be faster_be OTHER_DRUG gelusil_af acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
26,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,gelusil,mechanism,Moxifloxacin_bf DRUG reacts_be faster_be sucralfate_be OTHER_DRUG acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
27,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,erythromycin,mechanism,Moxifloxacin_bf DRUG reacts_be faster_be sucralfate_be gelusil_be acidic_be media_be whereas_be OTHER_DRUG basic_af media_af multi-minerals_af neutral_af media_af ._af
28,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,Lomefloxacin,multi-minerals,mechanism,Moxifloxacin_bf DRUG reacts_be faster_be sucralfate_be gelusil_be acidic_be media_be whereas_be erythromycin_be basic_be media_be OTHER_DRUG neutral_af media_af ._af
29,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,sucralfate,gelusil,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf DRUG OTHER_DRUG acidic_af media_af whereas_af erythromycin_af basic_af media_af multi-minerals_af neutral_af media_af ._af
30,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,sucralfate,erythromycin,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf DRUG gelusil_be acidic_be media_be whereas_be OTHER_DRUG basic_af media_af multi-minerals_af neutral_af media_af ._af
31,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,sucralfate,multi-minerals,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf DRUG gelusil_be acidic_be media_be whereas_be erythromycin_be basic_be media_be OTHER_DRUG neutral_af media_af ._af
32,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,gelusil,erythromycin,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf sucralfate_bf DRUG acidic_be media_be whereas_be OTHER_DRUG basic_af media_af multi-minerals_af neutral_af media_af ._af
33,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,gelusil,multi-minerals,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf sucralfate_bf DRUG acidic_be media_be whereas_be erythromycin_be basic_be media_be OTHER_DRUG neutral_af media_af ._af
34,Moxifloxacin and Lomefloxacin reacts faster with sucralfate and gelusil in acidic media whereas with erythromycin in basic media and multi-minerals in neutral media. ,erythromycin,multi-minerals,No interaction,Moxifloxacin_bf Lomefloxacin_bf reacts_bf faster_bf sucralfate_bf gelusil_bf acidic_bf media_bf whereas_bf DRUG basic_be media_be OTHER_DRUG neutral_af media_af ._af
35,"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
",S-ketamine,itraconazole,No interaction,Exposure_bf oral_bf DRUG unaffected_be OTHER_DRUG greatly_af increased_af ticlopidine_af ._af
36,"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
",S-ketamine,ticlopidine,effect,Exposure_bf oral_bf DRUG unaffected_be itraconazole_be greatly_be increased_be OTHER_DRUG ._af
37,"Exposure to oral S-ketamine is unaffected by itraconazole but greatly increased by ticlopidine.
",itraconazole,ticlopidine,No interaction,Exposure_bf oral_bf S-ketamine_bf unaffected_bf DRUG greatly_be increased_be OTHER_DRUG ._af
38,This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ,S-ketamine,ticlopidine,No interaction,This_bf study_bf examined_bf drug-drug_bf interactions_bf oral_bf DRUG cytochrome_be P450_be (CYP)_be 2B6_be inhibitor_be OTHER_DRUG CYP3A_af inhibitor_af itraconazole_af ._af
39,This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ,S-ketamine,itraconazole,No interaction,This_bf study_bf examined_bf drug-drug_bf interactions_bf oral_bf DRUG cytochrome_be P450_be (CYP)_be 2B6_be inhibitor_be ticlopidine_be CYP3A_be inhibitor_be OTHER_DRUG ._af
40,This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. ,ticlopidine,itraconazole,No interaction,This_bf study_bf examined_bf drug-drug_bf interactions_bf oral_bf S-ketamine_bf cytochrome_bf P450_bf (CYP)_bf 2B6_bf inhibitor_bf DRUG CYP3A_be inhibitor_be OTHER_DRUG ._af
41,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",S-ketamine,ticlopidine,No interaction,"In_bf randomized_bf ,_bf blinded_bf ,_bf crossover_bf study_bf ,_bf 11_bf healthy_bf volunteers_bf ingested_bf 0_bf ._bf 2_bf mg/kg_bf DRUG pretreatments_be oral_be OTHER_DRUG (250_af mg_af twice_af daily)_af ,_af itraconazole_af (200_af mg_af daily)_af ,_af placebo_af 6-day_af treatment_af periods_af intervals_af 4_af weeks_af ._af"
42,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",S-ketamine,itraconazole,No interaction,"In_bf randomized_bf ,_bf blinded_bf ,_bf crossover_bf study_bf ,_bf 11_bf healthy_bf volunteers_bf ingested_bf 0_bf ._bf 2_bf mg/kg_bf DRUG pretreatments_be oral_be ticlopidine_be (250_be mg_be twice_be daily)_be ,_be OTHER_DRUG (200_af mg_af daily)_af ,_af placebo_af 6-day_af treatment_af periods_af intervals_af 4_af weeks_af ._af"
43,"In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. ",ticlopidine,itraconazole,No interaction,"In_bf randomized_bf ,_bf blinded_bf ,_bf crossover_bf study_bf ,_bf 11_bf healthy_bf volunteers_bf ingested_bf 0_bf ._bf 2_bf mg/kg_bf S-ketamine_bf pretreatments_bf oral_bf DRUG (250_be mg_be twice_be daily)_be ,_be OTHER_DRUG (200_af mg_af daily)_af ,_af placebo_af 6-day_af treatment_af periods_af intervals_af 4_af weeks_af ._af"
44,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",Ticlopidine,ketamine,mechanism,"DRUG treatment_be increased_be mean_be area_be plasma_be concentration-time_be curve_be extrapolated_be infinity_be (AUC(0-_be ))_be oral_be OTHER_DRUG 2_af ._af 4-fold_af ,_af whereas_af itraconazole_af treatment_af increase_af exposure_af S-ketamine_af ._af"
45,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",Ticlopidine,itraconazole,No interaction,"DRUG treatment_be increased_be mean_be area_be plasma_be concentration-time_be curve_be extrapolated_be infinity_be (AUC(0-_be ))_be oral_be ketamine_be 2_be ._be 4-fold_be ,_be whereas_be OTHER_DRUG treatment_af increase_af exposure_af S-ketamine_af ._af"
46,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",Ticlopidine,S-ketamine,No interaction,"DRUG treatment_be increased_be mean_be area_be plasma_be concentration-time_be curve_be extrapolated_be infinity_be (AUC(0-_be ))_be oral_be ketamine_be 2_be ._be 4-fold_be ,_be whereas_be itraconazole_be treatment_be increase_be exposure_be OTHER_DRUG ._af"
47,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",ketamine,itraconazole,No interaction,"Ticlopidine_bf treatment_bf increased_bf mean_bf area_bf plasma_bf concentration-time_bf curve_bf extrapolated_bf infinity_bf (AUC(0-_bf ))_bf oral_bf DRUG 2_be ._be 4-fold_be ,_be whereas_be OTHER_DRUG treatment_af increase_af exposure_af S-ketamine_af ._af"
48,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",ketamine,S-ketamine,No interaction,"Ticlopidine_bf treatment_bf increased_bf mean_bf area_bf plasma_bf concentration-time_bf curve_bf extrapolated_bf infinity_bf (AUC(0-_bf ))_bf oral_bf DRUG 2_be ._be 4-fold_be ,_be whereas_be itraconazole_be treatment_be increase_be exposure_be OTHER_DRUG ._af"
49,"Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-   )) of oral ketamine by 2.4-fold, whereas itraconazole treatment did not increase the exposure to S-ketamine. ",itraconazole,S-ketamine,No interaction,"Ticlopidine_bf treatment_bf increased_bf mean_bf area_bf plasma_bf concentration-time_bf curve_bf extrapolated_bf infinity_bf (AUC(0-_bf ))_bf oral_bf ketamine_bf 2_bf ._bf 4-fold_bf ,_bf whereas_bf DRUG treatment_be increase_be exposure_be OTHER_DRUG ._af"
50,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,norketamine,ketamine,No interaction,The_bf ratio_bf DRUG AUC(0-_be )_be OTHER_DRUG AUC(0-_af )_af significantly_af decreased_af ticlopidine_af (P_af &lt;_af 0_af ._af 001)_af itraconazole_af phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
51,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,norketamine,ticlopidine,No interaction,The_bf ratio_bf DRUG AUC(0-_be )_be ketamine_be AUC(0-_be )_be significantly_be decreased_be OTHER_DRUG (P_af &lt;_af 0_af ._af 001)_af itraconazole_af phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
52,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,norketamine,itraconazole,No interaction,The_bf ratio_bf DRUG AUC(0-_be )_be ketamine_be AUC(0-_be )_be significantly_be decreased_be ticlopidine_be (P_be &lt;_be 0_be ._be 001)_be OTHER_DRUG phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
53,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,ketamine,ticlopidine,No interaction,The_bf ratio_bf norketamine_bf AUC(0-_bf )_bf DRUG AUC(0-_be )_be significantly_be decreased_be OTHER_DRUG (P_af &lt;_af 0_af ._af 001)_af itraconazole_af phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
54,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,ketamine,itraconazole,No interaction,The_bf ratio_bf norketamine_bf AUC(0-_bf )_bf DRUG AUC(0-_be )_be significantly_be decreased_be ticlopidine_be (P_be &lt;_be 0_be ._be 001)_be OTHER_DRUG phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
55,The ratio of norketamine AUC(0-   ) to ketamine AUC(0-   ) was significantly decreased in the ticlopidine (P &lt; 0.001) and itraconazole phases (P = 0.006) as compared to placebo. ,ticlopidine,itraconazole,No interaction,The_bf ratio_bf norketamine_bf AUC(0-_bf )_bf ketamine_bf AUC(0-_bf )_bf significantly_bf decreased_bf DRUG (P_be &lt;_be 0_be ._be 001)_be OTHER_DRUG phases_af (P_af =_af 0_af ._af 006)_af compared_af placebo_af ._af
56,"In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). ",ticlopidine,itraconazole,No interaction,"In_bf DRUG OTHER_DRUG phases_af ,_af areas_af effect-time_af curves_af (self-reported_af drowsiness_af performance)_af significantly_af higher_af placebo_af phase_af (P_af <_af 0_af ._af 05)_af ._af"
57,The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.,S-ketamine,ticlopidine,advise,The_bf findings_bf suggest_bf dosage_bf DRUG reduced_be patients_be receiving_be OTHER_DRUG ._af
58,"The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor activities in a broad range of solid tumors and acute myeloid leukemia. ",3-Deazaneplanocin A,DZNep,No interaction,"The_bf 3-Deazaneplanocin_bf A_bf (DZNep)_bf ,_bf one_bf S-adenosylhomocysteine_bf (AdoHcy)_bf hydrolase_bf inhibitors_bf ,_bf shown_bf antitumor_bf activities_bf broad_bf range_bf solid_bf tumors_bf acute_bf myeloid_bf leukemia_bf ._bf"
59,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,DZNep,No interaction,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf DRUG insensitive_be cells_be ,_be cotreatment_be DRUG ABT-737_af ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af DRUG insensitive_af MM_af cells_af ._af"
60,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,ABT-737,No interaction,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf DRUG insensitive_be cells_be ,_be cotreatment_be DRUG OTHER_DRUG ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af DRUG insensitive_af MM_af cells_af ._af"
61,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,DZNep,No interaction,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf DRUG insensitive_be cells_be ,_be cotreatment_be DRUG ABT-737_af ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af DRUG insensitive_af MM_af cells_af ._af"
62,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,ABT-737,effect,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf DRUG insensitive_be cells_be ,_be cotreatment_be DRUG OTHER_DRUG ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af DRUG insensitive_af MM_af cells_af ._af"
63,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",DZNep,DZNep,No interaction,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf DRUG insensitive_be cells_be ,_be cotreatment_be DRUG ABT-737_af ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af DRUG insensitive_af MM_af cells_af ._af"
64,"We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. ",ABT-737,DZNep,No interaction,"We_bf also_bf found_bf Bcl-2_bf overexpressed_bf OTHER_DRUG insensitive_be cells_be ,_be cotreatment_be OTHER_DRUG DRUG ,_af Bcl-2_af family_af inhibitor_af ,_af synergistically_af inhibited_af growth_af induced_af apoptosis_af OTHER_DRUG insensitive_af MM_af cells_af ._af"
65,"In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ",DZNep,ABT-737,No interaction,"In_bf addition_bf ,_bf DRUG insensitivity_be might_be associated_be overexpression_be Bcl-2_be ,_be combination_be OTHER_DRUG DRUG could_af synergistically_af induced_af apoptosis_af ._af"
66,"In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ",DZNep,DZNep,No interaction,"In_bf addition_bf ,_bf DRUG insensitivity_be might_be associated_be overexpression_be Bcl-2_be ,_be combination_be ABT-737_be DRUG could_af synergistically_af induced_af apoptosis_af ._af"
67,"In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of ABT-737 and DZNep could synergistically induced apoptosis. ",ABT-737,DZNep,effect,"In_bf addition_bf ,_bf OTHER_DRUG insensitivity_be might_be associated_be overexpression_be Bcl-2_be ,_be combination_be DRUG OTHER_DRUG could_af synergistically_af induced_af apoptosis_af ._af"
68,Implanon   failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies.,Implanon,antiretroviral,effect,DRUG failure_be HIV-positive_be woman_be OTHER_DRUG therapy_af resulting_af two_af ectopic_af pregnancies_af ._af
69,We present an interesting case of an HIV-positive woman on antiretroviral therapy having tubal pregnancies on two separate occasions with Implanon in place.,antiretroviral,Implanon,effect,We_bf present_bf interesting_bf case_bf HIV-positive_bf woman_bf DRUG therapy_be tubal_be pregnancies_be two_be separate_be occasions_be OTHER_DRUG place_af ._af
70,"Antidepressant-warfarin interaction and associated gastrointestinal bleeding risk in a case-control study.
",Antidepressant,warfarin,No interaction,Antidepressant-warfarin_bf interaction_bf associated_bf gastrointestinal_bf bleeding_bf risk_bf case-control_bf study_bf ._bf
71,We sought to evaluate whether initiation of an antidepressant increases the risk of hospitalization for gastrointestinal bleeding in warfarin users.,antidepressant,warfarin,No interaction,We_bf sought_bf evaluate_bf whether_bf initiation_bf DRUG increases_be risk_be hospitalization_be gastrointestinal_be bleeding_be OTHER_DRUG users_af ._af
72,"In total, 430,455 warfarin users contributed 407,370 person-years of warfarin use. ",warfarin,warfarin,No interaction,"In_bf total_bf ,_bf 430_bf ,_bf 455_bf DRUG users_be contributed_be 407_be ,_be 370_be person-years_be DRUG use_af ._af"
73,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,citalopram,effect,"DRUG users_be increased_be odds_be ratio_be gastrointestinal_be bleeding_be upon_be initiation_be OTHER_DRUG (OR_af =_af 1_af ._af 73_af [95%_af CI_af ,_af 1_af ._af 25-2_af ._af 38])_af ,_af fluoxetine_af (OR_af =_af 1_af ._af 63_af [95%_af CI_af ,_af 1_af ._af 11-2_af ._af 38])_af ,_af paroxetine_af (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
74,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,fluoxetine,effect,"DRUG users_be increased_be odds_be ratio_be gastrointestinal_be bleeding_be upon_be initiation_be citalopram_be (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 63_af [95%_af CI_af ,_af 1_af ._af 11-2_af ._af 38])_af ,_af paroxetine_af (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
75,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,paroxetine,effect,"DRUG users_be increased_be odds_be ratio_be gastrointestinal_be bleeding_be upon_be initiation_be citalopram_be (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be fluoxetine_be (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
76,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",Warfarin,amitriptyline,effect,"DRUG users_be increased_be odds_be ratio_be gastrointestinal_be bleeding_be upon_be initiation_be citalopram_be (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be fluoxetine_be (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be paroxetine_be (OR_be =_be 1_be ._be 64_be [95%_be CI_be ,_be 1_be ._be 27-2_be ._be 12])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
77,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",citalopram,fluoxetine,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf DRUG (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 63_af [95%_af CI_af ,_af 1_af ._af 11-2_af ._af 38])_af ,_af paroxetine_af (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
78,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",citalopram,paroxetine,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf DRUG (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be fluoxetine_be (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
79,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",citalopram,amitriptyline,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf DRUG (OR_be =_be 1_be ._be 73_be [95%_be CI_be ,_be 1_be ._be 25-2_be ._be 38])_be ,_be fluoxetine_be (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be paroxetine_be (OR_be =_be 1_be ._be 64_be [95%_be CI_be ,_be 1_be ._be 27-2_be ._be 12])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
80,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",fluoxetine,paroxetine,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf citalopram_bf (OR_bf =_bf 1_bf ._bf 73_bf [95%_bf CI_bf ,_bf 1_bf ._bf 25-2_bf ._bf 38])_bf ,_bf DRUG (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 64_af [95%_af CI_af ,_af 1_af ._af 27-2_af ._af 12])_af ,_af amitriptyline_af (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
81,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",fluoxetine,amitriptyline,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf citalopram_bf (OR_bf =_bf 1_bf ._bf 73_bf [95%_bf CI_bf ,_bf 1_bf ._bf 25-2_bf ._bf 38])_bf ,_bf DRUG (OR_be =_be 1_be ._be 63_be [95%_be CI_be ,_be 1_be ._be 11-2_be ._be 38])_be ,_be paroxetine_be (OR_be =_be 1_be ._be 64_be [95%_be CI_be ,_be 1_be ._be 27-2_be ._be 12])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
82,"Warfarin users had an increased odds ratio of gastrointestinal bleeding upon initiation of citalopram (OR   =   1.73 [95% CI, 1.25-2.38]), fluoxetine (OR   =   1.63 [95% CI, 1.11-2.38]), paroxetine (OR   =   1.64 [95% CI, 1.27-2.12]), amitriptyline (OR   =   1.47 [95% CI, 1.02-2.11]). ",paroxetine,amitriptyline,No interaction,"Warfarin_bf users_bf increased_bf odds_bf ratio_bf gastrointestinal_bf bleeding_bf upon_bf initiation_bf citalopram_bf (OR_bf =_bf 1_bf ._bf 73_bf [95%_bf CI_bf ,_bf 1_bf ._bf 25-2_bf ._bf 38])_bf ,_bf fluoxetine_bf (OR_bf =_bf 1_bf ._bf 63_bf [95%_bf CI_bf ,_bf 1_bf ._bf 11-2_bf ._bf 38])_bf ,_bf DRUG (OR_be =_be 1_be ._be 64_be [95%_be CI_be ,_be 1_be ._be 27-2_be ._be 12])_be ,_be OTHER_DRUG (OR_af =_af 1_af ._af 47_af [95%_af CI_af ,_af 1_af ._af 02-2_af ._af 11])_af ._af"
83,"Also mirtazapine, which is not believed to interact with warfarin, increased the risk of GI bleeding (OR   =   1.75 [95% CI, 1.30-2.35]). ",mirtazapine,warfarin,effect,"Also_bf DRUG ,_be believed_be interact_be OTHER_DRUG ,_af increased_af risk_af GI_af bleeding_af (OR_af =_af 1_af ._af 75_af [95%_af CI_af ,_af 1_af ._af 30-2_af ._af 35])_af ._af"
84,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,citalopram,effect,"DRUG users_be initiated_be OTHER_DRUG ,_af fluoxetine_af ,_af paroxetine_af ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
85,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,fluoxetine,effect,"DRUG users_be initiated_be citalopram_be ,_be OTHER_DRUG ,_af paroxetine_af ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
86,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,paroxetine,effect,"DRUG users_be initiated_be citalopram_be ,_be fluoxetine_be ,_be OTHER_DRUG ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
87,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,amitriptyline,effect,"DRUG users_be initiated_be citalopram_be ,_be fluoxetine_be ,_be paroxetine_be ,_be OTHER_DRUG ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
88,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",Warfarin,mirtazapine,effect,"DRUG users_be initiated_be citalopram_be ,_be fluoxetine_be ,_be paroxetine_be ,_be amitriptyline_be ,_be OTHER_DRUG increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
89,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,fluoxetine,No interaction,"Warfarin_bf users_bf initiated_bf DRUG ,_be OTHER_DRUG ,_af paroxetine_af ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
90,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,paroxetine,No interaction,"Warfarin_bf users_bf initiated_bf DRUG ,_be fluoxetine_be ,_be OTHER_DRUG ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
91,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,amitriptyline,No interaction,"Warfarin_bf users_bf initiated_bf DRUG ,_be fluoxetine_be ,_be paroxetine_be ,_be OTHER_DRUG ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
92,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",citalopram,mirtazapine,No interaction,"Warfarin_bf users_bf initiated_bf DRUG ,_be fluoxetine_be ,_be paroxetine_be ,_be amitriptyline_be ,_be OTHER_DRUG increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
93,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",fluoxetine,paroxetine,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf DRUG ,_be OTHER_DRUG ,_af amitriptyline_af ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
94,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",fluoxetine,amitriptyline,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf DRUG ,_be paroxetine_be ,_be OTHER_DRUG ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
95,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",fluoxetine,mirtazapine,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf DRUG ,_be paroxetine_be ,_be amitriptyline_be ,_be OTHER_DRUG increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
96,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",paroxetine,amitriptyline,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf fluoxetine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af mirtazapine_af increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
97,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",paroxetine,mirtazapine,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf fluoxetine_bf ,_bf DRUG ,_be amitriptyline_be ,_be OTHER_DRUG increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
98,"Warfarin users who initiated citalopram, fluoxetine, paroxetine, amitriptyline, or mirtazapine had an increased risk of hospitalization for gastrointestinal bleeding. ",amitriptyline,mirtazapine,No interaction,"Warfarin_bf users_bf initiated_bf citalopram_bf ,_bf fluoxetine_bf ,_bf paroxetine_bf ,_bf DRUG ,_be OTHER_DRUG increased_af risk_af hospitalization_af gastrointestinal_af bleeding_af ._af"
99,"The incubations were performed in the absence and presence of the non-specific CYP inhibitor, 1-aminobenzotriazole (ABT) and isoform-specific inhibitors. ",1-aminobenzotriazole,ABT,No interaction,"The_bf incubations_bf performed_bf absence_bf presence_bf non-specific_bf CYP_bf inhibitor_bf ,_bf DRUG (ABT)_be isoform-specific_be inhibitors_be ._be"
100,"ABT decreased the toxicity of precocene I, increased exposure to parent compound, and decreased metabolite levels in a dose-dependent manner. ",ABT,precocene I,effect,"DRUG decreased_be toxicity_be precocene_be I_be ,_be increased_be exposure_be parent_be compound_be ,_be decreased_be metabolite_be levels_be dose-dependent_be manner_be ._be"
101,"Of the isoform-specific CYP inhibitors tested for an effect on the precocene I metabolite profile, only tranylcypromine was noticeably effective, indicating a role of CYPs 2A6, 2C9, 2Cl9, and 2E1. ",precocene I,tranylcypromine,No interaction,"Of_bf isoform-specific_bf CYP_bf inhibitors_bf tested_bf effect_bf precocene_bf I_bf metabolite_bf profile_bf ,_bf OTHER_DRUG noticeably_be effective_be ,_be indicating_be role_be CYPs_be 2A6_be ,_be 2C9_be ,_be 2Cl9_be ,_be 2E1_be ._be"
102,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",ABT,diethyldithiocarbamate,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
103,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",ABT,tranylcypromine,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
104,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",ABT,ketoconazole,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
105,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",diethyldithiocarbamate,tranylcypromine,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
106,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",diethyldithiocarbamate,ketoconazole,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
107,"With respect to toxicity, the order of CYP inhibitor effectiveness was ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole. ",tranylcypromine,ketoconazole,No interaction,"With_bf respect_bf toxicity_bf ,_bf order_bf CYP_bf inhibitor_bf effectiveness_bf ABT>diethyldithiocarbamate~tranylcypromine>ketoconazole_bf ._bf"
108,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",Furafylline,sulfaphenazole,No interaction,"DRUG OTHER_DRUG effect_af ,_af quinidine_af appeared_af augment_af precocene_af I_af toxicity_af ._af"
109,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",Furafylline,quinidine,No interaction,"DRUG sulfaphenazole_be effect_be ,_be OTHER_DRUG appeared_af augment_af precocene_af I_af toxicity_af ._af"
110,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",Furafylline,precocene I,No interaction,"DRUG sulfaphenazole_be effect_be ,_be quinidine_be appeared_be augment_be precocene_be I_be toxicity_be ._be"
111,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",sulfaphenazole,quinidine,No interaction,"Furafylline_bf DRUG effect_be ,_be OTHER_DRUG appeared_af augment_af precocene_af I_af toxicity_af ._af"
112,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",sulfaphenazole,precocene I,No interaction,"Furafylline_bf DRUG effect_be ,_be quinidine_be appeared_be augment_be precocene_be I_be toxicity_be ._be"
113,"Furafylline and sulfaphenazole had no effect, while quinidine appeared to augment precocene I toxicity. ",quinidine,precocene I,effect,"Furafylline_bf sulfaphenazole_bf effect_bf ,_bf DRUG appeared_be augment_be precocene_be I_be toxicity_be ._be"
114,These results suggest that rat liver slices do not reproduce the reported in vivo biotransformation of precocene I and therefore may not be an appropriate model for precocene I metabolism. ,precocene I,precocene I,No interaction,These_bf results_bf suggest_bf rat_bf liver_bf slices_bf reproduce_bf reported_bf vivo_bf biotransformation_bf precocene_bf I_bf therefore_bf may_bf appropriate_bf model_bf precocene_bf I_bf metabolism_bf ._bf
115,To determine whether the co-injection of extracellular matrix degrading enzymes improves retinal transduction following intravitreal delivery of adeno-associated virus-2 (AAV2).,adeno-associated virus-2,AAV2,No interaction,To_bf determine_bf whether_bf co-injection_bf extracellular_bf matrix_bf degrading_bf enzymes_bf improves_bf retinal_bf transduction_bf following_bf intravitreal_bf delivery_bf adeno-associated_bf virus-2_bf (AAV2)_bf ._bf
116,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",AAV2,collagenase,No interaction,"DRUG containing_be cDNA_be encoding_be enhanced_be green_be fluorescent_be protein_be (GFP)_be ,_be control_be chicken_be -actin_be promoter_be ,_be delivered_be intravitreal_be injection_be adult_be mice_be conjunction_be enzymes_be including_be OTHER_DRUG ,_af hyaluronan_af lyase_af ,_af heparinase_af III_af ,_af chondroitin_af ABC_af lyase_af ._af"
117,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",AAV2,hyaluronan lyase,No interaction,"DRUG containing_be cDNA_be encoding_be enhanced_be green_be fluorescent_be protein_be (GFP)_be ,_be control_be chicken_be -actin_be promoter_be ,_be delivered_be intravitreal_be injection_be adult_be mice_be conjunction_be enzymes_be including_be collagenase_be ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
118,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",AAV2,heparinase III,No interaction,"DRUG containing_be cDNA_be encoding_be enhanced_be green_be fluorescent_be protein_be (GFP)_be ,_be control_be chicken_be -actin_be promoter_be ,_be delivered_be intravitreal_be injection_be adult_be mice_be conjunction_be enzymes_be including_be collagenase_be ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
119,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",AAV2,chondroitin ABC lyase,No interaction,"DRUG containing_be cDNA_be encoding_be enhanced_be green_be fluorescent_be protein_be (GFP)_be ,_be control_be chicken_be -actin_be promoter_be ,_be delivered_be intravitreal_be injection_be adult_be mice_be conjunction_be enzymes_be including_be collagenase_be ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
120,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",collagenase,hyaluronan lyase,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf DRUG ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
121,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",collagenase,heparinase III,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf DRUG ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
122,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",collagenase,chondroitin ABC lyase,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf DRUG ,_be hyaluronan_be lyase_be ,_be heparinase_be III_be ,_be chondroitin_be ABC_be lyase_be ._be"
123,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",hyaluronan lyase,heparinase III,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf collagenase_bf ,_bf hyaluronan_bf lyase_bf ,_bf heparinase_bf III_bf ,_bf chondroitin_bf ABC_bf lyase_bf ._bf"
124,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",hyaluronan lyase,chondroitin ABC lyase,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf collagenase_bf ,_bf hyaluronan_bf lyase_bf ,_bf heparinase_bf III_bf ,_bf chondroitin_bf ABC_bf lyase_bf ._bf"
125,"AAV2 containing cDNA encoding enhanced green fluorescent protein (GFP), under the control of a chicken   -actin promoter, was delivered by intravitreal injection to adult mice in conjunction with enzymes including collagenase, hyaluronan lyase, heparinase III, or chondroitin ABC lyase. ",heparinase III,chondroitin ABC lyase,No interaction,"AAV2_bf containing_bf cDNA_bf encoding_bf enhanced_bf green_bf fluorescent_bf protein_bf (GFP)_bf ,_bf control_bf chicken_bf -actin_bf promoter_bf ,_bf delivered_bf intravitreal_bf injection_bf adult_bf mice_bf conjunction_bf enzymes_bf including_bf collagenase_bf ,_bf hyaluronan_bf lyase_bf ,_bf heparinase_bf III_bf ,_bf chondroitin_bf ABC_bf lyase_bf ._bf"
126,The addition of heparinase III or chondroitin ABC lyase greatly enhanced transduction of the retinal ganglion cell layer and increased the depth of transduction into the outer retina. ,heparinase III,chondroitin ABC lyase,No interaction,The_bf addition_bf heparinase_bf III_bf chondroitin_bf ABC_bf lyase_bf greatly_bf enhanced_bf transduction_bf retinal_bf ganglion_bf cell_bf layer_bf increased_bf depth_bf transduction_bf outer_bf retina_bf ._bf
127,Hyaluronan lyase had a limited effect and collagenase was ineffective. ,Hyaluronan lyase,collagenase,No interaction,Hyaluronan_bf lyase_bf limited_bf effect_bf OTHER_DRUG ineffective_be ._be
128,Electroretinograms survived with higher concentrations of heparinase III and chondroitin ABC lyase than were required for optimal retinal transduction. ,heparinase III,chondroitin ABC lyase,No interaction,Electroretinograms_bf survived_bf higher_bf concentrations_bf heparinase_bf III_bf chondroitin_bf ABC_bf lyase_bf required_bf optimal_bf retinal_bf transduction_bf ._bf
129,AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ,AAV2,heparinase III,effect,AAV2-mediated_bf retinal_bf transduction_bf improved_bf co-injection_bf heparinase_bf III_bf chondroitin_bf ABC_bf lyase_bf ._bf
130,AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ,AAV2,chondroitin ABC lyase,effect,AAV2-mediated_bf retinal_bf transduction_bf improved_bf co-injection_bf heparinase_bf III_bf chondroitin_bf ABC_bf lyase_bf ._bf
131,AAV2-mediated retinal transduction is improved by co-injection of heparinase III or chondroitin ABC lyase. ,heparinase III,chondroitin ABC lyase,No interaction,AAV2-mediated_bf retinal_bf transduction_bf improved_bf co-injection_bf heparinase_bf III_bf chondroitin_bf ABC_bf lyase_bf ._bf
132,"Prevention of emergence agitation in seven children receiving low-dose ketamine and propofol total intravenous anesthesia.
",ketamine,propofol,No interaction,Prevention_bf emergence_bf agitation_bf seven_bf children_bf receiving_bf low-dose_bf DRUG OTHER_DRUG total_af intravenous_af anesthesia_af ._af
133,We retrospectively reviewed the records of 7 pediatric oncology patients who received low-dose ketamine in conjunction with propofol for total intravenous anesthesia (TIVA) repeatedly for radiation therapy. ,ketamine,propofol,No interaction,We_bf retrospectively_bf reviewed_bf records_bf 7_bf pediatric_bf oncology_bf patients_bf received_bf low-dose_bf DRUG conjunction_be OTHER_DRUG total_af intravenous_af anesthesia_af (TIVA)_af repeatedly_af radiation_af therapy_af ._af
134,EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ,propofol,ketamine,No interaction,EA_bf signs_bf observed_bf 7_bf patients_bf association_bf DRUG TIVA_be recur_be 123_be subsequent_be anesthetics_be sessions_be low-dose_be OTHER_DRUG added_af DRUG ._af
135,EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ,propofol,propofol,No interaction,EA_bf signs_bf observed_bf 7_bf patients_bf association_bf DRUG TIVA_be recur_be 123_be subsequent_be anesthetics_be sessions_be low-dose_be ketamine_be added_be DRUG ._af
136,EA signs were observed in all 7 patients in association with propofol TIVA but did not recur in any of 123 subsequent anesthetics sessions during which low-dose ketamine was added to propofol. ,ketamine,propofol,No interaction,EA_bf signs_bf observed_bf 7_bf patients_bf association_bf OTHER_DRUG TIVA_be recur_be 123_be subsequent_be anesthetics_be sessions_be low-dose_be DRUG added_af OTHER_DRUG ._af
137,"Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.",ketamine,propofol,effect,"Based_bf experience_bf ,_bf suggest_bf low-dose_bf DRUG added_be OTHER_DRUG may_af associated_af prevention_af EA_af children_af history_af EA_af OTHER_DRUG TIVA_af ._af"
138,"Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.",ketamine,propofol,No interaction,"Based_bf experience_bf ,_bf suggest_bf low-dose_bf DRUG added_be OTHER_DRUG may_af associated_af prevention_af EA_af children_af history_af EA_af OTHER_DRUG TIVA_af ._af"
139,"Based on this experience, we suggest that low-dose ketamine added to propofol may be associated with prevention of EA in children with a history of EA with propofol TIVA.",propofol,propofol,No interaction,"Based_bf experience_bf ,_bf suggest_bf low-dose_bf ketamine_bf added_bf DRUG may_be associated_be prevention_be EA_be children_be history_be EA_be DRUG TIVA_af ._af"
140,"Tamoxifen, an estrogen antagonist, is the standard hormone treatment for breast cancer. ",Tamoxifen,estrogen antagonist,No interaction,"DRUG ,_be estrogen_be antagonist_be ,_be standard_be hormone_be treatment_be breast_be cancer_be ._be"
141,Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ,Paroxetine,fluoxetine,No interaction,DRUG OTHER_DRUG reduce_af plasma_af concentration_af endoxifen_af 50%_af ._af
142,Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ,Paroxetine,endoxifen,mechanism,DRUG fluoxetine_be reduce_be plasma_be concentration_be OTHER_DRUG 50%_af ._af
143,Paroxetine and fluoxetine reduce the plasma concentration of endoxifen by about 50%. ,fluoxetine,endoxifen,mechanism,Paroxetine_bf DRUG reduce_be plasma_be concentration_be OTHER_DRUG 50%_af ._af
144,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,SSRI antidepressants,advise,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf DRUG breast_be cancer_be ,_be especially_be SSRI_be antidepressants_be paroxetine_be fluoxetine_be ._be"
145,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,paroxetine,advise,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf DRUG breast_be cancer_be ,_be especially_be SSRI_be antidepressants_be OTHER_DRUG fluoxetine_af ._af"
146,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",tamoxifen,fluoxetine,advise,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf DRUG breast_be cancer_be ,_be especially_be SSRI_be antidepressants_be paroxetine_be OTHER_DRUG ._af"
147,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",SSRI antidepressants,paroxetine,No interaction,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf tamoxifen_bf breast_bf cancer_bf ,_bf especially_bf SSRI_bf antidepressants_bf OTHER_DRUG fluoxetine_be ._be"
148,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",SSRI antidepressants,fluoxetine,No interaction,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf tamoxifen_bf breast_bf cancer_bf ,_bf especially_bf SSRI_bf antidepressants_bf paroxetine_bf OTHER_DRUG ._be"
149,"It is better to avoid prescribing isoenzyme CYP 2D6 inhibitors to women treated with tamoxifen for breast cancer, especially SSRI antidepressants such as paroxetine and fluoxetine. ",paroxetine,fluoxetine,No interaction,"It_bf better_bf avoid_bf prescribing_bf isoenzyme_bf CYP_bf 2D6_bf inhibitors_bf women_bf treated_bf tamoxifen_bf breast_bf cancer_bf ,_bf especially_bf SSRI_bf antidepressants_bf DRUG OTHER_DRUG ._af"
150,"Depression does not always require antidepressant drug therapy, and antidepressants have no proven preventive impact on hot flushes linked to the menopause. ",antidepressant drug,antidepressants,No interaction,"Depression_bf always_bf require_bf antidepressant_bf drug_bf therapy_bf ,_bf OTHER_DRUG proven_be preventive_be impact_be hot_be flushes_be linked_be menopause_be ._be"
151,"If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.",antidepressant,tamoxifen,advise,"If_bf certain_bf cases_bf ,_bf DRUG considered_be necessary_be ,_be may_be advisable_be replace_be OTHER_DRUG anastrozole_af ._af"
152,"If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.",antidepressant,anastrozole,No interaction,"If_bf certain_bf cases_bf ,_bf DRUG considered_be necessary_be ,_be may_be advisable_be replace_be tamoxifen_be OTHER_DRUG ._af"
153,"If in certain cases, an antidepressant is considered necessary, it may be advisable to replace tamoxifen with anastrozole.",tamoxifen,anastrozole,No interaction,"If_bf certain_bf cases_bf ,_bf antidepressant_bf considered_bf necessary_bf ,_bf may_bf advisable_bf replace_bf DRUG OTHER_DRUG ._af"
154,"Amphetamine locomotor sensitization and conditioned place preference in adolescent male and female rats neonatally treated with quinpirole.
",Amphetamine,quinpirole,No interaction,DRUG locomotor_be sensitization_be conditioned_be place_be preference_be adolescent_be male_be female_be rats_be neonatally_be treated_be OTHER_DRUG ._af
155,The objective was to analyze the effects of neonatal quinpirole treatment on effects of amphetamine in adolescent rats using locomotor sensitization and conditioned place preference procedures. ,quinpirole,amphetamine,No interaction,The_bf objective_bf analyze_bf effects_bf neonatal_bf DRUG treatment_be effects_be OTHER_DRUG adolescent_af rats_af using_af locomotor_af sensitization_af conditioned_af place_af preference_af procedures_af ._af
156,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",quinpirole,amphetamine,effect,"In_bf female_bf rats_bf ,_bf neonatal_bf DRUG treatment_be enhanced_be OTHER_DRUG locomotor_af sensitization_af compared_af quinpirole-free_af controls_af sensitized_af OTHER_DRUG ._af"
157,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",quinpirole,quinpirole,No interaction,"In_bf female_bf rats_bf ,_bf neonatal_bf DRUG treatment_be enhanced_be amphetamine_be locomotor_be sensitization_be compared_be quinpirole-free_be controls_be sensitized_be amphetamine_be ._be"
158,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",quinpirole,amphetamine,No interaction,"In_bf female_bf rats_bf ,_bf neonatal_bf DRUG treatment_be enhanced_be OTHER_DRUG locomotor_af sensitization_af compared_af quinpirole-free_af controls_af sensitized_af OTHER_DRUG ._af"
159,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",amphetamine,quinpirole,No interaction,"In_bf female_bf rats_bf ,_bf neonatal_bf OTHER_DRUG treatment_be enhanced_be DRUG locomotor_af sensitization_af compared_af quinpirole-free_af controls_af sensitized_af DRUG ._af"
160,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",amphetamine,amphetamine,No interaction,"In_bf female_bf rats_bf ,_bf neonatal_bf quinpirole_bf treatment_bf enhanced_bf DRUG locomotor_be sensitization_be compared_be quinpirole-free_be controls_be sensitized_be DRUG ._af"
161,"In female rats, neonatal quinpirole treatment enhanced amphetamine locomotor sensitization compared with quinpirole-free controls sensitized to amphetamine. ",quinpirole,amphetamine,No interaction,"In_bf female_bf rats_bf ,_bf neonatal_bf DRUG treatment_be enhanced_be OTHER_DRUG locomotor_af sensitization_af compared_af quinpirole-free_af controls_af sensitized_af OTHER_DRUG ._af"
162,"Male rats demonstrated sensitization to amphetamine, although this was muted compared with female rats, and were unaffected by neonatal quinpirole. ",amphetamine,quinpirole,No interaction,"Male_bf rats_bf demonstrated_bf sensitization_bf DRUG ,_be although_be muted_be compared_be female_be rats_be ,_be unaffected_be neonatal_be OTHER_DRUG ._af"
163,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be OTHER_DRUG ,_af female_af controls_af conditioned_af OTHER_DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
164,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,quinpirole,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be amphetamine_be ,_be female_be controls_be conditioned_be amphetamine_be spent_be time_be drug-paired_be context_be compared_be saline-treated_be controls_be ._be"
165,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be OTHER_DRUG ,_af female_af controls_af conditioned_af OTHER_DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
166,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be OTHER_DRUG ,_af female_af controls_af conditioned_af OTHER_DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
167,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,quinpirole,No interaction,"Rats_bf treated_bf neonatal_bf OTHER_DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be DRUG ,_af female_af controls_af conditioned_af DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
168,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf quinpirole_bf enhanced_bf time_bf spent_bf amphetamine-paired_bf context_bf compared_bf quinpirole-free_bf controls_bf conditioned_bf DRUG ,_be female_be controls_be conditioned_be DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
169,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf quinpirole_bf enhanced_bf time_bf spent_bf amphetamine-paired_bf context_bf compared_bf quinpirole-free_bf controls_bf conditioned_bf DRUG ,_be female_be controls_be conditioned_be DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
170,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be OTHER_DRUG ,_af female_af controls_af conditioned_af OTHER_DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
171,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",quinpirole,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf DRUG enhanced_be time_be spent_be amphetamine-paired_be context_be compared_be quinpirole-free_be controls_be conditioned_be OTHER_DRUG ,_af female_af controls_af conditioned_af OTHER_DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
172,"Rats treated with neonatal quinpirole enhanced time spent in the amphetamine-paired context compared with quinpirole-free controls conditioned with amphetamine, but only female controls conditioned with amphetamine spent more time in the drug-paired context compared with saline-treated controls. ",amphetamine,amphetamine,No interaction,"Rats_bf treated_bf neonatal_bf quinpirole_bf enhanced_bf time_bf spent_bf amphetamine-paired_bf context_bf compared_bf quinpirole-free_bf controls_bf conditioned_bf DRUG ,_be female_be controls_be conditioned_be DRUG spent_af time_af drug-paired_af context_af compared_af saline-treated_af controls_af ._af"
173,"In vivo CYP3A activity is significantly lower in cyclosporine-treated as compared with tacrolimus-treated renal allograft recipients.
",cyclosporine,tacrolimus,No interaction,In_bf vivo_bf CYP3A_bf activity_bf significantly_bf lower_bf cyclosporine-treated_bf compared_bf tacrolimus-treated_bf renal_bf allograft_bf recipients_bf ._bf
174,In vitro studies have identified cyclosporine and tacrolimus as CYP3A inhibitors. ,cyclosporine,tacrolimus,No interaction,In_bf vitro_bf studies_bf identified_bf DRUG OTHER_DRUG CYP3A_af inhibitors_af ._af
175,"Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ",midazolam,cyclosporine,mechanism,"Systemic_bf apparent_bf oral_bf DRUG clearance_be 24%_be (269_be 73_be vs_be ._be 354_be 102_be ml/min_be ,_be P_be =_be 0_be ._be 022)_be 31%_be (479_be 190_be vs_be ._be 688_be 265_be ml/min_be ,_be P_be =_be 0_be ._be 013)_be ,_be respectively_be ,_be lower_be cyclosporine-treated_be patients_be (n_be =_be 20)_be matched_be tacrolimus-treated_be patients_be (n_be =_be 20)_be ._be"
176,"Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ",midazolam,tacrolimus,No interaction,"Systemic_bf apparent_bf oral_bf DRUG clearance_be 24%_be (269_be 73_be vs_be ._be 354_be 102_be ml/min_be ,_be P_be =_be 0_be ._be 022)_be 31%_be (479_be 190_be vs_be ._be 688_be 265_be ml/min_be ,_be P_be =_be 0_be ._be 013)_be ,_be respectively_be ,_be lower_be cyclosporine-treated_be patients_be (n_be =_be 20)_be matched_be tacrolimus-treated_be patients_be (n_be =_be 20)_be ._be"
177,"Systemic and apparent oral midazolam clearance were 24% (269    73 vs. 354    102  ml/min, P = 0.022) and 31% (479    190 vs. 688    265  ml/min, P = 0.013), respectively, lower in cyclosporine-treated patients (n = 20) than in matched tacrolimus-treated patients (n = 20). ",cyclosporine,tacrolimus,No interaction,"Systemic_bf apparent_bf oral_bf midazolam_bf clearance_bf 24%_bf (269_bf 73_bf vs_bf ._bf 354_bf 102_bf ml/min_bf ,_bf P_bf =_bf 0_bf ._bf 022)_bf 31%_bf (479_bf 190_bf vs_bf ._bf 688_bf 265_bf ml/min_bf ,_bf P_bf =_bf 0_bf ._bf 013)_bf ,_bf respectively_bf ,_bf lower_bf cyclosporine-treated_bf patients_bf (n_bf =_bf 20)_bf matched_bf tacrolimus-treated_bf patients_bf (n_bf =_bf 20)_bf ._bf"
178,The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ,midazolam,tacrolimus,No interaction,The_bf latter_bf displayed_bf DRUG clearances_be similar_be two_be larger_be cohorts_be nonmatched_be tacrolimus-treated_be patients_be (n_be =_be 58_be n_be =_be 80)_be receiving_be calcineurin_be inhibitor-free_be regimen_be (n_be =_be 6)_be ._be
179,The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ,midazolam,calcineurin inhibitor,No interaction,The_bf latter_bf displayed_bf DRUG clearances_be similar_be two_be larger_be cohorts_be nonmatched_be tacrolimus-treated_be patients_be (n_be =_be 58_be n_be =_be 80)_be receiving_be calcineurin_be inhibitor-free_be regimen_be (n_be =_be 6)_be ._be
180,The latter displayed midazolam clearances similar to those in two larger cohorts of nonmatched tacrolimus-treated patients (n = 58 and n = 80) and to those receiving a calcineurin inhibitor-free regimen (n = 6). ,tacrolimus,calcineurin inhibitor,No interaction,The_bf latter_bf displayed_bf midazolam_bf clearances_bf similar_bf two_bf larger_bf cohorts_bf nonmatched_bf tacrolimus-treated_bf patients_bf (n_bf =_bf 58_bf n_bf =_bf 80)_bf receiving_bf calcineurin_bf inhibitor-free_bf regimen_bf (n_bf =_bf 6)_bf ._bf
181,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ",cyclosporine,tacrolimus,No interaction,"This_bf implies_bf vivo_bf hepatic_bf first-pass_bf CYP3A_bf activities_bf significantly_bf lower_bf patients_bf receiving_bf DRUG receiving_be OTHER_DRUG ,_af indicating_af ,_af doses_af generally_af used_af clinical_af practice_af ,_af DRUG stronger_af two_af respect_af CYP3A_af inhibition_af ._af"
182,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ",cyclosporine,cyclosporine,No interaction,"This_bf implies_bf vivo_bf hepatic_bf first-pass_bf CYP3A_bf activities_bf significantly_bf lower_bf patients_bf receiving_bf DRUG receiving_be tacrolimus_be ,_be indicating_be ,_be doses_be generally_be used_be clinical_be practice_be ,_be DRUG stronger_af two_af respect_af CYP3A_af inhibition_af ._af"
183,"This implies that in vivo hepatic and first-pass CYP3A activities are significantly lower in patients receiving cyclosporine than in those receiving tacrolimus, indicating that, at the doses generally used in clinical practice, cyclosporine is the stronger of the two with respect to CYP3A inhibition. ",tacrolimus,cyclosporine,No interaction,"This_bf implies_bf vivo_bf hepatic_bf first-pass_bf CYP3A_bf activities_bf significantly_bf lower_bf patients_bf receiving_bf OTHER_DRUG receiving_be DRUG ,_af indicating_af ,_af doses_af generally_af used_af clinical_af practice_af ,_af OTHER_DRUG stronger_af two_af respect_af CYP3A_af inhibition_af ._af"
184,"Improved parathyroid hormone control by cinacalcet is associated with reduction in darbepoetin requirement in patients with end-stage renal disease.
",cinacalcet,darbepoetin,No interaction,Improved_bf parathyroid_bf hormone_bf control_bf DRUG associated_be reduction_be OTHER_DRUG requirement_af patients_af end-stage_af renal_af disease_af ._af
185,"Uncontrolled hy-per-parathyroidism causes bone marrow fibrosis, leading to erythropoietin (EPO) resistance. ",erythropoietin,EPO,No interaction,"Uncontrolled_bf hy-per-parathyroidism_bf causes_bf bone_bf marrow_bf fibrosis_bf ,_bf leading_bf DRUG (EPO)_be resistance_be ._be"
186,"Medical treatment with cinacalcet is effective in reducing plasma parathyroid hormone (PTH) levels, but its effect on darbepoetin dosing is unknown. ",cinacalcet,darbepoetin,No interaction,"Medical_bf treatment_bf DRUG effective_be reducing_be plasma_be parathyroid_be hormone_be (PTH)_be levels_be ,_be effect_be OTHER_DRUG dosing_af unknown_af ._af"
187,The primary objective of the study was to ascertain the difference in darbepoetin responsiveness before and after 12 months of cinacalcet therapy. ,darbepoetin,cinacalcet,No interaction,The_bf primary_bf objective_bf study_bf ascertain_bf difference_bf DRUG responsiveness_be 12_be months_be OTHER_DRUG therapy_af ._af
188,Reduction of PTH by cinacalcet is associated with a decrease in darbepoetin requirement. ,cinacalcet,darbepoetin,effect,Reduction_bf PTH_bf DRUG associated_be decrease_be OTHER_DRUG requirement_af ._af
189,"Interaction of celecoxib with different anti-cancer drugs is antagonistic in breast but not in other cancer cells.
",celecoxib,anti-cancer drugs,effect,Interaction_bf DRUG different_be anti-cancer_be drugs_be antagonistic_be breast_be cancer_be cells_be ._be
190,This study investigates the ability of cyclooxygenase-2 inhibitors to sensitize cells from different origins to several chemotherapeutic agents. ,cyclooxygenase-2 inhibitors,chemotherapeutic agents,No interaction,This_bf study_bf investigates_bf ability_bf cyclooxygenase-2_bf inhibitors_bf sensitize_bf cells_bf different_bf origins_bf several_bf chemotherapeutic_bf agents_bf ._bf
191,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",5-FU,cisplatin,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf DRUG ,_be OTHER_DRUG ,_af doxorubicin_af etoposide_af celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
192,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",5-FU,doxorubicin,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf DRUG ,_be cisplatin_be ,_be OTHER_DRUG etoposide_af celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
193,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",5-FU,etoposide,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf DRUG ,_be cisplatin_be ,_be doxorubicin_be OTHER_DRUG celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
194,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",5-FU,celecoxib,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf DRUG ,_be cisplatin_be ,_be doxorubicin_be etoposide_be OTHER_DRUG following_af different_af incubation_af schedules_af analyzed_af ._af"
195,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",cisplatin,doxorubicin,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf DRUG ,_be OTHER_DRUG etoposide_af celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
196,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",cisplatin,etoposide,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf DRUG ,_be doxorubicin_be OTHER_DRUG celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
197,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",cisplatin,celecoxib,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf DRUG ,_be doxorubicin_be etoposide_be OTHER_DRUG following_af different_af incubation_af schedules_af analyzed_af ._af"
198,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",doxorubicin,etoposide,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf cisplatin_bf ,_bf DRUG OTHER_DRUG celecoxib_af following_af different_af incubation_af schedules_af analyzed_af ._af"
199,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",doxorubicin,celecoxib,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf cisplatin_bf ,_bf DRUG etoposide_be OTHER_DRUG following_af different_af incubation_af schedules_af analyzed_af ._af"
200,"The sensitivity, cell cycle, apoptosis and DNA damage of five different cancer cell lines (HeLa, HCT116, HepG2, MCF7 and U251) to 5-FU, cisplatin, doxorubicin and etoposide   celecoxib following different incubation schedules were analyzed.",etoposide,celecoxib,No interaction,"The_bf sensitivity_bf ,_bf cell_bf cycle_bf ,_bf apoptosis_bf DNA_bf damage_bf five_bf different_bf cancer_bf cell_bf lines_bf (HeLa_bf ,_bf HCT116_bf ,_bf HepG2_bf ,_bf MCF7_bf U251)_bf 5-FU_bf ,_bf cisplatin_bf ,_bf doxorubicin_bf DRUG OTHER_DRUG following_af different_af incubation_af schedules_af analyzed_af ._af"
201,We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ,celecoxib,celecoxib,No interaction,We_bf found_bf antagonism_bf DRUG four_be drugs_be breast_be cancer_be cells_be MCF7_be following_be incubation_be schedules_be DRUG doxorubicin_af cell_af lines_af except_af two_af combinations_af HCT116_af cells_af ._af
202,We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ,celecoxib,doxorubicin,No interaction,We_bf found_bf antagonism_bf DRUG four_be drugs_be breast_be cancer_be cells_be MCF7_be following_be incubation_be schedules_be DRUG OTHER_DRUG cell_af lines_af except_af two_af combinations_af HCT116_af cells_af ._af
203,We found antagonism between celecoxib and the four drugs in the breast cancer cells MCF7 following all incubation schedules and between celecoxib and doxorubicin in all cell lines except for two combinations in HCT116 cells. ,celecoxib,doxorubicin,effect,We_bf found_bf antagonism_bf DRUG four_be drugs_be breast_be cancer_be cells_be MCF7_be following_be incubation_be schedules_be DRUG OTHER_DRUG cell_af lines_af except_af two_af combinations_af HCT116_af cells_af ._af
204,"These results, if confirmed in-vivo, indicate that celecoxib is not a suitable chemosensitizer for breast cancer or with doxorubicin for other cancers. ",celecoxib,doxorubicin,No interaction,"These_bf results_bf ,_bf confirmed_bf in-vivo_bf ,_bf indicate_bf DRUG suitable_be chemosensitizer_be breast_be cancer_be OTHER_DRUG cancers_af ._af"
205,"[Interaction between clopidogrel and proton pump inhibitors].
",clopidogrel,proton pump inhibitors,No interaction,[Interaction_bf DRUG proton_be pump_be inhibitors]_be ._be
206,The drug interaction between proton pump inhibitors and clopidogrel has been the subject of much study in recent years. ,proton pump inhibitors,clopidogrel,No interaction,The_bf drug_bf interaction_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG subject_be much_be study_be recent_be years_be ._be
207,Contradictory results regarding the effect of proton pump inhibitors on platelet reactivity and on clinical outcome in clopidogrel-treated patients have been reported in literature. ,proton pump inhibitors,clopidogrel,No interaction,Contradictory_bf results_bf regarding_bf effect_bf proton_bf pump_bf inhibitors_bf platelet_bf reactivity_bf clinical_bf outcome_bf clopidogrel-treated_bf patients_bf reported_bf literature_bf ._bf
208,"Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ",omeprazole,clopidogrel,mechanism,"Concomitant_bf use_bf DRUG OTHER_DRUG found_af decrease_af exposure_af (AUC)_af clopidogrel's_af active_af metabolite_af 50%_af sharply_af increase_af platelet_af reactivity_af ,_af result_af inhibition_af DRUG CYP2C19_af ,_af cytochrome_af P450_af (CYP)_af enzyme_af ._af"
209,"Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ",omeprazole,omeprazole,No interaction,"Concomitant_bf use_bf DRUG clopidogrel_be found_be decrease_be exposure_be (AUC)_be clopidogrel's_be active_be metabolite_be 50%_be sharply_be increase_be platelet_be reactivity_be ,_be result_be inhibition_be DRUG CYP2C19_af ,_af cytochrome_af P450_af (CYP)_af enzyme_af ._af"
210,"Concomitant use of omeprazole and clopidogrel was found to decrease the exposure (AUC) to clopidogrel's active metabolite by 50% and to sharply increase platelet reactivity, as a result of inhibition by omeprazole of CYP2C19, a cytochrome P450 (CYP) enzyme. ",clopidogrel,omeprazole,No interaction,"Concomitant_bf use_bf OTHER_DRUG DRUG found_af decrease_af exposure_af (AUC)_af clopidogrel's_af active_af metabolite_af 50%_af sharply_af increase_af platelet_af reactivity_af ,_af result_af inhibition_af OTHER_DRUG CYP2C19_af ,_af cytochrome_af P450_af (CYP)_af enzyme_af ._af"
211,Pantoprazole has a much weaker effect on clopidogrel's pharmacokinetics and on platelet reactivity during concomitant use. ,Pantoprazole,clopidogrel,mechanism,DRUG much_be weaker_be effect_be clopidogrel's_be pharmacokinetics_be platelet_be reactivity_be concomitant_be use_be ._be
212,The influence of the other proton pump inhibitors when used simultaneously with clopidogrel has not yet been investigated in adequately randomized studies. ,proton pump inhibitors,clopidogrel,No interaction,The_bf influence_bf proton_bf pump_bf inhibitors_bf used_bf simultaneously_bf OTHER_DRUG yet_be investigated_be adequately_be randomized_be studies_be ._be
213,Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ,clopidogrel,omeprazole,advise,Regulatory_bf agencies_bf state_bf combination_bf DRUG CYP2C19_be inhibitors_be OTHER_DRUG esomeprazole_af avoided_af ._af
214,Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ,clopidogrel,esomeprazole,advise,Regulatory_bf agencies_bf state_bf combination_bf DRUG CYP2C19_be inhibitors_be omeprazole_be OTHER_DRUG avoided_af ._af
215,Regulatory agencies state that the combination of clopidogrel and the CYP2C19 inhibitors omeprazole and esomeprazole should be avoided. ,omeprazole,esomeprazole,No interaction,Regulatory_bf agencies_bf state_bf combination_bf clopidogrel_bf CYP2C19_bf inhibitors_bf DRUG OTHER_DRUG avoided_af ._af
216,"To date, there is no conclusive evidence of a clinically-relevant interaction between any of the proton pump inhibitors and clopidogrel.",proton pump inhibitors,clopidogrel,No interaction,"To_bf date_bf ,_bf conclusive_bf evidence_bf clinically-relevant_bf interaction_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG ._be"
217,"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
",minocycline,fosfomycin,No interaction,In_bf vitro_bf activity_bf DRUG combined_be OTHER_DRUG clinical_af isolates_af methicillin-resistant_af Staphylococcus_af aureus_af ._af
218,"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
",minocycline,methicillin,No interaction,In_bf vitro_bf activity_bf DRUG combined_be fosfomycin_be clinical_be isolates_be methicillin-resistant_be Staphylococcus_be aureus_be ._be
219,"In vitro activity of minocycline combined with fosfomycin against clinical isolates of methicillin-resistant Staphylococcus aureus.
",fosfomycin,methicillin,No interaction,In_bf vitro_bf activity_bf minocycline_bf combined_bf DRUG clinical_be isolates_be methicillin-resistant_be Staphylococcus_be aureus_be ._be
220,This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ,minocycline,fosfomycin,No interaction,This_bf study_bf aimed_bf evaluate_bf vitro_bf activity_bf DRUG combined_be OTHER_DRUG isolates_af methicillin-resistant_af Staphylococcus_af aureus_af (MRSA)_af ._af
221,This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ,minocycline,methicillin,No interaction,This_bf study_bf aimed_bf evaluate_bf vitro_bf activity_bf DRUG combined_be fosfomycin_be isolates_be methicillin-resistant_be Staphylococcus_be aureus_be (MRSA)_be ._be
222,This study aimed to evaluate the in vitro activity of minocycline combined with fosfomycin against isolates of methicillin-resistant Staphylococcus aureus (MRSA). ,fosfomycin,methicillin,No interaction,This_bf study_bf aimed_bf evaluate_bf vitro_bf activity_bf minocycline_bf combined_bf DRUG isolates_be methicillin-resistant_be Staphylococcus_be aureus_be (MRSA)_be ._be
223,The susceptibility results for minocycline and fosfomycin were interpreted according to the most relevant criteria. ,minocycline,fosfomycin,No interaction,The_bf susceptibility_bf results_bf DRUG OTHER_DRUG interpreted_af according_af relevant_af criteria_af ._af
224,The combination of minocycline and fosfomycin can be synergistic against MRSA. ,minocycline,fosfomycin,effect,The_bf combination_bf DRUG OTHER_DRUG synergistic_af MRSA_af ._af
225,The authors report the case of an infant with confirmed congenital hypothyroidism on levothyroxine who experienced a possible drug interaction with simeticone. ,levothyroxine,simeticone,int,The_bf authors_bf report_bf case_bf infant_bf confirmed_bf congenital_bf hypothyroidism_bf DRUG experienced_be possible_be drug_be interaction_be OTHER_DRUG ._af
226,Questioning revealed the child was taking Infacol drops before feeds while on levothyroxine. ,Infacol,levothyroxine,No interaction,Questioning_bf revealed_bf child_bf taking_bf DRUG drops_be feeds_be OTHER_DRUG ._af
227,Drug interaction of thyroxine with simeticone has not been reported previously and is not listed in the British National Formulary for Children. ,thyroxine,simeticone,No interaction,Drug_bf interaction_bf DRUG OTHER_DRUG reported_af previously_af listed_af British_af National_af Formulary_af Children_af ._af
228,Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.,Calcium,nonheme iron,No interaction,DRUG inhibit_be absorption_be 5_be milligrams_be nonheme_be heme_be iron_be doses_be less_be 800_be milligrams_be nonpregnant_be women_be ._be
229,Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.,Calcium,heme iron,No interaction,DRUG inhibit_be absorption_be 5_be milligrams_be nonheme_be heme_be iron_be doses_be less_be 800_be milligrams_be nonpregnant_be women_be ._be
230,Calcium does not inhibit the absorption of 5 milligrams of nonheme or heme iron at doses less than 800 milligrams in nonpregnant women.,nonheme iron,heme iron,No interaction,Calcium_bf inhibit_bf absorption_bf 5_bf milligrams_bf nonheme_bf heme_bf iron_bf doses_bf less_bf 800_bf milligrams_bf nonpregnant_bf women_bf ._bf
231,Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ,Calcium,nonheme iron,mechanism,DRUG known_be component_be diet_be may_be affect_be absorption_be nonheme_be heme_be iron_be ._be
232,Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ,Calcium,heme iron,mechanism,DRUG known_be component_be diet_be may_be affect_be absorption_be nonheme_be heme_be iron_be ._be
233,Calcium is the only known component in the diet that may affect absorption of both nonheme and heme iron. ,nonheme iron,heme iron,No interaction,Calcium_bf known_bf component_bf diet_bf may_bf affect_bf absorption_bf nonheme_bf heme_bf iron_bf ._bf
234,"However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ",calcium,iron,mechanism,"However_bf ,_bf evidence_bf DRUG effect_be OTHER_DRUG absorption_af mainly_af comes_af studies_af isolate_af effect_af DRUG dietary_af components_af ,_af detected_af single-meal_af studies_af ._af"
235,"However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ",calcium,calcium,No interaction,"However_bf ,_bf evidence_bf DRUG effect_be iron_be absorption_be mainly_be comes_be studies_be isolate_be effect_be DRUG dietary_af components_af ,_af detected_af single-meal_af studies_af ._af"
236,"However, the evidence for a calcium effect on iron absorption mainly comes from studies that did not isolate the effect of calcium from that of other dietary components, because it was detected in single-meal studies. ",iron,calcium,No interaction,"However_bf ,_bf evidence_bf OTHER_DRUG effect_be DRUG absorption_af mainly_af comes_af studies_af isolate_af effect_af OTHER_DRUG dietary_af components_af ,_af detected_af single-meal_af studies_af ._af"
237,Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ,calcium,nonheme iron,No interaction,Our_bf objective_bf establish_bf potential_bf effects_bf DRUG absorption_be nonheme_be heme_be iron_be dose_be response_be effect_be absence_be meal_be ._be
238,Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ,calcium,heme iron,No interaction,Our_bf objective_bf establish_bf potential_bf effects_bf DRUG absorption_be nonheme_be heme_be iron_be dose_be response_be effect_be absence_be meal_be ._be
239,Our objective was to establish potential effects of calcium on absorption of nonheme and heme iron and the dose response for this effect in the absence of a meal. ,nonheme iron,heme iron,No interaction,Our_bf objective_bf establish_bf potential_bf effects_bf calcium_bf absorption_bf nonheme_bf heme_bf iron_bf dose_bf response_bf effect_bf absence_bf meal_bf ._bf
240,We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). ,calcium,nonheme iron,No interaction,We_bf evaluated_bf effects_bf DRUG doses_be 200_be 1500_be mg_be absorption_be 5_be mg_be nonheme_be iron_be (as_be ferrous_be sulfate)_be ._be
241,We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). ,calcium,ferrous sulfate,No interaction,We_bf evaluated_bf effects_bf DRUG doses_be 200_be 1500_be mg_be absorption_be 5_be mg_be nonheme_be iron_be (as_be ferrous_be sulfate)_be ._be
242,We evaluated the effects of calcium doses between 200 and 1500 mg on absorption of 5 mg nonheme iron (as ferrous sulfate). ,nonheme iron,ferrous sulfate,No interaction,We_bf evaluated_bf effects_bf calcium_bf doses_bf 200_bf 1500_bf mg_bf absorption_bf 5_bf mg_bf nonheme_bf iron_bf (as_bf ferrous_bf sulfate)_bf ._bf
243,We also evaluated the effects of calcium doses between 200 and 800 mg on absorption of 5 mg heme iron [as concentrated RBC (CRBC)]. ,calcium,heme iron,No interaction,We_bf also_bf evaluated_bf effects_bf DRUG doses_be 200_be 800_be mg_be absorption_be 5_be mg_be heme_be iron_be [as_be concentrated_be RBC_be (CRBC)]_be ._be
244,Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. ,Calcium,calcium chloride,No interaction,DRUG administered_be DRUG chloride_af studies_af minerals_af ingested_af empty_af stomach_af ._af
245,Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. ,Calcium,minerals,No interaction,DRUG administered_be DRUG chloride_af studies_af OTHER_DRUG ingested_af empty_af stomach_af ._af
246,Calcium was administered as calcium chloride in all studies and minerals were ingested on an empty stomach. ,calcium chloride,minerals,No interaction,Calcium_bf administered_bf calcium_bf chloride_bf studies_bf OTHER_DRUG ingested_be empty_be stomach_be ._be
247,Calcium doses   1000 mg diminished nonheme iron absorption by an average of 49.6%.,Calcium,nonheme iron,mechanism,DRUG doses_be 1000_be mg_be diminished_be nonheme_be iron_be absorption_be average_be 49_be ._be 6%_be ._be
248,A calcium dose of 800 mg diminished absorption of 5 mg heme iron by 37.7%. ,calcium,heme iron,mechanism,A_bf DRUG dose_be 800_be mg_be diminished_be absorption_be 5_be mg_be heme_be iron_be 37_be ._be 7%_be ._be
249,"In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",calcium,nonheme iron,mechanism,"In_bf conclusion_bf ,_bf demonstrated_bf isolated_bf effect_bf DRUG (as_be chloride)_be absorption_be 5_be mg_be iron_be provided_be nonheme_be (as_be sulfate)_be heme_be (as_be CRBC)_be iron_be ._be"
250,"In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",calcium,heme iron,mechanism,"In_bf conclusion_bf ,_bf demonstrated_bf isolated_bf effect_bf DRUG (as_be chloride)_be absorption_be 5_be mg_be iron_be provided_be nonheme_be (as_be sulfate)_be heme_be (as_be CRBC)_be iron_be ._be"
251,"In conclusion, we demonstrated an isolated effect of calcium (as chloride) on absorption of 5 mg of iron provided as nonheme (as sulfate) and heme (as CRBC) iron. ",nonheme iron,heme iron,No interaction,"In_bf conclusion_bf ,_bf demonstrated_bf isolated_bf effect_bf calcium_bf (as_bf chloride)_bf absorption_bf 5_bf mg_bf iron_bf provided_bf nonheme_bf (as_bf sulfate)_bf heme_bf (as_bf CRBC)_bf iron_bf ._bf"
252,Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non-small lung cancer with EGFR TKIs-resistant mutation.,sunitinib,docetaxel,int,Synergistic_bf interaction_bf DRUG OTHER_DRUG sequence_af dependent_af human_af non-small_af lung_af cancer_af EGFR_af TKIs-resistant_af mutation_af ._af
253,This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.,sunitinib,sunitinib,No interaction,This_bf study_bf aimed_bf investigate_bf efficacy_bf single_bf use_bf DRUG concurrent_be sequential_be administration_be DRUG docetaxel_af NSCLC_af cell_af lines_af resistant_af EGFR_af TKIs_af ._af
254,This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.,sunitinib,docetaxel,No interaction,This_bf study_bf aimed_bf investigate_bf efficacy_bf single_bf use_bf DRUG concurrent_be sequential_be administration_be DRUG OTHER_DRUG NSCLC_af cell_af lines_af resistant_af EGFR_af TKIs_af ._af
255,This study was aimed to investigate the efficacy of single use of sunitinib and that of concurrent or sequential administration of sunitinib and docetaxel in NSCLC cell lines that are resistant to EGFR TKIs.,sunitinib,docetaxel,No interaction,This_bf study_bf aimed_bf investigate_bf efficacy_bf single_bf use_bf DRUG concurrent_be sequential_be administration_be DRUG OTHER_DRUG NSCLC_af cell_af lines_af resistant_af EGFR_af TKIs_af ._af
256,NSCLC cell lines with EGFR T790M mutation and K-ras mutation were exposed to either sunitinib or docetaxel or both based on various sequential administrations. ,sunitinib,docetaxel,No interaction,NSCLC_bf cell_bf lines_bf EGFR_bf T790M_bf mutation_bf K-ras_bf mutation_bf exposed_bf either_bf DRUG OTHER_DRUG based_af various_af sequential_af administrations_af ._af
257,"Sunitinib exhibited dose-dependent growth inhibition in NSCLC cell lines and arrested cell cycle at G1 phase, whereas docetaxel arrested at S phase. ",Sunitinib,docetaxel,No interaction,"DRUG exhibited_be dose-dependent_be growth_be inhibition_be NSCLC_be cell_be lines_be arrested_be cell_be cycle_be G1_be phase_be ,_be whereas_be OTHER_DRUG arrested_af S_af phase_af ._af"
258,"Although single or concurrent use of sunitinib and docetaxel has some anti-proliferative effects, the sequential administrations of both drugs remarkably enhanced anti-tumor activity. ",sunitinib,docetaxel,effect,"Although_bf single_bf concurrent_bf use_bf DRUG OTHER_DRUG anti-proliferative_af effects_af ,_af sequential_af administrations_af drugs_af remarkably_af enhanced_af anti-tumor_af activity_af ._af"
259,"When cells were exposed to docetaxel followed by sunitinib, synergism was observed. ",docetaxel,sunitinib,effect,"When_bf cells_bf exposed_bf DRUG followed_be OTHER_DRUG ,_af synergism_af observed_af ._af"
260,The molecular basis of this synergism is that the signaling pathways that were initially activated by docetaxel exposure were efficiently suppressed by the subsequent exposure to sunitinib. ,docetaxel,sunitinib,effect,The_bf molecular_bf basis_bf synergism_bf signaling_bf pathways_bf initially_bf activated_bf DRUG exposure_be efficiently_be suppressed_be subsequent_be exposure_be OTHER_DRUG ._af
261,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,Sunitinib,docetaxel,No interaction,DRUG single_be agent_be exhibits_be anti-proliferative_be effects_be vitro_be NSCLC_be cell_be lines_be EGFR_be T790M_be K-ras_be mutations_be sequential_be administration_be OTHER_DRUG followed_af DRUG superior_af DRUG followed_af OTHER_DRUG concurrent_af administration_af ._af
262,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,Sunitinib,sunitinib,No interaction,DRUG single_be agent_be exhibits_be anti-proliferative_be effects_be vitro_be NSCLC_be cell_be lines_be EGFR_be T790M_be K-ras_be mutations_be sequential_be administration_be docetaxel_be followed_be DRUG superior_af DRUG followed_af docetaxel_af concurrent_af administration_af ._af
263,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,Sunitinib,sunitinib,No interaction,DRUG single_be agent_be exhibits_be anti-proliferative_be effects_be vitro_be NSCLC_be cell_be lines_be EGFR_be T790M_be K-ras_be mutations_be sequential_be administration_be docetaxel_be followed_be DRUG superior_af DRUG followed_af docetaxel_af concurrent_af administration_af ._af
264,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,Sunitinib,docetaxel,No interaction,DRUG single_be agent_be exhibits_be anti-proliferative_be effects_be vitro_be NSCLC_be cell_be lines_be EGFR_be T790M_be K-ras_be mutations_be sequential_be administration_be OTHER_DRUG followed_af DRUG superior_af DRUG followed_af OTHER_DRUG concurrent_af administration_af ._af
265,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,docetaxel,sunitinib,effect,OTHER_DRUG single_be agent_be exhibits_be anti-proliferative_be effects_be vitro_be NSCLC_be cell_be lines_be EGFR_be T790M_be K-ras_be mutations_be sequential_be administration_be DRUG followed_af OTHER_DRUG superior_af OTHER_DRUG followed_af DRUG concurrent_af administration_af ._af
266,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,docetaxel,sunitinib,No interaction,OTHER_DRUG single_be agent_be exhibits_be anti-proliferative_be effects_be vitro_be NSCLC_be cell_be lines_be EGFR_be T790M_be K-ras_be mutations_be sequential_be administration_be DRUG followed_af OTHER_DRUG superior_af OTHER_DRUG followed_af DRUG concurrent_af administration_af ._af
267,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,docetaxel,docetaxel,No interaction,Sunitinib_bf single_bf agent_bf exhibits_bf anti-proliferative_bf effects_bf vitro_bf NSCLC_bf cell_bf lines_bf EGFR_bf T790M_bf K-ras_bf mutations_bf sequential_bf administration_bf DRUG followed_be sunitinib_be superior_be sunitinib_be followed_be DRUG concurrent_af administration_af ._af
268,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,sunitinib,sunitinib,No interaction,DRUG single_be agent_be exhibits_be anti-proliferative_be effects_be vitro_be NSCLC_be cell_be lines_be EGFR_be T790M_be K-ras_be mutations_be sequential_be administration_be docetaxel_be followed_be DRUG superior_af DRUG followed_af docetaxel_af concurrent_af administration_af ._af
269,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,sunitinib,docetaxel,No interaction,DRUG single_be agent_be exhibits_be anti-proliferative_be effects_be vitro_be NSCLC_be cell_be lines_be EGFR_be T790M_be K-ras_be mutations_be sequential_be administration_be OTHER_DRUG followed_af DRUG superior_af DRUG followed_af OTHER_DRUG concurrent_af administration_af ._af
270,Sunitinib as a single agent exhibits anti-proliferative effects in vitro in NSCLC cell lines with EGFR T790M and K-ras mutations but the sequential administration of docetaxel followed by sunitinib is superior to sunitinib followed by docetaxel and concurrent administration.,sunitinib,docetaxel,No interaction,DRUG single_be agent_be exhibits_be anti-proliferative_be effects_be vitro_be NSCLC_be cell_be lines_be EGFR_be T790M_be K-ras_be mutations_be sequential_be administration_be OTHER_DRUG followed_af DRUG superior_af DRUG followed_af OTHER_DRUG concurrent_af administration_af ._af
271,"Distinct synergistic action of piperacillin and methylglyoxal against Pseudomonas aeruginosa.
",piperacillin,methylglyoxal,No interaction,Distinct_bf synergistic_bf action_bf DRUG OTHER_DRUG Pseudomonas_af aeruginosa_af ._af
272,"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ",piperacillin,carbenicillin,No interaction,"Results_bf revealed_bf strains_bf resistant_bf many_bf drugs_bf high_bf levels_bf ,_bf DRUG ,_be OTHER_DRUG ,_af amikacin_af ciprofloxacin_af showed_af resistances_af comparatively_af lower_af levels_af ._af"
273,"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ",piperacillin,amikacin,No interaction,"Results_bf revealed_bf strains_bf resistant_bf many_bf drugs_bf high_bf levels_bf ,_bf DRUG ,_be carbenicillin_be ,_be OTHER_DRUG ciprofloxacin_af showed_af resistances_af comparatively_af lower_af levels_af ._af"
274,"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ",piperacillin,ciprofloxacin,No interaction,"Results_bf revealed_bf strains_bf resistant_bf many_bf drugs_bf high_bf levels_bf ,_bf DRUG ,_be carbenicillin_be ,_be amikacin_be OTHER_DRUG showed_af resistances_af comparatively_af lower_af levels_af ._af"
275,"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ",carbenicillin,amikacin,No interaction,"Results_bf revealed_bf strains_bf resistant_bf many_bf drugs_bf high_bf levels_bf ,_bf piperacillin_bf ,_bf DRUG ,_be OTHER_DRUG ciprofloxacin_af showed_af resistances_af comparatively_af lower_af levels_af ._af"
276,"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ",carbenicillin,ciprofloxacin,No interaction,"Results_bf revealed_bf strains_bf resistant_bf many_bf drugs_bf high_bf levels_bf ,_bf piperacillin_bf ,_bf DRUG ,_be amikacin_be OTHER_DRUG showed_af resistances_af comparatively_af lower_af levels_af ._af"
277,"Results revealed that the strains were resistant to many drugs at high levels, only piperacillin, carbenicillin, amikacin and ciprofloxacin showed resistances at comparatively lower levels. ",amikacin,ciprofloxacin,No interaction,"Results_bf revealed_bf strains_bf resistant_bf many_bf drugs_bf high_bf levels_bf ,_bf piperacillin_bf ,_bf carbenicillin_bf ,_bf DRUG OTHER_DRUG showed_af resistances_af comparatively_af lower_af levels_af ._af"
278,Distinct and statistically significant synergism was observed between methylglyoxal and piperacillin by disc diffusion tests when compared with their individual effects. ,methylglyoxal,piperacillin,effect,Distinct_bf statistically_bf significant_bf synergism_bf observed_bf DRUG OTHER_DRUG disc_af diffusion_af tests_af compared_af individual_af effects_af ._af
279,Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.,methylglyoxal,carbenicillin,effect,Synergism_bf also_bf noted_bf DRUG combined_be OTHER_DRUG amikacin_af ._af
280,Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.,methylglyoxal,amikacin,effect,Synergism_bf also_bf noted_bf DRUG combined_be carbenicillin_be OTHER_DRUG ._af
281,Synergism was also noted when methylglyoxal was combined with carbenicillin and amikacin.,carbenicillin,amikacin,No interaction,Synergism_bf also_bf noted_bf methylglyoxal_bf combined_bf DRUG OTHER_DRUG ._af
282,Protective effect of acetyl-l-carnitine and  alpha lipoic acid against the acute toxicity of diepoxybutane to human lymphocytes.,acetyl-l-carnitine,alpha lipoic acid,No interaction,Protective_bf effect_bf DRUG alpha_be lipoic_be acid_be acute_be toxicity_be diepoxybutane_be human_be lymphocytes_be ._be
283,"(ii) acetyl-l-carnitine elicits a significant protective effect on DEB induced toxicity, which was potentiated by  alpha-lipoic acid.",acetyl-l-carnitine,alpha-lipoic acid,effect,"(ii)_bf DRUG elicits_be significant_be protective_be effect_be DEB_be induced_be toxicity_be ,_be potentiated_be alpha-lipoic_be acid_be ._be"
284,"[Influence of hemantane and doxycycline on MPTP-evoked behavior violations in C57BL/6 mice].
",hemantane,doxycycline,No interaction,[Influence_bf DRUG OTHER_DRUG MPTP-evoked_af behavior_af violations_af C57BL/6_af mice]_af ._af
285,"The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ",anti-parkinsonian drug,hemantane,No interaction,"The_bf effects_bf anti-parkinsonian_bf drug_bf OTHER_DRUG [(2-adamantyl)hexamethylenimine]_be (10_be mg/kg_be ,_be p_be ._be ._be )_be"
286,"The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ",anti-parkinsonian drug,(2-adamantyl)hexamethylenimine,No interaction,"The_bf effects_bf anti-parkinsonian_bf drug_bf hemantane_bf [(2-adamantyl)hexamethylenimine]_bf (10_bf mg/kg_bf ,_bf p_bf ._bf ._bf )_bf"
287,"The effects of anti-parkinsonian drug hemantane [(2-adamantyl)hexamethylenimine] (10 mg/kg, p. o.) ",hemantane,(2-adamantyl)hexamethylenimine,No interaction,"The_bf effects_bf anti-parkinsonian_bf drug_bf DRUG [(2-adamantyl)hexamethylenimine]_be (10_be mg/kg_be ,_be p_be ._be ._be )_be"
288,"and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ",antibiotic drug,doxycycline,No interaction,"and/or_bf antibiotic_bf drug_bf OTHER_DRUG (100_be mg/kg_be ,_be p_be ._be ._be )_be ,_be well_be neurotoxin_be 1-methyl-4-phenyl-1_be ,_be 2_be ,_be 3_be ,_be 4-tetrahydropyridine_be (MPTP)_be (4_be x_be 20_be mg/kg_be ,_be ._be p_be ._be )_be"
289,"and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ",antibiotic drug,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine",No interaction,"and/or_bf antibiotic_bf drug_bf doxycycline_bf (100_bf mg/kg_bf ,_bf p_bf ._bf ._bf )_bf ,_bf well_bf neurotoxin_bf 1-methyl-4-phenyl-1_bf ,_bf 2_bf ,_bf 3_bf ,_bf 4-tetrahydropyridine_bf (MPTP)_bf (4_bf x_bf 20_bf mg/kg_bf ,_bf ._bf p_bf ._bf )_bf"
290,"and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ",antibiotic drug,MPTP,No interaction,"and/or_bf antibiotic_bf drug_bf doxycycline_bf (100_bf mg/kg_bf ,_bf p_bf ._bf ._bf )_bf ,_bf well_bf neurotoxin_bf 1-methyl-4-phenyl-1_bf ,_bf 2_bf ,_bf 3_bf ,_bf 4-tetrahydropyridine_bf (MPTP)_bf (4_bf x_bf 20_bf mg/kg_bf ,_bf ._bf p_bf ._bf )_bf"
291,"and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ",doxycycline,"1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine",No interaction,"and/or_bf antibiotic_bf drug_bf DRUG (100_be mg/kg_be ,_be p_be ._be ._be )_be ,_be well_be neurotoxin_be 1-methyl-4-phenyl-1_be ,_be 2_be ,_be 3_be ,_be 4-tetrahydropyridine_be (MPTP)_be (4_be x_be 20_be mg/kg_be ,_be ._be p_be ._be )_be"
292,"and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ",doxycycline,MPTP,No interaction,"and/or_bf antibiotic_bf drug_bf DRUG (100_be mg/kg_be ,_be p_be ._be ._be )_be ,_be well_be neurotoxin_be 1-methyl-4-phenyl-1_be ,_be 2_be ,_be 3_be ,_be 4-tetrahydropyridine_be (MPTP)_be (4_be x_be 20_be mg/kg_be ,_be ._be p_be ._be )_be"
293,"and/or antibiotic drug doxycycline (100 mg/kg, p. o.), as well as that of neurotoxin 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine (MPTP) (4 x 20 mg/kg, i. p.) ","1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine",MPTP,No interaction,"and/or_bf antibiotic_bf drug_bf doxycycline_bf (100_bf mg/kg_bf ,_bf p_bf ._bf ._bf )_bf ,_bf well_bf neurotoxin_bf 1-methyl-4-phenyl-1_bf ,_bf 2_bf ,_bf 3_bf ,_bf 4-tetrahydropyridine_bf (MPTP)_bf (4_bf x_bf 20_bf mg/kg_bf ,_bf ._bf p_bf ._bf )_bf"
294,"Acute administration of hemantane or doxycycline failed to influence locomotion in mice, while their combination normalized motor activity. ",hemantane,doxycycline,effect,"Acute_bf administration_bf DRUG OTHER_DRUG failed_af influence_af locomotion_af mice_af ,_af combination_af normalized_af motor_af activity_af ._af"
295,"The role of p27(Kip1) in dasatinib-enhanced paclitaxel cytotoxicity in human ovarian cancer cells.
",dasatinib,paclitaxel,effect,The_bf role_bf p27(Kip1)_bf dasatinib-enhanced_bf OTHER_DRUG cytotoxicity_be human_be ovarian_be cancer_be cells_be ._be
296,"The effect of dasatinib, an inhibitor of Src and Abl kinases, on paclitaxel sensitivity was measured in ovarian cancer cells and HEY xenografts. ",dasatinib,paclitaxel,No interaction,"The_bf effect_bf DRUG ,_be inhibitor_be Src_be Abl_be kinases_be ,_be OTHER_DRUG sensitivity_af measured_af ovarian_af cancer_af cells_af HEY_af xenografts_af ._af"
297,"The roles of p27(Kip1), Bcl-2, and Cdk1 in apoptosis induced by dasatinib and paclitaxel were assessed using a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay, siRNA knockdown of gene expression, transfection with Bcl-2 and Cdk1 expression vectors, and flow cytometry. ",dasatinib,paclitaxel,No interaction,"The_bf roles_bf p27(Kip1)_bf ,_bf Bcl-2_bf ,_bf Cdk1_bf apoptosis_bf induced_bf DRUG OTHER_DRUG assessed_af using_af terminal_af deoxynucleotidyl_af transferase-mediated_af dUTP_af nick-end_af labeling_af (TUNEL)_af assay_af ,_af siRNA_af knockdown_af gene_af expression_af ,_af transfection_af Bcl-2_af Cdk1_af expression_af vectors_af ,_af flow_af cytometry_af ._af"
298,HEY cells treated with dasatinib plus paclitaxel formed fewer colonies than did cells treated with either agent alone. ,dasatinib,paclitaxel,effect,HEY_bf cells_bf treated_bf DRUG plus_be OTHER_DRUG formed_af fewer_af colonies_af cells_af treated_af either_af agent_af alone_af ._af
299,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,effect,"Treatment_bf HEY_bf xenograft-bearing_bf mice_bf DRUG plus_be OTHER_DRUG inhibited_af tumor_af growth_af treatment_af either_af agent_af alone_af (average_af tumor_af volume_af per_af mouse_af ,_af DRUG +_af OTHER_DRUG vs_af paclitaxel:_af 0_af ._af 28_af vs_af ._af 0_af ._af 81_af cm3_af ,_af difference_af =_af 0_af ._af 53_af cm3_af ,_af 95%_af confidence_af interval_af [CI]_af =_af 0_af ._af 44_af 0_af ._af 62_af cm3_af ,_af P_af =_af ._af 014);_af"
300,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,dasatinib,No interaction,"Treatment_bf HEY_bf xenograft-bearing_bf mice_bf DRUG plus_be paclitaxel_be inhibited_be tumor_be growth_be treatment_be either_be agent_be alone_be (average_be tumor_be volume_be per_be mouse_be ,_be DRUG +_af paclitaxel_af vs_af paclitaxel:_af 0_af ._af 28_af vs_af ._af 0_af ._af 81_af cm3_af ,_af difference_af =_af 0_af ._af 53_af cm3_af ,_af 95%_af confidence_af interval_af [CI]_af =_af 0_af ._af 44_af 0_af ._af 62_af cm3_af ,_af P_af =_af ._af 014);_af"
301,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,No interaction,"Treatment_bf HEY_bf xenograft-bearing_bf mice_bf DRUG plus_be OTHER_DRUG inhibited_af tumor_af growth_af treatment_af either_af agent_af alone_af (average_af tumor_af volume_af per_af mouse_af ,_af DRUG +_af OTHER_DRUG vs_af paclitaxel:_af 0_af ._af 28_af vs_af ._af 0_af ._af 81_af cm3_af ,_af difference_af =_af 0_af ._af 53_af cm3_af ,_af 95%_af confidence_af interval_af [CI]_af =_af 0_af ._af 44_af 0_af ._af 62_af cm3_af ,_af P_af =_af ._af 014);_af"
302,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,No interaction,"Treatment_bf HEY_bf xenograft-bearing_bf mice_bf DRUG plus_be OTHER_DRUG inhibited_af tumor_af growth_af treatment_af either_af agent_af alone_af (average_af tumor_af volume_af per_af mouse_af ,_af DRUG +_af OTHER_DRUG vs_af paclitaxel:_af 0_af ._af 28_af vs_af ._af 0_af ._af 81_af cm3_af ,_af difference_af =_af 0_af ._af 53_af cm3_af ,_af 95%_af confidence_af interval_af [CI]_af =_af 0_af ._af 44_af 0_af ._af 62_af cm3_af ,_af P_af =_af ._af 014);_af"
303,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",paclitaxel,dasatinib,No interaction,"Treatment_bf HEY_bf xenograft-bearing_bf mice_bf OTHER_DRUG plus_be DRUG inhibited_af tumor_af growth_af treatment_af either_af agent_af alone_af (average_af tumor_af volume_af per_af mouse_af ,_af OTHER_DRUG +_af DRUG vs_af paclitaxel:_af 0_af ._af 28_af vs_af ._af 0_af ._af 81_af cm3_af ,_af difference_af =_af 0_af ._af 53_af cm3_af ,_af 95%_af confidence_af interval_af [CI]_af =_af 0_af ._af 44_af 0_af ._af 62_af cm3_af ,_af P_af =_af ._af 014);_af"
304,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",paclitaxel,paclitaxel,No interaction,"Treatment_bf HEY_bf xenograft-bearing_bf mice_bf dasatinib_bf plus_bf DRUG inhibited_be tumor_be growth_be treatment_be either_be agent_be alone_be (average_be tumor_be volume_be per_be mouse_be ,_be dasatinib_be +_be DRUG vs_af paclitaxel:_af 0_af ._af 28_af vs_af ._af 0_af ._af 81_af cm3_af ,_af difference_af =_af 0_af ._af 53_af cm3_af ,_af 95%_af confidence_af interval_af [CI]_af =_af 0_af ._af 44_af 0_af ._af 62_af cm3_af ,_af P_af =_af ._af 014);_af"
305,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",paclitaxel,paclitaxel,No interaction,"Treatment_bf HEY_bf xenograft-bearing_bf mice_bf dasatinib_bf plus_bf DRUG inhibited_be tumor_be growth_be treatment_be either_be agent_be alone_be (average_be tumor_be volume_be per_be mouse_be ,_be dasatinib_be +_be DRUG vs_af paclitaxel:_af 0_af ._af 28_af vs_af ._af 0_af ._af 81_af cm3_af ,_af difference_af =_af 0_af ._af 53_af cm3_af ,_af 95%_af confidence_af interval_af [CI]_af =_af 0_af ._af 44_af 0_af ._af 62_af cm3_af ,_af P_af =_af ._af 014);_af"
306,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,No interaction,"Treatment_bf HEY_bf xenograft-bearing_bf mice_bf DRUG plus_be OTHER_DRUG inhibited_af tumor_af growth_af treatment_af either_af agent_af alone_af (average_af tumor_af volume_af per_af mouse_af ,_af DRUG +_af OTHER_DRUG vs_af paclitaxel:_af 0_af ._af 28_af vs_af ._af 0_af ._af 81_af cm3_af ,_af difference_af =_af 0_af ._af 53_af cm3_af ,_af 95%_af confidence_af interval_af [CI]_af =_af 0_af ._af 44_af 0_af ._af 62_af cm3_af ,_af P_af =_af ._af 014);_af"
307,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",dasatinib,paclitaxel,No interaction,"Treatment_bf HEY_bf xenograft-bearing_bf mice_bf DRUG plus_be OTHER_DRUG inhibited_af tumor_af growth_af treatment_af either_af agent_af alone_af (average_af tumor_af volume_af per_af mouse_af ,_af DRUG +_af OTHER_DRUG vs_af paclitaxel:_af 0_af ._af 28_af vs_af ._af 0_af ._af 81_af cm3_af ,_af difference_af =_af 0_af ._af 53_af cm3_af ,_af 95%_af confidence_af interval_af [CI]_af =_af 0_af ._af 44_af 0_af ._af 62_af cm3_af ,_af P_af =_af ._af 014);_af"
308,"Treatment of HEY xenograft-bearing mice with dasatinib plus paclitaxel inhibited tumor growth more than treatment with either agent alone (average tumor volume per mouse, dasatinib + paclitaxel vs paclitaxel: 0.28 vs. 0.81 cm3, difference = 0.53 cm3, 95% confidence interval [CI] = 0.44 to 0.62 cm3, P = .014); ",paclitaxel,paclitaxel,No interaction,"Treatment_bf HEY_bf xenograft-bearing_bf mice_bf dasatinib_bf plus_bf DRUG inhibited_be tumor_be growth_be treatment_be either_be agent_be alone_be (average_be tumor_be volume_be per_be mouse_be ,_be dasatinib_be +_be DRUG vs_af paclitaxel:_af 0_af ._af 28_af vs_af ._af 0_af ._af 81_af cm3_af ,_af difference_af =_af 0_af ._af 53_af cm3_af ,_af 95%_af confidence_af interval_af [CI]_af =_af 0_af ._af 44_af 0_af ._af 62_af cm3_af ,_af P_af =_af ._af 014);_af"
309,dasatinib + paclitaxel vs. ,dasatinib,paclitaxel,No interaction,DRUG +_be OTHER_DRUG vs_af ._af
310,"The siRNA knockdown of p27(Kip1) decreased dasatinib- and paclitaxel-induced apoptosis compared with a negative control siRNA (sub-G1 fraction, control siRNA vs. p27(Kip1) siRNA: 42.5% vs. 20.1%, difference = 22.4%, 95% CI = 20.1% to 24.7%, P = .017). ",dasatinib,paclitaxel,No interaction,"The_bf siRNA_bf knockdown_bf p27(Kip1)_bf decreased_bf dasatinib-_bf paclitaxel-induced_bf apoptosis_bf compared_bf negative_bf control_bf siRNA_bf (sub-G1_bf fraction_bf ,_bf control_bf siRNA_bf vs_bf ._bf p27(Kip1)_bf siRNA:_bf 42_bf ._bf 5%_bf vs_bf ._bf 20_bf ._bf 1%_bf ,_bf difference_bf =_bf 22_bf ._bf 4%_bf ,_bf 95%_bf CI_bf =_bf 20_bf ._bf 1%_bf 24_bf ._bf 7%_bf ,_bf P_bf =_bf ._bf 017)_bf ._bf"
311,Studies with forced expression and siRNA knockdown of Bcl-2 and Cdk1 suggest that dasatinib-mediated induction of p27(Kip1) enhanced paclitaxel-induced apoptosis by negatively regulating Bcl-2 and Cdk1 expression. ,dasatinib,paclitaxel,effect,Studies_bf forced_bf expression_bf siRNA_bf knockdown_bf Bcl-2_bf Cdk1_bf suggest_bf dasatinib-mediated_bf induction_bf p27(Kip1)_bf enhanced_bf paclitaxel-induced_bf apoptosis_bf negatively_bf regulating_bf Bcl-2_bf Cdk1_bf expression_bf ._bf
312,Inhibition of Src family and Abl kinases with either siRNAs or dasatinib enhances paclitaxel sensitivity of ovarian cancer cells through p27(Kip1)-mediated suppression of Bcl-2 and Cdk1 expression.,dasatinib,paclitaxel,effect,Inhibition_bf Src_bf family_bf Abl_bf kinases_bf either_bf siRNAs_bf DRUG enhances_be OTHER_DRUG sensitivity_af ovarian_af cancer_af cells_af p27(Kip1)-mediated_af suppression_af Bcl-2_af Cdk1_af expression_af ._af
313,"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
",lenalidomide,CCI-779,No interaction,Phase_bf I_bf trial_bf DRUG OTHER_DRUG patients_af relapsed_af multiple_af myeloma:_af evidence_af lenalidomide-CCI-779_af interaction_af via_af P-glycoprotein_af ._af
314,"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
",lenalidomide,lenalidomide,No interaction,Phase_bf I_bf trial_bf DRUG CCI-779_be patients_be relapsed_be multiple_be myeloma:_be evidence_be lenalidomide-CCI-779_be interaction_be via_be P-glycoprotein_be ._be
315,"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
",lenalidomide,CCI-779,No interaction,Phase_bf I_bf trial_bf DRUG OTHER_DRUG patients_af relapsed_af multiple_af myeloma:_af evidence_af lenalidomide-CCI-779_af interaction_af via_af P-glycoprotein_af ._af
316,"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
",CCI-779,lenalidomide,No interaction,Phase_bf I_bf trial_bf OTHER_DRUG DRUG patients_af relapsed_af multiple_af myeloma:_af evidence_af lenalidomide-CCI-779_af interaction_af via_af P-glycoprotein_af ._af
317,"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
",CCI-779,CCI-779,No interaction,Phase_bf I_bf trial_bf lenalidomide_bf DRUG patients_be relapsed_be multiple_be myeloma:_be evidence_be lenalidomide-CCI-779_be interaction_be via_be P-glycoprotein_be ._be
318,"Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
",lenalidomide,CCI-779,No interaction,Phase_bf I_bf trial_bf DRUG OTHER_DRUG patients_af relapsed_af multiple_af myeloma:_af evidence_af lenalidomide-CCI-779_af interaction_af via_af P-glycoprotein_af ._af
319,The preclinical combination of lenalidomide with the mTOR inhibitor CCI-779 has displayed synergy in vitro and represents a novel combination in MM.,lenalidomide,CCI-779,effect,The_bf preclinical_bf combination_bf DRUG mTOR_be inhibitor_be OTHER_DRUG displayed_af synergy_af vitro_af represents_af novel_af combination_af MM_af ._af
320,"Enhancement of humoral immune responses to inactivated Newcastle disease and avian influenza vaccines by oral administration of ginseng stem-and-leaf saponins in chickens.
",avian influenza vaccines,ginseng stem-and-leaf saponins,No interaction,Enhancement_bf humoral_bf immune_bf responses_bf inactivated_bf Newcastle_bf disease_bf avian_bf influenza_bf vaccines_bf oral_bf administration_bf ginseng_bf stem-and-leaf_bf saponins_bf chickens_bf ._bf
321,The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,ginseng stem-and-leaf saponins,GSLS,No interaction,The_bf objective_bf study_bf evaluate_bf effect_bf oral_bf administration_bf ginseng_bf stem-and-leaf_bf saponins_bf (GSLS)_bf humoral_bf immune_bf responses_bf chickens_bf inactivated_bf ND_bf AI_bf vaccines_bf ._bf
322,The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,ginseng stem-and-leaf saponins,inactivated ND vaccines,No interaction,The_bf objective_bf study_bf evaluate_bf effect_bf oral_bf administration_bf ginseng_bf stem-and-leaf_bf saponins_bf (GSLS)_bf humoral_bf immune_bf responses_bf chickens_bf inactivated_bf ND_bf AI_bf vaccines_bf ._bf
323,The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,ginseng stem-and-leaf saponins,inactivated AI vaccines,No interaction,The_bf objective_bf study_bf evaluate_bf effect_bf oral_bf administration_bf ginseng_bf stem-and-leaf_bf saponins_bf (GSLS)_bf humoral_bf immune_bf responses_bf chickens_bf inactivated_bf ND_bf AI_bf vaccines_bf ._bf
324,The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,GSLS,inactivated ND vaccines,No interaction,The_bf objective_bf study_bf evaluate_bf effect_bf oral_bf administration_bf ginseng_bf stem-and-leaf_bf saponins_bf (GSLS)_bf humoral_bf immune_bf responses_bf chickens_bf inactivated_bf ND_bf AI_bf vaccines_bf ._bf
325,The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,GSLS,inactivated AI vaccines,No interaction,The_bf objective_bf study_bf evaluate_bf effect_bf oral_bf administration_bf ginseng_bf stem-and-leaf_bf saponins_bf (GSLS)_bf humoral_bf immune_bf responses_bf chickens_bf inactivated_bf ND_bf AI_bf vaccines_bf ._bf
326,The objective of this study was to evaluate the effect of oral administration of ginseng stem-and-leaf saponins (GSLS) on the humoral immune responses of chickens to inactivated ND and AI vaccines. ,inactivated ND vaccines,inactivated AI vaccines,No interaction,The_bf objective_bf study_bf evaluate_bf effect_bf oral_bf administration_bf ginseng_bf stem-and-leaf_bf saponins_bf (GSLS)_bf humoral_bf immune_bf responses_bf chickens_bf inactivated_bf ND_bf AI_bf vaccines_bf ._bf
327,"In experiment 1, oral administration of GSLS at a dose of 5 mg/kg of BW for 7 d on the immune response in chickens intramuscularly injected with inactivated ND vaccine was evaluated. ",GSLS,inactivated ND vaccine,No interaction,"In_bf experiment_bf 1_bf ,_bf oral_bf administration_bf DRUG dose_be 5_be mg/kg_be BW_be 7_be immune_be response_be chickens_be intramuscularly_be injected_be inactivated_be ND_be vaccine_be evaluated_be ._be"
328,"In experiment 2, the same regimen of GSLS was administered to chickens inoculated with inactivated AI vaccines, and an enhanced serum antibody response to AI vaccination was also observed. ",GSLS,inactivated AI vaccines,effect,"In_bf experiment_bf 2_bf ,_bf regimen_bf DRUG administered_be chickens_be inoculated_be inactivated_be AI_be vaccines_be ,_be enhanced_be serum_be antibody_be response_be AI_be vaccination_be also_be observed_be ._be"
329,"Considering the safety of GSLS, because no adverse effect was found throughout the experiments, GSLS may be a promising oral adjuvant to improve immunization in poultry.",GSLS,GSLS,No interaction,"Considering_bf safety_bf DRUG ,_be adverse_be effect_be found_be throughout_be experiments_be ,_be DRUG may_af promising_af oral_af adjuvant_af improve_af immunization_af poultry_af ._af"
330,"Interaction of dacarbazine and imexon, in vitro and in vivo, in human A375 melanoma cells.
",dacarbazine,imexon,No interaction,"Interaction_bf DRUG OTHER_DRUG ,_af vitro_af vivo_af ,_af human_af A375_af melanoma_af cells_af ._af"
331,"We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.",dacarbazine,DTIC,No interaction,"We_bf evaluated_bf mechanisms_bf interaction_bf alkyating_bf agent_bf DRUG (DTIC)_be pro-oxidant_be ,_be imexon_be ,_be human_be A375_be melanoma_be cell_be line_be ._be"
332,"We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.",dacarbazine,imexon,No interaction,"We_bf evaluated_bf mechanisms_bf interaction_bf alkyating_bf agent_bf DRUG (DTIC)_be pro-oxidant_be ,_be OTHER_DRUG ,_af human_af A375_af melanoma_af cell_af line_af ._af"
333,"We evaluated mechanisms of interaction between the alkyating agent dacarbazine (DTIC) and the pro-oxidant, imexon, in the human A375 melanoma cell line.",DTIC,imexon,No interaction,"We_bf evaluated_bf mechanisms_bf interaction_bf alkyating_bf agent_bf dacarbazine_bf (DTIC)_bf pro-oxidant_bf ,_bf OTHER_DRUG ,_be human_be A375_be melanoma_be cell_be line_be ._be"
334,"The effect of DTIC and imexon, alone and in combination, was evaluated for growth inhibition (MTT), radiolabeled drug uptake, cellular thiol content (HPLC), and DNA strand breaks (Comet assay). ",DTIC,imexon,No interaction,"The_bf effect_bf DRUG OTHER_DRUG ,_af alone_af combination_af ,_af evaluated_af growth_af inhibition_af (MTT)_af ,_af radiolabeled_af drug_af uptake_af ,_af cellular_af thiol_af content_af (HPLC)_af ,_af DNA_af strand_af breaks_af (Comet_af assay)_af ._af"
335,There was a >75% reduction in cellular glutathione and cysteine with imexon but not DTIC. ,imexon,DTIC,No interaction,There_bf >75%_bf reduction_bf cellular_bf glutathione_bf cysteine_bf DRUG OTHER_DRUG ._af
336,Imexon and dacarbazine show additive effects in vitro but not in vivo in human A375 melanoma cells.,Imexon,dacarbazine,effect,DRUG OTHER_DRUG show_af additive_af effects_af vitro_af vivo_af human_af A375_af melanoma_af cells_af ._af
337,"The aim of the present study was to investigate whether HB-EGF is a therapeutic target for T-ALL, and to further elucidate the antitumor effects of a specific inhibitor of HB-EGF, cross-reacting material 197 (CRM197). ",cross-reacting material 197,CRM197,No interaction,"The_bf aim_bf present_bf study_bf investigate_bf whether_bf HB-EGF_bf therapeutic_bf target_bf T-ALL_bf ,_bf elucidate_bf antitumor_bf effects_bf specific_bf inhibitor_bf HB-EGF_bf ,_bf cross-reacting_bf material_bf 197_bf (CRM197)_bf ._bf"
338,"We elucidated the expression of HB-EGF in T-ALL cell lines, and evaluated the effect of CRM197 on these cells alone or in combination with anticancer agent. ",CRM197,anticancer agent,No interaction,"We_bf elucidated_bf expression_bf HB-EGF_bf T-ALL_bf cell_bf lines_bf ,_bf evaluated_bf effect_bf DRUG cells_be alone_be combination_be anticancer_be agent_be ._be"
339,"CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ",CRM197,CRM197,No interaction,"DRUG induced_be apoptosis_be ,_be furthermore_be ,_be combination_be DRUG plus_af doxorubicin_af enhanced_af cytotoxicity_af T-ALL_af cell_af line_af ._af"
340,"CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ",CRM197,doxorubicin,No interaction,"DRUG induced_be apoptosis_be ,_be furthermore_be ,_be combination_be DRUG plus_af OTHER_DRUG enhanced_af cytotoxicity_af T-ALL_af cell_af line_af ._af"
341,"CRM197 induced apoptosis, and furthermore, the combination of CRM197 plus doxorubicin enhanced cytotoxicity in a T-ALL cell line. ",CRM197,doxorubicin,effect,"DRUG induced_be apoptosis_be ,_be furthermore_be ,_be combination_be DRUG plus_af OTHER_DRUG enhanced_af cytotoxicity_af T-ALL_af cell_af line_af ._af"
342,"Ephedrine enhances the antinociceptive effect of dexmedetomidine in mice.
",Ephedrine,dexmedetomidine,effect,DRUG enhances_be antinociceptive_be effect_be OTHER_DRUG mice_af ._af
343,The purpose of this study was to evaluate whether the psychostimulant drug ephedrine has any effect on dexmedetomidine-induced antinociception and locomotor inhibitor activity in mice in acute application.,ephedrine,dexmedetomidine,No interaction,The_bf purpose_bf study_bf evaluate_bf whether_bf psychostimulant_bf drug_bf DRUG effect_be dexmedetomidine-induced_be antinociception_be locomotor_be inhibitor_be activity_be mice_be acute_be application_be ._be
344,"saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",ephedrine,dexmedetomidine,No interaction,"saline_bf +_bf saline_bf ,_bf DRUG (10_be mg/kg)_be +_be saline_be ,_be saline_be +_be OTHER_DRUG (15_af g/kg)_af DRUG (10_af mg/kg)_af +_af OTHER_DRUG (15_af g/kg)_af ,_af intraperitoneally_af ,_af 30_af min_af hot_af plate_af holed_af open_af field_af tests_af ._af"
345,"saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",ephedrine,ephedrine,No interaction,"saline_bf +_bf saline_bf ,_bf DRUG (10_be mg/kg)_be +_be saline_be ,_be saline_be +_be dexmedetomidine_be (15_be g/kg)_be DRUG (10_af mg/kg)_af +_af dexmedetomidine_af (15_af g/kg)_af ,_af intraperitoneally_af ,_af 30_af min_af hot_af plate_af holed_af open_af field_af tests_af ._af"
346,"saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",ephedrine,dexmedetomidine,No interaction,"saline_bf +_bf saline_bf ,_bf DRUG (10_be mg/kg)_be +_be saline_be ,_be saline_be +_be OTHER_DRUG (15_af g/kg)_af DRUG (10_af mg/kg)_af +_af OTHER_DRUG (15_af g/kg)_af ,_af intraperitoneally_af ,_af 30_af min_af hot_af plate_af holed_af open_af field_af tests_af ._af"
347,"saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",dexmedetomidine,ephedrine,No interaction,"saline_bf +_bf saline_bf ,_bf OTHER_DRUG (10_be mg/kg)_be +_be saline_be ,_be saline_be +_be DRUG (15_af g/kg)_af OTHER_DRUG (10_af mg/kg)_af +_af DRUG (15_af g/kg)_af ,_af intraperitoneally_af ,_af 30_af min_af hot_af plate_af holed_af open_af field_af tests_af ._af"
348,"saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",dexmedetomidine,dexmedetomidine,No interaction,"saline_bf +_bf saline_bf ,_bf ephedrine_bf (10_bf mg/kg)_bf +_bf saline_bf ,_bf saline_bf +_bf DRUG (15_be g/kg)_be ephedrine_be (10_be mg/kg)_be +_be DRUG (15_af g/kg)_af ,_af intraperitoneally_af ,_af 30_af min_af hot_af plate_af holed_af open_af field_af tests_af ._af"
349,"saline + saline, ephedrine (10   mg/kg) + saline, saline + dexmedetomidine (15     g/kg) and ephedrine (10   mg/kg) + dexmedetomidine (15     g/kg), intraperitoneally, 30 min before hot plate or holed open field tests. ",ephedrine,dexmedetomidine,No interaction,"saline_bf +_bf saline_bf ,_bf DRUG (10_be mg/kg)_be +_be saline_be ,_be saline_be +_be OTHER_DRUG (15_af g/kg)_af DRUG (10_af mg/kg)_af +_af OTHER_DRUG (15_af g/kg)_af ,_af intraperitoneally_af ,_af 30_af min_af hot_af plate_af holed_af open_af field_af tests_af ._af"
350,"In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ",dexmedetomidine,ephedrine,effect,"In_bf hot_bf plate_bf test_bf mice_bf ,_bf co-administration_bf 15_bf g/kg_bf DRUG 10_be mg/kg_be OTHER_DRUG intraperitoneally_af enhanced_af ,_af also_af prolonged_af duration_af antinociception_af induced_af DRUG ._af"
351,"In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ",dexmedetomidine,dexmedetomidine,No interaction,"In_bf hot_bf plate_bf test_bf mice_bf ,_bf co-administration_bf 15_bf g/kg_bf DRUG 10_be mg/kg_be ephedrine_be intraperitoneally_be enhanced_be ,_be also_be prolonged_be duration_be antinociception_be induced_be DRUG ._af"
352,"In the hot plate test in mice, co-administration of 15     g/kg dexmedetomidine with 10   mg/kg ephedrine intraperitoneally not only enhanced, but also prolonged the duration of antinociception induced by dexmedetomidine. ",ephedrine,dexmedetomidine,No interaction,"In_bf hot_bf plate_bf test_bf mice_bf ,_bf co-administration_bf 15_bf g/kg_bf OTHER_DRUG 10_be mg/kg_be DRUG intraperitoneally_af enhanced_af ,_af also_af prolonged_af duration_af antinociception_af induced_af OTHER_DRUG ._af"
353,"At the same time, the locomotor inhibitory effect of dexmedetomidine was counteracted by ephedrine. ",dexmedetomidine,ephedrine,effect,"At_bf time_bf ,_bf locomotor_bf inhibitory_bf effect_bf DRUG counteracted_be OTHER_DRUG ._af"
354,"We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.",dexmedetomidine,ephedrine,effect,"We_bf concluded_bf combined_bf administration_bf DRUG OTHER_DRUG may_af beneficial_af effects_af treatment_af pain_af without_af causing_af sedation_af ,_af limits_af use_af DRUG analgesic_af humans_af ._af"
355,"We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.",dexmedetomidine,dexmedetomidine,No interaction,"We_bf concluded_bf combined_bf administration_bf DRUG ephedrine_be may_be beneficial_be effects_be treatment_be pain_be without_be causing_be sedation_be ,_be limits_be use_be DRUG analgesic_af humans_af ._af"
356,"We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.",dexmedetomidine,analgesic,No interaction,"We_bf concluded_bf combined_bf administration_bf DRUG ephedrine_be may_be beneficial_be effects_be treatment_be pain_be without_be causing_be sedation_be ,_be limits_be use_be DRUG OTHER_DRUG humans_af ._af"
357,"We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.",ephedrine,dexmedetomidine,No interaction,"We_bf concluded_bf combined_bf administration_bf OTHER_DRUG DRUG may_af beneficial_af effects_af treatment_af pain_af without_af causing_af sedation_af ,_af limits_af use_af OTHER_DRUG analgesic_af humans_af ._af"
358,"We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.",ephedrine,analgesic,No interaction,"We_bf concluded_bf combined_bf administration_bf dexmedetomidine_bf DRUG may_be beneficial_be effects_be treatment_be pain_be without_be causing_be sedation_be ,_be limits_be use_be dexmedetomidine_be OTHER_DRUG humans_af ._af"
359,"We concluded that the combined administration of dexmedetomidine with ephedrine may have beneficial effects in the treatment of pain without causing sedation, which limits the use of dexmedetomidine as an analgesic in humans.",dexmedetomidine,analgesic,No interaction,"We_bf concluded_bf combined_bf administration_bf DRUG ephedrine_be may_be beneficial_be effects_be treatment_be pain_be without_be causing_be sedation_be ,_be limits_be use_be DRUG OTHER_DRUG humans_af ._af"
360,[Efficacy of fixed combination amlodipine/valsartan in hospitalized patients with hypertensive disease],amlodipine,valsartan,No interaction,[Efficacy_bf fixed_bf combination_bf amlodipine/valsartan_bf hospitalized_bf patients_bf hypertensive_bf disease]_bf
361,Efficacy and tolerability of fixed amlodipine/valsartan combination was studied in 86 patients with hypertensive disease hospitalized in departments of general internal medicine or cardiology. ,amlodipine,valsartan,No interaction,Efficacy_bf tolerability_bf fixed_bf amlodipine/valsartan_bf combination_bf studied_bf 86_bf patients_bf hypertensive_bf disease_bf hospitalized_bf departments_bf general_bf internal_bf medicine_bf cardiology_bf ._bf
362,All patients had indications for antihypertensive therapy and were randomized either to fixed combination amlodipine/valsartan (n=43) or to therapy which corresponded to the hospital formulary (n=43). ,amlodipine,valsartan,No interaction,All_bf patients_bf indications_bf antihypertensive_bf therapy_bf randomized_bf either_bf fixed_bf combination_bf amlodipine/valsartan_bf (n=43)_bf therapy_bf corresponded_bf hospital_bf formulary_bf (n=43)_bf ._bf
363,Rate of achievement of target BP with fixed combination amlodipine/valsartan (93%) was comparable with that on traditional therapy (90%). ,amlodipine,valsartan,No interaction,Rate_bf achievement_bf target_bf BP_bf fixed_bf combination_bf amlodipine/valsartan_bf (93%)_bf comparable_bf traditional_bf therapy_bf (90%)_bf ._bf
364,"But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",amlodipine,valsartan,effect,"But_bf use_bf fixed_bf combination_bf amlodipine/valsartan_bf compared_bf traditional_bf therapy_bf associated_bf lower_bf clinical_bf self_bf measured_bf BP_bf ,_bf quicker_bf achievement_bf target_bf BP_bf (5_bf ._bf 8+/-2_bf ._bf 3_bf 9_bf ._bf 2+/-1_bf ._bf 8_bf days_bf ,_bf respectively_bf ,_bf 0_bf ._bf 05)_bf ,_bf lesser_bf number_bf antihypertensive_bf drugs_bf (2_bf ._bf 5+/-0_bf ._bf 6_bf 3_bf ._bf 0+/-0_bf ._bf 9_bf days_bf ,_bf respectively)_bf ,_bf lower_bf rate_bf concealed_bf inefficacy_bf treatment_bf (12_bf 31%_bf ,_bf respectively_bf ,_bf 0_bf ._bf 05)_bf ._bf"
365,"But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",amlodipine,antihypertensive drugs,No interaction,"But_bf use_bf fixed_bf combination_bf amlodipine/valsartan_bf compared_bf traditional_bf therapy_bf associated_bf lower_bf clinical_bf self_bf measured_bf BP_bf ,_bf quicker_bf achievement_bf target_bf BP_bf (5_bf ._bf 8+/-2_bf ._bf 3_bf 9_bf ._bf 2+/-1_bf ._bf 8_bf days_bf ,_bf respectively_bf ,_bf 0_bf ._bf 05)_bf ,_bf lesser_bf number_bf antihypertensive_bf drugs_bf (2_bf ._bf 5+/-0_bf ._bf 6_bf 3_bf ._bf 0+/-0_bf ._bf 9_bf days_bf ,_bf respectively)_bf ,_bf lower_bf rate_bf concealed_bf inefficacy_bf treatment_bf (12_bf 31%_bf ,_bf respectively_bf ,_bf 0_bf ._bf 05)_bf ._bf"
366,"But the use of fixed combination amlodipine/valsartan compared with traditional therapy was associated with lower clinical and self measured BP, quicker achievement of target BP (5.8+/-2.3 and 9.2+/-1.8 days, respectively, 0.05), lesser number of antihypertensive drugs (2.5+/-0.6 and 3.0+/-0.9 days, respectively), lower rate of concealed inefficacy of treatment (12 and 31%, respectively, 0.05). ",valsartan,antihypertensive drugs,No interaction,"But_bf use_bf fixed_bf combination_bf amlodipine/valsartan_bf compared_bf traditional_bf therapy_bf associated_bf lower_bf clinical_bf self_bf measured_bf BP_bf ,_bf quicker_bf achievement_bf target_bf BP_bf (5_bf ._bf 8+/-2_bf ._bf 3_bf 9_bf ._bf 2+/-1_bf ._bf 8_bf days_bf ,_bf respectively_bf ,_bf 0_bf ._bf 05)_bf ,_bf lesser_bf number_bf antihypertensive_bf drugs_bf (2_bf ._bf 5+/-0_bf ._bf 6_bf 3_bf ._bf 0+/-0_bf ._bf 9_bf days_bf ,_bf respectively)_bf ,_bf lower_bf rate_bf concealed_bf inefficacy_bf treatment_bf (12_bf 31%_bf ,_bf respectively_bf ,_bf 0_bf ._bf 05)_bf ._bf"
367,"We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.",amlodipine,valsartan,effect,"We_bf demonstrated_bf appropriateness_bf inhospital_bf administration_bf fixed_bf amlodipine/valsartan_bf combination_bf approach_bf allowing_bf achieve_bf target_bf BP_bf shorter_bf time_bf ,_bf use_bf fewer_bf antihypertensive_bf drugs_bf ,_bf diminishing_bf concealed_bf inefficacy_bf treatment_bf ._bf"
368,"We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.",amlodipine,antihypertensive drugs,No interaction,"We_bf demonstrated_bf appropriateness_bf inhospital_bf administration_bf fixed_bf amlodipine/valsartan_bf combination_bf approach_bf allowing_bf achieve_bf target_bf BP_bf shorter_bf time_bf ,_bf use_bf fewer_bf antihypertensive_bf drugs_bf ,_bf diminishing_bf concealed_bf inefficacy_bf treatment_bf ._bf"
369,"We have demonstrated appropriateness of inhospital administration of fixed amlodipine/valsartan combination as an approach allowing to achieve target BP in shorter time, with the use of fewer antihypertensive drugs, and diminishing concealed inefficacy of treatment.",valsartan,antihypertensive drugs,No interaction,"We_bf demonstrated_bf appropriateness_bf inhospital_bf administration_bf fixed_bf amlodipine/valsartan_bf combination_bf approach_bf allowing_bf achieve_bf target_bf BP_bf shorter_bf time_bf ,_bf use_bf fewer_bf antihypertensive_bf drugs_bf ,_bf diminishing_bf concealed_bf inefficacy_bf treatment_bf ._bf"
370,Ticagrelor (Brilinta)--better than clopidogrel (Plavix),Ticagrelor,Brilinta,No interaction,DRUG (Brilinta)--better_be clopidogrel_be (Plavix)_be
371,Ticagrelor (Brilinta)--better than clopidogrel (Plavix),Ticagrelor,clopidogrel,No interaction,DRUG (Brilinta)--better_be OTHER_DRUG (Plavix)_af
372,Ticagrelor (Brilinta)--better than clopidogrel (Plavix),Ticagrelor,Plavix,No interaction,DRUG (Brilinta)--better_be clopidogrel_be (Plavix)_be
373,Ticagrelor (Brilinta)--better than clopidogrel (Plavix),Brilinta,clopidogrel,No interaction,Ticagrelor_bf (Brilinta)--better_bf OTHER_DRUG (Plavix)_be
374,Ticagrelor (Brilinta)--better than clopidogrel (Plavix),Brilinta,Plavix,No interaction,Ticagrelor_bf (Brilinta)--better_bf clopidogrel_bf (Plavix)_bf
375,Ticagrelor (Brilinta)--better than clopidogrel (Plavix),clopidogrel,Plavix,No interaction,Ticagrelor_bf (Brilinta)--better_bf DRUG (Plavix)_be
376,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",ticagrelor,Brilinta,No interaction,"The_bf FDA_bf approved_bf DRUG (Brilinta-AstraZeneca)_be ,_be oral_be antiplatelet_be drug_be ,_be use_be low-dose_be aspirin_be reduce_be rate_be thrombotic_be cardiovascular_be events_be patients_be acute_be coronary_be syndrome_be (ACS)_be ._be"
377,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",ticagrelor,antiplatelet drug,No interaction,"The_bf FDA_bf approved_bf DRUG (Brilinta-AstraZeneca)_be ,_be oral_be antiplatelet_be drug_be ,_be use_be low-dose_be aspirin_be reduce_be rate_be thrombotic_be cardiovascular_be events_be patients_be acute_be coronary_be syndrome_be (ACS)_be ._be"
378,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",ticagrelor,aspirin,effect,"The_bf FDA_bf approved_bf DRUG (Brilinta-AstraZeneca)_be ,_be oral_be antiplatelet_be drug_be ,_be use_be low-dose_be OTHER_DRUG reduce_af rate_af thrombotic_af cardiovascular_af events_af patients_af acute_af coronary_af syndrome_af (ACS)_af ._af"
379,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",Brilinta,antiplatelet drug,No interaction,"The_bf FDA_bf approved_bf ticagrelor_bf (Brilinta-AstraZeneca)_bf ,_bf oral_bf antiplatelet_bf drug_bf ,_bf use_bf low-dose_bf aspirin_bf reduce_bf rate_bf thrombotic_bf cardiovascular_bf events_bf patients_bf acute_bf coronary_bf syndrome_bf (ACS)_bf ._bf"
380,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",Brilinta,aspirin,effect,"The_bf FDA_bf approved_bf ticagrelor_bf (Brilinta-AstraZeneca)_bf ,_bf oral_bf antiplatelet_bf drug_bf ,_bf use_bf low-dose_bf OTHER_DRUG reduce_be rate_be thrombotic_be cardiovascular_be events_be patients_be acute_be coronary_be syndrome_be (ACS)_be ._be"
381,"The FDA has approved ticagrelor (Brilinta-AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). ",antiplatelet drug,aspirin,No interaction,"The_bf FDA_bf approved_bf ticagrelor_bf (Brilinta-AstraZeneca)_bf ,_bf oral_bf antiplatelet_bf drug_bf ,_bf use_bf low-dose_bf OTHER_DRUG reduce_be rate_be thrombotic_be cardiovascular_be events_be patients_be acute_be coronary_be syndrome_be (ACS)_be ._be"
382,It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ,clopidogrel,Plavix,No interaction,It_bf compete_bf DRUG (Plavix)_be prasugrel_be (Effient)_be use_be ._be
383,It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ,clopidogrel,prasugrel,No interaction,It_bf compete_bf DRUG (Plavix)_be OTHER_DRUG (Effient)_af use_af ._af
384,It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ,clopidogrel,Effient,No interaction,It_bf compete_bf DRUG (Plavix)_be prasugrel_be (Effient)_be use_be ._be
385,It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ,Plavix,prasugrel,No interaction,It_bf compete_bf clopidogrel_bf (Plavix)_bf OTHER_DRUG (Effient)_be use_be ._be
386,It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ,Plavix,Effient,No interaction,It_bf compete_bf clopidogrel_bf (Plavix)_bf prasugrel_bf (Effient)_bf use_bf ._bf
387,It will compete with clopidogrel (Plavix) and prasugrel (Effient) for such use. ,prasugrel,Effient,No interaction,It_bf compete_bf clopidogrel_bf (Plavix)_bf DRUG (Effient)_be use_be ._be
388,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,abacavir,lamivudine,No interaction,Pharmacokinetic_bf properties_bf DRUG altered_be addition_be either_be OTHER_DRUG zidovudine_af combination_af OTHER_DRUG zidovudine_af ._af
389,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,abacavir,zidovudine,No interaction,Pharmacokinetic_bf properties_bf DRUG altered_be addition_be either_be lamivudine_be OTHER_DRUG combination_af lamivudine_af OTHER_DRUG ._af
390,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,abacavir,lamivudine,No interaction,Pharmacokinetic_bf properties_bf DRUG altered_be addition_be either_be OTHER_DRUG zidovudine_af combination_af OTHER_DRUG zidovudine_af ._af
391,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,abacavir,zidovudine,No interaction,Pharmacokinetic_bf properties_bf DRUG altered_be addition_be either_be lamivudine_be OTHER_DRUG combination_af lamivudine_af OTHER_DRUG ._af
392,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,lamivudine,zidovudine,No interaction,Pharmacokinetic_bf properties_bf abacavir_bf altered_bf addition_bf either_bf DRUG OTHER_DRUG combination_af DRUG OTHER_DRUG ._af
393,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,lamivudine,lamivudine,No interaction,Pharmacokinetic_bf properties_bf abacavir_bf altered_bf addition_bf either_bf DRUG zidovudine_be combination_be DRUG zidovudine_af ._af
394,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,lamivudine,zidovudine,No interaction,Pharmacokinetic_bf properties_bf abacavir_bf altered_bf addition_bf either_bf DRUG OTHER_DRUG combination_af DRUG OTHER_DRUG ._af
395,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,zidovudine,lamivudine,No interaction,Pharmacokinetic_bf properties_bf abacavir_bf altered_bf addition_bf either_bf OTHER_DRUG DRUG combination_af OTHER_DRUG DRUG ._af
396,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,zidovudine,zidovudine,No interaction,Pharmacokinetic_bf properties_bf abacavir_bf altered_bf addition_bf either_bf lamivudine_bf DRUG combination_be lamivudine_be DRUG ._af
397,Pharmacokinetic properties of abacavir were not altered by the addition of either lamivudine or zidovudine or the combination of lamivudine and zidovudine. ,lamivudine,zidovudine,No interaction,Pharmacokinetic_bf properties_bf abacavir_bf altered_bf addition_bf either_bf DRUG OTHER_DRUG combination_af DRUG OTHER_DRUG ._af
398,No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. ,lamivudine,zidovudine,No interaction,No_bf clinically_bf significant_bf changes_bf DRUG OTHER_DRUG pharmacokinetics_af observed_af following_af concomitant_af administration_af abacavir_af ._af
399,No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. ,lamivudine,abacavir,No interaction,No_bf clinically_bf significant_bf changes_bf DRUG zidovudine_be pharmacokinetics_be observed_be following_be concomitant_be administration_be OTHER_DRUG ._af
400,No clinically significant changes to lamivudine or zidovudine pharmacokinetics were observed following concomitant administration of abacavir. ,zidovudine,abacavir,No interaction,No_bf clinically_bf significant_bf changes_bf lamivudine_bf DRUG pharmacokinetics_be observed_be following_be concomitant_be administration_be OTHER_DRUG ._af
401,Abacavir has no effect on the pharmacokinetic properties of ethanol. ,Abacavir,ethanol,No interaction,DRUG effect_be pharmacokinetic_be properties_be OTHER_DRUG ._af
402,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,Ethanol,abacavir,mechanism,DRUG decreases_be elimination_be OTHER_DRUG causing_af increase_af overall_af exposure_af ._af The_af addition_af methadone_af clinically_af significant_af effect_af pharmacokinetic_af properties_af OTHER_DRUG ._af
403,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,Ethanol,methadone,No interaction,DRUG decreases_be elimination_be abacavir_be causing_be increase_be overall_be exposure_be ._be The_be addition_be OTHER_DRUG clinically_af significant_af effect_af pharmacokinetic_af properties_af abacavir_af ._af
404,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,Ethanol,abacavir,No interaction,DRUG decreases_be elimination_be OTHER_DRUG causing_af increase_af overall_af exposure_af ._af The_af addition_af methadone_af clinically_af significant_af effect_af pharmacokinetic_af properties_af OTHER_DRUG ._af
405,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,abacavir,methadone,No interaction,Ethanol_bf decreases_bf elimination_bf DRUG causing_be increase_be overall_be exposure_be ._be The_be addition_be OTHER_DRUG clinically_af significant_af effect_af pharmacokinetic_af properties_af DRUG ._af
406,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,abacavir,abacavir,No interaction,Ethanol_bf decreases_bf elimination_bf DRUG causing_be increase_be overall_be exposure_be ._be The_be addition_be methadone_be clinically_be significant_be effect_be pharmacokinetic_be properties_be DRUG ._af
407,Ethanol decreases the elimination of abacavir causing an increase in overall exposure . The addition of methadone has no clinically significant effect on the pharmacokinetic properties of abacavir. ,methadone,abacavir,No interaction,Ethanol_bf decreases_bf elimination_bf OTHER_DRUG causing_be increase_be overall_be exposure_be ._be The_be addition_be DRUG clinically_af significant_af effect_af pharmacokinetic_af properties_af OTHER_DRUG ._af
408,"In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ",methadone,ZIAGEN,mechanism,"In_bf study_bf 11_bf HIV-infected_bf patients_bf receiving_bf methadone-maintenance_bf therapy_bf (40_bf mg_bf 90_bf mg_bf daily)_bf 600_bf mg_bf OTHER_DRUG twice_be daily_be (twice_be currently_be recommended_be dose)_be ,_be oral_be DRUG clearance_af increased_af 22%_af (90%_af CI_af 6%_af 42%)_af ._af"
409,"In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ",methadone,methadone,No interaction,"In_bf study_bf 11_bf HIV-infected_bf patients_bf receiving_bf methadone-maintenance_bf therapy_bf (40_bf mg_bf 90_bf mg_bf daily)_bf 600_bf mg_bf ZIAGEN_bf twice_bf daily_bf (twice_bf currently_bf recommended_bf dose)_bf ,_bf oral_bf DRUG clearance_be increased_be 22%_be (90%_be CI_be 6%_be 42%)_be ._be"
410,"In a study of 11 HIV-infected patients receiving methadone-maintenance therapy (40 mg and 90 mg daily) with 600 mg of ZIAGEN twice daily (twice the currently recommended dose), oral methadone clearance increased 22% (90% CI 6% to 42%). ",ZIAGEN,methadone,No interaction,"In_bf study_bf 11_bf HIV-infected_bf patients_bf receiving_bf methadone-maintenance_bf therapy_bf (40_bf mg_bf 90_bf mg_bf daily)_bf 600_bf mg_bf DRUG twice_be daily_be (twice_be currently_be recommended_be dose)_be ,_be oral_be OTHER_DRUG clearance_af increased_af 22%_af (90%_af CI_af 6%_af 42%)_af ._af"
411,Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ,Cholestyramine,cholestyramine,No interaction,Cholestyramine:_bf Concomitant_bf DRUG administration_be decreased_be mean_be AUC_be total_be ezetimibe_be approximately_be 55%_be ._be
412,Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ,Cholestyramine,ezetimibe,No interaction,Cholestyramine:_bf Concomitant_bf DRUG administration_be decreased_be mean_be AUC_be total_be OTHER_DRUG approximately_af 55%_af ._af
413,Cholestyramine: Concomitant cholestyramine administration decreased the mean AUC of total ezetimibe approximately 55%. ,cholestyramine,ezetimibe,mechanism,Cholestyramine:_bf Concomitant_bf DRUG administration_be decreased_be mean_be AUC_be total_be OTHER_DRUG approximately_af 55%_af ._af
414,The incremental LDL-C reduction due to adding ezetimibe to cholestyramine may be reduced by this interaction. ,ezetimibe,cholestyramine,effect,The_bf incremental_bf LDL-C_bf reduction_bf due_bf adding_bf DRUG OTHER_DRUG may_af reduced_af interaction_af ._af
415,Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. ,Fibrates,ezetimibe,No interaction,Fibrates:_bf The_bf safety_bf effectiveness_bf OTHER_DRUG administered_be DRUG established_af ._af
416,Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. ,Fibrates,fibrates,No interaction,Fibrates:_bf The_bf safety_bf effectiveness_bf ezetimibe_bf administered_bf DRUG established_be ._be
417,Fibrates: The safety and effectiveness of ezetimibe administered with fibrates have not been established. ,ezetimibe,fibrates,No interaction,Fibrates:_bf The_bf safety_bf effectiveness_bf DRUG administered_be OTHER_DRUG established_af ._af
418,Co-administration of ZETIA with fibrates is not recommended until use in patients is studied. ,ZETIA,fibrates,advise,Co-administration_bf DRUG OTHER_DRUG recommended_af use_af patients_af studied_af ._af
419,"Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ",Fenofibrate,fenofibrate,No interaction,"Fenofibrate:_bf In_bf pharmacokinetic_bf study_bf ,_bf concomitant_bf DRUG administration_be increased_be total_be ezetimibe_be concentrations_be approximately_be 1_be ._be 5-fold_be ._be"
420,"Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ",Fenofibrate,ezetimibe,No interaction,"Fenofibrate:_bf In_bf pharmacokinetic_bf study_bf ,_bf concomitant_bf DRUG administration_be increased_be total_be OTHER_DRUG concentrations_af approximately_af 1_af ._af 5-fold_af ._af"
421,"Fenofibrate: In a pharmacokinetic study, concomitant fenofibrate administration increased total ezetimibe concentrations approximately 1.5-fold. ",fenofibrate,ezetimibe,mechanism,"Fenofibrate:_bf In_bf pharmacokinetic_bf study_bf ,_bf concomitant_bf DRUG administration_be increased_be total_be OTHER_DRUG concentrations_af approximately_af 1_af ._af 5-fold_af ._af"
422,"Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. ",Gemfibrozil,gemfibrozil,No interaction,"Gemfibrozil:_bf In_bf pharmacokinetic_bf study_bf ,_bf concomitant_bf DRUG administration_be increased_be total_be ezetimibe_be concentrations_be approximately_be 1_be ._be 7-fold_be ._be"
423,"Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. ",Gemfibrozil,ezetimibe,No interaction,"Gemfibrozil:_bf In_bf pharmacokinetic_bf study_bf ,_bf concomitant_bf DRUG administration_be increased_be total_be OTHER_DRUG concentrations_af approximately_af 1_af ._af 7-fold_af ._af"
424,"Gemfibrozil: In a pharmacokinetic study, concomitant gemfibrozil administration increased total ezetimibe concentrations approximately 1.7-fold. ",gemfibrozil,ezetimibe,No interaction,"Gemfibrozil:_bf In_bf pharmacokinetic_bf study_bf ,_bf concomitant_bf DRUG administration_be increased_be total_be OTHER_DRUG concentrations_af approximately_af 1_af ._af 7-fold_af ._af"
425,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",HMG-CoA reductase inhibitors,ezetimibe,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf OTHER_DRUG co-administered_be atorvastatin_be ,_be simvastatin_be ,_be pravastatin_be ,_be lovastatin_be ,_be fluvastatin_be ._be"
426,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",HMG-CoA reductase inhibitors,atorvastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf OTHER_DRUG ,_be simvastatin_be ,_be pravastatin_be ,_be lovastatin_be ,_be fluvastatin_be ._be"
427,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",HMG-CoA reductase inhibitors,simvastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf atorvastatin_bf ,_bf OTHER_DRUG ,_be pravastatin_be ,_be lovastatin_be ,_be fluvastatin_be ._be"
428,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",HMG-CoA reductase inhibitors,pravastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf atorvastatin_bf ,_bf simvastatin_bf ,_bf OTHER_DRUG ,_be lovastatin_be ,_be fluvastatin_be ._be"
429,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",HMG-CoA reductase inhibitors,lovastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf atorvastatin_bf ,_bf simvastatin_bf ,_bf pravastatin_bf ,_bf OTHER_DRUG ,_be fluvastatin_be ._be"
430,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",HMG-CoA reductase inhibitors,fluvastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf atorvastatin_bf ,_bf simvastatin_bf ,_bf pravastatin_bf ,_bf lovastatin_bf ,_bf OTHER_DRUG ._be"
431,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",ezetimibe,atorvastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf DRUG co-administered_be OTHER_DRUG ,_af simvastatin_af ,_af pravastatin_af ,_af lovastatin_af ,_af fluvastatin_af ._af"
432,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",ezetimibe,simvastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf DRUG co-administered_be atorvastatin_be ,_be OTHER_DRUG ,_af pravastatin_af ,_af lovastatin_af ,_af fluvastatin_af ._af"
433,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",ezetimibe,pravastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf DRUG co-administered_be atorvastatin_be ,_be simvastatin_be ,_be OTHER_DRUG ,_af lovastatin_af ,_af fluvastatin_af ._af"
434,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",ezetimibe,lovastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf DRUG co-administered_be atorvastatin_be ,_be simvastatin_be ,_be pravastatin_be ,_be OTHER_DRUG ,_af fluvastatin_af ._af"
435,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",ezetimibe,fluvastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf DRUG co-administered_be atorvastatin_be ,_be simvastatin_be ,_be pravastatin_be ,_be lovastatin_be ,_be OTHER_DRUG ._af"
436,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",atorvastatin,simvastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf DRUG ,_be OTHER_DRUG ,_af pravastatin_af ,_af lovastatin_af ,_af fluvastatin_af ._af"
437,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",atorvastatin,pravastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf DRUG ,_be simvastatin_be ,_be OTHER_DRUG ,_af lovastatin_af ,_af fluvastatin_af ._af"
438,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",atorvastatin,lovastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf DRUG ,_be simvastatin_be ,_be pravastatin_be ,_be OTHER_DRUG ,_af fluvastatin_af ._af"
439,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",atorvastatin,fluvastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf DRUG ,_be simvastatin_be ,_be pravastatin_be ,_be lovastatin_be ,_be OTHER_DRUG ._af"
440,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",simvastatin,pravastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf atorvastatin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af lovastatin_af ,_af fluvastatin_af ._af"
441,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",simvastatin,lovastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf atorvastatin_bf ,_bf DRUG ,_be pravastatin_be ,_be OTHER_DRUG ,_af fluvastatin_af ._af"
442,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",simvastatin,fluvastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf atorvastatin_bf ,_bf DRUG ,_be pravastatin_be ,_be lovastatin_be ,_be OTHER_DRUG ._af"
443,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",pravastatin,lovastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf atorvastatin_bf ,_bf simvastatin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af fluvastatin_af ._af"
444,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",pravastatin,fluvastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf atorvastatin_bf ,_bf simvastatin_bf ,_bf DRUG ,_be lovastatin_be ,_be OTHER_DRUG ._af"
445,"HMG-CoA reductase inhibitors: No clinically significant pharmacokinetic interactions were seen when ezetimibe was co-administered with atorvastatin, simvastatin, pravastatin, lovastatin, or fluvastatin. ",lovastatin,fluvastatin,No interaction,"HMG-CoA_bf reductase_bf inhibitors:_bf No_bf clinically_bf significant_bf pharmacokinetic_bf interactions_bf seen_bf ezetimibe_bf co-administered_bf atorvastatin_bf ,_bf simvastatin_bf ,_bf pravastatin_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
446,"Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ",Cyclosporine,ezetimibe,No interaction,"Cyclosporine:_bf The_bf total_bf OTHER_DRUG level_be increased_be 12-fold_be one_be renal_be transplant_be patient_be receiving_be multiple_be medications_be ,_be including_be DRUG ._af"
447,"Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ",Cyclosporine,cyclosporine,No interaction,"Cyclosporine:_bf The_bf total_bf ezetimibe_bf level_bf increased_bf 12-fold_bf one_bf renal_bf transplant_bf patient_bf receiving_bf multiple_bf medications_bf ,_bf including_bf DRUG ._be"
448,"Cyclosporine: The total ezetimibe level increased 12-fold in one renal transplant patient receiving multiple medications, including cyclosporine. ",ezetimibe,cyclosporine,mechanism,"Cyclosporine:_bf The_bf total_bf DRUG level_be increased_be 12-fold_be one_be renal_be transplant_be patient_be receiving_be multiple_be medications_be ,_be including_be OTHER_DRUG ._af"
449,Patients who take both ezetimibe and cyclosporine should be carefully monitored. ,ezetimibe,cyclosporine,advise,Patients_bf take_bf DRUG OTHER_DRUG carefully_af monitored_af ._af
450,"Carcinogenesis, Mutagenesis, Impairment of Fertility A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). ",ezetimibe,ezetimibe,No interaction,"Carcinogenesis_bf ,_bf Mutagenesis_bf ,_bf Impairment_bf Fertility_bf A_bf 104-week_bf dietary_bf carcinogenicity_bf study_bf DRUG conducted_be rats_be doses_be 1500_be mg/kg/day_be (males)_be 500_be mg/kg/day_be (females)_be (~20_be times_be human_be exposure_be 10_be mg_be daily_be based_be AUC0-24hr_be total_be ezetimibe)_be ._be"
451,A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). ,ezetimibe,ezetimibe,No interaction,A_bf 104-week_bf dietary_bf carcinogenicity_bf study_bf DRUG also_be conducted_be mice_be doses_be 500_be mg/kg/day_be (>150_be times_be human_be exposure_be 10_be mg_be daily_be based_be AUC0-24hr_be total_be ezetimibe)_be ._be
452,"In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1000 mg/kg/day in male or female rats (~7 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). ",ezetimibe,ezetimibe,No interaction,"In_bf oral_bf (gavage)_bf fertility_bf studies_bf DRUG conducted_be rats_be ,_be evidence_be reproductive_be toxicity_be doses_be 1000_be mg/kg/day_be male_be female_be rats_be (~7_be times_be human_be exposure_be 10_be mg_be daily_be based_be AUC0-24hr_be total_be ezetimibe)_be ._be"
453,"In rabbits treated with ezetimibe, an increased incidence of extra thoracic ribs was observed at 1000 mg/kg/day (150 times the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). ",ezetimibe,ezetimibe,No interaction,"In_bf rabbits_bf treated_bf DRUG ,_be increased_be incidence_be extra_be thoracic_be ribs_be observed_be 1000_be mg/kg/day_be (150_be times_be human_be exposure_be 10_be mg_be daily_be based_be AUC0-24hr_be total_be ezetimibe)_be ._be"
454,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,ezetimibe,HMG-CoA reductase inhibitors,No interaction,Multiple_bf dose_bf studies_bf DRUG given_be combination_be HMG-CoA_be reductase_be inhibitors_be (statins)_be rats_be rabbits_be organogenesis_be result_be higher_be DRUG statin_af exposures_af ._af
455,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,ezetimibe,statins,No interaction,Multiple_bf dose_bf studies_bf DRUG given_be combination_be HMG-CoA_be reductase_be inhibitors_be (statins)_be rats_be rabbits_be organogenesis_be result_be higher_be DRUG statin_af exposures_af ._af
456,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,ezetimibe,ezetimibe,No interaction,Multiple_bf dose_bf studies_bf DRUG given_be combination_be HMG-CoA_be reductase_be inhibitors_be (statins)_be rats_be rabbits_be organogenesis_be result_be higher_be DRUG statin_af exposures_af ._af
457,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,HMG-CoA reductase inhibitors,statins,No interaction,Multiple_bf dose_bf studies_bf ezetimibe_bf given_bf combination_bf HMG-CoA_bf reductase_bf inhibitors_bf (statins)_bf rats_bf rabbits_bf organogenesis_bf result_bf higher_bf ezetimibe_bf statin_bf exposures_bf ._bf
458,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,HMG-CoA reductase inhibitors,ezetimibe,No interaction,Multiple_bf dose_bf studies_bf OTHER_DRUG given_be combination_be HMG-CoA_be reductase_be inhibitors_be (statins)_be rats_be rabbits_be organogenesis_be result_be higher_be OTHER_DRUG statin_af exposures_af ._af
459,Multiple dose studies of ezetimibe given in combination with HMG-CoA reductase inhibitors (statins) in rats and rabbits during organogenesis result in higher ezetimibe and statin exposures. ,statins,ezetimibe,No interaction,Multiple_bf dose_bf studies_bf OTHER_DRUG given_be combination_be HMG-CoA_be reductase_be inhibitors_be (statins)_be rats_be rabbits_be organogenesis_be result_be higher_be OTHER_DRUG statin_af exposures_af ._af
460,"When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. ",ZETIA,HMG-CoA reductase inhibitor,No interaction,"When_bf DRUG administered_be HMG-CoA_be reductase_be inhibitor_be woman_be childbearing_be potential_be ,_be refer_be pregnancy_be category_be package_be labeling_be HMG-CoA_be reductase_be inhibitor_be ._be"
461,"When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. ",ZETIA,HMG-CoA reductase inhibitor,No interaction,"When_bf DRUG administered_be HMG-CoA_be reductase_be inhibitor_be woman_be childbearing_be potential_be ,_be refer_be pregnancy_be category_be package_be labeling_be HMG-CoA_be reductase_be inhibitor_be ._be"
462,"When ZETIA is administered with an HMG-CoA reductase inhibitor in a woman of childbearing potential, refer to the pregnancy category and package labeling for the HMG-CoA reductase inhibitor. ",HMG-CoA reductase inhibitor,HMG-CoA reductase inhibitor,No interaction,"When_bf ZETIA_bf administered_bf HMG-CoA_bf reductase_bf inhibitor_bf woman_bf childbearing_bf potential_bf ,_bf refer_bf pregnancy_bf category_bf package_bf labeling_bf HMG-CoA_bf reductase_bf inhibitor_bf ._bf"
463,Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.,cimetidine,mebendazole,mechanism,Preliminary_bf evidence_bf suggests_bf DRUG inhibits_be OTHER_DRUG metabolism_af may_af result_af increase_af plasma_af concentrations_af OTHER_DRUG ._af
464,Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.,cimetidine,mebendazole,No interaction,Preliminary_bf evidence_bf suggests_bf DRUG inhibits_be OTHER_DRUG metabolism_af may_af result_af increase_af plasma_af concentrations_af OTHER_DRUG ._af
465,Preliminary evidence suggests that cimetidine inhibits mebendazole metabolism and may result in an increase in plasma concentrations of mebendazole.,mebendazole,mebendazole,No interaction,Preliminary_bf evidence_bf suggests_bf cimetidine_bf inhibits_bf DRUG metabolism_be may_be result_be increase_be plasma_be concentrations_be DRUG ._af
466,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,antibiotics,sulfonamides,No interaction,Patients_bf receiving_bf DRUG OTHER_DRUG generally_af treated_af ganglion_af blockers_af ._af
467,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,antibiotics,ganglion blockers,advise,Patients_bf receiving_bf DRUG sulfonamides_be generally_be treated_be ganglion_be blockers_be ._be
468,Patients receiving antibiotics and sulfonamides generally should not be treated with ganglion blockers.  ,sulfonamides,ganglion blockers,advise,Patients_bf receiving_bf antibiotics_bf DRUG generally_be treated_be ganglion_be blockers_be ._be
469,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",Mecamylamine,antihypertensive drugs,effect,"The_bf action_bf DRUG may_be potentiated_be anesthesia_be ,_be antihypertensive_be drugs_be alcohol_be ._be"
470,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",Mecamylamine,alcohol,effect,"The_bf action_bf DRUG may_be potentiated_be anesthesia_be ,_be antihypertensive_be drugs_be OTHER_DRUG ._af"
471,"The action of Mecamylamine may be potentiated by anesthesia, other antihypertensive drugs and alcohol.",antihypertensive drugs,alcohol,No interaction,"The_bf action_bf Mecamylamine_bf may_bf potentiated_bf anesthesia_bf ,_bf antihypertensive_bf drugs_bf OTHER_DRUG ._be"
472,Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. ,Aminoglutethimide,depo-subQ provera 104,mechanism,DRUG administered_be concomitantly_be depo-subQ_be provera_be 104_be may_be significantly_be decrease_be serum_be concentrations_be MPA_be ._be
473,Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. ,Aminoglutethimide,MPA,No interaction,DRUG administered_be concomitantly_be depo-subQ_be provera_be 104_be may_be significantly_be decrease_be serum_be concentrations_be OTHER_DRUG ._af
474,Aminoglutethimide administered concomitantly with depo-subQ provera 104 may significantly decrease the serum concentrations of MPA. ,depo-subQ provera 104,MPA,No interaction,Aminoglutethimide_bf administered_bf concomitantly_bf depo-subQ_bf provera_bf 104_bf may_bf significantly_bf decrease_bf serum_bf concentrations_bf OTHER_DRUG ._be
475,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. ,zidovudine,rifabutin,No interaction,Pharmacokinetic_bf studies_bf show_bf significant_bf alterations_bf pharmacokinetic_bf parameters_bf DRUG OTHER_DRUG warrant_af dosage_af adjustment_af megestrol_af acetate_af administered_af drugs_af ._af
476,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. ,zidovudine,megestrol acetate,No interaction,Pharmacokinetic_bf studies_bf show_bf significant_bf alterations_bf pharmacokinetic_bf parameters_bf DRUG rifabutin_be warrant_be dosage_be adjustment_be megestrol_be acetate_be administered_be drugs_be ._be
477,Pharmacokinetic studies show that there are no significant alterations in pharmacokinetic parameters of zidovudine or rifabutin to warrant dosage adjustment when megestrol acetate is administered with these drugs. ,rifabutin,megestrol acetate,No interaction,Pharmacokinetic_bf studies_bf show_bf significant_bf alterations_bf pharmacokinetic_bf parameters_bf zidovudine_bf DRUG warrant_be dosage_be adjustment_be megestrol_be acetate_be administered_be drugs_be ._be
478,A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ,megestrol acetate,indinavir,mechanism,A_bf pharmacokinetic_bf study_bf demonstrated_bf coadministration_bf megestrol_bf acetate_bf OTHER_DRUG results_be significant_be decrease_be pharmacokinetic_be parameters_be (~36%_be Cmax_be ~28%_be AUC)_be OTHER_DRUG ._af
479,A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ,megestrol acetate,indinavir,No interaction,A_bf pharmacokinetic_bf study_bf demonstrated_bf coadministration_bf megestrol_bf acetate_bf OTHER_DRUG results_be significant_be decrease_be pharmacokinetic_be parameters_be (~36%_be Cmax_be ~28%_be AUC)_be OTHER_DRUG ._af
480,A pharmacokinetic study demonstrated that coadministration of megestrol acetate and indinavir results in a significant decrease in the pharmacokinetic parameters (~36% for Cmax and ~28% for AUC) of indinavir. ,indinavir,indinavir,No interaction,A_bf pharmacokinetic_bf study_bf demonstrated_bf coadministration_bf megestrol_bf acetate_bf DRUG results_be significant_be decrease_be pharmacokinetic_be parameters_be (~36%_be Cmax_be ~28%_be AUC)_be DRUG ._af
481,Administration of a higher dose of indinavir should be considered when coadministering with megestrol acetate. ,indinavir,megestrol acetate,advise,Administration_bf higher_bf dose_bf DRUG considered_be coadministering_be megestrol_be acetate_be ._be
482,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",indinavir,zidovudine,No interaction,"The_bf effects_bf DRUG ,_be OTHER_DRUG rifabutin_af pharmacokinetics_af megestrol_af acetate_af studied_af ._af"
483,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",indinavir,rifabutin,No interaction,"The_bf effects_bf DRUG ,_be zidovudine_be OTHER_DRUG pharmacokinetics_af megestrol_af acetate_af studied_af ._af"
484,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",indinavir,megestrol acetate,No interaction,"The_bf effects_bf DRUG ,_be zidovudine_be rifabutin_be pharmacokinetics_be megestrol_be acetate_be studied_be ._be"
485,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",zidovudine,rifabutin,No interaction,"The_bf effects_bf indinavir_bf ,_bf DRUG OTHER_DRUG pharmacokinetics_af megestrol_af acetate_af studied_af ._af"
486,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",zidovudine,megestrol acetate,No interaction,"The_bf effects_bf indinavir_bf ,_bf DRUG rifabutin_be pharmacokinetics_be megestrol_be acetate_be studied_be ._be"
487,"The effects of indinavir, zidovudine or rifabutin on the pharmacokinetics of megestrol acetate were not studied.",rifabutin,megestrol acetate,No interaction,"The_bf effects_bf indinavir_bf ,_bf zidovudine_bf DRUG pharmacokinetics_be megestrol_be acetate_be studied_be ._be"
488,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,aspirin,int,"DRUG may_be interact_be following_be drugs:_be OTHER_DRUG NSAIDs_af (may_af lower_af DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
489,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,NSAIDs,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be OTHER_DRUG (may_af lower_af DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
490,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
491,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,fluvoxamine,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af OTHER_DRUG (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
492,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
493,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,beta blockers,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
494,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
495,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,fluoxetine,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af OTHER_DRUG (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
496,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,progestin,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
497,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
498,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,progestin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
499,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,benzodiazepenes,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
500,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,corticosteroids,int,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
501,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
502,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
503,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",Melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
504,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,NSAIDs,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf DRUG OTHER_DRUG (may_af lower_af melatonin_af levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af melatonin_af increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af melatonin_af levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af melatonin_af progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
505,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be DRUG NSAIDs_af (may_af lower_af OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
506,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,fluvoxamine,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf DRUG NSAIDs_be (may_be lower_be melatonin_be levels)_be ,_be OTHER_DRUG (bioavailability_af oral_af melatonin_af increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af melatonin_af levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af melatonin_af progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
507,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be DRUG NSAIDs_af (may_af lower_af OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
508,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,beta blockers,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf DRUG NSAIDs_be (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be corticosteroids_be (coadministration_be melatonin_be corticosteroids_be may_be interfere_be efficacy_be corticosteroids)_be ._be"
509,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be DRUG NSAIDs_af (may_af lower_af OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
510,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,fluoxetine,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf DRUG NSAIDs_be (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be OTHER_DRUG (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af melatonin_af progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
511,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,progestin,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf DRUG NSAIDs_be (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
512,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be DRUG NSAIDs_af (may_af lower_af OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
513,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,progestin,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf DRUG NSAIDs_be (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
514,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,benzodiazepenes,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf DRUG NSAIDs_be (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
515,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf DRUG NSAIDs_be (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
516,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be DRUG NSAIDs_af (may_af lower_af OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
517,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf DRUG NSAIDs_be (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
518,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",aspirin,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf DRUG NSAIDs_be (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
519,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be DRUG (may_af lower_af OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
520,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,fluvoxamine,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf DRUG (may_be lower_be melatonin_be levels)_be ,_be OTHER_DRUG (bioavailability_af oral_af melatonin_af increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af melatonin_af levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af melatonin_af progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
521,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be DRUG (may_af lower_af OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
522,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,beta blockers,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf DRUG (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be corticosteroids_be (coadministration_be melatonin_be corticosteroids_be may_be interfere_be efficacy_be corticosteroids)_be ._be"
523,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be DRUG (may_af lower_af OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
524,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,fluoxetine,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf DRUG (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be OTHER_DRUG (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af melatonin_af progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
525,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,progestin,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf DRUG (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
526,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be DRUG (may_af lower_af OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
527,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,progestin,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf DRUG (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
528,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,benzodiazepenes,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf DRUG (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
529,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf DRUG (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
530,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be DRUG (may_af lower_af OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
531,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf DRUG (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
532,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",NSAIDs,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf DRUG (may_be lower_be melatonin_be levels)_be ,_be fluvoxamine_be (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
533,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,fluvoxamine,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af OTHER_DRUG (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
534,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
535,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,beta blockers,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
536,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
537,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,fluoxetine,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af OTHER_DRUG (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
538,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,progestin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
539,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
540,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,progestin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
541,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,benzodiazepenes,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
542,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
543,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
544,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
545,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
546,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af DRUG (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
547,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,beta blockers,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf DRUG (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be corticosteroids_be (coadministration_be melatonin_be corticosteroids_be may_be interfere_be efficacy_be corticosteroids)_be ._be"
548,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af DRUG (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
549,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,fluoxetine,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf DRUG (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be OTHER_DRUG (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af melatonin_af progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
550,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,progestin,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf DRUG (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
551,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af DRUG (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
552,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,progestin,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf DRUG (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
553,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,benzodiazepenes,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf DRUG (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
554,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf DRUG (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
555,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af DRUG (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
556,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf DRUG (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
557,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluvoxamine,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf DRUG (bioavailability_be oral_be melatonin_be increased_be coadministration)_be ,_be beta_be blockers_be (may_be decrease_be melatonin_be levels)_be ,_be fluoxetine_be (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
558,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,beta blockers,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
559,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
560,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,fluoxetine,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af OTHER_DRUG (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
561,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,progestin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
562,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
563,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,progestin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
564,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,benzodiazepenes,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
565,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
566,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
567,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
568,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
569,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",beta blockers,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
570,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",beta blockers,fluoxetine,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf OTHER_DRUG (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be corticosteroids_be (coadministration_be melatonin_be corticosteroids_be may_be interfere_be efficacy_be corticosteroids)_be ._be"
571,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",beta blockers,progestin,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf OTHER_DRUG (coadministration_be melatonin_be OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
572,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",beta blockers,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
573,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",beta blockers,progestin,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf OTHER_DRUG (coadministration_be melatonin_be OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
574,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",beta blockers,benzodiazepenes,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf progestin_bf (coadministration_bf melatonin_bf progestin_bf inhibit_bf ovarian_bf function_bf women)_bf ,_bf OTHER_DRUG sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be corticosteroids_be (coadministration_be melatonin_be corticosteroids_be may_be interfere_be efficacy_be corticosteroids)_be ._be"
575,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",beta blockers,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf progestin_bf (coadministration_bf melatonin_bf progestin_bf inhibit_bf ovarian_bf function_bf women)_bf ,_bf benzodiazepenes_bf sedating_bf drugs_bf (may_bf result_bf additive_bf sedation_bf increased_bf incidence_bf adverse_bf effects)_bf ,_bf OTHER_DRUG (coadministration_be melatonin_be OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
576,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",beta blockers,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
577,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",beta blockers,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf progestin_bf (coadministration_bf melatonin_bf progestin_bf inhibit_bf ovarian_bf function_bf women)_bf ,_bf benzodiazepenes_bf sedating_bf drugs_bf (may_bf result_bf additive_bf sedation_bf increased_bf incidence_bf adverse_bf effects)_bf ,_bf OTHER_DRUG (coadministration_be melatonin_be OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
578,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",beta blockers,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf progestin_bf (coadministration_bf melatonin_bf progestin_bf inhibit_bf ovarian_bf function_bf women)_bf ,_bf benzodiazepenes_bf sedating_bf drugs_bf (may_bf result_bf additive_bf sedation_bf increased_bf incidence_bf adverse_bf effects)_bf ,_bf OTHER_DRUG (coadministration_be melatonin_be OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
579,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,fluoxetine,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af OTHER_DRUG (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
580,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,progestin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
581,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
582,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,progestin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
583,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,benzodiazepenes,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
584,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
585,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
586,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
587,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
588,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluoxetine,progestin,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf DRUG (reports_be psychotic_be episodes_be coadministered)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
589,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluoxetine,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af DRUG (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
590,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluoxetine,progestin,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf DRUG (reports_be psychotic_be episodes_be coadministered)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
591,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluoxetine,benzodiazepenes,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf DRUG (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
592,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluoxetine,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf DRUG (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
593,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluoxetine,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af DRUG (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
594,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluoxetine,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf DRUG (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
595,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",fluoxetine,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf DRUG (reports_be psychotic_be episodes_be coadministered)_be ,_be progestin_be (coadministration_be melatonin_be progestin_be inhibit_be ovarian_be function_be women)_be ,_be benzodiazepenes_be sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
596,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af DRUG (coadministration_af OTHER_DRUG DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
597,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,progestin,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
598,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,benzodiazepenes,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG inhibit_af ovarian_af function_af women)_af ,_af OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
599,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
600,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af DRUG (coadministration_af OTHER_DRUG DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
601,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
602,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
603,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,progestin,effect,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
604,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,benzodiazepenes,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
605,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
606,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,melatonin,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
607,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
608,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
609,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,benzodiazepenes,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG inhibit_af ovarian_af function_af women)_af ,_af OTHER_DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af melatonin_af corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
610,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
611,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af DRUG (coadministration_af OTHER_DRUG DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
612,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
613,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",progestin,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
614,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",benzodiazepenes,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf progestin_bf (coadministration_bf melatonin_bf progestin_bf inhibit_bf ovarian_bf function_bf women)_bf ,_bf DRUG sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
615,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",benzodiazepenes,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af DRUG sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af corticosteroids_af (coadministration_af OTHER_DRUG corticosteroids_af may_af interfere_af efficacy_af corticosteroids)_af ._af"
616,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",benzodiazepenes,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf progestin_bf (coadministration_bf melatonin_bf progestin_bf inhibit_bf ovarian_bf function_bf women)_bf ,_bf DRUG sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
617,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",benzodiazepenes,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf progestin_bf (coadministration_bf melatonin_bf progestin_bf inhibit_bf ovarian_bf function_bf women)_bf ,_bf DRUG sedating_be drugs_be (may_be result_be additive_be sedation_be increased_be incidence_be adverse_be effects)_be ,_be OTHER_DRUG (coadministration_af melatonin_af OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
618,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",corticosteroids,melatonin,No interaction,"OTHER_DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be OTHER_DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af OTHER_DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af OTHER_DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af OTHER_DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af DRUG (coadministration_af OTHER_DRUG DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
619,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",corticosteroids,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf progestin_bf (coadministration_bf melatonin_bf progestin_bf inhibit_bf ovarian_bf function_bf women)_bf ,_bf benzodiazepenes_bf sedating_bf drugs_bf (may_bf result_bf additive_bf sedation_bf increased_bf incidence_bf adverse_bf effects)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
620,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",corticosteroids,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf progestin_bf (coadministration_bf melatonin_bf progestin_bf inhibit_bf ovarian_bf function_bf women)_bf ,_bf benzodiazepenes_bf sedating_bf drugs_bf (may_bf result_bf additive_bf sedation_bf increased_bf incidence_bf adverse_bf effects)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
621,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,effect,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
622,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",melatonin,corticosteroids,No interaction,"DRUG may_be interact_be following_be drugs:_be aspirin_be NSAIDs_be (may_be lower_be DRUG levels)_af ,_af fluvoxamine_af (bioavailability_af oral_af DRUG increased_af coadministration)_af ,_af beta_af blockers_af (may_af decrease_af DRUG levels)_af ,_af fluoxetine_af (reports_af psychotic_af episodes_af coadministered)_af ,_af progestin_af (coadministration_af DRUG progestin_af inhibit_af ovarian_af function_af women)_af ,_af benzodiazepenes_af sedating_af drugs_af (may_af result_af additive_af sedation_af increased_af incidence_af adverse_af effects)_af ,_af OTHER_DRUG (coadministration_af DRUG OTHER_DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
623,"Melatonin may interact with the following drugs: aspirin and other NSAIDs (may lower melatonin levels), fluvoxamine (bioavailability of oral melatonin is increased with coadministration), beta blockers (may decrease melatonin levels), fluoxetine (reports of psychotic episodes when coadministered), progestin (coadministration of melatonin with progestin can inhibit ovarian function in women), benzodiazepenes and other sedating drugs (may result in additive sedation and an increased incidence of adverse effects), and corticosteroids (coadministration of melatonin and corticosteroids may interfere with the efficacy of the corticosteroids).",corticosteroids,corticosteroids,No interaction,"Melatonin_bf may_bf interact_bf following_bf drugs:_bf aspirin_bf NSAIDs_bf (may_bf lower_bf melatonin_bf levels)_bf ,_bf fluvoxamine_bf (bioavailability_bf oral_bf melatonin_bf increased_bf coadministration)_bf ,_bf beta_bf blockers_bf (may_bf decrease_bf melatonin_bf levels)_bf ,_bf fluoxetine_bf (reports_bf psychotic_bf episodes_bf coadministered)_bf ,_bf progestin_bf (coadministration_bf melatonin_bf progestin_bf inhibit_bf ovarian_bf function_bf women)_bf ,_bf benzodiazepenes_bf sedating_bf drugs_bf (may_bf result_bf additive_bf sedation_bf increased_bf incidence_bf adverse_bf effects)_bf ,_bf DRUG (coadministration_be melatonin_be DRUG may_af interfere_af efficacy_af corticosteroids)_af ._af"
624,ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,ACE inhibitors,NSAIDs,No interaction,ACE_bf inhibitors_bf Reports_bf suggest_bf OTHER_DRUG may_be diminish_be antihypertensive_be effect_be angiotensin-converting_be enzyme_be (ACE)_be inhibitors_be ._be
625,ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,ACE inhibitors,angiotensin-converting enzyme (ACE) inhibitors,No interaction,ACE_bf inhibitors_bf Reports_bf suggest_bf NSAIDs_bf may_bf diminish_bf antihypertensive_bf effect_bf angiotensin-converting_bf enzyme_bf (ACE)_bf inhibitors_bf ._bf
626,ACE inhibitors Reports suggest that NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. ,NSAIDs,angiotensin-converting enzyme (ACE) inhibitors,effect,ACE_bf inhibitors_bf Reports_bf suggest_bf DRUG may_be diminish_be antihypertensive_be effect_be angiotensin-converting_be enzyme_be (ACE)_be inhibitors_be ._be
627,This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE inhibitors. ,NSAIDs,ACE inhibitors,advise,This_bf interaction_bf given_bf consideration_bf patients_bf taking_bf DRUG concomitantly_be ACE_be inhibitors_be ._be
628,Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,Aspirin,aspirin,No interaction,Aspirin:_bf Concomitant_bf administration_bf DRUG (1000_be mg_be TID)_be healthy_be volunteers_be tended_be increase_be AUC_be (10%)_be Cmax_be (24%)_be meloxicam_be ._be
629,Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,Aspirin,meloxicam,No interaction,Aspirin:_bf Concomitant_bf administration_bf DRUG (1000_be mg_be TID)_be healthy_be volunteers_be tended_be increase_be AUC_be (10%)_be Cmax_be (24%)_be OTHER_DRUG ._af
630,Aspirin: Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and Cmax (24%) of meloxicam. ,aspirin,meloxicam,mechanism,Aspirin:_bf Concomitant_bf administration_bf DRUG (1000_be mg_be TID)_be healthy_be volunteers_be tended_be increase_be AUC_be (10%)_be Cmax_be (24%)_be OTHER_DRUG ._af
631,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",NSAIDs,meloxicam,No interaction,"however_bf ,_bf DRUG ,_be concomitant_be administration_be OTHER_DRUG aspirin_af generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
632,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",NSAIDs,aspirin,advise,"however_bf ,_bf DRUG ,_be concomitant_be administration_be meloxicam_be OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
633,"however, as with other NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. ",meloxicam,aspirin,advise,"however_bf ,_bf NSAIDs_bf ,_bf concomitant_bf administration_bf DRUG OTHER_DRUG generally_af recommended_af potential_af increased_af adverse_af effects_af ._af"
634,"Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ",aspirin,MOBIC,effect,"Concomitant_bf administration_bf low-dose_bf DRUG OTHER_DRUG may_af result_af increased_af rate_af GI_af ulceration_af complications_af ,_af compared_af use_af OTHER_DRUG alone_af ._af"
635,"Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ",aspirin,MOBIC,No interaction,"Concomitant_bf administration_bf low-dose_bf DRUG OTHER_DRUG may_af result_af increased_af rate_af GI_af ulceration_af complications_af ,_af compared_af use_af OTHER_DRUG alone_af ._af"
636,"Concomitant administration of low-dose aspirin with MOBIC may result in an increased rate of GI ulceration or other complications, compared to use of MOBIC alone. ",MOBIC,MOBIC,No interaction,"Concomitant_bf administration_bf low-dose_bf aspirin_bf DRUG may_be result_be increased_be rate_be GI_be ulceration_be complications_be ,_be compared_be use_be DRUG alone_af ._af"
637,MOBIC is not a substitute for aspirin for cardiovascular prophylaxis. ,MOBIC,aspirin,No interaction,DRUG substitute_be OTHER_DRUG cardiovascular_af prophylaxis_af ._af
638,Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. ,Cholestyramine,cholestyramine,No interaction,Cholestyramine:_bf Pretreatment_bf four_bf days_bf DRUG significantly_be increased_be clearance_be meloxicam_be 50%_be ._be
639,Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. ,Cholestyramine,meloxicam,No interaction,Cholestyramine:_bf Pretreatment_bf four_bf days_bf DRUG significantly_be increased_be clearance_be OTHER_DRUG 50%_af ._af
640,Cholestyramine: Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. ,cholestyramine,meloxicam,mechanism,Cholestyramine:_bf Pretreatment_bf four_bf days_bf DRUG significantly_be increased_be clearance_be OTHER_DRUG 50%_af ._af
641,Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. ,Cimetidine,cimetidine,No interaction,Cimetidine:_bf Concomitant_bf administration_bf 200_bf mg_bf DRUG QID_be alter_be single-dose_be pharmacokinetics_be 30_be mg_be meloxicam_be ._be
642,Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. ,Cimetidine,meloxicam,No interaction,Cimetidine:_bf Concomitant_bf administration_bf 200_bf mg_bf DRUG QID_be alter_be single-dose_be pharmacokinetics_be 30_be mg_be OTHER_DRUG ._af
643,Cimetidine: Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam. ,cimetidine,meloxicam,No interaction,Cimetidine:_bf Concomitant_bf administration_bf 200_bf mg_bf DRUG QID_be alter_be single-dose_be pharmacokinetics_be 30_be mg_be OTHER_DRUG ._af
644,Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. ,Digoxin,Meloxicam,No interaction,Digoxin:_bf OTHER_DRUG 15_be mg_be daily_be 7_be days_be alter_be plasma_be concentration_be profile_be DRUG b-acetyldigoxin_af administration_af 7_af days_af clinical_af doses_af ._af
645,Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. ,Digoxin,digoxin,No interaction,Digoxin:_bf Meloxicam_bf 15_bf mg_bf daily_bf 7_bf days_bf alter_bf plasma_bf concentration_bf profile_bf DRUG b-acetyldigoxin_be administration_be 7_be days_be clinical_be doses_be ._be
646,Digoxin: Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. ,Meloxicam,digoxin,No interaction,Digoxin:_bf DRUG 15_be mg_be daily_be 7_be days_be alter_be plasma_be concentration_be profile_be OTHER_DRUG b-acetyldigoxin_af administration_af 7_af days_af clinical_af doses_af ._af
647,In vitro testing found no protein binding drug interaction between digoxin and meloxicam. ,digoxin,meloxicam,No interaction,In_bf vitro_bf testing_bf found_bf protein_bf binding_bf drug_bf interaction_bf DRUG OTHER_DRUG ._af
648,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",Furosemide,NSAIDs,No interaction,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf OTHER_DRUG reduce_be natriuretic_be effect_be DRUG thiazide_af diuretics_af patients_af ._af"
649,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",Furosemide,furosemide,No interaction,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf NSAIDs_bf reduce_bf natriuretic_bf effect_bf DRUG thiazide_be diuretics_be patients_be ._be"
650,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",Furosemide,thiazide diuretics,No interaction,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf NSAIDs_bf reduce_bf natriuretic_bf effect_bf DRUG thiazide_be diuretics_be patients_be ._be"
651,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",NSAIDs,furosemide,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be OTHER_DRUG thiazide_af diuretics_af patients_af ._af"
652,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",NSAIDs,thiazide diuretics,effect,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf DRUG reduce_be natriuretic_be effect_be furosemide_be thiazide_be diuretics_be patients_be ._be"
653,"Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. ",furosemide,thiazide diuretics,No interaction,"Furosemide:_bf Clinical_bf studies_bf ,_bf well_bf post-marketing_bf observations_bf ,_bf shown_bf NSAIDs_bf reduce_bf natriuretic_bf effect_bf DRUG thiazide_be diuretics_be patients_be ._be"
654,Studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. ,furosemide,meloxicam,No interaction,Studies_bf DRUG agents_be OTHER_DRUG demonstrated_af reduction_af natriuretic_af effect_af ._af
655,Furosemide: single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam. ,Furosemide,meloxicam,No interaction,Furosemide:_bf single_bf multiple_bf dose_bf pharmacodynamics_bf pharmacokinetics_bf affected_bf multiple_bf doses_bf OTHER_DRUG ._be
656,"Nevertheless, during concomitant therapy with furosemide and MOBIC, patients should be observed closely for signs of declining renal function, as well as to assure diuretic efficacy. ",furosemide,MOBIC,advise,"Nevertheless_bf ,_bf concomitant_bf therapy_bf DRUG OTHER_DRUG ,_af patients_af observed_af closely_af signs_af declining_af renal_af function_af ,_af well_af assure_af diuretic_af efficacy_af ._af"
657,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",Lithium,NSAIDs,No interaction,"Lithium:_bf In_bf clinical_bf trials_bf ,_bf OTHER_DRUG produced_be elevation_be plasma_be DRUG levels_af reduction_af renal_af DRUG clearance_af ._af"
658,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",Lithium,lithium,No interaction,"Lithium:_bf In_bf clinical_bf trials_bf ,_bf NSAIDs_bf produced_bf elevation_bf plasma_bf DRUG levels_be reduction_be renal_be DRUG clearance_af ._af"
659,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",Lithium,lithium,No interaction,"Lithium:_bf In_bf clinical_bf trials_bf ,_bf NSAIDs_bf produced_bf elevation_bf plasma_bf DRUG levels_be reduction_be renal_be DRUG clearance_af ._af"
660,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",NSAIDs,lithium,mechanism,"Lithium:_bf In_bf clinical_bf trials_bf ,_bf DRUG produced_be elevation_be plasma_be OTHER_DRUG levels_af reduction_af renal_af OTHER_DRUG clearance_af ._af"
661,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",NSAIDs,lithium,No interaction,"Lithium:_bf In_bf clinical_bf trials_bf ,_bf DRUG produced_be elevation_be plasma_be OTHER_DRUG levels_af reduction_af renal_af OTHER_DRUG clearance_af ._af"
662,"Lithium: In clinical trials, NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. ",lithium,lithium,No interaction,"Lithium:_bf In_bf clinical_bf trials_bf ,_bf NSAIDs_bf produced_bf elevation_bf plasma_bf DRUG levels_be reduction_be renal_be DRUG clearance_af ._af"
663,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",lithium,lithium,No interaction,"In_bf study_bf conducted_bf healthy_bf subjects_bf ,_bf mean_bf pre-dose_bf DRUG concentration_be AUC_be increased_be 21%_be subjects_be receiving_be DRUG doses_af ranging_af 804_af 1072_af mg_af BID_af meloxicam_af 15_af mg_af QD_af compared_af subjects_af receiving_af DRUG alone_af ._af"
664,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",lithium,meloxicam,No interaction,"In_bf study_bf conducted_bf healthy_bf subjects_bf ,_bf mean_bf pre-dose_bf DRUG concentration_be AUC_be increased_be 21%_be subjects_be receiving_be DRUG doses_af ranging_af 804_af 1072_af mg_af BID_af OTHER_DRUG 15_af mg_af QD_af compared_af subjects_af receiving_af DRUG alone_af ._af"
665,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",lithium,lithium,No interaction,"In_bf study_bf conducted_bf healthy_bf subjects_bf ,_bf mean_bf pre-dose_bf DRUG concentration_be AUC_be increased_be 21%_be subjects_be receiving_be DRUG doses_af ranging_af 804_af 1072_af mg_af BID_af meloxicam_af 15_af mg_af QD_af compared_af subjects_af receiving_af DRUG alone_af ._af"
666,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",lithium,meloxicam,mechanism,"In_bf study_bf conducted_bf healthy_bf subjects_bf ,_bf mean_bf pre-dose_bf DRUG concentration_be AUC_be increased_be 21%_be subjects_be receiving_be DRUG doses_af ranging_af 804_af 1072_af mg_af BID_af OTHER_DRUG 15_af mg_af QD_af compared_af subjects_af receiving_af DRUG alone_af ._af"
667,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",lithium,lithium,No interaction,"In_bf study_bf conducted_bf healthy_bf subjects_bf ,_bf mean_bf pre-dose_bf DRUG concentration_be AUC_be increased_be 21%_be subjects_be receiving_be DRUG doses_af ranging_af 804_af 1072_af mg_af BID_af meloxicam_af 15_af mg_af QD_af compared_af subjects_af receiving_af DRUG alone_af ._af"
668,"In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. ",meloxicam,lithium,No interaction,"In_bf study_bf conducted_bf healthy_bf subjects_bf ,_bf mean_bf pre-dose_bf OTHER_DRUG concentration_be AUC_be increased_be 21%_be subjects_be receiving_be OTHER_DRUG doses_af ranging_af 804_af 1072_af mg_af BID_af DRUG 15_af mg_af QD_af compared_af subjects_af receiving_af OTHER_DRUG alone_af ._af"
669,Patients on lithium treatment should be closely monitored when MOBIC is introduced or withdrawn. ,lithium,MOBIC,advise,Patients_bf DRUG treatment_be closely_be monitored_be OTHER_DRUG introduced_af withdrawn_af ._af
670,Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. ,Methotrexate,meloxicam,No interaction,Methotrexate:_bf A_bf study_bf 13_bf rheumatoid_bf arthritis_bf (RA)_bf patients_bf evaluated_bf effects_bf multiple_bf doses_bf OTHER_DRUG pharmacokinetics_be DRUG taken_af weekly_af ._af
671,Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. ,Methotrexate,methotrexate,No interaction,Methotrexate:_bf A_bf study_bf 13_bf rheumatoid_bf arthritis_bf (RA)_bf patients_bf evaluated_bf effects_bf multiple_bf doses_bf meloxicam_bf pharmacokinetics_bf DRUG taken_be weekly_be ._be
672,Methotrexate: A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. ,meloxicam,methotrexate,No interaction,Methotrexate:_bf A_bf study_bf 13_bf rheumatoid_bf arthritis_bf (RA)_bf patients_bf evaluated_bf effects_bf multiple_bf doses_bf DRUG pharmacokinetics_be OTHER_DRUG taken_af weekly_af ._af
673,Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate. ,Meloxicam,methotrexate,No interaction,DRUG significant_be effect_be pharmacokinetics_be single_be doses_be OTHER_DRUG ._af
674,"In vitro, methotrexate did not displace meloxicam from its human serum binding sites. ",methotrexate,meloxicam,No interaction,"In_bf vitro_bf ,_bf DRUG displace_be OTHER_DRUG human_af serum_af binding_af sites_af ._af"
675,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ",Warfarin,MOBIC,No interaction,"Warfarin:_bf Anticoagulant_bf activity_bf monitored_bf ,_bf particularly_bf first_bf days_bf initiating_bf changing_bf OTHER_DRUG therapy_be patients_be receiving_be DRUG similar_af agents_af ,_af since_af patients_af increased_af risk_af bleeding_af ._af"
676,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ",Warfarin,warfarin,No interaction,"Warfarin:_bf Anticoagulant_bf activity_bf monitored_bf ,_bf particularly_bf first_bf days_bf initiating_bf changing_bf MOBIC_bf therapy_bf patients_bf receiving_bf DRUG similar_be agents_be ,_be since_be patients_be increased_be risk_be bleeding_be ._be"
677,"Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing MOBIC therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. ",MOBIC,warfarin,advise,"Warfarin:_bf Anticoagulant_bf activity_bf monitored_bf ,_bf particularly_bf first_bf days_bf initiating_bf changing_bf DRUG therapy_be patients_be receiving_be OTHER_DRUG similar_af agents_af ,_af since_af patients_af increased_af risk_af bleeding_af ._af"
678,The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,meloxicam,warfarin,No interaction,The_bf effect_bf DRUG anticoagulant_be effect_be OTHER_DRUG studied_af group_af healthy_af subjects_af receiving_af daily_af doses_af OTHER_DRUG produced_af INR_af (International_af Normalized_af Ratio)_af 1_af ._af 2_af 1_af ._af 8_af ._af
679,The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,meloxicam,warfarin,No interaction,The_bf effect_bf DRUG anticoagulant_be effect_be OTHER_DRUG studied_af group_af healthy_af subjects_af receiving_af daily_af doses_af OTHER_DRUG produced_af INR_af (International_af Normalized_af Ratio)_af 1_af ._af 2_af 1_af ._af 8_af ._af
680,The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. ,warfarin,warfarin,No interaction,The_bf effect_bf meloxicam_bf anticoagulant_bf effect_bf DRUG studied_be group_be healthy_be subjects_be receiving_be daily_be doses_be DRUG produced_af INR_af (International_af Normalized_af Ratio)_af 1_af ._af 2_af 1_af ._af 8_af ._af
681,"In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. ",meloxicam,warfarin,No interaction,"In_bf subjects_bf ,_bf DRUG alter_be OTHER_DRUG pharmacokinetics_af average_af anticoagulant_af effect_af OTHER_DRUG determined_af prothrombin_af time_af ._af"
682,"In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. ",meloxicam,warfarin,No interaction,"In_bf subjects_bf ,_bf DRUG alter_be OTHER_DRUG pharmacokinetics_af average_af anticoagulant_af effect_af OTHER_DRUG determined_af prothrombin_af time_af ._af"
683,"In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. ",warfarin,warfarin,No interaction,"In_bf subjects_bf ,_bf meloxicam_bf alter_bf DRUG pharmacokinetics_be average_be anticoagulant_be effect_be DRUG determined_af prothrombin_af time_af ._af"
684,Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,MOBIC,warfarin,advise,Caution_bf used_bf administering_bf DRUG OTHER_DRUG since_af patients_af OTHER_DRUG may_af experience_af changes_af INR_af increased_af risk_af bleeding_af complications_af new_af medication_af introduced_af ._af
685,Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,MOBIC,warfarin,No interaction,Caution_bf used_bf administering_bf DRUG OTHER_DRUG since_af patients_af OTHER_DRUG may_af experience_af changes_af INR_af increased_af risk_af bleeding_af complications_af new_af medication_af introduced_af ._af
686,Caution should be used when administering MOBIC with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.,warfarin,warfarin,No interaction,Caution_bf used_bf administering_bf MOBIC_bf DRUG since_be patients_be DRUG may_af experience_af changes_af INR_af increased_af risk_af bleeding_af complications_af new_af medication_af introduced_af ._af
687,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,ALKERAN,live organism vaccines,No interaction,DRUG_bf INTERACTIONS_bf There_bf known_bf drug/drug_bf interactions_bf oral_bf DRUG Vaccinations_be live_be organism_be vaccines_be recommended_be immunocompromised_be individuals_be Nalidixic_be acid_be together_be high-dose_be intravenous_be melphalan_be caused_be deaths_be children_be due_be haemorrhagic_be enterocolitis_be ._be
688,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,ALKERAN,Nalidixic acid,No interaction,DRUG_bf INTERACTIONS_bf There_bf known_bf drug/drug_bf interactions_bf oral_bf DRUG Vaccinations_be live_be organism_be vaccines_be recommended_be immunocompromised_be individuals_be Nalidixic_be acid_be together_be high-dose_be intravenous_be melphalan_be caused_be deaths_be children_be due_be haemorrhagic_be enterocolitis_be ._be
689,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,ALKERAN,melphalan,No interaction,DRUG_bf INTERACTIONS_bf There_bf known_bf drug/drug_bf interactions_bf oral_bf DRUG Vaccinations_be live_be organism_be vaccines_be recommended_be immunocompromised_be individuals_be Nalidixic_be acid_be together_be high-dose_be intravenous_be OTHER_DRUG caused_af deaths_af children_af due_af haemorrhagic_af enterocolitis_af ._af
690,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,live organism vaccines,Nalidixic acid,No interaction,DRUG_bf INTERACTIONS_bf There_bf known_bf drug/drug_bf interactions_bf oral_bf ALKERAN_bf Vaccinations_bf live_bf organism_bf vaccines_bf recommended_bf immunocompromised_bf individuals_bf Nalidixic_bf acid_bf together_bf high-dose_bf intravenous_bf melphalan_bf caused_bf deaths_bf children_bf due_bf haemorrhagic_bf enterocolitis_bf ._bf
691,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,live organism vaccines,melphalan,No interaction,DRUG_bf INTERACTIONS_bf There_bf known_bf drug/drug_bf interactions_bf oral_bf ALKERAN_bf Vaccinations_bf live_bf organism_bf vaccines_bf recommended_bf immunocompromised_bf individuals_bf Nalidixic_bf acid_bf together_bf high-dose_bf intravenous_bf OTHER_DRUG caused_be deaths_be children_be due_be haemorrhagic_be enterocolitis_be ._be
692,DRUG INTERACTIONS  There are no known drug/drug interactions with oral ALKERAN  Vaccinations with live organism vaccines are not recommended in immunocompromised individuals  Nalidixic acid together with high-dose intravenous melphalan has caused deaths in children due to haemorrhagic enterocolitis.  ,Nalidixic acid,melphalan,effect,DRUG_bf INTERACTIONS_bf There_bf known_bf drug/drug_bf interactions_bf oral_bf ALKERAN_bf Vaccinations_bf live_bf organism_bf vaccines_bf recommended_bf immunocompromised_bf individuals_bf Nalidixic_bf acid_bf together_bf high-dose_bf intravenous_bf OTHER_DRUG caused_be deaths_be children_be due_be haemorrhagic_be enterocolitis_be ._be
693,Impaired renal function has been described in bone marrow transplant patients who were conditioned with high-dose intravenous melphalan and who subsequently received cyclosporin to prevent graft-versus-host disease,melphalan,cyclosporin,effect,Impaired_bf renal_bf function_bf described_bf bone_bf marrow_bf transplant_bf patients_bf conditioned_bf high-dose_bf intravenous_bf DRUG subsequently_be received_be OTHER_DRUG prevent_af graft-versus-host_af disease_af
694,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,amantadine,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf OTHER_DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
695,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antiarrhythmic agents of class I,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
696,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,quinidine,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
697,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antihistamines,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf OTHER_DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
698,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,antipsychotic agents,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
699,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,phenothiazines,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
700,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,benzodiazepines,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf OTHER_DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
701,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,MAO inhibitors,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
702,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,narcotic analgesics,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
703,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,meperidine,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
704,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,nitrates,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf OTHER_DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
705,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,nitrites,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf OTHER_DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
706,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,sympathomimetic agents,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
707,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",anticholinergic drugs,tricyclic antidepressants,effect,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
708,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,antiarrhythmic agents of class I,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
709,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,quinidine,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
710,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,antihistamines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be OTHER_DRUG ,_af antipsychotic_af agents_af (e_af ._af g_af ._af ,_af phenothiazines)_af ,_af benzodiazepines_af ,_af MAO_af inhibitors_af ,_af narcotic_af analgesics_af (e_af ._af g_af ._af ,_af meperidine)_af ,_af nitrates_af nitrites_af ,_af sympathomimetic_af agents_af ,_af tricyclic_af antidepressants_af ,_af drugs_af anticholinergic_af activity_af ._af"
711,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,antipsychotic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
712,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,phenothiazines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
713,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,benzodiazepines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be OTHER_DRUG ,_af MAO_af inhibitors_af ,_af narcotic_af analgesics_af (e_af ._af g_af ._af ,_af meperidine)_af ,_af nitrates_af nitrites_af ,_af sympathomimetic_af agents_af ,_af tricyclic_af antidepressants_af ,_af drugs_af anticholinergic_af activity_af ._af"
714,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,MAO inhibitors,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
715,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,narcotic analgesics,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
716,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,meperidine,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
717,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,nitrates,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be OTHER_DRUG nitrites_af ,_af sympathomimetic_af agents_af ,_af tricyclic_af antidepressants_af ,_af drugs_af anticholinergic_af activity_af ._af"
718,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,nitrites,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be OTHER_DRUG ,_af sympathomimetic_af agents_af ,_af tricyclic_af antidepressants_af ,_af drugs_af anticholinergic_af activity_af ._af"
719,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
720,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",amantadine,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf DRUG ,_be antiarrhythmic_be agents_be class_be I_be (e_be ._be g_be ._be ,_be quinidine)_be ,_be antihistamines_be ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
721,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,quinidine,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
722,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,antihistamines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf OTHER_DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
723,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,antipsychotic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
724,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,phenothiazines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
725,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,benzodiazepines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf OTHER_DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
726,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,MAO inhibitors,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
727,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,narcotic analgesics,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
728,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,meperidine,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
729,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,nitrates,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf OTHER_DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
730,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,nitrites,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf OTHER_DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
731,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
732,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antiarrhythmic agents of class I,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
733,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",quinidine,antihistamines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf OTHER_DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
734,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",quinidine,antipsychotic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
735,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",quinidine,phenothiazines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
736,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",quinidine,benzodiazepines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf OTHER_DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
737,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",quinidine,MAO inhibitors,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
738,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",quinidine,narcotic analgesics,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
739,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",quinidine,meperidine,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
740,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",quinidine,nitrates,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf OTHER_DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
741,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",quinidine,nitrites,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf OTHER_DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
742,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",quinidine,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
743,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",quinidine,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
744,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antihistamines,antipsychotic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
745,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antihistamines,phenothiazines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
746,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antihistamines,benzodiazepines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be OTHER_DRUG ,_af MAO_af inhibitors_af ,_af narcotic_af analgesics_af (e_af ._af g_af ._af ,_af meperidine)_af ,_af nitrates_af nitrites_af ,_af sympathomimetic_af agents_af ,_af tricyclic_af antidepressants_af ,_af drugs_af anticholinergic_af activity_af ._af"
747,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antihistamines,MAO inhibitors,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
748,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antihistamines,narcotic analgesics,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
749,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antihistamines,meperidine,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
750,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antihistamines,nitrates,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be OTHER_DRUG nitrites_af ,_af sympathomimetic_af agents_af ,_af tricyclic_af antidepressants_af ,_af drugs_af anticholinergic_af activity_af ._af"
751,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antihistamines,nitrites,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be OTHER_DRUG ,_af sympathomimetic_af agents_af ,_af tricyclic_af antidepressants_af ,_af drugs_af anticholinergic_af activity_af ._af"
752,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antihistamines,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
753,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antihistamines,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf DRUG ,_be antipsychotic_be agents_be (e_be ._be g_be ._be ,_be phenothiazines)_be ,_be benzodiazepines_be ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
754,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antipsychotic agents,phenothiazines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
755,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antipsychotic agents,benzodiazepines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf OTHER_DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
756,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antipsychotic agents,MAO inhibitors,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
757,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antipsychotic agents,narcotic analgesics,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
758,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antipsychotic agents,meperidine,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
759,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antipsychotic agents,nitrates,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf OTHER_DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
760,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antipsychotic agents,nitrites,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf OTHER_DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
761,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antipsychotic agents,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
762,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",antipsychotic agents,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
763,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",phenothiazines,benzodiazepines,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf OTHER_DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
764,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",phenothiazines,MAO inhibitors,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
765,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",phenothiazines,narcotic analgesics,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
766,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",phenothiazines,meperidine,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
767,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",phenothiazines,nitrates,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf OTHER_DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
768,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",phenothiazines,nitrites,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf OTHER_DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
769,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",phenothiazines,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
770,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",phenothiazines,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
771,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",benzodiazepines,MAO inhibitors,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
772,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",benzodiazepines,narcotic analgesics,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
773,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",benzodiazepines,meperidine,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
774,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",benzodiazepines,nitrates,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be OTHER_DRUG nitrites_af ,_af sympathomimetic_af agents_af ,_af tricyclic_af antidepressants_af ,_af drugs_af anticholinergic_af activity_af ._af"
775,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",benzodiazepines,nitrites,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be OTHER_DRUG ,_af sympathomimetic_af agents_af ,_af tricyclic_af antidepressants_af ,_af drugs_af anticholinergic_af activity_af ._af"
776,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",benzodiazepines,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
777,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",benzodiazepines,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf DRUG ,_be MAO_be inhibitors_be ,_be narcotic_be analgesics_be (e_be ._be g_be ._be ,_be meperidine)_be ,_be nitrates_be nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
778,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",MAO inhibitors,narcotic analgesics,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
779,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",MAO inhibitors,meperidine,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
780,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",MAO inhibitors,nitrates,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf OTHER_DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
781,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",MAO inhibitors,nitrites,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf OTHER_DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
782,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",MAO inhibitors,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
783,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",MAO inhibitors,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
784,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",narcotic analgesics,meperidine,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
785,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",narcotic analgesics,nitrates,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf OTHER_DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
786,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",narcotic analgesics,nitrites,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf OTHER_DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
787,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",narcotic analgesics,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
788,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",narcotic analgesics,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
789,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",meperidine,nitrates,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf OTHER_DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
790,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",meperidine,nitrites,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf OTHER_DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
791,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",meperidine,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
792,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",meperidine,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
793,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",nitrates,nitrites,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf DRUG OTHER_DRUG ,_af sympathomimetic_af agents_af ,_af tricyclic_af antidepressants_af ,_af drugs_af anticholinergic_af activity_af ._af"
794,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",nitrates,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
795,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",nitrates,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf DRUG nitrites_be ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
796,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",nitrites,sympathomimetic agents,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
797,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",nitrites,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf DRUG ,_be sympathomimetic_be agents_be ,_be tricyclic_be antidepressants_be ,_be drugs_be anticholinergic_be activity_be ._be"
798,"The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. ",sympathomimetic agents,tricyclic antidepressants,No interaction,"The_bf following_bf agents_bf may_bf increase_bf certain_bf actions_bf side_bf effects_bf anticholinergic_bf drugs:_bf amantadine_bf ,_bf antiarrhythmic_bf agents_bf class_bf I_bf (e_bf ._bf g_bf ._bf ,_bf quinidine)_bf ,_bf antihistamines_bf ,_bf antipsychotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf phenothiazines)_bf ,_bf benzodiazepines_bf ,_bf MAO_bf inhibitors_bf ,_bf narcotic_bf analgesics_bf (e_bf ._bf g_bf ._bf ,_bf meperidine)_bf ,_bf nitrates_bf nitrites_bf ,_bf sympathomimetic_bf agents_bf ,_bf tricyclic_bf antidepressants_bf ,_bf drugs_bf anticholinergic_bf activity_bf ._bf"
799,Anticholinergics antagonize the effects of antiglaucoma agents. ,Anticholinergics,antiglaucoma agents,effect,DRUG antagonize_be effects_be antiglaucoma_be agents_be ._be
800,Anticholinergic drugs in the presence of increased intraocular pressure may be hazardous when taken concurrently with agents such as corticosteroids. ,Anticholinergic drugs,corticosteroids,effect,Anticholinergic_bf drugs_bf presence_bf increased_bf intraocular_bf pressure_bf may_bf hazardous_bf taken_bf concurrently_bf agents_bf OTHER_DRUG ._be
801,"Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin; ",Anticholinergic agents,digoxin,mechanism,"Anticholinergic_bf agents_bf may_bf affect_bf gastrointestinal_bf absorption_bf various_bf drugs_bf ,_bf slowly_bf dissolving_bf dosage_bf forms_bf digoxin;_bf"
802,"Anticholinergic drugs may antagonize the effects of drugs that alter gastrointestinal motility, such as metoclopramide. ",Anticholinergic drugs,metoclopramide,effect,"Anticholinergic_bf drugs_bf may_bf antagonize_bf effects_bf drugs_bf alter_bf gastrointestinal_bf motility_bf ,_bf OTHER_DRUG ._be"
803,"Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided. ",antacids,anticholinergic agents,mechanism,"Because_bf DRUG may_be interfere_be absorption_be anticholinergic_be agents_be ,_be simultaneous_be use_be drugs_be avoided_be ._be"
804,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,alcohol,effect,"DRUG may_be enhance_be effects_be OTHER_DRUG ,_af barbiturates_af CNS_af depressants_af ._af"
805,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,barbiturates,effect,"DRUG may_be enhance_be effects_be alcohol_be ,_be OTHER_DRUG CNS_af depressants_af ._af"
806,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",SKELAXIN,CNS depressants,effect,"DRUG may_be enhance_be effects_be alcohol_be ,_be barbiturates_be CNS_be depressants_be ._be"
807,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",alcohol,barbiturates,No interaction,"SKELAXIN_bf may_bf enhance_bf effects_bf DRUG ,_be OTHER_DRUG CNS_af depressants_af ._af"
808,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",alcohol,CNS depressants,No interaction,"SKELAXIN_bf may_bf enhance_bf effects_bf DRUG ,_be barbiturates_be CNS_be depressants_be ._be"
809,"SKELAXIN may enhance the effects of alcohol, barbiturates and other CNS depressants.",barbiturates,CNS depressants,No interaction,"SKELAXIN_bf may_bf enhance_bf effects_bf alcohol_bf ,_bf DRUG CNS_be depressants_be ._be"
810,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,methazolamide,advise,"Caution_bf advised_bf patients_bf receiving_bf high-dose_bf DRUG OTHER_DRUG concomitantly_af ,_af anorexia_af ,_af tachypnea_af ,_af lethargy_af ,_af coma_af death_af reported_af concomitant_af use_af high-dose_af DRUG carbonic_af anhydrase_af inhibitors_af ._af"
811,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,aspirin,No interaction,"Caution_bf advised_bf patients_bf receiving_bf high-dose_bf DRUG methazolamide_be concomitantly_be ,_be anorexia_be ,_be tachypnea_be ,_be lethargy_be ,_be coma_be death_be reported_be concomitant_be use_be high-dose_be DRUG carbonic_af anhydrase_af inhibitors_af ._af"
812,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,carbonic anhydrase inhibitors,No interaction,"Caution_bf advised_bf patients_bf receiving_bf high-dose_bf DRUG methazolamide_be concomitantly_be ,_be anorexia_be ,_be tachypnea_be ,_be lethargy_be ,_be coma_be death_be reported_be concomitant_be use_be high-dose_be DRUG carbonic_af anhydrase_af inhibitors_af ._af"
813,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",methazolamide,aspirin,No interaction,"Caution_bf advised_bf patients_bf receiving_bf high-dose_bf OTHER_DRUG DRUG concomitantly_af ,_af anorexia_af ,_af tachypnea_af ,_af lethargy_af ,_af coma_af death_af reported_af concomitant_af use_af high-dose_af OTHER_DRUG carbonic_af anhydrase_af inhibitors_af ._af"
814,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",methazolamide,carbonic anhydrase inhibitors,No interaction,"Caution_bf advised_bf patients_bf receiving_bf high-dose_bf aspirin_bf DRUG concomitantly_be ,_be anorexia_be ,_be tachypnea_be ,_be lethargy_be ,_be coma_be death_be reported_be concomitant_be use_be high-dose_be aspirin_be carbonic_be anhydrase_be inhibitors_be ._be"
815,"Caution is advised for patients receiving high-dose aspirin and methazolamide concomitantly, as anorexia, tachypnea, lethargy, coma and death have been reported with concomitant use of high-dose aspirin and carbonic anhydrase inhibitors.",aspirin,carbonic anhydrase inhibitors,effect,"Caution_bf advised_bf patients_bf receiving_bf high-dose_bf DRUG methazolamide_be concomitantly_be ,_be anorexia_be ,_be tachypnea_be ,_be lethargy_be ,_be coma_be death_be reported_be concomitant_be use_be high-dose_be DRUG carbonic_af anhydrase_af inhibitors_af ._af"
816,Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,Anticoagulants,anticoagulants,No interaction,DRUG (oral):_be The_be activity_be oral_be DRUG may_af potentiated_af anti-vitamin-K_af activity_af attributed_af methimazole_af ._af
817,Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,Anticoagulants,methimazole,No interaction,DRUG (oral):_be The_be activity_be oral_be DRUG may_af potentiated_af anti-vitamin-K_af activity_af attributed_af OTHER_DRUG ._af
818,Anticoagulants (oral): The activity of oral anticoagulants may be potentiated by anti-vitamin-K activity attributed to methimazole.    ,anticoagulants,methimazole,effect,DRUG (oral):_be The_be activity_be oral_be DRUG may_af potentiated_af anti-vitamin-K_af activity_af attributed_af OTHER_DRUG ._af
819,Digitalis glycosides: Serum digitalis levels may be increased when hyperthyroid patients on a stable digitalis glycoside regimen become euthyroid; ,Digitalis glycosides,digitalis glycoside,No interaction,Digitalis_bf glycosides:_bf Serum_bf digitalis_bf levels_bf may_bf increased_bf hyperthyroid_bf patients_bf stable_bf digitalis_bf glycoside_bf regimen_bf become_bf euthyroid;_bf
820,Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; ,Theophylline,Theophylline,No interaction,Theophylline:_bf DRUG clearance_be may_be decrease_be hyperthyroid_be patients_be stable_be DRUG regimen_af become_af euthyroid;_af
821,Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; ,Theophylline,theophylline,No interaction,Theophylline:_bf DRUG clearance_be may_be decrease_be hyperthyroid_be patients_be stable_be DRUG regimen_af become_af euthyroid;_af
822,Theophylline: Theophylline clearance may decrease when hyperthyroid patients on a stable theophylline regimen become euthyroid; ,Theophylline,theophylline,No interaction,Theophylline:_bf DRUG clearance_be may_be decrease_be hyperthyroid_be patients_be stable_be DRUG regimen_af become_af euthyroid;_af
823,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",opioids,levomepromazine,effect,"Dosages_bf concomitantly_bf administered_bf DRUG reduced_be approximately_be half_be ,_be OTHER_DRUG amplifies_af therapeutic_af actions_af side-effects_af DRUG ._af"
824,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",opioids,opioids,No interaction,"Dosages_bf concomitantly_bf administered_bf DRUG reduced_be approximately_be half_be ,_be levomepromazine_be amplifies_be therapeutic_be actions_be side-effects_be DRUG ._af"
825,"Dosages of concomitantly administered opioids should be reduced by approximately half, because levomepromazine amplifies the therapeutic actions and side-effects of opioids. ",levomepromazine,opioids,effect,"Dosages_bf concomitantly_bf administered_bf OTHER_DRUG reduced_be approximately_be half_be ,_be DRUG amplifies_af therapeutic_af actions_af side-effects_af OTHER_DRUG ._af"
826,Combination with tramadol (Ultram) is associated with increased risk of seizures. ,tramadol,Ultram,No interaction,Combination_bf DRUG (Ultram)_be associated_be increased_be risk_be seizures_be ._be
827,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,levomepromazine,benzodiazepines,effect,Additive_bf sedative_bf effects_bf confusional_bf states_bf may_bf emerge_bf DRUG given_be OTHER_DRUG barbiturates_af ._af
828,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,levomepromazine,barbiturates,effect,Additive_bf sedative_bf effects_bf confusional_bf states_bf may_bf emerge_bf DRUG given_be benzodiazepines_be OTHER_DRUG ._af
829,Additive sedative effects and confusional states may emerge if levomepromazine is given with benzodiazepines or barbiturates. ,benzodiazepines,barbiturates,No interaction,Additive_bf sedative_bf effects_bf confusional_bf states_bf may_bf emerge_bf levomepromazine_bf given_bf DRUG OTHER_DRUG ._af
830,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,anticholinergic drugs,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian-agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
831,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,tricyclic antidepressants,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian-agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
832,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",levomepromazine,antiparkinsonian-agents,advise,"Exert_bf particular_bf caution_bf combining_bf DRUG anticholinergic_be drugs_be (tricyclic_be antidepressants_be antiparkinsonian-agents):_be Particularly_be elderly_be may_be develop_be delirium_be ,_be high_be fever_be ,_be severe_be obstipation_be ,_be even_be ileus_be glaucoma_be ._be"
833,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",anticholinergic drugs,tricyclic antidepressants,No interaction,"Exert_bf particular_bf caution_bf combining_bf levomepromazine_bf anticholinergic_bf drugs_bf (tricyclic_bf antidepressants_bf antiparkinsonian-agents):_bf Particularly_bf elderly_bf may_bf develop_bf delirium_bf ,_bf high_bf fever_bf ,_bf severe_bf obstipation_bf ,_bf even_bf ileus_bf glaucoma_bf ._bf"
834,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",anticholinergic drugs,antiparkinsonian-agents,No interaction,"Exert_bf particular_bf caution_bf combining_bf levomepromazine_bf anticholinergic_bf drugs_bf (tricyclic_bf antidepressants_bf antiparkinsonian-agents):_bf Particularly_bf elderly_bf may_bf develop_bf delirium_bf ,_bf high_bf fever_bf ,_bf severe_bf obstipation_bf ,_bf even_bf ileus_bf glaucoma_bf ._bf"
835,"Exert particular caution in combining levomepromazine with other anticholinergic drugs (tricyclic antidepressants and antiparkinsonian-agents): Particularly the elderly may develop delirium, high fever, severe obstipation, even ileus and glaucoma. ",tricyclic antidepressants,antiparkinsonian-agents,No interaction,"Exert_bf particular_bf caution_bf combining_bf levomepromazine_bf anticholinergic_bf drugs_bf (tricyclic_bf antidepressants_bf antiparkinsonian-agents):_bf Particularly_bf elderly_bf may_bf develop_bf delirium_bf ,_bf high_bf fever_bf ,_bf severe_bf obstipation_bf ,_bf even_bf ileus_bf glaucoma_bf ._bf"
836,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,Caffeine,ephedrine,No interaction,DRUG and/or_be stimulantes_be ephedrine/amphetamine_be type_be may_be counteract_be specific_be actions_be levomepromazine_be ._be
837,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,Caffeine,amphetamine,No interaction,DRUG and/or_be stimulantes_be ephedrine/amphetamine_be type_be may_be counteract_be specific_be actions_be levomepromazine_be ._be
838,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,Caffeine,levomepromazine,effect,DRUG and/or_be stimulantes_be ephedrine/amphetamine_be type_be may_be counteract_be specific_be actions_be OTHER_DRUG ._af
839,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,ephedrine,amphetamine,No interaction,Caffeine_bf and/or_bf stimulantes_bf ephedrine/amphetamine_bf type_bf may_bf counteract_bf specific_bf actions_bf levomepromazine_bf ._bf
840,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,ephedrine,levomepromazine,effect,Caffeine_bf and/or_bf stimulantes_bf ephedrine/amphetamine_bf type_bf may_bf counteract_bf specific_bf actions_bf OTHER_DRUG ._be
841,Caffeine and/or stimulantes of the ephedrine/amphetamine type may counteract the specific actions of levomepromazine. ,amphetamine,levomepromazine,effect,Caffeine_bf and/or_bf stimulantes_bf ephedrine/amphetamine_bf type_bf may_bf counteract_bf specific_bf actions_bf OTHER_DRUG ._be
842,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",Celontin,methsuximide,No interaction,"Since_bf DRUG (methsuximide)_be may_be interact_be concurrently_be administered_be antiepileptic_be drugs_be ,_be periodic_be serum_be level_be determinations_be drugs_be may_be necessary_be (eg_be OTHER_DRUG may_af increase_af plasma_af concentrations_af phenytoin_af phenobarbital)_af ._af"
843,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",Celontin,antiepileptic drugs,advise,"Since_bf DRUG (methsuximide)_be may_be interact_be concurrently_be administered_be antiepileptic_be drugs_be ,_be periodic_be serum_be level_be determinations_be drugs_be may_be necessary_be (eg_be methsuximide_be may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
844,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",Celontin,methsuximide,No interaction,"Since_bf DRUG (methsuximide)_be may_be interact_be concurrently_be administered_be antiepileptic_be drugs_be ,_be periodic_be serum_be level_be determinations_be drugs_be may_be necessary_be (eg_be OTHER_DRUG may_af increase_af plasma_af concentrations_af phenytoin_af phenobarbital)_af ._af"
845,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",Celontin,phenytoin,No interaction,"Since_bf DRUG (methsuximide)_be may_be interact_be concurrently_be administered_be antiepileptic_be drugs_be ,_be periodic_be serum_be level_be determinations_be drugs_be may_be necessary_be (eg_be methsuximide_be may_be increase_be plasma_be concentrations_be OTHER_DRUG phenobarbital)_af ._af"
846,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",Celontin,phenobarbital,No interaction,"Since_bf DRUG (methsuximide)_be may_be interact_be concurrently_be administered_be antiepileptic_be drugs_be ,_be periodic_be serum_be level_be determinations_be drugs_be may_be necessary_be (eg_be methsuximide_be may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
847,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,antiepileptic drugs,advise,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
848,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,methsuximide,No interaction,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
849,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenytoin,No interaction,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be OTHER_DRUG phenobarbital)_af ._af"
850,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenobarbital,No interaction,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
851,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",antiepileptic drugs,methsuximide,No interaction,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf OTHER_DRUG may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
852,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",antiepileptic drugs,phenytoin,No interaction,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf methsuximide_bf may_bf increase_bf plasma_bf concentrations_bf OTHER_DRUG phenobarbital)_be ._be"
853,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",antiepileptic drugs,phenobarbital,No interaction,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf methsuximide_bf may_bf increase_bf plasma_bf concentrations_bf phenytoin_bf phenobarbital)_bf ._bf"
854,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenytoin,mechanism,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be OTHER_DRUG phenobarbital)_af ._af"
855,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",methsuximide,phenobarbital,mechanism,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf DRUG may_be increase_be plasma_be concentrations_be phenytoin_be phenobarbital)_be ._be"
856,"Since Celontin (methsuximide) may interact with concurrently administered antiepileptic drugs, periodic serum level determinations of these drugs may be necessary (eg methsuximide may increase the plasma concentrations of phenytoin and phenobarbital).",phenytoin,phenobarbital,No interaction,"Since_bf Celontin_bf (methsuximide)_bf may_bf interact_bf concurrently_bf administered_bf antiepileptic_bf drugs_bf ,_bf periodic_bf serum_bf level_bf determinations_bf drugs_bf may_bf necessary_bf (eg_bf methsuximide_bf may_bf increase_bf plasma_bf concentrations_bf DRUG phenobarbital)_be ._be"
857,Hypokalemia may develop during concomitant use of steroids or ACTH. ,steroids,ACTH,No interaction,Hypokalemia_bf may_bf develop_bf concomitant_bf use_bf DRUG OTHER_DRUG ._af
858,Thiazides may decrease arterial responsiveness to norepinephrine. ,Thiazides,norepinephrine,effect,DRUG may_be decrease_be arterial_be responsiveness_be OTHER_DRUG ._af
859,Thiazide drugs may increase the responsiveness of tubocurarine. ,Thiazide drugs,tubocurarine,effect,Thiazide_bf drugs_bf may_bf increase_bf responsiveness_bf OTHER_DRUG ._be
860,"Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. ",Lithium,thiazides,mechanism,"DRUG renal_be clearance_be reduced_be OTHER_DRUG ,_af increasing_af risk_af DRUG toxicity_af ._af"
861,"Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. ",Lithium,lithium,No interaction,"DRUG renal_be clearance_be reduced_be thiazides_be ,_be increasing_be risk_be DRUG toxicity_af ._af"
862,"Lithium renal clearance is reduced by thiazides, increasing the risk of lithium toxicity. ",thiazides,lithium,No interaction,"OTHER_DRUG renal_be clearance_be reduced_be DRUG ,_af increasing_af risk_af OTHER_DRUG toxicity_af ._af"
863,Thiazides may add to or potentiate the action of other antihypertensive drugs. ,Thiazides,antihypertensive drugs,effect,DRUG may_be add_be potentiate_be action_be antihypertensive_be drugs_be ._be
864,Potentiation occurs with ganglionic or peripheral adrenergic blocking drugs.,ganglionic adrenergic blocking drugs,peripheral adrenergic blocking drugs,No interaction,Potentiation_bf occurs_bf ganglionic_bf peripheral_bf adrenergic_bf blocking_bf drugs_bf ._bf
865,"When methyldopa is used with other antihypertensive drugs, potentiation of antihypertensive effect may occur. ",methyldopa,antihypertensive drugs,effect,"When_bf DRUG used_be antihypertensive_be drugs_be ,_be potentiation_be antihypertensive_be effect_be may_be occur_be ._be"
866,Patients may require reduced doses of anesthetics when on methyldopa. ,anesthetics,methyldopa,advise,Patients_bf may_bf require_bf reduced_bf doses_bf DRUG OTHER_DRUG ._af
867,When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ,methyldopa,lithium,advise,When_bf DRUG OTHER_DRUG given_af concomitantly_af patient_af carefully_af monitored_af symptoms_af OTHER_DRUG toxicity_af ._af
868,When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ,methyldopa,lithium,No interaction,When_bf DRUG OTHER_DRUG given_af concomitantly_af patient_af carefully_af monitored_af symptoms_af OTHER_DRUG toxicity_af ._af
869,When methyldopa and lithium are given concomitantly the patient should be carefully monitored for symptoms of lithium toxicity. ,lithium,lithium,No interaction,When_bf methyldopa_bf DRUG given_be concomitantly_be patient_be carefully_be monitored_be symptoms_be DRUG toxicity_af ._af
870,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,methyldopa,ferrous sulfate,mechanism,Several_bf studies_bf demonstrate_bf decrease_bf bioavailability_bf DRUG ingested_be ferrous_be sulfate_be ferrous_be gluconate_be ._be
871,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,methyldopa,ferrous gluconate,mechanism,Several_bf studies_bf demonstrate_bf decrease_bf bioavailability_bf DRUG ingested_be ferrous_be sulfate_be ferrous_be gluconate_be ._be
872,Several studies demonstrate a decrease in the bioavailability of methyldopa when it is ingested with ferrous sulfate or ferrous gluconate. ,ferrous sulfate,ferrous gluconate,No interaction,Several_bf studies_bf demonstrate_bf decrease_bf bioavailability_bf methyldopa_bf ingested_bf ferrous_bf sulfate_bf ferrous_bf gluconate_bf ._bf
873,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,methyldopa,ferrous sulfate,advise,Coadministration_bf DRUG ferrous_be sulfate_be ferrous_be gluconate_be recommended_be ._be
874,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,methyldopa,ferrous gluconate,advise,Coadministration_bf DRUG ferrous_be sulfate_be ferrous_be gluconate_be recommended_be ._be
875,Coadministration of methyldopa with ferrous sulfate or ferrous gluconate is not recommended. ,ferrous sulfate,ferrous gluconate,No interaction,Coadministration_bf methyldopa_bf ferrous_bf sulfate_bf ferrous_bf gluconate_bf recommended_bf ._bf
876,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",Methyldopa,VMA,No interaction,"DRUG interfere_be measurement_be OTHER_DRUG (vanillylmandelic_af acid)_af ,_af test_af pheochromocytoma_af ,_af methods_af convert_af OTHER_DRUG vanillin_af ._af"
877,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",Methyldopa,vanillylmandelic acid,No interaction,"DRUG interfere_be measurement_be VMA_be (vanillylmandelic_be acid)_be ,_be test_be pheochromocytoma_be ,_be methods_be convert_be VMA_be vanillin_be ._be"
878,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",Methyldopa,VMA,No interaction,"DRUG interfere_be measurement_be OTHER_DRUG (vanillylmandelic_af acid)_af ,_af test_af pheochromocytoma_af ,_af methods_af convert_af OTHER_DRUG vanillin_af ._af"
879,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",Methyldopa,vanillin,No interaction,"DRUG interfere_be measurement_be VMA_be (vanillylmandelic_be acid)_be ,_be test_be pheochromocytoma_be ,_be methods_be convert_be VMA_be OTHER_DRUG ._af"
880,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",VMA,vanillylmandelic acid,No interaction,"Methyldopa_bf interfere_bf measurement_bf DRUG (vanillylmandelic_be acid)_be ,_be test_be pheochromocytoma_be ,_be methods_be convert_be DRUG vanillin_af ._af"
881,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",VMA,VMA,No interaction,"Methyldopa_bf interfere_bf measurement_bf DRUG (vanillylmandelic_be acid)_be ,_be test_be pheochromocytoma_be ,_be methods_be convert_be DRUG vanillin_af ._af"
882,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",VMA,vanillin,No interaction,"Methyldopa_bf interfere_bf measurement_bf DRUG (vanillylmandelic_be acid)_be ,_be test_be pheochromocytoma_be ,_be methods_be convert_be DRUG OTHER_DRUG ._af"
883,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",vanillylmandelic acid,VMA,No interaction,"Methyldopa_bf interfere_bf measurement_bf OTHER_DRUG (vanillylmandelic_be acid)_be ,_be test_be pheochromocytoma_be ,_be methods_be convert_be OTHER_DRUG vanillin_af ._af"
884,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",vanillylmandelic acid,vanillin,No interaction,"Methyldopa_bf interfere_bf measurement_bf VMA_bf (vanillylmandelic_bf acid)_bf ,_bf test_bf pheochromocytoma_bf ,_bf methods_bf convert_bf VMA_bf OTHER_DRUG ._be"
885,"Methyldopa does not interfere with measurement of VMA (vanillylmandelic acid), a test for pheochromocytoma, by those methods which convert VMA to vanillin. ",VMA,vanillin,No interaction,"Methyldopa_bf interfere_bf measurement_bf DRUG (vanillylmandelic_be acid)_be ,_be test_be pheochromocytoma_be ,_be methods_be convert_be DRUG OTHER_DRUG ._af"
886,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",Macrolide Antibiotics,Protease Inhibitors,No interaction,"CYP_bf 3A4_bf Inhibitors_bf (e_bf ._bf g_bf ._bf Macrolide_bf Antibiotics_bf Protease_bf Inhibitors)_bf There_bf rare_bf reports_bf serious_bf adverse_bf events_bf connection_bf coadministration_bf certain_bf ergot_bf alkaloid_bf drugs_bf (e_bf ._bf g_bf ._bf dihydroergotamine_bf ergotamine)_bf potent_bf CYP_bf 3A4_bf inhibitors_bf ,_bf resulting_bf vasospasm_bf leading_bf cerebral_bf ischemia_bf and/or_bf ischemia_bf extremities_bf ._bf"
887,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",Macrolide Antibiotics,ergot alkaloid drugs,No interaction,"CYP_bf 3A4_bf Inhibitors_bf (e_bf ._bf g_bf ._bf Macrolide_bf Antibiotics_bf Protease_bf Inhibitors)_bf There_bf rare_bf reports_bf serious_bf adverse_bf events_bf connection_bf coadministration_bf certain_bf ergot_bf alkaloid_bf drugs_bf (e_bf ._bf g_bf ._bf dihydroergotamine_bf ergotamine)_bf potent_bf CYP_bf 3A4_bf inhibitors_bf ,_bf resulting_bf vasospasm_bf leading_bf cerebral_bf ischemia_bf and/or_bf ischemia_bf extremities_bf ._bf"
888,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",Macrolide Antibiotics,dihydroergotamine,No interaction,"CYP_bf 3A4_bf Inhibitors_bf (e_bf ._bf g_bf ._bf Macrolide_bf Antibiotics_bf Protease_bf Inhibitors)_bf There_bf rare_bf reports_bf serious_bf adverse_bf events_bf connection_bf coadministration_bf certain_bf ergot_bf alkaloid_bf drugs_bf (e_bf ._bf g_bf ._bf OTHER_DRUG ergotamine)_be potent_be CYP_be 3A4_be inhibitors_be ,_be resulting_be vasospasm_be leading_be cerebral_be ischemia_be and/or_be ischemia_be extremities_be ._be"
889,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",Macrolide Antibiotics,ergotamine,No interaction,"CYP_bf 3A4_bf Inhibitors_bf (e_bf ._bf g_bf ._bf Macrolide_bf Antibiotics_bf Protease_bf Inhibitors)_bf There_bf rare_bf reports_bf serious_bf adverse_bf events_bf connection_bf coadministration_bf certain_bf ergot_bf alkaloid_bf drugs_bf (e_bf ._bf g_bf ._bf dihydroergotamine_bf ergotamine)_bf potent_bf CYP_bf 3A4_bf inhibitors_bf ,_bf resulting_bf vasospasm_bf leading_bf cerebral_bf ischemia_bf and/or_bf ischemia_bf extremities_bf ._bf"
890,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",Protease Inhibitors,ergot alkaloid drugs,No interaction,"CYP_bf 3A4_bf Inhibitors_bf (e_bf ._bf g_bf ._bf Macrolide_bf Antibiotics_bf Protease_bf Inhibitors)_bf There_bf rare_bf reports_bf serious_bf adverse_bf events_bf connection_bf coadministration_bf certain_bf ergot_bf alkaloid_bf drugs_bf (e_bf ._bf g_bf ._bf dihydroergotamine_bf ergotamine)_bf potent_bf CYP_bf 3A4_bf inhibitors_bf ,_bf resulting_bf vasospasm_bf leading_bf cerebral_bf ischemia_bf and/or_bf ischemia_bf extremities_bf ._bf"
891,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",Protease Inhibitors,dihydroergotamine,No interaction,"CYP_bf 3A4_bf Inhibitors_bf (e_bf ._bf g_bf ._bf Macrolide_bf Antibiotics_bf Protease_bf Inhibitors)_bf There_bf rare_bf reports_bf serious_bf adverse_bf events_bf connection_bf coadministration_bf certain_bf ergot_bf alkaloid_bf drugs_bf (e_bf ._bf g_bf ._bf OTHER_DRUG ergotamine)_be potent_be CYP_be 3A4_be inhibitors_be ,_be resulting_be vasospasm_be leading_be cerebral_be ischemia_be and/or_be ischemia_be extremities_be ._be"
892,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",Protease Inhibitors,ergotamine,No interaction,"CYP_bf 3A4_bf Inhibitors_bf (e_bf ._bf g_bf ._bf Macrolide_bf Antibiotics_bf Protease_bf Inhibitors)_bf There_bf rare_bf reports_bf serious_bf adverse_bf events_bf connection_bf coadministration_bf certain_bf ergot_bf alkaloid_bf drugs_bf (e_bf ._bf g_bf ._bf dihydroergotamine_bf ergotamine)_bf potent_bf CYP_bf 3A4_bf inhibitors_bf ,_bf resulting_bf vasospasm_bf leading_bf cerebral_bf ischemia_bf and/or_bf ischemia_bf extremities_bf ._bf"
893,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",ergot alkaloid drugs,dihydroergotamine,No interaction,"CYP_bf 3A4_bf Inhibitors_bf (e_bf ._bf g_bf ._bf Macrolide_bf Antibiotics_bf Protease_bf Inhibitors)_bf There_bf rare_bf reports_bf serious_bf adverse_bf events_bf connection_bf coadministration_bf certain_bf ergot_bf alkaloid_bf drugs_bf (e_bf ._bf g_bf ._bf OTHER_DRUG ergotamine)_be potent_be CYP_be 3A4_be inhibitors_be ,_be resulting_be vasospasm_be leading_be cerebral_be ischemia_be and/or_be ischemia_be extremities_be ._be"
894,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",ergot alkaloid drugs,ergotamine,No interaction,"CYP_bf 3A4_bf Inhibitors_bf (e_bf ._bf g_bf ._bf Macrolide_bf Antibiotics_bf Protease_bf Inhibitors)_bf There_bf rare_bf reports_bf serious_bf adverse_bf events_bf connection_bf coadministration_bf certain_bf ergot_bf alkaloid_bf drugs_bf (e_bf ._bf g_bf ._bf dihydroergotamine_bf ergotamine)_bf potent_bf CYP_bf 3A4_bf inhibitors_bf ,_bf resulting_bf vasospasm_bf leading_bf cerebral_bf ischemia_bf and/or_bf ischemia_bf extremities_bf ._bf"
895,"CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities. ",dihydroergotamine,ergotamine,No interaction,"CYP_bf 3A4_bf Inhibitors_bf (e_bf ._bf g_bf ._bf Macrolide_bf Antibiotics_bf Protease_bf Inhibitors)_bf There_bf rare_bf reports_bf serious_bf adverse_bf events_bf connection_bf coadministration_bf certain_bf ergot_bf alkaloid_bf drugs_bf (e_bf ._bf g_bf ._bf DRUG ergotamine)_be potent_be CYP_be 3A4_be inhibitors_be ,_be resulting_be vasospasm_be leading_be cerebral_be ischemia_be and/or_be ischemia_be extremities_be ._be"
896,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,erythromycin,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
897,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,troleandomycin,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf OTHER_DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
898,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,clarithromycin,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
899,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,HIV protease inhibitors,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
900,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,reverse transcriptase inhibitors,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
901,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,ritonavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
902,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,indinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf OTHER_DRUG ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
903,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,nelfinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf OTHER_DRUG ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
904,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,delavirdine,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
905,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,azole antifungals,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
906,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,ketoconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be itraconazole_be ,_be voriconazole)_be ._be"
907,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf OTHER_DRUG ,_be voriconazole)_be ._be"
908,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",macrolide antibiotics,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
909,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,troleandomycin,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af clarithromycin)_af ,_af HIV_af protease_af reverse_af transcriptase_af inhibitors_af (e_af ._af g_af ._af ,_af ritonavir_af ,_af indinavir_af ,_af nelfinavir_af ,_af delavirdine)_af azole_af antifungals_af (e_af ._af g_af ._af ,_af ketoconazole_af ,_af itraconazole_af ,_af voriconazole)_af ._af"
910,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,clarithromycin,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
911,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,HIV protease inhibitors,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
912,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,reverse transcriptase inhibitors,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
913,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,ritonavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af indinavir_af ,_af nelfinavir_af ,_af delavirdine)_af azole_af antifungals_af (e_af ._af g_af ._af ,_af ketoconazole_af ,_af itraconazole_af ,_af voriconazole)_af ._af"
914,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,indinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be OTHER_DRUG ,_af nelfinavir_af ,_af delavirdine)_af azole_af antifungals_af (e_af ._af g_af ._af ,_af ketoconazole_af ,_af itraconazole_af ,_af voriconazole)_af ._af"
915,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,nelfinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be OTHER_DRUG ,_af delavirdine)_af azole_af antifungals_af (e_af ._af g_af ._af ,_af ketoconazole_af ,_af itraconazole_af ,_af voriconazole)_af ._af"
916,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,delavirdine,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
917,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,azole antifungals,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
918,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,ketoconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af itraconazole_af ,_af voriconazole)_af ._af"
919,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af voriconazole)_af ._af"
920,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",erythromycin,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be troleandomycin_be ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
921,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",troleandomycin,clarithromycin,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
922,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",troleandomycin,HIV protease inhibitors,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
923,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",troleandomycin,reverse transcriptase inhibitors,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
924,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",troleandomycin,ritonavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af indinavir_af ,_af nelfinavir_af ,_af delavirdine)_af azole_af antifungals_af (e_af ._af g_af ._af ,_af ketoconazole_af ,_af itraconazole_af ,_af voriconazole)_af ._af"
925,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",troleandomycin,indinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be OTHER_DRUG ,_af nelfinavir_af ,_af delavirdine)_af azole_af antifungals_af (e_af ._af g_af ._af ,_af ketoconazole_af ,_af itraconazole_af ,_af voriconazole)_af ._af"
926,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",troleandomycin,nelfinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be OTHER_DRUG ,_af delavirdine)_af azole_af antifungals_af (e_af ._af g_af ._af ,_af ketoconazole_af ,_af itraconazole_af ,_af voriconazole)_af ._af"
927,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",troleandomycin,delavirdine,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
928,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",troleandomycin,azole antifungals,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
929,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",troleandomycin,ketoconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af itraconazole_af ,_af voriconazole)_af ._af"
930,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",troleandomycin,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af voriconazole)_af ._af"
931,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",troleandomycin,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf DRUG ,_be clarithromycin)_be ,_be HIV_be protease_be reverse_be transcriptase_be inhibitors_be (e_be ._be g_be ._be ,_be ritonavir_be ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
932,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",clarithromycin,HIV protease inhibitors,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
933,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",clarithromycin,reverse transcriptase inhibitors,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
934,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",clarithromycin,ritonavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
935,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",clarithromycin,indinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf OTHER_DRUG ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
936,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",clarithromycin,nelfinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf OTHER_DRUG ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
937,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",clarithromycin,delavirdine,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
938,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",clarithromycin,azole antifungals,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
939,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",clarithromycin,ketoconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be itraconazole_be ,_be voriconazole)_be ._be"
940,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",clarithromycin,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf OTHER_DRUG ,_be voriconazole)_be ._be"
941,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",clarithromycin,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
942,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",HIV protease inhibitors,reverse transcriptase inhibitors,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
943,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",HIV protease inhibitors,ritonavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
944,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",HIV protease inhibitors,indinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf OTHER_DRUG ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
945,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",HIV protease inhibitors,nelfinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf OTHER_DRUG ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
946,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",HIV protease inhibitors,delavirdine,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
947,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",HIV protease inhibitors,azole antifungals,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
948,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",HIV protease inhibitors,ketoconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be itraconazole_be ,_be voriconazole)_be ._be"
949,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",HIV protease inhibitors,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf OTHER_DRUG ,_be voriconazole)_be ._be"
950,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",HIV protease inhibitors,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
951,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",reverse transcriptase inhibitors,ritonavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
952,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",reverse transcriptase inhibitors,indinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf OTHER_DRUG ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
953,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",reverse transcriptase inhibitors,nelfinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf OTHER_DRUG ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
954,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",reverse transcriptase inhibitors,delavirdine,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
955,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",reverse transcriptase inhibitors,azole antifungals,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
956,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",reverse transcriptase inhibitors,ketoconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be itraconazole_be ,_be voriconazole)_be ._be"
957,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",reverse transcriptase inhibitors,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf OTHER_DRUG ,_be voriconazole)_be ._be"
958,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",reverse transcriptase inhibitors,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
959,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",ritonavir,indinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af nelfinavir_af ,_af delavirdine)_af azole_af antifungals_af (e_af ._af g_af ._af ,_af ketoconazole_af ,_af itraconazole_af ,_af voriconazole)_af ._af"
960,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",ritonavir,nelfinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be indinavir_be ,_be OTHER_DRUG ,_af delavirdine)_af azole_af antifungals_af (e_af ._af g_af ._af ,_af ketoconazole_af ,_af itraconazole_af ,_af voriconazole)_af ._af"
961,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",ritonavir,delavirdine,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
962,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",ritonavir,azole antifungals,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
963,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",ritonavir,ketoconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af itraconazole_af ,_af voriconazole)_af ._af"
964,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",ritonavir,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af voriconazole)_af ._af"
965,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",ritonavir,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be indinavir_be ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
966,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",indinavir,nelfinavir,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf DRUG ,_be OTHER_DRUG ,_af delavirdine)_af azole_af antifungals_af (e_af ._af g_af ._af ,_af ketoconazole_af ,_af itraconazole_af ,_af voriconazole)_af ._af"
967,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",indinavir,delavirdine,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf DRUG ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
968,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",indinavir,azole antifungals,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf DRUG ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
969,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",indinavir,ketoconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf DRUG ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af itraconazole_af ,_af voriconazole)_af ._af"
970,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",indinavir,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf DRUG ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af voriconazole)_af ._af"
971,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",indinavir,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf DRUG ,_be nelfinavir_be ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
972,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",nelfinavir,delavirdine,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf DRUG ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
973,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",nelfinavir,azole antifungals,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf DRUG ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
974,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",nelfinavir,ketoconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf DRUG ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af itraconazole_af ,_af voriconazole)_af ._af"
975,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",nelfinavir,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf DRUG ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be OTHER_DRUG ,_af voriconazole)_af ._af"
976,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",nelfinavir,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf DRUG ,_be delavirdine)_be azole_be antifungals_be (e_be ._be g_be ._be ,_be ketoconazole_be ,_be itraconazole_be ,_be voriconazole)_be ._be"
977,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",delavirdine,azole antifungals,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
978,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",delavirdine,ketoconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be itraconazole_be ,_be voriconazole)_be ._be"
979,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",delavirdine,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf OTHER_DRUG ,_be voriconazole)_be ._be"
980,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",delavirdine,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
981,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",azole antifungals,ketoconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be itraconazole_be ,_be voriconazole)_be ._be"
982,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",azole antifungals,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf OTHER_DRUG ,_be voriconazole)_be ._be"
983,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",azole antifungals,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf voriconazole)_bf ._bf"
984,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",ketoconazole,itraconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af voriconazole)_af ._af"
985,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",ketoconazole,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be itraconazole_be ,_be voriconazole)_be ._be"
986,"Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). ",itraconazole,voriconazole,No interaction,"Examples_bf potent_bf CYP_bf 3A4_bf inhibitors_bf include_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf ,_bf troleandomycin_bf ,_bf clarithromycin)_bf ,_bf HIV_bf protease_bf reverse_bf transcriptase_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf ritonavir_bf ,_bf indinavir_bf ,_bf nelfinavir_bf ,_bf delavirdine)_bf azole_bf antifungals_bf (e_bf ._bf g_bf ._bf ,_bf ketoconazole_bf ,_bf DRUG ,_be voriconazole)_be ._be"
987,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",saquinavir,nefazodone,No interaction,"Less_bf potent_bf inhibitors_bf include_bf DRUG ,_be OTHER_DRUG ,_af fluconazole_af ,_af grapefruit_af juice_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af zileuton_af ,_af clotrimazole_af ._af"
988,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",saquinavir,fluconazole,No interaction,"Less_bf potent_bf inhibitors_bf include_bf DRUG ,_be nefazodone_be ,_be OTHER_DRUG ,_af grapefruit_af juice_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af zileuton_af ,_af clotrimazole_af ._af"
989,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",saquinavir,fluoxetine,No interaction,"Less_bf potent_bf inhibitors_bf include_bf DRUG ,_be nefazodone_be ,_be fluconazole_be ,_be grapefruit_be juice_be ,_be OTHER_DRUG ,_af fluvoxamine_af ,_af zileuton_af ,_af clotrimazole_af ._af"
990,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",saquinavir,fluvoxamine,No interaction,"Less_bf potent_bf inhibitors_bf include_bf DRUG ,_be nefazodone_be ,_be fluconazole_be ,_be grapefruit_be juice_be ,_be fluoxetine_be ,_be OTHER_DRUG ,_af zileuton_af ,_af clotrimazole_af ._af"
991,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",saquinavir,zileuton,No interaction,"Less_bf potent_bf inhibitors_bf include_bf DRUG ,_be nefazodone_be ,_be fluconazole_be ,_be grapefruit_be juice_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be OTHER_DRUG ,_af clotrimazole_af ._af"
992,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",saquinavir,clotrimazole,No interaction,"Less_bf potent_bf inhibitors_bf include_bf DRUG ,_be nefazodone_be ,_be fluconazole_be ,_be grapefruit_be juice_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be zileuton_be ,_be OTHER_DRUG ._af"
993,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",nefazodone,fluconazole,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf DRUG ,_be OTHER_DRUG ,_af grapefruit_af juice_af ,_af fluoxetine_af ,_af fluvoxamine_af ,_af zileuton_af ,_af clotrimazole_af ._af"
994,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",nefazodone,fluoxetine,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf DRUG ,_be fluconazole_be ,_be grapefruit_be juice_be ,_be OTHER_DRUG ,_af fluvoxamine_af ,_af zileuton_af ,_af clotrimazole_af ._af"
995,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",nefazodone,fluvoxamine,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf DRUG ,_be fluconazole_be ,_be grapefruit_be juice_be ,_be fluoxetine_be ,_be OTHER_DRUG ,_af zileuton_af ,_af clotrimazole_af ._af"
996,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",nefazodone,zileuton,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf DRUG ,_be fluconazole_be ,_be grapefruit_be juice_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be OTHER_DRUG ,_af clotrimazole_af ._af"
997,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",nefazodone,clotrimazole,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf DRUG ,_be fluconazole_be ,_be grapefruit_be juice_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be zileuton_be ,_be OTHER_DRUG ._af"
998,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",fluconazole,fluoxetine,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf nefazodone_bf ,_bf DRUG ,_be grapefruit_be juice_be ,_be OTHER_DRUG ,_af fluvoxamine_af ,_af zileuton_af ,_af clotrimazole_af ._af"
999,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",fluconazole,fluvoxamine,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf nefazodone_bf ,_bf DRUG ,_be grapefruit_be juice_be ,_be fluoxetine_be ,_be OTHER_DRUG ,_af zileuton_af ,_af clotrimazole_af ._af"
1000,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",fluconazole,zileuton,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf nefazodone_bf ,_bf DRUG ,_be grapefruit_be juice_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be OTHER_DRUG ,_af clotrimazole_af ._af"
1001,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",fluconazole,clotrimazole,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf nefazodone_bf ,_bf DRUG ,_be grapefruit_be juice_be ,_be fluoxetine_be ,_be fluvoxamine_be ,_be zileuton_be ,_be OTHER_DRUG ._af"
1002,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",fluoxetine,fluvoxamine,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf nefazodone_bf ,_bf fluconazole_bf ,_bf grapefruit_bf juice_bf ,_bf DRUG ,_be OTHER_DRUG ,_af zileuton_af ,_af clotrimazole_af ._af"
1003,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",fluoxetine,zileuton,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf nefazodone_bf ,_bf fluconazole_bf ,_bf grapefruit_bf juice_bf ,_bf DRUG ,_be fluvoxamine_be ,_be OTHER_DRUG ,_af clotrimazole_af ._af"
1004,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",fluoxetine,clotrimazole,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf nefazodone_bf ,_bf fluconazole_bf ,_bf grapefruit_bf juice_bf ,_bf DRUG ,_be fluvoxamine_be ,_be zileuton_be ,_be OTHER_DRUG ._af"
1005,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",fluvoxamine,zileuton,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf nefazodone_bf ,_bf fluconazole_bf ,_bf grapefruit_bf juice_bf ,_bf fluoxetine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af clotrimazole_af ._af"
1006,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",fluvoxamine,clotrimazole,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf nefazodone_bf ,_bf fluconazole_bf ,_bf grapefruit_bf juice_bf ,_bf fluoxetine_bf ,_bf DRUG ,_be zileuton_be ,_be OTHER_DRUG ._af"
1007,"Less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole. ",zileuton,clotrimazole,No interaction,"Less_bf potent_bf inhibitors_bf include_bf saquinavir_bf ,_bf nefazodone_bf ,_bf fluconazole_bf ,_bf grapefruit_bf juice_bf ,_bf fluoxetine_bf ,_bf fluvoxamine_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
1008,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,Methergine,methylergonovine maleate,No interaction,Caution_bf exercised_bf DRUG (methylergonovine_be maleate)_be used_be concurrently_be vasoconstrictors_be ergot_be alkaloids_be ._be
1009,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,Methergine,vasoconstrictors,advise,Caution_bf exercised_bf DRUG (methylergonovine_be maleate)_be used_be concurrently_be OTHER_DRUG ergot_af alkaloids_af ._af
1010,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,Methergine,ergot alkaloids,advise,Caution_bf exercised_bf DRUG (methylergonovine_be maleate)_be used_be concurrently_be vasoconstrictors_be ergot_be alkaloids_be ._be
1011,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,methylergonovine maleate,vasoconstrictors,advise,Caution_bf exercised_bf Methergine_bf (methylergonovine_bf maleate)_bf used_bf concurrently_bf OTHER_DRUG ergot_be alkaloids_be ._be
1012,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,methylergonovine maleate,ergot alkaloids,No interaction,Caution_bf exercised_bf Methergine_bf (methylergonovine_bf maleate)_bf used_bf concurrently_bf vasoconstrictors_bf ergot_bf alkaloids_bf ._bf
1013,Caution should be exercised when Methergine    (methylergonovine maleate) is used concurrently with other vasoconstrictors or ergot alkaloids.,vasoconstrictors,ergot alkaloids,No interaction,Caution_bf exercised_bf Methergine_bf (methylergonovine_bf maleate)_bf used_bf concurrently_bf DRUG ergot_be alkaloids_be ._be
1014,Ritalin may decrease the hypotensive effect of guanethidine. ,Ritalin,guanethidine,effect,DRUG may_be decrease_be hypotensive_be effect_be OTHER_DRUG ._af
1015,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,coumarin anticoagulants,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1016,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,anticonvulsants,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be OTHER_DRUG (phenobarbital_af ,_af diphenylhydantoin_af ,_af primidone)_af ,_af phenylbutazone_af ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
1017,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,phenobarbital,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1018,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,diphenylhydantoin,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be OTHER_DRUG ,_af primidone)_af ,_af phenylbutazone_af ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
1019,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,primidone,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1020,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,phenylbutazone,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be OTHER_DRUG ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
1021,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,tricyclic drugs,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1022,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,imipramine,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1023,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,clomipramine,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be OTHER_DRUG ,_af desipramine)_af ._af"
1024,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",Ritalin,desipramine,mechanism,"Human_bf pharmacologic_bf studies_bf shown_bf DRUG may_be inhibit_be metabolism_be coumarin_be anticoagulants_be ,_be anticonvulsants_be (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1025,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",coumarin anticoagulants,anticonvulsants,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf OTHER_DRUG (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1026,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",coumarin anticoagulants,phenobarbital,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1027,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",coumarin anticoagulants,diphenylhydantoin,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf OTHER_DRUG ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1028,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",coumarin anticoagulants,primidone,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1029,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",coumarin anticoagulants,phenylbutazone,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf OTHER_DRUG ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1030,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",coumarin anticoagulants,tricyclic drugs,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1031,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",coumarin anticoagulants,imipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1032,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",coumarin anticoagulants,clomipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf OTHER_DRUG ,_be desipramine)_be ._be"
1033,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",coumarin anticoagulants,desipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1034,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",anticonvulsants,phenobarbital,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf DRUG (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1035,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",anticonvulsants,diphenylhydantoin,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf DRUG (phenobarbital_be ,_be OTHER_DRUG ,_af primidone)_af ,_af phenylbutazone_af ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
1036,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",anticonvulsants,primidone,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf DRUG (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1037,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",anticonvulsants,phenylbutazone,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf DRUG (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be OTHER_DRUG ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
1038,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",anticonvulsants,tricyclic drugs,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf DRUG (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1039,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",anticonvulsants,imipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf DRUG (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1040,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",anticonvulsants,clomipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf DRUG (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be OTHER_DRUG ,_af desipramine)_af ._af"
1041,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",anticonvulsants,desipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf DRUG (phenobarbital_be ,_be diphenylhydantoin_be ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1042,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",phenobarbital,diphenylhydantoin,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf OTHER_DRUG ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1043,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",phenobarbital,primidone,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1044,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",phenobarbital,phenylbutazone,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf OTHER_DRUG ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1045,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",phenobarbital,tricyclic drugs,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1046,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",phenobarbital,imipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1047,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",phenobarbital,clomipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf OTHER_DRUG ,_be desipramine)_be ._be"
1048,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",phenobarbital,desipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1049,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",diphenylhydantoin,primidone,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf DRUG ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1050,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",diphenylhydantoin,phenylbutazone,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf DRUG ,_be primidone)_be ,_be OTHER_DRUG ,_af tricyclic_af drugs_af (imipramine_af ,_af clomipramine_af ,_af desipramine)_af ._af"
1051,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",diphenylhydantoin,tricyclic drugs,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf DRUG ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1052,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",diphenylhydantoin,imipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf DRUG ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1053,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",diphenylhydantoin,clomipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf DRUG ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be OTHER_DRUG ,_af desipramine)_af ._af"
1054,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",diphenylhydantoin,desipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf DRUG ,_be primidone)_be ,_be phenylbutazone_be ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1055,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",primidone,phenylbutazone,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf OTHER_DRUG ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1056,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",primidone,tricyclic drugs,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1057,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",primidone,imipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1058,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",primidone,clomipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf OTHER_DRUG ,_be desipramine)_be ._be"
1059,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",primidone,desipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1060,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",phenylbutazone,tricyclic drugs,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf DRUG ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1061,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",phenylbutazone,imipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf DRUG ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1062,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",phenylbutazone,clomipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf DRUG ,_be tricyclic_be drugs_be (imipramine_be ,_be OTHER_DRUG ,_af desipramine)_af ._af"
1063,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",phenylbutazone,desipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf DRUG ,_be tricyclic_be drugs_be (imipramine_be ,_be clomipramine_be ,_be desipramine)_be ._be"
1064,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",tricyclic drugs,imipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1065,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",tricyclic drugs,clomipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf OTHER_DRUG ,_be desipramine)_be ._be"
1066,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",tricyclic drugs,desipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1067,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",imipramine,clomipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf OTHER_DRUG ,_be desipramine)_be ._be"
1068,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",imipramine,desipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf clomipramine_bf ,_bf desipramine)_bf ._bf"
1069,"Human pharmacologic studies have shown that Ritalin may inhibit the metabolism of coumarin anticoagulants, anticonvulsants (phenobarbital, diphenylhydantoin, primidone), phenylbutazone, and tricyclic drugs (imipramine, clomipramine, desipramine). ",clomipramine,desipramine,No interaction,"Human_bf pharmacologic_bf studies_bf shown_bf Ritalin_bf may_bf inhibit_bf metabolism_bf coumarin_bf anticoagulants_bf ,_bf anticonvulsants_bf (phenobarbital_bf ,_bf diphenylhydantoin_bf ,_bf primidone)_bf ,_bf phenylbutazone_bf ,_bf tricyclic_bf drugs_bf (imipramine_bf ,_bf DRUG ,_be desipramine)_be ._be"
1070,The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.    ,methylphenidate,clonidine,No interaction,The_bf safety_bf using_bf DRUG combination_be OTHER_DRUG centrally_af acting_af alpha-2_af agonists_af systemically_af evaluated_af ._af
1071,The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.    ,methylphenidate,alpha-2 agonists,No interaction,The_bf safety_bf using_bf DRUG combination_be clonidine_be centrally_be acting_be alpha-2_be agonists_be systemically_be evaluated_be ._be
1072,The safety of using methylphenidate in combination with clonidine or other centrally acting alpha-2 agonists has not been systemically evaluated.    ,clonidine,alpha-2 agonists,No interaction,The_bf safety_bf using_bf methylphenidate_bf combination_bf DRUG centrally_be acting_be alpha-2_be agonists_be systemically_be evaluated_be ._be
1073,Mutual inhibition of metabolism occurs with concurrent use of cyclosporin and methylprednisolone; ,cyclosporin,methylprednisolone,mechanism,Mutual_bf inhibition_bf metabolism_bf occurs_bf concurrent_bf use_bf DRUG methylprednisolone;_be
1074,convulsions have been reported with concurrent use of methylprednisolone and cyclosporin. ,methylprednisolone,cyclosporin,effect,convulsions_bf reported_bf concurrent_bf use_bf DRUG OTHER_DRUG ._af
1075,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,phenytoin,No interaction,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be OTHER_DRUG ,_af rifampin_af may_af increase_af clearance_af methylprednisolone_af may_af require_af increased_af methylprednisolone_af dose_af achieve_af desired_af response_af ._af"
1076,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,rifampin,No interaction,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be ,_be OTHER_DRUG may_af increase_af clearance_af methylprednisolone_af may_af require_af increased_af methylprednisolone_af dose_af achieve_af desired_af response_af ._af"
1077,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,methylprednisolone,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1078,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenobarbital,methylprednisolone,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1079,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenytoin,rifampin,No interaction,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG ,_be OTHER_DRUG may_af increase_af clearance_af methylprednisolone_af may_af require_af increased_af methylprednisolone_af dose_af achieve_af desired_af response_af ._af"
1080,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenytoin,methylprednisolone,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1081,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",phenytoin,methylprednisolone,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG ,_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1082,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",rifampin,methylprednisolone,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf ,_bf DRUG may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1083,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",rifampin,methylprednisolone,advise,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf ,_bf DRUG may_be increase_be clearance_be OTHER_DRUG may_af require_af increased_af OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
1084,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin, and rifampin may increase the clearance of methylprednisolone and may require increased in methylprednisolone dose to achieve the desired response. ",methylprednisolone,methylprednisolone,No interaction,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf ,_bf rifampin_bf may_bf increase_bf clearance_bf DRUG may_be require_be increased_be DRUG dose_af achieve_af desired_af response_af ._af"
1085,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,troleandomycin,ketoconazole,No interaction,Drugs_bf DRUG OTHER_DRUG may_af inhibit_af metabolism_af methylprednisolone_af thus_af decrease_af clearance_af ._af
1086,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,troleandomycin,methylprednisolone,mechanism,Drugs_bf DRUG ketoconazole_be may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
1087,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of methylprednisolone and thus decrease its clearance. ,ketoconazole,methylprednisolone,mechanism,Drugs_bf troleandomycin_bf DRUG may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
1088,Methylprednisolone may increase the clearance of chronic high dose aspirin. ,Methylprednisolone,aspirin,mechanism,DRUG may_be increase_be clearance_be chronic_be high_be dose_be OTHER_DRUG ._af
1089,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ,salicylate,salicylate,No interaction,This_bf could_bf lead_bf decreased_bf DRUG serum_be levels_be increase_be risk_be DRUG toxicity_af methylprednisolone_af withdrawn_af ._af
1090,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ,salicylate,methylprednisolone,No interaction,This_bf could_bf lead_bf decreased_bf DRUG serum_be levels_be increase_be risk_be DRUG toxicity_af OTHER_DRUG withdrawn_af ._af
1091,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when methylprednisolone is withdrawn. ,salicylate,methylprednisolone,effect,This_bf could_bf lead_bf decreased_bf DRUG serum_be levels_be increase_be risk_be DRUG toxicity_af OTHER_DRUG withdrawn_af ._af
1092,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,advise,DRUG used_be cautiously_be conjunction_be OTHER_DRUG patients_af suffering_af hypoprothrombinemia_af ._af
1093,The effect of methylprednisolone on oral anticoagulants is variable. ,methylprednisolone,anticoagulants,No interaction,The_bf effect_bf DRUG oral_be OTHER_DRUG variable_af ._af
1094,There are reports of enhanced as well as diminished effects of anticoagulant when given concurrently with corticosteroids. ,anticoagulant,corticosteroids,effect,There_bf reports_bf enhanced_bf well_bf diminished_bf effects_bf DRUG given_be concurrently_be OTHER_DRUG ._af
1095,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,antidepressants,No interaction,"DRUG may_be interact_be OTHER_DRUG (tricyclic_af type)_af ,_af MAO_af inhibitors_af (e_af ._af g_af ._af ,_af phenelzine_af ,_af linezolid_af ,_af tranylcypromine_af ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1096,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,tricyclic,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1097,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,MAO inhibitors,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1098,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,phenelzine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af linezolid_af ,_af tranylcypromine_af ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1099,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,linezolid,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be OTHER_DRUG ,_af tranylcypromine_af ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1100,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,tranylcypromine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be OTHER_DRUG ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1101,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,isocarboxazid,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be OTHER_DRUG ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1102,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,selegiline,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be OTHER_DRUG ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1103,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,furazolidone,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1104,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,quinidine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be OTHER_DRUG ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1105,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,amantadine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be OTHER_DRUG ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1106,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,antihistamines,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1107,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,diphenhydramine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1108,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,anticholinergics,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be OTHER_DRUG ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1109,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,potassium chloride,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1110,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,antacids,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1111,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,absorbent-type anti-diarrhea medicines,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1112,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,kaolin,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1113,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,pectin,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1114,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,phenothiazines,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1115,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,chlorpromazine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1116,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",Methscopolamine,promethazine,int,"DRUG may_be interact_be antidepressants_be (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1117,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,tricyclic,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1118,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,MAO inhibitors,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1119,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,phenelzine,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af linezolid_af ,_af tranylcypromine_af ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1120,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,linezolid,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be OTHER_DRUG ,_af tranylcypromine_af ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1121,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,tranylcypromine,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be OTHER_DRUG ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1122,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,isocarboxazid,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be OTHER_DRUG ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1123,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,selegiline,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be OTHER_DRUG ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1124,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,furazolidone,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1125,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,quinidine,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be OTHER_DRUG ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1126,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,amantadine,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be OTHER_DRUG ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1127,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,antihistamines,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1128,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1129,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be OTHER_DRUG ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1130,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1131,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1132,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1133,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1134,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1135,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1136,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1137,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antidepressants,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf DRUG (tricyclic_be type)_be ,_be MAO_be inhibitors_be (e_be ._be g_be ._be ,_be phenelzine_be ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1138,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,MAO inhibitors,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1139,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,phenelzine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1140,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,linezolid,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf OTHER_DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1141,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,tranylcypromine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf OTHER_DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1142,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,isocarboxazid,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf OTHER_DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1143,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,selegiline,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf OTHER_DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1144,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,furazolidone,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1145,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,quinidine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf OTHER_DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1146,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,amantadine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf OTHER_DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1147,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,antihistamines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1148,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1149,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf OTHER_DRUG ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1150,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1151,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf OTHER_DRUG ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1152,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1153,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1154,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1155,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1156,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be promethazine)_be ._be"
1157,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tricyclic,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1158,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,phenelzine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1159,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,linezolid,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf OTHER_DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1160,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,tranylcypromine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf OTHER_DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1161,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,isocarboxazid,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf OTHER_DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1162,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,selegiline,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf OTHER_DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1163,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,furazolidone,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1164,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,quinidine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf OTHER_DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1165,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,amantadine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf OTHER_DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1166,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,antihistamines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1167,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1168,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf OTHER_DRUG ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1169,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1170,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf OTHER_DRUG ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1171,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1172,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1173,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1174,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1175,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be promethazine)_be ._be"
1176,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",MAO inhibitors,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1177,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,linezolid,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af tranylcypromine_af ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1178,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,tranylcypromine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be OTHER_DRUG ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1179,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,isocarboxazid,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be OTHER_DRUG ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1180,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,selegiline,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be OTHER_DRUG ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1181,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,furazolidone,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1182,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,quinidine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be OTHER_DRUG ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1183,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,amantadine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be OTHER_DRUG ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1184,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,antihistamines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1185,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1186,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be OTHER_DRUG ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1187,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1188,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1189,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1190,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1191,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1192,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1193,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1194,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenelzine,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be linezolid_be ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1195,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,tranylcypromine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af isocarboxazid_af ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1196,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,isocarboxazid,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be OTHER_DRUG ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1197,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,selegiline,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be OTHER_DRUG ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1198,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,furazolidone,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1199,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,quinidine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be OTHER_DRUG ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1200,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,amantadine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be OTHER_DRUG ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1201,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,antihistamines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1202,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1203,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be OTHER_DRUG ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1204,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1205,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1206,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1207,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1208,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1209,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1210,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1211,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",linezolid,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf DRUG ,_be tranylcypromine_be ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1212,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,isocarboxazid,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be OTHER_DRUG ,_af selegiline_af ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1213,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,selegiline,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be OTHER_DRUG ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1214,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,furazolidone,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1215,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,quinidine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be OTHER_DRUG ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1216,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,amantadine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be OTHER_DRUG ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1217,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,antihistamines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1218,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1219,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be OTHER_DRUG ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1220,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1221,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1222,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1223,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1224,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1225,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1226,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1227,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",tranylcypromine,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf DRUG ,_be isocarboxazid_be ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1228,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,selegiline,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af furazolidone)_af ,_af quinidine_af ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1229,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,furazolidone,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1230,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,quinidine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be OTHER_DRUG ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1231,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,amantadine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be OTHER_DRUG ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1232,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,antihistamines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1233,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1234,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be OTHER_DRUG ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1235,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1236,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1237,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1238,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1239,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1240,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1241,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1242,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",isocarboxazid,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf DRUG ,_be selegiline_be ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1243,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,furazolidone,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1244,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,quinidine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be OTHER_DRUG ,_af amantadine_af ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1245,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,amantadine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be OTHER_DRUG ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1246,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,antihistamines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1247,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1248,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be OTHER_DRUG ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1249,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1250,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1251,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1252,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1253,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1254,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1255,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1256,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",selegiline,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf DRUG ,_be furazolidone)_be ,_be quinidine_be ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1257,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,quinidine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf OTHER_DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1258,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,amantadine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf OTHER_DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1259,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,antihistamines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1260,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1261,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf OTHER_DRUG ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1262,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1263,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf OTHER_DRUG ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1264,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1265,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1266,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1267,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1268,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be promethazine)_be ._be"
1269,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",furazolidone,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1270,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,amantadine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be OTHER_DRUG ,_af antihistamines_af (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1271,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,antihistamines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be amantadine_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1272,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1273,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be OTHER_DRUG ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1274,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1275,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1276,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1277,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1278,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1279,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1280,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1281,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",quinidine,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf DRUG ,_be amantadine_be ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1282,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",amantadine,antihistamines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf DRUG ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af diphenhydramine)_af ,_af anticholinergics_af ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1283,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",amantadine,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1284,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",amantadine,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be OTHER_DRUG ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1285,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",amantadine,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1286,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",amantadine,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1287,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",amantadine,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1288,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",amantadine,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1289,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",amantadine,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1290,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",amantadine,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1291,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",amantadine,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1292,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",amantadine,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf DRUG ,_be antihistamines_be (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1293,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antihistamines,diphenhydramine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1294,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antihistamines,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be OTHER_DRUG ,_af potassium_af chloride_af supplements_af ,_af antacids_af ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1295,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antihistamines,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1296,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antihistamines,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1297,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antihistamines,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1298,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antihistamines,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1299,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antihistamines,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1300,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antihistamines,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1301,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antihistamines,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1302,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antihistamines,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf DRUG (e_be ._be g_be ._be ,_be diphenhydramine)_be ,_be anticholinergics_be ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1303,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",diphenhydramine,anticholinergics,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf OTHER_DRUG ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1304,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",diphenhydramine,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1305,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",diphenhydramine,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf OTHER_DRUG ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1306,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",diphenhydramine,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1307,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",diphenhydramine,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1308,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",diphenhydramine,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1309,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",diphenhydramine,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1310,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",diphenhydramine,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be promethazine)_be ._be"
1311,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",diphenhydramine,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1312,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",anticholinergics,potassium chloride,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf DRUG ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1313,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",anticholinergics,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf DRUG ,_be potassium_be chloride_be supplements_be ,_be OTHER_DRUG ,_af absorbent-type_af anti-diarrhea_af medicines_af (e_af ._af g_af ._af ,_af kaolin-pectin)_af ,_af phenothiazines_af (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1314,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",anticholinergics,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf DRUG ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1315,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",anticholinergics,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf DRUG ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1316,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",anticholinergics,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf DRUG ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1317,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",anticholinergics,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf DRUG ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1318,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",anticholinergics,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf DRUG ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1319,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",anticholinergics,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf DRUG ,_be potassium_be chloride_be supplements_be ,_be antacids_be ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1320,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",potassium chloride,antacids,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf OTHER_DRUG ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1321,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",potassium chloride,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1322,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",potassium chloride,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1323,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",potassium chloride,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1324,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",potassium chloride,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1325,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",potassium chloride,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be promethazine)_be ._be"
1326,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",potassium chloride,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1327,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antacids,absorbent-type anti-diarrhea medicines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf DRUG ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1328,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antacids,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf DRUG ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1329,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antacids,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf DRUG ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1330,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antacids,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf DRUG ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be OTHER_DRUG (e_af ._af g_af ._af ,_af chlorpromazine_af ,_af promethazine)_af ._af"
1331,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antacids,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf DRUG ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1332,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",antacids,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf DRUG ,_be absorbent-type_be anti-diarrhea_be medicines_be (e_be ._be g_be ._be ,_be kaolin-pectin)_be ,_be phenothiazines_be (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1333,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",absorbent-type anti-diarrhea medicines,kaolin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1334,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",absorbent-type anti-diarrhea medicines,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1335,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",absorbent-type anti-diarrhea medicines,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1336,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",absorbent-type anti-diarrhea medicines,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be promethazine)_be ._be"
1337,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",absorbent-type anti-diarrhea medicines,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1338,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",kaolin,pectin,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1339,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",kaolin,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1340,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",kaolin,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be promethazine)_be ._be"
1341,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",kaolin,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1342,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",pectin,phenothiazines,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1343,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",pectin,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be promethazine)_be ._be"
1344,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",pectin,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf chlorpromazine_bf ,_bf promethazine)_bf ._bf"
1345,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenothiazines,chlorpromazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf DRUG (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af promethazine)_af ._af"
1346,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",phenothiazines,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf DRUG (e_be ._be g_be ._be ,_be chlorpromazine_be ,_be promethazine)_be ._be"
1347,"Methscopolamine may interact with antidepressants (tricyclic type), MAO inhibitors (e.g., phenelzine, linezolid, tranylcypromine, isocarboxazid, selegiline, furazolidone), quinidine, amantadine, antihistamines (e.g., diphenhydramine), other anticholinergics, potassium chloride supplements, antacids, absorbent-type anti-diarrhea medicines (e.g., kaolin-pectin), phenothiazines (e.g., chlorpromazine, promethazine).",chlorpromazine,promethazine,No interaction,"Methscopolamine_bf may_bf interact_bf antidepressants_bf (tricyclic_bf type)_bf ,_bf MAO_bf inhibitors_bf (e_bf ._bf g_bf ._bf ,_bf phenelzine_bf ,_bf linezolid_bf ,_bf tranylcypromine_bf ,_bf isocarboxazid_bf ,_bf selegiline_bf ,_bf furazolidone)_bf ,_bf quinidine_bf ,_bf amantadine_bf ,_bf antihistamines_bf (e_bf ._bf g_bf ._bf ,_bf diphenhydramine)_bf ,_bf anticholinergics_bf ,_bf potassium_bf chloride_bf supplements_bf ,_bf antacids_bf ,_bf absorbent-type_bf anti-diarrhea_bf medicines_bf (e_bf ._bf g_bf ._bf ,_bf kaolin-pectin)_bf ,_bf phenothiazines_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be promethazine)_be ._be"
1348,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,alcohol,CNS depression-producing drugs,No interaction,Concurrent_bf use_bf DRUG CNS_be depression-producing_be drugs_be may_be increase_be CNS_be depressant_be effects_be methyprylon_be medications_be ._be
1349,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,alcohol,methyprylon,effect,Concurrent_bf use_bf DRUG CNS_be depression-producing_be drugs_be may_be increase_be CNS_be depressant_be effects_be OTHER_DRUG medications_af ._af
1350,Concurrent use of alcohol and other CNS depression-producing drugs may increase the CNS depressant effects of methyprylon or these other medications.,CNS depression-producing drugs,methyprylon,effect,Concurrent_bf use_bf alcohol_bf CNS_bf depression-producing_bf drugs_bf may_bf increase_bf CNS_bf depressant_bf effects_bf OTHER_DRUG medications_be ._be
1351,Methysergide may reverse the analgesic activity of narcotic analgesics. ,Methysergide,narcotic analgesics,effect,DRUG may_be reverse_be analgesic_be activity_be narcotic_be analgesics_be ._be
1352,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",vasoconstrictor agents,ergot alkaloids,No interaction,"Concurrent_bf use_bf vasoconstrictor_bf agents_bf including_bf ergot_bf alkaloids_bf ,_bf sumatriptan_bf ,_bf nicotine_bf (e_bf ._bf g_bf ._bf smoking)_bf may_bf result_bf enhanced_bf vasoconstriction_bf ._bf"
1353,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",vasoconstrictor agents,sumatriptan,No interaction,"Concurrent_bf use_bf vasoconstrictor_bf agents_bf including_bf ergot_bf alkaloids_bf ,_bf OTHER_DRUG ,_be nicotine_be (e_be ._be g_be ._be smoking)_be may_be result_be enhanced_be vasoconstriction_be ._be"
1354,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",vasoconstrictor agents,nicotine,No interaction,"Concurrent_bf use_bf vasoconstrictor_bf agents_bf including_bf ergot_bf alkaloids_bf ,_bf sumatriptan_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be smoking)_be may_be result_be enhanced_be vasoconstriction_be ._be"
1355,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",ergot alkaloids,sumatriptan,No interaction,"Concurrent_bf use_bf vasoconstrictor_bf agents_bf including_bf ergot_bf alkaloids_bf ,_bf OTHER_DRUG ,_be nicotine_be (e_be ._be g_be ._be smoking)_be may_be result_be enhanced_be vasoconstriction_be ._be"
1356,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",ergot alkaloids,nicotine,No interaction,"Concurrent_bf use_bf vasoconstrictor_bf agents_bf including_bf ergot_bf alkaloids_bf ,_bf sumatriptan_bf ,_bf OTHER_DRUG (e_be ._be g_be ._be smoking)_be may_be result_be enhanced_be vasoconstriction_be ._be"
1357,"Concurrent use with vasoconstrictor agents including ergot alkaloids, sumatriptan, and nicotine (e.g. smoking) may result in enhanced vasoconstriction.",sumatriptan,nicotine,No interaction,"Concurrent_bf use_bf vasoconstrictor_bf agents_bf including_bf ergot_bf alkaloids_bf ,_bf DRUG ,_be OTHER_DRUG (e_af ._af g_af ._af smoking)_af may_af result_af enhanced_af vasoconstriction_af ._af"
1358,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,metoclopramide,anticholinergic drugs,effect,The_bf effects_bf DRUG gastrointestinal_be motility_be antagonized_be anticholinergic_be drugs_be narcotic_be analgesics_be ._be
1359,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,metoclopramide,narcotic analgesics,effect,The_bf effects_bf DRUG gastrointestinal_be motility_be antagonized_be anticholinergic_be drugs_be narcotic_be analgesics_be ._be
1360,The effects of metoclopramide on gastrointestinal motility are antagonized by anticholinergic drugs and narcotic analgesics. ,anticholinergic drugs,narcotic analgesics,No interaction,The_bf effects_bf metoclopramide_bf gastrointestinal_bf motility_bf antagonized_bf anticholinergic_bf drugs_bf narcotic_bf analgesics_bf ._bf
1361,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,alcohol,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be OTHER_DRUG ,_af sedatives_af ,_af hypnotics_af ,_af narcotics_af ,_af tranquilizers_af ._af"
1362,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,sedatives,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be OTHER_DRUG ,_af hypnotics_af ,_af narcotics_af ,_af tranquilizers_af ._af"
1363,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,hypnotics,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be sedatives_be ,_be OTHER_DRUG ,_af narcotics_af ,_af tranquilizers_af ._af"
1364,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,narcotics,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be OTHER_DRUG ,_af tranquilizers_af ._af"
1365,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",metoclopramide,tranquilizers,effect,"Additive_bf sedative_bf effects_bf occur_bf DRUG given_be alcohol_be ,_be sedatives_be ,_be hypnotics_be ,_be narcotics_be ,_be OTHER_DRUG ._af"
1366,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",alcohol,sedatives,No interaction,"Additive_bf sedative_bf effects_bf occur_bf metoclopramide_bf given_bf DRUG ,_be OTHER_DRUG ,_af hypnotics_af ,_af narcotics_af ,_af tranquilizers_af ._af"
1367,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",alcohol,hypnotics,No interaction,"Additive_bf sedative_bf effects_bf occur_bf metoclopramide_bf given_bf DRUG ,_be sedatives_be ,_be OTHER_DRUG ,_af narcotics_af ,_af tranquilizers_af ._af"
1368,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",alcohol,narcotics,No interaction,"Additive_bf sedative_bf effects_bf occur_bf metoclopramide_bf given_bf DRUG ,_be sedatives_be ,_be hypnotics_be ,_be OTHER_DRUG ,_af tranquilizers_af ._af"
1369,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",alcohol,tranquilizers,No interaction,"Additive_bf sedative_bf effects_bf occur_bf metoclopramide_bf given_bf DRUG ,_be sedatives_be ,_be hypnotics_be ,_be narcotics_be ,_be OTHER_DRUG ._af"
1370,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",sedatives,hypnotics,No interaction,"Additive_bf sedative_bf effects_bf occur_bf metoclopramide_bf given_bf alcohol_bf ,_bf DRUG ,_be OTHER_DRUG ,_af narcotics_af ,_af tranquilizers_af ._af"
1371,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",sedatives,narcotics,No interaction,"Additive_bf sedative_bf effects_bf occur_bf metoclopramide_bf given_bf alcohol_bf ,_bf DRUG ,_be hypnotics_be ,_be OTHER_DRUG ,_af tranquilizers_af ._af"
1372,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",sedatives,tranquilizers,No interaction,"Additive_bf sedative_bf effects_bf occur_bf metoclopramide_bf given_bf alcohol_bf ,_bf DRUG ,_be hypnotics_be ,_be narcotics_be ,_be OTHER_DRUG ._af"
1373,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",hypnotics,narcotics,No interaction,"Additive_bf sedative_bf effects_bf occur_bf metoclopramide_bf given_bf alcohol_bf ,_bf sedatives_bf ,_bf DRUG ,_be OTHER_DRUG ,_af tranquilizers_af ._af"
1374,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",hypnotics,tranquilizers,No interaction,"Additive_bf sedative_bf effects_bf occur_bf metoclopramide_bf given_bf alcohol_bf ,_bf sedatives_bf ,_bf DRUG ,_be narcotics_be ,_be OTHER_DRUG ._af"
1375,"Additive sedative effects can occur when metoclopramide is given with alcohol, sedatives, hypnotics, narcotics, or tranquilizers. ",narcotics,tranquilizers,No interaction,"Additive_bf sedative_bf effects_bf occur_bf metoclopramide_bf given_bf alcohol_bf ,_bf sedatives_bf ,_bf hypnotics_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
1376,"The finding that metoclopramide releases catecholamines in patients with essential hypertension suggests that it should be used cautiously, if at all, in patients receiving monoamine oxi-dase inhibitors. ",metoclopramide,monoamine oxi-dase inhibitors,advise,"The_bf finding_bf DRUG releases_be catecholamines_be patients_be essential_be hypertension_be suggests_be used_be cautiously_be ,_be ,_be patients_be receiving_be monoamine_be oxi-dase_be inhibitors_be ._be"
1377,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",digoxin,metoclopramide,mechanism,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf OTHER_DRUG ,_be whereas_be rate_be and/or_be extent_be absorption_be drugs_be small_be bowel_be may_be increased_be (e_be ._be g_be ._be ,_be acetaminophen_be ,_be tetracycline_be ,_be levodopa_be ,_be ethanol_be ,_be cyclosporine)_be ._be"
1378,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",digoxin,acetaminophen,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be tetracycline_be ,_be levodopa_be ,_be ethanol_be ,_be cyclosporine)_be ._be"
1379,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",digoxin,tetracycline,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf acetaminophen_bf ,_bf OTHER_DRUG ,_be levodopa_be ,_be ethanol_be ,_be cyclosporine)_be ._be"
1380,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",digoxin,levodopa,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf acetaminophen_bf ,_bf tetracycline_bf ,_bf OTHER_DRUG ,_be ethanol_be ,_be cyclosporine)_be ._be"
1381,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",digoxin,ethanol,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf acetaminophen_bf ,_bf tetracycline_bf ,_bf levodopa_bf ,_bf OTHER_DRUG ,_be cyclosporine)_be ._be"
1382,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",digoxin,cyclosporine,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf acetaminophen_bf ,_bf tetracycline_bf ,_bf levodopa_bf ,_bf ethanol_bf ,_bf cyclosporine)_bf ._bf"
1383,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",metoclopramide,acetaminophen,mechanism,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf DRUG ,_be whereas_be rate_be and/or_be extent_be absorption_be drugs_be small_be bowel_be may_be increased_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af tetracycline_af ,_af levodopa_af ,_af ethanol_af ,_af cyclosporine)_af ._af"
1384,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",metoclopramide,tetracycline,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf DRUG ,_be whereas_be rate_be and/or_be extent_be absorption_be drugs_be small_be bowel_be may_be increased_be (e_be ._be g_be ._be ,_be acetaminophen_be ,_be OTHER_DRUG ,_af levodopa_af ,_af ethanol_af ,_af cyclosporine)_af ._af"
1385,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",metoclopramide,levodopa,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf DRUG ,_be whereas_be rate_be and/or_be extent_be absorption_be drugs_be small_be bowel_be may_be increased_be (e_be ._be g_be ._be ,_be acetaminophen_be ,_be tetracycline_be ,_be OTHER_DRUG ,_af ethanol_af ,_af cyclosporine)_af ._af"
1386,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",metoclopramide,ethanol,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf DRUG ,_be whereas_be rate_be and/or_be extent_be absorption_be drugs_be small_be bowel_be may_be increased_be (e_be ._be g_be ._be ,_be acetaminophen_be ,_be tetracycline_be ,_be levodopa_be ,_be OTHER_DRUG ,_af cyclosporine)_af ._af"
1387,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",metoclopramide,cyclosporine,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf DRUG ,_be whereas_be rate_be and/or_be extent_be absorption_be drugs_be small_be bowel_be may_be increased_be (e_be ._be g_be ._be ,_be acetaminophen_be ,_be tetracycline_be ,_be levodopa_be ,_be ethanol_be ,_be cyclosporine)_be ._be"
1388,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",acetaminophen,tetracycline,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af levodopa_af ,_af ethanol_af ,_af cyclosporine)_af ._af"
1389,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",acetaminophen,levodopa,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracycline_be ,_be OTHER_DRUG ,_af ethanol_af ,_af cyclosporine)_af ._af"
1390,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",acetaminophen,ethanol,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracycline_be ,_be levodopa_be ,_be OTHER_DRUG ,_af cyclosporine)_af ._af"
1391,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",acetaminophen,cyclosporine,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracycline_be ,_be levodopa_be ,_be ethanol_be ,_be cyclosporine)_be ._be"
1392,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",tetracycline,levodopa,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf acetaminophen_bf ,_bf DRUG ,_be OTHER_DRUG ,_af ethanol_af ,_af cyclosporine)_af ._af"
1393,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",tetracycline,ethanol,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf acetaminophen_bf ,_bf DRUG ,_be levodopa_be ,_be OTHER_DRUG ,_af cyclosporine)_af ._af"
1394,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",tetracycline,cyclosporine,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf acetaminophen_bf ,_bf DRUG ,_be levodopa_be ,_be ethanol_be ,_be cyclosporine)_be ._be"
1395,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",levodopa,ethanol,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf acetaminophen_bf ,_bf tetracycline_bf ,_bf DRUG ,_be OTHER_DRUG ,_af cyclosporine)_af ._af"
1396,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",levodopa,cyclosporine,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf acetaminophen_bf ,_bf tetracycline_bf ,_bf DRUG ,_be ethanol_be ,_be cyclosporine)_be ._be"
1397,"Absorption of drugs from the stomach may be diminished (e.g., digoxin) by metoclopramide, whereas the rate and/or extent of absorption of drugs from the small bowel may be increased (e.g., acetaminophen, tetracycline, levodopa, ethanol, cyclosporine). ",ethanol,cyclosporine,No interaction,"Absorption_bf drugs_bf stomach_bf may_bf diminished_bf (e_bf ._bf g_bf ._bf ,_bf digoxin)_bf metoclopramide_bf ,_bf whereas_bf rate_bf and/or_bf extent_bf absorption_bf drugs_bf small_bf bowel_bf may_bf increased_bf (e_bf ._bf g_bf ._bf ,_bf acetaminophen_bf ,_bf tetracycline_bf ,_bf levodopa_bf ,_bf DRUG ,_be cyclosporine)_be ._be"
1398,"Because the action of metoclopramide will influence the delivery of food to the intestines and thus the rate of absorption, insulin dosage or timing of dosage may require adjustment.",metoclopramide,insulin,advise,"Because_bf action_bf DRUG influence_be delivery_be food_be intestines_be thus_be rate_be absorption_be ,_be OTHER_DRUG dosage_af timing_af dosage_af may_af require_af adjustment_af ._af"
1399,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",metronidazole,coumarin,effect,"Oral_bf DRUG reported_be potentiate_be anticoagulant_be effect_be OTHER_DRUG warfarin_af ,_af resulting_af prolongation_af prothrombin_af time_af ._af"
1400,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",metronidazole,warfarin,effect,"Oral_bf DRUG reported_be potentiate_be anticoagulant_be effect_be coumarin_be OTHER_DRUG ,_af resulting_af prolongation_af prothrombin_af time_af ._af"
1401,"Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. ",coumarin,warfarin,No interaction,"Oral_bf metronidazole_bf reported_bf potentiate_bf anticoagulant_bf effect_bf DRUG OTHER_DRUG ,_af resulting_af prolongation_af prothrombin_af time_af ._af"
1402,"Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.    ",METROGEL,metronidazole,No interaction,"Drug_bf interactions_bf kept_bf mind_bf DRUG (metronidazole_be gel)_be ,_be 1%_be prescribed_be patients_be receiving_be anticoagulant_be treatment_be ,_be although_be less_be likely_be occur_be topical_be OTHER_DRUG administration_af low_af absorption_af ._af"
1403,"Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.    ",METROGEL,metronidazole,No interaction,"Drug_bf interactions_bf kept_bf mind_bf DRUG (metronidazole_be gel)_be ,_be 1%_be prescribed_be patients_be receiving_be anticoagulant_be treatment_be ,_be although_be less_be likely_be occur_be topical_be OTHER_DRUG administration_af low_af absorption_af ._af"
1404,"Drug interactions should be kept in mind when METROGEL (metronidazole gel), 1% is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.    ",metronidazole,metronidazole,No interaction,"Drug_bf interactions_bf kept_bf mind_bf METROGEL_bf (metronidazole_bf gel)_bf ,_bf 1%_bf prescribed_bf patients_bf receiving_bf anticoagulant_bf treatment_bf ,_bf although_bf less_bf likely_bf occur_bf topical_bf DRUG administration_be low_be absorption_be ._be"
1405,The metabolism of Metopirone is accelerated by phenytoin; ,Metopirone,phenytoin,mechanism,The_bf metabolism_bf DRUG accelerated_be phenytoin;_be
1406,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,Metopirone,acetaminophen,mechanism,DRUG inhibits_be glucuronidation_be OTHER_DRUG could_af possibly_af potentiate_af OTHER_DRUG toxicity_af ._af
1407,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,Metopirone,acetaminophen,effect,DRUG inhibits_be glucuronidation_be OTHER_DRUG could_af possibly_af potentiate_af OTHER_DRUG toxicity_af ._af
1408,Metopirone inhibits the glucuronidation of acetaminophen and could possibly potentiate acetaminophen toxicity.,acetaminophen,acetaminophen,No interaction,Metopirone_bf inhibits_bf glucuronidation_bf DRUG could_be possibly_be potentiate_be DRUG toxicity_af ._af
1409,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,phenothiazines,advise,Caution_bf observed_bf administering_bf DRUG patients_be receiving_be OTHER_DRUG haloperidol_af extrapyramidal_af effects_af drugs_af expected_af potentiated_af inhibition_af catecholamine_af synthesis_af ._af
1410,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,DEMSER,haloperidol,advise,Caution_bf observed_bf administering_bf DRUG patients_be receiving_be phenothiazines_be OTHER_DRUG extrapyramidal_af effects_af drugs_af expected_af potentiated_af inhibition_af catecholamine_af synthesis_af ._af
1411,Caution should be observed in administering DEMSER to patients receiving phenothiazines or haloperidol because the extrapyramidal effects of these drugs can be expected to be potentiated by inhibition of catecholamine synthesis. ,phenothiazines,haloperidol,No interaction,Caution_bf observed_bf administering_bf DEMSER_bf patients_bf receiving_bf DRUG OTHER_DRUG extrapyramidal_af effects_af drugs_af expected_af potentiated_af inhibition_af catecholamine_af synthesis_af ._af
1412,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DEMSER,alcohol,effect,Concurrent_bf use_bf DRUG OTHER_DRUG CNS_af depressants_af increase_af sedative_af effects_af ._af
1413,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,DEMSER,CNS depressants,effect,Concurrent_bf use_bf DRUG alcohol_be CNS_be depressants_be increase_be sedative_be effects_be ._be
1414,Concurrent use of DEMSER with alcohol or other CNS depressants can increase their sedative effects.,alcohol,CNS depressants,No interaction,Concurrent_bf use_bf DEMSER_bf DRUG CNS_be depressants_be increase_be sedative_be effects_be ._be
1415,"Since MEXITIL is a substrate for the metabolic pathways involving CYP2D6 and CYP1A2 enzymes, inhibition or induction of either of these enzymes would be expected to alter mexiletine plasma concentrations. ",MEXITIL,mexiletine,No interaction,"Since_bf DRUG substrate_be metabolic_be pathways_be involving_be CYP2D6_be CYP1A2_be enzymes_be ,_be inhibition_be induction_be either_be enzymes_be would_be expected_be alter_be OTHER_DRUG plasma_af concentrations_af ._af"
1416,"In a formal, single-dose interaction study (n = 6 males) the clearance of mexiletine was decreased by 38% following the coadministration of fluvoxamine, an inhibitor of CYP1A2. ",mexiletine,fluvoxamine,mechanism,"In_bf formal_bf ,_bf single-dose_bf interaction_bf study_bf (n_bf =_bf 6_bf males)_bf clearance_bf DRUG decreased_be 38%_be following_be coadministration_be OTHER_DRUG ,_af inhibitor_af CYP1A2_af ._af"
1417,"In another formal study (n = 8 extensive and n = 7 poor metabolizers of CYP2D6), coadministration of propafenone did not alter the kinetics of mexiletine in the poor CYP2D6 metabolizer group. ",propafenone,mexiletine,No interaction,"In_bf another_bf formal_bf study_bf (n_bf =_bf 8_bf extensive_bf n_bf =_bf 7_bf poor_bf metabolizers_bf CYP2D6)_bf ,_bf coadministration_bf DRUG alter_be kinetics_be OTHER_DRUG poor_af CYP2D6_af metabolizer_af group_af ._af"
1418,"In this crossover steady state study, the pharmacokinetics of propafenone were unaffected in either phenotype by the coadministration of mexiletine. ",propafenone,mexiletine,No interaction,"In_bf crossover_bf steady_bf state_bf study_bf ,_bf pharmacokinetics_bf DRUG unaffected_be either_be phenotype_be coadministration_be OTHER_DRUG ._af"
1419,"Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. ",mexiletine,propafenone,No interaction,"Addition_bf DRUG OTHER_DRUG lead_af electrocardiographic_af parameters_af changes_af QRS_af ,_af QTc_af ,_af RR_af ,_af PR_af intervals_af OTHER_DRUG alone_af ._af"
1420,"Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. ",mexiletine,propafenone,No interaction,"Addition_bf DRUG OTHER_DRUG lead_af electrocardiographic_af parameters_af changes_af QRS_af ,_af QTc_af ,_af RR_af ,_af PR_af intervals_af OTHER_DRUG alone_af ._af"
1421,"Addition of mexiletine to propafenone did not lead to further electrocardiographic parameters changes of QRS, QTc, RR, and PR intervals than propafenone alone. ",propafenone,propafenone,No interaction,"Addition_bf mexiletine_bf DRUG lead_be electrocardiographic_be parameters_be changes_be QRS_be ,_be QTc_be ,_be RR_be ,_be PR_be intervals_be DRUG alone_af ._af"
1422,"When concomitant administration of either of these two drugs with mexiletine is initiated, the dose of mexiletine should be slowly titrated to desired effect. ",mexiletine,mexiletine,No interaction,"When_bf concomitant_bf administration_bf either_bf two_bf drugs_bf DRUG initiated_be ,_be dose_be DRUG slowly_af titrated_af desired_af effect_af ._af"
1423,"In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. ",Mexitil,antihypertensive,No interaction,"In_bf large_bf compassionate_bf use_bf program_bf DRUG used_be concurrently_be commonly_be employed_be antianginal_be ,_be OTHER_DRUG ,_af anticoagulant_af drugs_af without_af observed_af interactions_af ._af"
1424,"In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. ",Mexitil,anticoagulant drugs,No interaction,"In_bf large_bf compassionate_bf use_bf program_bf DRUG used_be concurrently_be commonly_be employed_be antianginal_be ,_be antihypertensive_be ,_be anticoagulant_be drugs_be without_be observed_be interactions_be ._be"
1425,"In a large compassionate use program Mexitil    has been used concurrently with commonly employed antianginal, antihypertensive, and anticoagulant drugs without observed interactions. ",antihypertensive,anticoagulant drugs,No interaction,"In_bf large_bf compassionate_bf use_bf program_bf Mexitil_bf used_bf concurrently_bf commonly_bf employed_bf antianginal_bf ,_bf DRUG ,_be anticoagulant_be drugs_be without_be observed_be interactions_be ._be"
1426,"A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy. ",antiarrhythmics,quinidine,No interaction,"A_bf variety_bf DRUG OTHER_DRUG propranolol_af also_af added_af ,_af sometimes_af improved_af control_af ventricular_af ectopy_af ._af"
1427,"A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy. ",antiarrhythmics,propranolol,No interaction,"A_bf variety_bf DRUG quinidine_be OTHER_DRUG also_af added_af ,_af sometimes_af improved_af control_af ventricular_af ectopy_af ._af"
1428,"A variety of antiarrhythmics such as quinidine or propranolol were also added, sometimes with improved control of ventricular ectopy. ",quinidine,propranolol,No interaction,"A_bf variety_bf antiarrhythmics_bf DRUG OTHER_DRUG also_af added_af ,_af sometimes_af improved_af control_af ventricular_af ectopy_af ._af"
1429,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenytoin,rifampin,No interaction,"When_bf DRUG hepatic_be enzyme_be inducers_be OTHER_DRUG phenobarbital_af taken_af concurrently_af Mexitil_af ,_af lowered_af Mexitil_af plasma_af levels_af reported_af ._af"
1430,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenytoin,phenobarbital,No interaction,"When_bf DRUG hepatic_be enzyme_be inducers_be rifampin_be OTHER_DRUG taken_af concurrently_af Mexitil_af ,_af lowered_af Mexitil_af plasma_af levels_af reported_af ._af"
1431,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenytoin,Mexitil,mechanism,"When_bf DRUG hepatic_be enzyme_be inducers_be rifampin_be phenobarbital_be taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
1432,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenytoin,Mexitil,No interaction,"When_bf DRUG hepatic_be enzyme_be inducers_be rifampin_be phenobarbital_be taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
1433,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",rifampin,phenobarbital,No interaction,"When_bf phenytoin_bf hepatic_bf enzyme_bf inducers_bf DRUG OTHER_DRUG taken_af concurrently_af Mexitil_af ,_af lowered_af Mexitil_af plasma_af levels_af reported_af ._af"
1434,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",rifampin,Mexitil,mechanism,"When_bf phenytoin_bf hepatic_bf enzyme_bf inducers_bf DRUG phenobarbital_be taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
1435,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",rifampin,Mexitil,No interaction,"When_bf phenytoin_bf hepatic_bf enzyme_bf inducers_bf DRUG phenobarbital_be taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
1436,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenobarbital,Mexitil,mechanism,"When_bf phenytoin_bf hepatic_bf enzyme_bf inducers_bf rifampin_bf DRUG taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
1437,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",phenobarbital,Mexitil,No interaction,"When_bf phenytoin_bf hepatic_bf enzyme_bf inducers_bf rifampin_bf DRUG taken_be concurrently_be OTHER_DRUG ,_af lowered_af OTHER_DRUG plasma_af levels_af reported_af ._af"
1438,"When phenytoin or other hepatic enzyme inducers such as rifampin and phenobarbital have been taken concurrently with Mexitil   , lowered Mexitil    plasma levels have been reported. ",Mexitil,Mexitil,No interaction,"When_bf phenytoin_bf hepatic_bf enzyme_bf inducers_bf rifampin_bf phenobarbital_bf taken_bf concurrently_bf DRUG ,_be lowered_be DRUG plasma_af levels_af reported_af ._af"
1439,"In a formal study, benzodiazepines were shown not to affect Mexitil    plasma concentrations. ",benzodiazepines,Mexitil,No interaction,"In_bf formal_bf study_bf ,_bf DRUG shown_be affect_be OTHER_DRUG plasma_af concentrations_af ._af"
1440,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",Mexitil,digoxin,No interaction,"ECG_bf intervals_bf (PR_bf ,_bf QRS_bf ,_bf QT)_bf affected_bf concurrent_bf DRUG OTHER_DRUG ,_af diuretics_af ,_af propranolol_af ._af"
1441,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",Mexitil,diuretics,No interaction,"ECG_bf intervals_bf (PR_bf ,_bf QRS_bf ,_bf QT)_bf affected_bf concurrent_bf DRUG digoxin_be ,_be OTHER_DRUG ,_af propranolol_af ._af"
1442,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",Mexitil,propranolol,No interaction,"ECG_bf intervals_bf (PR_bf ,_bf QRS_bf ,_bf QT)_bf affected_bf concurrent_bf DRUG digoxin_be ,_be diuretics_be ,_be OTHER_DRUG ._af"
1443,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",digoxin,diuretics,No interaction,"ECG_bf intervals_bf (PR_bf ,_bf QRS_bf ,_bf QT)_bf affected_bf concurrent_bf Mexitil_bf DRUG ,_be OTHER_DRUG ,_af propranolol_af ._af"
1444,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",digoxin,propranolol,No interaction,"ECG_bf intervals_bf (PR_bf ,_bf QRS_bf ,_bf QT)_bf affected_bf concurrent_bf Mexitil_bf DRUG ,_be diuretics_be ,_be OTHER_DRUG ._af"
1445,"ECG intervals (PR, QRS, and QT) were not affected by concurrent Mexitil    and digoxin, diuretics, or propranolol. ",diuretics,propranolol,No interaction,"ECG_bf intervals_bf (PR_bf ,_bf QRS_bf ,_bf QT)_bf affected_bf concurrent_bf Mexitil_bf digoxin_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
1446,"Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; ",cimetidine,Mexitil,mechanism,"Concurrent_bf administration_bf DRUG OTHER_DRUG reported_af increase_af ,_af decrease_af ,_af leave_af unchanged_af OTHER_DRUG plasma_af levels;_af"
1447,"Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; ",cimetidine,Mexitil,No interaction,"Concurrent_bf administration_bf DRUG OTHER_DRUG reported_af increase_af ,_af decrease_af ,_af leave_af unchanged_af OTHER_DRUG plasma_af levels;_af"
1448,"Concurrent administration of cimetidine and Mexitil    has been reported to increase, decrease, or leave unchanged Mexitil    plasma levels; ",Mexitil,Mexitil,No interaction,"Concurrent_bf administration_bf cimetidine_bf DRUG reported_be increase_be ,_be decrease_be ,_be leave_be unchanged_be DRUG plasma_af levels;_af"
1449,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",Mexitil,digoxin,No interaction,"DRUG alter_be serum_be OTHER_DRUG levels_af magnesium-aluminum_af hydroxide_af ,_af used_af treat_af gastrointestinal_af symptoms_af due_af DRUG ,_af reported_af lower_af serum_af OTHER_DRUG levels_af ._af"
1450,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",Mexitil,magnesium-aluminum hydroxide,No interaction,"DRUG alter_be serum_be digoxin_be levels_be magnesium-aluminum_be hydroxide_be ,_be used_be treat_be gastrointestinal_be symptoms_be due_be DRUG ,_af reported_af lower_af serum_af digoxin_af levels_af ._af"
1451,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",Mexitil,Mexitil,No interaction,"DRUG alter_be serum_be digoxin_be levels_be magnesium-aluminum_be hydroxide_be ,_be used_be treat_be gastrointestinal_be symptoms_be due_be DRUG ,_af reported_af lower_af serum_af digoxin_af levels_af ._af"
1452,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",Mexitil,digoxin,No interaction,"DRUG alter_be serum_be OTHER_DRUG levels_af magnesium-aluminum_af hydroxide_af ,_af used_af treat_af gastrointestinal_af symptoms_af due_af DRUG ,_af reported_af lower_af serum_af OTHER_DRUG levels_af ._af"
1453,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",digoxin,magnesium-aluminum hydroxide,No interaction,"Mexitil_bf alter_bf serum_bf DRUG levels_be magnesium-aluminum_be hydroxide_be ,_be used_be treat_be gastrointestinal_be symptoms_be due_be Mexitil_be ,_be reported_be lower_be serum_be DRUG levels_af ._af"
1454,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",digoxin,Mexitil,No interaction,"OTHER_DRUG alter_be serum_be DRUG levels_af magnesium-aluminum_af hydroxide_af ,_af used_af treat_af gastrointestinal_af symptoms_af due_af OTHER_DRUG ,_af reported_af lower_af serum_af DRUG levels_af ._af"
1455,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",digoxin,digoxin,No interaction,"Mexitil_bf alter_bf serum_bf DRUG levels_be magnesium-aluminum_be hydroxide_be ,_be used_be treat_be gastrointestinal_be symptoms_be due_be Mexitil_be ,_be reported_be lower_be serum_be DRUG levels_af ._af"
1456,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",magnesium-aluminum hydroxide,Mexitil,No interaction,"OTHER_DRUG alter_be serum_be digoxin_be levels_be magnesium-aluminum_be hydroxide_be ,_be used_be treat_be gastrointestinal_be symptoms_be due_be OTHER_DRUG ,_af reported_af lower_af serum_af digoxin_af levels_af ._af"
1457,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",magnesium-aluminum hydroxide,digoxin,mechanism,"Mexitil_bf alter_bf serum_bf OTHER_DRUG levels_be magnesium-aluminum_be hydroxide_be ,_be used_be treat_be gastrointestinal_be symptoms_be due_be Mexitil_be ,_be reported_be lower_be serum_be OTHER_DRUG levels_af ._af"
1458,"Mexitil    does not alter serum digoxin levels but magnesium-aluminum hydroxide, when used to treat gastrointestinal symptoms due to Mexitil   , has been reported to lower serum digoxin levels. ",Mexitil,digoxin,No interaction,"DRUG alter_be serum_be OTHER_DRUG levels_af magnesium-aluminum_af hydroxide_af ,_af used_af treat_af gastrointestinal_af symptoms_af due_af DRUG ,_af reported_af lower_af serum_af OTHER_DRUG levels_af ._af"
1459,Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. ,Mexitil,theophylline,mechanism,Concurrent_bf use_bf DRUG OTHER_DRUG may_af lead_af increased_af plasma_af OTHER_DRUG levels_af ._af
1460,Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. ,Mexitil,theophylline,No interaction,Concurrent_bf use_bf DRUG OTHER_DRUG may_af lead_af increased_af plasma_af OTHER_DRUG levels_af ._af
1461,Concurrent use of Mexitil    and theophylline may lead to increased plasma theophylline levels. ,theophylline,theophylline,No interaction,Concurrent_bf use_bf Mexitil_bf DRUG may_be lead_be increased_be plasma_be DRUG levels_af ._af
1462,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,Theophylline,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be OTHER_DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af DRUG ._af If_af DRUG OTHER_DRUG used_af concurrently_af ,_af OTHER_DRUG blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1463,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be Theophylline_be plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be DRUG ._af If_af DRUG theophylline_af used_af concurrently_af ,_af theophylline_af blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1464,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be Theophylline_be plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be DRUG ._af If_af DRUG theophylline_af used_af concurrently_af ,_af theophylline_af blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1465,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be Theophylline_be plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be DRUG ._af If_af DRUG theophylline_af used_af concurrently_af ,_af theophylline_af blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1466,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be OTHER_DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af DRUG ._af If_af DRUG OTHER_DRUG used_af concurrently_af ,_af OTHER_DRUG blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1467,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be OTHER_DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af DRUG ._af If_af DRUG OTHER_DRUG used_af concurrently_af ,_af OTHER_DRUG blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1468,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be Theophylline_be plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be DRUG ._af If_af DRUG theophylline_af used_af concurrently_af ,_af theophylline_af blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1469,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Theophylline,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf OTHER_DRUG ._be DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af OTHER_DRUG ._af If_af OTHER_DRUG DRUG used_af concurrently_af ,_af DRUG blood_af levels_af monitored_af ,_af particularly_af OTHER_DRUG dose_af changed_af ._af"
1470,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Theophylline,Mexitil,mechanism,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf OTHER_DRUG ._be DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af OTHER_DRUG ._af If_af OTHER_DRUG DRUG used_af concurrently_af ,_af DRUG blood_af levels_af monitored_af ,_af particularly_af OTHER_DRUG dose_af changed_af ._af"
1471,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Theophylline,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf OTHER_DRUG ._be DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af OTHER_DRUG ._af If_af OTHER_DRUG DRUG used_af concurrently_af ,_af DRUG blood_af levels_af monitored_af ,_af particularly_af OTHER_DRUG dose_af changed_af ._af"
1472,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Theophylline,theophylline,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf Mexitil_bf ._bf DRUG plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be Mexitil_be ._be If_be Mexitil_be DRUG used_af concurrently_af ,_af DRUG blood_af levels_af monitored_af ,_af particularly_af Mexitil_af dose_af changed_af ._af"
1473,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Theophylline,theophylline,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf Mexitil_bf ._bf DRUG plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be Mexitil_be ._be If_be Mexitil_be DRUG used_af concurrently_af ,_af DRUG blood_af levels_af monitored_af ,_af particularly_af Mexitil_af dose_af changed_af ._af"
1474,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Theophylline,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf OTHER_DRUG ._be DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af OTHER_DRUG ._af If_af OTHER_DRUG DRUG used_af concurrently_af ,_af DRUG blood_af levels_af monitored_af ,_af particularly_af OTHER_DRUG dose_af changed_af ._af"
1475,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be Theophylline_be plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be DRUG ._af If_af DRUG theophylline_af used_af concurrently_af ,_af theophylline_af blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1476,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be Theophylline_be plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be DRUG ._af If_af DRUG theophylline_af used_af concurrently_af ,_af theophylline_af blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1477,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be OTHER_DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af DRUG ._af If_af DRUG OTHER_DRUG used_af concurrently_af ,_af OTHER_DRUG blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1478,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be OTHER_DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af DRUG ._af If_af DRUG OTHER_DRUG used_af concurrently_af ,_af OTHER_DRUG blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1479,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be Theophylline_be plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be DRUG ._af If_af DRUG theophylline_af used_af concurrently_af ,_af theophylline_af blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1480,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be Theophylline_be plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be DRUG ._af If_af DRUG theophylline_af used_af concurrently_af ,_af theophylline_af blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1481,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be OTHER_DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af DRUG ._af If_af DRUG OTHER_DRUG used_af concurrently_af ,_af OTHER_DRUG blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1482,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be OTHER_DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af DRUG ._af If_af DRUG OTHER_DRUG used_af concurrently_af ,_af OTHER_DRUG blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1483,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be Theophylline_be plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be DRUG ._af If_af DRUG theophylline_af used_af concurrently_af ,_af theophylline_af blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1484,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,advise,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be OTHER_DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af DRUG ._af If_af DRUG OTHER_DRUG used_af concurrently_af ,_af OTHER_DRUG blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1485,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,theophylline,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be OTHER_DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af DRUG ._af If_af DRUG OTHER_DRUG used_af concurrently_af ,_af OTHER_DRUG blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1486,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",Mexitil,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf DRUG ._be Theophylline_be plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be DRUG ._af If_af DRUG theophylline_af used_af concurrently_af ,_af theophylline_af blood_af levels_af monitored_af ,_af particularly_af DRUG dose_af changed_af ._af"
1487,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",theophylline,theophylline,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf Mexitil_bf ._bf DRUG plasma_be levels_be returned_be pre-Mexitil_be values_be within_be 48_be hours_be discontinuing_be Mexitil_be ._be If_be Mexitil_be DRUG used_af concurrently_af ,_af DRUG blood_af levels_af monitored_af ,_af particularly_af Mexitil_af dose_af changed_af ._af"
1488,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",theophylline,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf OTHER_DRUG ._be DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af OTHER_DRUG ._af If_af OTHER_DRUG DRUG used_af concurrently_af ,_af DRUG blood_af levels_af monitored_af ,_af particularly_af OTHER_DRUG dose_af changed_af ._af"
1489,"This increase was observed at the first test point which was the second day after starting Mexitil   . Theophylline plasma levels returned to pre-Mexitil    values within 48 hours after discontinuing Mexitil   . If Mexitil and theophylline are to be used concurrently, theophylline blood levels should be monitored, particularly when the Mexitil    dose is changed. ",theophylline,Mexitil,No interaction,"This_bf increase_bf observed_bf first_bf test_bf point_bf second_bf day_bf starting_bf OTHER_DRUG ._be DRUG plasma_af levels_af returned_af pre-Mexitil_af values_af within_af 48_af hours_af discontinuing_af OTHER_DRUG ._af If_af OTHER_DRUG DRUG used_af concurrently_af ,_af DRUG blood_af levels_af monitored_af ,_af particularly_af OTHER_DRUG dose_af changed_af ._af"
1490,"Additionally, in one controlled study in five normal subjects and seven patients, the clearance of caffeine was decreased 50% following the administration of Mexitil   .",caffeine,Mexitil,mechanism,"Additionally_bf ,_bf one_bf controlled_bf study_bf five_bf normal_bf subjects_bf seven_bf patients_bf ,_bf clearance_bf DRUG decreased_be 50%_be following_be administration_be OTHER_DRUG ._af"
1491,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,terfenadine,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be OTHER_DRUG ,_af astemizole_af ,_af cisapride_af ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
1492,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,astemizole,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be OTHER_DRUG ,_af cisapride_af ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
1493,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,cisapride,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be astemizole_be ,_be OTHER_DRUG ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
1494,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,cyclosporine,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be astemizole_be ,_be cisapride_be ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ._af"
1495,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",Posicor,tricyclic antidepressants,mechanism,"DRUG inhibits_be liver's_be ability_be metabolize_be drugs_be -_be terfenadine_be ,_be astemizole_be ,_be cisapride_be ,_be cyclosporine_be ,_be tricyclic_be antidepressants_be ._be"
1496,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",terfenadine,astemizole,No interaction,"Posicor_bf inhibits_bf liver's_bf ability_bf metabolize_bf drugs_bf -_bf DRUG ,_be OTHER_DRUG ,_af cisapride_af ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
1497,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",terfenadine,cisapride,No interaction,"Posicor_bf inhibits_bf liver's_bf ability_bf metabolize_bf drugs_bf -_bf DRUG ,_be astemizole_be ,_be OTHER_DRUG ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
1498,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",terfenadine,cyclosporine,No interaction,"Posicor_bf inhibits_bf liver's_bf ability_bf metabolize_bf drugs_bf -_bf DRUG ,_be astemizole_be ,_be cisapride_be ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ._af"
1499,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",terfenadine,tricyclic antidepressants,No interaction,"Posicor_bf inhibits_bf liver's_bf ability_bf metabolize_bf drugs_bf -_bf DRUG ,_be astemizole_be ,_be cisapride_be ,_be cyclosporine_be ,_be tricyclic_be antidepressants_be ._be"
1500,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",astemizole,cisapride,No interaction,"Posicor_bf inhibits_bf liver's_bf ability_bf metabolize_bf drugs_bf -_bf terfenadine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af cyclosporine_af ,_af tricyclic_af antidepressants_af ._af"
1501,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",astemizole,cyclosporine,No interaction,"Posicor_bf inhibits_bf liver's_bf ability_bf metabolize_bf drugs_bf -_bf terfenadine_bf ,_bf DRUG ,_be cisapride_be ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ._af"
1502,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",astemizole,tricyclic antidepressants,No interaction,"Posicor_bf inhibits_bf liver's_bf ability_bf metabolize_bf drugs_bf -_bf terfenadine_bf ,_bf DRUG ,_be cisapride_be ,_be cyclosporine_be ,_be tricyclic_be antidepressants_be ._be"
1503,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",cisapride,cyclosporine,No interaction,"Posicor_bf inhibits_bf liver's_bf ability_bf metabolize_bf drugs_bf -_bf terfenadine_bf ,_bf astemizole_bf ,_bf DRUG ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ._af"
1504,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",cisapride,tricyclic antidepressants,No interaction,"Posicor_bf inhibits_bf liver's_bf ability_bf metabolize_bf drugs_bf -_bf terfenadine_bf ,_bf astemizole_bf ,_bf DRUG ,_be cyclosporine_be ,_be tricyclic_be antidepressants_be ._be"
1505,"Posicor inhibits some of the liver's ability to metabolize some other drugs - terfenadine, astemizole, cisapride, cyclosporine, and tricyclic antidepressants. ",cyclosporine,tricyclic antidepressants,No interaction,"Posicor_bf inhibits_bf liver's_bf ability_bf metabolize_bf drugs_bf -_bf terfenadine_bf ,_bf astemizole_bf ,_bf cisapride_bf ,_bf DRUG ,_be tricyclic_be antidepressants_be ._be"
1506,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",MYCAMINE,mycophenolate mofetil,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be ritonavir_be ,_be rifampin_be ._be"
1507,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",MYCAMINE,cyclosporine,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf DRUG mycophenolate_be mofetil_be ,_be OTHER_DRUG ,_af tacrolimus_af ,_af prednisolone_af ,_af sirolimus_af ,_af nifedipine_af ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1508,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",MYCAMINE,tacrolimus,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be OTHER_DRUG ,_af prednisolone_af ,_af sirolimus_af ,_af nifedipine_af ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1509,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",MYCAMINE,prednisolone,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be OTHER_DRUG ,_af sirolimus_af ,_af nifedipine_af ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1510,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",MYCAMINE,sirolimus,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be prednisolone_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1511,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",MYCAMINE,nifedipine,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be prednisolone_be ,_be sirolimus_be ,_be OTHER_DRUG ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1512,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",MYCAMINE,fluconazole,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af rifampin_af ._af"
1513,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",MYCAMINE,ritonavir,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be OTHER_DRUG ,_af rifampin_af ._af"
1514,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",MYCAMINE,rifampin,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be ritonavir_be ,_be OTHER_DRUG ._af"
1515,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",mycophenolate mofetil,cyclosporine,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf OTHER_DRUG ,_be tacrolimus_be ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be ritonavir_be ,_be rifampin_be ._be"
1516,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",mycophenolate mofetil,tacrolimus,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf OTHER_DRUG ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be ritonavir_be ,_be rifampin_be ._be"
1517,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",mycophenolate mofetil,prednisolone,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf OTHER_DRUG ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be ritonavir_be ,_be rifampin_be ._be"
1518,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",mycophenolate mofetil,sirolimus,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf OTHER_DRUG ,_be nifedipine_be ,_be fluconazole_be ,_be ritonavir_be ,_be rifampin_be ._be"
1519,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",mycophenolate mofetil,nifedipine,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf sirolimus_bf ,_bf OTHER_DRUG ,_be fluconazole_be ,_be ritonavir_be ,_be rifampin_be ._be"
1520,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",mycophenolate mofetil,fluconazole,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf sirolimus_bf ,_bf nifedipine_bf ,_bf OTHER_DRUG ,_be ritonavir_be ,_be rifampin_be ._be"
1521,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",mycophenolate mofetil,ritonavir,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf sirolimus_bf ,_bf nifedipine_bf ,_bf fluconazole_bf ,_bf OTHER_DRUG ,_be rifampin_be ._be"
1522,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",mycophenolate mofetil,rifampin,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf sirolimus_bf ,_bf nifedipine_bf ,_bf fluconazole_bf ,_bf ritonavir_bf ,_bf OTHER_DRUG ._be"
1523,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",cyclosporine,tacrolimus,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf DRUG ,_be OTHER_DRUG ,_af prednisolone_af ,_af sirolimus_af ,_af nifedipine_af ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1524,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",cyclosporine,prednisolone,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf DRUG ,_be tacrolimus_be ,_be OTHER_DRUG ,_af sirolimus_af ,_af nifedipine_af ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1525,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",cyclosporine,sirolimus,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf DRUG ,_be tacrolimus_be ,_be prednisolone_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1526,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",cyclosporine,nifedipine,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf DRUG ,_be tacrolimus_be ,_be prednisolone_be ,_be sirolimus_be ,_be OTHER_DRUG ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1527,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",cyclosporine,fluconazole,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf DRUG ,_be tacrolimus_be ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af rifampin_af ._af"
1528,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",cyclosporine,ritonavir,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf DRUG ,_be tacrolimus_be ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be OTHER_DRUG ,_af rifampin_af ._af"
1529,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",cyclosporine,rifampin,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf DRUG ,_be tacrolimus_be ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be ritonavir_be ,_be OTHER_DRUG ._af"
1530,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",tacrolimus,prednisolone,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af sirolimus_af ,_af nifedipine_af ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1531,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",tacrolimus,sirolimus,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf DRUG ,_be prednisolone_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1532,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",tacrolimus,nifedipine,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf DRUG ,_be prednisolone_be ,_be sirolimus_be ,_be OTHER_DRUG ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1533,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",tacrolimus,fluconazole,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf DRUG ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af rifampin_af ._af"
1534,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",tacrolimus,ritonavir,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf DRUG ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be OTHER_DRUG ,_af rifampin_af ._af"
1535,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",tacrolimus,rifampin,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf DRUG ,_be prednisolone_be ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be ritonavir_be ,_be OTHER_DRUG ._af"
1536,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",prednisolone,sirolimus,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf DRUG ,_be OTHER_DRUG ,_af nifedipine_af ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1537,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",prednisolone,nifedipine,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf DRUG ,_be sirolimus_be ,_be OTHER_DRUG ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1538,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",prednisolone,fluconazole,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf DRUG ,_be sirolimus_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af rifampin_af ._af"
1539,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",prednisolone,ritonavir,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf DRUG ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be OTHER_DRUG ,_af rifampin_af ._af"
1540,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",prednisolone,rifampin,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf DRUG ,_be sirolimus_be ,_be nifedipine_be ,_be fluconazole_be ,_be ritonavir_be ,_be OTHER_DRUG ._af"
1541,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",sirolimus,nifedipine,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf DRUG ,_be OTHER_DRUG ,_af fluconazole_af ,_af ritonavir_af ,_af rifampin_af ._af"
1542,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",sirolimus,fluconazole,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf DRUG ,_be nifedipine_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af rifampin_af ._af"
1543,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",sirolimus,ritonavir,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf DRUG ,_be nifedipine_be ,_be fluconazole_be ,_be OTHER_DRUG ,_af rifampin_af ._af"
1544,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",sirolimus,rifampin,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf DRUG ,_be nifedipine_be ,_be fluconazole_be ,_be ritonavir_be ,_be OTHER_DRUG ._af"
1545,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",nifedipine,fluconazole,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf sirolimus_bf ,_bf DRUG ,_be OTHER_DRUG ,_af ritonavir_af ,_af rifampin_af ._af"
1546,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",nifedipine,ritonavir,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf sirolimus_bf ,_bf DRUG ,_be fluconazole_be ,_be OTHER_DRUG ,_af rifampin_af ._af"
1547,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",nifedipine,rifampin,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf sirolimus_bf ,_bf DRUG ,_be fluconazole_be ,_be ritonavir_be ,_be OTHER_DRUG ._af"
1548,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",fluconazole,ritonavir,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf sirolimus_bf ,_bf nifedipine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af rifampin_af ._af"
1549,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",fluconazole,rifampin,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf sirolimus_bf ,_bf nifedipine_bf ,_bf DRUG ,_be ritonavir_be ,_be OTHER_DRUG ._af"
1550,"A total of 11 clinical drug-drug interaction studies were conducted in healthy volunteers to evaluate the potential for interaction between MYCAMINE and mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, sirolimus, nifedipine, fluconazole, ritonavir, and rifampin. ",ritonavir,rifampin,No interaction,"A_bf total_bf 11_bf clinical_bf drug-drug_bf interaction_bf studies_bf conducted_bf healthy_bf volunteers_bf evaluate_bf potential_bf interaction_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf sirolimus_bf ,_bf nifedipine_bf ,_bf fluconazole_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
1551,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",MYCAMINE,mycophenolate mofetil,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be prednisolone_be ,_be fluconazole_be pharmacokinetics_be ._be"
1552,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",MYCAMINE,cyclosporine,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf DRUG mycophenolate_be mofetil_be ,_be OTHER_DRUG ,_af tacrolimus_af ,_af prednisolone_af ,_af fluconazole_af pharmacokinetics_af ._af"
1553,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",MYCAMINE,tacrolimus,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be OTHER_DRUG ,_af prednisolone_af ,_af fluconazole_af pharmacokinetics_af ._af"
1554,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",MYCAMINE,prednisolone,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be OTHER_DRUG ,_af fluconazole_af pharmacokinetics_af ._af"
1555,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",MYCAMINE,fluconazole,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf DRUG mycophenolate_be mofetil_be ,_be cyclosporine_be ,_be tacrolimus_be ,_be prednisolone_be ,_be OTHER_DRUG pharmacokinetics_af ._af"
1556,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",mycophenolate mofetil,cyclosporine,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf OTHER_DRUG ,_be tacrolimus_be ,_be prednisolone_be ,_be fluconazole_be pharmacokinetics_be ._be"
1557,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",mycophenolate mofetil,tacrolimus,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf OTHER_DRUG ,_be prednisolone_be ,_be fluconazole_be pharmacokinetics_be ._be"
1558,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",mycophenolate mofetil,prednisolone,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf OTHER_DRUG ,_be fluconazole_be pharmacokinetics_be ._be"
1559,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",mycophenolate mofetil,fluconazole,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf prednisolone_bf ,_bf OTHER_DRUG pharmacokinetics_be ._be"
1560,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",cyclosporine,tacrolimus,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf DRUG ,_be OTHER_DRUG ,_af prednisolone_af ,_af fluconazole_af pharmacokinetics_af ._af"
1561,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",cyclosporine,prednisolone,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf DRUG ,_be tacrolimus_be ,_be OTHER_DRUG ,_af fluconazole_af pharmacokinetics_af ._af"
1562,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",cyclosporine,fluconazole,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf DRUG ,_be tacrolimus_be ,_be prednisolone_be ,_be OTHER_DRUG pharmacokinetics_af ._af"
1563,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",tacrolimus,prednisolone,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af fluconazole_af pharmacokinetics_af ._af"
1564,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",tacrolimus,fluconazole,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf DRUG ,_be prednisolone_be ,_be OTHER_DRUG pharmacokinetics_af ._af"
1565,"There was no effect of a single dose or multiple doses of MYCAMINE on mycophenolate mofetil, cyclosporine, tacrolimus, prednisolone, and fluconazole pharmacokinetics. ",prednisolone,fluconazole,No interaction,"There_bf effect_bf single_bf dose_bf multiple_bf doses_bf MYCAMINE_bf mycophenolate_bf mofetil_bf ,_bf cyclosporine_bf ,_bf tacrolimus_bf ,_bf DRUG ,_be OTHER_DRUG pharmacokinetics_af ._af"
1566,Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. ,Sirolimus,MYCAMINE,mechanism,DRUG AUC_be increased_be 21%_be effect_be Cmax_be presence_be steady-state_be OTHER_DRUG compared_af DRUG alone_af ._af
1567,Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. ,Sirolimus,sirolimus,No interaction,DRUG AUC_be increased_be 21%_be effect_be Cmax_be presence_be steady-state_be MYCAMINE_be compared_be DRUG alone_af ._af
1568,Sirolimus AUC was increased by 21% with no effect on Cmax in the presence of steady-state MYCAMINE compared with sirolimus alone. ,MYCAMINE,sirolimus,No interaction,OTHER_DRUG AUC_be increased_be 21%_be effect_be Cmax_be presence_be steady-state_be DRUG compared_af OTHER_DRUG alone_af ._af
1569,"Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. ",Nifedipine,MYCAMINE,mechanism,"DRUG AUC_be Cmax_be increased_be 18%_be 42%_be ,_be respectively_be ,_be presence_be steady-state_be OTHER_DRUG compared_af DRUG alone_af ._af"
1570,"Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. ",Nifedipine,nifedipine,No interaction,"DRUG AUC_be Cmax_be increased_be 18%_be 42%_be ,_be respectively_be ,_be presence_be steady-state_be MYCAMINE_be compared_be DRUG alone_af ._af"
1571,"Nifedipine AUC and Cmax were increased by 18% and 42%, respectively, in the presence of steady-state MYCAMINE compared with nifedipine alone. ",MYCAMINE,nifedipine,No interaction,"OTHER_DRUG AUC_be Cmax_be increased_be 18%_be 42%_be ,_be respectively_be ,_be presence_be steady-state_be DRUG compared_af OTHER_DRUG alone_af ._af"
1572,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,nifedipine,No interaction,Patients_bf receiving_bf DRUG OTHER_DRUG combination_af MYCAMINE_af monitored_af DRUG OTHER_DRUG toxicity_af DRUG OTHER_DRUG dosage_af reduced_af necessary_af ._af
1573,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,MYCAMINE,advise,Patients_bf receiving_bf DRUG nifedipine_be combination_be OTHER_DRUG monitored_af DRUG nifedipine_af toxicity_af DRUG nifedipine_af dosage_af reduced_af necessary_af ._af
1574,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,sirolimus,No interaction,Patients_bf receiving_bf DRUG nifedipine_be combination_be MYCAMINE_be monitored_be DRUG nifedipine_af toxicity_af DRUG nifedipine_af dosage_af reduced_af necessary_af ._af
1575,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,nifedipine,No interaction,Patients_bf receiving_bf DRUG OTHER_DRUG combination_af MYCAMINE_af monitored_af DRUG OTHER_DRUG toxicity_af DRUG OTHER_DRUG dosage_af reduced_af necessary_af ._af
1576,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,sirolimus,No interaction,Patients_bf receiving_bf DRUG nifedipine_be combination_be MYCAMINE_be monitored_be DRUG nifedipine_af toxicity_af DRUG nifedipine_af dosage_af reduced_af necessary_af ._af
1577,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,nifedipine,No interaction,Patients_bf receiving_bf DRUG OTHER_DRUG combination_af MYCAMINE_af monitored_af DRUG OTHER_DRUG toxicity_af DRUG OTHER_DRUG dosage_af reduced_af necessary_af ._af
1578,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,nifedipine,MYCAMINE,advise,Patients_bf receiving_bf sirolimus_bf DRUG combination_be OTHER_DRUG monitored_af sirolimus_af DRUG toxicity_af sirolimus_af DRUG dosage_af reduced_af necessary_af ._af
1579,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,nifedipine,sirolimus,No interaction,Patients_bf receiving_bf OTHER_DRUG DRUG combination_af MYCAMINE_af monitored_af OTHER_DRUG DRUG toxicity_af OTHER_DRUG DRUG dosage_af reduced_af necessary_af ._af
1580,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,nifedipine,nifedipine,No interaction,Patients_bf receiving_bf sirolimus_bf DRUG combination_be MYCAMINE_be monitored_be sirolimus_be DRUG toxicity_af sirolimus_af DRUG dosage_af reduced_af necessary_af ._af
1581,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,nifedipine,sirolimus,No interaction,Patients_bf receiving_bf OTHER_DRUG DRUG combination_af MYCAMINE_af monitored_af OTHER_DRUG DRUG toxicity_af OTHER_DRUG DRUG dosage_af reduced_af necessary_af ._af
1582,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,nifedipine,nifedipine,No interaction,Patients_bf receiving_bf sirolimus_bf DRUG combination_be MYCAMINE_be monitored_be sirolimus_be DRUG toxicity_af sirolimus_af DRUG dosage_af reduced_af necessary_af ._af
1583,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,MYCAMINE,sirolimus,No interaction,Patients_bf receiving_bf OTHER_DRUG nifedipine_be combination_be DRUG monitored_af OTHER_DRUG nifedipine_af toxicity_af OTHER_DRUG nifedipine_af dosage_af reduced_af necessary_af ._af
1584,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,MYCAMINE,nifedipine,No interaction,Patients_bf receiving_bf sirolimus_bf OTHER_DRUG combination_be DRUG monitored_af sirolimus_af OTHER_DRUG toxicity_af sirolimus_af OTHER_DRUG dosage_af reduced_af necessary_af ._af
1585,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,MYCAMINE,sirolimus,No interaction,Patients_bf receiving_bf OTHER_DRUG nifedipine_be combination_be DRUG monitored_af OTHER_DRUG nifedipine_af toxicity_af OTHER_DRUG nifedipine_af dosage_af reduced_af necessary_af ._af
1586,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,MYCAMINE,nifedipine,No interaction,Patients_bf receiving_bf sirolimus_bf OTHER_DRUG combination_be DRUG monitored_af sirolimus_af OTHER_DRUG toxicity_af sirolimus_af OTHER_DRUG dosage_af reduced_af necessary_af ._af
1587,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,nifedipine,No interaction,Patients_bf receiving_bf DRUG OTHER_DRUG combination_af MYCAMINE_af monitored_af DRUG OTHER_DRUG toxicity_af DRUG OTHER_DRUG dosage_af reduced_af necessary_af ._af
1588,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,sirolimus,No interaction,Patients_bf receiving_bf DRUG nifedipine_be combination_be MYCAMINE_be monitored_be DRUG nifedipine_af toxicity_af DRUG nifedipine_af dosage_af reduced_af necessary_af ._af
1589,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,nifedipine,No interaction,Patients_bf receiving_bf DRUG OTHER_DRUG combination_af MYCAMINE_af monitored_af DRUG OTHER_DRUG toxicity_af DRUG OTHER_DRUG dosage_af reduced_af necessary_af ._af
1590,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,nifedipine,sirolimus,No interaction,Patients_bf receiving_bf OTHER_DRUG DRUG combination_af MYCAMINE_af monitored_af OTHER_DRUG DRUG toxicity_af OTHER_DRUG DRUG dosage_af reduced_af necessary_af ._af
1591,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,nifedipine,nifedipine,No interaction,Patients_bf receiving_bf sirolimus_bf DRUG combination_be MYCAMINE_be monitored_be sirolimus_be DRUG toxicity_af sirolimus_af DRUG dosage_af reduced_af necessary_af ._af
1592,Patients receiving sirolimus or nifedipine in combination with MYCAMINE should be monitored for sirolimus or nifedipine toxicity and sirolimus or nifedipine dosage should be reduced if necessary. ,sirolimus,nifedipine,No interaction,Patients_bf receiving_bf DRUG OTHER_DRUG combination_af MYCAMINE_af monitored_af DRUG OTHER_DRUG toxicity_af DRUG OTHER_DRUG dosage_af reduced_af necessary_af ._af
1593,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,azole antimycotics,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
1594,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,protease inhibitors,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
1595,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,calcium channel antagonists,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
1596,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",midazolam,macrolide antibiotics,advise,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf DRUG administered_be concomitantly_be drugs_be known_be inhibit_be cytochrome_be P450_be 3A4_be enzyme_be system_be (ie_be ,_be drugs_be drug_be classes_be azole_be antimycotics_be ,_be protease_be inhibitors_be ,_be calcium_be channel_be antagonists_be ,_be macrolide_be antibiotics)_be ._be"
1597,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",azole antimycotics,protease inhibitors,No interaction,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf midazolam_bf administered_bf concomitantly_bf drugs_bf known_bf inhibit_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf (ie_bf ,_bf drugs_bf drug_bf classes_bf azole_bf antimycotics_bf ,_bf protease_bf inhibitors_bf ,_bf calcium_bf channel_bf antagonists_bf ,_bf macrolide_bf antibiotics)_bf ._bf"
1598,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",azole antimycotics,calcium channel antagonists,No interaction,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf midazolam_bf administered_bf concomitantly_bf drugs_bf known_bf inhibit_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf (ie_bf ,_bf drugs_bf drug_bf classes_bf azole_bf antimycotics_bf ,_bf protease_bf inhibitors_bf ,_bf calcium_bf channel_bf antagonists_bf ,_bf macrolide_bf antibiotics)_bf ._bf"
1599,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",azole antimycotics,macrolide antibiotics,No interaction,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf midazolam_bf administered_bf concomitantly_bf drugs_bf known_bf inhibit_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf (ie_bf ,_bf drugs_bf drug_bf classes_bf azole_bf antimycotics_bf ,_bf protease_bf inhibitors_bf ,_bf calcium_bf channel_bf antagonists_bf ,_bf macrolide_bf antibiotics)_bf ._bf"
1600,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",protease inhibitors,calcium channel antagonists,No interaction,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf midazolam_bf administered_bf concomitantly_bf drugs_bf known_bf inhibit_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf (ie_bf ,_bf drugs_bf drug_bf classes_bf azole_bf antimycotics_bf ,_bf protease_bf inhibitors_bf ,_bf calcium_bf channel_bf antagonists_bf ,_bf macrolide_bf antibiotics)_bf ._bf"
1601,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",protease inhibitors,macrolide antibiotics,No interaction,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf midazolam_bf administered_bf concomitantly_bf drugs_bf known_bf inhibit_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf (ie_bf ,_bf drugs_bf drug_bf classes_bf azole_bf antimycotics_bf ,_bf protease_bf inhibitors_bf ,_bf calcium_bf channel_bf antagonists_bf ,_bf macrolide_bf antibiotics)_bf ._bf"
1602,"Drug Interactions: Inhibitors of CYP3A4 Isozymes: Caution is advised when midazolam is administered concomitantly with drugs that are known to inhibit the cytochrome P450 3A4 enzyme system (ie, some drugs in the drug classes of azole antimycotics, protease inhibitors, calcium channel antagonists, and macrolide antibiotics). ",calcium channel antagonists,macrolide antibiotics,No interaction,"Drug_bf Interactions:_bf Inhibitors_bf CYP3A4_bf Isozymes:_bf Caution_bf advised_bf midazolam_bf administered_bf concomitantly_bf drugs_bf known_bf inhibit_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf (ie_bf ,_bf drugs_bf drug_bf classes_bf azole_bf antimycotics_bf ,_bf protease_bf inhibitors_bf ,_bf calcium_bf channel_bf antagonists_bf ,_bf macrolide_bf antibiotics)_bf ._bf"
1603,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",erythromycin,diltiazem,No interaction,"Drugs_bf DRUG ,_be OTHER_DRUG ,_af verapamil_af ,_af ketoconazole_af ,_af fluconazole_af itraconazole_af shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1604,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",erythromycin,verapamil,No interaction,"Drugs_bf DRUG ,_be diltiazem_be ,_be OTHER_DRUG ,_af ketoconazole_af ,_af fluconazole_af itraconazole_af shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1605,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",erythromycin,ketoconazole,No interaction,"Drugs_bf DRUG ,_be diltiazem_be ,_be verapamil_be ,_be OTHER_DRUG ,_af fluconazole_af itraconazole_af shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1606,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",erythromycin,fluconazole,No interaction,"Drugs_bf DRUG ,_be diltiazem_be ,_be verapamil_be ,_be ketoconazole_be ,_be OTHER_DRUG itraconazole_af shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1607,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",erythromycin,itraconazole,No interaction,"Drugs_bf DRUG ,_be diltiazem_be ,_be verapamil_be ,_be ketoconazole_be ,_be fluconazole_be OTHER_DRUG shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1608,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",erythromycin,midazolam,mechanism,"Drugs_bf DRUG ,_be diltiazem_be ,_be verapamil_be ,_be ketoconazole_be ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1609,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",diltiazem,verapamil,No interaction,"Drugs_bf erythromycin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af ketoconazole_af ,_af fluconazole_af itraconazole_af shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1610,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",diltiazem,ketoconazole,No interaction,"Drugs_bf erythromycin_bf ,_bf DRUG ,_be verapamil_be ,_be OTHER_DRUG ,_af fluconazole_af itraconazole_af shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1611,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",diltiazem,fluconazole,No interaction,"Drugs_bf erythromycin_bf ,_bf DRUG ,_be verapamil_be ,_be ketoconazole_be ,_be OTHER_DRUG itraconazole_af shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1612,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",diltiazem,itraconazole,No interaction,"Drugs_bf erythromycin_bf ,_bf DRUG ,_be verapamil_be ,_be ketoconazole_be ,_be fluconazole_be OTHER_DRUG shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1613,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",diltiazem,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf DRUG ,_be verapamil_be ,_be ketoconazole_be ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1614,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",verapamil,ketoconazole,No interaction,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf DRUG ,_be OTHER_DRUG ,_af fluconazole_af itraconazole_af shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1615,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",verapamil,fluconazole,No interaction,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf DRUG ,_be ketoconazole_be ,_be OTHER_DRUG itraconazole_af shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1616,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",verapamil,itraconazole,No interaction,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf DRUG ,_be ketoconazole_be ,_be fluconazole_be OTHER_DRUG shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1617,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",verapamil,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf DRUG ,_be ketoconazole_be ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1618,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",ketoconazole,fluconazole,No interaction,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf DRUG ,_be OTHER_DRUG itraconazole_af shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1619,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",ketoconazole,itraconazole,No interaction,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf DRUG ,_be fluconazole_be OTHER_DRUG shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1620,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",ketoconazole,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf DRUG ,_be fluconazole_be itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1621,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",fluconazole,itraconazole,No interaction,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf ketoconazole_bf ,_bf DRUG OTHER_DRUG shown_af significantly_af increase_af C_af max_af AUC_af orally_af administered_af midazolam_af ._af"
1622,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",fluconazole,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf ketoconazole_bf ,_bf DRUG itraconazole_be shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1623,"Drugs such as erythromycin, diltiazem, verapamil, ketoconazole, fluconazole and itraconazole were shown to significantly increase the C max and AUC of orally administered midazolam. ",itraconazole,midazolam,mechanism,"Drugs_bf erythromycin_bf ,_bf diltiazem_bf ,_bf verapamil_bf ,_bf ketoconazole_bf ,_bf fluconazole_bf DRUG shown_be significantly_be increase_be C_be max_be AUC_be orally_be administered_be OTHER_DRUG ._af"
1624,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",ritonavir,nelfinavir,No interaction,"Although_bf studied_bf ,_bf potent_bf cytochrome_bf P450_bf 3A4_bf inhibitors_bf DRUG OTHER_DRUG may_af cause_af intense_af prolonged_af sedation_af respiratory_af depression_af due_af decrease_af plasma_af clearance_af midazolam_af ._af"
1625,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",ritonavir,midazolam,mechanism,"Although_bf studied_bf ,_bf potent_bf cytochrome_bf P450_bf 3A4_bf inhibitors_bf DRUG nelfinavir_be may_be cause_be intense_be prolonged_be sedation_be respiratory_be depression_be due_be decrease_be plasma_be clearance_be OTHER_DRUG ._af"
1626,"Although not studied, the potent cytochrome P450 3A4 inhibitors ritonavir and nelfinavir may cause intense and prolonged sedation and respiratory depression due to a decrease in plasma clearance of midazolam. ",nelfinavir,midazolam,mechanism,"Although_bf studied_bf ,_bf potent_bf cytochrome_bf P450_bf 3A4_bf inhibitors_bf ritonavir_bf DRUG may_be cause_be intense_be prolonged_be sedation_be respiratory_be depression_be due_be decrease_be plasma_be clearance_be OTHER_DRUG ._af"
1627,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",rifampin,carbamazepine,No interaction,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf DRUG ,_be OTHER_DRUG ,_af phenytoin_af ,_af induce_af metabolism_af caused_af markedly_af decreased_af C_af max_af AUC_af oral_af midazolam_af adult_af studies_af ._af"
1628,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",rifampin,phenytoin,No interaction,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf DRUG ,_be carbamazepine_be ,_be OTHER_DRUG ,_af induce_af metabolism_af caused_af markedly_af decreased_af C_af max_af AUC_af oral_af midazolam_af adult_af studies_af ._af"
1629,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",rifampin,midazolam,mechanism,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf DRUG ,_be carbamazepine_be ,_be phenytoin_be ,_be induce_be metabolism_be caused_be markedly_be decreased_be C_be max_be AUC_be oral_be OTHER_DRUG adult_af studies_af ._af"
1630,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",carbamazepine,phenytoin,No interaction,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf rifampin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af induce_af metabolism_af caused_af markedly_af decreased_af C_af max_af AUC_af oral_af midazolam_af adult_af studies_af ._af"
1631,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",carbamazepine,midazolam,mechanism,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf rifampin_bf ,_bf DRUG ,_be phenytoin_be ,_be induce_be metabolism_be caused_be markedly_be decreased_be C_be max_be AUC_be oral_be OTHER_DRUG adult_af studies_af ._af"
1632,"Inducers of CYP3A4 Isozymes: Cytochrome P450 inducers, such as rifampin, carbamazepine, and phenytoin, induce metabolism and caused a markedly decreased C max and AUC of oral midazolam in adult studies. ",phenytoin,midazolam,mechanism,"Inducers_bf CYP3A4_bf Isozymes:_bf Cytochrome_bf P450_bf inducers_bf ,_bf rifampin_bf ,_bf carbamazepine_bf ,_bf DRUG ,_be induce_be metabolism_be caused_be markedly_be decreased_be C_be max_be AUC_be oral_be OTHER_DRUG adult_af studies_af ._af"
1633,The difficulty in achieving adequate sedation may have been the result of decreased absorption of the sedatives due to both the gastrointestinal effects and stimulant effects of methylphenidate. ,sedatives,methylphenidate,No interaction,The_bf difficulty_bf achieving_bf adequate_bf sedation_bf may_bf result_bf decreased_bf absorption_bf DRUG due_be gastrointestinal_be effects_be stimulant_be effects_be OTHER_DRUG ._af
1634,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,narcotics,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf OTHER_DRUG (eg_be ,_be morphine_be ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1635,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,morphine,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf OTHER_DRUG ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1636,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,meperidine,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf OTHER_DRUG fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1637,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,fentanyl,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf droperidol_bf ._bf"
1638,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,propofol,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf OTHER_DRUG ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1639,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,ketamine,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf OTHER_DRUG ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1640,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,nitrous oxide,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf droperidol_bf ._bf"
1641,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,secobarbital,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf OTHER_DRUG droperidol_be ._be"
1642,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",VERSED Syrup,droperidol,effect,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf OTHER_DRUG ._be"
1643,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",narcotics,morphine,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf DRUG (eg_be ,_be OTHER_DRUG ,_af meperidine_af fentanyl)_af ,_af propofol_af ,_af ketamine_af ,_af nitrous_af oxide_af ,_af secobarbital_af droperidol_af ._af"
1644,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",narcotics,meperidine,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf DRUG (eg_be ,_be morphine_be ,_be OTHER_DRUG fentanyl)_af ,_af propofol_af ,_af ketamine_af ,_af nitrous_af oxide_af ,_af secobarbital_af droperidol_af ._af"
1645,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",narcotics,fentanyl,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf DRUG (eg_be ,_be morphine_be ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1646,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",narcotics,propofol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf DRUG (eg_be ,_be morphine_be ,_be meperidine_be fentanyl)_be ,_be OTHER_DRUG ,_af ketamine_af ,_af nitrous_af oxide_af ,_af secobarbital_af droperidol_af ._af"
1647,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",narcotics,ketamine,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf DRUG (eg_be ,_be morphine_be ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be OTHER_DRUG ,_af nitrous_af oxide_af ,_af secobarbital_af droperidol_af ._af"
1648,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",narcotics,nitrous oxide,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf DRUG (eg_be ,_be morphine_be ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1649,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",narcotics,secobarbital,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf DRUG (eg_be ,_be morphine_be ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be OTHER_DRUG droperidol_af ._af"
1650,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",narcotics,droperidol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf DRUG (eg_be ,_be morphine_be ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be OTHER_DRUG ._af"
1651,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",morphine,meperidine,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf DRUG ,_be OTHER_DRUG fentanyl)_af ,_af propofol_af ,_af ketamine_af ,_af nitrous_af oxide_af ,_af secobarbital_af droperidol_af ._af"
1652,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",morphine,fentanyl,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf DRUG ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1653,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",morphine,propofol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf DRUG ,_be meperidine_be fentanyl)_be ,_be OTHER_DRUG ,_af ketamine_af ,_af nitrous_af oxide_af ,_af secobarbital_af droperidol_af ._af"
1654,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",morphine,ketamine,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf DRUG ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be OTHER_DRUG ,_af nitrous_af oxide_af ,_af secobarbital_af droperidol_af ._af"
1655,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",morphine,nitrous oxide,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf DRUG ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1656,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",morphine,secobarbital,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf DRUG ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be OTHER_DRUG droperidol_af ._af"
1657,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",morphine,droperidol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf DRUG ,_be meperidine_be fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be OTHER_DRUG ._af"
1658,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",meperidine,fentanyl,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf DRUG fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1659,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",meperidine,propofol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf DRUG fentanyl)_be ,_be OTHER_DRUG ,_af ketamine_af ,_af nitrous_af oxide_af ,_af secobarbital_af droperidol_af ._af"
1660,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",meperidine,ketamine,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf DRUG fentanyl)_be ,_be propofol_be ,_be OTHER_DRUG ,_af nitrous_af oxide_af ,_af secobarbital_af droperidol_af ._af"
1661,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",meperidine,nitrous oxide,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf DRUG fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1662,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",meperidine,secobarbital,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf DRUG fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be OTHER_DRUG droperidol_af ._af"
1663,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",meperidine,droperidol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf DRUG fentanyl)_be ,_be propofol_be ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be OTHER_DRUG ._af"
1664,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",fentanyl,propofol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf OTHER_DRUG ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1665,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",fentanyl,ketamine,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf OTHER_DRUG ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1666,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",fentanyl,nitrous oxide,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf droperidol_bf ._bf"
1667,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",fentanyl,secobarbital,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf OTHER_DRUG droperidol_be ._be"
1668,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",fentanyl,droperidol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf OTHER_DRUG ._be"
1669,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",propofol,ketamine,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf DRUG ,_be OTHER_DRUG ,_af nitrous_af oxide_af ,_af secobarbital_af droperidol_af ._af"
1670,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",propofol,nitrous oxide,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf DRUG ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1671,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",propofol,secobarbital,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf DRUG ,_be ketamine_be ,_be nitrous_be oxide_be ,_be OTHER_DRUG droperidol_af ._af"
1672,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",propofol,droperidol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf DRUG ,_be ketamine_be ,_be nitrous_be oxide_be ,_be secobarbital_be OTHER_DRUG ._af"
1673,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",ketamine,nitrous oxide,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf DRUG ,_be nitrous_be oxide_be ,_be secobarbital_be droperidol_be ._be"
1674,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",ketamine,secobarbital,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf DRUG ,_be nitrous_be oxide_be ,_be OTHER_DRUG droperidol_af ._af"
1675,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",ketamine,droperidol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf DRUG ,_be nitrous_be oxide_be ,_be secobarbital_be OTHER_DRUG ._af"
1676,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",nitrous oxide,secobarbital,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf OTHER_DRUG droperidol_be ._be"
1677,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",nitrous oxide,droperidol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf secobarbital_bf OTHER_DRUG ._be"
1678,"The sedative effect of VERSED Syrup is accentuated by any concomitantly administered medication which depresses the central nervous system, particularly narcotics (eg, morphine, meperidine and fentanyl), propofol, ketamine, nitrous oxide, secobarbital and droperidol. ",secobarbital,droperidol,No interaction,"The_bf sedative_bf effect_bf VERSED_bf Syrup_bf accentuated_bf concomitantly_bf administered_bf medication_bf depresses_bf central_bf nervous_bf system_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf meperidine_bf fentanyl)_bf ,_bf propofol_bf ,_bf ketamine_bf ,_bf nitrous_bf oxide_bf ,_bf DRUG OTHER_DRUG ._af"
1679,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",atropine,scopolamine,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf DRUG ,_be OTHER_DRUG ,_af glycopyrrolate_af ,_af diazepam_af ,_af hydroxyzine_af ,_af muscle_af relaxants)_af local_af anesthetics_af observed_af ._af"
1680,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",atropine,glycopyrrolate,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf DRUG ,_be scopolamine_be ,_be OTHER_DRUG ,_af diazepam_af ,_af hydroxyzine_af ,_af muscle_af relaxants)_af local_af anesthetics_af observed_af ._af"
1681,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",atropine,diazepam,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf DRUG ,_be scopolamine_be ,_be glycopyrrolate_be ,_be OTHER_DRUG ,_af hydroxyzine_af ,_af muscle_af relaxants)_af local_af anesthetics_af observed_af ._af"
1682,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",atropine,hydroxyzine,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf DRUG ,_be scopolamine_be ,_be glycopyrrolate_be ,_be diazepam_be ,_be OTHER_DRUG ,_af muscle_af relaxants)_af local_af anesthetics_af observed_af ._af"
1683,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",atropine,muscle relaxants,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf DRUG ,_be scopolamine_be ,_be glycopyrrolate_be ,_be diazepam_be ,_be hydroxyzine_be ,_be muscle_be relaxants)_be local_be anesthetics_be observed_be ._be"
1684,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",atropine,anesthetics,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf DRUG ,_be scopolamine_be ,_be glycopyrrolate_be ,_be diazepam_be ,_be hydroxyzine_be ,_be muscle_be relaxants)_be local_be OTHER_DRUG observed_af ._af"
1685,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",scopolamine,glycopyrrolate,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af diazepam_af ,_af hydroxyzine_af ,_af muscle_af relaxants)_af local_af anesthetics_af observed_af ._af"
1686,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",scopolamine,diazepam,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf DRUG ,_be glycopyrrolate_be ,_be OTHER_DRUG ,_af hydroxyzine_af ,_af muscle_af relaxants)_af local_af anesthetics_af observed_af ._af"
1687,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",scopolamine,hydroxyzine,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf DRUG ,_be glycopyrrolate_be ,_be diazepam_be ,_be OTHER_DRUG ,_af muscle_af relaxants)_af local_af anesthetics_af observed_af ._af"
1688,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",scopolamine,muscle relaxants,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf DRUG ,_be glycopyrrolate_be ,_be diazepam_be ,_be hydroxyzine_be ,_be muscle_be relaxants)_be local_be anesthetics_be observed_be ._be"
1689,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",scopolamine,anesthetics,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf DRUG ,_be glycopyrrolate_be ,_be diazepam_be ,_be hydroxyzine_be ,_be muscle_be relaxants)_be local_be OTHER_DRUG observed_af ._af"
1690,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",glycopyrrolate,diazepam,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf scopolamine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af hydroxyzine_af ,_af muscle_af relaxants)_af local_af anesthetics_af observed_af ._af"
1691,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",glycopyrrolate,hydroxyzine,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf scopolamine_bf ,_bf DRUG ,_be diazepam_be ,_be OTHER_DRUG ,_af muscle_af relaxants)_af local_af anesthetics_af observed_af ._af"
1692,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",glycopyrrolate,muscle relaxants,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf scopolamine_bf ,_bf DRUG ,_be diazepam_be ,_be hydroxyzine_be ,_be muscle_be relaxants)_be local_be anesthetics_be observed_be ._be"
1693,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",glycopyrrolate,anesthetics,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf scopolamine_bf ,_bf DRUG ,_be diazepam_be ,_be hydroxyzine_be ,_be muscle_be relaxants)_be local_be OTHER_DRUG observed_af ._af"
1694,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",diazepam,hydroxyzine,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf scopolamine_bf ,_bf glycopyrrolate_bf ,_bf DRUG ,_be OTHER_DRUG ,_af muscle_af relaxants)_af local_af anesthetics_af observed_af ._af"
1695,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",diazepam,muscle relaxants,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf scopolamine_bf ,_bf glycopyrrolate_bf ,_bf DRUG ,_be hydroxyzine_be ,_be muscle_be relaxants)_be local_be anesthetics_be observed_be ._be"
1696,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",diazepam,anesthetics,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf scopolamine_bf ,_bf glycopyrrolate_bf ,_bf DRUG ,_be hydroxyzine_be ,_be muscle_be relaxants)_be local_be OTHER_DRUG observed_af ._af"
1697,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",hydroxyzine,muscle relaxants,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf scopolamine_bf ,_bf glycopyrrolate_bf ,_bf diazepam_bf ,_bf DRUG ,_be muscle_be relaxants)_be local_be anesthetics_be observed_be ._be"
1698,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",hydroxyzine,anesthetics,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf scopolamine_bf ,_bf glycopyrrolate_bf ,_bf diazepam_bf ,_bf DRUG ,_be muscle_be relaxants)_be local_be OTHER_DRUG observed_af ._af"
1699,"No significant adverse interactions with common premedications (such as atropine, scopolamine, glycopyrrolate, diazepam, hydroxyzine, and other muscle relaxants) or local anesthetics have been observed.",muscle relaxants,anesthetics,No interaction,"No_bf significant_bf adverse_bf interactions_bf common_bf premedications_bf (such_bf atropine_bf ,_bf scopolamine_bf ,_bf glycopyrrolate_bf ,_bf diazepam_bf ,_bf hydroxyzine_bf ,_bf muscle_bf relaxants)_bf local_bf OTHER_DRUG observed_be ._be"
1700,"When administered concomitantly with ProAmatine   , cardiac glycosides may enhance or precipitate bradycardia, A.V. ",ProAmatine,cardiac glycosides,effect,"When_bf administered_bf concomitantly_bf DRUG ,_be cardiac_be glycosides_be may_be enhance_be precipitate_be bradycardia_be ,_be A_be ._be V_be ._be"
1701,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,pseudoephedrine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af ephedrine_af ,_af phenylpropanolamine_af dihydroergotamine)_af may_af enhance_af potentiate_af pressor_af effects_af ProAmatine_af ._af Therefore_af ,_af caution_af used_af ProAmatine_af administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1702,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,ephedrine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be pseudoephedrine_be ,_be OTHER_DRUG ,_af phenylpropanolamine_af dihydroergotamine)_af may_af enhance_af potentiate_af pressor_af effects_af ProAmatine_af ._af Therefore_af ,_af caution_af used_af ProAmatine_af administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1703,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,phenylpropanolamine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be pseudoephedrine_be ,_be ephedrine_be ,_be OTHER_DRUG dihydroergotamine)_af may_af enhance_af potentiate_af pressor_af effects_af ProAmatine_af ._af Therefore_af ,_af caution_af used_af ProAmatine_af administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1704,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,dihydroergotamine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be pseudoephedrine_be ,_be ephedrine_be ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be ProAmatine_be ._be Therefore_be ,_be caution_be used_be ProAmatine_be administered_be concomitantly_be agents_be cause_be vasoconstriction_be ._be"
1705,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be pseudoephedrine_be ,_be ephedrine_be ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1706,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylephrine,ProAmatine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be pseudoephedrine_be ,_be ephedrine_be ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1707,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,ephedrine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af phenylpropanolamine_af dihydroergotamine)_af may_af enhance_af potentiate_af pressor_af effects_af ProAmatine_af ._af Therefore_af ,_af caution_af used_af ProAmatine_af administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1708,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,phenylpropanolamine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf DRUG ,_be ephedrine_be ,_be OTHER_DRUG dihydroergotamine)_af may_af enhance_af potentiate_af pressor_af effects_af ProAmatine_af ._af Therefore_af ,_af caution_af used_af ProAmatine_af administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1709,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,dihydroergotamine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf DRUG ,_be ephedrine_be ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be ProAmatine_be ._be Therefore_be ,_be caution_be used_be ProAmatine_be administered_be concomitantly_be agents_be cause_be vasoconstriction_be ._be"
1710,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf DRUG ,_be ephedrine_be ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1711,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",pseudoephedrine,ProAmatine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf DRUG ,_be ephedrine_be ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1712,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,phenylpropanolamine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf DRUG ,_be OTHER_DRUG dihydroergotamine)_af may_af enhance_af potentiate_af pressor_af effects_af ProAmatine_af ._af Therefore_af ,_af caution_af used_af ProAmatine_af administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1713,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,dihydroergotamine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf DRUG ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be ProAmatine_be ._be Therefore_be ,_be caution_be used_be ProAmatine_be administered_be concomitantly_be agents_be cause_be vasoconstriction_be ._be"
1714,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf DRUG ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1715,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",ephedrine,ProAmatine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf DRUG ,_be phenylpropanolamine_be dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1716,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylpropanolamine,dihydroergotamine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf ephedrine_bf ,_bf DRUG dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be ProAmatine_be ._be Therefore_be ,_be caution_be used_be ProAmatine_be administered_be concomitantly_be agents_be cause_be vasoconstriction_be ._be"
1717,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylpropanolamine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf ephedrine_bf ,_bf DRUG dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1718,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",phenylpropanolamine,ProAmatine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf ephedrine_bf ,_bf DRUG dihydroergotamine)_be may_be enhance_be potentiate_be pressor_be effects_be OTHER_DRUG ._af Therefore_af ,_af caution_af used_af OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1719,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",dihydroergotamine,ProAmatine,effect,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf ephedrine_bf ,_bf phenylpropanolamine_bf dihydroergotamine)_bf may_bf enhance_bf potentiate_bf pressor_bf effects_bf OTHER_DRUG ._be Therefore_be ,_be caution_be used_be OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1720,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",dihydroergotamine,ProAmatine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf ephedrine_bf ,_bf phenylpropanolamine_bf dihydroergotamine)_bf may_bf enhance_bf potentiate_bf pressor_bf effects_bf OTHER_DRUG ._be Therefore_be ,_be caution_be used_be OTHER_DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1721,"The use of drugs that stimulate alpha-adrenergic receptors (e.g., phenylephrine, pseudoephedrine, ephedrine, phenylpropanolamine or dihydroergotamine) may enhance or potentiate the pressor effects of ProAmatine   . Therefore, caution should be used when ProAmatine    is administered concomitantly with agents that cause vasoconstriction. ",ProAmatine,ProAmatine,No interaction,"The_bf use_bf drugs_bf stimulate_bf alpha-adrenergic_bf receptors_bf (e_bf ._bf g_bf ._bf ,_bf phenylephrine_bf ,_bf pseudoephedrine_bf ,_bf ephedrine_bf ,_bf phenylpropanolamine_bf dihydroergotamine)_bf may_bf enhance_bf potentiate_bf pressor_bf effects_bf DRUG ._be Therefore_be ,_be caution_be used_be DRUG administered_af concomitantly_af agents_af cause_af vasoconstriction_af ._af"
1722,"ProAmatine    has been used in patients concomitantly treated with salt-retaining steroid therapy (i.e., fludrocortisone acetate), with or without salt supplementation. ",ProAmatine,fludrocortisone acetate,No interaction,"DRUG used_be patients_be concomitantly_be treated_be salt-retaining_be steroid_be therapy_be (i_be ._be ._be ,_be fludrocortisone_be acetate)_be ,_be without_be salt_be supplementation_be ._be"
1723,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,Alpha-adrenergic blocking agents,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1724,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,prazosin,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be OTHER_DRUG ,_af terazosin_af ,_af doxazosin_af ,_af antagonize_af effects_af DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1725,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,terazosin,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be OTHER_DRUG ,_af doxazosin_af ,_af antagonize_af effects_af DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1726,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,doxazosin,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be OTHER_DRUG ,_af antagonize_af effects_af DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1727,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,ProAmatine,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1728,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,desglymidodrine,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af OTHER_DRUG (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1729,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,metformin,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af OTHER_DRUG ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1730,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,cimetidine,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af OTHER_DRUG ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1731,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,ranitidine,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af OTHER_DRUG ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1732,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,procainamide,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af OTHER_DRUG ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1733,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,triamterene,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
1734,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,flecainide,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af OTHER_DRUG ,_af quinidine_af ._af"
1735,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,quinidine,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af OTHER_DRUG ._af"
1736,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,prazosin,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf OTHER_DRUG ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be quinidine_be ._be"
1737,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,terazosin,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf OTHER_DRUG ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be quinidine_be ._be"
1738,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,doxazosin,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf OTHER_DRUG ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be quinidine_be ._be"
1739,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1740,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,desglymidodrine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf OTHER_DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be quinidine_be ._be"
1741,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,metformin,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf OTHER_DRUG ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be quinidine_be ._be"
1742,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,cimetidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf OTHER_DRUG ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be quinidine_be ._be"
1743,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,ranitidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf OTHER_DRUG ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be quinidine_be ._be"
1744,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,procainamide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf OTHER_DRUG ,_be triamterene_be ,_be flecainide_be ,_be quinidine_be ._be"
1745,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,triamterene,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf procainamide_bf ,_bf OTHER_DRUG ,_be flecainide_be ,_be quinidine_be ._be"
1746,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,flecainide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf procainamide_bf ,_bf triamterene_bf ,_bf OTHER_DRUG ,_be quinidine_be ._be"
1747,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",Alpha-adrenergic blocking agents,quinidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf procainamide_bf ,_bf triamterene_bf ,_bf flecainide_bf ,_bf OTHER_DRUG ._be"
1748,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,terazosin,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf DRUG ,_be OTHER_DRUG ,_af doxazosin_af ,_af antagonize_af effects_af ProAmatine_af ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1749,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,doxazosin,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf DRUG ,_be terazosin_be ,_be OTHER_DRUG ,_af antagonize_af effects_af ProAmatine_af ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1750,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be DRUG ,_af terazosin_af ,_af doxazosin_af ,_af antagonize_af effects_af OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1751,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,desglymidodrine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf DRUG ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be OTHER_DRUG (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1752,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,metformin,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf DRUG ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be OTHER_DRUG ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1753,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,cimetidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf DRUG ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be OTHER_DRUG ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1754,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,ranitidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf DRUG ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be OTHER_DRUG ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1755,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,procainamide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf DRUG ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be OTHER_DRUG ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1756,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,triamterene,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf DRUG ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
1757,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,flecainide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf DRUG ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1758,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",prazosin,quinidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf DRUG ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be OTHER_DRUG ._af"
1759,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,doxazosin,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af antagonize_af effects_af ProAmatine_af ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1760,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be DRUG ,_af doxazosin_af ,_af antagonize_af effects_af OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1761,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,desglymidodrine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf DRUG ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be OTHER_DRUG (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1762,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,metformin,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf DRUG ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be OTHER_DRUG ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1763,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,cimetidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf DRUG ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be OTHER_DRUG ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1764,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,ranitidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf DRUG ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be OTHER_DRUG ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1765,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,procainamide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf DRUG ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be OTHER_DRUG ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1766,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,triamterene,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf DRUG ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
1767,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,flecainide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf DRUG ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1768,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",terazosin,quinidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf DRUG ,_be doxazosin_be ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be OTHER_DRUG ._af"
1769,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,ProAmatine,effect,"OTHER_DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be DRUG ,_af antagonize_af effects_af OTHER_DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1770,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,desglymidodrine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf DRUG ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be OTHER_DRUG (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1771,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,metformin,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf DRUG ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be OTHER_DRUG ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1772,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,cimetidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf DRUG ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be OTHER_DRUG ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1773,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,ranitidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf DRUG ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be OTHER_DRUG ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1774,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,procainamide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf DRUG ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be OTHER_DRUG ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1775,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,triamterene,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf DRUG ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
1776,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,flecainide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf DRUG ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1777,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",doxazosin,quinidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf DRUG ,_be antagonize_be effects_be ProAmatine_be ._be Potential_be Drug_be Interactions:_be It_be appears_be possible_be ,_be although_be supporting_be experimental_be evidence_be ,_be high_be renal_be clearance_be desglymidodrine_be (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be OTHER_DRUG ._af"
1778,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,desglymidodrine,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af OTHER_DRUG (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1779,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,metformin,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af OTHER_DRUG ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1780,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,cimetidine,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af OTHER_DRUG ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1781,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,ranitidine,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af OTHER_DRUG ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1782,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,procainamide,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af OTHER_DRUG ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1783,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,triamterene,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
1784,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,flecainide,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af OTHER_DRUG ,_af quinidine_af ._af"
1785,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ProAmatine,quinidine,No interaction,"DRUG ._be Alpha-adrenergic_be blocking_be agents_be ,_be prazosin_be ,_be terazosin_be ,_be doxazosin_be ,_be antagonize_be effects_be DRUG ._af Potential_af Drug_af Interactions:_af It_af appears_af possible_af ,_af although_af supporting_af experimental_af evidence_af ,_af high_af renal_af clearance_af desglymidodrine_af (a_af base)_af due_af active_af tubular_af secretion_af base-secreting_af system_af also_af responsible_af secretion_af drugs_af metformin_af ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af OTHER_DRUG ._af"
1786,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,metformin,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be OTHER_DRUG ,_af cimetidine_af ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1787,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,cimetidine,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be OTHER_DRUG ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1788,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,ranitidine,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be OTHER_DRUG ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1789,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,procainamide,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be OTHER_DRUG ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1790,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,triamterene,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
1791,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,flecainide,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1792,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",desglymidodrine,quinidine,mechanism,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf DRUG (a_be base)_be due_be active_be tubular_be secretion_be base-secreting_be system_be also_be responsible_be secretion_be drugs_be metformin_be ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be OTHER_DRUG ._af"
1793,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",metformin,cimetidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf DRUG ,_be OTHER_DRUG ,_af ranitidine_af ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1794,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",metformin,ranitidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf DRUG ,_be cimetidine_be ,_be OTHER_DRUG ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1795,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",metformin,procainamide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf DRUG ,_be cimetidine_be ,_be ranitidine_be ,_be OTHER_DRUG ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1796,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",metformin,triamterene,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf DRUG ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
1797,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",metformin,flecainide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf DRUG ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1798,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",metformin,quinidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf DRUG ,_be cimetidine_be ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be OTHER_DRUG ._af"
1799,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",cimetidine,ranitidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af procainamide_af ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1800,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",cimetidine,procainamide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf DRUG ,_be ranitidine_be ,_be OTHER_DRUG ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1801,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",cimetidine,triamterene,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf DRUG ,_be ranitidine_be ,_be procainamide_be ,_be OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
1802,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",cimetidine,flecainide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf DRUG ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1803,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",cimetidine,quinidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf DRUG ,_be ranitidine_be ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be OTHER_DRUG ._af"
1804,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ranitidine,procainamide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af triamterene_af ,_af flecainide_af ,_af quinidine_af ._af"
1805,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ranitidine,triamterene,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf DRUG ,_be procainamide_be ,_be OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
1806,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ranitidine,flecainide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf DRUG ,_be procainamide_be ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1807,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",ranitidine,quinidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf DRUG ,_be procainamide_be ,_be triamterene_be ,_be flecainide_be ,_be OTHER_DRUG ._af"
1808,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",procainamide,triamterene,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af flecainide_af ,_af quinidine_af ._af"
1809,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",procainamide,flecainide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1810,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",procainamide,quinidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be flecainide_be ,_be OTHER_DRUG ._af"
1811,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",triamterene,flecainide,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf procainamide_bf ,_bf DRUG ,_be OTHER_DRUG ,_af quinidine_af ._af"
1812,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",triamterene,quinidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf procainamide_bf ,_bf DRUG ,_be flecainide_be ,_be OTHER_DRUG ._af"
1813,"ProAmatine. Alpha-adrenergic blocking agents, such as prazosin, terazosin, and doxazosin, can antagonize the effects of ProAmatine. Potential for Drug Interactions: It appears possible, although there is no supporting experimental evidence, that the high renal clearance of desglymidodrine (a base) is due to active tubular secretion by the base-secreting system also responsible for the secretion of such drugs as metformin, cimetidine, ranitidine, procainamide, triamterene, flecainide, and quinidine. ",flecainide,quinidine,No interaction,"ProAmatine_bf ._bf Alpha-adrenergic_bf blocking_bf agents_bf ,_bf prazosin_bf ,_bf terazosin_bf ,_bf doxazosin_bf ,_bf antagonize_bf effects_bf ProAmatine_bf ._bf Potential_bf Drug_bf Interactions:_bf It_bf appears_bf possible_bf ,_bf although_bf supporting_bf experimental_bf evidence_bf ,_bf high_bf renal_bf clearance_bf desglymidodrine_bf (a_bf base)_bf due_bf active_bf tubular_bf secretion_bf base-secreting_bf system_bf also_bf responsible_bf secretion_bf drugs_bf metformin_bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf procainamide_bf ,_bf triamterene_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
1814,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",mifepristone,ketoconazole,No interaction,"Although_bf specific_bf drug_bf food_bf interactions_bf DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be OTHER_DRUG ,_af itraconazole_af ,_af erythromycin_af ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1815,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",mifepristone,itraconazole,No interaction,"Although_bf specific_bf drug_bf food_bf interactions_bf DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be ketoconazole_be ,_be OTHER_DRUG ,_af erythromycin_af ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1816,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",mifepristone,erythromycin,No interaction,"Although_bf specific_bf drug_bf food_bf interactions_bf DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be ketoconazole_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1817,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",mifepristone,mifepristone,No interaction,"Although_bf specific_bf drug_bf food_bf interactions_bf DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be ketoconazole_be ,_be itraconazole_be ,_be erythromycin_be ,_be grapefruit_be juice_be may_be inhibit_be metabolism_be (increasing_be serum_be levels_be mifepristone)_be ._be"
1818,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",ketoconazole,itraconazole,No interaction,"Although_bf specific_bf drug_bf food_bf interactions_bf mifepristone_bf studied_bf ,_bf basis_bf drug_bf metabolism_bf CYP_bf 3A4_bf ,_bf possible_bf DRUG ,_be OTHER_DRUG ,_af erythromycin_af ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1819,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",ketoconazole,erythromycin,No interaction,"Although_bf specific_bf drug_bf food_bf interactions_bf mifepristone_bf studied_bf ,_bf basis_bf drug_bf metabolism_bf CYP_bf 3A4_bf ,_bf possible_bf DRUG ,_be itraconazole_be ,_be OTHER_DRUG ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1820,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",ketoconazole,mifepristone,mechanism,"Although_bf specific_bf drug_bf food_bf interactions_bf OTHER_DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be DRUG ,_af itraconazole_af ,_af erythromycin_af ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1821,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",itraconazole,erythromycin,No interaction,"Although_bf specific_bf drug_bf food_bf interactions_bf mifepristone_bf studied_bf ,_bf basis_bf drug_bf metabolism_bf CYP_bf 3A4_bf ,_bf possible_bf ketoconazole_bf ,_bf DRUG ,_be OTHER_DRUG ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1822,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",itraconazole,mifepristone,mechanism,"Although_bf specific_bf drug_bf food_bf interactions_bf OTHER_DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be ketoconazole_be ,_be DRUG ,_af erythromycin_af ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1823,"Although specific drug or food interactions with mifepristone have not been studied, on the basis of this drug   s metabolism by CYP 3A4, it is possible that ketoconazole, itraconazole, erythromycin, and grapefruit juice may inhibit its metabolism (increasing serum levels of mifepristone). ",erythromycin,mifepristone,mechanism,"Although_bf specific_bf drug_bf food_bf interactions_bf OTHER_DRUG studied_be ,_be basis_be drug_be metabolism_be CYP_be 3A4_be ,_be possible_be ketoconazole_be ,_be itraconazole_be ,_be DRUG ,_af grapefruit_af juice_af may_af inhibit_af metabolism_af (increasing_af serum_af levels_af mifepristone)_af ._af"
1824,"Furthermore, rifampin, dexamethasone, St. ",rifampin,dexamethasone,No interaction,"Furthermore_bf ,_bf DRUG ,_be OTHER_DRUG ,_af St_af ._af"
1825,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",anticonvulsants,phenytoin,No interaction,"John_bf Wort_bf ,_bf certain_bf DRUG (phenytoin_be ,_be phenobarbital_be ,_be carbamazepine)_be may_be induce_be mifepristone_be metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
1826,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",anticonvulsants,phenobarbital,No interaction,"John_bf Wort_bf ,_bf certain_bf DRUG (phenytoin_be ,_be OTHER_DRUG ,_af carbamazepine)_af may_af induce_af mifepristone_af metabolism_af (lowering_af serum_af levels_af mifepristone)_af ._af"
1827,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",anticonvulsants,carbamazepine,No interaction,"John_bf Wort_bf ,_bf certain_bf DRUG (phenytoin_be ,_be phenobarbital_be ,_be carbamazepine)_be may_be induce_be mifepristone_be metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
1828,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",anticonvulsants,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf DRUG (phenytoin_be ,_be phenobarbital_be ,_be carbamazepine)_be may_be induce_be OTHER_DRUG metabolism_af (lowering_af serum_af levels_af mifepristone)_af ._af"
1829,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",anticonvulsants,mifepristone,No interaction,"John_bf Wort_bf ,_bf certain_bf DRUG (phenytoin_be ,_be phenobarbital_be ,_be carbamazepine)_be may_be induce_be OTHER_DRUG metabolism_af (lowering_af serum_af levels_af mifepristone)_af ._af"
1830,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenytoin,phenobarbital,No interaction,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf OTHER_DRUG ,_be carbamazepine)_be may_be induce_be mifepristone_be metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
1831,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenytoin,carbamazepine,No interaction,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf phenobarbital_bf ,_bf carbamazepine)_bf may_bf induce_bf mifepristone_bf metabolism_bf (lowering_bf serum_bf levels_bf mifepristone)_bf ._bf"
1832,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenytoin,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf phenobarbital_bf ,_bf carbamazepine)_bf may_bf induce_bf OTHER_DRUG metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
1833,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenytoin,mifepristone,No interaction,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf phenobarbital_bf ,_bf carbamazepine)_bf may_bf induce_bf OTHER_DRUG metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
1834,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenobarbital,carbamazepine,No interaction,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf DRUG ,_be carbamazepine)_be may_be induce_be mifepristone_be metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
1835,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenobarbital,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf DRUG ,_be carbamazepine)_be may_be induce_be OTHER_DRUG metabolism_af (lowering_af serum_af levels_af mifepristone)_af ._af"
1836,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",phenobarbital,mifepristone,No interaction,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf DRUG ,_be carbamazepine)_be may_be induce_be OTHER_DRUG metabolism_af (lowering_af serum_af levels_af mifepristone)_af ._af"
1837,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",carbamazepine,mifepristone,mechanism,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf phenobarbital_bf ,_bf carbamazepine)_bf may_bf induce_bf OTHER_DRUG metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
1838,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",carbamazepine,mifepristone,No interaction,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf phenobarbital_bf ,_bf carbamazepine)_bf may_bf induce_bf OTHER_DRUG metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
1839,"John   s Wort, and certain anticonvulsants (phenytoin, phenobarbital, carbamazepine) may induce mifepristone metabolism (lowering serum levels of mifepristone). ",mifepristone,mifepristone,No interaction,"John_bf Wort_bf ,_bf certain_bf anticonvulsants_bf (phenytoin_bf ,_bf phenobarbital_bf ,_bf carbamazepine)_bf may_bf induce_bf DRUG metabolism_be (lowering_be serum_be levels_be mifepristone)_be ._be"
1840,"While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ",ZAVESCA,Cerezyme,mechanism,"While_bf co-administration_bf DRUG appeared_be increase_be clearance_be OTHER_DRUG 70%_af ,_af results_af conclusive_af small_af number_af subjects_af studied_af patients_af took_af variable_af doses_af OTHER_DRUG ._af"
1841,"While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ",ZAVESCA,Cerezyme,No interaction,"While_bf co-administration_bf DRUG appeared_be increase_be clearance_be OTHER_DRUG 70%_af ,_af results_af conclusive_af small_af number_af subjects_af studied_af patients_af took_af variable_af doses_af OTHER_DRUG ._af"
1842,"While co-administration of ZAVESCA    appeared to increase the clearance of Cerezyme by 70%, these results are not conclusive because of the small number of subjects studied and because patients took variable doses of Cerezyme. ",Cerezyme,Cerezyme,No interaction,"While_bf co-administration_bf ZAVESCA_bf appeared_bf increase_bf clearance_bf DRUG 70%_be ,_be results_be conclusive_be small_be number_be subjects_be studied_be patients_be took_be variable_be doses_be DRUG ._af"
1843,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,Cerezyme,imiglucerase,No interaction,Combination_bf therapy_bf DRUG (imiglucerase)_be ZAVESCA_be indicated_be ._be
1844,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,Cerezyme,ZAVESCA,advise,Combination_bf therapy_bf DRUG (imiglucerase)_be OTHER_DRUG indicated_af ._af
1845,Combination therapy with Cerezyme    (imiglucerase) and ZAVESCA    is not indicated.,imiglucerase,ZAVESCA,advise,Combination_bf therapy_bf Cerezyme_bf (imiglucerase)_bf OTHER_DRUG indicated_be ._be
1846,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ",tetracyclines,anticoagulant,advise,"Because_bf DRUG shown_be depress_be plasma_be prothrombin_be activity_be ,_be patients_be OTHER_DRUG therapy_af may_af require_af downward_af adjustment_af OTHER_DRUG dosage_af ._af"
1847,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ",tetracyclines,anticoagulant,No interaction,"Because_bf DRUG shown_be depress_be plasma_be prothrombin_be activity_be ,_be patients_be OTHER_DRUG therapy_af may_af require_af downward_af adjustment_af OTHER_DRUG dosage_af ._af"
1848,"Because tetracyclines have been shown to depress plasma prothrombin activity, patients who are on anticoagulant therapy may require downward adjustment of their anticoagulant dosage. ",anticoagulant,anticoagulant,No interaction,"Because_bf tetracyclines_bf shown_bf depress_bf plasma_bf prothrombin_bf activity_bf ,_bf patients_bf DRUG therapy_be may_be require_be downward_be adjustment_be DRUG dosage_af ._af"
1849,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. ",penicillin,tetracycline class drugs,No interaction,"Since_bf bacteriostatic_bf drugs_bf may_bf interfere_bf bactericidal_bf action_bf DRUG ,_be advisable_be avoid_be giving_be tetracycline_be class_be drugs_be conjunction_be DRUG ._af"
1850,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. ",penicillin,penicillin,No interaction,"Since_bf bacteriostatic_bf drugs_bf may_bf interfere_bf bactericidal_bf action_bf DRUG ,_be advisable_be avoid_be giving_be tetracycline_be class_be drugs_be conjunction_be DRUG ._af"
1851,"Since bacteriostatic drugs may interfere with the bactericidal action of penicillin, it is advisable to avoid giving tetracycline class drugs in conjunction with penicillin. ",tetracycline class drugs,penicillin,advise,"Since_bf bacteriostatic_bf drugs_bf may_bf interfere_bf bactericidal_bf action_bf OTHER_DRUG ,_be advisable_be avoid_be giving_be tetracycline_be class_be drugs_be conjunction_be OTHER_DRUG ._af"
1852,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,antacids,No interaction,"Absorption_bf DRUG impaired_be OTHER_DRUG containing_af aluminum_af ,_af calcium_af magnesium_af ,_af iron-containing_af preparations_af ._af"
1853,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,aluminum,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be OTHER_DRUG ,_af calcium_af magnesium_af ,_af iron-containing_af preparations_af ._af"
1854,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,calcium,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be OTHER_DRUG magnesium_af ,_af iron-containing_af preparations_af ._af"
1855,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,magnesium,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be calcium_be OTHER_DRUG ,_af iron-containing_af preparations_af ._af"
1856,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",tetracyclines,iron,mechanism,"Absorption_bf DRUG impaired_be antacids_be containing_be aluminum_be ,_be calcium_be magnesium_be ,_be iron-containing_be preparations_be ._be"
1857,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",antacids,aluminum,No interaction,"Absorption_bf tetracyclines_bf impaired_bf DRUG containing_be OTHER_DRUG ,_af calcium_af magnesium_af ,_af iron-containing_af preparations_af ._af"
1858,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",antacids,calcium,No interaction,"Absorption_bf tetracyclines_bf impaired_bf DRUG containing_be aluminum_be ,_be OTHER_DRUG magnesium_af ,_af iron-containing_af preparations_af ._af"
1859,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",antacids,magnesium,No interaction,"Absorption_bf tetracyclines_bf impaired_bf DRUG containing_be aluminum_be ,_be calcium_be OTHER_DRUG ,_af iron-containing_af preparations_af ._af"
1860,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",antacids,iron,No interaction,"Absorption_bf tetracyclines_bf impaired_bf DRUG containing_be aluminum_be ,_be calcium_be magnesium_be ,_be iron-containing_be preparations_be ._be"
1861,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",aluminum,calcium,No interaction,"Absorption_bf tetracyclines_bf impaired_bf antacids_bf containing_bf DRUG ,_be OTHER_DRUG magnesium_af ,_af iron-containing_af preparations_af ._af"
1862,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",aluminum,magnesium,No interaction,"Absorption_bf tetracyclines_bf impaired_bf antacids_bf containing_bf DRUG ,_be calcium_be OTHER_DRUG ,_af iron-containing_af preparations_af ._af"
1863,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",aluminum,iron,No interaction,"Absorption_bf tetracyclines_bf impaired_bf antacids_bf containing_bf DRUG ,_be calcium_be magnesium_be ,_be iron-containing_be preparations_be ._be"
1864,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",calcium,magnesium,No interaction,"Absorption_bf tetracyclines_bf impaired_bf antacids_bf containing_bf aluminum_bf ,_bf DRUG OTHER_DRUG ,_af iron-containing_af preparations_af ._af"
1865,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",calcium,iron,No interaction,"Absorption_bf tetracyclines_bf impaired_bf antacids_bf containing_bf aluminum_bf ,_bf DRUG magnesium_be ,_be iron-containing_be preparations_be ._be"
1866,"Absorption of tetracyclines is impaired by antacids containing aluminum, calcium or magnesium, and iron-containing preparations. ",magnesium,iron,No interaction,"Absorption_bf tetracyclines_bf impaired_bf antacids_bf containing_bf aluminum_bf ,_bf calcium_bf DRUG ,_be iron-containing_be preparations_be ._be"
1867,The concurrent use of tetracycline and methoxyflurane has been reported to result in fatal renal toxicity. ,tetracycline,methoxyflurane,effect,The_bf concurrent_bf use_bf DRUG OTHER_DRUG reported_af result_af fatal_af renal_af toxicity_af ._af
1868,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,tetracyclines,contraceptives,effect,Concurrent_bf use_bf DRUG oral_be OTHER_DRUG may_af render_af oral_af OTHER_DRUG less_af effective_af ._af
1869,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,tetracyclines,contraceptives,No interaction,Concurrent_bf use_bf DRUG oral_be OTHER_DRUG may_af render_af oral_af OTHER_DRUG less_af effective_af ._af
1870,Concurrent use of tetracyclines with oral contraceptives may render oral contraceptives less effective.,contraceptives,contraceptives,No interaction,Concurrent_bf use_bf tetracyclines_bf oral_bf DRUG may_be render_be oral_be DRUG less_af effective_af ._af
1871,"Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ",Guanethidine,minoxidil,No interaction,"Interaction_bf Guanethidine:_bf Although_bf OTHER_DRUG cause_be orthostatic_be hypotension_be ,_be administration_be patients_be already_be receiving_be DRUG result_af profound_af orthostatic_af effects_af ._af"
1872,"Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ",Guanethidine,guanethidine,No interaction,"Interaction_bf Guanethidine:_bf Although_bf minoxidil_bf cause_bf orthostatic_bf hypotension_bf ,_bf administration_bf patients_bf already_bf receiving_bf DRUG result_be profound_be orthostatic_be effects_be ._be"
1873,"Interaction with Guanethidine: Although minoxidil does not itself cause orthostatic hypotension, its administration to patients already receiving guanethidine can result in profound orthostatic effects. ",minoxidil,guanethidine,effect,"Interaction_bf Guanethidine:_bf Although_bf DRUG cause_be orthostatic_be hypotension_be ,_be administration_be patients_be already_be receiving_be OTHER_DRUG result_af profound_af orthostatic_af effects_af ._af"
1874,If at all possible guanethidine should be discontinued well before minoxidil is begun. ,guanethidine,minoxidil,advise,If_bf possible_bf DRUG discontinued_be well_be OTHER_DRUG begun_af ._af
1875,Drugs Affecting Hepatic Metabolism The metabolism and pharmacokinetics of REMERON SolTab    (mirtazapine) Orally Disintegrating Tablets may be affected by the induction or inhibition of drug-metab-olizing enzymes. ,REMERON SolTab,mirtazapine,No interaction,Drugs_bf Affecting_bf Hepatic_bf Metabolism_bf The_bf metabolism_bf pharmacokinetics_bf REMERON_bf SolTab_bf (mirtazapine)_bf Orally_bf Disintegrating_bf Tablets_bf may_bf affected_bf induction_bf inhibition_bf drug-metab-olizing_bf enzymes_bf ._bf
1876,"While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. ",mirtazapine,mirtazapine,No interaction,"While_bf vitro_bf studies_bf shown_bf DRUG potent_be inhibitor_be enzymes_be ,_be indication_be DRUG likely_af clinically_af significant_af inhibitory_af effect_af metabolism_af drugs_af substrates_af cytochrome_af P450_af enzymes_af ,_af concomitant_af use_af REMERON_af SolTab_af drugs_af metabolized_af enzymes_af formally_af studied_af ._af"
1877,"While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. ",mirtazapine,REMERON SolTab,No interaction,"While_bf vitro_bf studies_bf shown_bf DRUG potent_be inhibitor_be enzymes_be ,_be indication_be DRUG likely_af clinically_af significant_af inhibitory_af effect_af metabolism_af drugs_af substrates_af cytochrome_af P450_af enzymes_af ,_af concomitant_af use_af REMERON_af SolTab_af drugs_af metabolized_af enzymes_af formally_af studied_af ._af"
1878,"While in vitro studies have shown that mirtazapine is not a potent inhibitor of any of these enzymes, an indication that mirtazapine is not likely to have a clinically significant inhibitory effect on the metabolism of other drugs that are substrates for these cytochrome P450 enzymes, the concomitant use of REMERON SolTab with most other drugs metabolized by these enzymes has not been formally studied. ",mirtazapine,REMERON SolTab,No interaction,"While_bf vitro_bf studies_bf shown_bf DRUG potent_be inhibitor_be enzymes_be ,_be indication_be DRUG likely_af clinically_af significant_af inhibitory_af effect_af metabolism_af drugs_af substrates_af cytochrome_af P450_af enzymes_af ,_af concomitant_af use_af REMERON_af SolTab_af drugs_af metabolized_af enzymes_af formally_af studied_af ._af"
1879,Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,Alcohol,alcohol,No interaction,Alcohol:_bf Concomitant_bf administration_bf DRUG (equivalent_be 60_be g)_be minimal_be effect_be plasma_be levels_be mirtazapine_be (15_be mg)_be 6_be healthy_be male_be subjects_be ._be
1880,Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,Alcohol,mirtazapine,No interaction,Alcohol:_bf Concomitant_bf administration_bf DRUG (equivalent_be 60_be g)_be minimal_be effect_be plasma_be levels_be OTHER_DRUG (15_af mg)_af 6_af healthy_af male_af subjects_af ._af
1881,Alcohol: Concomitant administration of alcohol (equivalent to 60 g) had a minimal effect on plasma levels of mirtazapine (15 mg) in 6 healthy male subjects. ,alcohol,mirtazapine,mechanism,Alcohol:_bf Concomitant_bf administration_bf DRUG (equivalent_be 60_be g)_be minimal_be effect_be plasma_be levels_be OTHER_DRUG (15_af mg)_af 6_af healthy_af male_af subjects_af ._af
1882,"However, the impairment of cognitive and motor skills produced by REMERON    were shown to be additive with those produced by alcohol. ",REMERON,alcohol,effect,"However_bf ,_bf impairment_bf cognitive_bf motor_bf skills_bf produced_bf DRUG shown_be additive_be produced_be OTHER_DRUG ._af"
1883,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",alcohol,REMERON SolTab,advise,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf DRUG taking_be REMERON_be SolTab_be ._be Diazepam:_be Concomitant_be administration_be diazepam_be (15_be mg)_be minimal_be effect_be plasma_be levels_be mirtazapine_be (15_be mg)_be 12_be healthy_be subjects_be ._be"
1884,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",alcohol,Diazepam,No interaction,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf DRUG taking_be REMERON_be SolTab_be ._be Diazepam:_be Concomitant_be administration_be OTHER_DRUG (15_af mg)_af minimal_af effect_af plasma_af levels_af mirtazapine_af (15_af mg)_af 12_af healthy_af subjects_af ._af"
1885,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",alcohol,diazepam,No interaction,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf DRUG taking_be REMERON_be SolTab_be ._be Diazepam:_be Concomitant_be administration_be OTHER_DRUG (15_af mg)_af minimal_af effect_af plasma_af levels_af mirtazapine_af (15_af mg)_af 12_af healthy_af subjects_af ._af"
1886,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",alcohol,mirtazapine,No interaction,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf DRUG taking_be REMERON_be SolTab_be ._be Diazepam:_be Concomitant_be administration_be diazepam_be (15_be mg)_be minimal_be effect_be plasma_be levels_be OTHER_DRUG (15_af mg)_af 12_af healthy_af subjects_af ._af"
1887,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",REMERON SolTab,Diazepam,No interaction,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf alcohol_bf taking_bf REMERON_bf SolTab_bf ._bf Diazepam:_bf Concomitant_bf administration_bf OTHER_DRUG (15_be mg)_be minimal_be effect_be plasma_be levels_be mirtazapine_be (15_be mg)_be 12_be healthy_be subjects_be ._be"
1888,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",REMERON SolTab,diazepam,No interaction,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf alcohol_bf taking_bf REMERON_bf SolTab_bf ._bf Diazepam:_bf Concomitant_bf administration_bf OTHER_DRUG (15_be mg)_be minimal_be effect_be plasma_be levels_be mirtazapine_be (15_be mg)_be 12_be healthy_be subjects_be ._be"
1889,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",REMERON SolTab,mirtazapine,No interaction,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf alcohol_bf taking_bf REMERON_bf SolTab_bf ._bf Diazepam:_bf Concomitant_bf administration_bf diazepam_bf (15_bf mg)_bf minimal_bf effect_bf plasma_bf levels_bf OTHER_DRUG (15_be mg)_be 12_be healthy_be subjects_be ._be"
1890,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",Diazepam,diazepam,No interaction,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf alcohol_bf taking_bf REMERON_bf SolTab_bf ._bf Diazepam:_bf Concomitant_bf administration_bf DRUG (15_be mg)_be minimal_be effect_be plasma_be levels_be mirtazapine_be (15_be mg)_be 12_be healthy_be subjects_be ._be"
1891,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",Diazepam,mirtazapine,No interaction,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf alcohol_bf taking_bf REMERON_bf SolTab_bf ._bf Diazepam:_bf Concomitant_bf administration_bf DRUG (15_be mg)_be minimal_be effect_be plasma_be levels_be OTHER_DRUG (15_af mg)_af 12_af healthy_af subjects_af ._af"
1892,"Accordingly, patients should be advised to avoid alcohol while taking REMERON SolTab. Diazepam: Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. ",diazepam,mirtazapine,mechanism,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf alcohol_bf taking_bf REMERON_bf SolTab_bf ._bf Diazepam:_bf Concomitant_bf administration_bf DRUG (15_be mg)_be minimal_be effect_be plasma_be levels_be OTHER_DRUG (15_af mg)_af 12_af healthy_af subjects_af ._af"
1893,"However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. ",REMERON,diazepam,effect,"However_bf ,_bf impairment_bf motor_bf skills_bf produced_bf DRUG shown_be additive_be caused_be OTHER_DRUG ._af"
1894,"Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON SolTab.",diazepam,REMERON SolTab,advise,"Accordingly_bf ,_bf patients_bf advised_bf avoid_bf DRUG similar_be drugs_be taking_be REMERON_be SolTab_be ._be"
1895,"Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ",Mitotane,warfarin,mechanism,"DRUG reported_be accelerate_be metabolism_be OTHER_DRUG mechanism_af hepatic_af microsomal_af enzyme_af induction_af ,_af leading_af increase_af dosage_af requirements_af OTHER_DRUG ._af"
1896,"Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ",Mitotane,warfarin,No interaction,"DRUG reported_be accelerate_be metabolism_be OTHER_DRUG mechanism_af hepatic_af microsomal_af enzyme_af induction_af ,_af leading_af increase_af dosage_af requirements_af OTHER_DRUG ._af"
1897,"Mitotane has been reported to accelerate the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, leading to an increase in dosage requirements for warfarin. ",warfarin,warfarin,No interaction,"Mitotane_bf reported_bf accelerate_bf metabolism_bf DRUG mechanism_be hepatic_be microsomal_be enzyme_be induction_be ,_be leading_be increase_be dosage_be requirements_be DRUG ._af"
1898,"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ",anticoagulant,Mitotane,No interaction,"Therefore_bf ,_bf physicians_bf closely_bf monitor_bf patients_bf change_bf DRUG dosage_be requirements_be administering_be OTHER_DRUG patients_af coumarin-type_af anticoagulants_af ._af"
1899,"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ",anticoagulant,coumarin-type anticoagulants,No interaction,"Therefore_bf ,_bf physicians_bf closely_bf monitor_bf patients_bf change_bf DRUG dosage_be requirements_be administering_be Mitotane_be patients_be coumarin-type_be anticoagulants_be ._be"
1900,"Therefore, physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants. ",Mitotane,coumarin-type anticoagulants,advise,"Therefore_bf ,_bf physicians_bf closely_bf monitor_bf patients_bf change_bf anticoagulant_bf dosage_bf requirements_bf administering_bf DRUG patients_be coumarin-type_be anticoagulants_be ._be"
1901,"Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied. ",MIVACRON,MIVACRON,No interaction,"Although_bf DRUG (a_be mixture_be three_be stereoisomers)_be administered_be safely_be following_be succinylcholine-facilitated_be tracheal_be intubation_be ,_be interaction_be DRUG succinylcholine_af systematically_af studied_af ._af"
1902,"Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied. ",MIVACRON,succinylcholine,No interaction,"Although_bf DRUG (a_be mixture_be three_be stereoisomers)_be administered_be safely_be following_be succinylcholine-facilitated_be tracheal_be intubation_be ,_be interaction_be DRUG OTHER_DRUG systematically_af studied_af ._af"
1903,"Although MIVACRON (a mixture of three stereoisomers) has been administered safely following succinylcholine-facilitated tracheal intubation, the interaction between MIVACRON and succinylcholine has not been systematically studied. ",MIVACRON,succinylcholine,No interaction,"Although_bf DRUG (a_be mixture_be three_be stereoisomers)_be administered_be safely_be following_be succinylcholine-facilitated_be tracheal_be intubation_be ,_be interaction_be DRUG OTHER_DRUG systematically_af studied_af ._af"
1904,Prior administration of succinylcholine can potentiate the neuromuscular blocking effects of nondepolarizing agents. ,succinylcholine,nondepolarizing agents,effect,Prior_bf administration_bf DRUG potentiate_be neuromuscular_be blocking_be effects_be nondepolarizing_be agents_be ._be
1905,Evidence of spontaneous recovery from succinylcholine should be observed before the administration of MIVACRON. ,succinylcholine,MIVACRON,advise,Evidence_bf spontaneous_bf recovery_bf DRUG observed_be administration_be OTHER_DRUG ._af
1906,The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied. ,MIVACRON,succinylcholine,No interaction,The_bf use_bf DRUG OTHER_DRUG attenuate_af side_af effects_af OTHER_DRUG studied_af ._af
1907,The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied. ,MIVACRON,succinylcholine,No interaction,The_bf use_bf DRUG OTHER_DRUG attenuate_af side_af effects_af OTHER_DRUG studied_af ._af
1908,The use of MIVACRON before succinylcholine to attenuate some of the side effects of succinylcholine has not been studied. ,succinylcholine,succinylcholine,No interaction,The_bf use_bf MIVACRON_bf DRUG attenuate_be side_be effects_be DRUG studied_af ._af
1909,There are no clinical data on the use of MIVACRON with other nondepolarizing neuromuscular blocking agents. ,MIVACRON,nondepolarizing neuromuscular blocking agents,No interaction,There_bf clinical_bf data_bf use_bf DRUG nondepolarizing_be neuromuscular_be blocking_be agents_be ._be
1910,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,Isoflurane,enflurane,No interaction,DRUG OTHER_DRUG (administered_af nitrous_af oxide/oxygen_af achieve_af 1_af ._af 25_af M_af ._af C_af ._af
1911,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,Isoflurane,nitrous oxide,No interaction,DRUG enflurane_be (administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be M_be ._be C_be ._be
1912,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,Isoflurane,oxygen,No interaction,DRUG enflurane_be (administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be M_be ._be C_be ._be
1913,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,enflurane,nitrous oxide,No interaction,Isoflurane_bf DRUG (administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be M_be ._be C_be ._be
1914,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,enflurane,oxygen,No interaction,Isoflurane_bf DRUG (administered_be nitrous_be oxide/oxygen_be achieve_be 1_be ._be 25_be M_be ._be C_be ._be
1915,Isoflurane and enflurane (administered with nitrous oxide/oxygen to achieve 1.25 M.C. ,nitrous oxide,oxygen,No interaction,Isoflurane_bf enflurane_bf (administered_bf nitrous_bf oxide/oxygen_bf achieve_bf 1_bf ._bf 25_bf M_bf ._bf C_bf ._bf
1916,A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane. ,MIVACRON,enflurane,No interaction,A_bf greater_bf potentiation_bf neuromuscular_bf blocking_bf effects_bf DRUG may_be expected_be higher_be concentrations_be OTHER_DRUG isoflurane_af ._af
1917,A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane. ,MIVACRON,isoflurane,No interaction,A_bf greater_bf potentiation_bf neuromuscular_bf blocking_bf effects_bf DRUG may_be expected_be higher_be concentrations_be enflurane_be OTHER_DRUG ._af
1918,A greater potentiation of the neuromuscular blocking effects of MIVACRON may be expected with higher concentrations of enflurane or isoflurane. ,enflurane,isoflurane,No interaction,A_bf greater_bf potentiation_bf neuromuscular_bf blocking_bf effects_bf MIVACRON_bf may_bf expected_bf higher_bf concentrations_bf DRUG OTHER_DRUG ._af
1919,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,MIVACRON,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf OTHER_DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1920,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,antibiotics,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf OTHER_DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1921,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,aminoglycosides,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1922,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,tetracyclines,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf OTHER_DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1923,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,bacitracin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf OTHER_DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1924,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,polymyxins,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf OTHER_DRUG ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1925,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,lincomycin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf OTHER_DRUG ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1926,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,clindamycin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf OTHER_DRUG ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1927,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,colistin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf OTHER_DRUG ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1928,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,sodium colistimethate,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf procainamide_bf ,_bf quinidine_bf ._bf"
1929,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,magnesium,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf OTHER_DRUG salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1930,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,lithium,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf OTHER_DRUG ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1931,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,anesthetics,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf OTHER_DRUG ,_be procainamide_be ,_be quinidine_be ._be"
1932,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,procainamide,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf OTHER_DRUG ,_be quinidine_be ._be"
1933,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",nondepolarizing agents,quinidine,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf procainamide_bf ,_bf OTHER_DRUG ._be"
1934,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,antibiotics,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be OTHER_DRUG (e_af ._af g_af ._af ,_af aminoglycosides_af ,_af tetracyclines_af ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1935,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,aminoglycosides,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af tetracyclines_af ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1936,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,tetracyclines,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be OTHER_DRUG ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1937,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,bacitracin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be OTHER_DRUG ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1938,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,polymyxins,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be OTHER_DRUG ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1939,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,lincomycin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be OTHER_DRUG ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1940,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,clindamycin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be OTHER_DRUG ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1941,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,colistin,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be OTHER_DRUG ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1942,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,sodium colistimethate,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1943,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,magnesium,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1944,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,lithium,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1945,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,anesthetics,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
1946,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,procainamide,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1947,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",MIVACRON,quinidine,int,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf DRUG include_be certain_be antibiotics_be (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
1948,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,aminoglycosides,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af tetracyclines_af ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1949,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,tetracyclines,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be OTHER_DRUG ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1950,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,bacitracin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be OTHER_DRUG ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1951,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,polymyxins,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be OTHER_DRUG ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1952,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,lincomycin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be OTHER_DRUG ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1953,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,clindamycin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be OTHER_DRUG ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1954,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,colistin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be OTHER_DRUG ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1955,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,sodium colistimethate,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1956,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,magnesium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1957,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,lithium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1958,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,anesthetics,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
1959,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1960,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",antibiotics,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf DRUG (e_be ._be g_be ._be ,_be aminoglycosides_be ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
1961,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,tetracyclines,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af bacitracin_af ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1962,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,bacitracin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracyclines_be ,_be OTHER_DRUG ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1963,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,polymyxins,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be OTHER_DRUG ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1964,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,lincomycin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be OTHER_DRUG ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1965,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,clindamycin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be OTHER_DRUG ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1966,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,colistin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be OTHER_DRUG ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1967,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,sodium colistimethate,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1968,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,magnesium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1969,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,lithium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1970,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,anesthetics,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
1971,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1972,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",aminoglycosides,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be tetracyclines_be ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
1973,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",tetracyclines,bacitracin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be OTHER_DRUG ,_af polymyxins_af ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1974,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",tetracyclines,polymyxins,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be bacitracin_be ,_be OTHER_DRUG ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1975,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",tetracyclines,lincomycin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be OTHER_DRUG ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1976,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",tetracyclines,clindamycin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be OTHER_DRUG ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1977,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",tetracyclines,colistin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be OTHER_DRUG ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1978,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",tetracyclines,sodium colistimethate,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1979,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",tetracyclines,magnesium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1980,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",tetracyclines,lithium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1981,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",tetracyclines,anesthetics,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
1982,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",tetracyclines,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1983,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",tetracyclines,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
1984,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",bacitracin,polymyxins,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf DRUG ,_be OTHER_DRUG ,_af lincomycin_af ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1985,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",bacitracin,lincomycin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf DRUG ,_be polymyxins_be ,_be OTHER_DRUG ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1986,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",bacitracin,clindamycin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be OTHER_DRUG ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1987,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",bacitracin,colistin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be OTHER_DRUG ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1988,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",bacitracin,sodium colistimethate,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1989,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",bacitracin,magnesium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1990,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",bacitracin,lithium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1991,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",bacitracin,anesthetics,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
1992,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",bacitracin,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
1993,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",bacitracin,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf DRUG ,_be polymyxins_be ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
1994,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",polymyxins,lincomycin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af clindamycin_af ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1995,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",polymyxins,clindamycin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf DRUG ,_be lincomycin_be ,_be OTHER_DRUG ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1996,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",polymyxins,colistin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf DRUG ,_be lincomycin_be ,_be clindamycin_be ,_be OTHER_DRUG ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1997,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",polymyxins,sodium colistimethate,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf DRUG ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
1998,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",polymyxins,magnesium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf DRUG ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
1999,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",polymyxins,lithium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf DRUG ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
2000,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",polymyxins,anesthetics,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf DRUG ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
2001,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",polymyxins,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf DRUG ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
2002,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",polymyxins,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf DRUG ,_be lincomycin_be ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
2003,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",lincomycin,clindamycin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf DRUG ,_be OTHER_DRUG ,_af colistin_af ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
2004,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",lincomycin,colistin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf DRUG ,_be clindamycin_be ,_be OTHER_DRUG ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
2005,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",lincomycin,sodium colistimethate,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf DRUG ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
2006,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",lincomycin,magnesium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf DRUG ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
2007,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",lincomycin,lithium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf DRUG ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
2008,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",lincomycin,anesthetics,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf DRUG ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
2009,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",lincomycin,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf DRUG ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
2010,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",lincomycin,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf DRUG ,_be clindamycin_be ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
2011,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",clindamycin,colistin,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af sodium_af colistimethate)_af ,_af magnesium_af salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
2012,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",clindamycin,sodium colistimethate,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf DRUG ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
2013,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",clindamycin,magnesium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf DRUG ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
2014,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",clindamycin,lithium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf DRUG ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
2015,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",clindamycin,anesthetics,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf DRUG ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
2016,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",clindamycin,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf DRUG ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
2017,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",clindamycin,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf DRUG ,_be colistin_be ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
2018,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",colistin,sodium colistimethate,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf DRUG ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
2019,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",colistin,magnesium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf DRUG ,_be sodium_be colistimethate)_be ,_be OTHER_DRUG salts_af ,_af lithium_af ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
2020,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",colistin,lithium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf DRUG ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
2021,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",colistin,anesthetics,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf DRUG ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
2022,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",colistin,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf DRUG ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
2023,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",colistin,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf DRUG ,_be sodium_be colistimethate)_be ,_be magnesium_be salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
2024,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",sodium colistimethate,magnesium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf OTHER_DRUG salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
2025,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",sodium colistimethate,lithium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf OTHER_DRUG ,_be local_be anesthetics_be ,_be procainamide_be ,_be quinidine_be ._be"
2026,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",sodium colistimethate,anesthetics,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf OTHER_DRUG ,_be procainamide_be ,_be quinidine_be ._be"
2027,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",sodium colistimethate,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf OTHER_DRUG ,_be quinidine_be ._be"
2028,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",sodium colistimethate,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf procainamide_bf ,_bf OTHER_DRUG ._be"
2029,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",magnesium,lithium,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf DRUG salts_be ,_be OTHER_DRUG ,_af local_af anesthetics_af ,_af procainamide_af ,_af quinidine_af ._af"
2030,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",magnesium,anesthetics,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf DRUG salts_be ,_be lithium_be ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
2031,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",magnesium,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf DRUG salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
2032,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",magnesium,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf DRUG salts_be ,_be lithium_be ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
2033,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",lithium,anesthetics,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf DRUG ,_be local_be OTHER_DRUG ,_af procainamide_af ,_af quinidine_af ._af"
2034,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",lithium,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf DRUG ,_be local_be anesthetics_be ,_be OTHER_DRUG ,_af quinidine_af ._af"
2035,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",lithium,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf DRUG ,_be local_be anesthetics_be ,_be procainamide_be ,_be OTHER_DRUG ._af"
2036,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",anesthetics,procainamide,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf DRUG ,_be OTHER_DRUG ,_af quinidine_af ._af"
2037,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",anesthetics,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf DRUG ,_be procainamide_be ,_be OTHER_DRUG ._af"
2038,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine. ",procainamide,quinidine,No interaction,"Other_bf drugs_bf may_bf enhance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf agents_bf MIVACRON_bf include_bf certain_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf aminoglycosides_bf ,_bf tetracyclines_bf ,_bf bacitracin_bf ,_bf polymyxins_bf ,_bf lincomycin_bf ,_bf clindamycin_bf ,_bf colistin_bf ,_bf sodium_bf colistimethate)_bf ,_bf magnesium_bf salts_bf ,_bf lithium_bf ,_bf local_bf anesthetics_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
2039,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,contraceptives,effect,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be OTHER_DRUG ,_af glucocorticoids_af ,_af certain_af monoamine_af oxidase_af inhibitors)_af drugs_af irreversibly_af inhibit_af plasma_af cholinesterase_af ._af Resistance_af neuromuscular_af blocking_af action_af nondepolarizing_af neuromuscular_af blocking_af agents_af demonstrated_af patients_af chronically_af administered_af phenytoin_af carbamazepine_af ._af"
2040,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,glucocorticoids,effect,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be contraceptives_be ,_be OTHER_DRUG ,_af certain_af monoamine_af oxidase_af inhibitors)_af drugs_af irreversibly_af inhibit_af plasma_af cholinesterase_af ._af Resistance_af neuromuscular_af blocking_af action_af nondepolarizing_af neuromuscular_af blocking_af agents_af demonstrated_af patients_af chronically_af administered_af phenytoin_af carbamazepine_af ._af"
2041,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,monoamine oxidase inhibitors,effect,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be contraceptives_be ,_be glucocorticoids_be ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be phenytoin_be carbamazepine_be ._be"
2042,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,neuromuscular blocking agents,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be contraceptives_be ,_be glucocorticoids_be ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be phenytoin_be carbamazepine_be ._be"
2043,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,phenytoin,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be contraceptives_be ,_be glucocorticoids_be ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be OTHER_DRUG carbamazepine_af ._af"
2044,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",MIVACRON,carbamazepine,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf DRUG may_be enhanced_be drugs_be reduce_be plasma_be cholinesterase_be activity_be (e_be ._be g_be ._be ,_be chronically_be administered_be oral_be contraceptives_be ,_be glucocorticoids_be ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be phenytoin_be OTHER_DRUG ._af"
2045,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",contraceptives,glucocorticoids,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf DRUG ,_be OTHER_DRUG ,_af certain_af monoamine_af oxidase_af inhibitors)_af drugs_af irreversibly_af inhibit_af plasma_af cholinesterase_af ._af Resistance_af neuromuscular_af blocking_af action_af nondepolarizing_af neuromuscular_af blocking_af agents_af demonstrated_af patients_af chronically_af administered_af phenytoin_af carbamazepine_af ._af"
2046,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",contraceptives,monoamine oxidase inhibitors,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf DRUG ,_be glucocorticoids_be ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be phenytoin_be carbamazepine_be ._be"
2047,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",contraceptives,neuromuscular blocking agents,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf DRUG ,_be glucocorticoids_be ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be phenytoin_be carbamazepine_be ._be"
2048,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",contraceptives,phenytoin,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf DRUG ,_be glucocorticoids_be ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be OTHER_DRUG carbamazepine_af ._af"
2049,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",contraceptives,carbamazepine,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf DRUG ,_be glucocorticoids_be ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be phenytoin_be OTHER_DRUG ._af"
2050,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",glucocorticoids,monoamine oxidase inhibitors,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf DRUG ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be phenytoin_be carbamazepine_be ._be"
2051,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",glucocorticoids,neuromuscular blocking agents,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf DRUG ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be phenytoin_be carbamazepine_be ._be"
2052,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",glucocorticoids,phenytoin,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf DRUG ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be OTHER_DRUG carbamazepine_af ._af"
2053,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",glucocorticoids,carbamazepine,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf DRUG ,_be certain_be monoamine_be oxidase_be inhibitors)_be drugs_be irreversibly_be inhibit_be plasma_be cholinesterase_be ._be Resistance_be neuromuscular_be blocking_be action_be nondepolarizing_be neuromuscular_be blocking_be agents_be demonstrated_be patients_be chronically_be administered_be phenytoin_be OTHER_DRUG ._af"
2054,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",monoamine oxidase inhibitors,neuromuscular blocking agents,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf glucocorticoids_bf ,_bf certain_bf monoamine_bf oxidase_bf inhibitors)_bf drugs_bf irreversibly_bf inhibit_bf plasma_bf cholinesterase_bf ._bf Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf phenytoin_bf carbamazepine_bf ._bf"
2055,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",monoamine oxidase inhibitors,phenytoin,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf glucocorticoids_bf ,_bf certain_bf monoamine_bf oxidase_bf inhibitors)_bf drugs_bf irreversibly_bf inhibit_bf plasma_bf cholinesterase_bf ._bf Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf OTHER_DRUG carbamazepine_be ._be"
2056,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",monoamine oxidase inhibitors,carbamazepine,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf glucocorticoids_bf ,_bf certain_bf monoamine_bf oxidase_bf inhibitors)_bf drugs_bf irreversibly_bf inhibit_bf plasma_bf cholinesterase_bf ._bf Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf phenytoin_bf OTHER_DRUG ._be"
2057,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",neuromuscular blocking agents,phenytoin,effect,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf glucocorticoids_bf ,_bf certain_bf monoamine_bf oxidase_bf inhibitors)_bf drugs_bf irreversibly_bf inhibit_bf plasma_bf cholinesterase_bf ._bf Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf OTHER_DRUG carbamazepine_be ._be"
2058,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",neuromuscular blocking agents,carbamazepine,effect,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf glucocorticoids_bf ,_bf certain_bf monoamine_bf oxidase_bf inhibitors)_bf drugs_bf irreversibly_bf inhibit_bf plasma_bf cholinesterase_bf ._bf Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf phenytoin_bf OTHER_DRUG ._be"
2059,"The neuromuscular blocking effect of MIVACRON may be enhanced by drugs that reduce plasma cholinesterase activity (e.g., chronically administered oral contraceptives, glucocorticoids, or certain monoamine oxidase inhibitors) or by drugs that irreversibly inhibit plasma cholinesterase . Resistance to the neuromuscular blocking action of nondepolarizing neuromuscular blocking agents has been demonstrated in patients chronically administered phenytoin or carbamazepine. ",phenytoin,carbamazepine,No interaction,"The_bf neuromuscular_bf blocking_bf effect_bf MIVACRON_bf may_bf enhanced_bf drugs_bf reduce_bf plasma_bf cholinesterase_bf activity_bf (e_bf ._bf g_bf ._bf ,_bf chronically_bf administered_bf oral_bf contraceptives_bf ,_bf glucocorticoids_bf ,_bf certain_bf monoamine_bf oxidase_bf inhibitors)_bf drugs_bf irreversibly_bf inhibit_bf plasma_bf cholinesterase_bf ._bf Resistance_bf neuromuscular_bf blocking_bf action_bf nondepolarizing_bf neuromuscular_bf blocking_bf agents_bf demonstrated_bf patients_bf chronically_bf administered_bf DRUG OTHER_DRUG ._af"
2060,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",phenytoin,carbamazepine,No interaction,"While_bf effects_bf chronic_bf DRUG OTHER_DRUG therapy_af action_af MIVACRON_af unknown_af ,_af slightly_af shorter_af durations_af neuromuscular_af block_af may_af anticipated_af infusion_af rate_af requirements_af may_af higher_af ._af"
2061,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",phenytoin,MIVACRON,effect,"While_bf effects_bf chronic_bf DRUG carbamazepine_be therapy_be action_be OTHER_DRUG unknown_af ,_af slightly_af shorter_af durations_af neuromuscular_af block_af may_af anticipated_af infusion_af rate_af requirements_af may_af higher_af ._af"
2062,"While the effects of chronic phenytoin or carbamazepine therapy on the action of MIVACRON are unknown, slightly shorter durations of neuromuscular block may be anticipated and infusion rate requirements may be higher. ",carbamazepine,MIVACRON,effect,"While_bf effects_bf chronic_bf phenytoin_bf DRUG therapy_be action_be OTHER_DRUG unknown_af ,_af slightly_af shorter_af durations_af neuromuscular_af block_af may_af anticipated_af infusion_af rate_af requirements_af may_af higher_af ._af"
2063,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,phenytoin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be OTHER_DRUG carbamazepine_af -_af certain_af antibiotics_af given_af injection_af -_af cisplatin_af -_af edrophonium_af -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2064,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,carbamazepine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be OTHER_DRUG -_af certain_af antibiotics_af given_af injection_af -_af cisplatin_af -_af edrophonium_af -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2065,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,antibiotics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be carbamazepine_be -_be certain_be OTHER_DRUG given_af injection_af -_af cisplatin_af -_af edrophonium_af -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2066,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,cisplatin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be OTHER_DRUG -_af edrophonium_af -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2067,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,edrophonium,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be OTHER_DRUG -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2068,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,neostigmine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be OTHER_DRUG -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2069,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,polymyxin B,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2070,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,bacitracin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be OTHER_DRUG -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2071,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2072,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,procaine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be OTHER_DRUG -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2073,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2074,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be OTHER_DRUG muscle_af relaxants_af
2075,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,corticosteroids,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf DRUG -_be medicines_be angina_be high_be blood_be pressure_be -_be medicines_be pain_be -_be medicines_be control_be seizures_be phenytoin_be carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2076,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,carbamazepine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG OTHER_DRUG -_af certain_af antibiotics_af given_af injection_af -_af cisplatin_af -_af edrophonium_af -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2077,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,antibiotics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG carbamazepine_be -_be certain_be OTHER_DRUG given_af injection_af -_af cisplatin_af -_af edrophonium_af -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2078,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,cisplatin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be OTHER_DRUG -_af edrophonium_af -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2079,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,edrophonium,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be OTHER_DRUG -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2080,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,neostigmine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be OTHER_DRUG -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2081,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,polymyxin B,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2082,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,bacitracin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be OTHER_DRUG -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2083,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2084,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,procaine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be OTHER_DRUG -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2085,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2086,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be OTHER_DRUG muscle_af relaxants_af
2087,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,phenytoin,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf DRUG carbamazepine_be -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2088,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,carbamazepine,antibiotics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf DRUG -_be certain_be OTHER_DRUG given_af injection_af -_af cisplatin_af -_af edrophonium_af -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2089,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,carbamazepine,cisplatin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf DRUG -_be certain_be antibiotics_be given_be injection_be -_be OTHER_DRUG -_af edrophonium_af -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2090,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,carbamazepine,edrophonium,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf DRUG -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be OTHER_DRUG -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2091,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,carbamazepine,neostigmine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf DRUG -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be OTHER_DRUG -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2092,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,carbamazepine,polymyxin B,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf DRUG -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2093,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,carbamazepine,bacitracin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf DRUG -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be OTHER_DRUG -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2094,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,carbamazepine,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf DRUG -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2095,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,carbamazepine,procaine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf DRUG -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be OTHER_DRUG -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2096,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,carbamazepine,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf DRUG -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2097,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,carbamazepine,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf DRUG -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be OTHER_DRUG muscle_af relaxants_af
2098,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,carbamazepine,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf DRUG -_be certain_be antibiotics_be given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2099,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,antibiotics,cisplatin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf DRUG given_be injection_be -_be OTHER_DRUG -_af edrophonium_af -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2100,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,antibiotics,edrophonium,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf DRUG given_be injection_be -_be cisplatin_be -_be OTHER_DRUG -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2101,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,antibiotics,neostigmine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf DRUG given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be OTHER_DRUG -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2102,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,antibiotics,polymyxin B,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf DRUG given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2103,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,antibiotics,bacitracin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf DRUG given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be OTHER_DRUG -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2104,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,antibiotics,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf DRUG given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2105,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,antibiotics,procaine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf DRUG given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be OTHER_DRUG -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2106,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,antibiotics,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf DRUG given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2107,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,antibiotics,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf DRUG given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be OTHER_DRUG muscle_af relaxants_af
2108,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,antibiotics,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf DRUG given_be injection_be -_be cisplatin_be -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2109,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,cisplatin,edrophonium,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf DRUG -_be OTHER_DRUG -_af neostigmine_af -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2110,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,cisplatin,neostigmine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf DRUG -_be edrophonium_be -_be OTHER_DRUG -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2111,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,cisplatin,polymyxin B,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf DRUG -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2112,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,cisplatin,bacitracin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf DRUG -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be OTHER_DRUG -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2113,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,cisplatin,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf DRUG -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2114,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,cisplatin,procaine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf DRUG -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be OTHER_DRUG -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2115,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,cisplatin,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf DRUG -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2116,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,cisplatin,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf DRUG -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be OTHER_DRUG muscle_af relaxants_af
2117,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,cisplatin,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf DRUG -_be edrophonium_be -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2118,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,edrophonium,neostigmine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf DRUG -_be OTHER_DRUG -_af polymyxin_af B_af bacitracin_af -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2119,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,edrophonium,polymyxin B,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf DRUG -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2120,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,edrophonium,bacitracin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf DRUG -_be neostigmine_be -_be polymyxin_be B_be OTHER_DRUG -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2121,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,edrophonium,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf DRUG -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2122,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,edrophonium,procaine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf DRUG -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be OTHER_DRUG -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2123,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,edrophonium,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf DRUG -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2124,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,edrophonium,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf DRUG -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be OTHER_DRUG muscle_af relaxants_af
2125,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,edrophonium,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf DRUG -_be neostigmine_be -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2126,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,neostigmine,polymyxin B,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf DRUG -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2127,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,neostigmine,bacitracin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf DRUG -_be polymyxin_be B_be OTHER_DRUG -_af local_af anesthetics_af procaine_af -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2128,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,neostigmine,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf DRUG -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2129,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,neostigmine,procaine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf DRUG -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be OTHER_DRUG -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2130,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,neostigmine,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf DRUG -_be polymyxin_be B_be bacitracin_be -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2131,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,neostigmine,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf DRUG -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be OTHER_DRUG muscle_af relaxants_af
2132,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,neostigmine,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf DRUG -_be polymyxin_be B_be bacitracin_be -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2133,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,polymyxin B,bacitracin,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf OTHER_DRUG -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2134,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,polymyxin B,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf OTHER_DRUG procaine_be -_be general_be OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2135,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,polymyxin B,procaine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf anesthetics_bf OTHER_DRUG -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2136,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,polymyxin B,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf OTHER_DRUG procaine_be -_be general_be OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2137,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,polymyxin B,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf anesthetics_bf procaine_bf -_bf general_bf anesthetics_bf -_bf OTHER_DRUG muscle_be relaxants_be
2138,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,polymyxin B,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf anesthetics_bf procaine_bf -_bf general_bf anesthetics_bf -_bf succinylcholine_bf muscle_bf relaxants_bf
2139,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,bacitracin,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf DRUG -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2140,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,bacitracin,procaine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf DRUG -_be local_be anesthetics_be OTHER_DRUG -_af general_af anesthetics_af -_af succinylcholine_af muscle_af relaxants_af
2141,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,bacitracin,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf DRUG -_be local_be OTHER_DRUG procaine_af -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2142,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,bacitracin,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf DRUG -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be OTHER_DRUG muscle_af relaxants_af
2143,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,bacitracin,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf DRUG -_be local_be anesthetics_be procaine_be -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2144,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,anesthetics,procaine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf DRUG OTHER_DRUG -_af general_af DRUG -_af succinylcholine_af muscle_af relaxants_af
2145,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,anesthetics,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf DRUG procaine_be -_be general_be DRUG -_af succinylcholine_af muscle_af relaxants_af
2146,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,anesthetics,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf DRUG procaine_be -_be general_be DRUG -_af OTHER_DRUG muscle_af relaxants_af
2147,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,anesthetics,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf DRUG procaine_be -_be general_be DRUG -_af succinylcholine_af muscle_af relaxants_af
2148,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,procaine,anesthetics,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf OTHER_DRUG DRUG -_af general_af OTHER_DRUG -_af succinylcholine_af muscle_af relaxants_af
2149,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,procaine,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf anesthetics_bf DRUG -_be general_be anesthetics_be -_be OTHER_DRUG muscle_af relaxants_af
2150,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,procaine,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf anesthetics_bf DRUG -_be general_be anesthetics_be -_be succinylcholine_be muscle_be relaxants_be
2151,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,anesthetics,succinylcholine,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf DRUG procaine_be -_be general_be DRUG -_af OTHER_DRUG muscle_af relaxants_af
2152,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,anesthetics,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf DRUG procaine_be -_be general_be DRUG -_af succinylcholine_af muscle_af relaxants_af
2153,Some drug interactions are:  - birth control pills - corticosteroids - medicines for angina or high blood pressure - medicines for pain - medicines to control seizures such as phenytoin or carbamazepine - certain antibiotics given by injection - cisplatin - edrophonium - neostigmine - polymyxin B or bacitracin - local anesthetics such as procaine - general anesthetics - succinylcholine or other muscle relaxants,succinylcholine,muscle relaxants,No interaction,Some_bf drug_bf interactions_bf are:_bf -_bf birth_bf control_bf pills_bf -_bf corticosteroids_bf -_bf medicines_bf angina_bf high_bf blood_bf pressure_bf -_bf medicines_bf pain_bf -_bf medicines_bf control_bf seizures_bf phenytoin_bf carbamazepine_bf -_bf certain_bf antibiotics_bf given_bf injection_bf -_bf cisplatin_bf -_bf edrophonium_bf -_bf neostigmine_bf -_bf polymyxin_bf B_bf bacitracin_bf -_bf local_bf anesthetics_bf procaine_bf -_bf general_bf anesthetics_bf -_bf DRUG muscle_be relaxants_be
2154,Diuretics: Excessive reductions in blood pressure may occur in patients on diuretic therapy when ACE inhibitors are started. ,Diuretics,ACE inhibitors,No interaction,Diuretics:_bf Excessive_bf reductions_bf blood_bf pressure_bf may_bf occur_bf patients_bf diuretic_bf therapy_bf ACE_bf inhibitors_bf started_bf ._bf
2155,"The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. ",UNIVASC,UNIVASC,No interaction,"The_bf possibility_bf hypotensive_bf effects_bf DRUG minimized_be discontinuing_be diuretic_be therapy_be several_be days_be cautiously_be increasing_be salt_be intake_be initiation_be treatment_be DRUG ._af If_af possible_af ,_af starting_af dose_af moexpril_af reduced_af ._af ._af"
2156,"The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. ",UNIVASC,moexpril,No interaction,"The_bf possibility_bf hypotensive_bf effects_bf DRUG minimized_be discontinuing_be diuretic_be therapy_be several_be days_be cautiously_be increasing_be salt_be intake_be initiation_be treatment_be DRUG ._af If_af possible_af ,_af starting_af dose_af OTHER_DRUG reduced_af ._af ._af"
2157,"The possibility of hypotensive effects with UNIVASC    can be minimized by discontinuing diuretic therapy for several days or cautiously increasing salt intake before initiation of treatment with UNIVASC   . If this is not possible, the starting dose of moexpril should be reduced.. ",UNIVASC,moexpril,No interaction,"The_bf possibility_bf hypotensive_bf effects_bf DRUG minimized_be discontinuing_be diuretic_be therapy_be several_be days_be cautiously_be increasing_be salt_be intake_be initiation_be treatment_be DRUG ._af If_af possible_af ,_af starting_af dose_af OTHER_DRUG reduced_af ._af ._af"
2158,Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. ,Potassium,Potassium-Sparing Diuretics,No interaction,DRUG Supplements_be Potassium-Sparing_be Diuretics:_be UNIVASC_be increase_be serum_be DRUG decreases_af aldosterone_af secretion_af ._af
2159,Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. ,Potassium,UNIVASC,No interaction,DRUG Supplements_be Potassium-Sparing_be Diuretics:_be OTHER_DRUG increase_af serum_af DRUG decreases_af aldosterone_af secretion_af ._af
2160,Potassium Supplements and Potassium-Sparing Diuretics: UNIVASC    can increase serum potassium because it decreases aldosterone secretion. ,Potassium-Sparing Diuretics,UNIVASC,No interaction,Potassium_bf Supplements_bf Potassium-Sparing_bf Diuretics:_bf OTHER_DRUG increase_be serum_be potassium_be decreases_be aldosterone_be secretion_be ._be
2161,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium-sparing diuretics,spironolactone,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
2162,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium-sparing diuretics,triamterene,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf OTHER_DRUG ,_be amiloride)_be potassium_be supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
2163,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium-sparing diuretics,amiloride,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
2164,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium-sparing diuretics,potassium,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf OTHER_DRUG supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
2165,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium-sparing diuretics,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
2166,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",spironolactone,triamterene,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf OTHER_DRUG ,_be amiloride)_be potassium_be supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
2167,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",spironolactone,amiloride,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
2168,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",spironolactone,potassium,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf OTHER_DRUG supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
2169,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",spironolactone,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
2170,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",triamterene,amiloride,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf DRUG ,_be amiloride)_be potassium_be supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
2171,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",triamterene,potassium,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf DRUG ,_be amiloride)_be OTHER_DRUG supplements_af concomitantly_af ACE_af inhibitors_af increase_af risk_af hyperkalemia_af ._af"
2172,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",triamterene,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf DRUG ,_be amiloride)_be potassium_be supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
2173,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",amiloride,potassium,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf OTHER_DRUG supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
2174,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",amiloride,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf potassium_bf supplements_bf concomitantly_bf ACE_bf inhibitors_bf increase_bf risk_bf hyperkalemia_bf ._bf"
2175,"Use of potassium-sparing diuretics (spironolactone, triamterene, amiloride) or potassium supplements concomitantly with ACE inhibitors can increase the risk of hyperkalemia. ",potassium,ACE inhibitors,effect,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf triamterene_bf ,_bf amiloride)_bf DRUG supplements_be concomitantly_be ACE_be inhibitors_be increase_be risk_be hyperkalemia_be ._be"
2176,Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. ,Anticoagulants,warfarin,No interaction,Oral_bf Anticoagulants:_bf Interaction_bf studies_bf OTHER_DRUG failed_be identify_be clinically_be important_be effect_be serum_be concentrations_be anticoagulant_be anticoagulant_be effect_be ._be
2177,Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. ,Anticoagulants,anticoagulant,No interaction,Oral_bf Anticoagulants:_bf Interaction_bf studies_bf warfarin_bf failed_bf identify_bf clinically_bf important_bf effect_bf serum_bf concentrations_bf OTHER_DRUG OTHER_DRUG effect_af ._af
2178,Oral Anticoagulants: Interaction studies with warfarin failed to identify any clinically important effect on the serum concentrations of the anticoagulant or on its anticoagulant effect. ,warfarin,anticoagulant,No interaction,Oral_bf Anticoagulants:_bf Interaction_bf studies_bf DRUG failed_be identify_be clinically_be important_be effect_be serum_be concentrations_be OTHER_DRUG OTHER_DRUG effect_af ._af
2179,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,Lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG levels_be symptoms_be DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af DRUG ._af
2180,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,Lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG levels_be symptoms_be DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af DRUG ._af
2181,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,Lithium,ACE inhibitors,No interaction,Lithium:_bf Increased_bf serum_bf DRUG levels_be symptoms_be DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af DRUG ._af
2182,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,Lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG levels_be symptoms_be DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af DRUG ._af
2183,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG levels_be symptoms_be DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af DRUG ._af
2184,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,lithium,ACE inhibitors,No interaction,Lithium:_bf Increased_bf serum_bf DRUG levels_be symptoms_be DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af DRUG ._af
2185,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG levels_be symptoms_be DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af DRUG ._af
2186,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,lithium,ACE inhibitors,No interaction,Lithium:_bf Increased_bf serum_bf DRUG levels_be symptoms_be DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af DRUG ._af
2187,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG levels_be symptoms_be DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af DRUG ._af
2188,Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors during therapy with lithium. ,ACE inhibitors,lithium,effect,Lithium:_bf Increased_bf serum_bf OTHER_DRUG levels_be symptoms_be OTHER_DRUG toxicity_af reported_af patients_af receiving_af ACE_af inhibitors_af therapy_af OTHER_DRUG ._af
2189,"If a diuretic is also used, the risk of lithium toxicity may be increased. ",diuretic,lithium,effect,"If_bf DRUG also_be used_be ,_be risk_be OTHER_DRUG toxicity_af may_af increased_af ._af"
2190,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",UNIVASC,hydrochlorothiazide,No interaction,"Other_bf Agents:_bf No_bf clinically_bf important_bf pharmacokinetic_bf interactions_bf occurred_bf DRUG administered_be concomitantly_be OTHER_DRUG ,_af digoxin_af ,_af cimetidine_af ._af"
2191,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",UNIVASC,digoxin,No interaction,"Other_bf Agents:_bf No_bf clinically_bf important_bf pharmacokinetic_bf interactions_bf occurred_bf DRUG administered_be concomitantly_be hydrochlorothiazide_be ,_be OTHER_DRUG ,_af cimetidine_af ._af"
2192,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",UNIVASC,cimetidine,No interaction,"Other_bf Agents:_bf No_bf clinically_bf important_bf pharmacokinetic_bf interactions_bf occurred_bf DRUG administered_be concomitantly_be hydrochlorothiazide_be ,_be digoxin_be ,_be OTHER_DRUG ._af"
2193,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",hydrochlorothiazide,digoxin,No interaction,"Other_bf Agents:_bf No_bf clinically_bf important_bf pharmacokinetic_bf interactions_bf occurred_bf UNIVASC_bf administered_bf concomitantly_bf DRUG ,_be OTHER_DRUG ,_af cimetidine_af ._af"
2194,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",hydrochlorothiazide,cimetidine,No interaction,"Other_bf Agents:_bf No_bf clinically_bf important_bf pharmacokinetic_bf interactions_bf occurred_bf UNIVASC_bf administered_bf concomitantly_bf DRUG ,_be digoxin_be ,_be OTHER_DRUG ._af"
2195,"Other Agents: No clinically important pharmacokinetic interactions occurred when UNIVASC    was administered concomitantly with hydrochlorothiazide, digoxin, or cimetidine. ",digoxin,cimetidine,No interaction,"Other_bf Agents:_bf No_bf clinically_bf important_bf pharmacokinetic_bf interactions_bf occurred_bf UNIVASC_bf administered_bf concomitantly_bf hydrochlorothiazide_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
2196,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",UNIVASC,calcium-channel-blocking agents,No interaction,"DRUG used_be clinical_be trials_be concomitantly_be calcium-channel-blocking_be agents_be ,_be diuretics_be ,_be H2_be blockers_be ,_be digoxin_be ,_be oral_be hypoglycemic_be agents_be ,_be cholesterol-lowering_be agents_be ._be"
2197,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",UNIVASC,diuretics,No interaction,"DRUG used_be clinical_be trials_be concomitantly_be calcium-channel-blocking_be agents_be ,_be OTHER_DRUG ,_af H2_af blockers_af ,_af digoxin_af ,_af oral_af hypoglycemic_af agents_af ,_af cholesterol-lowering_af agents_af ._af"
2198,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",UNIVASC,H2 blockers,No interaction,"DRUG used_be clinical_be trials_be concomitantly_be calcium-channel-blocking_be agents_be ,_be diuretics_be ,_be H2_be blockers_be ,_be digoxin_be ,_be oral_be hypoglycemic_be agents_be ,_be cholesterol-lowering_be agents_be ._be"
2199,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",UNIVASC,digoxin,No interaction,"DRUG used_be clinical_be trials_be concomitantly_be calcium-channel-blocking_be agents_be ,_be diuretics_be ,_be H2_be blockers_be ,_be OTHER_DRUG ,_af oral_af hypoglycemic_af agents_af ,_af cholesterol-lowering_af agents_af ._af"
2200,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",UNIVASC,hypoglycemic agents,No interaction,"DRUG used_be clinical_be trials_be concomitantly_be calcium-channel-blocking_be agents_be ,_be diuretics_be ,_be H2_be blockers_be ,_be digoxin_be ,_be oral_be hypoglycemic_be agents_be ,_be cholesterol-lowering_be agents_be ._be"
2201,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",calcium-channel-blocking agents,diuretics,No interaction,"UNIVASC_bf used_bf clinical_bf trials_bf concomitantly_bf calcium-channel-blocking_bf agents_bf ,_bf OTHER_DRUG ,_be H2_be blockers_be ,_be digoxin_be ,_be oral_be hypoglycemic_be agents_be ,_be cholesterol-lowering_be agents_be ._be"
2202,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",calcium-channel-blocking agents,H2 blockers,No interaction,"UNIVASC_bf used_bf clinical_bf trials_bf concomitantly_bf calcium-channel-blocking_bf agents_bf ,_bf diuretics_bf ,_bf H2_bf blockers_bf ,_bf digoxin_bf ,_bf oral_bf hypoglycemic_bf agents_bf ,_bf cholesterol-lowering_bf agents_bf ._bf"
2203,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",calcium-channel-blocking agents,digoxin,No interaction,"UNIVASC_bf used_bf clinical_bf trials_bf concomitantly_bf calcium-channel-blocking_bf agents_bf ,_bf diuretics_bf ,_bf H2_bf blockers_bf ,_bf OTHER_DRUG ,_be oral_be hypoglycemic_be agents_be ,_be cholesterol-lowering_be agents_be ._be"
2204,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",calcium-channel-blocking agents,hypoglycemic agents,No interaction,"UNIVASC_bf used_bf clinical_bf trials_bf concomitantly_bf calcium-channel-blocking_bf agents_bf ,_bf diuretics_bf ,_bf H2_bf blockers_bf ,_bf digoxin_bf ,_bf oral_bf hypoglycemic_bf agents_bf ,_bf cholesterol-lowering_bf agents_bf ._bf"
2205,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",diuretics,H2 blockers,No interaction,"UNIVASC_bf used_bf clinical_bf trials_bf concomitantly_bf calcium-channel-blocking_bf agents_bf ,_bf DRUG ,_be H2_be blockers_be ,_be digoxin_be ,_be oral_be hypoglycemic_be agents_be ,_be cholesterol-lowering_be agents_be ._be"
2206,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",diuretics,digoxin,No interaction,"UNIVASC_bf used_bf clinical_bf trials_bf concomitantly_bf calcium-channel-blocking_bf agents_bf ,_bf DRUG ,_be H2_be blockers_be ,_be OTHER_DRUG ,_af oral_af hypoglycemic_af agents_af ,_af cholesterol-lowering_af agents_af ._af"
2207,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",diuretics,hypoglycemic agents,No interaction,"UNIVASC_bf used_bf clinical_bf trials_bf concomitantly_bf calcium-channel-blocking_bf agents_bf ,_bf DRUG ,_be H2_be blockers_be ,_be digoxin_be ,_be oral_be hypoglycemic_be agents_be ,_be cholesterol-lowering_be agents_be ._be"
2208,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",H2 blockers,digoxin,No interaction,"UNIVASC_bf used_bf clinical_bf trials_bf concomitantly_bf calcium-channel-blocking_bf agents_bf ,_bf diuretics_bf ,_bf H2_bf blockers_bf ,_bf OTHER_DRUG ,_be oral_be hypoglycemic_be agents_be ,_be cholesterol-lowering_be agents_be ._be"
2209,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",H2 blockers,hypoglycemic agents,No interaction,"UNIVASC_bf used_bf clinical_bf trials_bf concomitantly_bf calcium-channel-blocking_bf agents_bf ,_bf diuretics_bf ,_bf H2_bf blockers_bf ,_bf digoxin_bf ,_bf oral_bf hypoglycemic_bf agents_bf ,_bf cholesterol-lowering_bf agents_bf ._bf"
2210,"UNIVASC    has been used in clinical trials concomitantly with calcium-channel-blocking agents, diuretics, H2 blockers, digoxin, oral hypoglycemic agents, and cholesterol-lowering agents. ",digoxin,hypoglycemic agents,No interaction,"UNIVASC_bf used_bf clinical_bf trials_bf concomitantly_bf calcium-channel-blocking_bf agents_bf ,_bf diuretics_bf ,_bf H2_bf blockers_bf ,_bf DRUG ,_be oral_be hypoglycemic_be agents_be ,_be cholesterol-lowering_be agents_be ._be"
2211,"However, ketoconazole, a potent inhibitor of cytochrome P450 3A4, may increase plasma levels of mometasone furoate during concomitant dosing.",ketoconazole,mometasone furoate,mechanism,"However_bf ,_bf DRUG ,_be potent_be inhibitor_be cytochrome_be P450_be 3A4_be ,_be may_be increase_be plasma_be levels_be mometasone_be furoate_be concomitant_be dosing_be ._be"
2212,Montelukast at a Dose of 10 mg Once Daily Dosed to Pharmacokinetic Steady State  - did not cause clinically significant changes in the kinetics of a single intravenous dose of theophylline (predominantly a cytochrome P450 1A2 substrate). ,Montelukast,theophylline,No interaction,DRUG Dose_be 10_be mg_be Once_be Daily_be Dosed_be Pharmacokinetic_be Steady_be State_be -_be cause_be clinically_be significant_be changes_be kinetics_be single_be intravenous_be dose_be OTHER_DRUG (predominantly_af cytochrome_af P450_af 1A2_af substrate)_af ._af
2213,- did not change the pharmacokinetic profile of warfarin (a substrate of cytochromes P450 2A6 and 2C9) or influence the effect of a single 30-mg oral dose of warfarin on prothrombin time or the INR (International Normalized Ratio). ,warfarin,warfarin,No interaction,-_bf change_bf pharmacokinetic_bf profile_bf DRUG (a_be substrate_be cytochromes_be P450_be 2A6_be 2C9)_be influence_be effect_be single_be 30-mg_be oral_be dose_be DRUG prothrombin_af time_af INR_af (International_af Normalized_af Ratio)_af ._af
2214,"- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. ",terfenadine,fexofenadine,No interaction,"-_bf change_bf plasma_bf concentration_bf profile_bf DRUG (a_be substrate_be cytochrome_be P450_be 3A4)_be OTHER_DRUG ,_af carboxylated_af metabolite_af ,_af prolong_af QTc_af interval_af following_af co-administration_af DRUG 60_af mg_af twice_af daily_af ._af"
2215,"- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. ",terfenadine,terfenadine,No interaction,"-_bf change_bf plasma_bf concentration_bf profile_bf DRUG (a_be substrate_be cytochrome_be P450_be 3A4)_be fexofenadine_be ,_be carboxylated_be metabolite_be ,_be prolong_be QTc_be interval_be following_be co-administration_be DRUG 60_af mg_af twice_af daily_af ._af"
2216,"- did not change the plasma concentration profile of terfenadine (a substrate of cytochrome P450 3A4) or fexofenadine, its carboxylated metabolite, and did not prolong the QTc interval following co-administration with terfenadine 60 mg twice daily. ",fexofenadine,terfenadine,No interaction,"-_bf change_bf plasma_bf concentration_bf profile_bf OTHER_DRUG (a_be substrate_be cytochrome_be P450_be 3A4)_be DRUG ,_af carboxylated_af metabolite_af ,_af prolong_af QTc_af interval_af following_af co-administration_af OTHER_DRUG 60_af mg_af twice_af daily_af ._af"
2217,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,Montelukast,contraceptive,No interaction,DRUG Doses_be 100_be mg_be Daily_be Dosed_be Pharmacokinetic_be Steady_be State:_be -_be significantly_be alter_be plasma_be concentrations_be either_be component_be oral_be OTHER_DRUG containing_af norethindrone_af 1_af mg/ethinyl_af estradiol_af 35_af mcg_af ._af
2218,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,Montelukast,norethindrone,No interaction,DRUG Doses_be 100_be mg_be Daily_be Dosed_be Pharmacokinetic_be Steady_be State:_be -_be significantly_be alter_be plasma_be concentrations_be either_be component_be oral_be contraceptive_be containing_be OTHER_DRUG 1_af mg/ethinyl_af estradiol_af 35_af mcg_af ._af
2219,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,Montelukast,estradiol,No interaction,DRUG Doses_be 100_be mg_be Daily_be Dosed_be Pharmacokinetic_be Steady_be State:_be -_be significantly_be alter_be plasma_be concentrations_be either_be component_be oral_be contraceptive_be containing_be norethindrone_be 1_be mg/ethinyl_be OTHER_DRUG 35_af mcg_af ._af
2220,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,contraceptive,norethindrone,No interaction,Montelukast_bf Doses_bf 100_bf mg_bf Daily_bf Dosed_bf Pharmacokinetic_bf Steady_bf State:_bf -_bf significantly_bf alter_bf plasma_bf concentrations_bf either_bf component_bf oral_bf DRUG containing_be OTHER_DRUG 1_af mg/ethinyl_af estradiol_af 35_af mcg_af ._af
2221,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,contraceptive,estradiol,No interaction,Montelukast_bf Doses_bf 100_bf mg_bf Daily_bf Dosed_bf Pharmacokinetic_bf Steady_bf State:_bf -_bf significantly_bf alter_bf plasma_bf concentrations_bf either_bf component_bf oral_bf DRUG containing_be norethindrone_be 1_be mg/ethinyl_be OTHER_DRUG 35_af mcg_af ._af
2222,Montelukast at Doses of    100 mg Daily Dosed to Pharmacokinetic Steady State:  - did not significantly alter the plasma concentrations of either component of an oral contraceptive containing norethindrone 1 mg/ethinyl estradiol 35 mcg. ,norethindrone,estradiol,No interaction,Montelukast_bf Doses_bf 100_bf mg_bf Daily_bf Dosed_bf Pharmacokinetic_bf Steady_bf State:_bf -_bf significantly_bf alter_bf plasma_bf concentrations_bf either_bf component_bf oral_bf contraceptive_bf containing_bf DRUG 1_be mg/ethinyl_be OTHER_DRUG 35_af mcg_af ._af
2223,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,prednisone,prednisolone,No interaction,-_bf cause_bf clinically_bf significant_bf change_bf plasma_bf profiles_bf DRUG OTHER_DRUG following_af administration_af either_af oral_af DRUG intravenous_af OTHER_DRUG ._af
2224,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,prednisone,prednisone,No interaction,-_bf cause_bf clinically_bf significant_bf change_bf plasma_bf profiles_bf DRUG prednisolone_be following_be administration_be either_be oral_be DRUG intravenous_af prednisolone_af ._af
2225,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,prednisone,prednisolone,No interaction,-_bf cause_bf clinically_bf significant_bf change_bf plasma_bf profiles_bf DRUG OTHER_DRUG following_af administration_af either_af oral_af DRUG intravenous_af OTHER_DRUG ._af
2226,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,prednisolone,prednisone,No interaction,-_bf cause_bf clinically_bf significant_bf change_bf plasma_bf profiles_bf OTHER_DRUG DRUG following_af administration_af either_af oral_af OTHER_DRUG intravenous_af DRUG ._af
2227,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,prednisolone,prednisolone,No interaction,-_bf cause_bf clinically_bf significant_bf change_bf plasma_bf profiles_bf prednisone_bf DRUG following_be administration_be either_be oral_be prednisone_be intravenous_be DRUG ._af
2228,- did not cause any clinically significant change in plasma profiles of prednisone or prednisolone following administration of either oral prednisone or intravenous prednisolone.  ,prednisone,prednisolone,No interaction,-_bf cause_bf clinically_bf significant_bf change_bf plasma_bf profiles_bf DRUG OTHER_DRUG following_af administration_af either_af oral_af DRUG intravenous_af OTHER_DRUG ._af
2229,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",Phenobarbital,montelukast,No interaction,"DRUG ,_be induces_be hepatic_be metabolism_be ,_be decreased_be AUC_be OTHER_DRUG approximately_af 40%_af following_af single_af 10-mg_af dose_af OTHER_DRUG ._af"
2230,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",Phenobarbital,montelukast,No interaction,"DRUG ,_be induces_be hepatic_be metabolism_be ,_be decreased_be AUC_be OTHER_DRUG approximately_af 40%_af following_af single_af 10-mg_af dose_af OTHER_DRUG ._af"
2231,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",montelukast,montelukast,No interaction,"Phenobarbital_bf ,_bf induces_bf hepatic_bf metabolism_bf ,_bf decreased_bf AUC_bf DRUG approximately_be 40%_be following_be single_be 10-mg_be dose_be DRUG ._af"
2232,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",phenobarbital,rifampin,No interaction,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf DRUG OTHER_DRUG ,_af co-administered_af montelukast_af ._af"
2233,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",phenobarbital,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf DRUG rifampin_be ,_be co-administered_be OTHER_DRUG ._af"
2234,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast. ",rifampin,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf phenobarbital_bf DRUG ,_be co-administered_be OTHER_DRUG ._af"
2235,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",montelukast,theophylline,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf DRUG clinically_be important_be effects_be pharmacokinetics_be following_be drugs:_be OTHER_DRUG ,_af prednisone_af ,_af prednisolone_af ,_af oral_af contraceptives_af (norethindrone_af 1_af mg/ethinyl_af estradiol_af 35_af mcg)_af ,_af terfenadine_af ,_af digoxin_af ,_af warfarin_af ._af"
2236,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",montelukast,prednisone,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf DRUG clinically_be important_be effects_be pharmacokinetics_be following_be drugs:_be theophylline_be ,_be OTHER_DRUG ,_af prednisolone_af ,_af oral_af contraceptives_af (norethindrone_af 1_af mg/ethinyl_af estradiol_af 35_af mcg)_af ,_af terfenadine_af ,_af digoxin_af ,_af warfarin_af ._af"
2237,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",montelukast,prednisolone,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf DRUG clinically_be important_be effects_be pharmacokinetics_be following_be drugs:_be theophylline_be ,_be prednisone_be ,_be OTHER_DRUG ,_af oral_af contraceptives_af (norethindrone_af 1_af mg/ethinyl_af estradiol_af 35_af mcg)_af ,_af terfenadine_af ,_af digoxin_af ,_af warfarin_af ._af"
2238,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",montelukast,contraceptives,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf DRUG clinically_be important_be effects_be pharmacokinetics_be following_be drugs:_be theophylline_be ,_be prednisone_be ,_be prednisolone_be ,_be oral_be OTHER_DRUG (norethindrone_af 1_af mg/ethinyl_af estradiol_af 35_af mcg)_af ,_af terfenadine_af ,_af digoxin_af ,_af warfarin_af ._af"
2239,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",montelukast,norethindrone,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf DRUG clinically_be important_be effects_be pharmacokinetics_be following_be drugs:_be theophylline_be ,_be prednisone_be ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be warfarin_be ._be"
2240,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",montelukast,ethinyl estradiol,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf DRUG clinically_be important_be effects_be pharmacokinetics_be following_be drugs:_be theophylline_be ,_be prednisone_be ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be warfarin_be ._be"
2241,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",montelukast,terfenadine,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf DRUG clinically_be important_be effects_be pharmacokinetics_be following_be drugs:_be theophylline_be ,_be prednisone_be ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be OTHER_DRUG ,_af digoxin_af ,_af warfarin_af ._af"
2242,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",montelukast,digoxin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf DRUG clinically_be important_be effects_be pharmacokinetics_be following_be drugs:_be theophylline_be ,_be prednisone_be ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be OTHER_DRUG ,_af warfarin_af ._af"
2243,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",montelukast,warfarin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf DRUG clinically_be important_be effects_be pharmacokinetics_be following_be drugs:_be theophylline_be ,_be prednisone_be ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be OTHER_DRUG ._af"
2244,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",theophylline,prednisone,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf DRUG ,_be OTHER_DRUG ,_af prednisolone_af ,_af oral_af contraceptives_af (norethindrone_af 1_af mg/ethinyl_af estradiol_af 35_af mcg)_af ,_af terfenadine_af ,_af digoxin_af ,_af warfarin_af ._af"
2245,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",theophylline,prednisolone,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf DRUG ,_be prednisone_be ,_be OTHER_DRUG ,_af oral_af contraceptives_af (norethindrone_af 1_af mg/ethinyl_af estradiol_af 35_af mcg)_af ,_af terfenadine_af ,_af digoxin_af ,_af warfarin_af ._af"
2246,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",theophylline,contraceptives,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf DRUG ,_be prednisone_be ,_be prednisolone_be ,_be oral_be OTHER_DRUG (norethindrone_af 1_af mg/ethinyl_af estradiol_af 35_af mcg)_af ,_af terfenadine_af ,_af digoxin_af ,_af warfarin_af ._af"
2247,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",theophylline,norethindrone,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf DRUG ,_be prednisone_be ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be warfarin_be ._be"
2248,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",theophylline,ethinyl estradiol,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf DRUG ,_be prednisone_be ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be warfarin_be ._be"
2249,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",theophylline,terfenadine,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf DRUG ,_be prednisone_be ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be OTHER_DRUG ,_af digoxin_af ,_af warfarin_af ._af"
2250,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",theophylline,digoxin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf DRUG ,_be prednisone_be ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be OTHER_DRUG ,_af warfarin_af ._af"
2251,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",theophylline,warfarin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf DRUG ,_be prednisone_be ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be OTHER_DRUG ._af"
2252,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisone,prednisolone,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf DRUG ,_be OTHER_DRUG ,_af oral_af contraceptives_af (norethindrone_af 1_af mg/ethinyl_af estradiol_af 35_af mcg)_af ,_af terfenadine_af ,_af digoxin_af ,_af warfarin_af ._af"
2253,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisone,contraceptives,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf DRUG ,_be prednisolone_be ,_be oral_be OTHER_DRUG (norethindrone_af 1_af mg/ethinyl_af estradiol_af 35_af mcg)_af ,_af terfenadine_af ,_af digoxin_af ,_af warfarin_af ._af"
2254,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisone,norethindrone,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf DRUG ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be warfarin_be ._be"
2255,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisone,ethinyl estradiol,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf DRUG ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be warfarin_be ._be"
2256,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisone,terfenadine,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf DRUG ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be OTHER_DRUG ,_af digoxin_af ,_af warfarin_af ._af"
2257,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisone,digoxin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf DRUG ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be OTHER_DRUG ,_af warfarin_af ._af"
2258,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisone,warfarin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf DRUG ,_be prednisolone_be ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be OTHER_DRUG ._af"
2259,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisolone,contraceptives,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf DRUG ,_be oral_be OTHER_DRUG (norethindrone_af 1_af mg/ethinyl_af estradiol_af 35_af mcg)_af ,_af terfenadine_af ,_af digoxin_af ,_af warfarin_af ._af"
2260,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisolone,norethindrone,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf DRUG ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be warfarin_be ._be"
2261,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisolone,ethinyl estradiol,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf DRUG ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be warfarin_be ._be"
2262,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisolone,terfenadine,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf DRUG ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be OTHER_DRUG ,_af digoxin_af ,_af warfarin_af ._af"
2263,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisolone,digoxin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf DRUG ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be OTHER_DRUG ,_af warfarin_af ._af"
2264,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",prednisolone,warfarin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf DRUG ,_be oral_be contraceptives_be (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be OTHER_DRUG ._af"
2265,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",contraceptives,norethindrone,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf DRUG (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be warfarin_be ._be"
2266,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",contraceptives,ethinyl estradiol,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf DRUG (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be warfarin_be ._be"
2267,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",contraceptives,terfenadine,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf DRUG (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be OTHER_DRUG ,_af digoxin_af ,_af warfarin_af ._af"
2268,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",contraceptives,digoxin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf DRUG (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be OTHER_DRUG ,_af warfarin_af ._af"
2269,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",contraceptives,warfarin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf DRUG (norethindrone_be 1_be mg/ethinyl_be estradiol_be 35_be mcg)_be ,_be terfenadine_be ,_be digoxin_be ,_be OTHER_DRUG ._af"
2270,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",norethindrone,ethinyl estradiol,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf contraceptives_bf (norethindrone_bf 1_bf mg/ethinyl_bf estradiol_bf 35_bf mcg)_bf ,_bf terfenadine_bf ,_bf digoxin_bf ,_bf warfarin_bf ._bf"
2271,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",norethindrone,terfenadine,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf contraceptives_bf (norethindrone_bf 1_bf mg/ethinyl_bf estradiol_bf 35_bf mcg)_bf ,_bf OTHER_DRUG ,_be digoxin_be ,_be warfarin_be ._be"
2272,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",norethindrone,digoxin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf contraceptives_bf (norethindrone_bf 1_bf mg/ethinyl_bf estradiol_bf 35_bf mcg)_bf ,_bf terfenadine_bf ,_bf OTHER_DRUG ,_be warfarin_be ._be"
2273,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",norethindrone,warfarin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf contraceptives_bf (norethindrone_bf 1_bf mg/ethinyl_bf estradiol_bf 35_bf mcg)_bf ,_bf terfenadine_bf ,_bf digoxin_bf ,_bf OTHER_DRUG ._be"
2274,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",ethinyl estradiol,terfenadine,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf contraceptives_bf (norethindrone_bf 1_bf mg/ethinyl_bf estradiol_bf 35_bf mcg)_bf ,_bf OTHER_DRUG ,_be digoxin_be ,_be warfarin_be ._be"
2275,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",ethinyl estradiol,digoxin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf contraceptives_bf (norethindrone_bf 1_bf mg/ethinyl_bf estradiol_bf 35_bf mcg)_bf ,_bf terfenadine_bf ,_bf OTHER_DRUG ,_be warfarin_be ._be"
2276,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",ethinyl estradiol,warfarin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf contraceptives_bf (norethindrone_bf 1_bf mg/ethinyl_bf estradiol_bf 35_bf mcg)_bf ,_bf terfenadine_bf ,_bf digoxin_bf ,_bf OTHER_DRUG ._be"
2277,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",terfenadine,digoxin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf contraceptives_bf (norethindrone_bf 1_bf mg/ethinyl_bf estradiol_bf 35_bf mcg)_bf ,_bf DRUG ,_be OTHER_DRUG ,_af warfarin_af ._af"
2278,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",terfenadine,warfarin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf contraceptives_bf (norethindrone_bf 1_bf mg/ethinyl_bf estradiol_bf 35_bf mcg)_bf ,_bf DRUG ,_be digoxin_be ,_be OTHER_DRUG ._af"
2279,"In drug-interaction studies, the recommended clinical dose of montelukast did not have clinically important effects on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (norethindrone 1 mg/ethinyl estradiol 35 mcg), terfenadine, digoxin, and warfarin. ",digoxin,warfarin,No interaction,"In_bf drug-interaction_bf studies_bf ,_bf recommended_bf clinical_bf dose_bf montelukast_bf clinically_bf important_bf effects_bf pharmacokinetics_bf following_bf drugs:_bf theophylline_bf ,_bf prednisone_bf ,_bf prednisolone_bf ,_bf oral_bf contraceptives_bf (norethindrone_bf 1_bf mg/ethinyl_bf estradiol_bf 35_bf mcg)_bf ,_bf terfenadine_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
2280,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",thyroid hormones,sedative hypnotics,No interaction,"These_bf medications_bf included_bf thyroid_bf hormones_bf ,_bf sedative_bf hypnotics_bf ,_bf non-steroidal_bf anti-inflammatory_bf agents_bf ,_bf benzodiazepines_bf ,_bf decongestants_bf ._bf"
2281,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",thyroid hormones,non-steroidal anti-inflammatory agents,No interaction,"These_bf medications_bf included_bf thyroid_bf hormones_bf ,_bf sedative_bf hypnotics_bf ,_bf non-steroidal_bf anti-inflammatory_bf agents_bf ,_bf benzodiazepines_bf ,_bf decongestants_bf ._bf"
2282,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",thyroid hormones,benzodiazepines,No interaction,"These_bf medications_bf included_bf thyroid_bf hormones_bf ,_bf sedative_bf hypnotics_bf ,_bf non-steroidal_bf anti-inflammatory_bf agents_bf ,_bf OTHER_DRUG ,_be decongestants_be ._be"
2283,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",thyroid hormones,decongestants,No interaction,"These_bf medications_bf included_bf thyroid_bf hormones_bf ,_bf sedative_bf hypnotics_bf ,_bf non-steroidal_bf anti-inflammatory_bf agents_bf ,_bf benzodiazepines_bf ,_bf OTHER_DRUG ._be"
2284,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",sedative hypnotics,non-steroidal anti-inflammatory agents,No interaction,"These_bf medications_bf included_bf thyroid_bf hormones_bf ,_bf sedative_bf hypnotics_bf ,_bf non-steroidal_bf anti-inflammatory_bf agents_bf ,_bf benzodiazepines_bf ,_bf decongestants_bf ._bf"
2285,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",sedative hypnotics,benzodiazepines,No interaction,"These_bf medications_bf included_bf thyroid_bf hormones_bf ,_bf sedative_bf hypnotics_bf ,_bf non-steroidal_bf anti-inflammatory_bf agents_bf ,_bf OTHER_DRUG ,_be decongestants_be ._be"
2286,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",sedative hypnotics,decongestants,No interaction,"These_bf medications_bf included_bf thyroid_bf hormones_bf ,_bf sedative_bf hypnotics_bf ,_bf non-steroidal_bf anti-inflammatory_bf agents_bf ,_bf benzodiazepines_bf ,_bf OTHER_DRUG ._be"
2287,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",non-steroidal anti-inflammatory agents,benzodiazepines,No interaction,"These_bf medications_bf included_bf thyroid_bf hormones_bf ,_bf sedative_bf hypnotics_bf ,_bf non-steroidal_bf anti-inflammatory_bf agents_bf ,_bf OTHER_DRUG ,_be decongestants_be ._be"
2288,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",non-steroidal anti-inflammatory agents,decongestants,No interaction,"These_bf medications_bf included_bf thyroid_bf hormones_bf ,_bf sedative_bf hypnotics_bf ,_bf non-steroidal_bf anti-inflammatory_bf agents_bf ,_bf benzodiazepines_bf ,_bf OTHER_DRUG ._be"
2289,"These medications included thyroid hormones, sedative hypnotics, non-steroidal anti-inflammatory agents, benzodiazepines, and decongestants. ",benzodiazepines,decongestants,No interaction,"These_bf medications_bf included_bf thyroid_bf hormones_bf ,_bf sedative_bf hypnotics_bf ,_bf non-steroidal_bf anti-inflammatory_bf agents_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
2290,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",Phenobarbital,montelukast,No interaction,"DRUG ,_be induces_be hepatic_be metabolism_be ,_be decreased_be AUC_be OTHER_DRUG approximately_af 40%_af following_af single_af 10-mg_af dose_af OTHER_DRUG ._af"
2291,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",Phenobarbital,montelukast,No interaction,"DRUG ,_be induces_be hepatic_be metabolism_be ,_be decreased_be AUC_be OTHER_DRUG approximately_af 40%_af following_af single_af 10-mg_af dose_af OTHER_DRUG ._af"
2292,"Phenobarbital, which induces hepatic metabolism, decreased the AUC of montelukast approximately 40% following a single 10-mg dose of montelukast. ",montelukast,montelukast,No interaction,"Phenobarbital_bf ,_bf induces_bf hepatic_bf metabolism_bf ,_bf decreased_bf AUC_bf DRUG approximately_be 40%_be following_be single_be 10-mg_be dose_be DRUG ._af"
2293,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",phenobarbital,rifampin,No interaction,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf DRUG OTHER_DRUG ,_af co-administered_af montelukast_af ._af"
2294,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",phenobarbital,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf DRUG rifampin_be ,_be co-administered_be OTHER_DRUG ._af"
2295,"It is reasonable to employ appropriate clinical monitoring when potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast.",rifampin,montelukast,advise,"It_bf reasonable_bf employ_bf appropriate_bf clinical_bf monitoring_bf potent_bf cytochrome_bf P450_bf enzyme_bf inducers_bf ,_bf phenobarbital_bf DRUG ,_be co-administered_be OTHER_DRUG ._af"
2296,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",Central Nervous System Depressants,morphine,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf OTHER_DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be sedatives_be ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
2297,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",Central Nervous System Depressants,CNS depressants,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf alcohol_bf ,_bf sedatives_bf ,_bf antihistaminics_bf ,_bf psychotropic_bf drugs_bf ._bf"
2298,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",Central Nervous System Depressants,alcohol,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf OTHER_DRUG ,_be sedatives_be ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
2299,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",Central Nervous System Depressants,sedatives,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf alcohol_bf ,_bf OTHER_DRUG ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
2300,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",Central Nervous System Depressants,antihistaminics,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf alcohol_bf ,_bf sedatives_bf ,_bf OTHER_DRUG ,_be psychotropic_be drugs_be ._be"
2301,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",Central Nervous System Depressants,psychotropic drugs,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf alcohol_bf ,_bf sedatives_bf ,_bf antihistaminics_bf ,_bf psychotropic_bf drugs_bf ._bf"
2302,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,CNS depressants,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be sedatives_be ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
2303,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,alcohol,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be OTHER_DRUG ,_af sedatives_af ,_af antihistaminics_af ,_af psychotropic_af drugs_af ._af"
2304,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,sedatives,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be OTHER_DRUG ,_af antihistaminics_af ,_af psychotropic_af drugs_af ._af"
2305,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,antihistaminics,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be sedatives_be ,_be OTHER_DRUG ,_af psychotropic_af drugs_af ._af"
2306,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",morphine,psychotropic drugs,effect,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf DRUG potentiated_be presence_be CNS_be depressants_be alcohol_be ,_be sedatives_be ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
2307,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",CNS depressants,alcohol,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf OTHER_DRUG ,_be sedatives_be ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
2308,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",CNS depressants,sedatives,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf alcohol_bf ,_bf OTHER_DRUG ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
2309,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",CNS depressants,antihistaminics,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf alcohol_bf ,_bf sedatives_bf ,_bf OTHER_DRUG ,_be psychotropic_be drugs_be ._be"
2310,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",CNS depressants,psychotropic drugs,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf alcohol_bf ,_bf sedatives_bf ,_bf antihistaminics_bf ,_bf psychotropic_bf drugs_bf ._bf"
2311,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",alcohol,sedatives,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf DRUG ,_be OTHER_DRUG ,_af antihistaminics_af ,_af psychotropic_af drugs_af ._af"
2312,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",alcohol,antihistaminics,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf DRUG ,_be sedatives_be ,_be OTHER_DRUG ,_af psychotropic_af drugs_af ._af"
2313,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",alcohol,psychotropic drugs,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf DRUG ,_be sedatives_be ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
2314,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",sedatives,antihistaminics,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf alcohol_bf ,_bf DRUG ,_be OTHER_DRUG ,_af psychotropic_af drugs_af ._af"
2315,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",sedatives,psychotropic drugs,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf alcohol_bf ,_bf DRUG ,_be antihistaminics_be ,_be psychotropic_be drugs_be ._be"
2316,"Use with Other Central Nervous System Depressants: The depressant effects of morphine are potentiated by the presence of other CNS depressants such as alcohol, sedatives, antihistaminics, or psychotropic drugs. ",antihistaminics,psychotropic drugs,No interaction,"Use_bf Other_bf Central_bf Nervous_bf System_bf Depressants:_bf The_bf depressant_bf effects_bf morphine_bf potentiated_bf presence_bf CNS_bf depressants_bf alcohol_bf ,_bf sedatives_bf ,_bf DRUG ,_be psychotropic_be drugs_be ._be"
2317,"Use of neuroleptics in conjunction with oral morphine may increase the risk of respiratory depression, hypotension and profound sedation or coma. ",neuroleptics,morphine,effect,"Use_bf DRUG conjunction_be oral_be OTHER_DRUG may_af increase_af risk_af respiratory_af depression_af ,_af hypotension_af profound_af sedation_af coma_af ._af"
2318,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Mixed Agonist/Antagonist Opioid Analgesics,Agonist/antagonist analgesics,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf buprenorphine)_bf NOT_bf administered_bf patients_bf received_bf receiving_bf course_bf therapy_bf proof_bf opioid_bf agonist_bf analgesic_bf ._bf"
2319,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Mixed Agonist/Antagonist Opioid Analgesics,pentazocine,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf OTHER_DRUG ,_be nalbuphine_be ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2320,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Mixed Agonist/Antagonist Opioid Analgesics,nalbuphine,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf OTHER_DRUG ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2321,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Mixed Agonist/Antagonist Opioid Analgesics,butorphanol,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf OTHER_DRUG ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2322,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Mixed Agonist/Antagonist Opioid Analgesics,buprenorphine,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf buprenorphine)_bf NOT_bf administered_bf patients_bf received_bf receiving_bf course_bf therapy_bf proof_bf opioid_bf agonist_bf analgesic_bf ._bf"
2323,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Mixed Agonist/Antagonist Opioid Analgesics,opioid agonist analgesic,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf buprenorphine)_bf NOT_bf administered_bf patients_bf received_bf receiving_bf course_bf therapy_bf proof_bf opioid_bf agonist_bf analgesic_bf ._bf"
2324,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Agonist/antagonist analgesics,pentazocine,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf OTHER_DRUG ,_be nalbuphine_be ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2325,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Agonist/antagonist analgesics,nalbuphine,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf OTHER_DRUG ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2326,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Agonist/antagonist analgesics,butorphanol,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf OTHER_DRUG ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2327,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Agonist/antagonist analgesics,buprenorphine,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf buprenorphine)_bf NOT_bf administered_bf patients_bf received_bf receiving_bf course_bf therapy_bf proof_bf opioid_bf agonist_bf analgesic_bf ._bf"
2328,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",Agonist/antagonist analgesics,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf buprenorphine)_bf NOT_bf administered_bf patients_bf received_bf receiving_bf course_bf therapy_bf proof_bf opioid_bf agonist_bf analgesic_bf ._bf"
2329,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",pentazocine,nalbuphine,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af butorphanol_af ,_af buprenorphine)_af NOT_af administered_af patients_af received_af receiving_af course_af therapy_af proof_af opioid_af agonist_af analgesic_af ._af"
2330,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",pentazocine,butorphanol,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf DRUG ,_be nalbuphine_be ,_be OTHER_DRUG ,_af buprenorphine)_af NOT_af administered_af patients_af received_af receiving_af course_af therapy_af proof_af opioid_af agonist_af analgesic_af ._af"
2331,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",pentazocine,buprenorphine,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf DRUG ,_be nalbuphine_be ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2332,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",pentazocine,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf DRUG ,_be nalbuphine_be ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2333,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",nalbuphine,butorphanol,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af buprenorphine)_af NOT_af administered_af patients_af received_af receiving_af course_af therapy_af proof_af opioid_af agonist_af analgesic_af ._af"
2334,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",nalbuphine,buprenorphine,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf DRUG ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2335,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",nalbuphine,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf DRUG ,_be butorphanol_be ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2336,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",butorphanol,buprenorphine,No interaction,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf DRUG ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2337,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",butorphanol,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf DRUG ,_be buprenorphine)_be NOT_be administered_be patients_be received_be receiving_be course_be therapy_be proof_be opioid_be agonist_be analgesic_be ._be"
2338,"Interaction with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, or buprenorphine) should NOT be administered to patients who have received or are receiving a course of therapy with a proof opioid agonist analgesic. ",buprenorphine,opioid agonist analgesic,advise,"Interaction_bf Mixed_bf Agonist/Antagonist_bf Opioid_bf Analgesics:_bf Agonist/antagonist_bf analgesics_bf (i_bf ._bf ._bf ,_bf pentazocine_bf ,_bf nalbuphine_bf ,_bf butorphanol_bf ,_bf buprenorphine)_bf NOT_bf administered_bf patients_bf received_bf receiving_bf course_bf therapy_bf proof_bf opioid_bf agonist_bf analgesic_bf ._bf"
2339,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Antacids,Myfortic,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf OTHER_DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be DRUG (30_af mL):_af mean_af Cmax_af AUC(0-t)_af values_af MPA_af 25%_af 37%_af lower_af ,_af respectively_af ,_af OTHER_DRUG administered_af alone_af fasting_af conditions_af ._af"
2340,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Antacids,magnesium,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf Myfortic_bf decreased_bf administered_bf 12_bf stable_bf renal_bf transplant_bf patients_bf also_bf taking_bf magnesium-aluminum_bf containing_bf DRUG (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be Myfortic_be administered_be alone_be fasting_be conditions_be ._be"
2341,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Antacids,aluminum,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf Myfortic_bf decreased_bf administered_bf 12_bf stable_bf renal_bf transplant_bf patients_bf also_bf taking_bf magnesium-aluminum_bf containing_bf DRUG (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be Myfortic_be administered_be alone_be fasting_be conditions_be ._be"
2342,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Antacids,antacids,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf Myfortic_bf decreased_bf administered_bf 12_bf stable_bf renal_bf transplant_bf patients_bf also_bf taking_bf magnesium-aluminum_bf containing_bf DRUG (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be Myfortic_be administered_be alone_be fasting_be conditions_be ._be"
2343,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Antacids,Myfortic,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf OTHER_DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be DRUG (30_af mL):_af mean_af Cmax_af AUC(0-t)_af values_af MPA_af 25%_af 37%_af lower_af ,_af respectively_af ,_af OTHER_DRUG administered_af alone_af fasting_af conditions_af ._af"
2344,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,magnesium,mechanism,"Antacids:_bf Absorption_bf single_bf dose_bf DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be antacids_be (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be DRUG administered_af alone_af fasting_af conditions_af ._af"
2345,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,aluminum,mechanism,"Antacids:_bf Absorption_bf single_bf dose_bf DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be antacids_be (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be DRUG administered_af alone_af fasting_af conditions_af ._af"
2346,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,antacids,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be OTHER_DRUG (30_af mL):_af mean_af Cmax_af AUC(0-t)_af values_af MPA_af 25%_af 37%_af lower_af ,_af respectively_af ,_af DRUG administered_af alone_af fasting_af conditions_af ._af"
2347,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",Myfortic,Myfortic,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be antacids_be (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be DRUG administered_af alone_af fasting_af conditions_af ._af"
2348,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",magnesium,aluminum,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf Myfortic_bf decreased_bf administered_bf 12_bf stable_bf renal_bf transplant_bf patients_bf also_bf taking_bf magnesium-aluminum_bf containing_bf antacids_bf (30_bf mL):_bf mean_bf Cmax_bf AUC(0-t)_bf values_bf MPA_bf 25%_bf 37%_bf lower_bf ,_bf respectively_bf ,_bf Myfortic_bf administered_bf alone_bf fasting_bf conditions_bf ._bf"
2349,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",magnesium,antacids,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf Myfortic_bf decreased_bf administered_bf 12_bf stable_bf renal_bf transplant_bf patients_bf also_bf taking_bf magnesium-aluminum_bf containing_bf OTHER_DRUG (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be Myfortic_be administered_be alone_be fasting_be conditions_be ._be"
2350,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",magnesium,Myfortic,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf OTHER_DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be antacids_be (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be OTHER_DRUG administered_af alone_af fasting_af conditions_af ._af"
2351,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",aluminum,antacids,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf Myfortic_bf decreased_bf administered_bf 12_bf stable_bf renal_bf transplant_bf patients_bf also_bf taking_bf magnesium-aluminum_bf containing_bf OTHER_DRUG (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be Myfortic_be administered_be alone_be fasting_be conditions_be ._be"
2352,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",aluminum,Myfortic,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf OTHER_DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be antacids_be (30_be mL):_be mean_be Cmax_be AUC(0-t)_be values_be MPA_be 25%_be 37%_be lower_be ,_be respectively_be ,_be OTHER_DRUG administered_af alone_af fasting_af conditions_af ._af"
2353,"Antacids: Absorption of a single dose of Myfortic was decreased when administered to 12 stable renal transplant patients also taking magnesium-aluminum containing antacids (30 mL): the mean Cmax and AUC(0-t) values for MPA were 25% and 37% lower, respectively, than when Myfortic was administered alone under fasting conditions. ",antacids,Myfortic,No interaction,"Antacids:_bf Absorption_bf single_bf dose_bf OTHER_DRUG decreased_be administered_be 12_be stable_be renal_be transplant_be patients_be also_be taking_be magnesium-aluminum_be containing_be DRUG (30_af mL):_af mean_af Cmax_af AUC(0-t)_af values_af MPA_af 25%_af 37%_af lower_af ,_af respectively_af ,_af OTHER_DRUG administered_af alone_af fasting_af conditions_af ._af"
2354,It is recommended that Myfortic and antacids not be administered simultaneously. ,Myfortic,antacids,advise,It_bf recommended_bf DRUG OTHER_DRUG administered_af simultaneously_af ._af
2355,"Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. ",Cyclosporine,cyclosporine,No interaction,"Cyclosporine:_bf When_bf studied_bf stable_bf renal_bf transplant_bf patients_bf ,_bf DRUG ,_be USP_be (MODIFIED)_be pharmacokinetics_be unaffected_be steady_be state_be dosing_be Myfortic_be ._be"
2356,"Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. ",Cyclosporine,Myfortic,No interaction,"Cyclosporine:_bf When_bf studied_bf stable_bf renal_bf transplant_bf patients_bf ,_bf DRUG ,_be USP_be (MODIFIED)_be pharmacokinetics_be unaffected_be steady_be state_be dosing_be OTHER_DRUG ._af"
2357,"Cyclosporine: When studied in stable renal transplant patients, cyclosporine, USP (MODIFIED) pharmacokinetics were unaffected by steady state dosing of Myfortic. ",cyclosporine,Myfortic,No interaction,"Cyclosporine:_bf When_bf studied_bf stable_bf renal_bf transplant_bf patients_bf ,_bf DRUG ,_be USP_be (MODIFIED)_be pharmacokinetics_be unaffected_be steady_be state_be dosing_be OTHER_DRUG ._af"
2358,Acyclovir/Ganciclovir: may be taken with Myfortic; ,Acyclovir,Ganciclovir,No interaction,Acyclovir/Ganciclovir:_bf may_bf taken_bf Myfortic;_bf
2359,Acyclovir/Ganciclovir: may be taken with Myfortic; ,Acyclovir,Myfortic,No interaction,Acyclovir/Ganciclovir:_bf may_bf taken_bf Myfortic;_bf
2360,Acyclovir/Ganciclovir: may be taken with Myfortic; ,Ganciclovir,Myfortic,No interaction,Acyclovir/Ganciclovir:_bf may_bf taken_bf Myfortic;_bf
2361,"Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",acyclovir,ganciclovir,No interaction,"Both_bf acyclovir/ganciclovir_bf MPAG_bf concentrations_bf increased_bf presence_bf renal_bf impairment_bf ,_bf coexistence_bf may_bf compete_bf tubular_bf secretion_bf increase_bf concentrations_bf two_bf ._bf"
2362,"Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",acyclovir,MPAG,No interaction,"Both_bf acyclovir/ganciclovir_bf OTHER_DRUG concentrations_be increased_be presence_be renal_be impairment_be ,_be coexistence_be may_be compete_be tubular_be secretion_be increase_be concentrations_be two_be ._be"
2363,"Both acyclovir/ganciclovir and MPAG concentrations are increased in the presence of renal impairment, their coexistence may compete for tubular secretion and further increase in the concentrations of the two. ",ganciclovir,MPAG,No interaction,"Both_bf acyclovir/ganciclovir_bf OTHER_DRUG concentrations_be increased_be presence_be renal_be impairment_be ,_be coexistence_be may_be compete_be tubular_be secretion_be increase_be concentrations_be two_be ._be"
2364,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Azathioprine,Mycophenolate Mofetil,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be DRUG mycophenolate_af mofetil_af ._af"
2365,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Azathioprine,azathioprine,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be DRUG mycophenolate_af mofetil_af ._af"
2366,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Azathioprine,mycophenolate mofetil,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be DRUG mycophenolate_af mofetil_af ._af"
2367,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Azathioprine,Myfortic,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be OTHER_DRUG administered_af concomitantly_af DRUG mycophenolate_af mofetil_af ._af"
2368,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Azathioprine,azathioprine,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be DRUG mycophenolate_af mofetil_af ._af"
2369,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Azathioprine,mycophenolate mofetil,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be DRUG mycophenolate_af mofetil_af ._af"
2370,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Mycophenolate Mofetil,azathioprine,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf OTHER_DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be OTHER_DRUG mycophenolate_af mofetil_af ._af"
2371,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Mycophenolate Mofetil,mycophenolate mofetil,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf azathioprine_bf mycophenolate_bf mofetil_bf inhibit_bf purine_bf metabolism_bf ,_bf recommended_bf Myfortic_bf administered_bf concomitantly_bf azathioprine_bf mycophenolate_bf mofetil_bf ._bf"
2372,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Mycophenolate Mofetil,Myfortic,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf azathioprine_bf mycophenolate_bf mofetil_bf inhibit_bf purine_bf metabolism_bf ,_bf recommended_bf OTHER_DRUG administered_be concomitantly_be azathioprine_be mycophenolate_be mofetil_be ._be"
2373,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Mycophenolate Mofetil,azathioprine,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf OTHER_DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be OTHER_DRUG mycophenolate_af mofetil_af ._af"
2374,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Mycophenolate Mofetil,mycophenolate mofetil,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf azathioprine_bf mycophenolate_bf mofetil_bf inhibit_bf purine_bf metabolism_bf ,_bf recommended_bf Myfortic_bf administered_bf concomitantly_bf azathioprine_bf mycophenolate_bf mofetil_bf ._bf"
2375,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",azathioprine,mycophenolate mofetil,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be DRUG mycophenolate_af mofetil_af ._af"
2376,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",azathioprine,Myfortic,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be OTHER_DRUG administered_af concomitantly_af DRUG mycophenolate_af mofetil_af ._af"
2377,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",azathioprine,azathioprine,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be DRUG mycophenolate_af mofetil_af ._af"
2378,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",azathioprine,mycophenolate mofetil,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be DRUG mycophenolate_af mofetil_af ._af"
2379,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",mycophenolate mofetil,Myfortic,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf azathioprine_bf mycophenolate_bf mofetil_bf inhibit_bf purine_bf metabolism_bf ,_bf recommended_bf OTHER_DRUG administered_be concomitantly_be azathioprine_be mycophenolate_be mofetil_be ._be"
2380,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",mycophenolate mofetil,azathioprine,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf OTHER_DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be OTHER_DRUG mycophenolate_af mofetil_af ._af"
2381,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",mycophenolate mofetil,mycophenolate mofetil,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf azathioprine_bf mycophenolate_bf mofetil_bf inhibit_bf purine_bf metabolism_bf ,_bf recommended_bf Myfortic_bf administered_bf concomitantly_bf azathioprine_bf mycophenolate_bf mofetil_bf ._bf"
2382,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Myfortic,azathioprine,advise,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf OTHER_DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be DRUG administered_af concomitantly_af OTHER_DRUG mycophenolate_af mofetil_af ._af"
2383,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",Myfortic,mycophenolate mofetil,advise,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf azathioprine_bf mycophenolate_bf mofetil_bf inhibit_bf purine_bf metabolism_bf ,_bf recommended_bf DRUG administered_be concomitantly_be azathioprine_be mycophenolate_be mofetil_be ._be"
2384,"Azathioprine/Mycophenolate Mofetil: Given that azathioprine and mycophenolate mofetil inhibit purine metabolism, it is recommended that Myfortic not be administered concomitantly with azathioprine or mycophenolate mofetil. ",azathioprine,mycophenolate mofetil,No interaction,"Azathioprine/Mycophenolate_bf Mofetil:_bf Given_bf DRUG mycophenolate_be mofetil_be inhibit_be purine_be metabolism_be ,_be recommended_be Myfortic_be administered_be concomitantly_be DRUG mycophenolate_af mofetil_af ._af"
2385,Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. ,Cholestyramine,MPA,No interaction,DRUG Drugs_be Bind_be Bile_be Acids:_be These_be drugs_be interrupt_be enterohepatic_be recirculation_be reduce_be OTHER_DRUG exposure_af coadministered_af mycophenolate_af mofetil_af ._af
2386,Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. ,Cholestyramine,mycophenolate mofetil,No interaction,DRUG Drugs_be Bind_be Bile_be Acids:_be These_be drugs_be interrupt_be enterohepatic_be recirculation_be reduce_be MPA_be exposure_be coadministered_be mycophenolate_be mofetil_be ._be
2387,Cholestyramine and Drugs that Bind Bile Acids: These drugs interrupt enterohepatic recirculation and reduce MPA exposure when coadministered with mycophenolate mofetil. ,MPA,mycophenolate mofetil,No interaction,Cholestyramine_bf Drugs_bf Bind_bf Bile_bf Acids:_bf These_bf drugs_bf interrupt_bf enterohepatic_bf recirculation_bf reduce_bf DRUG exposure_be coadministered_be mycophenolate_be mofetil_be ._be
2388,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",Myfortic,cholestyramine,advise,"Therefore_bf ,_bf administer_bf DRUG OTHER_DRUG agents_af may_af interfere_af enterohepatic_af recirculation_af drugs_af may_af bind_af bile_af acids_af ,_af example_af bile_af acid_af sequestrates_af oral_af activated_af charcoal_af ,_af potential_af reduce_af efficacy_af DRUG ._af"
2389,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",Myfortic,activated charcoal,advise,"Therefore_bf ,_bf administer_bf DRUG cholestyramine_be agents_be may_be interfere_be enterohepatic_be recirculation_be drugs_be may_be bind_be bile_be acids_be ,_be example_be bile_be acid_be sequestrates_be oral_be activated_be charcoal_be ,_be potential_be reduce_be efficacy_be DRUG ._af"
2390,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",Myfortic,Myfortic,No interaction,"Therefore_bf ,_bf administer_bf DRUG cholestyramine_be agents_be may_be interfere_be enterohepatic_be recirculation_be drugs_be may_be bind_be bile_be acids_be ,_be example_be bile_be acid_be sequestrates_be oral_be activated_be charcoal_be ,_be potential_be reduce_be efficacy_be DRUG ._af"
2391,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",cholestyramine,activated charcoal,No interaction,"Therefore_bf ,_bf administer_bf Myfortic_bf DRUG agents_be may_be interfere_be enterohepatic_be recirculation_be drugs_be may_be bind_be bile_be acids_be ,_be example_be bile_be acid_be sequestrates_be oral_be activated_be charcoal_be ,_be potential_be reduce_be efficacy_be Myfortic_be ._be"
2392,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",cholestyramine,Myfortic,No interaction,"Therefore_bf ,_bf administer_bf OTHER_DRUG DRUG agents_af may_af interfere_af enterohepatic_af recirculation_af drugs_af may_af bind_af bile_af acids_af ,_af example_af bile_af acid_af sequestrates_af oral_af activated_af charcoal_af ,_af potential_af reduce_af efficacy_af OTHER_DRUG ._af"
2393,"Therefore, do not administer Myfortic with cholestyramine or other agents that may interfere with enterohepatic recirculation or drugs that may bind bile acids, for example bile acid sequestrates or oral activated charcoal, because of the potential to reduce the efficacy of Myfortic. ",activated charcoal,Myfortic,No interaction,"Therefore_bf ,_bf administer_bf OTHER_DRUG cholestyramine_be agents_be may_be interfere_be enterohepatic_be recirculation_be drugs_be may_be bind_be bile_be acids_be ,_be example_be bile_be acid_be sequestrates_be oral_be activated_be charcoal_be ,_be potential_be reduce_be efficacy_be OTHER_DRUG ._af"
2394,"Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected. ",Contraceptives,Myfortic,No interaction,"Oral_bf Contraceptives:_bf Given_bf different_bf metabolism_bf OTHER_DRUG oral_be DRUG ,_af drug_af interaction_af two_af classes_af drug_af expected_af ._af"
2395,"Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected. ",Contraceptives,contraceptives,No interaction,"Oral_bf Contraceptives:_bf Given_bf different_bf metabolism_bf Myfortic_bf oral_bf DRUG ,_be drug_be interaction_be two_be classes_be drug_be expected_be ._be"
2396,"Oral Contraceptives: Given the different metabolism of Myfortic and oral contraceptives, no drug interaction between these two classes of drug is expected. ",Myfortic,contraceptives,No interaction,"Oral_bf Contraceptives:_bf Given_bf different_bf metabolism_bf DRUG oral_be OTHER_DRUG ,_af drug_af interaction_af two_af classes_af drug_af expected_af ._af"
2397,"However, in a drug-drug interaction study, mean levonorgesterol AUC was decreased by 15% when coadministered with mycophenolate mofetil. ",levonorgesterol,mycophenolate mofetil,mechanism,"However_bf ,_bf drug-drug_bf interaction_bf study_bf ,_bf mean_bf DRUG AUC_be decreased_be 15%_be coadministered_be mycophenolate_be mofetil_be ._be"
2398,"Therefore, it is recommended that oral contraceptives are co- administered with Myfortic with caution and additional birth control methods be considered. ",contraceptives,Myfortic,advise,"Therefore_bf ,_bf recommended_bf oral_bf DRUG co-_be administered_be OTHER_DRUG caution_af additional_af birth_af control_af methods_af considered_af ._af"
2399,"Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",Live Vaccines,Myfortic,No interaction,"Live_bf Vaccines:_bf During_bf treatment_bf OTHER_DRUG ,_be use_be live_be attenuated_be vaccines_be avoided_be patients_be advised_be vaccinations_be may_be less_be effective_be ._be"
2400,"Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",Live Vaccines,live attenuated vaccines,No interaction,"Live_bf Vaccines:_bf During_bf treatment_bf Myfortic_bf ,_bf use_bf live_bf attenuated_bf vaccines_bf avoided_bf patients_bf advised_bf vaccinations_bf may_bf less_bf effective_bf ._bf"
2401,"Live Vaccines: During treatment with Myfortic, the use of live attenuated vaccines should be avoided and patients should be advised that vaccinations may be less effective. ",Myfortic,live attenuated vaccines,advise,"Live_bf Vaccines:_bf During_bf treatment_bf DRUG ,_be use_be live_be attenuated_be vaccines_be avoided_be patients_be advised_be vaccinations_be may_be less_be effective_be ._be"
2402,Interference of MPAG hydrolysis may lead to less MPA available for absorption.,MPAG,MPA,No interaction,Interference_bf DRUG hydrolysis_be may_be lead_be less_be OTHER_DRUG available_af absorption_af ._af
2403,"Because ondansetron is metabolized by hepatic cytochrome P-450 drug-metabolizing enzymes (CYP3A4, CYP2D6, CYP1A2), inducers or inhibitors of these enzymes may change the clearance and, hence, the half-life of ondansetron. ",ondansetron,ondansetron,No interaction,"Because_bf DRUG metabolized_be hepatic_be cytochrome_be P-450_be drug-metabolizing_be enzymes_be (CYP3A4_be ,_be CYP2D6_be ,_be CYP1A2)_be ,_be inducers_be inhibitors_be enzymes_be may_be change_be clearance_be ,_be hence_be ,_be half-life_be DRUG ._af"
2404,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Phenytoin,Carbamazepine,No interaction,"DRUG ,_be OTHER_DRUG ,_af Rifampicin:_af In_af patients_af treated_af potent_af inducers_af CYP3A4_af (i_af ._af ._af ,_af DRUG ,_af OTHER_DRUG ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2405,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Phenytoin,Rifampicin,No interaction,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2406,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Phenytoin,phenytoin,No interaction,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2407,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Phenytoin,carbamazepine,No interaction,"DRUG ,_be OTHER_DRUG ,_af Rifampicin:_af In_af patients_af treated_af potent_af inducers_af CYP3A4_af (i_af ._af ._af ,_af DRUG ,_af OTHER_DRUG ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2408,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Phenytoin,rifampicin,No interaction,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2409,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Phenytoin,ondansetron,No interaction,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2410,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Phenytoin,ondansetron,No interaction,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2411,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Carbamazepine,Rifampicin,No interaction,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2412,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Carbamazepine,phenytoin,No interaction,"OTHER_DRUG ,_be DRUG ,_af Rifampicin:_af In_af patients_af treated_af potent_af inducers_af CYP3A4_af (i_af ._af ._af ,_af OTHER_DRUG ,_af DRUG ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2413,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Carbamazepine,carbamazepine,No interaction,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2414,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Carbamazepine,rifampicin,No interaction,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2415,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Carbamazepine,ondansetron,No interaction,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2416,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Carbamazepine,ondansetron,No interaction,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2417,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Rifampicin,phenytoin,No interaction,"OTHER_DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2418,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Rifampicin,carbamazepine,No interaction,"Phenytoin_bf ,_bf OTHER_DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be OTHER_DRUG ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2419,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Rifampicin,rifampicin,No interaction,"Phenytoin_bf ,_bf Carbamazepine_bf ,_bf Rifampicin:_bf In_bf patients_bf treated_bf potent_bf inducers_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampicin)_bf ,_bf clearance_bf ondansetron_bf significantly_bf increased_bf ondansetron_bf blood_bf concentrations_bf decreased_bf ._bf"
2420,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Rifampicin,ondansetron,No interaction,"Phenytoin_bf ,_bf Carbamazepine_bf ,_bf Rifampicin:_bf In_bf patients_bf treated_bf potent_bf inducers_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampicin)_bf ,_bf clearance_bf OTHER_DRUG significantly_be increased_be OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2421,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",Rifampicin,ondansetron,No interaction,"Phenytoin_bf ,_bf Carbamazepine_bf ,_bf Rifampicin:_bf In_bf patients_bf treated_bf potent_bf inducers_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampicin)_bf ,_bf clearance_bf OTHER_DRUG significantly_be increased_be OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2422,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,carbamazepine,No interaction,"DRUG ,_be OTHER_DRUG ,_af Rifampicin:_af In_af patients_af treated_af potent_af inducers_af CYP3A4_af (i_af ._af ._af ,_af DRUG ,_af OTHER_DRUG ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2423,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,rifampicin,No interaction,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2424,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,ondansetron,mechanism,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2425,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",phenytoin,ondansetron,mechanism,"DRUG ,_be Carbamazepine_be ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be DRUG ,_af carbamazepine_af ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2426,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",carbamazepine,rifampicin,No interaction,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af ondansetron_af significantly_af increased_af ondansetron_af blood_af concentrations_af decreased_af ._af"
2427,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",carbamazepine,ondansetron,mechanism,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2428,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",carbamazepine,ondansetron,mechanism,"Phenytoin_bf ,_bf DRUG ,_be Rifampicin:_be In_be patients_be treated_be potent_be inducers_be CYP3A4_be (i_be ._be ._be ,_be phenytoin_be ,_be DRUG ,_af rifampicin)_af ,_af clearance_af OTHER_DRUG significantly_af increased_af OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2429,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",rifampicin,ondansetron,mechanism,"Phenytoin_bf ,_bf Carbamazepine_bf ,_bf Rifampicin:_bf In_bf patients_bf treated_bf potent_bf inducers_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampicin)_bf ,_bf clearance_bf OTHER_DRUG significantly_be increased_be OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2430,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",rifampicin,ondansetron,mechanism,"Phenytoin_bf ,_bf Carbamazepine_bf ,_bf Rifampicin:_bf In_bf patients_bf treated_bf potent_bf inducers_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampicin)_bf ,_bf clearance_bf OTHER_DRUG significantly_be increased_be OTHER_DRUG blood_af concentrations_af decreased_af ._af"
2431,"Phenytoin, Carbamazepine, and Rifampicin: In patients treated with potent inducers of CYP3A4 (i.e., phenytoin, carbamazepine, and rifampicin), the clearance of ondansetron was significantly increased and ondansetron blood concentrations were decreased. ",ondansetron,ondansetron,No interaction,"Phenytoin_bf ,_bf Carbamazepine_bf ,_bf Rifampicin:_bf In_bf patients_bf treated_bf potent_bf inducers_bf CYP3A4_bf (i_bf ._bf ._bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf rifampicin)_bf ,_bf clearance_bf DRUG significantly_be increased_be DRUG blood_af concentrations_af decreased_af ._af"
2432,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,Tramadol,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG OTHER_DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af OTHER_DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2433,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG tramadol_af observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af tramadol_af ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2434,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,tramadol,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG OTHER_DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af OTHER_DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2435,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG tramadol_af observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af tramadol_af ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2436,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,tramadol,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG OTHER_DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af OTHER_DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2437,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG tramadol_af observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af tramadol_af ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2438,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",Tramadol,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf OTHER_DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be OTHER_DRUG DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af OTHER_DRUG may_af associated_af increase_af patient_af controlled_af administration_af DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af OTHER_DRUG ._af"
2439,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",Tramadol,tramadol,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf ondansetron_bf recommended_bf patients_bf drugs_bf ._bf 1_bf ,_bf 3_bf Tramadol:_bf Although_bf pharmacokinetic_bf drug_bf interaction_bf ondansetron_bf DRUG observed_be ,_be data_be 2_be small_be studies_be indicate_be ondansetron_be may_be associated_be increase_be patient_be controlled_be administration_be DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af ondansetron_af ._af"
2440,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",Tramadol,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf OTHER_DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be OTHER_DRUG DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af OTHER_DRUG may_af associated_af increase_af patient_af controlled_af administration_af DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af OTHER_DRUG ._af"
2441,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",Tramadol,tramadol,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf ondansetron_bf recommended_bf patients_bf drugs_bf ._bf 1_bf ,_bf 3_bf Tramadol:_bf Although_bf pharmacokinetic_bf drug_bf interaction_bf ondansetron_bf DRUG observed_be ,_be data_be 2_be small_be studies_be indicate_be ondansetron_be may_be associated_be increase_be patient_be controlled_be administration_be DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af ondansetron_af ._af"
2442,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",Tramadol,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf OTHER_DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be OTHER_DRUG DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af OTHER_DRUG may_af associated_af increase_af patient_af controlled_af administration_af DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af OTHER_DRUG ._af"
2443,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,tramadol,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG OTHER_DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af OTHER_DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2444,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG tramadol_af observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af tramadol_af ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2445,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,tramadol,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG OTHER_DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af OTHER_DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2446,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG tramadol_af observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af tramadol_af ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2447,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",tramadol,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf OTHER_DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be OTHER_DRUG DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af OTHER_DRUG may_af associated_af increase_af patient_af controlled_af administration_af DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af OTHER_DRUG ._af"
2448,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",tramadol,tramadol,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf ondansetron_bf recommended_bf patients_bf drugs_bf ._bf 1_bf ,_bf 3_bf Tramadol:_bf Although_bf pharmacokinetic_bf drug_bf interaction_bf ondansetron_bf DRUG observed_be ,_be data_be 2_be small_be studies_be indicate_be ondansetron_be may_be associated_be increase_be patient_be controlled_be administration_be DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af ondansetron_af ._af"
2449,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",tramadol,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf OTHER_DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be OTHER_DRUG DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af OTHER_DRUG may_af associated_af increase_af patient_af controlled_af administration_af DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af OTHER_DRUG ._af"
2450,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,tramadol,effect,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG OTHER_DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af OTHER_DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2451,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",ondansetron,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be DRUG tramadol_af observed_af ,_af data_af 2_af small_af studies_af indicate_af DRUG may_af associated_af increase_af patient_af controlled_af administration_af tramadol_af ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af DRUG ._af"
2452,"However, on the basis of available data, no dosage adjustment for ondansetron is recommended for patients on these drugs.1,3  Tramadol: Although no pharmacokinetic drug interaction between ondansetron and tramadol has been observed, data from 2 small studies indicate that ondansetron may be associated with an increase in patient controlled administration of tramadol.4,5  Chemotherapy: Tumor response to chemotherapy in the P 388 mouse leukemia model is not affected by ondansetron. ",tramadol,ondansetron,No interaction,"However_bf ,_bf basis_bf available_bf data_bf ,_bf dosage_bf adjustment_bf OTHER_DRUG recommended_be patients_be drugs_be ._be 1_be ,_be 3_be Tramadol:_be Although_be pharmacokinetic_be drug_be interaction_be OTHER_DRUG DRUG observed_af ,_af data_af 2_af small_af studies_af indicate_af OTHER_DRUG may_af associated_af increase_af patient_af controlled_af administration_af DRUG ._af 4_af ,_af 5_af Chemotherapy:_af Tumor_af response_af chemotherapy_af P_af 388_af mouse_af leukemia_af model_af affected_af OTHER_DRUG ._af"
2453,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",carmustine,etoposide,No interaction,"In_bf humans_bf ,_bf DRUG ,_be OTHER_DRUG ,_af cisplatin_af affect_af pharmacokinetics_af ondansetron_af ._af"
2454,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",carmustine,cisplatin,No interaction,"In_bf humans_bf ,_bf DRUG ,_be etoposide_be ,_be OTHER_DRUG affect_af pharmacokinetics_af ondansetron_af ._af"
2455,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",carmustine,ondansetron,No interaction,"In_bf humans_bf ,_bf DRUG ,_be etoposide_be ,_be cisplatin_be affect_be pharmacokinetics_be OTHER_DRUG ._af"
2456,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",etoposide,cisplatin,No interaction,"In_bf humans_bf ,_bf carmustine_bf ,_bf DRUG ,_be OTHER_DRUG affect_af pharmacokinetics_af ondansetron_af ._af"
2457,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",etoposide,ondansetron,No interaction,"In_bf humans_bf ,_bf carmustine_bf ,_bf DRUG ,_be cisplatin_be affect_be pharmacokinetics_be OTHER_DRUG ._af"
2458,"In humans, carmustine, etoposide, and cisplatin do not affect the pharmacokinetics of ondansetron.  ",cisplatin,ondansetron,No interaction,"In_bf humans_bf ,_bf carmustine_bf ,_bf etoposide_bf ,_bf DRUG affect_be pharmacokinetics_be OTHER_DRUG ._af"
2459,ondansetron did not increase blood levels of high-dose methotrexate.,ondansetron,methotrexate,No interaction,DRUG increase_be blood_be levels_be high-dose_be OTHER_DRUG ._af
2460,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,beta adrenergic aerosol bronchodilators,Alupent,advise,Other_bf beta_bf adrenergic_bf aerosol_bf bronchodilators_bf used_bf concomitantly_bf OTHER_DRUG (metaproterenol_be sulfate_be USP)_be may_be additive_be effects_be ._be
2461,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,beta adrenergic aerosol bronchodilators,metaproterenol sulfate,advise,Other_bf beta_bf adrenergic_bf aerosol_bf bronchodilators_bf used_bf concomitantly_bf Alupent_bf (metaproterenol_bf sulfate_bf USP)_bf may_bf additive_bf effects_bf ._bf
2462,Other beta adrenergic aerosol bronchodilators should not be used concomitantly with Alupent    (metaproterenol sulfate USP) because they may have additive effects. ,Alupent,metaproterenol sulfate,No interaction,Other_bf beta_bf adrenergic_bf aerosol_bf bronchodilators_bf used_bf concomitantly_bf DRUG (metaproterenol_be sulfate_be USP)_be may_be additive_be effects_be ._be
2463,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",Beta adrenergic agonists,monoamine oxidase inhibitors,advise,"Beta_bf adrenergic_bf agonists_bf administered_bf caution_bf patients_bf treated_bf monoamine_bf oxidase_bf inhibitors_bf tricyclic_bf antidepressants_bf ,_bf since_bf action_bf beta_bf adrenergic_bf agonists_bf vascular_bf system_bf may_bf potentiated_bf ._bf"
2464,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",Beta adrenergic agonists,tricyclic antidepressants,advise,"Beta_bf adrenergic_bf agonists_bf administered_bf caution_bf patients_bf treated_bf monoamine_bf oxidase_bf inhibitors_bf tricyclic_bf antidepressants_bf ,_bf since_bf action_bf beta_bf adrenergic_bf agonists_bf vascular_bf system_bf may_bf potentiated_bf ._bf"
2465,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",Beta adrenergic agonists,beta adrenergic agonists,No interaction,"Beta_bf adrenergic_bf agonists_bf administered_bf caution_bf patients_bf treated_bf monoamine_bf oxidase_bf inhibitors_bf tricyclic_bf antidepressants_bf ,_bf since_bf action_bf beta_bf adrenergic_bf agonists_bf vascular_bf system_bf may_bf potentiated_bf ._bf"
2466,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",monoamine oxidase inhibitors,tricyclic antidepressants,No interaction,"Beta_bf adrenergic_bf agonists_bf administered_bf caution_bf patients_bf treated_bf monoamine_bf oxidase_bf inhibitors_bf tricyclic_bf antidepressants_bf ,_bf since_bf action_bf beta_bf adrenergic_bf agonists_bf vascular_bf system_bf may_bf potentiated_bf ._bf"
2467,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",monoamine oxidase inhibitors,beta adrenergic agonists,No interaction,"Beta_bf adrenergic_bf agonists_bf administered_bf caution_bf patients_bf treated_bf monoamine_bf oxidase_bf inhibitors_bf tricyclic_bf antidepressants_bf ,_bf since_bf action_bf beta_bf adrenergic_bf agonists_bf vascular_bf system_bf may_bf potentiated_bf ._bf"
2468,"Beta adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta adrenergic agonists on the vascular system may be potentiated.",tricyclic antidepressants,beta adrenergic agonists,No interaction,"Beta_bf adrenergic_bf agonists_bf administered_bf caution_bf patients_bf treated_bf monoamine_bf oxidase_bf inhibitors_bf tricyclic_bf antidepressants_bf ,_bf since_bf action_bf beta_bf adrenergic_bf agonists_bf vascular_bf system_bf may_bf potentiated_bf ._bf"
2469,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",Alcohol,XENICAL,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf OTHER_DRUG 40_be grams_be DRUG (e_af ._af g_af ._af ,_af approximately_af 3_af glasses_af wine)_af result_af alteration_af DRUG pharmacokinetics_af ,_af orlistat_af pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af orlistat_af ._af"
2470,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",Alcohol,alcohol,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf XENICAL_bf 40_bf grams_bf DRUG (e_be ._be g_be ._be ,_be approximately_be 3_be glasses_be wine)_be result_be alteration_be DRUG pharmacokinetics_af ,_af orlistat_af pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af orlistat_af ._af"
2471,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",Alcohol,alcohol,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf XENICAL_bf 40_bf grams_bf DRUG (e_be ._be g_be ._be ,_be approximately_be 3_be glasses_be wine)_be result_be alteration_be DRUG pharmacokinetics_af ,_af orlistat_af pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af orlistat_af ._af"
2472,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",Alcohol,orlistat,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf XENICAL_bf 40_bf grams_bf DRUG (e_be ._be g_be ._be ,_be approximately_be 3_be glasses_be wine)_be result_be alteration_be DRUG pharmacokinetics_af ,_af OTHER_DRUG pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af OTHER_DRUG ._af"
2473,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",Alcohol,orlistat,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf XENICAL_bf 40_bf grams_bf DRUG (e_be ._be g_be ._be ,_be approximately_be 3_be glasses_be wine)_be result_be alteration_be DRUG pharmacokinetics_af ,_af OTHER_DRUG pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af OTHER_DRUG ._af"
2474,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",XENICAL,alcohol,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf DRUG 40_be grams_be OTHER_DRUG (e_af ._af g_af ._af ,_af approximately_af 3_af glasses_af wine)_af result_af alteration_af OTHER_DRUG pharmacokinetics_af ,_af orlistat_af pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af orlistat_af ._af"
2475,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",XENICAL,alcohol,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf DRUG 40_be grams_be OTHER_DRUG (e_af ._af g_af ._af ,_af approximately_af 3_af glasses_af wine)_af result_af alteration_af OTHER_DRUG pharmacokinetics_af ,_af orlistat_af pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af orlistat_af ._af"
2476,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",XENICAL,orlistat,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf DRUG 40_be grams_be alcohol_be (e_be ._be g_be ._be ,_be approximately_be 3_be glasses_be wine)_be result_be alteration_be alcohol_be pharmacokinetics_be ,_be OTHER_DRUG pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af OTHER_DRUG ._af"
2477,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",XENICAL,orlistat,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf DRUG 40_be grams_be alcohol_be (e_be ._be g_be ._be ,_be approximately_be 3_be glasses_be wine)_be result_be alteration_be alcohol_be pharmacokinetics_be ,_be OTHER_DRUG pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af OTHER_DRUG ._af"
2478,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",alcohol,alcohol,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf XENICAL_bf 40_bf grams_bf DRUG (e_be ._be g_be ._be ,_be approximately_be 3_be glasses_be wine)_be result_be alteration_be DRUG pharmacokinetics_af ,_af orlistat_af pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af orlistat_af ._af"
2479,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",alcohol,orlistat,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf XENICAL_bf 40_bf grams_bf DRUG (e_be ._be g_be ._be ,_be approximately_be 3_be glasses_be wine)_be result_be alteration_be DRUG pharmacokinetics_af ,_af OTHER_DRUG pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af OTHER_DRUG ._af"
2480,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",alcohol,orlistat,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf XENICAL_bf 40_bf grams_bf DRUG (e_be ._be g_be ._be ,_be approximately_be 3_be glasses_be wine)_be result_be alteration_be DRUG pharmacokinetics_af ,_af OTHER_DRUG pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af OTHER_DRUG ._af"
2481,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",alcohol,orlistat,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf XENICAL_bf 40_bf grams_bf DRUG (e_be ._be g_be ._be ,_be approximately_be 3_be glasses_be wine)_be result_be alteration_be DRUG pharmacokinetics_af ,_af OTHER_DRUG pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af OTHER_DRUG ._af"
2482,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",alcohol,orlistat,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf XENICAL_bf 40_bf grams_bf DRUG (e_be ._be g_be ._be ,_be approximately_be 3_be glasses_be wine)_be result_be alteration_be DRUG pharmacokinetics_af ,_af OTHER_DRUG pharmacodynamics_af (fecal_af fat_af excretion)_af ,_af systemic_af exposure_af OTHER_DRUG ._af"
2483,"Alcohol: In a multiple-dose study in 30 normal weight subjects, coadministration of XENICAL and 40 grams of alcohol (e.g., approximately 3 glasses of wine) did not result in alteration of alcohol pharmacokinetics, orlistat pharmacodynamics (fecal fat excretion), or systemic exposure to orlistat. ",orlistat,orlistat,No interaction,"Alcohol:_bf In_bf multiple-dose_bf study_bf 30_bf normal_bf weight_bf subjects_bf ,_bf coadministration_bf XENICAL_bf 40_bf grams_bf alcohol_bf (e_bf ._bf g_bf ._bf ,_bf approximately_bf 3_bf glasses_bf wine)_bf result_bf alteration_bf alcohol_bf pharmacokinetics_bf ,_bf DRUG pharmacodynamics_be (fecal_be fat_be excretion)_be ,_be systemic_be exposure_be DRUG ._af"
2484,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,Cyclosporine,XENICAL,No interaction,Cyclosporine:_bf Preliminary_bf data_bf OTHER_DRUG DRUG drug_af interaction_af study_af indicate_af reduction_af DRUG plasma_af levels_af OTHER_DRUG coadministered_af DRUG ._af
2485,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,Cyclosporine,cyclosporine,No interaction,Cyclosporine:_bf Preliminary_bf data_bf XENICAL_bf DRUG drug_be interaction_be study_be indicate_be reduction_be DRUG plasma_af levels_af XENICAL_af coadministered_af DRUG ._af
2486,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,Cyclosporine,cyclosporine,No interaction,Cyclosporine:_bf Preliminary_bf data_bf XENICAL_bf DRUG drug_be interaction_be study_be indicate_be reduction_be DRUG plasma_af levels_af XENICAL_af coadministered_af DRUG ._af
2487,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,Cyclosporine,XENICAL,No interaction,Cyclosporine:_bf Preliminary_bf data_bf OTHER_DRUG DRUG drug_af interaction_af study_af indicate_af reduction_af DRUG plasma_af levels_af OTHER_DRUG coadministered_af DRUG ._af
2488,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,Cyclosporine,cyclosporine,No interaction,Cyclosporine:_bf Preliminary_bf data_bf XENICAL_bf DRUG drug_be interaction_be study_be indicate_be reduction_be DRUG plasma_af levels_af XENICAL_af coadministered_af DRUG ._af
2489,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,XENICAL,cyclosporine,No interaction,Cyclosporine:_bf Preliminary_bf data_bf DRUG OTHER_DRUG drug_af interaction_af study_af indicate_af reduction_af OTHER_DRUG plasma_af levels_af DRUG coadministered_af OTHER_DRUG ._af
2490,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,XENICAL,cyclosporine,No interaction,Cyclosporine:_bf Preliminary_bf data_bf DRUG OTHER_DRUG drug_af interaction_af study_af indicate_af reduction_af OTHER_DRUG plasma_af levels_af DRUG coadministered_af OTHER_DRUG ._af
2491,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,XENICAL,XENICAL,No interaction,Cyclosporine:_bf Preliminary_bf data_bf DRUG cyclosporine_be drug_be interaction_be study_be indicate_be reduction_be cyclosporine_be plasma_be levels_be DRUG coadministered_af cyclosporine_af ._af
2492,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,XENICAL,cyclosporine,No interaction,Cyclosporine:_bf Preliminary_bf data_bf DRUG OTHER_DRUG drug_af interaction_af study_af indicate_af reduction_af OTHER_DRUG plasma_af levels_af DRUG coadministered_af OTHER_DRUG ._af
2493,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,cyclosporine,cyclosporine,No interaction,Cyclosporine:_bf Preliminary_bf data_bf XENICAL_bf DRUG drug_be interaction_be study_be indicate_be reduction_be DRUG plasma_af levels_af XENICAL_af coadministered_af DRUG ._af
2494,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,cyclosporine,XENICAL,No interaction,Cyclosporine:_bf Preliminary_bf data_bf OTHER_DRUG DRUG drug_af interaction_af study_af indicate_af reduction_af DRUG plasma_af levels_af OTHER_DRUG coadministered_af DRUG ._af
2495,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,cyclosporine,cyclosporine,No interaction,Cyclosporine:_bf Preliminary_bf data_bf XENICAL_bf DRUG drug_be interaction_be study_be indicate_be reduction_be DRUG plasma_af levels_af XENICAL_af coadministered_af DRUG ._af
2496,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,cyclosporine,XENICAL,No interaction,Cyclosporine:_bf Preliminary_bf data_bf OTHER_DRUG DRUG drug_af interaction_af study_af indicate_af reduction_af DRUG plasma_af levels_af OTHER_DRUG coadministered_af DRUG ._af
2497,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,cyclosporine,cyclosporine,No interaction,Cyclosporine:_bf Preliminary_bf data_bf XENICAL_bf DRUG drug_be interaction_be study_be indicate_be reduction_be DRUG plasma_af levels_af XENICAL_af coadministered_af DRUG ._af
2498,Cyclosporine: Preliminary data from a XENICAL and cyclosporine drug interaction study indicate a reduction in cyclosporine plasma levels when XENICAL was coadministered with cyclosporine. ,XENICAL,cyclosporine,mechanism,Cyclosporine:_bf Preliminary_bf data_bf DRUG OTHER_DRUG drug_af interaction_af study_af indicate_af reduction_af OTHER_DRUG plasma_af levels_af DRUG coadministered_af OTHER_DRUG ._af
2499,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",Digoxin,XENICAL,No interaction,"Digoxin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf OTHER_DRUG 120_be mg_be three_be times_be day_be 6_be days_be ,_be OTHER_DRUG alter_af pharmacokinetics_af single_af dose_af DRUG ._af"
2500,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",Digoxin,XENICAL,No interaction,"Digoxin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf OTHER_DRUG 120_be mg_be three_be times_be day_be 6_be days_be ,_be OTHER_DRUG alter_af pharmacokinetics_af single_af dose_af DRUG ._af"
2501,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",Digoxin,digoxin,No interaction,"Digoxin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf XENICAL_bf 120_bf mg_bf three_bf times_bf day_bf 6_bf days_bf ,_bf XENICAL_bf alter_bf pharmacokinetics_bf single_bf dose_bf DRUG ._be"
2502,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",XENICAL,XENICAL,No interaction,"Digoxin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf DRUG 120_be mg_be three_be times_be day_be 6_be days_be ,_be DRUG alter_af pharmacokinetics_af single_af dose_af digoxin_af ._af"
2503,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",XENICAL,digoxin,No interaction,"Digoxin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf DRUG 120_be mg_be three_be times_be day_be 6_be days_be ,_be DRUG alter_af pharmacokinetics_af single_af dose_af OTHER_DRUG ._af"
2504,"Digoxin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the pharmacokinetics of a single dose of digoxin. ",XENICAL,digoxin,No interaction,"Digoxin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf DRUG 120_be mg_be three_be times_be day_be 6_be days_be ,_be DRUG alter_af pharmacokinetics_af single_af dose_af OTHER_DRUG ._af"
2505,Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ,Fat-soluble Vitamin Supplements,beta-carotene,No interaction,Fat-soluble_bf Vitamin_bf Supplements_bf Analogues:_bf A_bf pharmacokinetic_bf interaction_bf study_bf showed_bf 30%_bf reduction_bf OTHER_DRUG supplement_be absorption_be concomitantly_be administered_be XENICAL_be ._be
2506,Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ,Fat-soluble Vitamin Supplements,XENICAL,No interaction,Fat-soluble_bf Vitamin_bf Supplements_bf Analogues:_bf A_bf pharmacokinetic_bf interaction_bf study_bf showed_bf 30%_bf reduction_bf beta-carotene_bf supplement_bf absorption_bf concomitantly_bf administered_bf OTHER_DRUG ._be
2507,Fat-soluble Vitamin Supplements and Analogues: A pharmacokinetic interaction study showed a 30% reduction in beta-carotene supplement absorption when concomitantly administered with XENICAL. ,beta-carotene,XENICAL,mechanism,Fat-soluble_bf Vitamin_bf Supplements_bf Analogues:_bf A_bf pharmacokinetic_bf interaction_bf study_bf showed_bf 30%_bf reduction_bf DRUG supplement_be absorption_be concomitantly_be administered_be OTHER_DRUG ._af
2508,XENICAL inhibited absorption of a vitamin E acetate supplement by approximately 60%. ,XENICAL,vitamin E acetate,mechanism,DRUG inhibited_be absorption_be vitamin_be E_be acetate_be supplement_be approximately_be 60%_be ._be
2509,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",orlistat,vitamin D,No interaction,"The_bf effect_bf DRUG absorption_be supplemental_be vitamin_be D_be ,_be vitamin_be A_be ,_be nutritionally-derived_be vitamin_be K_be known_be time_be ._be"
2510,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",orlistat,vitamin A,No interaction,"The_bf effect_bf DRUG absorption_be supplemental_be vitamin_be D_be ,_be vitamin_be A_be ,_be nutritionally-derived_be vitamin_be K_be known_be time_be ._be"
2511,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",orlistat,vitamin K,No interaction,"The_bf effect_bf DRUG absorption_be supplemental_be vitamin_be D_be ,_be vitamin_be A_be ,_be nutritionally-derived_be vitamin_be K_be known_be time_be ._be"
2512,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",vitamin D,vitamin A,No interaction,"The_bf effect_bf orlistat_bf absorption_bf supplemental_bf vitamin_bf D_bf ,_bf vitamin_bf A_bf ,_bf nutritionally-derived_bf vitamin_bf K_bf known_bf time_bf ._bf"
2513,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",vitamin D,vitamin K,No interaction,"The_bf effect_bf orlistat_bf absorption_bf supplemental_bf vitamin_bf D_bf ,_bf vitamin_bf A_bf ,_bf nutritionally-derived_bf vitamin_bf K_bf known_bf time_bf ._bf"
2514,"The effect of orlistat on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time. ",vitamin A,vitamin K,No interaction,"The_bf effect_bf orlistat_bf absorption_bf supplemental_bf vitamin_bf D_bf ,_bf vitamin_bf A_bf ,_bf nutritionally-derived_bf vitamin_bf K_bf known_bf time_bf ._bf"
2515,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",Glyburide,orlistat,No interaction,"Glyburide:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf OTHER_DRUG 80_be mg_be three_be times_be day_be 5_be days_be ,_be OTHER_DRUG alter_af pharmacokinetics_af pharmacodynamics_af (blood_af glucose-lowering)_af DRUG ._af"
2516,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",Glyburide,orlistat,No interaction,"Glyburide:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf OTHER_DRUG 80_be mg_be three_be times_be day_be 5_be days_be ,_be OTHER_DRUG alter_af pharmacokinetics_af pharmacodynamics_af (blood_af glucose-lowering)_af DRUG ._af"
2517,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",Glyburide,glyburide,No interaction,"Glyburide:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf orlistat_bf 80_bf mg_bf three_bf times_bf day_bf 5_bf days_bf ,_bf orlistat_bf alter_bf pharmacokinetics_bf pharmacodynamics_bf (blood_bf glucose-lowering)_bf DRUG ._be"
2518,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",orlistat,orlistat,No interaction,"Glyburide:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf DRUG 80_be mg_be three_be times_be day_be 5_be days_be ,_be DRUG alter_af pharmacokinetics_af pharmacodynamics_af (blood_af glucose-lowering)_af glyburide_af ._af"
2519,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",orlistat,glyburide,No interaction,"Glyburide:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf DRUG 80_be mg_be three_be times_be day_be 5_be days_be ,_be DRUG alter_af pharmacokinetics_af pharmacodynamics_af (blood_af glucose-lowering)_af OTHER_DRUG ._af"
2520,"Glyburide: In 12 normal-weight subjects receiving orlistat 80 mg three times a day for 5 days, orlistat did not alter the pharmacokinetics or pharmacodynamics (blood glucose-lowering) of glyburide. ",orlistat,glyburide,No interaction,"Glyburide:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf DRUG 80_be mg_be three_be times_be day_be 5_be days_be ,_be DRUG alter_af pharmacokinetics_af pharmacodynamics_af (blood_af glucose-lowering)_af OTHER_DRUG ._af"
2521,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",Nifedipine,XENICAL,No interaction,"DRUG (extended-release_be tablets):_be In_be 17_be normal-weight_be subjects_be receiving_be OTHER_DRUG 120_af mg_af three_af times_af day_af 6_af days_af ,_af OTHER_DRUG alter_af bioavailability_af DRUG (extended-release_af tablets)_af ._af"
2522,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",Nifedipine,XENICAL,No interaction,"DRUG (extended-release_be tablets):_be In_be 17_be normal-weight_be subjects_be receiving_be OTHER_DRUG 120_af mg_af three_af times_af day_af 6_af days_af ,_af OTHER_DRUG alter_af bioavailability_af DRUG (extended-release_af tablets)_af ._af"
2523,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",Nifedipine,nifedipine,No interaction,"DRUG (extended-release_be tablets):_be In_be 17_be normal-weight_be subjects_be receiving_be XENICAL_be 120_be mg_be three_be times_be day_be 6_be days_be ,_be XENICAL_be alter_be bioavailability_be DRUG (extended-release_af tablets)_af ._af"
2524,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",XENICAL,XENICAL,No interaction,"Nifedipine_bf (extended-release_bf tablets):_bf In_bf 17_bf normal-weight_bf subjects_bf receiving_bf DRUG 120_be mg_be three_be times_be day_be 6_be days_be ,_be DRUG alter_af bioavailability_af nifedipine_af (extended-release_af tablets)_af ._af"
2525,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",XENICAL,nifedipine,No interaction,"OTHER_DRUG (extended-release_be tablets):_be In_be 17_be normal-weight_be subjects_be receiving_be DRUG 120_af mg_af three_af times_af day_af 6_af days_af ,_af DRUG alter_af bioavailability_af OTHER_DRUG (extended-release_af tablets)_af ._af"
2526,"Nifedipine (extended-release tablets): In 17 normal-weight subjects receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not alter the bioavailability of nifedipine (extended-release tablets). ",XENICAL,nifedipine,No interaction,"OTHER_DRUG (extended-release_be tablets):_be In_be 17_be normal-weight_be subjects_be receiving_be DRUG 120_af mg_af three_af times_af day_af 6_af days_af ,_af DRUG alter_af bioavailability_af OTHER_DRUG (extended-release_af tablets)_af ._af"
2527,"Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. ",Contraceptives,XENICAL,No interaction,"Oral_bf Contraceptives:_bf In_bf 20_bf normal-weight_bf female_bf subjects_bf ,_bf treatment_bf OTHER_DRUG 120_be mg_be three_be times_be day_be 23_be days_be resulted_be changes_be ovulation-suppressing_be action_be oral_be DRUG ._af"
2528,"Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. ",Contraceptives,contraceptives,No interaction,"Oral_bf Contraceptives:_bf In_bf 20_bf normal-weight_bf female_bf subjects_bf ,_bf treatment_bf XENICAL_bf 120_bf mg_bf three_bf times_bf day_bf 23_bf days_bf resulted_bf changes_bf ovulation-suppressing_bf action_bf oral_bf DRUG ._be"
2529,"Oral Contraceptives: In 20 normal-weight female subjects, the treatment of XENICAL 120 mg three times a day for 23 days resulted in no changes in the ovulation-suppressing action of oral contraceptives. ",XENICAL,contraceptives,No interaction,"Oral_bf Contraceptives:_bf In_bf 20_bf normal-weight_bf female_bf subjects_bf ,_bf treatment_bf DRUG 120_be mg_be three_be times_be day_be 23_be days_be resulted_be changes_be ovulation-suppressing_be action_be oral_be OTHER_DRUG ._af"
2530,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",Phenytoin,XENICAL,No interaction,"Phenytoin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf OTHER_DRUG 120_be mg_be three_be times_be day_be 7_be days_be ,_be OTHER_DRUG alter_af pharmacokinetics_af single_af 300-mg_af dose_af DRUG ._af"
2531,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",Phenytoin,XENICAL,No interaction,"Phenytoin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf OTHER_DRUG 120_be mg_be three_be times_be day_be 7_be days_be ,_be OTHER_DRUG alter_af pharmacokinetics_af single_af 300-mg_af dose_af DRUG ._af"
2532,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",Phenytoin,phenytoin,No interaction,"Phenytoin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf XENICAL_bf 120_bf mg_bf three_bf times_bf day_bf 7_bf days_bf ,_bf XENICAL_bf alter_bf pharmacokinetics_bf single_bf 300-mg_bf dose_bf DRUG ._be"
2533,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",XENICAL,XENICAL,No interaction,"Phenytoin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf DRUG 120_be mg_be three_be times_be day_be 7_be days_be ,_be DRUG alter_af pharmacokinetics_af single_af 300-mg_af dose_af phenytoin_af ._af"
2534,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",XENICAL,phenytoin,No interaction,"Phenytoin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf DRUG 120_be mg_be three_be times_be day_be 7_be days_be ,_be DRUG alter_af pharmacokinetics_af single_af 300-mg_af dose_af OTHER_DRUG ._af"
2535,"Phenytoin: In 12 normal-weight subjects receiving XENICAL 120 mg three times a day for 7 days, XENICAL did not alter the pharmacokinetics of a single 300-mg dose of phenytoin. ",XENICAL,phenytoin,No interaction,"Phenytoin:_bf In_bf 12_bf normal-weight_bf subjects_bf receiving_bf DRUG 120_be mg_be three_be times_be day_be 7_be days_be ,_be DRUG alter_af pharmacokinetics_af single_af 300-mg_af dose_af OTHER_DRUG ._af"
2536,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",Pravastatin,XENICAL,No interaction,"Pravastatin:_bf In_bf 2-way_bf crossover_bf study_bf 24_bf normal-weight_bf ,_bf mildly_bf hypercholesterolemic_bf patients_bf receiving_bf OTHER_DRUG 120_be mg_be three_be times_be day_be 6_be days_be ,_be OTHER_DRUG affect_af pharmacokinetics_af DRUG ._af"
2537,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",Pravastatin,XENICAL,No interaction,"Pravastatin:_bf In_bf 2-way_bf crossover_bf study_bf 24_bf normal-weight_bf ,_bf mildly_bf hypercholesterolemic_bf patients_bf receiving_bf OTHER_DRUG 120_be mg_be three_be times_be day_be 6_be days_be ,_be OTHER_DRUG affect_af pharmacokinetics_af DRUG ._af"
2538,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",Pravastatin,pravastatin,No interaction,"Pravastatin:_bf In_bf 2-way_bf crossover_bf study_bf 24_bf normal-weight_bf ,_bf mildly_bf hypercholesterolemic_bf patients_bf receiving_bf XENICAL_bf 120_bf mg_bf three_bf times_bf day_bf 6_bf days_bf ,_bf XENICAL_bf affect_bf pharmacokinetics_bf DRUG ._be"
2539,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",XENICAL,XENICAL,No interaction,"Pravastatin:_bf In_bf 2-way_bf crossover_bf study_bf 24_bf normal-weight_bf ,_bf mildly_bf hypercholesterolemic_bf patients_bf receiving_bf DRUG 120_be mg_be three_be times_be day_be 6_be days_be ,_be DRUG affect_af pharmacokinetics_af pravastatin_af ._af"
2540,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",XENICAL,pravastatin,No interaction,"Pravastatin:_bf In_bf 2-way_bf crossover_bf study_bf 24_bf normal-weight_bf ,_bf mildly_bf hypercholesterolemic_bf patients_bf receiving_bf DRUG 120_be mg_be three_be times_be day_be 6_be days_be ,_be DRUG affect_af pharmacokinetics_af OTHER_DRUG ._af"
2541,"Pravastatin: In a 2-way crossover study of 24 normal-weight, mildly hypercholesterolemic patients receiving XENICAL 120 mg three times a day for 6 days, XENICAL did not affect the pharmacokinetics of pravastatin. ",XENICAL,pravastatin,No interaction,"Pravastatin:_bf In_bf 2-way_bf crossover_bf study_bf 24_bf normal-weight_bf ,_bf mildly_bf hypercholesterolemic_bf patients_bf receiving_bf DRUG 120_be mg_be three_be times_be day_be 6_be days_be ,_be DRUG affect_af pharmacokinetics_af OTHER_DRUG ._af"
2542,"Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",Warfarin,XENICAL,No interaction,"Warfarin:_bf In_bf 12_bf normal-weight_bf subjects_bf ,_bf administration_bf OTHER_DRUG 120_be mg_be three_be times_be day_be 16_be days_be result_be change_be either_be DRUG pharmacokinetics_af (both_af R-_af S-enantiomers)_af pharmacodynamics_af (prothrombin_af time_af serum_af Factor_af VII)_af ._af"
2543,"Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",Warfarin,warfarin,No interaction,"Warfarin:_bf In_bf 12_bf normal-weight_bf subjects_bf ,_bf administration_bf XENICAL_bf 120_bf mg_bf three_bf times_bf day_bf 16_bf days_bf result_bf change_bf either_bf DRUG pharmacokinetics_be (both_be R-_be S-enantiomers)_be pharmacodynamics_be (prothrombin_be time_be serum_be Factor_be VII)_be ._be"
2544,"Warfarin: In 12 normal-weight subjects, administration of XENICAL 120 mg three times a day for 16 days did not result in any change in either warfarin pharmacokinetics (both R- and S-enantiomers) or pharmacodynamics (prothrombin time and serum Factor VII). ",XENICAL,warfarin,No interaction,"Warfarin:_bf In_bf 12_bf normal-weight_bf subjects_bf ,_bf administration_bf DRUG 120_be mg_be three_be times_be day_be 16_be days_be result_be change_be either_be OTHER_DRUG pharmacokinetics_af (both_af R-_af S-enantiomers)_af pharmacodynamics_af (prothrombin_af time_af serum_af Factor_af VII)_af ._af"
2545,"Although undercarboxylated osteocalcin, a marker of vitamin K nutritional status, was unaltered with XENICAL administration, vitamin K levels tended to decline in subjects taking XENICAL. ",XENICAL,XENICAL,No interaction,"Although_bf undercarboxylated_bf osteocalcin_bf ,_bf marker_bf vitamin_bf K_bf nutritional_bf status_bf ,_bf unaltered_bf DRUG administration_be ,_be vitamin_be K_be levels_be tended_be decline_be subjects_be taking_be DRUG ._af"
2546,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",vitamin K,XENICAL,mechanism,"Therefore_bf ,_bf vitamin_bf K_bf absorption_bf may_bf decreased_bf OTHER_DRUG ,_be patients_be chronic_be stable_be doses_be warfarin_be prescribed_be OTHER_DRUG monitored_af closely_af changes_af coagulation_af parameters_af ._af"
2547,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",vitamin K,warfarin,No interaction,"Therefore_bf ,_bf vitamin_bf K_bf absorption_bf may_bf decreased_bf XENICAL_bf ,_bf patients_bf chronic_bf stable_bf doses_bf OTHER_DRUG prescribed_be XENICAL_be monitored_be closely_be changes_be coagulation_be parameters_be ._be"
2548,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",vitamin K,XENICAL,No interaction,"Therefore_bf ,_bf vitamin_bf K_bf absorption_bf may_bf decreased_bf OTHER_DRUG ,_be patients_be chronic_be stable_be doses_be warfarin_be prescribed_be OTHER_DRUG monitored_af closely_af changes_af coagulation_af parameters_af ._af"
2549,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",XENICAL,warfarin,No interaction,"Therefore_bf ,_bf vitamin_bf K_bf absorption_bf may_bf decreased_bf DRUG ,_be patients_be chronic_be stable_be doses_be OTHER_DRUG prescribed_af DRUG monitored_af closely_af changes_af coagulation_af parameters_af ._af"
2550,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",XENICAL,XENICAL,No interaction,"Therefore_bf ,_bf vitamin_bf K_bf absorption_bf may_bf decreased_bf DRUG ,_be patients_be chronic_be stable_be doses_be warfarin_be prescribed_be DRUG monitored_af closely_af changes_af coagulation_af parameters_af ._af"
2551,"Therefore, as vitamin K absorption may be decreased with XENICAL, patients on chronic stable doses of warfarin who are prescribed XENICAL should be monitored closely for changes in coagulation parameters.",warfarin,XENICAL,advise,"Therefore_bf ,_bf vitamin_bf K_bf absorption_bf may_bf decreased_bf OTHER_DRUG ,_be patients_be chronic_be stable_be doses_be DRUG prescribed_af OTHER_DRUG monitored_af closely_af changes_af coagulation_af parameters_af ._af"
2552,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,antibiotic,No interaction,"DRUG ,_be bacteriostatic_be OTHER_DRUG ,_af may_af antagonize_af bactericidal_af effect_af penicillin_af concurrent_af use_af drugs_af avoided_af ._af"
2553,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",Tetracycline,penicillin,effect,"DRUG ,_be bacteriostatic_be antibiotic_be ,_be may_be antagonize_be bactericidal_be effect_be OTHER_DRUG concurrent_af use_af drugs_af avoided_af ._af"
2554,"Tetracycline, a bacteriostatic antibiotic, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.",antibiotic,penicillin,No interaction,"Tetracycline_bf ,_bf bacteriostatic_bf DRUG ,_be may_be antagonize_be bactericidal_be effect_be OTHER_DRUG concurrent_af use_af drugs_af avoided_af ._af"
2555,No pharmacokinetic interaction between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks. ,ELOXATIN,5-FU,No interaction,No_bf pharmacokinetic_bf interaction_bf 85_bf mg/m2_bf DRUG infusional_be OTHER_DRUG observed_af patients_af treated_af every_af 2_af weeks_af ._af
2556,Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2 ELOXATIN dosed every 3 weeks. ,5-FU,ELOXATIN,mechanism,Increases_bf DRUG plasma_be concentrations_be approximately_be 20%_be observed_be doses_be 130_be mg/m2_be OTHER_DRUG dosed_af every_af 3_af weeks_af ._af
2557,Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. ,Anticoagulants,Anabolic steroids,No interaction,DRUG Anabolic_be steroids_be may_be increase_be sensitivity_be oral_be DRUG ._af
2558,Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. ,Anticoagulants,anticoagulants,No interaction,DRUG Anabolic_be steroids_be may_be increase_be sensitivity_be oral_be DRUG ._af
2559,Anticoagulants Anabolic steroids may increase sensitivity to oral anticoagulants. ,Anabolic steroids,anticoagulants,effect,OTHER_DRUG Anabolic_be steroids_be may_be increase_be sensitivity_be oral_be OTHER_DRUG ._af
2560,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",Warfarin,oxandrolone,No interaction,"Warfarin:_bf A_bf multidose_bf study_bf OTHER_DRUG ,_be given_be 5_be 10_be mg_be BID_be 15_be healthy_be subjects_be concurrently_be treated_be DRUG ,_af resulted_af mean_af increase_af S-warfarin_af half-life_af 26_af 48_af hours_af AUC_af 4_af ._af 55_af 12_af ._af 08_af ng*hr/mL:_af similar_af increases_af R-warfarin_af half-life_af AUC_af also_af detected_af ._af"
2561,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",Warfarin,warfarin,No interaction,"Warfarin:_bf A_bf multidose_bf study_bf oxandrolone_bf ,_bf given_bf 5_bf 10_bf mg_bf BID_bf 15_bf healthy_bf subjects_bf concurrently_bf treated_bf DRUG ,_be resulted_be mean_be increase_be S-warfarin_be half-life_be 26_be 48_be hours_be AUC_be 4_be ._be 55_be 12_be ._be 08_be ng*hr/mL:_be similar_be increases_be R-warfarin_be half-life_be AUC_be also_be detected_be ._be"
2562,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",Warfarin,S-warfarin,No interaction,"Warfarin:_bf A_bf multidose_bf study_bf oxandrolone_bf ,_bf given_bf 5_bf 10_bf mg_bf BID_bf 15_bf healthy_bf subjects_bf concurrently_bf treated_bf DRUG ,_be resulted_be mean_be increase_be OTHER_DRUG half-life_af 26_af 48_af hours_af AUC_af 4_af ._af 55_af 12_af ._af 08_af ng*hr/mL:_af similar_af increases_af R-warfarin_af half-life_af AUC_af also_af detected_af ._af"
2563,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",Warfarin,R-warfarin,No interaction,"Warfarin:_bf A_bf multidose_bf study_bf oxandrolone_bf ,_bf given_bf 5_bf 10_bf mg_bf BID_bf 15_bf healthy_bf subjects_bf concurrently_bf treated_bf DRUG ,_be resulted_be mean_be increase_be S-warfarin_be half-life_be 26_be 48_be hours_be AUC_be 4_be ._be 55_be 12_be ._be 08_be ng*hr/mL:_be similar_be increases_be OTHER_DRUG half-life_af AUC_af also_af detected_af ._af"
2564,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",oxandrolone,warfarin,mechanism,"Warfarin:_bf A_bf multidose_bf study_bf DRUG ,_be given_be 5_be 10_be mg_be BID_be 15_be healthy_be subjects_be concurrently_be treated_be OTHER_DRUG ,_af resulted_af mean_af increase_af S-warfarin_af half-life_af 26_af 48_af hours_af AUC_af 4_af ._af 55_af 12_af ._af 08_af ng*hr/mL:_af similar_af increases_af R-warfarin_af half-life_af AUC_af also_af detected_af ._af"
2565,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",oxandrolone,S-warfarin,No interaction,"Warfarin:_bf A_bf multidose_bf study_bf DRUG ,_be given_be 5_be 10_be mg_be BID_be 15_be healthy_be subjects_be concurrently_be treated_be warfarin_be ,_be resulted_be mean_be increase_be OTHER_DRUG half-life_af 26_af 48_af hours_af AUC_af 4_af ._af 55_af 12_af ._af 08_af ng*hr/mL:_af similar_af increases_af R-warfarin_af half-life_af AUC_af also_af detected_af ._af"
2566,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",oxandrolone,R-warfarin,No interaction,"Warfarin:_bf A_bf multidose_bf study_bf DRUG ,_be given_be 5_be 10_be mg_be BID_be 15_be healthy_be subjects_be concurrently_be treated_be warfarin_be ,_be resulted_be mean_be increase_be S-warfarin_be half-life_be 26_be 48_be hours_be AUC_be 4_be ._be 55_be 12_be ._be 08_be ng*hr/mL:_be similar_be increases_be OTHER_DRUG half-life_af AUC_af also_af detected_af ._af"
2567,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",warfarin,S-warfarin,No interaction,"Warfarin:_bf A_bf multidose_bf study_bf oxandrolone_bf ,_bf given_bf 5_bf 10_bf mg_bf BID_bf 15_bf healthy_bf subjects_bf concurrently_bf treated_bf DRUG ,_be resulted_be mean_be increase_be OTHER_DRUG half-life_af 26_af 48_af hours_af AUC_af 4_af ._af 55_af 12_af ._af 08_af ng*hr/mL:_af similar_af increases_af R-warfarin_af half-life_af AUC_af also_af detected_af ._af"
2568,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",warfarin,R-warfarin,No interaction,"Warfarin:_bf A_bf multidose_bf study_bf oxandrolone_bf ,_bf given_bf 5_bf 10_bf mg_bf BID_bf 15_bf healthy_bf subjects_bf concurrently_bf treated_bf DRUG ,_be resulted_be mean_be increase_be S-warfarin_be half-life_be 26_be 48_be hours_be AUC_be 4_be ._be 55_be 12_be ._be 08_be ng*hr/mL:_be similar_be increases_be OTHER_DRUG half-life_af AUC_af also_af detected_af ._af"
2569,"Warfarin: A multidose study of oxandrolone, given as 5 or 10 mg BID in 15 healthy subjects concurrently treated with warfarin, resulted in a mean increase in S-warfarin half-life from 26 to 48 hours and AUC from 4.55 to 12.08 ng*hr/mL: similar increases in R-warfarin half-life and AUC were also detected. ",S-warfarin,R-warfarin,No interaction,"Warfarin:_bf A_bf multidose_bf study_bf oxandrolone_bf ,_bf given_bf 5_bf 10_bf mg_bf BID_bf 15_bf healthy_bf subjects_bf concurrently_bf treated_bf warfarin_bf ,_bf resulted_bf mean_bf increase_bf DRUG half-life_be 26_be 48_be hours_be AUC_be 4_be ._be 55_be 12_be ._be 08_be ng*hr/mL:_be similar_be increases_be OTHER_DRUG half-life_af AUC_af also_af detected_af ._af"
2570,"A 5.5-fold decrease in the mean warfarin dose from 6.13 mg/day to 1.13 mg/day (approximately 80-85% reduction of warfarin dose), was necessary to maintain a target INR of 1.5. ",warfarin,warfarin,No interaction,"A_bf 5_bf ._bf 5-fold_bf decrease_bf mean_bf DRUG dose_be 6_be ._be 13_be mg/day_be 1_be ._be 13_be mg/day_be (approximately_be 80-85%_be reduction_be DRUG dose)_af ,_af necessary_af maintain_af target_af INR_af 1_af ._af 5_af ._af"
2571,"When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ",oxandrolone,warfarin,advise,"When_bf DRUG therapy_be initiated_be patient_be already_be receiving_be treatment_be OTHER_DRUG ,_af INR_af prothrombin_af time_af (PT)_af monitored_af closely_af dose_af OTHER_DRUG adjusted_af necessary_af stable_af target_af INR_af PT_af achieved_af ._af"
2572,"When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ",oxandrolone,warfarin,No interaction,"When_bf DRUG therapy_be initiated_be patient_be already_be receiving_be treatment_be OTHER_DRUG ,_af INR_af prothrombin_af time_af (PT)_af monitored_af closely_af dose_af OTHER_DRUG adjusted_af necessary_af stable_af target_af INR_af PT_af achieved_af ._af"
2573,"When oxandrolone therapy is initiated in a patient already receiving treatment with warfarin, the INR or prothrombin time (PT) should be monitored closely and the dose of warfarin adjusted as necessary until a stable target INR or PT has been achieved. ",warfarin,warfarin,No interaction,"When_bf oxandrolone_bf therapy_bf initiated_bf patient_bf already_bf receiving_bf treatment_bf DRUG ,_be INR_be prothrombin_be time_be (PT)_be monitored_be closely_be dose_be DRUG adjusted_af necessary_af stable_af target_af INR_af PT_af achieved_af ._af"
2574,"Furthermore, in patients receiving both drugs, careful monitoring of the INR or PT, and adjustment of the warfarin dosage if indicated are recommended when the oxandrolone dose is changed or discontinued. ",warfarin,oxandrolone,advise,"Furthermore_bf ,_bf patients_bf receiving_bf drugs_bf ,_bf careful_bf monitoring_bf INR_bf PT_bf ,_bf adjustment_bf DRUG dosage_be indicated_be recommended_be OTHER_DRUG dose_af changed_af discontinued_af ._af"
2575,Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ,hypoglycemic agents,Oxandrolone,No interaction,Oral_bf hypoglycemic_bf agents_bf OTHER_DRUG may_be inhibit_be metabolism_be oral_be hypoglycemic_be agents_be ._be
2576,Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ,hypoglycemic agents,hypoglycemic agents,No interaction,Oral_bf hypoglycemic_bf agents_bf Oxandrolone_bf may_bf inhibit_bf metabolism_bf oral_bf hypoglycemic_bf agents_bf ._bf
2577,Oral hypoglycemic agents Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. ,Oxandrolone,hypoglycemic agents,mechanism,Oral_bf hypoglycemic_bf agents_bf DRUG may_be inhibit_be metabolism_be oral_be hypoglycemic_be agents_be ._be
2578,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",Adrenal steroids,ACTH,No interaction,"Adrenal_bf steroids_bf OTHER_DRUG In_be patients_be edema_be ,_be concomitant_be administration_be adrenal_be cortical_be steroids_be OTHER_DRUG may_af increase_af edema_af ._af"
2579,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",Adrenal steroids,adrenal cortical steroids,No interaction,"Adrenal_bf steroids_bf ACTH_bf In_bf patients_bf edema_bf ,_bf concomitant_bf administration_bf adrenal_bf cortical_bf steroids_bf ACTH_bf may_bf increase_bf edema_bf ._bf"
2580,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",Adrenal steroids,ACTH,No interaction,"Adrenal_bf steroids_bf OTHER_DRUG In_be patients_be edema_be ,_be concomitant_be administration_be adrenal_be cortical_be steroids_be OTHER_DRUG may_af increase_af edema_af ._af"
2581,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",ACTH,adrenal cortical steroids,No interaction,"Adrenal_bf steroids_bf DRUG In_be patients_be edema_be ,_be concomitant_be administration_be adrenal_be cortical_be steroids_be DRUG may_af increase_af edema_af ._af"
2582,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",ACTH,ACTH,No interaction,"Adrenal_bf steroids_bf DRUG In_be patients_be edema_be ,_be concomitant_be administration_be adrenal_be cortical_be steroids_be DRUG may_af increase_af edema_af ._af"
2583,"Adrenal steroids or ACTH In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema. ",adrenal cortical steroids,ACTH,No interaction,"Adrenal_bf steroids_bf OTHER_DRUG In_be patients_be edema_be ,_be concomitant_be administration_be adrenal_be cortical_be steroids_be OTHER_DRUG may_af increase_af edema_af ._af"
2584,"The concomitant use of oxybutynin with other anticholinergic drugs or with other agents which produce dry mouth, constipation, somnolence (drowsiness), and/or other anticholinergic-like effects may increase the frequency and/or severity of such effects. ",oxybutynin,anticholinergic drugs,effect,"The_bf concomitant_bf use_bf DRUG anticholinergic_be drugs_be agents_be produce_be dry_be mouth_be ,_be constipation_be ,_be somnolence_be (drowsiness)_be ,_be and/or_be anticholinergic-like_be effects_be may_be increase_be frequency_be and/or_be severity_be effects_be ._be"
2585,"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ",oxybutynin chloride,DITROPAN XL,No interaction,"Mean_bf oxybutynin_bf chloride_bf plasma_bf concentrations_bf approximately_bf 2_bf fold_bf higher_bf DITROPAN_bf XL_bf administered_bf ketoconazole_bf ,_bf potent_bf CYP3A4_bf inhibitor_bf ._bf"
2586,"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ",oxybutynin chloride,ketoconazole,No interaction,"Mean_bf oxybutynin_bf chloride_bf plasma_bf concentrations_bf approximately_bf 2_bf fold_bf higher_bf DITROPAN_bf XL_bf administered_bf OTHER_DRUG ,_be potent_be CYP3A4_be inhibitor_be ._be"
2587,"Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor. ",DITROPAN XL,ketoconazole,mechanism,"Mean_bf oxybutynin_bf chloride_bf plasma_bf concentrations_bf approximately_bf 2_bf fold_bf higher_bf DITROPAN_bf XL_bf administered_bf OTHER_DRUG ,_be potent_be CYP3A4_be inhibitor_be ._be"
2588,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",antimycotic agents,itraconazole,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG miconazole)_be macrolide_be antibiotics_be (e_be ._be g_be ._be ,_be erythromycin_be clarithromycin)_be ,_be may_be alter_be oxybutynin_be mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2589,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",antimycotic agents,miconazole,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf oxybutynin_bf mean_bf pharmacokinetic_bf parameters_bf (i_bf ._bf ._bf ,_bf Cmax_bf AUC)_bf ._bf"
2590,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",antimycotic agents,macrolide antibiotics,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf oxybutynin_bf mean_bf pharmacokinetic_bf parameters_bf (i_bf ._bf ._bf ,_bf Cmax_bf AUC)_bf ._bf"
2591,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",antimycotic agents,erythromycin,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG clarithromycin)_be ,_be may_be alter_be oxybutynin_be mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2592,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",antimycotic agents,clarithromycin,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf oxybutynin_bf mean_bf pharmacokinetic_bf parameters_bf (i_bf ._bf ._bf ,_bf Cmax_bf AUC)_bf ._bf"
2593,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",antimycotic agents,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2594,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,miconazole,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf DRUG miconazole)_be macrolide_be antibiotics_be (e_be ._be g_be ._be ,_be erythromycin_be clarithromycin)_be ,_be may_be alter_be oxybutynin_be mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2595,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,macrolide antibiotics,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf DRUG miconazole)_be macrolide_be antibiotics_be (e_be ._be g_be ._be ,_be erythromycin_be clarithromycin)_be ,_be may_be alter_be oxybutynin_be mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2596,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,erythromycin,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf DRUG miconazole)_be macrolide_be antibiotics_be (e_be ._be g_be ._be ,_be OTHER_DRUG clarithromycin)_af ,_af may_af alter_af oxybutynin_af mean_af pharmacokinetic_af parameters_af (i_af ._af ._af ,_af Cmax_af AUC)_af ._af"
2597,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,clarithromycin,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf DRUG miconazole)_be macrolide_be antibiotics_be (e_be ._be g_be ._be ,_be erythromycin_be clarithromycin)_be ,_be may_be alter_be oxybutynin_be mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2598,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",itraconazole,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf DRUG miconazole)_be macrolide_be antibiotics_be (e_be ._be g_be ._be ,_be erythromycin_be clarithromycin)_be ,_be may_be alter_be OTHER_DRUG mean_af pharmacokinetic_af parameters_af (i_af ._af ._af ,_af Cmax_af AUC)_af ._af"
2599,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,macrolide antibiotics,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf oxybutynin_bf mean_bf pharmacokinetic_bf parameters_bf (i_bf ._bf ._bf ,_bf Cmax_bf AUC)_bf ._bf"
2600,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,erythromycin,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG clarithromycin)_be ,_be may_be alter_be oxybutynin_be mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2601,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,clarithromycin,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf oxybutynin_bf mean_bf pharmacokinetic_bf parameters_bf (i_bf ._bf ._bf ,_bf Cmax_bf AUC)_bf ._bf"
2602,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",miconazole,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2603,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",macrolide antibiotics,erythromycin,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG clarithromycin)_be ,_be may_be alter_be oxybutynin_be mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2604,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",macrolide antibiotics,clarithromycin,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf oxybutynin_bf mean_bf pharmacokinetic_bf parameters_bf (i_bf ._bf ._bf ,_bf Cmax_bf AUC)_bf ._bf"
2605,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",macrolide antibiotics,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2606,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",erythromycin,clarithromycin,No interaction,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG clarithromycin)_be ,_be may_be alter_be oxybutynin_be mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2607,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",erythromycin,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf DRUG clarithromycin)_be ,_be may_be alter_be OTHER_DRUG mean_af pharmacokinetic_af parameters_af (i_af ._af ._af ,_af Cmax_af AUC)_af ._af"
2608,"Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC). ",clarithromycin,oxybutynin,mechanism,"Other_bf inhibitors_bf cytochrome_bf P450_bf 3A4_bf enzyme_bf system_bf ,_bf antimycotic_bf agents_bf (e_bf ._bf g_bf ._bf ,_bf itraconazole_bf miconazole)_bf macrolide_bf antibiotics_bf (e_bf ._bf g_bf ._bf ,_bf erythromycin_bf clarithromycin)_bf ,_bf may_bf alter_bf OTHER_DRUG mean_be pharmacokinetic_be parameters_be (i_be ._be ._be ,_be Cmax_be AUC)_be ._be"
2609,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",antacid,antacid,No interaction,"Concurrent_bf ingestion_bf DRUG (20_be mL_be DRUG containing_af aluminum_af hydroxide_af ,_af magnesium_af hydroxide_af ,_af simethicone)_af significantly_af affect_af exposure_af oxybutynin_af desethyloxybutynin_af ._af"
2610,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",antacid,aluminum hydroxide,No interaction,"Concurrent_bf ingestion_bf DRUG (20_be mL_be DRUG containing_af aluminum_af hydroxide_af ,_af magnesium_af hydroxide_af ,_af simethicone)_af significantly_af affect_af exposure_af oxybutynin_af desethyloxybutynin_af ._af"
2611,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",antacid,magnesium hydroxide,No interaction,"Concurrent_bf ingestion_bf DRUG (20_be mL_be DRUG containing_af aluminum_af hydroxide_af ,_af magnesium_af hydroxide_af ,_af simethicone)_af significantly_af affect_af exposure_af oxybutynin_af desethyloxybutynin_af ._af"
2612,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",antacid,simethicone,No interaction,"Concurrent_bf ingestion_bf DRUG (20_be mL_be DRUG containing_af aluminum_af hydroxide_af ,_af magnesium_af hydroxide_af ,_af simethicone)_af significantly_af affect_af exposure_af oxybutynin_af desethyloxybutynin_af ._af"
2613,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",antacid,oxybutynin,No interaction,"Concurrent_bf ingestion_bf DRUG (20_be mL_be DRUG containing_af aluminum_af hydroxide_af ,_af magnesium_af hydroxide_af ,_af simethicone)_af significantly_af affect_af exposure_af OTHER_DRUG desethyloxybutynin_af ._af"
2614,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",antacid,desethyloxybutynin,No interaction,"Concurrent_bf ingestion_bf DRUG (20_be mL_be DRUG containing_af aluminum_af hydroxide_af ,_af magnesium_af hydroxide_af ,_af simethicone)_af significantly_af affect_af exposure_af oxybutynin_af OTHER_DRUG ._af"
2615,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",antacid,aluminum hydroxide,No interaction,"Concurrent_bf ingestion_bf DRUG (20_be mL_be DRUG containing_af aluminum_af hydroxide_af ,_af magnesium_af hydroxide_af ,_af simethicone)_af significantly_af affect_af exposure_af oxybutynin_af desethyloxybutynin_af ._af"
2616,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",antacid,magnesium hydroxide,No interaction,"Concurrent_bf ingestion_bf DRUG (20_be mL_be DRUG containing_af aluminum_af hydroxide_af ,_af magnesium_af hydroxide_af ,_af simethicone)_af significantly_af affect_af exposure_af oxybutynin_af desethyloxybutynin_af ._af"
2617,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",antacid,simethicone,No interaction,"Concurrent_bf ingestion_bf DRUG (20_be mL_be DRUG containing_af aluminum_af hydroxide_af ,_af magnesium_af hydroxide_af ,_af simethicone)_af significantly_af affect_af exposure_af oxybutynin_af desethyloxybutynin_af ._af"
2618,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",antacid,oxybutynin,No interaction,"Concurrent_bf ingestion_bf DRUG (20_be mL_be DRUG containing_af aluminum_af hydroxide_af ,_af magnesium_af hydroxide_af ,_af simethicone)_af significantly_af affect_af exposure_af OTHER_DRUG desethyloxybutynin_af ._af"
2619,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",antacid,desethyloxybutynin,No interaction,"Concurrent_bf ingestion_bf DRUG (20_be mL_be DRUG containing_af aluminum_af hydroxide_af ,_af magnesium_af hydroxide_af ,_af simethicone)_af significantly_af affect_af exposure_af oxybutynin_af OTHER_DRUG ._af"
2620,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",aluminum hydroxide,magnesium hydroxide,No interaction,"Concurrent_bf ingestion_bf antacid_bf (20_bf mL_bf antacid_bf containing_bf aluminum_bf hydroxide_bf ,_bf magnesium_bf hydroxide_bf ,_bf simethicone)_bf significantly_bf affect_bf exposure_bf oxybutynin_bf desethyloxybutynin_bf ._bf"
2621,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",aluminum hydroxide,simethicone,No interaction,"Concurrent_bf ingestion_bf antacid_bf (20_bf mL_bf antacid_bf containing_bf aluminum_bf hydroxide_bf ,_bf magnesium_bf hydroxide_bf ,_bf simethicone)_bf significantly_bf affect_bf exposure_bf oxybutynin_bf desethyloxybutynin_bf ._bf"
2622,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",aluminum hydroxide,oxybutynin,No interaction,"Concurrent_bf ingestion_bf antacid_bf (20_bf mL_bf antacid_bf containing_bf aluminum_bf hydroxide_bf ,_bf magnesium_bf hydroxide_bf ,_bf simethicone)_bf significantly_bf affect_bf exposure_bf OTHER_DRUG desethyloxybutynin_be ._be"
2623,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",aluminum hydroxide,desethyloxybutynin,No interaction,"Concurrent_bf ingestion_bf antacid_bf (20_bf mL_bf antacid_bf containing_bf aluminum_bf hydroxide_bf ,_bf magnesium_bf hydroxide_bf ,_bf simethicone)_bf significantly_bf affect_bf exposure_bf oxybutynin_bf OTHER_DRUG ._be"
2624,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",magnesium hydroxide,simethicone,No interaction,"Concurrent_bf ingestion_bf antacid_bf (20_bf mL_bf antacid_bf containing_bf aluminum_bf hydroxide_bf ,_bf magnesium_bf hydroxide_bf ,_bf simethicone)_bf significantly_bf affect_bf exposure_bf oxybutynin_bf desethyloxybutynin_bf ._bf"
2625,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",magnesium hydroxide,oxybutynin,No interaction,"Concurrent_bf ingestion_bf antacid_bf (20_bf mL_bf antacid_bf containing_bf aluminum_bf hydroxide_bf ,_bf magnesium_bf hydroxide_bf ,_bf simethicone)_bf significantly_bf affect_bf exposure_bf OTHER_DRUG desethyloxybutynin_be ._be"
2626,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",magnesium hydroxide,desethyloxybutynin,No interaction,"Concurrent_bf ingestion_bf antacid_bf (20_bf mL_bf antacid_bf containing_bf aluminum_bf hydroxide_bf ,_bf magnesium_bf hydroxide_bf ,_bf simethicone)_bf significantly_bf affect_bf exposure_bf oxybutynin_bf OTHER_DRUG ._be"
2627,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",simethicone,oxybutynin,No interaction,"Concurrent_bf ingestion_bf antacid_bf (20_bf mL_bf antacid_bf containing_bf aluminum_bf hydroxide_bf ,_bf magnesium_bf hydroxide_bf ,_bf simethicone)_bf significantly_bf affect_bf exposure_bf OTHER_DRUG desethyloxybutynin_be ._be"
2628,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",simethicone,desethyloxybutynin,No interaction,"Concurrent_bf ingestion_bf antacid_bf (20_bf mL_bf antacid_bf containing_bf aluminum_bf hydroxide_bf ,_bf magnesium_bf hydroxide_bf ,_bf simethicone)_bf significantly_bf affect_bf exposure_bf oxybutynin_bf OTHER_DRUG ._be"
2629,"Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.    ",oxybutynin,desethyloxybutynin,No interaction,"Concurrent_bf ingestion_bf antacid_bf (20_bf mL_bf antacid_bf containing_bf aluminum_bf hydroxide_bf ,_bf magnesium_bf hydroxide_bf ,_bf simethicone)_bf significantly_bf affect_bf exposure_bf DRUG OTHER_DRUG ._af"
2630,The CNS depressant effects of oxycodone hydrochloride may be additive with that of other CNS depressants..,oxycodone hydrochloride,CNS depressants,effect,The_bf CNS_bf depressant_bf effects_bf oxycodone_bf hydrochloride_bf may_bf additive_bf CNS_bf depressants_bf ._bf ._bf
2631,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",CNS depressants,sedatives,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf OTHER_DRUG ,_be hypnotics_be ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2632,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",CNS depressants,hypnotics,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf OTHER_DRUG ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2633,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",CNS depressants,tranquilizers,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf OTHER_DRUG ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2634,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",CNS depressants,anesthetics,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf OTHER_DRUG ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2635,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",CNS depressants,phenothiazines,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf OTHER_DRUG ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2636,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",CNS depressants,opioids,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf OTHER_DRUG ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2637,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",CNS depressants,tricyclic antidepressants,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf opioids_bf ,_bf tricyclic_bf antidepressants_bf ,_bf monoamine_bf oxidase_bf (MAO)_bf inhibitors_bf ,_bf alcohol_bf may_bf produce_bf additive_bf CNS_bf depressant_bf effects_bf ._bf"
2638,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",CNS depressants,monoamine oxidase (MAO) inhibitors,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf opioids_bf ,_bf tricyclic_bf antidepressants_bf ,_bf monoamine_bf oxidase_bf (MAO)_bf inhibitors_bf ,_bf alcohol_bf may_bf produce_bf additive_bf CNS_bf depressant_bf effects_bf ._bf"
2639,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",CNS depressants,alcohol,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf opioids_bf ,_bf tricyclic_bf antidepressants_bf ,_bf monoamine_bf oxidase_bf (MAO)_bf inhibitors_bf ,_bf OTHER_DRUG may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2640,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",sedatives,hypnotics,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf DRUG ,_be OTHER_DRUG ,_af tranquilizers_af ,_af general_af anesthetics_af ,_af phenothiazines_af ,_af opioids_af ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2641,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",sedatives,tranquilizers,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf DRUG ,_be hypnotics_be ,_be OTHER_DRUG ,_af general_af anesthetics_af ,_af phenothiazines_af ,_af opioids_af ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2642,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",sedatives,anesthetics,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf DRUG ,_be hypnotics_be ,_be tranquilizers_be ,_be general_be OTHER_DRUG ,_af phenothiazines_af ,_af opioids_af ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2643,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",sedatives,phenothiazines,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf DRUG ,_be hypnotics_be ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be OTHER_DRUG ,_af opioids_af ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2644,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",sedatives,opioids,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf DRUG ,_be hypnotics_be ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2645,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",sedatives,tricyclic antidepressants,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf DRUG ,_be hypnotics_be ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2646,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",sedatives,monoamine oxidase (MAO) inhibitors,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf DRUG ,_be hypnotics_be ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2647,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",sedatives,alcohol,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf DRUG ,_be hypnotics_be ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be OTHER_DRUG may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2648,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",hypnotics,tranquilizers,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf DRUG ,_be OTHER_DRUG ,_af general_af anesthetics_af ,_af phenothiazines_af ,_af opioids_af ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2649,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",hypnotics,anesthetics,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf DRUG ,_be tranquilizers_be ,_be general_be OTHER_DRUG ,_af phenothiazines_af ,_af opioids_af ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2650,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",hypnotics,phenothiazines,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf DRUG ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be OTHER_DRUG ,_af opioids_af ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2651,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",hypnotics,opioids,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf DRUG ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2652,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",hypnotics,tricyclic antidepressants,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf DRUG ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2653,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",hypnotics,monoamine oxidase (MAO) inhibitors,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf DRUG ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2654,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",hypnotics,alcohol,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf DRUG ,_be tranquilizers_be ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be OTHER_DRUG may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2655,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",tranquilizers,anesthetics,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf DRUG ,_be general_be OTHER_DRUG ,_af phenothiazines_af ,_af opioids_af ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2656,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",tranquilizers,phenothiazines,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf DRUG ,_be general_be anesthetics_be ,_be OTHER_DRUG ,_af opioids_af ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2657,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",tranquilizers,opioids,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf DRUG ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2658,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",tranquilizers,tricyclic antidepressants,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf DRUG ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2659,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",tranquilizers,monoamine oxidase (MAO) inhibitors,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf DRUG ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2660,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",tranquilizers,alcohol,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf DRUG ,_be general_be anesthetics_be ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be OTHER_DRUG may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2661,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",anesthetics,phenothiazines,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf DRUG ,_be OTHER_DRUG ,_af opioids_af ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2662,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",anesthetics,opioids,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf DRUG ,_be phenothiazines_be ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2663,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",anesthetics,tricyclic antidepressants,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf DRUG ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2664,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",anesthetics,monoamine oxidase (MAO) inhibitors,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf DRUG ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2665,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",anesthetics,alcohol,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf DRUG ,_be phenothiazines_be ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be OTHER_DRUG may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2666,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",phenothiazines,opioids,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf DRUG ,_be OTHER_DRUG ,_af tricyclic_af antidepressants_af ,_af monoamine_af oxidase_af (MAO)_af inhibitors_af ,_af alcohol_af may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2667,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",phenothiazines,tricyclic antidepressants,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf DRUG ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2668,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",phenothiazines,monoamine oxidase (MAO) inhibitors,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf DRUG ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2669,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",phenothiazines,alcohol,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf DRUG ,_be opioids_be ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be OTHER_DRUG may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2670,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",opioids,tricyclic antidepressants,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf DRUG ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2671,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",opioids,monoamine oxidase (MAO) inhibitors,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf DRUG ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be alcohol_be may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2672,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",opioids,alcohol,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf DRUG ,_be tricyclic_be antidepressants_be ,_be monoamine_be oxidase_be (MAO)_be inhibitors_be ,_be OTHER_DRUG may_af produce_af additive_af CNS_af depressant_af effects_af ._af"
2673,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",tricyclic antidepressants,monoamine oxidase (MAO) inhibitors,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf opioids_bf ,_bf tricyclic_bf antidepressants_bf ,_bf monoamine_bf oxidase_bf (MAO)_bf inhibitors_bf ,_bf alcohol_bf may_bf produce_bf additive_bf CNS_bf depressant_bf effects_bf ._bf"
2674,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",tricyclic antidepressants,alcohol,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf opioids_bf ,_bf tricyclic_bf antidepressants_bf ,_bf monoamine_bf oxidase_bf (MAO)_bf inhibitors_bf ,_bf OTHER_DRUG may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2675,"The concomitant use of other CNS depressants including sedatives, hypnotics, tranquilizers, general anesthetics, phenothiazines, other opioids, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, and alcohol may produce additive CNS depressant effects. ",monoamine oxidase (MAO) inhibitors,alcohol,No interaction,"The_bf concomitant_bf use_bf CNS_bf depressants_bf including_bf sedatives_bf ,_bf hypnotics_bf ,_bf tranquilizers_bf ,_bf general_bf anesthetics_bf ,_bf phenothiazines_bf ,_bf opioids_bf ,_bf tricyclic_bf antidepressants_bf ,_bf monoamine_bf oxidase_bf (MAO)_bf inhibitors_bf ,_bf OTHER_DRUG may_be produce_be additive_be CNS_be depressant_be effects_be ._be"
2676,"Anticholinergics or other medications with anticholinergic activity when used concurrently with opioid analgesics may result in increased risk of urinary retention and/or severe constipation, which may lead to paralytic ileus. ",Anticholinergics,opioid analgesics,effect,"DRUG medications_be anticholinergic_be activity_be used_be concurrently_be opioid_be analgesics_be may_be result_be increased_be risk_be urinary_be retention_be and/or_be severe_be constipation_be ,_be may_be lead_be paralytic_be ileus_be ._be"
2677,It has been reported that the incidence of bradycardia was increased when oxymorphone was combined with propofol for induction of anesthesia. ,oxymorphone,propofol,effect,It_bf reported_bf incidence_bf bradycardia_bf increased_bf DRUG combined_be OTHER_DRUG induction_af anesthesia_af ._af
2678,"In addition, CNS toxicity has been reported (confusion, disorientation, respiratory depression, apnea, seizures) following coadministration of cimetidine with opioid analgesics; ",cimetidine,opioid analgesics,effect,"In_bf addition_bf ,_bf CNS_bf toxicity_bf reported_bf (confusion_bf ,_bf disorientation_bf ,_bf respiratory_bf depression_bf ,_bf apnea_bf ,_bf seizures)_bf following_bf coadministration_bf DRUG opioid_be analgesics;_be"
2679,Potential for INVEGA    to Affect Other Drugs Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. ,INVEGA,Paliperidone,No interaction,Potential_bf DRUG Affect_be Other_be Drugs_be OTHER_DRUG expected_af cause_af clinically_af important_af pharmacokinetic_af interactions_af drugs_af metabolized_af cytochrome_af P450_af isozymes_af ._af
2680,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",paliperidone,INVEGA,No interaction,"Given_bf primary_bf CNS_bf effects_bf DRUG ,_be OTHER_DRUG used_af caution_af combination_af centrally_af acting_af drugs_af alcohol_af ._af"
2681,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",paliperidone,centrally acting drugs,advise,"Given_bf primary_bf CNS_bf effects_bf DRUG ,_be INVEGA_be used_be caution_be combination_be centrally_be acting_be drugs_be alcohol_be ._be"
2682,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",paliperidone,alcohol,advise,"Given_bf primary_bf CNS_bf effects_bf DRUG ,_be INVEGA_be used_be caution_be combination_be centrally_be acting_be drugs_be OTHER_DRUG ._af"
2683,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",INVEGA,centrally acting drugs,advise,"Given_bf primary_bf CNS_bf effects_bf paliperidone_bf ,_bf DRUG used_be caution_be combination_be centrally_be acting_be drugs_be alcohol_be ._be"
2684,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",INVEGA,alcohol,advise,"Given_bf primary_bf CNS_bf effects_bf paliperidone_bf ,_bf DRUG used_be caution_be combination_be centrally_be acting_be drugs_be OTHER_DRUG ._af"
2685,"Given the primary CNS effects of paliperidone, INVEGA    should be used with caution in combination with other centrally acting drugs and alcohol. ",centrally acting drugs,alcohol,No interaction,"Given_bf primary_bf CNS_bf effects_bf paliperidone_bf ,_bf INVEGA_bf used_bf caution_bf combination_bf centrally_bf acting_bf drugs_bf OTHER_DRUG ._be"
2686,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,Paliperidone,levodopa,effect,DRUG may_be antagonize_be effect_be OTHER_DRUG dopamine_af agonists_af ._af
2687,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,Paliperidone,dopamine agonists,effect,DRUG may_be antagonize_be effect_be levodopa_be dopamine_be agonists_be ._be
2688,Paliperidone may antagonize the effect of levodopa and other dopamine agonists. ,levodopa,dopamine agonists,No interaction,Paliperidone_bf may_bf antagonize_bf effect_bf DRUG dopamine_be agonists_be ._be
2689,"Potential for Other Drugs to Affect INVEGA    Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19, so that an interaction with inhibitors or inducers of these isozymes is unlikely. ",INVEGA,Paliperidone,No interaction,"Potential_bf Other_bf Drugs_bf Affect_bf DRUG OTHER_DRUG substrate_af CYP1A2_af ,_af CYP2A6_af ,_af CYP2C9_af ,_af CYP2C19_af ,_af interaction_af inhibitors_af inducers_af isozymes_af unlikely_af ._af"
2690,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,theophylline,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be OTHER_DRUG ,_af cisapride_af ,_af antipyrine_af ,_af caffeine_af ,_af carbamazepine_af ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2691,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,cisapride,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be OTHER_DRUG ,_af antipyrine_af ,_af caffeine_af ,_af carbamazepine_af ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2692,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,antipyrine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be OTHER_DRUG ,_af caffeine_af ,_af carbamazepine_af ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2693,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,caffeine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2694,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,carbamazepine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be OTHER_DRUG ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2695,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,diazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be OTHER_DRUG (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2696,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,desmethyldiazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2697,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,diclofenac,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be OTHER_DRUG ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2698,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,naproxen,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be OTHER_DRUG ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2699,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,piroxicam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be OTHER_DRUG ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2700,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,digoxin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be OTHER_DRUG ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2701,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be OTHER_DRUG ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2702,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2703,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2704,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2705,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2706,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2707,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2708,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2709,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2710,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2711,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2712,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2713,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",pantoprazole,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf DRUG drugs_be ,_be dosage_be adjustment_be needed_be concomitant_be use_be following:_be theophylline_be ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2714,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,cisapride,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be OTHER_DRUG ,_af antipyrine_af ,_af caffeine_af ,_af carbamazepine_af ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2715,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,antipyrine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be OTHER_DRUG ,_af caffeine_af ,_af carbamazepine_af ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2716,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,caffeine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2717,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,carbamazepine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be OTHER_DRUG ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2718,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,diazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be OTHER_DRUG (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2719,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,desmethyldiazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2720,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,diclofenac,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be OTHER_DRUG ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2721,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,naproxen,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be OTHER_DRUG ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2722,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,piroxicam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be OTHER_DRUG ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2723,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,digoxin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be OTHER_DRUG ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2724,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be OTHER_DRUG ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2725,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2726,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2727,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2728,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2729,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2730,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2731,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2732,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2733,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2734,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2735,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2736,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",theophylline,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf DRUG ,_be cisapride_be ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2737,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,antipyrine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be OTHER_DRUG ,_af caffeine_af ,_af carbamazepine_af ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2738,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,caffeine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2739,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,carbamazepine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be OTHER_DRUG ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2740,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,diazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be OTHER_DRUG (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2741,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,desmethyldiazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2742,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,diclofenac,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be OTHER_DRUG ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2743,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,naproxen,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be OTHER_DRUG ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2744,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,piroxicam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be OTHER_DRUG ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2745,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,digoxin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be OTHER_DRUG ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2746,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be OTHER_DRUG ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2747,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2748,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2749,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2750,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2751,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2752,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2753,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2754,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2755,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2756,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2757,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2758,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",cisapride,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf DRUG ,_be antipyrine_be ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2759,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,caffeine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be OTHER_DRUG ,_af carbamazepine_af ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2760,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,carbamazepine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be OTHER_DRUG ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2761,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,diazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be OTHER_DRUG (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2762,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,desmethyldiazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2763,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,diclofenac,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be OTHER_DRUG ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2764,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,naproxen,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be OTHER_DRUG ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2765,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,piroxicam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be OTHER_DRUG ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2766,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,digoxin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be OTHER_DRUG ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2767,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be OTHER_DRUG ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2768,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2769,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2770,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2771,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2772,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2773,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2774,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2775,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2776,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2777,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2778,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2779,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",antipyrine,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf DRUG ,_be caffeine_be ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2780,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,carbamazepine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af diazepam_af (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2781,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,diazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be OTHER_DRUG (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2782,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,desmethyldiazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2783,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,diclofenac,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be OTHER_DRUG ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2784,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,naproxen,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be OTHER_DRUG ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2785,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,piroxicam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be OTHER_DRUG ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2786,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,digoxin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be OTHER_DRUG ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2787,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be OTHER_DRUG ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2788,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2789,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2790,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2791,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2792,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2793,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2794,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2795,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2796,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2797,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2798,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2799,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",caffeine,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf DRUG ,_be carbamazepine_be ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2800,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,diazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be OTHER_DRUG (and_af active_af metabolite_af ,_af desmethyldiazepam)_af ,_af diclofenac_af ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2801,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,desmethyldiazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2802,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,diclofenac,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be OTHER_DRUG ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2803,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,naproxen,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be OTHER_DRUG ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2804,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,piroxicam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be OTHER_DRUG ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2805,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,digoxin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be OTHER_DRUG ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2806,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be OTHER_DRUG ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2807,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2808,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2809,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2810,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2811,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2812,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2813,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2814,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2815,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2816,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2817,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2818,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",carbamazepine,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf DRUG ,_be diazepam_be (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2819,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,desmethyldiazepam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2820,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,diclofenac,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be OTHER_DRUG ,_af naproxen_af ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2821,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,naproxen,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be OTHER_DRUG ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2822,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,piroxicam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be OTHER_DRUG ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2823,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,digoxin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be OTHER_DRUG ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2824,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be OTHER_DRUG ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2825,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2826,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2827,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2828,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2829,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2830,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2831,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2832,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2833,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2834,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2835,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2836,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diazepam,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf DRUG (and_be active_be metabolite_be ,_be desmethyldiazepam)_be ,_be diclofenac_be ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2837,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,diclofenac,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf OTHER_DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2838,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,naproxen,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf OTHER_DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2839,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,piroxicam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf OTHER_DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2840,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,digoxin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf OTHER_DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2841,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf OTHER_DRUG ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2842,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf OTHER_DRUG ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2843,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf OTHER_DRUG (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2844,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf clarithromycin_bf ,_bf metronidazole_bf ,_bf amoxicillin_bf ._bf"
2845,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf clarithromycin_bf ,_bf metronidazole_bf ,_bf amoxicillin_bf ._bf"
2846,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf OTHER_DRUG ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2847,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf OTHER_DRUG ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2848,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf OTHER_DRUG ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2849,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf OTHER_DRUG ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2850,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf OTHER_DRUG ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2851,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf OTHER_DRUG ,_be metronidazole_be ,_be amoxicillin_be ._be"
2852,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf clarithromycin_bf ,_bf OTHER_DRUG ,_be amoxicillin_be ._be"
2853,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",desmethyldiazepam,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf clarithromycin_bf ,_bf metronidazole_bf ,_bf OTHER_DRUG ._be"
2854,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,naproxen,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be OTHER_DRUG ,_af piroxicam_af ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2855,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,piroxicam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be OTHER_DRUG ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2856,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,digoxin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be OTHER_DRUG ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2857,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be OTHER_DRUG ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2858,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2859,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2860,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2861,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2862,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2863,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2864,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2865,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2866,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2867,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2868,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2869,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",diclofenac,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf DRUG ,_be naproxen_be ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2870,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,piroxicam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be OTHER_DRUG ,_af digoxin_af ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2871,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,digoxin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be OTHER_DRUG ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2872,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be OTHER_DRUG ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2873,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2874,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2875,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2876,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2877,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2878,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2879,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2880,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2881,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2882,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2883,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2884,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",naproxen,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf DRUG ,_be piroxicam_be ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2885,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,digoxin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be OTHER_DRUG ,_af ethanol_af ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2886,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be OTHER_DRUG ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2887,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2888,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2889,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2890,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2891,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2892,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2893,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2894,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2895,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2896,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2897,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2898,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",piroxicam,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf DRUG ,_be digoxin_be ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2899,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,ethanol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be OTHER_DRUG ,_af glyburide_af ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2900,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2901,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2902,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2903,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2904,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2905,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2906,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2907,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2908,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2909,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2910,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2911,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",digoxin,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf DRUG ,_be ethanol_be ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2912,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,glyburide,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af oral_af contraceptive_af (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2913,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be glyburide_be ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2914,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2915,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2916,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2917,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2918,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2919,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2920,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2921,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2922,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2923,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethanol,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf DRUG ,_be glyburide_be ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2924,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",glyburide,contraceptive,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf DRUG ,_be oral_be OTHER_DRUG (levonorgestrel/ethinyl_af estradiol)_af ,_af metoprolol_af ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2925,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",glyburide,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf DRUG ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2926,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",glyburide,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf DRUG ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2927,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",glyburide,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf DRUG ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2928,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",glyburide,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf DRUG ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2929,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",glyburide,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf DRUG ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2930,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",glyburide,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf DRUG ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2931,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",glyburide,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf DRUG ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2932,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",glyburide,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf DRUG ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2933,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",glyburide,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf DRUG ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2934,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",glyburide,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf DRUG ,_be oral_be contraceptive_be (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2935,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",contraceptive,levonorgestrel,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf DRUG (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2936,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",contraceptive,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf DRUG (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2937,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",contraceptive,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf DRUG (levonorgestrel/ethinyl_be estradiol)_be ,_be OTHER_DRUG ,_af nifedipine_af ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2938,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",contraceptive,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf DRUG (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2939,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",contraceptive,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf DRUG (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2940,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",contraceptive,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf DRUG (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2941,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",contraceptive,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf DRUG (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2942,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",contraceptive,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf DRUG (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2943,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",contraceptive,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf DRUG (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2944,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",contraceptive,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf DRUG (levonorgestrel/ethinyl_be estradiol)_be ,_be metoprolol_be ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2945,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",levonorgestrel,ethinyl estradiol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf clarithromycin_bf ,_bf metronidazole_bf ,_bf amoxicillin_bf ._bf"
2946,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",levonorgestrel,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf OTHER_DRUG ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2947,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",levonorgestrel,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf OTHER_DRUG ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2948,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",levonorgestrel,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf OTHER_DRUG ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2949,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",levonorgestrel,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf OTHER_DRUG ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2950,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",levonorgestrel,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf OTHER_DRUG ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2951,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",levonorgestrel,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf OTHER_DRUG ,_be metronidazole_be ,_be amoxicillin_be ._be"
2952,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",levonorgestrel,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf clarithromycin_bf ,_bf OTHER_DRUG ,_be amoxicillin_be ._be"
2953,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",levonorgestrel,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf clarithromycin_bf ,_bf metronidazole_bf ,_bf OTHER_DRUG ._be"
2954,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethinyl estradiol,metoprolol,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf OTHER_DRUG ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2955,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethinyl estradiol,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf OTHER_DRUG ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2956,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethinyl estradiol,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf OTHER_DRUG ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2957,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethinyl estradiol,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf OTHER_DRUG ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2958,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethinyl estradiol,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf OTHER_DRUG ,_be clarithromycin_be ,_be metronidazole_be ,_be amoxicillin_be ._be"
2959,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethinyl estradiol,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf OTHER_DRUG ,_be metronidazole_be ,_be amoxicillin_be ._be"
2960,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethinyl estradiol,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf clarithromycin_bf ,_bf OTHER_DRUG ,_be amoxicillin_be ._be"
2961,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",ethinyl estradiol,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf clarithromycin_bf ,_bf metronidazole_bf ,_bf OTHER_DRUG ._be"
2962,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",metoprolol,nifedipine,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf DRUG ,_be OTHER_DRUG ,_af phenytoin_af ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2963,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",metoprolol,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf DRUG ,_be nifedipine_be ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2964,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",metoprolol,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf DRUG ,_be nifedipine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2965,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",metoprolol,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf DRUG ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2966,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",metoprolol,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf DRUG ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2967,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",metoprolol,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf DRUG ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2968,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",metoprolol,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf DRUG ,_be nifedipine_be ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2969,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",nifedipine,phenytoin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf DRUG ,_be OTHER_DRUG ,_af warfarin_af ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2970,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",nifedipine,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf DRUG ,_be phenytoin_be ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2971,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",nifedipine,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf DRUG ,_be phenytoin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2972,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",nifedipine,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf DRUG ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2973,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",nifedipine,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf DRUG ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2974,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",nifedipine,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf DRUG ,_be phenytoin_be ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2975,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",phenytoin,warfarin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af midazolam_af ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2976,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",phenytoin,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf DRUG ,_be warfarin_be ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2977,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",phenytoin,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf DRUG ,_be warfarin_be ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2978,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",phenytoin,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf DRUG ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2979,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",phenytoin,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf DRUG ,_be warfarin_be ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2980,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",warfarin,midazolam,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af clarithromycin_af ,_af metronidazole_af ,_af amoxicillin_af ._af"
2981,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",warfarin,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf DRUG ,_be midazolam_be ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2982,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",warfarin,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf DRUG ,_be midazolam_be ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2983,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",warfarin,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf DRUG ,_be midazolam_be ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2984,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",midazolam,clarithromycin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af metronidazole_af ,_af amoxicillin_af ._af"
2985,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",midazolam,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf DRUG ,_be clarithromycin_be ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2986,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",midazolam,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf DRUG ,_be clarithromycin_be ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2987,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",clarithromycin,metronidazole,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf DRUG ,_be OTHER_DRUG ,_af amoxicillin_af ._af"
2988,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",clarithromycin,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf DRUG ,_be metronidazole_be ,_be OTHER_DRUG ._af"
2989,"Based on studies evaluating possible interactions of pantoprazole with other drugs, no dosage adjustment is needed with concomitant use of the following: theophylline, cisapride, antipyrine, caffeine, carbamazepine, diazepam (and its active metabolite, desmethyldiazepam), diclofenac, naproxen, piroxicam, digoxin, ethanol, glyburide, an oral contraceptive (levonorgestrel/ethinyl estradiol), metoprolol, nifedipine, phenytoin, warfarin, midazolam, clarithromycin, metronidazole, or amoxicillin. ",metronidazole,amoxicillin,No interaction,"Based_bf studies_bf evaluating_bf possible_bf interactions_bf pantoprazole_bf drugs_bf ,_bf dosage_bf adjustment_bf needed_bf concomitant_bf use_bf following:_bf theophylline_bf ,_bf cisapride_bf ,_bf antipyrine_bf ,_bf caffeine_bf ,_bf carbamazepine_bf ,_bf diazepam_bf (and_bf active_bf metabolite_bf ,_bf desmethyldiazepam)_bf ,_bf diclofenac_bf ,_bf naproxen_bf ,_bf piroxicam_bf ,_bf digoxin_bf ,_bf ethanol_bf ,_bf glyburide_bf ,_bf oral_bf contraceptive_bf (levonorgestrel/ethinyl_bf estradiol)_bf ,_bf metoprolol_bf ,_bf nifedipine_bf ,_bf phenytoin_bf ,_bf warfarin_bf ,_bf midazolam_bf ,_bf clarithromycin_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
2990,"Therefore, when coadministered with pantoprazole, adjustment of the dosage of pantoprazole or of such drugs may not be necessary. ",pantoprazole,pantoprazole,No interaction,"Therefore_bf ,_bf coadministered_bf DRUG ,_be adjustment_be dosage_be DRUG drugs_af may_af necessary_af ._af"
2991,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",proton pump inhibitors,pantoprazole,No interaction,"There_bf postmarketing_bf reports_bf increased_bf INR_bf prothrombin_bf time_bf patients_bf receiving_bf proton_bf pump_bf inhibitors_bf ,_bf including_bf OTHER_DRUG ,_be warfarin_be concomitantly_be ._be"
2992,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",proton pump inhibitors,warfarin,effect,"There_bf postmarketing_bf reports_bf increased_bf INR_bf prothrombin_bf time_bf patients_bf receiving_bf proton_bf pump_bf inhibitors_bf ,_bf including_bf pantoprazole_bf ,_bf OTHER_DRUG concomitantly_be ._be"
2993,"There have been postmarketing reports of increased INR and prothrombin time in patients receiving proton pump inhibitors, including pantoprazole, and warfarin concomitantly. ",pantoprazole,warfarin,effect,"There_bf postmarketing_bf reports_bf increased_bf INR_bf prothrombin_bf time_bf patients_bf receiving_bf proton_bf pump_bf inhibitors_bf ,_bf including_bf DRUG ,_be OTHER_DRUG concomitantly_af ._af"
2994,Patients treated with proton pump inhibitors and warfarin concomitantly should be monitored for increases in INR and prothrombin time. ,proton pump inhibitors,warfarin,advise,Patients_bf treated_bf proton_bf pump_bf inhibitors_bf OTHER_DRUG concomitantly_be monitored_be increases_be INR_be prothrombin_be time_be ._be
2995,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,ketoconazole,mechanism,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be OTHER_DRUG ,_af ampicillin_af esters_af ,_af iron_af salts)_af ._af"
2996,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,ampicillin,mechanism,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be ketoconazole_be ,_be OTHER_DRUG esters_af ,_af iron_af salts)_af ._af"
2997,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",pantoprazole,iron,mechanism,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf DRUG may_be interfere_be absorption_be drugs_be gastric_be pH_be important_be determinant_be bioavailability_be (eg_be ,_be ketoconazole_be ,_be ampicillin_be esters_be ,_be OTHER_DRUG salts)_af ._af"
2998,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",ketoconazole,ampicillin,No interaction,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf pantoprazole_bf may_bf interfere_bf absorption_bf drugs_bf gastric_bf pH_bf important_bf determinant_bf bioavailability_bf (eg_bf ,_bf DRUG ,_be OTHER_DRUG esters_af ,_af iron_af salts)_af ._af"
2999,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",ketoconazole,iron,No interaction,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf pantoprazole_bf may_bf interfere_bf absorption_bf drugs_bf gastric_bf pH_bf important_bf determinant_bf bioavailability_bf (eg_bf ,_bf DRUG ,_be ampicillin_be esters_be ,_be OTHER_DRUG salts)_af ._af"
3000,"Because of profound and long lasting inhibition of gastric acid secretion, pantoprazole may interfere with absorption of drugs where gastric pH is an important determinant of their bioavailability (eg, ketoconazole, ampicillin esters, and iron salts). ",ampicillin,iron,No interaction,"Because_bf profound_bf long_bf lasting_bf inhibition_bf gastric_bf acid_bf secretion_bf ,_bf pantoprazole_bf may_bf interfere_bf absorption_bf drugs_bf gastric_bf pH_bf important_bf determinant_bf bioavailability_bf (eg_bf ,_bf ketoconazole_bf ,_bf DRUG esters_be ,_be OTHER_DRUG salts)_af ._af"
3001,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",tetrahydrocannabinol,THC,No interaction,"Laboratory_bf Tests_bf There_bf reports_bf false-positive_bf urine_bf screening_bf tests_bf DRUG (THC)_be patients_be receiving_be proton_be pump_be inhibitors_be ,_be including_be pantoprazole_be ._be"
3002,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",tetrahydrocannabinol,proton pump inhibitors,No interaction,"Laboratory_bf Tests_bf There_bf reports_bf false-positive_bf urine_bf screening_bf tests_bf DRUG (THC)_be patients_be receiving_be proton_be pump_be inhibitors_be ,_be including_be pantoprazole_be ._be"
3003,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",tetrahydrocannabinol,pantoprazole,No interaction,"Laboratory_bf Tests_bf There_bf reports_bf false-positive_bf urine_bf screening_bf tests_bf DRUG (THC)_be patients_be receiving_be proton_be pump_be inhibitors_be ,_be including_be OTHER_DRUG ._af"
3004,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",THC,proton pump inhibitors,No interaction,"Laboratory_bf Tests_bf There_bf reports_bf false-positive_bf urine_bf screening_bf tests_bf tetrahydrocannabinol_bf (THC)_bf patients_bf receiving_bf proton_bf pump_bf inhibitors_bf ,_bf including_bf pantoprazole_bf ._bf"
3005,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",THC,pantoprazole,No interaction,"Laboratory_bf Tests_bf There_bf reports_bf false-positive_bf urine_bf screening_bf tests_bf tetrahydrocannabinol_bf (THC)_bf patients_bf receiving_bf proton_bf pump_bf inhibitors_bf ,_bf including_bf OTHER_DRUG ._be"
3006,"Laboratory Tests There have been reports of false-positive urine screening tests for tetrahydrocannabinol (THC) in patients receiving most proton pump inhibitors, including pantoprazole. ",proton pump inhibitors,pantoprazole,No interaction,"Laboratory_bf Tests_bf There_bf reports_bf false-positive_bf urine_bf screening_bf tests_bf tetrahydrocannabinol_bf (THC)_bf patients_bf receiving_bf proton_bf pump_bf inhibitors_bf ,_bf including_bf OTHER_DRUG ._be"
3007,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,paricalcitol,mechanism,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be OTHER_DRUG AUC0-_af ._af Since_af OTHER_DRUG partially_af metabolized_af CYP3A_af DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af OTHER_DRUG DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3008,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,paricalcitol,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be OTHER_DRUG AUC0-_af ._af Since_af OTHER_DRUG partially_af metabolized_af CYP3A_af DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af OTHER_DRUG DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3009,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,ketoconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3010,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,paricalcitol,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be OTHER_DRUG AUC0-_af ._af Since_af OTHER_DRUG partially_af metabolized_af CYP3A_af DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af OTHER_DRUG DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3011,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,ketoconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3012,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,atazanavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af OTHER_DRUG ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3013,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,clarithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af OTHER_DRUG ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3014,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,indinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3015,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,itraconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3016,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,nefazodone,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3017,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,nelfinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3018,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,ritonavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3019,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3020,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af OTHER_DRUG voriconazole_af ._af"
3021,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af OTHER_DRUG ._af"
3022,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,paricalcitol,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3023,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ketoconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf OTHER_DRUG approximately_be doubled_be DRUG AUC0-_af ._af Since_af DRUG partially_af metabolized_af CYP3A_af OTHER_DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG OTHER_DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3024,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,paricalcitol,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3025,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ketoconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf OTHER_DRUG approximately_be doubled_be DRUG AUC0-_af ._af Since_af DRUG partially_af metabolized_af CYP3A_af OTHER_DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG OTHER_DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3026,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,atazanavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af OTHER_DRUG ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3027,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,clarithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af OTHER_DRUG ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3028,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,indinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3029,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,itraconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3030,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nefazodone,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3031,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nelfinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3032,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ritonavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3033,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3034,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af OTHER_DRUG voriconazole_af ._af"
3035,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af OTHER_DRUG ._af"
3036,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ketoconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf OTHER_DRUG approximately_be doubled_be DRUG AUC0-_af ._af Since_af DRUG partially_af metabolized_af CYP3A_af OTHER_DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG OTHER_DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3037,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,paricalcitol,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3038,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ketoconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf OTHER_DRUG approximately_be doubled_be DRUG AUC0-_af ._af Since_af DRUG partially_af metabolized_af CYP3A_af OTHER_DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG OTHER_DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3039,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,atazanavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af OTHER_DRUG ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3040,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,clarithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af OTHER_DRUG ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3041,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,indinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3042,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,itraconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3043,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nefazodone,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3044,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nelfinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3045,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ritonavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3046,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3047,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af OTHER_DRUG voriconazole_af ._af"
3048,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af OTHER_DRUG ._af"
3049,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,paricalcitol,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be OTHER_DRUG AUC0-_af ._af Since_af OTHER_DRUG partially_af metabolized_af CYP3A_af DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af OTHER_DRUG DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3050,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,ketoconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3051,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,atazanavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af OTHER_DRUG ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3052,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,clarithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af OTHER_DRUG ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3053,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,indinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3054,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,itraconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3055,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,nefazodone,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3056,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,nelfinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3057,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,ritonavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3058,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3059,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af OTHER_DRUG voriconazole_af ._af"
3060,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af OTHER_DRUG ._af"
3061,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ketoconazole,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf OTHER_DRUG approximately_be doubled_be DRUG AUC0-_af ._af Since_af DRUG partially_af metabolized_af CYP3A_af OTHER_DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG OTHER_DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3062,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,atazanavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af OTHER_DRUG ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3063,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,clarithromycin,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af OTHER_DRUG ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3064,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,indinavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3065,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,itraconazole,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3066,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nefazodone,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3067,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,nelfinavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3068,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,ritonavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3069,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,saquinavir,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3070,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,telithromycin,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af OTHER_DRUG voriconazole_af ._af"
3071,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",paricalcitol,voriconazole,advise,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf DRUG AUC0-_be ._be Since_be DRUG partially_af metabolized_af CYP3A_af ketoconazole_af le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af DRUG ketoconazole_af strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af OTHER_DRUG ._af"
3072,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,atazanavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af OTHER_DRUG ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3073,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,clarithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af OTHER_DRUG ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3074,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,indinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3075,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,itraconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3076,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,nefazodone,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3077,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,nelfinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3078,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,ritonavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3079,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3080,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af OTHER_DRUG voriconazole_af ._af"
3081,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ketoconazole,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf DRUG approximately_be doubled_be paricalcitol_be AUC0-_be ._be Since_be paricalcitol_be partially_be metabolized_be CYP3A_be DRUG le_af known_af strong_af inhibitor_af cytochrome_af P450_af 3A_af enzyme_af ,_af care_af taken_af dosing_af paricalcitol_af DRUG strong_af P450_af 3A_af inhibitors_af including_af atazanavir_af ,_af clarithromycin_af ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af OTHER_DRUG ._af"
3082,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",atazanavir,clarithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf DRUG ,_be OTHER_DRUG ,_af indinavir_af ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3083,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",atazanavir,indinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf DRUG ,_be clarithromycin_be ,_be OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3084,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",atazanavir,itraconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf DRUG ,_be clarithromycin_be ,_be indinavir_be ,_be OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3085,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",atazanavir,nefazodone,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf DRUG ,_be clarithromycin_be ,_be indinavir_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3086,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",atazanavir,nelfinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf DRUG ,_be clarithromycin_be ,_be indinavir_be ,_be itraconazole_be ,_be nefazodone_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3087,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",atazanavir,ritonavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf DRUG ,_be clarithromycin_be ,_be indinavir_be ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3088,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",atazanavir,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf DRUG ,_be clarithromycin_be ,_be indinavir_be ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3089,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",atazanavir,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf DRUG ,_be clarithromycin_be ,_be indinavir_be ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be saquinavir_be ,_be OTHER_DRUG voriconazole_af ._af"
3090,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",atazanavir,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf DRUG ,_be clarithromycin_be ,_be indinavir_be ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be saquinavir_be ,_be telithromycin_be OTHER_DRUG ._af"
3091,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",clarithromycin,indinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf DRUG ,_be OTHER_DRUG ,_af itraconazole_af ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3092,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",clarithromycin,itraconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf DRUG ,_be indinavir_be ,_be OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3093,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",clarithromycin,nefazodone,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf DRUG ,_be indinavir_be ,_be itraconazole_be ,_be OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3094,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",clarithromycin,nelfinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf DRUG ,_be indinavir_be ,_be itraconazole_be ,_be nefazodone_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3095,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",clarithromycin,ritonavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf DRUG ,_be indinavir_be ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3096,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",clarithromycin,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf DRUG ,_be indinavir_be ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3097,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",clarithromycin,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf DRUG ,_be indinavir_be ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be saquinavir_be ,_be OTHER_DRUG voriconazole_af ._af"
3098,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",clarithromycin,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf DRUG ,_be indinavir_be ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be saquinavir_be ,_be telithromycin_be OTHER_DRUG ._af"
3099,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",indinavir,itraconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af nefazodone_af ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3100,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",indinavir,nefazodone,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf DRUG ,_be itraconazole_be ,_be OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3101,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",indinavir,nelfinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf DRUG ,_be itraconazole_be ,_be nefazodone_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3102,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",indinavir,ritonavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf DRUG ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3103,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",indinavir,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf DRUG ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3104,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",indinavir,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf DRUG ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be saquinavir_be ,_be OTHER_DRUG voriconazole_af ._af"
3105,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",indinavir,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf DRUG ,_be itraconazole_be ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be saquinavir_be ,_be telithromycin_be OTHER_DRUG ._af"
3106,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",itraconazole,nefazodone,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf DRUG ,_be OTHER_DRUG ,_af nelfinavir_af ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3107,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",itraconazole,nelfinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf DRUG ,_be nefazodone_be ,_be OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3108,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",itraconazole,ritonavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf DRUG ,_be nefazodone_be ,_be nelfinavir_be ,_be OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3109,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",itraconazole,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf DRUG ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3110,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",itraconazole,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf DRUG ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be saquinavir_be ,_be OTHER_DRUG voriconazole_af ._af"
3111,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",itraconazole,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf DRUG ,_be nefazodone_be ,_be nelfinavir_be ,_be ritonavir_be ,_be saquinavir_be ,_be telithromycin_be OTHER_DRUG ._af"
3112,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",nefazodone,nelfinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf DRUG ,_be OTHER_DRUG ,_af ritonavir_af ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3113,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",nefazodone,ritonavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf DRUG ,_be nelfinavir_be ,_be OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3114,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",nefazodone,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf DRUG ,_be nelfinavir_be ,_be ritonavir_be ,_be OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3115,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",nefazodone,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf DRUG ,_be nelfinavir_be ,_be ritonavir_be ,_be saquinavir_be ,_be OTHER_DRUG voriconazole_af ._af"
3116,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",nefazodone,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf DRUG ,_be nelfinavir_be ,_be ritonavir_be ,_be saquinavir_be ,_be telithromycin_be OTHER_DRUG ._af"
3117,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",nelfinavir,ritonavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf nefazodone_bf ,_bf DRUG ,_be OTHER_DRUG ,_af saquinavir_af ,_af telithromycin_af voriconazole_af ._af"
3118,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",nelfinavir,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf nefazodone_bf ,_bf DRUG ,_be ritonavir_be ,_be OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3119,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",nelfinavir,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf nefazodone_bf ,_bf DRUG ,_be ritonavir_be ,_be saquinavir_be ,_be OTHER_DRUG voriconazole_af ._af"
3120,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",nelfinavir,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf nefazodone_bf ,_bf DRUG ,_be ritonavir_be ,_be saquinavir_be ,_be telithromycin_be OTHER_DRUG ._af"
3121,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ritonavir,saquinavir,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf nefazodone_bf ,_bf nelfinavir_bf ,_bf DRUG ,_be OTHER_DRUG ,_af telithromycin_af voriconazole_af ._af"
3122,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ritonavir,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf nefazodone_bf ,_bf nelfinavir_bf ,_bf DRUG ,_be saquinavir_be ,_be OTHER_DRUG voriconazole_af ._af"
3123,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",ritonavir,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf nefazodone_bf ,_bf nelfinavir_bf ,_bf DRUG ,_be saquinavir_be ,_be telithromycin_be OTHER_DRUG ._af"
3124,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",saquinavir,telithromycin,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf nefazodone_bf ,_bf nelfinavir_bf ,_bf ritonavir_bf ,_bf DRUG ,_be OTHER_DRUG voriconazole_af ._af"
3125,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",saquinavir,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf nefazodone_bf ,_bf nelfinavir_bf ,_bf ritonavir_bf ,_bf DRUG ,_be telithromycin_be OTHER_DRUG ._af"
3126,"A multiple dose drug-drug interaction study demonstrated that ketoconazole approximately doubled paricalcitol AUC0-   . Since paricalcitol is partially metabolized by CYP3A and ketoconazole le is known to be a strong inhibitor of cytochrome P450 3A enzyme, care should be taken while dosing paricalcitol with ketoconazole and other strong P450 3A inhibitors including atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin or voriconazole. ",telithromycin,voriconazole,No interaction,"A_bf multiple_bf dose_bf drug-drug_bf interaction_bf study_bf demonstrated_bf ketoconazole_bf approximately_bf doubled_bf paricalcitol_bf AUC0-_bf ._bf Since_bf paricalcitol_bf partially_bf metabolized_bf CYP3A_bf ketoconazole_bf le_bf known_bf strong_bf inhibitor_bf cytochrome_bf P450_bf 3A_bf enzyme_bf ,_bf care_bf taken_bf dosing_bf paricalcitol_bf ketoconazole_bf strong_bf P450_bf 3A_bf inhibitors_bf including_bf atazanavir_bf ,_bf clarithromycin_bf ,_bf indinavir_bf ,_bf itraconazole_bf ,_bf nefazodone_bf ,_bf nelfinavir_bf ,_bf ritonavir_bf ,_bf saquinavir_bf ,_bf DRUG OTHER_DRUG ._af"
3127,"Dose adjustment of Zemplar Capsules may be required, and iPTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor such as ketoconazole. ",Zemplar,ketoconazole,advise,"Dose_bf adjustment_bf DRUG Capsules_be may_be required_be ,_be iPTH_be serum_be calcium_be concentrations_be closely_be monitored_be patient_be initiates_be discontinues_be therapy_be strong_be CYP3A4_be inhibitor_be OTHER_DRUG ._af"
3128,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",fat-soluble vitamins,cholestyramine,mechanism,"Drugs_bf impair_bf intestinal_bf absorption_bf fat-soluble_bf vitamins_bf ,_bf OTHER_DRUG ,_be may_be interfere_be absorption_be Zemplar_be Capsules_be ._be"
3129,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",fat-soluble vitamins,Zemplar,No interaction,"Drugs_bf impair_bf intestinal_bf absorption_bf fat-soluble_bf vitamins_bf ,_bf cholestyramine_bf ,_bf may_bf interfere_bf absorption_bf OTHER_DRUG Capsules_be ._be"
3130,"Drugs that impair intestinal absorption of fat-soluble vitamins, such as cholestyramine, may interfere with the absorption of Zemplar Capsules.",cholestyramine,Zemplar,mechanism,"Drugs_bf impair_bf intestinal_bf absorption_bf fat-soluble_bf vitamins_bf ,_bf DRUG ,_be may_be interfere_be absorption_be OTHER_DRUG Capsules_af ._af"
3131,patients receiving lithium and Neulasta should have more frequent monitoring of neutrophil counts.,lithium,Neulasta,advise,patients_bf receiving_bf DRUG OTHER_DRUG frequent_af monitoring_af neutrophil_af counts_af ._af
3132,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,insulin,hypoglycemic,No interaction,Acromegalic_bf patients_bf diabetes_bf mellitus_bf treated_bf DRUG and/or_be oral_be OTHER_DRUG agents_af may_af require_af dose_af reductions_af therapeutic_af agents_af initiation_af therapy_af SOMAVERT_af ._af
3133,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,insulin,SOMAVERT,advise,Acromegalic_bf patients_bf diabetes_bf mellitus_bf treated_bf DRUG and/or_be oral_be hypoglycemic_be agents_be may_be require_be dose_be reductions_be therapeutic_be agents_be initiation_be therapy_be OTHER_DRUG ._af
3134,Acromegalic patients with diabetes mellitus being treated with insulin and/or oral hypoglycemic agents may require dose reductions of these therapeutic agents after the initiation of therapy with SOMAVERT. ,hypoglycemic,SOMAVERT,advise,Acromegalic_bf patients_bf diabetes_bf mellitus_bf treated_bf insulin_bf and/or_bf oral_bf DRUG agents_be may_be require_be dose_be reductions_be therapeutic_be agents_be initiation_be therapy_be OTHER_DRUG ._af
3135,"In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ",opioids,pegvisomant,mechanism,"In_bf clinical_bf studies_bf ,_bf patients_bf DRUG often_be needed_be higher_be serum_be OTHER_DRUG concentrations_af achieve_af appropriate_af IGF-I_af suppression_af compared_af patients_af receiving_af DRUG ._af"
3136,"In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ",opioids,opioids,No interaction,"In_bf clinical_bf studies_bf ,_bf patients_bf DRUG often_be needed_be higher_be serum_be pegvisomant_be concentrations_be achieve_be appropriate_be IGF-I_be suppression_be compared_be patients_be receiving_be DRUG ._af"
3137,"In clinical studies, patients on opioids often needed higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opioids. ",pegvisomant,opioids,No interaction,"In_bf clinical_bf studies_bf ,_bf patients_bf OTHER_DRUG often_be needed_be higher_be serum_be DRUG concentrations_af achieve_af appropriate_af IGF-I_af suppression_af compared_af patients_af receiving_af OTHER_DRUG ._af"
3138,The interaction of CYLERT (pemoline) with other drugs has not been studied in humans. ,CYLERT,pemoline,No interaction,The_bf interaction_bf DRUG (pemoline)_be drugs_be studied_be humans_be ._be
3139,Decreased seizure threshold has been reported in patients receiving CYLERT concomitantly with antiepileptic medications.,CYLERT,antiepileptic medications,effect,Decreased_bf seizure_bf threshold_bf reported_bf patients_bf receiving_bf DRUG concomitantly_be antiepileptic_be medications_be ._be
3140,"Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.",Alcohol,alcohol,No interaction,"Usage_bf Alcohol:_bf Due_bf potential_bf increased_bf CNS_bf depressants_bf effects_bf ,_bf DRUG used_be caution_be patients_be currently_be receiving_be pentazocine_be ._be"
3141,"Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.",Alcohol,pentazocine,No interaction,"Usage_bf Alcohol:_bf Due_bf potential_bf increased_bf CNS_bf depressants_bf effects_bf ,_bf DRUG used_be caution_be patients_be currently_be receiving_be OTHER_DRUG ._af"
3142,"Usage with Alcohol: Due to the potential for increased CNS depressants effects, alcohol should be used with caution in patients who are currently receiving pentazocine.",alcohol,pentazocine,advise,"Usage_bf Alcohol:_bf Due_bf potential_bf increased_bf CNS_bf depressants_bf effects_bf ,_bf DRUG used_be caution_be patients_be currently_be receiving_be OTHER_DRUG ._af"
3143,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",TRENTAL,anticoagulants,effect,"Although_bf causal_bf relationship_bf established_bf ,_bf reports_bf bleeding_bf and/or_bf prolonged_bf prothrombin_bf time_bf patients_bf treated_bf DRUG without_be OTHER_DRUG platelet_af aggregation_af inhibitors_af ._af"
3144,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",TRENTAL,platelet aggregation inhibitors,effect,"Although_bf causal_bf relationship_bf established_bf ,_bf reports_bf bleeding_bf and/or_bf prolonged_bf prothrombin_bf time_bf patients_bf treated_bf DRUG without_be anticoagulants_be platelet_be aggregation_be inhibitors_be ._be"
3145,"Although a causal relationship has not been established, there have been reports of bleeding and/or prolonged prothrombin time in patients treated with TRENTAL with and without anticoagulants or platelet aggregation inhibitors. ",anticoagulants,platelet aggregation inhibitors,No interaction,"Although_bf causal_bf relationship_bf established_bf ,_bf reports_bf bleeding_bf and/or_bf prolonged_bf prothrombin_bf time_bf patients_bf treated_bf TRENTAL_bf without_bf DRUG platelet_be aggregation_be inhibitors_be ._be"
3146,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,TRENTAL,theophylline,mechanism,Concomitant_bf administration_bf DRUG theophylline-containing_be drugs_be leads_be increased_be OTHER_DRUG levels_af OTHER_DRUG toxicity_af individuals_af ._af
3147,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,TRENTAL,theophylline,No interaction,Concomitant_bf administration_bf DRUG theophylline-containing_be drugs_be leads_be increased_be OTHER_DRUG levels_af OTHER_DRUG toxicity_af individuals_af ._af
3148,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,TRENTAL,theophylline,No interaction,Concomitant_bf administration_bf DRUG theophylline-containing_be drugs_be leads_be increased_be OTHER_DRUG levels_af OTHER_DRUG toxicity_af individuals_af ._af
3149,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,theophylline,theophylline,No interaction,Concomitant_bf administration_bf TRENTAL_bf theophylline-containing_bf drugs_bf leads_bf increased_bf DRUG levels_be DRUG toxicity_af individuals_af ._af
3150,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,theophylline,theophylline,No interaction,Concomitant_bf administration_bf TRENTAL_bf theophylline-containing_bf drugs_bf leads_bf increased_bf DRUG levels_be DRUG toxicity_af individuals_af ._af
3151,Concomitant administration of TRENTAL and theophylline-containing drugs leads to increased theophylline levels and theophylline toxicity in some individuals. ,theophylline,theophylline,No interaction,Concomitant_bf administration_bf TRENTAL_bf theophylline-containing_bf drugs_bf leads_bf increased_bf DRUG levels_be DRUG toxicity_af individuals_af ._af
3152,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",TRENTAL,antihypertensive drugs,No interaction,"DRUG used_be concurrently_be antihypertensive_be drugs_be ,_be beta_be blockers_be ,_be digitalis_be ,_be diuretics_be ,_be antidiabetic_be agents_be ,_be antiarrhythmics_be ,_be without_be observed_be problems_be ._be"
3153,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",TRENTAL,beta blockers,No interaction,"DRUG used_be concurrently_be antihypertensive_be drugs_be ,_be beta_be blockers_be ,_be digitalis_be ,_be diuretics_be ,_be antidiabetic_be agents_be ,_be antiarrhythmics_be ,_be without_be observed_be problems_be ._be"
3154,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",TRENTAL,digitalis,No interaction,"DRUG used_be concurrently_be antihypertensive_be drugs_be ,_be beta_be blockers_be ,_be OTHER_DRUG ,_af diuretics_af ,_af antidiabetic_af agents_af ,_af antiarrhythmics_af ,_af without_af observed_af problems_af ._af"
3155,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",TRENTAL,diuretics,No interaction,"DRUG used_be concurrently_be antihypertensive_be drugs_be ,_be beta_be blockers_be ,_be digitalis_be ,_be OTHER_DRUG ,_af antidiabetic_af agents_af ,_af antiarrhythmics_af ,_af without_af observed_af problems_af ._af"
3156,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",TRENTAL,antidiabetic agents,No interaction,"DRUG used_be concurrently_be antihypertensive_be drugs_be ,_be beta_be blockers_be ,_be digitalis_be ,_be diuretics_be ,_be antidiabetic_be agents_be ,_be antiarrhythmics_be ,_be without_be observed_be problems_be ._be"
3157,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",TRENTAL,antiarrhythmics,No interaction,"DRUG used_be concurrently_be antihypertensive_be drugs_be ,_be beta_be blockers_be ,_be digitalis_be ,_be diuretics_be ,_be antidiabetic_be agents_be ,_be OTHER_DRUG ,_af without_af observed_af problems_af ._af"
3158,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",antihypertensive drugs,beta blockers,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf digitalis_bf ,_bf diuretics_bf ,_bf antidiabetic_bf agents_bf ,_bf antiarrhythmics_bf ,_bf without_bf observed_bf problems_bf ._bf"
3159,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",antihypertensive drugs,digitalis,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf OTHER_DRUG ,_be diuretics_be ,_be antidiabetic_be agents_be ,_be antiarrhythmics_be ,_be without_be observed_be problems_be ._be"
3160,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",antihypertensive drugs,diuretics,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf digitalis_bf ,_bf OTHER_DRUG ,_be antidiabetic_be agents_be ,_be antiarrhythmics_be ,_be without_be observed_be problems_be ._be"
3161,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",antihypertensive drugs,antidiabetic agents,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf digitalis_bf ,_bf diuretics_bf ,_bf antidiabetic_bf agents_bf ,_bf antiarrhythmics_bf ,_bf without_bf observed_bf problems_bf ._bf"
3162,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",antihypertensive drugs,antiarrhythmics,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf digitalis_bf ,_bf diuretics_bf ,_bf antidiabetic_bf agents_bf ,_bf OTHER_DRUG ,_be without_be observed_be problems_be ._be"
3163,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",beta blockers,digitalis,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf OTHER_DRUG ,_be diuretics_be ,_be antidiabetic_be agents_be ,_be antiarrhythmics_be ,_be without_be observed_be problems_be ._be"
3164,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",beta blockers,diuretics,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf digitalis_bf ,_bf OTHER_DRUG ,_be antidiabetic_be agents_be ,_be antiarrhythmics_be ,_be without_be observed_be problems_be ._be"
3165,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",beta blockers,antidiabetic agents,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf digitalis_bf ,_bf diuretics_bf ,_bf antidiabetic_bf agents_bf ,_bf antiarrhythmics_bf ,_bf without_bf observed_bf problems_bf ._bf"
3166,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",beta blockers,antiarrhythmics,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf digitalis_bf ,_bf diuretics_bf ,_bf antidiabetic_bf agents_bf ,_bf OTHER_DRUG ,_be without_be observed_be problems_be ._be"
3167,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",digitalis,diuretics,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf DRUG ,_be OTHER_DRUG ,_af antidiabetic_af agents_af ,_af antiarrhythmics_af ,_af without_af observed_af problems_af ._af"
3168,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",digitalis,antidiabetic agents,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf DRUG ,_be diuretics_be ,_be antidiabetic_be agents_be ,_be antiarrhythmics_be ,_be without_be observed_be problems_be ._be"
3169,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",digitalis,antiarrhythmics,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf DRUG ,_be diuretics_be ,_be antidiabetic_be agents_be ,_be OTHER_DRUG ,_af without_af observed_af problems_af ._af"
3170,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",diuretics,antidiabetic agents,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf digitalis_bf ,_bf DRUG ,_be antidiabetic_be agents_be ,_be antiarrhythmics_be ,_be without_be observed_be problems_be ._be"
3171,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",diuretics,antiarrhythmics,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf digitalis_bf ,_bf DRUG ,_be antidiabetic_be agents_be ,_be OTHER_DRUG ,_af without_af observed_af problems_af ._af"
3172,"TRENTAL has been used concurrently with antihypertensive drugs, beta blockers, digitalis, diuretics, antidiabetic agents, and antiarrhythmics, without observed problems. ",antidiabetic agents,antiarrhythmics,No interaction,"TRENTAL_bf used_bf concurrently_bf antihypertensive_bf drugs_bf ,_bf beta_bf blockers_bf ,_bf digitalis_bf ,_bf diuretics_bf ,_bf antidiabetic_bf agents_bf ,_bf OTHER_DRUG ,_be without_be observed_be problems_be ._be"
3173,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Dopamine antagonists,neuroleptics,No interaction,"Dopamine_bf antagonists_bf ,_bf OTHER_DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3174,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Dopamine antagonists,phenothiazines,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf metoclopramide_bf ,_bf ordinarily_bf administered_bf concurrently_bf Permax_bf (a_bf dopamine_bf agonist);_bf"
3175,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Dopamine antagonists,butyrophenones,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf OTHER_DRUG ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3176,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Dopamine antagonists,thioxanthines,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf OTHER_DRUG )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3177,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Dopamine antagonists,metoclopramide,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf OTHER_DRUG ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3178,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Dopamine antagonists,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf metoclopramide_bf ,_bf ordinarily_bf administered_bf concurrently_bf OTHER_DRUG (a_be dopamine_be agonist);_be"
3179,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Dopamine antagonists,dopamine agonist,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf metoclopramide_bf ,_bf ordinarily_bf administered_bf concurrently_bf Permax_bf (a_bf dopamine_bf agonist);_bf"
3180,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",neuroleptics,phenothiazines,No interaction,"Dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3181,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",neuroleptics,butyrophenones,No interaction,"Dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be OTHER_DRUG ,_af thioxanthines_af )_af metoclopramide_af ,_af ordinarily_af administered_af concurrently_af Permax_af (a_af dopamine_af agonist);_af"
3182,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",neuroleptics,thioxanthines,No interaction,"Dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be OTHER_DRUG )_af metoclopramide_af ,_af ordinarily_af administered_af concurrently_af Permax_af (a_af dopamine_af agonist);_af"
3183,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",neuroleptics,metoclopramide,No interaction,"Dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthines_be )_be OTHER_DRUG ,_af ordinarily_af administered_af concurrently_af Permax_af (a_af dopamine_af agonist);_af"
3184,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",neuroleptics,Permax,advise,"Dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
3185,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",neuroleptics,dopamine agonist,No interaction,"Dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3186,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",phenothiazines,butyrophenones,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf OTHER_DRUG ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3187,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",phenothiazines,thioxanthines,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf OTHER_DRUG )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3188,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",phenothiazines,metoclopramide,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf OTHER_DRUG ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3189,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",phenothiazines,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf metoclopramide_bf ,_bf ordinarily_bf administered_bf concurrently_bf OTHER_DRUG (a_be dopamine_be agonist);_be"
3190,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",phenothiazines,dopamine agonist,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf metoclopramide_bf ,_bf ordinarily_bf administered_bf concurrently_bf Permax_bf (a_bf dopamine_bf agonist);_bf"
3191,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",butyrophenones,thioxanthines,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be OTHER_DRUG )_af metoclopramide_af ,_af ordinarily_af administered_af concurrently_af Permax_af (a_af dopamine_af agonist);_af"
3192,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",butyrophenones,metoclopramide,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be thioxanthines_be )_be OTHER_DRUG ,_af ordinarily_af administered_af concurrently_af Permax_af (a_af dopamine_af agonist);_af"
3193,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",butyrophenones,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
3194,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",butyrophenones,dopamine agonist,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be thioxanthines_be )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3195,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",thioxanthines,metoclopramide,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf DRUG )_be OTHER_DRUG ,_af ordinarily_af administered_af concurrently_af Permax_af (a_af dopamine_af agonist);_af"
3196,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",thioxanthines,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf DRUG )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
3197,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",thioxanthines,dopamine agonist,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf DRUG )_be metoclopramide_be ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3198,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",metoclopramide,Permax,advise,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf DRUG ,_be ordinarily_be administered_be concurrently_be OTHER_DRUG (a_af dopamine_af agonist);_af"
3199,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",metoclopramide,dopamine agonist,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf DRUG ,_be ordinarily_be administered_be concurrently_be Permax_be (a_be dopamine_be agonist);_be"
3200,"Dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthines ) or metoclopramide, ordinarily should not be administered concurrently with Permax (a dopamine agonist); ",Permax,dopamine agonist,No interaction,"Dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthines_bf )_bf metoclopramide_bf ,_bf ordinarily_bf administered_bf concurrently_bf DRUG (a_be dopamine_be agonist);_be"
3201,"Because pergolide mesylate is approximately 90% bound to plasma proteins, caution should be exercised if pergolide mesylate is coadministered with other drugs known to affect protein binding.",pergolide mesylate,pergolide mesylate,No interaction,"Because_bf pergolide_bf mesylate_bf approximately_bf 90%_bf bound_bf plasma_bf proteins_bf ,_bf caution_bf exercised_bf pergolide_bf mesylate_bf coadministered_bf drugs_bf known_bf affect_bf protein_bf binding_bf ._bf"
3202,"Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. ",Diuretics,diuretics,No interaction,"Diuretics:_bf Patients_bf DRUG ,_be especially_be started_be recently_be ,_be may_be occasionally_be experience_be excessive_be reduction_be blood_be pressure_be initiation_be ACEON_be Tablets_be therapy_be ._be"
3203,"Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. ",Diuretics,ACEON,No interaction,"Diuretics:_bf Patients_bf DRUG ,_be especially_be started_be recently_be ,_be may_be occasionally_be experience_be excessive_be reduction_be blood_be pressure_be initiation_be OTHER_DRUG Tablets_af therapy_af ._af"
3204,"Diuretics: Patients on diuretics, and especially those started recently, may occasionally experience an excessive reduction of blood pressure after initiation of ACEON    Tablets therapy. ",diuretics,ACEON,effect,"Diuretics:_bf Patients_bf DRUG ,_be especially_be started_be recently_be ,_be may_be occasionally_be experience_be excessive_be reduction_be blood_be pressure_be initiation_be OTHER_DRUG Tablets_af therapy_af ._af"
3205,The possibility of hypotensive effects can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with perindopril. ,diuretic,perindopril,effect,The_bf possibility_bf hypotensive_bf effects_bf minimized_bf either_bf discontinuing_bf DRUG increasing_be salt_be intake_be prior_be initiation_be treatment_be OTHER_DRUG ._af
3206,"If diuretics cannot be interrupted, close medical supervision should be provided with the first dose of ACEON    Tablets, for at least two hours and until blood pressure has stabilized for another hour. ",diuretics,ACEON,advise,"If_bf DRUG cannot_be interrupted_be ,_be close_be medical_be supervision_be provided_be first_be dose_be OTHER_DRUG Tablets_af ,_af least_af two_af hours_af blood_af pressure_af stabilized_af another_af hour_af ._af"
3207,The rate and extent of perindopril absorption and elimination are not affected by concomitant diuretics. ,perindopril,diuretics,No interaction,The_bf rate_bf extent_bf DRUG absorption_be elimination_be affected_be concomitant_be OTHER_DRUG ._af
3208,"The bioavailability of perindoprilat was reduced by diuretics, however, and this was associated with a decrease in plasma ACE inhibition. ",perindoprilat,diuretics,No interaction,"The_bf bioavailability_bf DRUG reduced_be OTHER_DRUG ,_af however_af ,_af associated_af decrease_af plasma_af ACE_af inhibition_af ._af"
3209,Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. ,Potassium,Potassium-Sparing Diuretics,No interaction,DRUG Supplements_be Potassium-Sparing_be Diuretics:_be ACEON_be Tablets_be may_be increase_be serum_be DRUG potential_af decrease_af aldosterone_af production_af ._af
3210,Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. ,Potassium,ACEON,No interaction,DRUG Supplements_be Potassium-Sparing_be Diuretics:_be OTHER_DRUG Tablets_af may_af increase_af serum_af DRUG potential_af decrease_af aldosterone_af production_af ._af
3211,Potassium Supplements and Potassium-Sparing Diuretics: ACEON    Tablets may increase serum potassium because of its potential to decrease aldosterone production. ,Potassium-Sparing Diuretics,ACEON,No interaction,Potassium_bf Supplements_bf Potassium-Sparing_bf Diuretics:_bf OTHER_DRUG Tablets_be may_be increase_be serum_be potassium_be potential_be decrease_be aldosterone_be production_be ._be
3212,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",potassium-sparing diuretics,spironolactone,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf potassium_bf supplements_bf drugs_bf capable_bf increasing_bf serum_bf potassium_bf (indomethacin_bf ,_bf heparin_bf ,_bf cyclosporine_bf others)_bf increase_bf risk_bf hyperkalemia_bf ._bf"
3213,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",potassium-sparing diuretics,amiloride,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf OTHER_DRUG ,_be triamterene_be others)_be ,_be potassium_be supplements_be drugs_be capable_be increasing_be serum_be potassium_be (indomethacin_be ,_be heparin_be ,_be cyclosporine_be others)_be increase_be risk_be hyperkalemia_be ._be"
3214,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",potassium-sparing diuretics,triamterene,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf OTHER_DRUG others)_be ,_be potassium_be supplements_be drugs_be capable_be increasing_be serum_be potassium_be (indomethacin_be ,_be heparin_be ,_be cyclosporine_be others)_be increase_be risk_be hyperkalemia_be ._be"
3215,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",potassium-sparing diuretics,potassium,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf OTHER_DRUG supplements_be drugs_be capable_be increasing_be serum_be OTHER_DRUG (indomethacin_af ,_af heparin_af ,_af cyclosporine_af others)_af increase_af risk_af hyperkalemia_af ._af"
3216,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",potassium-sparing diuretics,indomethacin,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf potassium_bf supplements_bf drugs_bf capable_bf increasing_bf serum_bf potassium_bf (indomethacin_bf ,_bf heparin_bf ,_bf cyclosporine_bf others)_bf increase_bf risk_bf hyperkalemia_bf ._bf"
3217,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",potassium-sparing diuretics,heparin,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf potassium_bf supplements_bf drugs_bf capable_bf increasing_bf serum_bf potassium_bf (indomethacin_bf ,_bf OTHER_DRUG ,_be cyclosporine_be others)_be increase_be risk_be hyperkalemia_be ._be"
3218,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",potassium-sparing diuretics,cyclosporine,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf potassium_bf supplements_bf drugs_bf capable_bf increasing_bf serum_bf potassium_bf (indomethacin_bf ,_bf heparin_bf ,_bf OTHER_DRUG others)_be increase_be risk_be hyperkalemia_be ._be"
3219,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",spironolactone,amiloride,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf OTHER_DRUG ,_be triamterene_be others)_be ,_be potassium_be supplements_be drugs_be capable_be increasing_be serum_be potassium_be (indomethacin_be ,_be heparin_be ,_be cyclosporine_be others)_be increase_be risk_be hyperkalemia_be ._be"
3220,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",spironolactone,triamterene,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf OTHER_DRUG others)_be ,_be potassium_be supplements_be drugs_be capable_be increasing_be serum_be potassium_be (indomethacin_be ,_be heparin_be ,_be cyclosporine_be others)_be increase_be risk_be hyperkalemia_be ._be"
3221,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",spironolactone,potassium,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf OTHER_DRUG supplements_be drugs_be capable_be increasing_be serum_be OTHER_DRUG (indomethacin_af ,_af heparin_af ,_af cyclosporine_af others)_af increase_af risk_af hyperkalemia_af ._af"
3222,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",spironolactone,indomethacin,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf potassium_bf supplements_bf drugs_bf capable_bf increasing_bf serum_bf potassium_bf (indomethacin_bf ,_bf heparin_bf ,_bf cyclosporine_bf others)_bf increase_bf risk_bf hyperkalemia_bf ._bf"
3223,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",spironolactone,heparin,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf potassium_bf supplements_bf drugs_bf capable_bf increasing_bf serum_bf potassium_bf (indomethacin_bf ,_bf OTHER_DRUG ,_be cyclosporine_be others)_be increase_be risk_be hyperkalemia_be ._be"
3224,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",spironolactone,cyclosporine,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf potassium_bf supplements_bf drugs_bf capable_bf increasing_bf serum_bf potassium_bf (indomethacin_bf ,_bf heparin_bf ,_bf OTHER_DRUG others)_be increase_be risk_be hyperkalemia_be ._be"
3225,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",amiloride,triamterene,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf DRUG ,_be OTHER_DRUG others)_af ,_af potassium_af supplements_af drugs_af capable_af increasing_af serum_af potassium_af (indomethacin_af ,_af heparin_af ,_af cyclosporine_af others)_af increase_af risk_af hyperkalemia_af ._af"
3226,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",amiloride,potassium,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf DRUG ,_be triamterene_be others)_be ,_be OTHER_DRUG supplements_af drugs_af capable_af increasing_af serum_af OTHER_DRUG (indomethacin_af ,_af heparin_af ,_af cyclosporine_af others)_af increase_af risk_af hyperkalemia_af ._af"
3227,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",amiloride,indomethacin,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf DRUG ,_be triamterene_be others)_be ,_be potassium_be supplements_be drugs_be capable_be increasing_be serum_be potassium_be (indomethacin_be ,_be heparin_be ,_be cyclosporine_be others)_be increase_be risk_be hyperkalemia_be ._be"
3228,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",amiloride,heparin,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf DRUG ,_be triamterene_be others)_be ,_be potassium_be supplements_be drugs_be capable_be increasing_be serum_be potassium_be (indomethacin_be ,_be OTHER_DRUG ,_af cyclosporine_af others)_af increase_af risk_af hyperkalemia_af ._af"
3229,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",amiloride,cyclosporine,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf DRUG ,_be triamterene_be others)_be ,_be potassium_be supplements_be drugs_be capable_be increasing_be serum_be potassium_be (indomethacin_be ,_be heparin_be ,_be OTHER_DRUG others)_af increase_af risk_af hyperkalemia_af ._af"
3230,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",triamterene,potassium,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf DRUG others)_be ,_be OTHER_DRUG supplements_af drugs_af capable_af increasing_af serum_af OTHER_DRUG (indomethacin_af ,_af heparin_af ,_af cyclosporine_af others)_af increase_af risk_af hyperkalemia_af ._af"
3231,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",triamterene,indomethacin,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf DRUG others)_be ,_be potassium_be supplements_be drugs_be capable_be increasing_be serum_be potassium_be (indomethacin_be ,_be heparin_be ,_be cyclosporine_be others)_be increase_be risk_be hyperkalemia_be ._be"
3232,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",triamterene,heparin,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf DRUG others)_be ,_be potassium_be supplements_be drugs_be capable_be increasing_be serum_be potassium_be (indomethacin_be ,_be OTHER_DRUG ,_af cyclosporine_af others)_af increase_af risk_af hyperkalemia_af ._af"
3233,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",triamterene,cyclosporine,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf DRUG others)_be ,_be potassium_be supplements_be drugs_be capable_be increasing_be serum_be potassium_be (indomethacin_be ,_be heparin_be ,_be OTHER_DRUG others)_af increase_af risk_af hyperkalemia_af ._af"
3234,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",potassium,indomethacin,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf DRUG supplements_be drugs_be capable_be increasing_be serum_be DRUG (indomethacin_af ,_af heparin_af ,_af cyclosporine_af others)_af increase_af risk_af hyperkalemia_af ._af"
3235,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",potassium,heparin,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf DRUG supplements_be drugs_be capable_be increasing_be serum_be DRUG (indomethacin_af ,_af OTHER_DRUG ,_af cyclosporine_af others)_af increase_af risk_af hyperkalemia_af ._af"
3236,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",potassium,cyclosporine,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf DRUG supplements_be drugs_be capable_be increasing_be serum_be DRUG (indomethacin_af ,_af heparin_af ,_af OTHER_DRUG others)_af increase_af risk_af hyperkalemia_af ._af"
3237,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",indomethacin,heparin,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf potassium_bf supplements_bf drugs_bf capable_bf increasing_bf serum_bf potassium_bf (indomethacin_bf ,_bf OTHER_DRUG ,_be cyclosporine_be others)_be increase_be risk_be hyperkalemia_be ._be"
3238,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",indomethacin,cyclosporine,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf potassium_bf supplements_bf drugs_bf capable_bf increasing_bf serum_bf potassium_bf (indomethacin_bf ,_bf heparin_bf ,_bf OTHER_DRUG others)_be increase_be risk_be hyperkalemia_be ._be"
3239,"Use of potassium-sparing diuretics (spironolactone, amiloride, triamterene and others), potassium supplements or other drugs capable of increasing serum potassium (indomethacin, heparin, cyclosporine and others) can increase the risk of hyperkalemia. ",heparin,cyclosporine,No interaction,"Use_bf potassium-sparing_bf diuretics_bf (spironolactone_bf ,_bf amiloride_bf ,_bf triamterene_bf others)_bf ,_bf potassium_bf supplements_bf drugs_bf capable_bf increasing_bf serum_bf potassium_bf (indomethacin_bf ,_bf DRUG ,_be OTHER_DRUG others)_af increase_af risk_af hyperkalemia_af ._af"
3240,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,Lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG symptoms_be DRUG toxicity_af reported_af patients_af receiving_af concomitant_af DRUG ACE_af inhibitor_af therapy_af ._af
3241,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,Lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG symptoms_be DRUG toxicity_af reported_af patients_af receiving_af concomitant_af DRUG ACE_af inhibitor_af therapy_af ._af
3242,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,Lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG symptoms_be DRUG toxicity_af reported_af patients_af receiving_af concomitant_af DRUG ACE_af inhibitor_af therapy_af ._af
3243,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG symptoms_be DRUG toxicity_af reported_af patients_af receiving_af concomitant_af DRUG ACE_af inhibitor_af therapy_af ._af
3244,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG symptoms_be DRUG toxicity_af reported_af patients_af receiving_af concomitant_af DRUG ACE_af inhibitor_af therapy_af ._af
3245,Lithium: Increased serum lithium and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy. ,lithium,lithium,No interaction,Lithium:_bf Increased_bf serum_bf DRUG symptoms_be DRUG toxicity_af reported_af patients_af receiving_af concomitant_af DRUG ACE_af inhibitor_af therapy_af ._af
3246,Use of a diuretic may further increase the risk of lithium toxicity. ,diuretic,lithium,No interaction,Use_bf DRUG may_be increase_be risk_be OTHER_DRUG toxicity_af ._af
3247,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",Digoxin,digoxin,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3248,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",Digoxin,ACEON,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be OTHER_DRUG Tablets_af ,_af effect_af DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3249,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",Digoxin,digoxin,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3250,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",Digoxin,perindopril,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3251,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",Digoxin,perindoprilat,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3252,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,ACEON,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be OTHER_DRUG Tablets_af ,_af effect_af DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3253,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,digoxin,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3254,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindopril,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3255,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindoprilat,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3256,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",ACEON,digoxin,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf OTHER_DRUG concentrations_be coadministered_be DRUG Tablets_af ,_af effect_af OTHER_DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3257,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",ACEON,perindopril,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf digoxin_bf concentrations_bf coadministered_bf DRUG Tablets_be ,_be effect_be digoxin_be plasma_be concentration_be perindopril/perindoprilat_be excluded_be ._be"
3258,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",ACEON,perindoprilat,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf digoxin_bf concentrations_bf coadministered_bf DRUG Tablets_be ,_be effect_be digoxin_be plasma_be concentration_be perindopril/perindoprilat_be excluded_be ._be"
3259,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindopril,mechanism,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3260,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",digoxin,perindoprilat,mechanism,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf DRUG concentrations_be coadministered_be ACEON_be Tablets_be ,_be effect_be DRUG plasma_af concentration_af perindopril/perindoprilat_af excluded_af ._af"
3261,"Digoxin: A controlled pharmacokinetic study has shown no effect on plasma digoxin concentrations when coadministered with ACEON    Tablets, but an effect of digoxin on the plasma concentration of perindopril/perindoprilat has not been excluded. ",perindopril,perindoprilat,No interaction,"Digoxin:_bf A_bf controlled_bf pharmacokinetic_bf study_bf shown_bf effect_bf plasma_bf digoxin_bf concentrations_bf coadministered_bf ACEON_bf Tablets_bf ,_bf effect_bf digoxin_bf plasma_bf concentration_bf perindopril/perindoprilat_bf excluded_bf ._bf"
3262,Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. ,Gentamicin,perindopril,No interaction,Gentamicin:_bf Animal_bf data_bf suggested_bf possibility_bf interaction_bf OTHER_DRUG DRUG ._af
3263,Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. ,Gentamicin,gentamicin,No interaction,Gentamicin:_bf Animal_bf data_bf suggested_bf possibility_bf interaction_bf perindopril_bf DRUG ._be
3264,Gentamicin: Animal data have suggested the possibility of interaction between perindopril and gentamicin. ,perindopril,gentamicin,int,Gentamicin:_bf Animal_bf data_bf suggested_bf possibility_bf interaction_bf DRUG OTHER_DRUG ._af
3265,Food Interaction: Oral administration of ACEON    Tablets with food does not significantly lower the rate or extent of perindopril absorption relative to the fasted state. ,ACEON,perindopril,No interaction,Food_bf Interaction:_bf Oral_bf administration_bf DRUG Tablets_be food_be significantly_be lower_be rate_be extent_be OTHER_DRUG absorption_af relative_af fasted_af state_af ._af
3266,"However, the extent of biotransformation of perindopril to the active metabolite, perindoprilat, is reduced approximately 43%, resulting in a reduction in the plasma ACE inhibition curve of approximately 20%, probably clinically insignificant. ",perindopril,perindoprilat,No interaction,"However_bf ,_bf extent_bf biotransformation_bf DRUG active_be metabolite_be ,_be OTHER_DRUG ,_af reduced_af approximately_af 43%_af ,_af resulting_af reduction_af plasma_af ACE_af inhibition_af curve_af approximately_af 20%_af ,_af probably_af clinically_af insignificant_af ._af"
3267,Concomitant use of alcohol with phentermine hydrochloride may result in an adverse drug interaction.,alcohol,phentermine hydrochloride,int,Concomitant_bf use_bf DRUG phentermine_be hydrochloride_be may_be result_be adverse_be drug_be interaction_be ._be
3268,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",Vasopressors,metaraminol,No interaction,"DRUG ,_be particularly_be OTHER_DRUG ,_af may_af cause_af serious_af cardiac_af arrhythmias_af halothane_af anesthesia_af therefore_af used_af great_af caution_af ._af"
3269,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",Vasopressors,halothane,effect,"DRUG ,_be particularly_be metaraminol_be ,_be may_be cause_be serious_be cardiac_be arrhythmias_be OTHER_DRUG anesthesia_af therefore_af used_af great_af caution_af ._af"
3270,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",metaraminol,halothane,effect,"Vasopressors_bf ,_bf particularly_bf DRUG ,_be may_be cause_be serious_be cardiac_be arrhythmias_be OTHER_DRUG anesthesia_af therefore_af used_af great_af caution_af ._af"
3271,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,MAO Inhibitors,sympathomimetic pressor amines,No interaction,MAO_bf Inhibitors:_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3272,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,MAO Inhibitors,monoamine oxidase inhibitors,No interaction,MAO_bf Inhibitors:_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3273,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,MAO Inhibitors,MAOI,No interaction,MAO_bf Inhibitors:_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3274,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,monoamine oxidase inhibitors,effect,MAO_bf Inhibitors:_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3275,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,MAOI,effect,MAO_bf Inhibitors:_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3276,MAO Inhibitors: The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,monoamine oxidase inhibitors,MAOI,No interaction,MAO_bf Inhibitors:_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3277,The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.,adrenergic agents,tricyclic antidepressants,effect,The_bf pressor_bf response_bf adrenergic_bf agents_bf may_bf also_bf potentiated_bf tricyclic_bf antidepressants_bf ._bf
3278,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",Vasopressors,metaraminol,No interaction,"DRUG ,_be particularly_be OTHER_DRUG ,_af may_af cause_af serious_af cardiac_af arrhythmias_af halothane_af anesthesia_af therefore_af used_af great_af caution_af ._af"
3279,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",Vasopressors,halothane,effect,"DRUG ,_be particularly_be metaraminol_be ,_be may_be cause_be serious_be cardiac_be arrhythmias_be OTHER_DRUG anesthesia_af therefore_af used_af great_af caution_af ._af"
3280,"Vasopressors, particularly metaraminol, may cause serious cardiac arrhythmias during halothane anesthesia and therefore should be used only with great caution or not at all. ",metaraminol,halothane,effect,"Vasopressors_bf ,_bf particularly_bf DRUG ,_be may_be cause_be serious_be cardiac_be arrhythmias_be OTHER_DRUG anesthesia_af therefore_af used_af great_af caution_af ._af"
3281,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,MAO Inhibitors,sympathomimetic pressor amines,No interaction,MAO_bf Inhibitors_bf -_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3282,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,MAO Inhibitors,monoamine oxidase inhibitors,No interaction,MAO_bf Inhibitors_bf -_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3283,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,MAO Inhibitors,MAOI,No interaction,MAO_bf Inhibitors_bf -_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3284,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,monoamine oxidase inhibitors,effect,MAO_bf Inhibitors_bf -_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3285,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,sympathomimetic pressor amines,MAOI,effect,MAO_bf Inhibitors_bf -_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3286,MAO Inhibitors - The pressor effect of sympathomimetic pressor amines is markedly potentiated in patients receiving monoamine oxidase inhibitors (MAOI). ,monoamine oxidase inhibitors,MAOI,No interaction,MAO_bf Inhibitors_bf -_bf The_bf pressor_bf effect_bf sympathomimetic_bf pressor_bf amines_bf markedly_bf potentiated_bf patients_bf receiving_bf monoamine_bf oxidase_bf inhibitors_bf (MAOI)_bf ._bf
3287,The pressor response of adrenergic agents may also be potentiated by tricyclic antidepressants.,adrenergic agents,tricyclic antidepressants,effect,The_bf pressor_bf response_bf adrenergic_bf agents_bf may_bf also_bf potentiated_bf tricyclic_bf antidepressants_bf ._bf
3288,Pilocarpine should be administered with caution to patients taking beta adrenergic antagonists because of the possibility of conduction disturbances. ,Pilocarpine,beta adrenergic antagonists,advise,DRUG administered_be caution_be patients_be taking_be beta_be adrenergic_be antagonists_be possibility_be conduction_be disturbances_be ._be
3289,"These effects should be considered when anticholinergic properties may be contributing to the therapeutic effect of concomitant medication (e.g., atropine, inhaled ipratropium). ",atropine,ipratropium,No interaction,"These_bf effects_bf considered_bf anticholinergic_bf properties_bf may_bf contributing_bf therapeutic_bf effect_bf concomitant_bf medication_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be inhaled_be ipratropium)_be ._be"
3290,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,calcium,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf OTHER_DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be ibuprofen_be ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3291,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,conjugated estrogens,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf prednisone_bf ._bf"
3292,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,hydroxychloroquine sulfate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf prednisone_bf ._bf"
3293,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,ibuprofen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf OTHER_DRUG ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3294,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,levothyroxine sodium,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf prednisone_bf ._bf"
3295,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,medroxyprogesterone acetate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf prednisone_bf ._bf"
3296,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,methotrexate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf OTHER_DRUG ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3297,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,multivitamins,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf OTHER_DRUG ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3298,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,naproxen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf OTHER_DRUG ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3299,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,omeprazole,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf OTHER_DRUG ,_be paracetamol_be ,_be prednisone_be ._be"
3300,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,paracetamol,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf OTHER_DRUG ,_be prednisone_be ._be"
3301,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",acetylsalicylic acid,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf OTHER_DRUG ._be"
3302,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",calcium,conjugated estrogens,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be ibuprofen_be ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3303,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",calcium,hydroxychloroquine sulfate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be ibuprofen_be ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3304,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",calcium,ibuprofen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be OTHER_DRUG ,_af levothyroxine_af sodium_af ,_af medroxyprogesterone_af acetate_af ,_af methotrexate_af ,_af multivitamins_af ,_af naproxen_af ,_af omeprazole_af ,_af paracetamol_af ,_af prednisone_af ._af"
3305,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",calcium,levothyroxine sodium,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be ibuprofen_be ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3306,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",calcium,medroxyprogesterone acetate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be ibuprofen_be ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3307,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",calcium,methotrexate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be ibuprofen_be ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be OTHER_DRUG ,_af multivitamins_af ,_af naproxen_af ,_af omeprazole_af ,_af paracetamol_af ,_af prednisone_af ._af"
3308,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",calcium,multivitamins,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be ibuprofen_be ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be OTHER_DRUG ,_af naproxen_af ,_af omeprazole_af ,_af paracetamol_af ,_af prednisone_af ._af"
3309,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",calcium,naproxen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be ibuprofen_be ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be OTHER_DRUG ,_af omeprazole_af ,_af paracetamol_af ,_af prednisone_af ._af"
3310,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",calcium,omeprazole,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be ibuprofen_be ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be OTHER_DRUG ,_af paracetamol_af ,_af prednisone_af ._af"
3311,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",calcium,paracetamol,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be ibuprofen_be ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be OTHER_DRUG ,_af prednisone_af ._af"
3312,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",calcium,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf DRUG ,_be conjugated_be estrogens_be ,_be hydroxychloroquine_be sulfate_be ,_be ibuprofen_be ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be OTHER_DRUG ._af"
3313,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",conjugated estrogens,hydroxychloroquine sulfate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf prednisone_bf ._bf"
3314,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",conjugated estrogens,ibuprofen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf OTHER_DRUG ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3315,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",conjugated estrogens,levothyroxine sodium,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf prednisone_bf ._bf"
3316,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",conjugated estrogens,medroxyprogesterone acetate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf prednisone_bf ._bf"
3317,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",conjugated estrogens,methotrexate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf OTHER_DRUG ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3318,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",conjugated estrogens,multivitamins,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf OTHER_DRUG ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3319,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",conjugated estrogens,naproxen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf OTHER_DRUG ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3320,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",conjugated estrogens,omeprazole,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf OTHER_DRUG ,_be paracetamol_be ,_be prednisone_be ._be"
3321,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",conjugated estrogens,paracetamol,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf OTHER_DRUG ,_be prednisone_be ._be"
3322,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",conjugated estrogens,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf OTHER_DRUG ._be"
3323,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",hydroxychloroquine sulfate,ibuprofen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf OTHER_DRUG ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3324,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",hydroxychloroquine sulfate,levothyroxine sodium,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf prednisone_bf ._bf"
3325,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",hydroxychloroquine sulfate,medroxyprogesterone acetate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf prednisone_bf ._bf"
3326,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",hydroxychloroquine sulfate,methotrexate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf OTHER_DRUG ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3327,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",hydroxychloroquine sulfate,multivitamins,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf OTHER_DRUG ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3328,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",hydroxychloroquine sulfate,naproxen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf OTHER_DRUG ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3329,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",hydroxychloroquine sulfate,omeprazole,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf OTHER_DRUG ,_be paracetamol_be ,_be prednisone_be ._be"
3330,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",hydroxychloroquine sulfate,paracetamol,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf OTHER_DRUG ,_be prednisone_be ._be"
3331,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",hydroxychloroquine sulfate,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf OTHER_DRUG ._be"
3332,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",ibuprofen,levothyroxine sodium,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf DRUG ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3333,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",ibuprofen,medroxyprogesterone acetate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf DRUG ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3334,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",ibuprofen,methotrexate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf DRUG ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be OTHER_DRUG ,_af multivitamins_af ,_af naproxen_af ,_af omeprazole_af ,_af paracetamol_af ,_af prednisone_af ._af"
3335,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",ibuprofen,multivitamins,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf DRUG ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be OTHER_DRUG ,_af naproxen_af ,_af omeprazole_af ,_af paracetamol_af ,_af prednisone_af ._af"
3336,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",ibuprofen,naproxen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf DRUG ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be OTHER_DRUG ,_af omeprazole_af ,_af paracetamol_af ,_af prednisone_af ._af"
3337,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",ibuprofen,omeprazole,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf DRUG ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be OTHER_DRUG ,_af paracetamol_af ,_af prednisone_af ._af"
3338,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",ibuprofen,paracetamol,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf DRUG ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be OTHER_DRUG ,_af prednisone_af ._af"
3339,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",ibuprofen,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf DRUG ,_be levothyroxine_be sodium_be ,_be medroxyprogesterone_be acetate_be ,_be methotrexate_be ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be OTHER_DRUG ._af"
3340,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",levothyroxine sodium,medroxyprogesterone acetate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf prednisone_bf ._bf"
3341,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",levothyroxine sodium,methotrexate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf OTHER_DRUG ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3342,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",levothyroxine sodium,multivitamins,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf OTHER_DRUG ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3343,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",levothyroxine sodium,naproxen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf OTHER_DRUG ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3344,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",levothyroxine sodium,omeprazole,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf OTHER_DRUG ,_be paracetamol_be ,_be prednisone_be ._be"
3345,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",levothyroxine sodium,paracetamol,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf OTHER_DRUG ,_be prednisone_be ._be"
3346,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",levothyroxine sodium,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf OTHER_DRUG ._be"
3347,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",medroxyprogesterone acetate,methotrexate,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf OTHER_DRUG ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3348,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",medroxyprogesterone acetate,multivitamins,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf OTHER_DRUG ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3349,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",medroxyprogesterone acetate,naproxen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf OTHER_DRUG ,_be omeprazole_be ,_be paracetamol_be ,_be prednisone_be ._be"
3350,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",medroxyprogesterone acetate,omeprazole,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf OTHER_DRUG ,_be paracetamol_be ,_be prednisone_be ._be"
3351,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",medroxyprogesterone acetate,paracetamol,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf OTHER_DRUG ,_be prednisone_be ._be"
3352,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",medroxyprogesterone acetate,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf paracetamol_bf ,_bf OTHER_DRUG ._be"
3353,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",methotrexate,multivitamins,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf DRUG ,_be OTHER_DRUG ,_af naproxen_af ,_af omeprazole_af ,_af paracetamol_af ,_af prednisone_af ._af"
3354,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",methotrexate,naproxen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf DRUG ,_be multivitamins_be ,_be OTHER_DRUG ,_af omeprazole_af ,_af paracetamol_af ,_af prednisone_af ._af"
3355,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",methotrexate,omeprazole,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf DRUG ,_be multivitamins_be ,_be naproxen_be ,_be OTHER_DRUG ,_af paracetamol_af ,_af prednisone_af ._af"
3356,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",methotrexate,paracetamol,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf DRUG ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be OTHER_DRUG ,_af prednisone_af ._af"
3357,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",methotrexate,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf DRUG ,_be multivitamins_be ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be OTHER_DRUG ._af"
3358,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",multivitamins,naproxen,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf DRUG ,_be OTHER_DRUG ,_af omeprazole_af ,_af paracetamol_af ,_af prednisone_af ._af"
3359,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",multivitamins,omeprazole,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf DRUG ,_be naproxen_be ,_be OTHER_DRUG ,_af paracetamol_af ,_af prednisone_af ._af"
3360,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",multivitamins,paracetamol,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf DRUG ,_be naproxen_be ,_be omeprazole_be ,_be OTHER_DRUG ,_af prednisone_af ._af"
3361,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",multivitamins,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf DRUG ,_be naproxen_be ,_be omeprazole_be ,_be paracetamol_be ,_be OTHER_DRUG ._af"
3362,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",naproxen,omeprazole,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf DRUG ,_be OTHER_DRUG ,_af paracetamol_af ,_af prednisone_af ._af"
3363,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",naproxen,paracetamol,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf DRUG ,_be omeprazole_be ,_be OTHER_DRUG ,_af prednisone_af ._af"
3364,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",naproxen,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf DRUG ,_be omeprazole_be ,_be paracetamol_be ,_be OTHER_DRUG ._af"
3365,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",omeprazole,paracetamol,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf DRUG ,_be OTHER_DRUG ,_af prednisone_af ._af"
3366,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",omeprazole,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf DRUG ,_be paracetamol_be ,_be OTHER_DRUG ._af"
3367,"While no formal drug interaction studies have been performed, the following concomitant drugs were used in at least 10% of patients in either or both Sj   grens efficacy studies: acetylsalicylic acid, artificial tears, calcium, conjugated estrogens, hydroxychloroquine sulfate, ibuprofen, levothyroxine sodium, medroxyprogesterone acetate, methotrexate, multivitamins, naproxen, omeprazole, paracetamol, and prednisone.",paracetamol,prednisone,No interaction,"While_bf formal_bf drug_bf interaction_bf studies_bf performed_bf ,_bf following_bf concomitant_bf drugs_bf used_bf least_bf 10%_bf patients_bf either_bf Sj_bf grens_bf efficacy_bf studies:_bf acetylsalicylic_bf acid_bf ,_bf artificial_bf tears_bf ,_bf calcium_bf ,_bf conjugated_bf estrogens_bf ,_bf hydroxychloroquine_bf sulfate_bf ,_bf ibuprofen_bf ,_bf levothyroxine_bf sodium_bf ,_bf medroxyprogesterone_bf acetate_bf ,_bf methotrexate_bf ,_bf multivitamins_bf ,_bf naproxen_bf ,_bf omeprazole_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
3368,"Catecholamine-depleting drugs (e.g., reserpine) may have an additive effect when given with beta-blocking agents. ",reserpine,beta-blocking agents,effect,"Catecholamine-depleting_bf drugs_bf (e_bf ._bf g_bf ._bf ,_bf reserpine)_bf may_bf additive_bf effect_bf given_bf beta-blocking_bf agents_bf ._bf"
3369,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",Pindolol,antihypertensive agents,No interaction,"DRUG used_be variety_be antihypertensive_be agents_be ,_be including_be hydrochlorothiazide_be ,_be hydralazine_be ,_be guanethidine_be without_be unexpected_be adverse_be interactions_be ._be"
3370,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",Pindolol,hydrochlorothiazide,No interaction,"DRUG used_be variety_be antihypertensive_be agents_be ,_be including_be OTHER_DRUG ,_af hydralazine_af ,_af guanethidine_af without_af unexpected_af adverse_af interactions_af ._af"
3371,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",Pindolol,hydralazine,No interaction,"DRUG used_be variety_be antihypertensive_be agents_be ,_be including_be hydrochlorothiazide_be ,_be OTHER_DRUG ,_af guanethidine_af without_af unexpected_af adverse_af interactions_af ._af"
3372,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",Pindolol,guanethidine,No interaction,"DRUG used_be variety_be antihypertensive_be agents_be ,_be including_be hydrochlorothiazide_be ,_be hydralazine_be ,_be OTHER_DRUG without_af unexpected_af adverse_af interactions_af ._af"
3373,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",antihypertensive agents,hydrochlorothiazide,No interaction,"Pindolol_bf used_bf variety_bf antihypertensive_bf agents_bf ,_bf including_bf OTHER_DRUG ,_be hydralazine_be ,_be guanethidine_be without_be unexpected_be adverse_be interactions_be ._be"
3374,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",antihypertensive agents,hydralazine,No interaction,"Pindolol_bf used_bf variety_bf antihypertensive_bf agents_bf ,_bf including_bf hydrochlorothiazide_bf ,_bf OTHER_DRUG ,_be guanethidine_be without_be unexpected_be adverse_be interactions_be ._be"
3375,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",antihypertensive agents,guanethidine,No interaction,"Pindolol_bf used_bf variety_bf antihypertensive_bf agents_bf ,_bf including_bf hydrochlorothiazide_bf ,_bf hydralazine_bf ,_bf OTHER_DRUG without_be unexpected_be adverse_be interactions_be ._be"
3376,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",hydrochlorothiazide,hydralazine,No interaction,"Pindolol_bf used_bf variety_bf antihypertensive_bf agents_bf ,_bf including_bf DRUG ,_be OTHER_DRUG ,_af guanethidine_af without_af unexpected_af adverse_af interactions_af ._af"
3377,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",hydrochlorothiazide,guanethidine,No interaction,"Pindolol_bf used_bf variety_bf antihypertensive_bf agents_bf ,_bf including_bf DRUG ,_be hydralazine_be ,_be OTHER_DRUG without_af unexpected_af adverse_af interactions_af ._af"
3378,"Pindolol has been used with a variety of antihypertensive agents, including hydrochlorothiazide, hydralazine, and guanethidine without unexpected adverse interactions. ",hydralazine,guanethidine,No interaction,"Pindolol_bf used_bf variety_bf antihypertensive_bf agents_bf ,_bf including_bf hydrochlorothiazide_bf ,_bf DRUG ,_be OTHER_DRUG without_af unexpected_af adverse_af interactions_af ._af"
3379,Pindolol has been shown to increase serum thioridazine levels when both drugs are co-administered. ,Pindolol,thioridazine,mechanism,DRUG shown_be increase_be serum_be OTHER_DRUG levels_af drugs_af co-administered_af ._af
3380,Other short-acting beta adrenergic aerosol bronchodilators should not be used concomitantly with MAXAIR AUTOHALER because they may have additive effects.,short-acting beta adrenergic aerosol bronchodilators,MAXAIR AUTOHALER,advise,Other_bf short-acting_bf beta_bf adrenergic_bf aerosol_bf bronchodilators_bf used_bf concomitantly_bf MAXAIR_bf AUTOHALER_bf may_bf additive_bf effects_bf ._bf
3381,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",coumarin-type anticoagulants,coumarin-type anticoagulants,No interaction,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf FELDENE_bf since_bf marketing_bf ,_bf therefore_bf ,_bf physicians_bf closely_bf monitor_bf patients_bf change_bf dosage_bf requirements_bf administering_bf FELDENE_bf patients_bf coumarin-type_bf anticoagulants_bf highly_bf protein-bound_bf drugs_bf ._bf"
3382,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",coumarin-type anticoagulants,FELDENE,No interaction,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf OTHER_DRUG since_be marketing_be ,_be therefore_be ,_be physicians_be closely_be monitor_be patients_be change_be dosage_be requirements_be administering_be OTHER_DRUG patients_af coumarin-type_af anticoagulants_af highly_af protein-bound_af drugs_af ._af"
3383,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",coumarin-type anticoagulants,FELDENE,No interaction,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf OTHER_DRUG since_be marketing_be ,_be therefore_be ,_be physicians_be closely_be monitor_be patients_be change_be dosage_be requirements_be administering_be OTHER_DRUG patients_af coumarin-type_af anticoagulants_af highly_af protein-bound_af drugs_af ._af"
3384,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",coumarin-type anticoagulants,coumarin-type anticoagulants,No interaction,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf FELDENE_bf since_bf marketing_bf ,_bf therefore_bf ,_bf physicians_bf closely_bf monitor_bf patients_bf change_bf dosage_bf requirements_bf administering_bf FELDENE_bf patients_bf coumarin-type_bf anticoagulants_bf highly_bf protein-bound_bf drugs_bf ._bf"
3385,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",coumarin-type anticoagulants,FELDENE,int,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf OTHER_DRUG since_be marketing_be ,_be therefore_be ,_be physicians_be closely_be monitor_be patients_be change_be dosage_be requirements_be administering_be OTHER_DRUG patients_af coumarin-type_af anticoagulants_af highly_af protein-bound_af drugs_af ._af"
3386,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",coumarin-type anticoagulants,FELDENE,No interaction,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf OTHER_DRUG since_be marketing_be ,_be therefore_be ,_be physicians_be closely_be monitor_be patients_be change_be dosage_be requirements_be administering_be OTHER_DRUG patients_af coumarin-type_af anticoagulants_af highly_af protein-bound_af drugs_af ._af"
3387,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",coumarin-type anticoagulants,coumarin-type anticoagulants,No interaction,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf FELDENE_bf since_bf marketing_bf ,_bf therefore_bf ,_bf physicians_bf closely_bf monitor_bf patients_bf change_bf dosage_bf requirements_bf administering_bf FELDENE_bf patients_bf coumarin-type_bf anticoagulants_bf highly_bf protein-bound_bf drugs_bf ._bf"
3388,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",FELDENE,FELDENE,No interaction,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf DRUG since_be marketing_be ,_be therefore_be ,_be physicians_be closely_be monitor_be patients_be change_be dosage_be requirements_be administering_be DRUG patients_af coumarin-type_af anticoagulants_af highly_af protein-bound_af drugs_af ._af"
3389,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",FELDENE,coumarin-type anticoagulants,No interaction,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf DRUG since_be marketing_be ,_be therefore_be ,_be physicians_be closely_be monitor_be patients_be change_be dosage_be requirements_be administering_be DRUG patients_af coumarin-type_af anticoagulants_af highly_af protein-bound_af drugs_af ._af"
3390,"Although this has not occurred in in vitro studies with coumarin-type anticoagulants, interactions with coumarin-type anticoagulants have been reported with FELDENE since marketing, therefore, physicians should closely monitor patients for a change in dosage requirements when administering FELDENE to patients on coumarin-type anticoagulants and other highly protein-bound drugs. ",FELDENE,coumarin-type anticoagulants,advise,"Although_bf occurred_bf vitro_bf studies_bf coumarin-type_bf anticoagulants_bf ,_bf interactions_bf coumarin-type_bf anticoagulants_bf reported_bf DRUG since_be marketing_be ,_be therefore_be ,_be physicians_be closely_be monitor_be patients_be change_be dosage_be requirements_be administering_be DRUG patients_af coumarin-type_af anticoagulants_af highly_af protein-bound_af drugs_af ._af"
3391,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",piroxicam,FELDENE,No interaction,"Plasma_bf levels_bf DRUG depressed_be approximately_be 80%_be normal_be values_be OTHER_DRUG administered_af conjunction_af aspirin_af (3900_af mg/day)_af ,_af concomitant_af administration_af antacids_af effect_af DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af OTHER_DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3392,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",piroxicam,aspirin,No interaction,"Plasma_bf levels_bf DRUG depressed_be approximately_be 80%_be normal_be values_be FELDENE_be administered_be conjunction_be OTHER_DRUG (3900_af mg/day)_af ,_af concomitant_af administration_af antacids_af effect_af DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af FELDENE_af ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3393,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",piroxicam,antacids,No interaction,"Plasma_bf levels_bf DRUG depressed_be approximately_be 80%_be normal_be values_be FELDENE_be administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be OTHER_DRUG effect_af DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af FELDENE_af ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3394,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",piroxicam,piroxicam,No interaction,"Plasma_bf levels_bf DRUG depressed_be approximately_be 80%_be normal_be values_be FELDENE_be administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af FELDENE_af ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3395,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",piroxicam,Nonsteroidal anti-inflammatory agents,No interaction,"Plasma_bf levels_bf DRUG depressed_be approximately_be 80%_be normal_be values_be FELDENE_be administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af FELDENE_af ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3396,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",piroxicam,FELDENE,No interaction,"Plasma_bf levels_bf DRUG depressed_be approximately_be 80%_be normal_be values_be OTHER_DRUG administered_af conjunction_af aspirin_af (3900_af mg/day)_af ,_af concomitant_af administration_af antacids_af effect_af DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af OTHER_DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3397,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",piroxicam,lithium,No interaction,"Plasma_bf levels_bf DRUG depressed_be approximately_be 80%_be normal_be values_be FELDENE_be administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af FELDENE_af ,_af reported_af increase_af steady_af state_af plasma_af OTHER_DRUG levels_af ._af"
3398,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,aspirin,mechanism,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf DRUG administered_be conjunction_be OTHER_DRUG (3900_af mg/day)_af ,_af concomitant_af administration_af antacids_af effect_af piroxicam_af plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3399,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,antacids,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf DRUG administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be OTHER_DRUG effect_af piroxicam_af plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3400,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,piroxicam,No interaction,"Plasma_bf levels_bf OTHER_DRUG depressed_be approximately_be 80%_be normal_be values_be DRUG administered_af conjunction_af aspirin_af (3900_af mg/day)_af ,_af concomitant_af administration_af antacids_af effect_af OTHER_DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3401,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,Nonsteroidal anti-inflammatory agents,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf DRUG administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be piroxicam_be plasma_be levels_be ._be Nonsteroidal_be anti-inflammatory_be agents_be ,_be including_be DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3402,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,FELDENE,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf DRUG administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be piroxicam_be plasma_be levels_be ._be Nonsteroidal_be anti-inflammatory_be agents_be ,_be including_be DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3403,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,lithium,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf DRUG administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be piroxicam_be plasma_be levels_be ._be Nonsteroidal_be anti-inflammatory_be agents_be ,_be including_be DRUG ,_af reported_af increase_af steady_af state_af plasma_af OTHER_DRUG levels_af ._af"
3404,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",aspirin,antacids,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf FELDENE_bf administered_bf conjunction_bf DRUG (3900_be mg/day)_be ,_be concomitant_be administration_be OTHER_DRUG effect_af piroxicam_af plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af FELDENE_af ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3405,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",aspirin,piroxicam,No interaction,"Plasma_bf levels_bf OTHER_DRUG depressed_be approximately_be 80%_be normal_be values_be FELDENE_be administered_be conjunction_be DRUG (3900_af mg/day)_af ,_af concomitant_af administration_af antacids_af effect_af OTHER_DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af FELDENE_af ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3406,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",aspirin,Nonsteroidal anti-inflammatory agents,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf FELDENE_bf administered_bf conjunction_bf DRUG (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be piroxicam_be plasma_be levels_be ._be Nonsteroidal_be anti-inflammatory_be agents_be ,_be including_be FELDENE_be ,_be reported_be increase_be steady_be state_be plasma_be lithium_be levels_be ._be"
3407,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",aspirin,FELDENE,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf OTHER_DRUG administered_be conjunction_be DRUG (3900_af mg/day)_af ,_af concomitant_af administration_af antacids_af effect_af piroxicam_af plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af OTHER_DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3408,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",aspirin,lithium,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf FELDENE_bf administered_bf conjunction_bf DRUG (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be piroxicam_be plasma_be levels_be ._be Nonsteroidal_be anti-inflammatory_be agents_be ,_be including_be FELDENE_be ,_be reported_be increase_be steady_be state_be plasma_be OTHER_DRUG levels_af ._af"
3409,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",antacids,piroxicam,No interaction,"Plasma_bf levels_bf OTHER_DRUG depressed_be approximately_be 80%_be normal_be values_be FELDENE_be administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be DRUG effect_af OTHER_DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af FELDENE_af ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3410,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",antacids,Nonsteroidal anti-inflammatory agents,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf FELDENE_bf administered_bf conjunction_bf aspirin_bf (3900_bf mg/day)_bf ,_bf concomitant_bf administration_bf DRUG effect_be piroxicam_be plasma_be levels_be ._be Nonsteroidal_be anti-inflammatory_be agents_be ,_be including_be FELDENE_be ,_be reported_be increase_be steady_be state_be plasma_be lithium_be levels_be ._be"
3411,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",antacids,FELDENE,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf OTHER_DRUG administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be DRUG effect_af piroxicam_af plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af OTHER_DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3412,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",antacids,lithium,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf FELDENE_bf administered_bf conjunction_bf aspirin_bf (3900_bf mg/day)_bf ,_bf concomitant_bf administration_bf DRUG effect_be piroxicam_be plasma_be levels_be ._be Nonsteroidal_be anti-inflammatory_be agents_be ,_be including_be FELDENE_be ,_be reported_be increase_be steady_be state_be plasma_be OTHER_DRUG levels_af ._af"
3413,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",piroxicam,Nonsteroidal anti-inflammatory agents,No interaction,"Plasma_bf levels_bf DRUG depressed_be approximately_be 80%_be normal_be values_be FELDENE_be administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af FELDENE_af ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3414,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",piroxicam,FELDENE,No interaction,"Plasma_bf levels_bf DRUG depressed_be approximately_be 80%_be normal_be values_be OTHER_DRUG administered_af conjunction_af aspirin_af (3900_af mg/day)_af ,_af concomitant_af administration_af antacids_af effect_af DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af OTHER_DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3415,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",piroxicam,lithium,No interaction,"Plasma_bf levels_bf DRUG depressed_be approximately_be 80%_be normal_be values_be FELDENE_be administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be DRUG plasma_af levels_af ._af Nonsteroidal_af anti-inflammatory_af agents_af ,_af including_af FELDENE_af ,_af reported_af increase_af steady_af state_af plasma_af OTHER_DRUG levels_af ._af"
3416,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",Nonsteroidal anti-inflammatory agents,FELDENE,No interaction,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf OTHER_DRUG administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be piroxicam_be plasma_be levels_be ._be Nonsteroidal_be anti-inflammatory_be agents_be ,_be including_be OTHER_DRUG ,_af reported_af increase_af steady_af state_af plasma_af lithium_af levels_af ._af"
3417,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",Nonsteroidal anti-inflammatory agents,lithium,mechanism,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf FELDENE_bf administered_bf conjunction_bf aspirin_bf (3900_bf mg/day)_bf ,_bf concomitant_bf administration_bf antacids_bf effect_bf piroxicam_bf plasma_bf levels_bf ._bf Nonsteroidal_bf anti-inflammatory_bf agents_bf ,_bf including_bf FELDENE_bf ,_bf reported_bf increase_bf steady_bf state_bf plasma_bf OTHER_DRUG levels_be ._be"
3418,"Plasma levels of piroxicam are depressed to approximately 80% of their normal values when FELDENE is administered in conjunction with aspirin (3900 mg/day), but concomitant administration of antacids has no effect on piroxicam plasma levels . Nonsteroidal anti-inflammatory agents, including FELDENE, have been reported to increase steady state plasma lithium levels. ",FELDENE,lithium,mechanism,"Plasma_bf levels_bf piroxicam_bf depressed_bf approximately_bf 80%_bf normal_bf values_bf DRUG administered_be conjunction_be aspirin_be (3900_be mg/day)_be ,_be concomitant_be administration_be antacids_be effect_be piroxicam_be plasma_be levels_be ._be Nonsteroidal_be anti-inflammatory_be agents_be ,_be including_be DRUG ,_af reported_af increase_af steady_af state_af plasma_af OTHER_DRUG levels_af ._af"
3419,"It is recommended that plasma lithium levels be monitored when initiating, adjusting and discontinuing FELDENE.",lithium,FELDENE,advise,"It_bf recommended_bf plasma_bf DRUG levels_be monitored_be initiating_be ,_be adjusting_be discontinuing_be OTHER_DRUG ._af"
3420,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ",atropine,pralidoxime,effect,"When_bf DRUG OTHER_DRUG used_af together_af ,_af signs_af atropinization_af (flushing_af ,_af mydriasis_af ,_af tachycardia_af ,_af dryness_af mouth_af nose)_af may_af occur_af earlier_af might_af expected_af DRUG used_af alone_af ._af"
3421,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ",atropine,atropine,No interaction,"When_bf DRUG pralidoxime_be used_be together_be ,_be signs_be atropinization_be (flushing_be ,_be mydriasis_be ,_be tachycardia_be ,_be dryness_be mouth_be nose)_be may_be occur_be earlier_be might_be expected_be DRUG used_af alone_af ._af"
3422,"When atropine and pralidoxime are used together, the signs of atropinization (flushing, mydriasis, tachycardia, dryness of the mouth and nose) may occur earlier than might be expected when atropine is used alone. ",pralidoxime,atropine,No interaction,"When_bf OTHER_DRUG DRUG used_af together_af ,_af signs_af atropinization_af (flushing_af ,_af mydriasis_af ,_af tachycardia_af ,_af dryness_af mouth_af nose)_af may_af occur_af earlier_af might_af expected_af OTHER_DRUG used_af alone_af ._af"
3423,This is especially true if the total dose of atropine has been large and the administration of pralidoxime has been delayed. ,atropine,pralidoxime,No interaction,This_bf especially_bf true_bf total_bf dose_bf DRUG large_be administration_be OTHER_DRUG delayed_af ._af
3424,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ",pralidoxime,barbiturates,No interaction,"2_bf -_bf 4_bf The_bf following_bf precautions_bf kept_bf mind_bf treatment_bf anticholinesterase_bf poisoning_bf ,_bf although_bf bear_bf directly_bf use_bf pralidoxime:_bf since_bf OTHER_DRUG potentiated_be anticholinesterases_be ,_be used_be cautiously_be treatment_be convulsions;_be"
3425,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ",pralidoxime,anticholinesterases,No interaction,"2_bf -_bf 4_bf The_bf following_bf precautions_bf kept_bf mind_bf treatment_bf anticholinesterase_bf poisoning_bf ,_bf although_bf bear_bf directly_bf use_bf pralidoxime:_bf since_bf barbiturates_bf potentiated_bf OTHER_DRUG ,_be used_be cautiously_be treatment_be convulsions;_be"
3426,"2 - 4 The following precautions should be kept in mind in the treatment of anticholinesterase poisoning, although they do not bear directly on the use of pralidoxime: since barbiturates are potentiated by the anticholinesterases, they should be used cautiously in the treatment of convulsions; ",barbiturates,anticholinesterases,effect,"2_bf -_bf 4_bf The_bf following_bf precautions_bf kept_bf mind_bf treatment_bf anticholinesterase_bf poisoning_bf ,_bf although_bf bear_bf directly_bf use_bf pralidoxime:_bf since_bf DRUG potentiated_be OTHER_DRUG ,_af used_af cautiously_af treatment_af convulsions;_af"
3427,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",morphine,theophylline,No interaction,"DRUG ,_be OTHER_DRUG ,_af aminophylline_af ,_af succinylcholine_af ,_af reserpine_af ,_af phenothiazine-type_af tranquilizers_af avoided_af patients_af organophosphate_af poisoning_af ._af"
3428,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",morphine,aminophylline,No interaction,"DRUG ,_be theophylline_be ,_be OTHER_DRUG ,_af succinylcholine_af ,_af reserpine_af ,_af phenothiazine-type_af tranquilizers_af avoided_af patients_af organophosphate_af poisoning_af ._af"
3429,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",morphine,succinylcholine,No interaction,"DRUG ,_be theophylline_be ,_be aminophylline_be ,_be OTHER_DRUG ,_af reserpine_af ,_af phenothiazine-type_af tranquilizers_af avoided_af patients_af organophosphate_af poisoning_af ._af"
3430,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",morphine,reserpine,No interaction,"DRUG ,_be theophylline_be ,_be aminophylline_be ,_be succinylcholine_be ,_be OTHER_DRUG ,_af phenothiazine-type_af tranquilizers_af avoided_af patients_af organophosphate_af poisoning_af ._af"
3431,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",morphine,phenothiazine-type tranquilizers,No interaction,"DRUG ,_be theophylline_be ,_be aminophylline_be ,_be succinylcholine_be ,_be reserpine_be ,_be phenothiazine-type_be tranquilizers_be avoided_be patients_be organophosphate_be poisoning_be ._be"
3432,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",theophylline,aminophylline,No interaction,"morphine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af succinylcholine_af ,_af reserpine_af ,_af phenothiazine-type_af tranquilizers_af avoided_af patients_af organophosphate_af poisoning_af ._af"
3433,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",theophylline,succinylcholine,No interaction,"morphine_bf ,_bf DRUG ,_be aminophylline_be ,_be OTHER_DRUG ,_af reserpine_af ,_af phenothiazine-type_af tranquilizers_af avoided_af patients_af organophosphate_af poisoning_af ._af"
3434,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",theophylline,reserpine,No interaction,"morphine_bf ,_bf DRUG ,_be aminophylline_be ,_be succinylcholine_be ,_be OTHER_DRUG ,_af phenothiazine-type_af tranquilizers_af avoided_af patients_af organophosphate_af poisoning_af ._af"
3435,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",theophylline,phenothiazine-type tranquilizers,No interaction,"morphine_bf ,_bf DRUG ,_be aminophylline_be ,_be succinylcholine_be ,_be reserpine_be ,_be phenothiazine-type_be tranquilizers_be avoided_be patients_be organophosphate_be poisoning_be ._be"
3436,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",aminophylline,succinylcholine,No interaction,"morphine_bf ,_bf theophylline_bf ,_bf DRUG ,_be OTHER_DRUG ,_af reserpine_af ,_af phenothiazine-type_af tranquilizers_af avoided_af patients_af organophosphate_af poisoning_af ._af"
3437,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",aminophylline,reserpine,No interaction,"morphine_bf ,_bf theophylline_bf ,_bf DRUG ,_be succinylcholine_be ,_be OTHER_DRUG ,_af phenothiazine-type_af tranquilizers_af avoided_af patients_af organophosphate_af poisoning_af ._af"
3438,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",aminophylline,phenothiazine-type tranquilizers,No interaction,"morphine_bf ,_bf theophylline_bf ,_bf DRUG ,_be succinylcholine_be ,_be reserpine_be ,_be phenothiazine-type_be tranquilizers_be avoided_be patients_be organophosphate_be poisoning_be ._be"
3439,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",succinylcholine,reserpine,No interaction,"morphine_bf ,_bf theophylline_bf ,_bf aminophylline_bf ,_bf DRUG ,_be OTHER_DRUG ,_af phenothiazine-type_af tranquilizers_af avoided_af patients_af organophosphate_af poisoning_af ._af"
3440,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",succinylcholine,phenothiazine-type tranquilizers,No interaction,"morphine_bf ,_bf theophylline_bf ,_bf aminophylline_bf ,_bf DRUG ,_be reserpine_be ,_be phenothiazine-type_be tranquilizers_be avoided_be patients_be organophosphate_be poisoning_be ._be"
3441,"morphine, theophylline, aminophylline, succinylcholine, reserpine, and phenothiazine-type tranquilizers should be avoided in patients with organophosphate poisoning.",reserpine,phenothiazine-type tranquilizers,No interaction,"morphine_bf ,_bf theophylline_bf ,_bf aminophylline_bf ,_bf succinylcholine_bf ,_bf DRUG ,_be phenothiazine-type_be tranquilizers_be avoided_be patients_be organophosphate_be poisoning_be ._be"
3442,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,Carbidopa,Levodopa,No interaction,Carbidopa/Levodopa:_bf Carbidopa/Levodopa_bf influence_bf pharmacokinetics_bf pramipexole_bf healthy_bf volunteers_bf (N=_bf 10)_bf ._bf
3443,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,Carbidopa,Carbidopa,No interaction,Carbidopa/Levodopa:_bf Carbidopa/Levodopa_bf influence_bf pharmacokinetics_bf pramipexole_bf healthy_bf volunteers_bf (N=_bf 10)_bf ._bf
3444,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,Carbidopa,Levodopa,No interaction,Carbidopa/Levodopa:_bf Carbidopa/Levodopa_bf influence_bf pharmacokinetics_bf pramipexole_bf healthy_bf volunteers_bf (N=_bf 10)_bf ._bf
3445,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,Carbidopa,pramipexole,No interaction,Carbidopa/Levodopa:_bf Carbidopa/Levodopa_bf influence_bf pharmacokinetics_bf OTHER_DRUG healthy_be volunteers_be (N=_be 10)_be ._be
3446,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,Levodopa,Carbidopa,No interaction,Carbidopa/Levodopa:_bf Carbidopa/Levodopa_bf influence_bf pharmacokinetics_bf pramipexole_bf healthy_bf volunteers_bf (N=_bf 10)_bf ._bf
3447,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,Levodopa,Levodopa,No interaction,Carbidopa/Levodopa:_bf Carbidopa/Levodopa_bf influence_bf pharmacokinetics_bf pramipexole_bf healthy_bf volunteers_bf (N=_bf 10)_bf ._bf
3448,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,Levodopa,pramipexole,No interaction,Carbidopa/Levodopa:_bf Carbidopa/Levodopa_bf influence_bf pharmacokinetics_bf OTHER_DRUG healthy_be volunteers_be (N=_be 10)_be ._be
3449,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,Carbidopa,Levodopa,No interaction,Carbidopa/Levodopa:_bf Carbidopa/Levodopa_bf influence_bf pharmacokinetics_bf pramipexole_bf healthy_bf volunteers_bf (N=_bf 10)_bf ._bf
3450,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,Carbidopa,pramipexole,No interaction,Carbidopa/Levodopa:_bf Carbidopa/Levodopa_bf influence_bf pharmacokinetics_bf OTHER_DRUG healthy_be volunteers_be (N=_be 10)_be ._be
3451,Carbidopa/Levodopa: Carbidopa/Levodopa does not influence the pharmacokinetics of pramipexole in healthy volunteers (N= 10). ,Levodopa,pramipexole,No interaction,Carbidopa/Levodopa:_bf Carbidopa/Levodopa_bf influence_bf pharmacokinetics_bf OTHER_DRUG healthy_be volunteers_be (N=_be 10)_be ._be
3452,"Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. ",Selegiline,selegiline,No interaction,"Selegiline:_bf In_bf healthy_bf volunteers_bf (N=_bf 11)_bf ,_bf DRUG influence_be pharmacokinetics_be pramipexole_be ._be"
3453,"Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. ",Selegiline,pramipexole,No interaction,"Selegiline:_bf In_bf healthy_bf volunteers_bf (N=_bf 11)_bf ,_bf DRUG influence_be pharmacokinetics_be OTHER_DRUG ._af"
3454,"Selegiline: In healthy volunteers (N= 11), selegiline did not influence the pharmacokinetics of pramipexole. ",selegiline,pramipexole,No interaction,"Selegiline:_bf In_bf healthy_bf volunteers_bf (N=_bf 11)_bf ,_bf DRUG influence_be pharmacokinetics_be OTHER_DRUG ._af"
3455,Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). ,Amantadine,amantadine,No interaction,Amantadine:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf DRUG unlikely_be alter_be oral_be clearance_be pramipexole_be (N=_be 54)_be ._be
3456,Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). ,Amantadine,pramipexole,No interaction,Amantadine:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf DRUG unlikely_be alter_be oral_be clearance_be OTHER_DRUG (N=_af 54)_af ._af
3457,Amantadine: Population pharmacokinetic analysis suggests that amantadine is unlikely to alter the oral clearance of pramipexole (N= 54). ,amantadine,pramipexole,No interaction,Amantadine:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf DRUG unlikely_be alter_be oral_be clearance_be OTHER_DRUG (N=_af 54)_af ._af
3458,"Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",Cimetidine,Cimetidine,No interaction,"Cimetidine:_bf DRUG ,_be known_be inhibitor_be renal_be tubular_be secretion_be organic_be bases_be via_be cationic_be transport_be system_be ,_be caused_be 50%_be increase_be pramipexole_be AUC_be 40%_be increase_be half-life_be (N=_be 12)_be ._be"
3459,"Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",Cimetidine,pramipexole,No interaction,"Cimetidine:_bf DRUG ,_be known_be inhibitor_be renal_be tubular_be secretion_be organic_be bases_be via_be cationic_be transport_be system_be ,_be caused_be 50%_be increase_be OTHER_DRUG AUC_af 40%_af increase_af half-life_af (N=_af 12)_af ._af"
3460,"Cimetidine: Cimetidine, a known inhibitor of renal tubular secretion of organic bases via the cationic transport system, caused a 50% increase in pramipexole AUC and a 40% increase in half-life (N= 12). ",Cimetidine,pramipexole,mechanism,"Cimetidine:_bf DRUG ,_be known_be inhibitor_be renal_be tubular_be secretion_be organic_be bases_be via_be cationic_be transport_be system_be ,_be caused_be 50%_be increase_be OTHER_DRUG AUC_af 40%_af increase_af half-life_af (N=_af 12)_af ._af"
3461,"Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). ",Probenecid,Probenecid,No interaction,"Probenecid:_bf DRUG ,_be known_be inhibitor_be renal_be tubular_be secretion_be organic_be acids_be via_be aruonic_be transporter_be ,_be noticeably_be influence_be pramipexole_be pharmacokinetics_be (N=_be 12)_be ._be"
3462,"Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). ",Probenecid,pramipexole,No interaction,"Probenecid:_bf DRUG ,_be known_be inhibitor_be renal_be tubular_be secretion_be organic_be acids_be via_be aruonic_be transporter_be ,_be noticeably_be influence_be OTHER_DRUG pharmacokinetics_af (N=_af 12)_af ._af"
3463,"Probenecid: Probenecid, a known inhibitor of renal tubular secretion of organic acids via the aruonic transporter, did not noticeably influence pramipexole pharmacokinetics (N= 12). ",Probenecid,pramipexole,No interaction,"Probenecid:_bf DRUG ,_be known_be inhibitor_be renal_be tubular_be secretion_be organic_be acids_be via_be aruonic_be transporter_be ,_be noticeably_be influence_be OTHER_DRUG pharmacokinetics_af (N=_af 12)_af ._af"
3464,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,ranitidine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af diltiazem_af ,_af triamterene_af ,_af verapamil_af ,_af quinidine_af ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3465,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,diltiazem,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be OTHER_DRUG ,_af triamterene_af ,_af verapamil_af ,_af quinidine_af ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3466,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,triamterene,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be OTHER_DRUG ,_af verapamil_af ,_af quinidine_af ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3467,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,verapamil,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3468,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,quinidine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be OTHER_DRUG ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3469,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,quinine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3470,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3471,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,cephalosporins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3472,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,penicillins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be OTHER_DRUG ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3473,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,indomethacin,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be OTHER_DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3474,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,hydrochlorothiazide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be OTHER_DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3475,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3476,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cimetidine,pramipexole,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be ranitidine_be ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3477,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,diltiazem,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af triamterene_af ,_af verapamil_af ,_af quinidine_af ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3478,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,triamterene,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be OTHER_DRUG ,_af verapamil_af ,_af quinidine_af ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3479,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,verapamil,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3480,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,quinidine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be OTHER_DRUG ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3481,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,quinine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3482,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3483,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,cephalosporins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3484,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,penicillins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be OTHER_DRUG ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3485,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,indomethacin,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be OTHER_DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3486,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,hydrochlorothiazide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be OTHER_DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3487,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3488,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",ranitidine,pramipexole,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf DRUG ,_be diltiazem_be ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3489,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,triamterene,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af verapamil_af ,_af quinidine_af ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3490,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,verapamil,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be OTHER_DRUG ,_af quinidine_af ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3491,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,quinidine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be verapamil_be ,_be OTHER_DRUG ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3492,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,quinine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3493,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3494,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,cephalosporins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3495,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,penicillins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be OTHER_DRUG ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3496,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,indomethacin,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be OTHER_DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3497,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,hydrochlorothiazide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be OTHER_DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3498,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3499,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",diltiazem,pramipexole,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf DRUG ,_be triamterene_be ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3500,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,verapamil,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be OTHER_DRUG ,_af quinidine_af ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3501,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,quinidine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be verapamil_be ,_be OTHER_DRUG ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3502,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,quinine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3503,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3504,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,cephalosporins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3505,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,penicillins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be OTHER_DRUG ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3506,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,indomethacin,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be OTHER_DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3507,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,hydrochlorothiazide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be OTHER_DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3508,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3509,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",triamterene,pramipexole,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf DRUG ,_be verapamil_be ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3510,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,quinidine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf DRUG ,_be OTHER_DRUG ,_af quinine)_af decreases_af oral_af clearance_af pramipexole_af 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3511,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,quinine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf DRUG ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3512,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf DRUG ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3513,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,cephalosporins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf DRUG ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3514,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,penicillins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf DRUG ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be OTHER_DRUG ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3515,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,indomethacin,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf DRUG ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be OTHER_DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3516,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,hydrochlorothiazide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf DRUG ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be OTHER_DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3517,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf DRUG ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3518,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",verapamil,pramipexole,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf DRUG ,_be quinidine_be ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3519,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,quinine,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf DRUG ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3520,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf DRUG ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3521,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,cephalosporins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf DRUG ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3522,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,penicillins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf DRUG ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be OTHER_DRUG ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3523,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,indomethacin,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf DRUG ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be OTHER_DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3524,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,hydrochlorothiazide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf DRUG ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be OTHER_DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3525,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf DRUG ,_be quinine)_be decreases_be oral_be clearance_be pramipexole_be 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3526,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinidine,pramipexole,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf DRUG ,_be quinine)_be decreases_be oral_be clearance_be OTHER_DRUG 20%_af ,_af secreted_af anionic_af transport_af system_af (e_af ._af g_af ._af ,_af cephalosporins_af ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3527,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinine,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be OTHER_DRUG ._af"
3528,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinine,cephalosporins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3529,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinine,penicillins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cephalosporins_bf ,_bf OTHER_DRUG ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3530,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinine,indomethacin,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cephalosporins_bf ,_bf penicillins_bf ,_bf OTHER_DRUG ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3531,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinine,hydrochlorothiazide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cephalosporins_bf ,_bf penicillins_bf ,_bf indomethacin_bf ,_bf OTHER_DRUG ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3532,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinine,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cephalosporins_bf ,_bf penicillins_bf ,_bf indomethacin_bf ,_bf hydrochlorothiazide_bf ,_bf chlorpropamide)_bf likely_bf little_bf effect_bf oral_bf clearance_bf pramipexole_bf ._bf"
3533,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",quinine,pramipexole,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be OTHER_DRUG ._af"
3534,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",pramipexole,cephalosporins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af DRUG ._af"
3535,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",pramipexole,penicillins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be OTHER_DRUG ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af DRUG ._af"
3536,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",pramipexole,indomethacin,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be OTHER_DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af DRUG ._af"
3537,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",pramipexole,hydrochlorothiazide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be OTHER_DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af DRUG ._af"
3538,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",pramipexole,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be DRUG ._af"
3539,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",pramipexole,pramipexole,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be DRUG ._af"
3540,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cephalosporins,penicillins,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3541,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cephalosporins,indomethacin,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be penicillins_be ,_be OTHER_DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3542,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cephalosporins,hydrochlorothiazide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be penicillins_be ,_be indomethacin_be ,_be OTHER_DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3543,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cephalosporins,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3544,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",cephalosporins,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be DRUG ,_af penicillins_af ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3545,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",penicillins,indomethacin,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cephalosporins_bf ,_bf DRUG ,_be OTHER_DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3546,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",penicillins,hydrochlorothiazide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cephalosporins_bf ,_bf DRUG ,_be indomethacin_be ,_be OTHER_DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3547,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",penicillins,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cephalosporins_bf ,_bf DRUG ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3548,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",penicillins,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be DRUG ,_af indomethacin_af ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3549,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",indomethacin,hydrochlorothiazide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cephalosporins_bf ,_bf penicillins_bf ,_bf DRUG ,_be OTHER_DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af pramipexole_af ._af"
3550,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",indomethacin,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cephalosporins_bf ,_bf penicillins_bf ,_bf DRUG ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3551,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",indomethacin,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be DRUG ,_af hydrochlorothiazide_af ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3552,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",hydrochlorothiazide,chlorpropamide,No interaction,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf pramipexole_bf 20%_bf ,_bf secreted_bf anionic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cephalosporins_bf ,_bf penicillins_bf ,_bf indomethacin_bf ,_bf DRUG ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be pramipexole_be ._be"
3553,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",hydrochlorothiazide,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be DRUG ,_af chlorpropamide)_af likely_af little_af effect_af oral_af clearance_af OTHER_DRUG ._af"
3554,"Other drugs eliminated via renal secretion: Population pharmacokinetic analysis suggests that coadministration of drugs that are secreted by the cationic transport system (e.g., cimetidine, ranitidine, diltiazem, triamterene, verapamil, quinidine, and quinine) decreases the oral clearance of pramipexole by about 20%, while those secreted by the anionic transport system (e.g., cephalosporins, penicillins, indomethacin, hydrochlorothiazide, and chlorpropamide) are likely to have little effect on the oral clearance of pramipexole. ",chlorpropamide,pramipexole,mechanism,"Other_bf drugs_bf eliminated_bf via_bf renal_bf secretion:_bf Population_bf pharmacokinetic_bf analysis_bf suggests_bf coadministration_bf drugs_bf secreted_bf cationic_bf transport_bf system_bf (e_bf ._bf g_bf ._bf ,_bf cimetidine_bf ,_bf ranitidine_bf ,_bf diltiazem_bf ,_bf triamterene_bf ,_bf verapamil_bf ,_bf quinidine_bf ,_bf quinine)_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 20%_be ,_be secreted_be anionic_be transport_be system_be (e_be ._be g_be ._be ,_be cephalosporins_be ,_be penicillins_be ,_be indomethacin_be ,_be hydrochlorothiazide_be ,_be chlorpropamide)_be likely_be little_be effect_be oral_be clearance_be OTHER_DRUG ._af"
3555,CYP interactions: Inhibitors of cytochrome P450 enzymes would not be expected to affect pramipexole elimination because pramipexole is not appreciably metabolized by these enzymes in vivo or in vitro. ,pramipexole,pramipexole,No interaction,CYP_bf interactions:_bf Inhibitors_bf cytochrome_bf P450_bf enzymes_bf would_bf expected_bf affect_bf DRUG elimination_be DRUG appreciably_af metabolized_af enzymes_af vivo_af vitro_af ._af
3556,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",Dopamine antagonists,pramipexole,No interaction,"Dopamine_bf antagonists:_bf Since_bf OTHER_DRUG dopamine_be agonist_be ,_be possible_be dopamine_be antagonists_be ,_be neuroleptics_be (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3557,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",Dopamine antagonists,dopamine agonist,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf MIRAPEX_bf ._bf"
3558,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",Dopamine antagonists,dopamine antagonists,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf MIRAPEX_bf ._bf"
3559,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",Dopamine antagonists,neuroleptics,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf OTHER_DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3560,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",Dopamine antagonists,phenothiazines,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf MIRAPEX_bf ._bf"
3561,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",Dopamine antagonists,butyrophenones,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf OTHER_DRUG ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3562,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",Dopamine antagonists,thioxanthenes,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf MIRAPEX_bf ._bf"
3563,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",Dopamine antagonists,metoclopramide,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf OTHER_DRUG ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3564,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",Dopamine antagonists,MIRAPEX,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
3565,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",pramipexole,dopamine agonist,No interaction,"Dopamine_bf antagonists:_bf Since_bf DRUG dopamine_be agonist_be ,_be possible_be dopamine_be antagonists_be ,_be neuroleptics_be (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3566,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",pramipexole,dopamine antagonists,No interaction,"Dopamine_bf antagonists:_bf Since_bf DRUG dopamine_be agonist_be ,_be possible_be dopamine_be antagonists_be ,_be neuroleptics_be (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3567,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",pramipexole,neuroleptics,No interaction,"Dopamine_bf antagonists:_bf Since_bf DRUG dopamine_be agonist_be ,_be possible_be dopamine_be antagonists_be ,_be OTHER_DRUG (phenothiazines_af ,_af butyrophenones_af ,_af thioxanthenes)_af metoclopramide_af ,_af may_af diminish_af effectiveness_af MIRAPEX_af ._af"
3568,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",pramipexole,phenothiazines,No interaction,"Dopamine_bf antagonists:_bf Since_bf DRUG dopamine_be agonist_be ,_be possible_be dopamine_be antagonists_be ,_be neuroleptics_be (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3569,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",pramipexole,butyrophenones,No interaction,"Dopamine_bf antagonists:_bf Since_bf DRUG dopamine_be agonist_be ,_be possible_be dopamine_be antagonists_be ,_be neuroleptics_be (phenothiazines_be ,_be OTHER_DRUG ,_af thioxanthenes)_af metoclopramide_af ,_af may_af diminish_af effectiveness_af MIRAPEX_af ._af"
3570,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",pramipexole,thioxanthenes,No interaction,"Dopamine_bf antagonists:_bf Since_bf DRUG dopamine_be agonist_be ,_be possible_be dopamine_be antagonists_be ,_be neuroleptics_be (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3571,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",pramipexole,metoclopramide,No interaction,"Dopamine_bf antagonists:_bf Since_bf DRUG dopamine_be agonist_be ,_be possible_be dopamine_be antagonists_be ,_be neuroleptics_be (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be OTHER_DRUG ,_af may_af diminish_af effectiveness_af MIRAPEX_af ._af"
3572,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",pramipexole,MIRAPEX,No interaction,"Dopamine_bf antagonists:_bf Since_bf DRUG dopamine_be agonist_be ,_be possible_be dopamine_be antagonists_be ,_be neuroleptics_be (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be OTHER_DRUG ._af"
3573,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine agonist,dopamine antagonists,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf MIRAPEX_bf ._bf"
3574,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine agonist,neuroleptics,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf OTHER_DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3575,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine agonist,phenothiazines,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf MIRAPEX_bf ._bf"
3576,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine agonist,butyrophenones,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf OTHER_DRUG ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3577,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine agonist,thioxanthenes,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf MIRAPEX_bf ._bf"
3578,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine agonist,metoclopramide,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf OTHER_DRUG ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3579,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine agonist,MIRAPEX,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
3580,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine antagonists,neuroleptics,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf OTHER_DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3581,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine antagonists,phenothiazines,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf MIRAPEX_bf ._bf"
3582,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine antagonists,butyrophenones,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf OTHER_DRUG ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3583,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine antagonists,thioxanthenes,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf MIRAPEX_bf ._bf"
3584,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine antagonists,metoclopramide,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf OTHER_DRUG ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3585,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",dopamine antagonists,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
3586,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",neuroleptics,phenothiazines,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3587,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",neuroleptics,butyrophenones,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be OTHER_DRUG ,_af thioxanthenes)_af metoclopramide_af ,_af may_af diminish_af effectiveness_af MIRAPEX_af ._af"
3588,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",neuroleptics,thioxanthenes,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3589,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",neuroleptics,metoclopramide,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be OTHER_DRUG ,_af may_af diminish_af effectiveness_af MIRAPEX_af ._af"
3590,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",neuroleptics,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf DRUG (phenothiazines_be ,_be butyrophenones_be ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be OTHER_DRUG ._af"
3591,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",phenothiazines,butyrophenones,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf OTHER_DRUG ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3592,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",phenothiazines,thioxanthenes,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf MIRAPEX_bf ._bf"
3593,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",phenothiazines,metoclopramide,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf OTHER_DRUG ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3594,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",phenothiazines,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
3595,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",butyrophenones,thioxanthenes,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3596,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",butyrophenones,metoclopramide,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be thioxanthenes)_be OTHER_DRUG ,_af may_af diminish_af effectiveness_af MIRAPEX_af ._af"
3597,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",butyrophenones,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf DRUG ,_be thioxanthenes)_be metoclopramide_be ,_be may_be diminish_be effectiveness_be OTHER_DRUG ._af"
3598,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",thioxanthenes,metoclopramide,No interaction,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf OTHER_DRUG ,_be may_be diminish_be effectiveness_be MIRAPEX_be ._be"
3599,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",thioxanthenes,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf metoclopramide_bf ,_bf may_bf diminish_bf effectiveness_bf OTHER_DRUG ._be"
3600,"Dopamine antagonists: Since pramipexole is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of MIRAPEX. ",metoclopramide,MIRAPEX,effect,"Dopamine_bf antagonists:_bf Since_bf pramipexole_bf dopamine_bf agonist_bf ,_bf possible_bf dopamine_bf antagonists_bf ,_bf neuroleptics_bf (phenothiazines_bf ,_bf butyrophenones_bf ,_bf thioxanthenes)_bf DRUG ,_be may_be diminish_be effectiveness_be OTHER_DRUG ._af"
3601,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,phenytoin,No interaction,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be OTHER_DRUG rifampin_af may_af increase_af clearance_af corticosteroids_af may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
3602,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,rifampin,No interaction,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be OTHER_DRUG may_af increase_af clearance_af corticosteroids_af may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
3603,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
3604,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenobarbital,corticosteroid,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf DRUG ,_be phenytoin_be rifampin_be may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
3605,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenytoin,rifampin,No interaction,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG OTHER_DRUG may_af increase_af clearance_af corticosteroids_af may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
3606,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenytoin,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG rifampin_be may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
3607,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",phenytoin,corticosteroid,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf DRUG rifampin_be may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
3608,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",rifampin,corticosteroids,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf DRUG may_be increase_be clearance_be OTHER_DRUG may_af require_af increases_af corticosteroid_af dose_af achieve_af desired_af response_af ._af"
3609,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",rifampin,corticosteroid,mechanism,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf DRUG may_be increase_be clearance_be corticosteroids_be may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
3610,"Drugs that induce hepatic enzymes such as phenobarbital, phenytoin and rifampin may increase the clearance of corticosteroids and may require increases in corticosteroid dose to achieve the desired response. ",corticosteroids,corticosteroid,No interaction,"Drugs_bf induce_bf hepatic_bf enzymes_bf phenobarbital_bf ,_bf phenytoin_bf rifampin_bf may_bf increase_bf clearance_bf DRUG may_be require_be increases_be OTHER_DRUG dose_af achieve_af desired_af response_af ._af"
3611,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,troleandomycin,ketoconazole,No interaction,Drugs_bf DRUG OTHER_DRUG may_af inhibit_af metabolism_af corticosteroids_af thus_af decrease_af clearance_af ._af
3612,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,troleandomycin,corticosteroids,mechanism,Drugs_bf DRUG ketoconazole_be may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
3613,Drugs such as troleandomycin and ketoconazole may inhibit the metabolism of corticosteroids and thus decrease their clearance. ,ketoconazole,corticosteroids,mechanism,Drugs_bf troleandomycin_bf DRUG may_be inhibit_be metabolism_be OTHER_DRUG thus_af decrease_af clearance_af ._af
3614,Corticosteroids may increase the clearance of chronic high dose aspirin. ,Corticosteroids,aspirin,mechanism,DRUG may_be increase_be clearance_be chronic_be high_be dose_be OTHER_DRUG ._af
3615,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ,salicylate,salicylate,No interaction,This_bf could_bf lead_bf decreased_bf DRUG serum_be levels_be increase_be risk_be DRUG toxicity_af corticosteroid_af withdrawn_af ._af
3616,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ,salicylate,corticosteroid,No interaction,This_bf could_bf lead_bf decreased_bf DRUG serum_be levels_be increase_be risk_be DRUG toxicity_af OTHER_DRUG withdrawn_af ._af
3617,This could lead to decreased salicylate serum levels or increase the risk of salicylate toxicity when corticosteroid is withdrawn. ,salicylate,corticosteroid,effect,This_bf could_bf lead_bf decreased_bf DRUG serum_be levels_be increase_be risk_be DRUG toxicity_af OTHER_DRUG withdrawn_af ._af
3618,Aspirin should be used cautiously in conjunction with corticosteroids in patients suffering from hypoprothrombinemia. ,Aspirin,corticosteroids,advise,DRUG used_be cautiously_be conjunction_be OTHER_DRUG patients_af suffering_af hypoprothrombinemia_af ._af
3619,The effect of corticosteroids on oral anticoagulants is variable. ,corticosteroids,anticoagulants,effect,The_bf effect_bf DRUG oral_be OTHER_DRUG variable_af ._af
3620,There are reports of enhanced as well as diminished effects of anticoagulants when given concurrently with corticosteroids. ,anticoagulants,corticosteroids,effect,There_bf reports_bf enhanced_bf well_bf diminished_bf effects_bf DRUG given_be concurrently_be OTHER_DRUG ._af
3621,Thiazide diuretics may accentuate the orthostatic hypotension that may occur with phenothiazines. ,Thiazide diuretics,phenothiazines,effect,Thiazide_bf diuretics_bf may_bf accentuate_bf orthostatic_bf hypotension_bf may_bf occur_bf OTHER_DRUG ._be
3622,Antihypertensive effects of guanethidine and related compounds may be counteracted when phenothiazines are used concomitantly. ,guanethidine,phenothiazines,effect,Antihypertensive_bf effects_bf DRUG related_be compounds_be may_be counteracted_be OTHER_DRUG used_af concomitantly_af ._af
3623,Concomitant administration of propranolol with phenothiazines results in increased plasma levels of both drugs.,propranolol,phenothiazines,mechanism,Concomitant_bf administration_bf DRUG OTHER_DRUG results_af increased_af plasma_af levels_af drugs_af ._af
3624,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,narcotics,effect,"The_bf induction_bf dose_bf requirements_bf DRUG Injectable_be Emulsion_be may_be reduced_be patients_be intramuscular_be intravenous_be premedication_be ,_be particularly_be OTHER_DRUG (eg_af ,_af morphine_af ,_af meperidine_af ,_af fentanyl_af ,_af etc_af ._af )_af"
3625,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,morphine,effect,"The_bf induction_bf dose_bf requirements_bf DRUG Injectable_be Emulsion_be may_be reduced_be patients_be intramuscular_be intravenous_be premedication_be ,_be particularly_be narcotics_be (eg_be ,_be OTHER_DRUG ,_af meperidine_af ,_af fentanyl_af ,_af etc_af ._af )_af"
3626,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,meperidine,effect,"The_bf induction_bf dose_bf requirements_bf DRUG Injectable_be Emulsion_be may_be reduced_be patients_be intramuscular_be intravenous_be premedication_be ,_be particularly_be narcotics_be (eg_be ,_be morphine_be ,_be OTHER_DRUG ,_af fentanyl_af ,_af etc_af ._af )_af"
3627,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",DIPRIVAN,fentanyl,effect,"The_bf induction_bf dose_bf requirements_bf DRUG Injectable_be Emulsion_be may_be reduced_be patients_be intramuscular_be intravenous_be premedication_be ,_be particularly_be narcotics_be (eg_be ,_be morphine_be ,_be meperidine_be ,_be OTHER_DRUG ,_af etc_af ._af )_af"
3628,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",narcotics,morphine,No interaction,"The_bf induction_bf dose_bf requirements_bf DIPRIVAN_bf Injectable_bf Emulsion_bf may_bf reduced_bf patients_bf intramuscular_bf intravenous_bf premedication_bf ,_bf particularly_bf DRUG (eg_be ,_be OTHER_DRUG ,_af meperidine_af ,_af fentanyl_af ,_af etc_af ._af )_af"
3629,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",narcotics,meperidine,No interaction,"The_bf induction_bf dose_bf requirements_bf DIPRIVAN_bf Injectable_bf Emulsion_bf may_bf reduced_bf patients_bf intramuscular_bf intravenous_bf premedication_bf ,_bf particularly_bf DRUG (eg_be ,_be morphine_be ,_be OTHER_DRUG ,_af fentanyl_af ,_af etc_af ._af )_af"
3630,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",narcotics,fentanyl,No interaction,"The_bf induction_bf dose_bf requirements_bf DIPRIVAN_bf Injectable_bf Emulsion_bf may_bf reduced_bf patients_bf intramuscular_bf intravenous_bf premedication_bf ,_bf particularly_bf DRUG (eg_be ,_be morphine_be ,_be meperidine_be ,_be OTHER_DRUG ,_af etc_af ._af )_af"
3631,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",morphine,meperidine,No interaction,"The_bf induction_bf dose_bf requirements_bf DIPRIVAN_bf Injectable_bf Emulsion_bf may_bf reduced_bf patients_bf intramuscular_bf intravenous_bf premedication_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf DRUG ,_be OTHER_DRUG ,_af fentanyl_af ,_af etc_af ._af )_af"
3632,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",morphine,fentanyl,No interaction,"The_bf induction_bf dose_bf requirements_bf DIPRIVAN_bf Injectable_bf Emulsion_bf may_bf reduced_bf patients_bf intramuscular_bf intravenous_bf premedication_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf DRUG ,_be meperidine_be ,_be OTHER_DRUG ,_af etc_af ._af )_af"
3633,"The induction dose requirements of DIPRIVAN Injectable Emulsion may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (eg, morphine, meperidine, and fentanyl, etc.) ",meperidine,fentanyl,No interaction,"The_bf induction_bf dose_bf requirements_bf DIPRIVAN_bf Injectable_bf Emulsion_bf may_bf reduced_bf patients_bf intramuscular_bf intravenous_bf premedication_bf ,_bf particularly_bf narcotics_bf (eg_bf ,_bf morphine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af etc_af ._af )_af"
3634,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",opioids,sedatives,No interaction,"combinations_bf DRUG OTHER_DRUG (eg_af ,_af benzodiazepines_af ,_af barbiturates_af ,_af chloral_af hydrate_af ,_af droperidol_af ,_af etc_af ._af )_af ._af"
3635,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",opioids,benzodiazepines,No interaction,"combinations_bf DRUG sedatives_be (eg_be ,_be OTHER_DRUG ,_af barbiturates_af ,_af chloral_af hydrate_af ,_af droperidol_af ,_af etc_af ._af )_af ._af"
3636,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",opioids,barbiturates,No interaction,"combinations_bf DRUG sedatives_be (eg_be ,_be benzodiazepines_be ,_be OTHER_DRUG ,_af chloral_af hydrate_af ,_af droperidol_af ,_af etc_af ._af )_af ._af"
3637,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",opioids,chloral hydrate,No interaction,"combinations_bf DRUG sedatives_be (eg_be ,_be benzodiazepines_be ,_be barbiturates_be ,_be chloral_be hydrate_be ,_be droperidol_be ,_be etc_be ._be )_be ._be"
3638,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",opioids,droperidol,No interaction,"combinations_bf DRUG sedatives_be (eg_be ,_be benzodiazepines_be ,_be barbiturates_be ,_be chloral_be hydrate_be ,_be OTHER_DRUG ,_af etc_af ._af )_af ._af"
3639,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",sedatives,benzodiazepines,No interaction,"combinations_bf opioids_bf DRUG (eg_be ,_be OTHER_DRUG ,_af barbiturates_af ,_af chloral_af hydrate_af ,_af droperidol_af ,_af etc_af ._af )_af ._af"
3640,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",sedatives,barbiturates,No interaction,"combinations_bf opioids_bf DRUG (eg_be ,_be benzodiazepines_be ,_be OTHER_DRUG ,_af chloral_af hydrate_af ,_af droperidol_af ,_af etc_af ._af )_af ._af"
3641,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",sedatives,chloral hydrate,No interaction,"combinations_bf opioids_bf DRUG (eg_be ,_be benzodiazepines_be ,_be barbiturates_be ,_be chloral_be hydrate_be ,_be droperidol_be ,_be etc_be ._be )_be ._be"
3642,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",sedatives,droperidol,No interaction,"combinations_bf opioids_bf DRUG (eg_be ,_be benzodiazepines_be ,_be barbiturates_be ,_be chloral_be hydrate_be ,_be OTHER_DRUG ,_af etc_af ._af )_af ._af"
3643,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",benzodiazepines,barbiturates,No interaction,"combinations_bf opioids_bf sedatives_bf (eg_bf ,_bf DRUG ,_be OTHER_DRUG ,_af chloral_af hydrate_af ,_af droperidol_af ,_af etc_af ._af )_af ._af"
3644,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",benzodiazepines,chloral hydrate,No interaction,"combinations_bf opioids_bf sedatives_bf (eg_bf ,_bf DRUG ,_be barbiturates_be ,_be chloral_be hydrate_be ,_be droperidol_be ,_be etc_be ._be )_be ._be"
3645,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",benzodiazepines,droperidol,No interaction,"combinations_bf opioids_bf sedatives_bf (eg_bf ,_bf DRUG ,_be barbiturates_be ,_be chloral_be hydrate_be ,_be OTHER_DRUG ,_af etc_af ._af )_af ._af"
3646,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",barbiturates,chloral hydrate,No interaction,"combinations_bf opioids_bf sedatives_bf (eg_bf ,_bf benzodiazepines_bf ,_bf DRUG ,_be chloral_be hydrate_be ,_be droperidol_be ,_be etc_be ._be )_be ._be"
3647,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",barbiturates,droperidol,No interaction,"combinations_bf opioids_bf sedatives_bf (eg_bf ,_bf benzodiazepines_bf ,_bf DRUG ,_be chloral_be hydrate_be ,_be OTHER_DRUG ,_af etc_af ._af )_af ._af"
3648,"and combinations of opioids and sedatives (eg, benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). ",chloral hydrate,droperidol,No interaction,"combinations_bf opioids_bf sedatives_bf (eg_bf ,_bf benzodiazepines_bf ,_bf barbiturates_bf ,_bf chloral_bf hydrate_bf ,_bf OTHER_DRUG ,_be etc_be ._be )_be ._be"
3649,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,analgesic agents,advise,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DRUG Injectable_be Emulsion_be administration_be adjusted_be according_be desired_be level_be anesthesia_be sedation_be may_be reduced_be presence_be supplemental_be analgesic_be agents_be (eg_be ,_be nitrous_be oxide_be opioids)_be ._be"
3650,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,nitrous oxide,advise,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DRUG Injectable_be Emulsion_be administration_be adjusted_be according_be desired_be level_be anesthesia_be sedation_be may_be reduced_be presence_be supplemental_be analgesic_be agents_be (eg_be ,_be nitrous_be oxide_be opioids)_be ._be"
3651,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",DIPRIVAN,opioids,advise,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DRUG Injectable_be Emulsion_be administration_be adjusted_be according_be desired_be level_be anesthesia_be sedation_be may_be reduced_be presence_be supplemental_be analgesic_be agents_be (eg_be ,_be nitrous_be oxide_be opioids)_be ._be"
3652,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",analgesic agents,nitrous oxide,No interaction,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DIPRIVAN_bf Injectable_bf Emulsion_bf administration_bf adjusted_bf according_bf desired_bf level_bf anesthesia_bf sedation_bf may_bf reduced_bf presence_bf supplemental_bf analgesic_bf agents_bf (eg_bf ,_bf nitrous_bf oxide_bf opioids)_bf ._bf"
3653,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",analgesic agents,opioids,No interaction,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DIPRIVAN_bf Injectable_bf Emulsion_bf administration_bf adjusted_bf according_bf desired_bf level_bf anesthesia_bf sedation_bf may_bf reduced_bf presence_bf supplemental_bf analgesic_bf agents_bf (eg_bf ,_bf nitrous_bf oxide_bf opioids)_bf ._bf"
3654,"During maintenance of anesthesia or sedation, the rate of DIPRIVAN Injectable Emulsion administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (eg, nitrous oxide or opioids). ",nitrous oxide,opioids,No interaction,"During_bf maintenance_bf anesthesia_bf sedation_bf ,_bf rate_bf DIPRIVAN_bf Injectable_bf Emulsion_bf administration_bf adjusted_bf according_bf desired_bf level_bf anesthesia_bf sedation_bf may_bf reduced_bf presence_bf supplemental_bf analgesic_bf agents_bf (eg_bf ,_bf nitrous_bf oxide_bf opioids)_bf ._bf"
3655,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",isoflurane,enflurane,No interaction,"The_bf concurrent_bf administration_bf potent_bf inhalational_bf agents_bf (eg_bf ,_bf DRUG ,_be OTHER_DRUG ,_af halothane)_af maintenance_af DIPRIVAN_af Injectable_af Emulsion_af extensively_af evaluated_af ._af"
3656,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",isoflurane,halothane,No interaction,"The_bf concurrent_bf administration_bf potent_bf inhalational_bf agents_bf (eg_bf ,_bf DRUG ,_be enflurane_be ,_be halothane)_be maintenance_be DIPRIVAN_be Injectable_be Emulsion_be extensively_be evaluated_be ._be"
3657,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",isoflurane,DIPRIVAN,No interaction,"The_bf concurrent_bf administration_bf potent_bf inhalational_bf agents_bf (eg_bf ,_bf DRUG ,_be enflurane_be ,_be halothane)_be maintenance_be OTHER_DRUG Injectable_af Emulsion_af extensively_af evaluated_af ._af"
3658,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",enflurane,halothane,No interaction,"The_bf concurrent_bf administration_bf potent_bf inhalational_bf agents_bf (eg_bf ,_bf isoflurane_bf ,_bf DRUG ,_be halothane)_be maintenance_be DIPRIVAN_be Injectable_be Emulsion_be extensively_be evaluated_be ._be"
3659,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",enflurane,DIPRIVAN,No interaction,"The_bf concurrent_bf administration_bf potent_bf inhalational_bf agents_bf (eg_bf ,_bf isoflurane_bf ,_bf DRUG ,_be halothane)_be maintenance_be OTHER_DRUG Injectable_af Emulsion_af extensively_af evaluated_af ._af"
3660,"The concurrent administration of potent inhalational agents (eg, isoflurane, enflurane, and halothane) during maintenance with DIPRIVAN Injectable Emulsion has not been extensively evaluated. ",halothane,DIPRIVAN,No interaction,"The_bf concurrent_bf administration_bf potent_bf inhalational_bf agents_bf (eg_bf ,_bf isoflurane_bf ,_bf enflurane_bf ,_bf halothane)_bf maintenance_bf OTHER_DRUG Injectable_be Emulsion_be extensively_be evaluated_be ._be"
3661,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",DIPRIVAN,neuromuscular blocking agents,No interaction,"DRUG Injectable_be Emulsion_be cause_be clinically_be significant_be change_be onset_be ,_be intensity_be ,_be duration_be action_be commonly_be used_be neuromuscular_be blocking_be agents_be (eg_be ,_be succinylcholine_be nondepolarizing_be muscle_be relaxants)_be ._be"
3662,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",DIPRIVAN,succinylcholine,No interaction,"DRUG Injectable_be Emulsion_be cause_be clinically_be significant_be change_be onset_be ,_be intensity_be ,_be duration_be action_be commonly_be used_be neuromuscular_be blocking_be agents_be (eg_be ,_be OTHER_DRUG nondepolarizing_af muscle_af relaxants)_af ._af"
3663,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",DIPRIVAN,nondepolarizing muscle relaxants,No interaction,"DRUG Injectable_be Emulsion_be cause_be clinically_be significant_be change_be onset_be ,_be intensity_be ,_be duration_be action_be commonly_be used_be neuromuscular_be blocking_be agents_be (eg_be ,_be succinylcholine_be nondepolarizing_be muscle_be relaxants)_be ._be"
3664,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",neuromuscular blocking agents,succinylcholine,No interaction,"DIPRIVAN_bf Injectable_bf Emulsion_bf cause_bf clinically_bf significant_bf change_bf onset_bf ,_bf intensity_bf ,_bf duration_bf action_bf commonly_bf used_bf neuromuscular_bf blocking_bf agents_bf (eg_bf ,_bf OTHER_DRUG nondepolarizing_be muscle_be relaxants)_be ._be"
3665,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",neuromuscular blocking agents,nondepolarizing muscle relaxants,No interaction,"DIPRIVAN_bf Injectable_bf Emulsion_bf cause_bf clinically_bf significant_bf change_bf onset_bf ,_bf intensity_bf ,_bf duration_bf action_bf commonly_bf used_bf neuromuscular_bf blocking_bf agents_bf (eg_bf ,_bf succinylcholine_bf nondepolarizing_bf muscle_bf relaxants)_bf ._bf"
3666,"DIPRIVAN Injectable Emulsion does not cause a clinically significant change in onset, intensity, or duration of action of the commonly used neuromuscular blocking agents (eg, succinylcholine and nondepolarizing muscle relaxants). ",succinylcholine,nondepolarizing muscle relaxants,No interaction,"DIPRIVAN_bf Injectable_bf Emulsion_bf cause_bf clinically_bf significant_bf change_bf onset_bf ,_bf intensity_bf ,_bf duration_bf action_bf commonly_bf used_bf neuromuscular_bf blocking_bf agents_bf (eg_bf ,_bf DRUG nondepolarizing_be muscle_be relaxants)_be ._be"
3667,"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.",muscle relaxants,analgesic agents,No interaction,"No_bf significant_bf adverse_bf interactions_bf commonly_bf used_bf premedications_bf drugs_bf used_bf anesthesia_bf sedation_bf (including_bf range_bf muscle_bf relaxants_bf ,_bf inhalational_bf agents_bf ,_bf analgesic_bf agents_bf ,_bf local_bf anesthetic_bf agents)_bf observed_bf ._bf"
3668,"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.",muscle relaxants,anesthetic agents,No interaction,"No_bf significant_bf adverse_bf interactions_bf commonly_bf used_bf premedications_bf drugs_bf used_bf anesthesia_bf sedation_bf (including_bf range_bf muscle_bf relaxants_bf ,_bf inhalational_bf agents_bf ,_bf analgesic_bf agents_bf ,_bf local_bf anesthetic_bf agents)_bf observed_bf ._bf"
3669,"No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed.",analgesic agents,anesthetic agents,No interaction,"No_bf significant_bf adverse_bf interactions_bf commonly_bf used_bf premedications_bf drugs_bf used_bf anesthesia_bf sedation_bf (including_bf range_bf muscle_bf relaxants_bf ,_bf inhalational_bf agents_bf ,_bf analgesic_bf agents_bf ,_bf local_bf anesthetic_bf agents)_bf observed_bf ._bf"
3670,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",propoxyphene,CNS depressants,effect,"The_bf CNS-depressant_bf effect_bf DRUG additive_be CNS_be depressants_be ,_be including_be alcohol_be ._be"
3671,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",propoxyphene,alcohol,effect,"The_bf CNS-depressant_bf effect_bf DRUG additive_be CNS_be depressants_be ,_be including_be OTHER_DRUG ._af"
3672,"The CNS-depressant effect of propoxyphene is additive with that of other CNS depressants, including alcohol. ",CNS depressants,alcohol,No interaction,"The_bf CNS-depressant_bf effect_bf propoxyphene_bf additive_bf CNS_bf depressants_bf ,_bf including_bf OTHER_DRUG ._be"
3673,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",propoxyphene,antidepressants,No interaction,"Such_bf occurrences_bf reported_bf DRUG administered_be patients_be OTHER_DRUG ,_af anticonvulsants_af ,_af warfarin-like_af drugs_af ._af"
3674,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",propoxyphene,anticonvulsants,No interaction,"Such_bf occurrences_bf reported_bf DRUG administered_be patients_be antidepressants_be ,_be OTHER_DRUG ,_af warfarin-like_af drugs_af ._af"
3675,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",propoxyphene,warfarin,No interaction,"Such_bf occurrences_bf reported_bf DRUG administered_be patients_be antidepressants_be ,_be anticonvulsants_be ,_be warfarin-like_be drugs_be ._be"
3676,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",antidepressants,anticonvulsants,No interaction,"Such_bf occurrences_bf reported_bf propoxyphene_bf administered_bf patients_bf DRUG ,_be OTHER_DRUG ,_af warfarin-like_af drugs_af ._af"
3677,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",antidepressants,warfarin,No interaction,"Such_bf occurrences_bf reported_bf propoxyphene_bf administered_bf patients_bf DRUG ,_be anticonvulsants_be ,_be warfarin-like_be drugs_be ._be"
3678,"Such occurrences have been reported when propoxyphene was administered to patients on antidepressants, anticonvulsants, or warfarin-like drugs. ",anticonvulsants,warfarin,No interaction,"Such_bf occurrences_bf reported_bf propoxyphene_bf administered_bf patients_bf antidepressants_bf ,_bf DRUG ,_be warfarin-like_be drugs_be ._be"
3679,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,MAO inhibitors,beta adrenergic blockers,No interaction,MAO_bf inhibitors_bf beta_bf adrenergic_bf blockers_bf increase_bf effects_bf pseudoephedrine_bf ._bf
3680,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,MAO inhibitors,pseudoephedrine,effect,MAO_bf inhibitors_bf beta_bf adrenergic_bf blockers_bf increase_bf effects_bf OTHER_DRUG ._be
3681,MAO inhibitors and beta adrenergic blockers increase the effects of pseudoephedrine. ,beta adrenergic blockers,pseudoephedrine,effect,MAO_bf inhibitors_bf beta_bf adrenergic_bf blockers_bf increase_bf effects_bf OTHER_DRUG ._be
3682,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,methyldopa,effect,"DRUG may_be reduce_be antihypertensive_be effects_be OTHER_DRUG ,_af mecamylamine_af ,_af reserpine_af veratrum_af alkaloids_af ._af"
3683,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,mecamylamine,effect,"DRUG may_be reduce_be antihypertensive_be effects_be methyldopa_be ,_be OTHER_DRUG ,_af reserpine_af veratrum_af alkaloids_af ._af"
3684,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,reserpine,effect,"DRUG may_be reduce_be antihypertensive_be effects_be methyldopa_be ,_be mecamylamine_be ,_be OTHER_DRUG veratrum_af alkaloids_af ._af"
3685,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",Sympathomimetics,veratrum alkaloids,effect,"DRUG may_be reduce_be antihypertensive_be effects_be methyldopa_be ,_be mecamylamine_be ,_be reserpine_be veratrum_be alkaloids_be ._be"
3686,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",methyldopa,mecamylamine,No interaction,"Sympathomimetics_bf may_bf reduce_bf antihypertensive_bf effects_bf DRUG ,_be OTHER_DRUG ,_af reserpine_af veratrum_af alkaloids_af ._af"
3687,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",methyldopa,reserpine,No interaction,"Sympathomimetics_bf may_bf reduce_bf antihypertensive_bf effects_bf DRUG ,_be mecamylamine_be ,_be OTHER_DRUG veratrum_af alkaloids_af ._af"
3688,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",methyldopa,veratrum alkaloids,No interaction,"Sympathomimetics_bf may_bf reduce_bf antihypertensive_bf effects_bf DRUG ,_be mecamylamine_be ,_be reserpine_be veratrum_be alkaloids_be ._be"
3689,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",mecamylamine,reserpine,No interaction,"Sympathomimetics_bf may_bf reduce_bf antihypertensive_bf effects_bf methyldopa_bf ,_bf DRUG ,_be OTHER_DRUG veratrum_af alkaloids_af ._af"
3690,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",mecamylamine,veratrum alkaloids,No interaction,"Sympathomimetics_bf may_bf reduce_bf antihypertensive_bf effects_bf methyldopa_bf ,_bf DRUG ,_be reserpine_be veratrum_be alkaloids_be ._be"
3691,"Sympathomimetics may reduce the antihypertensive effects of methyldopa, mecamylamine, reserpine and veratrum alkaloids.",reserpine,veratrum alkaloids,No interaction,"Sympathomimetics_bf may_bf reduce_bf antihypertensive_bf effects_bf methyldopa_bf ,_bf mecamylamine_bf ,_bf DRUG veratrum_be alkaloids_be ._be"
3692,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",Pyrimethamine,sulfonamides,No interaction,"DRUG may_be used_be OTHER_DRUG ,_af quinine_af antimalarials_af ,_af antibiotics_af ._af"
3693,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",Pyrimethamine,quinine,No interaction,"DRUG may_be used_be sulfonamides_be ,_be OTHER_DRUG antimalarials_af ,_af antibiotics_af ._af"
3694,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",Pyrimethamine,antimalarials,No interaction,"DRUG may_be used_be sulfonamides_be ,_be quinine_be OTHER_DRUG ,_af antibiotics_af ._af"
3695,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",Pyrimethamine,antibiotics,No interaction,"DRUG may_be used_be sulfonamides_be ,_be quinine_be antimalarials_be ,_be OTHER_DRUG ._af"
3696,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",sulfonamides,quinine,No interaction,"Pyrimethamine_bf may_bf used_bf DRUG ,_be OTHER_DRUG antimalarials_af ,_af antibiotics_af ._af"
3697,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",sulfonamides,antimalarials,No interaction,"Pyrimethamine_bf may_bf used_bf DRUG ,_be quinine_be OTHER_DRUG ,_af antibiotics_af ._af"
3698,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",sulfonamides,antibiotics,No interaction,"Pyrimethamine_bf may_bf used_bf DRUG ,_be quinine_be antimalarials_be ,_be OTHER_DRUG ._af"
3699,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",quinine,antimalarials,No interaction,"Pyrimethamine_bf may_bf used_bf sulfonamides_bf ,_bf DRUG OTHER_DRUG ,_af antibiotics_af ._af"
3700,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",quinine,antibiotics,No interaction,"Pyrimethamine_bf may_bf used_bf sulfonamides_bf ,_bf DRUG antimalarials_be ,_be OTHER_DRUG ._af"
3701,"Pyrimethamine may be used with sulfonamides, quinine and other antimalarials, and with other antibiotics. ",antimalarials,antibiotics,No interaction,"Pyrimethamine_bf may_bf used_bf sulfonamides_bf ,_bf quinine_bf DRUG ,_be OTHER_DRUG ._af"
3702,Folinic acid (leucovorin) should be administered until normal hematopoiesis is restored. ,Folinic acid,leucovorin,No interaction,Folinic_bf acid_bf (leucovorin)_bf administered_bf normal_bf hematopoiesis_bf restored_bf ._bf
3703,Mild hepatotoxicity has been reported in some patients when lorazepam and pyrimethamine were administered concomitantly.,lorazepam,pyrimethamine,effect,Mild_bf hepatotoxicity_bf reported_bf patients_bf DRUG OTHER_DRUG administered_af concomitantly_af ._af
3704,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,Cholestyramine,No interaction,Cholestyramine:_bf DRUG causes_be 60%_be reduction_be absorption_be enterohepatic_be cycling_be raloxifene_be coadministered_be EVISTA_be ._be
3705,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,raloxifene,No interaction,Cholestyramine:_bf DRUG causes_be 60%_be reduction_be absorption_be enterohepatic_be cycling_be OTHER_DRUG coadministered_af EVISTA_af ._af
3706,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,EVISTA,No interaction,Cholestyramine:_bf DRUG causes_be 60%_be reduction_be absorption_be enterohepatic_be cycling_be raloxifene_be coadministered_be OTHER_DRUG ._af
3707,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,raloxifene,mechanism,Cholestyramine:_bf DRUG causes_be 60%_be reduction_be absorption_be enterohepatic_be cycling_be OTHER_DRUG coadministered_af EVISTA_af ._af
3708,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,Cholestyramine,EVISTA,advise,Cholestyramine:_bf DRUG causes_be 60%_be reduction_be absorption_be enterohepatic_be cycling_be raloxifene_be coadministered_be OTHER_DRUG ._af
3709,Cholestyramine: Cholestyramine causes a 60% reduction in the absorption and enterohepatic cycling of raloxifene and should not be coadministered with EVISTA. ,raloxifene,EVISTA,No interaction,Cholestyramine:_bf Cholestyramine_bf causes_bf 60%_bf reduction_bf absorption_bf enterohepatic_bf cycling_bf DRUG coadministered_be OTHER_DRUG ._af
3710,Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. ,Warfarin,EVISTA,No interaction,Warfarin:_bf The_bf coadministration_bf OTHER_DRUG DRUG assessed_af chronic_af conditions_af ._af
3711,Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. ,Warfarin,warfarin,No interaction,Warfarin:_bf The_bf coadministration_bf EVISTA_bf DRUG assessed_be chronic_be conditions_be ._be
3712,Warfarin: The coadministration of EVISTA and warfarin has not been assessed under chronic conditions. ,EVISTA,warfarin,No interaction,Warfarin:_bf The_bf coadministration_bf DRUG OTHER_DRUG assessed_af chronic_af conditions_af ._af
3713,"If EVISTA is given concurrently with warfarin, prothrombin time should be monitored. ",EVISTA,warfarin,advise,"If_bf DRUG given_be concurrently_be OTHER_DRUG ,_af prothrombin_af time_af monitored_af ._af"
3714,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",raloxifene,warfarin,No interaction,"In_bf vitro_bf ,_bf DRUG affect_be binding_be OTHER_DRUG ,_af phenytoin_af ,_af tamoxifen_af ._af"
3715,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",raloxifene,phenytoin,No interaction,"In_bf vitro_bf ,_bf DRUG affect_be binding_be warfarin_be ,_be OTHER_DRUG ,_af tamoxifen_af ._af"
3716,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",raloxifene,tamoxifen,No interaction,"In_bf vitro_bf ,_bf DRUG affect_be binding_be warfarin_be ,_be phenytoin_be ,_be OTHER_DRUG ._af"
3717,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",warfarin,phenytoin,No interaction,"In_bf vitro_bf ,_bf raloxifene_bf affect_bf binding_bf DRUG ,_be OTHER_DRUG ,_af tamoxifen_af ._af"
3718,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",warfarin,tamoxifen,No interaction,"In_bf vitro_bf ,_bf raloxifene_bf affect_bf binding_bf DRUG ,_be phenytoin_be ,_be OTHER_DRUG ._af"
3719,"In vitro, raloxifene did not affect the binding of warfarin, phenytoin, or tamoxifen. ",phenytoin,tamoxifen,No interaction,"In_bf vitro_bf ,_bf raloxifene_bf affect_bf binding_bf warfarin_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
3720,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,clofibrate,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be OTHER_DRUG ,_af indomethacin_af ,_af naproxen_af ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
3721,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,indomethacin,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be OTHER_DRUG ,_af naproxen_af ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
3722,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,naproxen,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be OTHER_DRUG ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
3723,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,ibuprofen,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be naproxen_be ,_be OTHER_DRUG ,_af diazepam_af ,_af diazoxide_af ._af"
3724,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,diazepam,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be naproxen_be ,_be ibuprofen_be ,_be OTHER_DRUG ,_af diazoxide_af ._af"
3725,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",EVISTA,diazoxide,advise,"Caution_bf used_bf DRUG coadministered_be highly_be protein-bound_be drugs_be ,_be clofibrate_be ,_be indomethacin_be ,_be naproxen_be ,_be ibuprofen_be ,_be diazepam_be ,_be OTHER_DRUG ._af"
3726,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",clofibrate,indomethacin,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf DRUG ,_be OTHER_DRUG ,_af naproxen_af ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
3727,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",clofibrate,naproxen,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf DRUG ,_be indomethacin_be ,_be OTHER_DRUG ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
3728,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",clofibrate,ibuprofen,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf DRUG ,_be indomethacin_be ,_be naproxen_be ,_be OTHER_DRUG ,_af diazepam_af ,_af diazoxide_af ._af"
3729,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",clofibrate,diazepam,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf DRUG ,_be indomethacin_be ,_be naproxen_be ,_be ibuprofen_be ,_be OTHER_DRUG ,_af diazoxide_af ._af"
3730,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",clofibrate,diazoxide,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf DRUG ,_be indomethacin_be ,_be naproxen_be ,_be ibuprofen_be ,_be diazepam_be ,_be OTHER_DRUG ._af"
3731,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",indomethacin,naproxen,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf clofibrate_bf ,_bf DRUG ,_be OTHER_DRUG ,_af ibuprofen_af ,_af diazepam_af ,_af diazoxide_af ._af"
3732,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",indomethacin,ibuprofen,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf clofibrate_bf ,_bf DRUG ,_be naproxen_be ,_be OTHER_DRUG ,_af diazepam_af ,_af diazoxide_af ._af"
3733,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",indomethacin,diazepam,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf clofibrate_bf ,_bf DRUG ,_be naproxen_be ,_be ibuprofen_be ,_be OTHER_DRUG ,_af diazoxide_af ._af"
3734,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",indomethacin,diazoxide,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf clofibrate_bf ,_bf DRUG ,_be naproxen_be ,_be ibuprofen_be ,_be diazepam_be ,_be OTHER_DRUG ._af"
3735,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",naproxen,ibuprofen,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf clofibrate_bf ,_bf indomethacin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af diazepam_af ,_af diazoxide_af ._af"
3736,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",naproxen,diazepam,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf clofibrate_bf ,_bf indomethacin_bf ,_bf DRUG ,_be ibuprofen_be ,_be OTHER_DRUG ,_af diazoxide_af ._af"
3737,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",naproxen,diazoxide,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf clofibrate_bf ,_bf indomethacin_bf ,_bf DRUG ,_be ibuprofen_be ,_be diazepam_be ,_be OTHER_DRUG ._af"
3738,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",ibuprofen,diazepam,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf clofibrate_bf ,_bf indomethacin_bf ,_bf naproxen_bf ,_bf DRUG ,_be OTHER_DRUG ,_af diazoxide_af ._af"
3739,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",ibuprofen,diazoxide,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf clofibrate_bf ,_bf indomethacin_bf ,_bf naproxen_bf ,_bf DRUG ,_be diazepam_be ,_be OTHER_DRUG ._af"
3740,"Caution should be used when EVISTA is coadministered with other highly protein-bound drugs, such as clofibrate, indomethacin, naproxen, ibuprofen, diazepam, and diazoxide. ",diazepam,diazoxide,No interaction,"Caution_bf used_bf EVISTA_bf coadministered_bf highly_bf protein-bound_bf drugs_bf ,_bf clofibrate_bf ,_bf indomethacin_bf ,_bf naproxen_bf ,_bf ibuprofen_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
3741,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,Vitamin B2,Riboflavin,No interaction,Interactions_bf Vitamin_bf B2_bf (Riboflavin):_bf Alcohol_bf -_bf impairs_bf intestinal_bf absorption_bf OTHER_DRUG
3742,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,Vitamin B2,Alcohol,No interaction,Interactions_bf Vitamin_bf B2_bf (Riboflavin):_bf OTHER_DRUG -_be impairs_be intestinal_be absorption_be riboflavin_be
3743,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,Vitamin B2,riboflavin,No interaction,Interactions_bf Vitamin_bf B2_bf (Riboflavin):_bf Alcohol_bf -_bf impairs_bf intestinal_bf absorption_bf OTHER_DRUG
3744,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,Riboflavin,Alcohol,No interaction,Interactions_bf Vitamin_bf B2_bf (Riboflavin):_bf OTHER_DRUG -_be impairs_be intestinal_be absorption_be DRUG
3745,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,Riboflavin,riboflavin,No interaction,Interactions_bf Vitamin_bf B2_bf (Riboflavin):_bf Alcohol_bf -_bf impairs_bf intestinal_bf absorption_bf DRUG
3746,Interactions for Vitamin B2 (Riboflavin):  Alcohol - impairs the intestinal absorption of riboflavin,Alcohol,riboflavin,mechanism,Interactions_bf Vitamin_bf B2_bf (Riboflavin):_bf DRUG -_be impairs_be intestinal_be absorption_be OTHER_DRUG
3747,Probenecid - concurrent use decreases gastrointestinal absorption of riboflavin; ,Probenecid,riboflavin,mechanism,DRUG -_be concurrent_be use_be decreases_be gastrointestinal_be absorption_be riboflavin;_be
3748,requirements for riboflavin may be increased in patients receiving probenecid.,riboflavin,probenecid,effect,requirements_bf DRUG may_be increased_be patients_be receiving_be OTHER_DRUG ._af
3749,Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known. ,Cimetidine,cimetidine,No interaction,Cimetidine:_bf The_bf effects_bf chronic_bf DRUG use_be metabolism_be rimantadine_be known_be ._be
3750,Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known. ,Cimetidine,rimantadine,No interaction,Cimetidine:_bf The_bf effects_bf chronic_bf DRUG use_be metabolism_be OTHER_DRUG known_af ._af
3751,Cimetidine: The effects of chronic cimetidine use on the metabolism of rimantadine are not known. ,cimetidine,rimantadine,No interaction,Cimetidine:_bf The_bf effects_bf chronic_bf DRUG use_be metabolism_be OTHER_DRUG known_af ._af
3752,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",rimantadine HCl,Cimetidine,mechanism,"When_bf single_bf 100_bf mg_bf dose_bf rimantadine_bf HCl_bf administered_bf one_bf hour_bf initiation_bf OTHER_DRUG (300_be mg_be four_be times_be day)_be ,_be apparent_be total_be rimantadine_be clearance_be single_be dose_be normal_be healthy_be adults_be reduced_be 18%_be (compared_be apparent_be total_be rimantadine_be clearance_be subjects_be absence_be cimetidine)_be ._be"
3753,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",rimantadine HCl,rimantadine,No interaction,"When_bf single_bf 100_bf mg_bf dose_bf OTHER_DRUG HCl_be administered_be one_be hour_be initiation_be Cimetidine_be (300_be mg_be four_be times_be day)_be ,_be apparent_be total_be OTHER_DRUG clearance_af single_af dose_af normal_af healthy_af adults_af reduced_af 18%_af (compared_af apparent_af total_af OTHER_DRUG clearance_af subjects_af absence_af cimetidine)_af ._af"
3754,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",rimantadine HCl,rimantadine,No interaction,"When_bf single_bf 100_bf mg_bf dose_bf OTHER_DRUG HCl_be administered_be one_be hour_be initiation_be Cimetidine_be (300_be mg_be four_be times_be day)_be ,_be apparent_be total_be OTHER_DRUG clearance_af single_af dose_af normal_af healthy_af adults_af reduced_af 18%_af (compared_af apparent_af total_af OTHER_DRUG clearance_af subjects_af absence_af cimetidine)_af ._af"
3755,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",rimantadine HCl,cimetidine,No interaction,"When_bf single_bf 100_bf mg_bf dose_bf rimantadine_bf HCl_bf administered_bf one_bf hour_bf initiation_bf OTHER_DRUG (300_be mg_be four_be times_be day)_be ,_be apparent_be total_be rimantadine_be clearance_be single_be dose_be normal_be healthy_be adults_be reduced_be 18%_be (compared_be apparent_be total_be rimantadine_be clearance_be subjects_be absence_be cimetidine)_be ._be"
3756,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",Cimetidine,rimantadine,No interaction,"When_bf single_bf 100_bf mg_bf dose_bf OTHER_DRUG HCl_be administered_be one_be hour_be initiation_be DRUG (300_af mg_af four_af times_af day)_af ,_af apparent_af total_af OTHER_DRUG clearance_af single_af dose_af normal_af healthy_af adults_af reduced_af 18%_af (compared_af apparent_af total_af OTHER_DRUG clearance_af subjects_af absence_af cimetidine)_af ._af"
3757,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",Cimetidine,rimantadine,No interaction,"When_bf single_bf 100_bf mg_bf dose_bf OTHER_DRUG HCl_be administered_be one_be hour_be initiation_be DRUG (300_af mg_af four_af times_af day)_af ,_af apparent_af total_af OTHER_DRUG clearance_af single_af dose_af normal_af healthy_af adults_af reduced_af 18%_af (compared_af apparent_af total_af OTHER_DRUG clearance_af subjects_af absence_af cimetidine)_af ._af"
3758,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",Cimetidine,cimetidine,No interaction,"When_bf single_bf 100_bf mg_bf dose_bf rimantadine_bf HCl_bf administered_bf one_bf hour_bf initiation_bf DRUG (300_be mg_be four_be times_be day)_be ,_be apparent_be total_be rimantadine_be clearance_be single_be dose_be normal_be healthy_be adults_be reduced_be 18%_be (compared_be apparent_be total_be rimantadine_be clearance_be subjects_be absence_be cimetidine)_be ._be"
3759,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",rimantadine,rimantadine,No interaction,"When_bf single_bf 100_bf mg_bf dose_bf DRUG HCl_be administered_be one_be hour_be initiation_be Cimetidine_be (300_be mg_be four_be times_be day)_be ,_be apparent_be total_be DRUG clearance_af single_af dose_af normal_af healthy_af adults_af reduced_af 18%_af (compared_af apparent_af total_af DRUG clearance_af subjects_af absence_af cimetidine)_af ._af"
3760,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",rimantadine,cimetidine,No interaction,"When_bf single_bf 100_bf mg_bf dose_bf DRUG HCl_be administered_be one_be hour_be initiation_be OTHER_DRUG (300_af mg_af four_af times_af day)_af ,_af apparent_af total_af DRUG clearance_af single_af dose_af normal_af healthy_af adults_af reduced_af 18%_af (compared_af apparent_af total_af DRUG clearance_af subjects_af absence_af cimetidine)_af ._af"
3761,"When a single 100 mg dose of rimantadine HCl was administered one hour after the initiation of Cimetidine (300 mg four times a day), the apparent total rimantadine clearance of this single dose in normal healthy adults was reduced by 18% (compared to the apparent total rimantadine clearance in the same subjects in the absence of cimetidine). ",rimantadine,cimetidine,No interaction,"When_bf single_bf 100_bf mg_bf dose_bf DRUG HCl_be administered_be one_be hour_be initiation_be OTHER_DRUG (300_af mg_af four_af times_af day)_af ,_af apparent_af total_af DRUG clearance_af single_af dose_af normal_af healthy_af adults_af reduced_af 18%_af (compared_af apparent_af total_af DRUG clearance_af subjects_af absence_af cimetidine)_af ._af"
3762,"Acetaminophen: Rimantadine HCl, 100 mg, was given twice daily for 13 days to 12 healthy volunteers. ",Acetaminophen,Rimantadine HCl,No interaction,"Acetaminophen:_bf Rimantadine_bf HCl_bf ,_bf 100_bf mg_bf ,_bf given_bf twice_bf daily_bf 13_bf days_bf 12_bf healthy_bf volunteers_bf ._bf"
3763,Coadministration with acetaminophen reduced the peak concentration and AUC values for rimantadine by approximately 11%. ,acetaminophen,rimantadine,mechanism,Coadministration_bf DRUG reduced_be peak_be concentration_be AUC_be values_be OTHER_DRUG approximately_af 11%_af ._af
3764,"Aspirin: Rimantadine HCl, 100 mg, was given twice daily fro 13 days to 12 healthy volunteers. ",Aspirin,Rimantadine HCl,No interaction,"Aspirin:_bf Rimantadine_bf HCl_bf ,_bf 100_bf mg_bf ,_bf given_bf twice_bf daily_bf fro_bf 13_bf days_bf 12_bf healthy_bf volunteers_bf ._bf"
3765,Peak plasma concentrations and AUC of rimantadine were reduced approximately 10% in the presence of aspirin.,rimantadine,aspirin,mechanism,Peak_bf plasma_bf concentrations_bf AUC_bf DRUG reduced_be approximately_be 10%_be presence_be OTHER_DRUG ._af
3766,Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. ,Exelon,rivastigmine tartrate,No interaction,Drug-Drug_bf Interactions_bf Effect_bf DRUG (rivastigmine_be tartrate)_be Metabolism_be Other_be Drugs:_be Rivastigmine_be primarily_be metabolized_be hydrolysis_be esterases_be ._be
3767,Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. ,Exelon,Rivastigmine,No interaction,Drug-Drug_bf Interactions_bf Effect_bf DRUG (rivastigmine_be tartrate)_be Metabolism_be Other_be Drugs:_be OTHER_DRUG primarily_af metabolized_af hydrolysis_af esterases_af ._af
3768,Drug-Drug Interactions Effect of Exelon    (rivastigmine tartrate) on the Metabolism of Other Drugs: Rivastigmine is primarily metabolized through hydrolysis by esterases. ,rivastigmine tartrate,Rivastigmine,No interaction,Drug-Drug_bf Interactions_bf Effect_bf Exelon_bf (rivastigmine_bf tartrate)_bf Metabolism_bf Other_bf Drugs:_bf OTHER_DRUG primarily_be metabolized_be hydrolysis_be esterases_be ._be
3769,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",rivastigmine,digoxin,No interaction,"No_bf pharmacokinetic_bf interaction_bf observed_bf DRUG OTHER_DRUG ,_af warfarin_af ,_af diazepam_af ,_af fluoxetine_af studies_af healthy_af volunteers_af ._af"
3770,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",rivastigmine,warfarin,No interaction,"No_bf pharmacokinetic_bf interaction_bf observed_bf DRUG digoxin_be ,_be OTHER_DRUG ,_af diazepam_af ,_af fluoxetine_af studies_af healthy_af volunteers_af ._af"
3771,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",rivastigmine,diazepam,No interaction,"No_bf pharmacokinetic_bf interaction_bf observed_bf DRUG digoxin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af fluoxetine_af studies_af healthy_af volunteers_af ._af"
3772,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",rivastigmine,fluoxetine,No interaction,"No_bf pharmacokinetic_bf interaction_bf observed_bf DRUG digoxin_be ,_be warfarin_be ,_be diazepam_be ,_be OTHER_DRUG studies_af healthy_af volunteers_af ._af"
3773,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",digoxin,warfarin,No interaction,"No_bf pharmacokinetic_bf interaction_bf observed_bf rivastigmine_bf DRUG ,_be OTHER_DRUG ,_af diazepam_af ,_af fluoxetine_af studies_af healthy_af volunteers_af ._af"
3774,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",digoxin,diazepam,No interaction,"No_bf pharmacokinetic_bf interaction_bf observed_bf rivastigmine_bf DRUG ,_be warfarin_be ,_be OTHER_DRUG ,_af fluoxetine_af studies_af healthy_af volunteers_af ._af"
3775,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",digoxin,fluoxetine,No interaction,"No_bf pharmacokinetic_bf interaction_bf observed_bf rivastigmine_bf DRUG ,_be warfarin_be ,_be diazepam_be ,_be OTHER_DRUG studies_af healthy_af volunteers_af ._af"
3776,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",warfarin,diazepam,No interaction,"No_bf pharmacokinetic_bf interaction_bf observed_bf rivastigmine_bf digoxin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af fluoxetine_af studies_af healthy_af volunteers_af ._af"
3777,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",warfarin,fluoxetine,No interaction,"No_bf pharmacokinetic_bf interaction_bf observed_bf rivastigmine_bf digoxin_bf ,_bf DRUG ,_be diazepam_be ,_be OTHER_DRUG studies_af healthy_af volunteers_af ._af"
3778,"No pharmacokinetic interaction was observed between rivastigmine and digoxin, warfarin, diazepam, or fluoxetine in studies in healthy volunteers. ",diazepam,fluoxetine,No interaction,"No_bf pharmacokinetic_bf interaction_bf observed_bf rivastigmine_bf digoxin_bf ,_bf warfarin_bf ,_bf DRUG ,_be OTHER_DRUG studies_af healthy_af volunteers_af ._af"
3779,The elevation of prothrombin time induced by warfarin is not affected by administration of Exelon. ,warfarin,Exelon,No interaction,The_bf elevation_bf prothrombin_bf time_bf induced_bf DRUG affected_be administration_be OTHER_DRUG ._af
3780,Effect of Other Drugs on the Metabolism of Exelon: Drugs that induce or inhibit CYP450 metabolism are not expected to alter the metabolism of rivastigmine. ,Exelon,rivastigmine,No interaction,Effect_bf Other_bf Drugs_bf Metabolism_bf Exelon:_bf Drugs_bf induce_bf inhibit_bf CYP450_bf metabolism_bf expected_bf alter_bf metabolism_bf OTHER_DRUG ._be
3781,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",rivastigmine,digoxin,No interaction,"Single_bf dose_bf pharmacokinetic_bf studies_bf demonstrated_bf metabolism_bf DRUG significantly_be affected_be concurrent_be administration_be OTHER_DRUG ,_af warfarin_af ,_af diazepam_af ,_af fluoxetine_af ._af"
3782,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",rivastigmine,warfarin,No interaction,"Single_bf dose_bf pharmacokinetic_bf studies_bf demonstrated_bf metabolism_bf DRUG significantly_be affected_be concurrent_be administration_be digoxin_be ,_be OTHER_DRUG ,_af diazepam_af ,_af fluoxetine_af ._af"
3783,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",rivastigmine,diazepam,No interaction,"Single_bf dose_bf pharmacokinetic_bf studies_bf demonstrated_bf metabolism_bf DRUG significantly_be affected_be concurrent_be administration_be digoxin_be ,_be warfarin_be ,_be OTHER_DRUG ,_af fluoxetine_af ._af"
3784,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",rivastigmine,fluoxetine,No interaction,"Single_bf dose_bf pharmacokinetic_bf studies_bf demonstrated_bf metabolism_bf DRUG significantly_be affected_be concurrent_be administration_be digoxin_be ,_be warfarin_be ,_be diazepam_be ,_be OTHER_DRUG ._af"
3785,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",digoxin,warfarin,No interaction,"Single_bf dose_bf pharmacokinetic_bf studies_bf demonstrated_bf metabolism_bf rivastigmine_bf significantly_bf affected_bf concurrent_bf administration_bf DRUG ,_be OTHER_DRUG ,_af diazepam_af ,_af fluoxetine_af ._af"
3786,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",digoxin,diazepam,No interaction,"Single_bf dose_bf pharmacokinetic_bf studies_bf demonstrated_bf metabolism_bf rivastigmine_bf significantly_bf affected_bf concurrent_bf administration_bf DRUG ,_be warfarin_be ,_be OTHER_DRUG ,_af fluoxetine_af ._af"
3787,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",digoxin,fluoxetine,No interaction,"Single_bf dose_bf pharmacokinetic_bf studies_bf demonstrated_bf metabolism_bf rivastigmine_bf significantly_bf affected_bf concurrent_bf administration_bf DRUG ,_be warfarin_be ,_be diazepam_be ,_be OTHER_DRUG ._af"
3788,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",warfarin,diazepam,No interaction,"Single_bf dose_bf pharmacokinetic_bf studies_bf demonstrated_bf metabolism_bf rivastigmine_bf significantly_bf affected_bf concurrent_bf administration_bf digoxin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af fluoxetine_af ._af"
3789,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",warfarin,fluoxetine,No interaction,"Single_bf dose_bf pharmacokinetic_bf studies_bf demonstrated_bf metabolism_bf rivastigmine_bf significantly_bf affected_bf concurrent_bf administration_bf digoxin_bf ,_bf DRUG ,_be diazepam_be ,_be OTHER_DRUG ._af"
3790,"Single dose pharmacokinetic studies demonstrated that the metabolism of rivastigmine is not significantly affected by concurrent administration of digoxin, warfarin, diazepam, or fluoxetine. ",diazepam,fluoxetine,No interaction,"Single_bf dose_bf pharmacokinetic_bf studies_bf demonstrated_bf metabolism_bf rivastigmine_bf significantly_bf affected_bf concurrent_bf administration_bf digoxin_bf ,_bf warfarin_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
3791,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",rivastigmine,antacids,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf DRUG influenced_be commonly_be prescribed_be medications_be OTHER_DRUG (n=77)_af ,_af antihypertensives_af (n=72)_af ,_af calcium_af channel_af blockers_af (n=75)_af ,_af antidiabetics_af (n=21)_af ,_af nonsteroidal_af anti-inflammatory_af drugs_af (n=79)_af ,_af estrogens_af (n=70)_af ,_af salicylate_af analgesics_af (n=177)_af ,_af antianginals_af (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3792,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",rivastigmine,antihypertensives,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf DRUG influenced_be commonly_be prescribed_be medications_be antacids_be (n=77)_be ,_be OTHER_DRUG (n=72)_af ,_af calcium_af channel_af blockers_af (n=75)_af ,_af antidiabetics_af (n=21)_af ,_af nonsteroidal_af anti-inflammatory_af drugs_af (n=79)_af ,_af estrogens_af (n=70)_af ,_af salicylate_af analgesics_af (n=177)_af ,_af antianginals_af (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3793,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",rivastigmine,calcium channel blockers,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf DRUG influenced_be commonly_be prescribed_be medications_be antacids_be (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3794,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",rivastigmine,antidiabetics,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf DRUG influenced_be commonly_be prescribed_be medications_be antacids_be (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be OTHER_DRUG (n=21)_af ,_af nonsteroidal_af anti-inflammatory_af drugs_af (n=79)_af ,_af estrogens_af (n=70)_af ,_af salicylate_af analgesics_af (n=177)_af ,_af antianginals_af (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3795,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",rivastigmine,nonsteroidal anti-inflammatory drugs,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf DRUG influenced_be commonly_be prescribed_be medications_be antacids_be (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3796,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",rivastigmine,estrogens,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf DRUG influenced_be commonly_be prescribed_be medications_be antacids_be (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be OTHER_DRUG (n=70)_af ,_af salicylate_af analgesics_af (n=177)_af ,_af antianginals_af (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3797,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",rivastigmine,salicylate analgesics,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf DRUG influenced_be commonly_be prescribed_be medications_be antacids_be (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3798,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",rivastigmine,antianginals,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf DRUG influenced_be commonly_be prescribed_be medications_be antacids_be (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be OTHER_DRUG (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3799,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",rivastigmine,antihistamines,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf DRUG influenced_be commonly_be prescribed_be medications_be antacids_be (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be OTHER_DRUG (n=15)_af ._af"
3800,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antacids,antihypertensives,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf DRUG (n=77)_be ,_be OTHER_DRUG (n=72)_af ,_af calcium_af channel_af blockers_af (n=75)_af ,_af antidiabetics_af (n=21)_af ,_af nonsteroidal_af anti-inflammatory_af drugs_af (n=79)_af ,_af estrogens_af (n=70)_af ,_af salicylate_af analgesics_af (n=177)_af ,_af antianginals_af (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3801,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antacids,calcium channel blockers,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf DRUG (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3802,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antacids,antidiabetics,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf DRUG (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be OTHER_DRUG (n=21)_af ,_af nonsteroidal_af anti-inflammatory_af drugs_af (n=79)_af ,_af estrogens_af (n=70)_af ,_af salicylate_af analgesics_af (n=177)_af ,_af antianginals_af (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3803,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antacids,nonsteroidal anti-inflammatory drugs,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf DRUG (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3804,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antacids,estrogens,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf DRUG (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be OTHER_DRUG (n=70)_af ,_af salicylate_af analgesics_af (n=177)_af ,_af antianginals_af (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3805,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antacids,salicylate analgesics,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf DRUG (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3806,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antacids,antianginals,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf DRUG (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be OTHER_DRUG (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3807,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antacids,antihistamines,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf DRUG (n=77)_be ,_be antihypertensives_be (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be OTHER_DRUG (n=15)_af ._af"
3808,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antihypertensives,calcium channel blockers,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf DRUG (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3809,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antihypertensives,antidiabetics,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf DRUG (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be OTHER_DRUG (n=21)_af ,_af nonsteroidal_af anti-inflammatory_af drugs_af (n=79)_af ,_af estrogens_af (n=70)_af ,_af salicylate_af analgesics_af (n=177)_af ,_af antianginals_af (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3810,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antihypertensives,nonsteroidal anti-inflammatory drugs,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf DRUG (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3811,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antihypertensives,estrogens,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf DRUG (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be OTHER_DRUG (n=70)_af ,_af salicylate_af analgesics_af (n=177)_af ,_af antianginals_af (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3812,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antihypertensives,salicylate analgesics,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf DRUG (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3813,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antihypertensives,antianginals,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf DRUG (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be OTHER_DRUG (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3814,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antihypertensives,antihistamines,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf DRUG (n=72)_be ,_be calcium_be channel_be blockers_be (n=75)_be ,_be antidiabetics_be (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be OTHER_DRUG (n=15)_af ._af"
3815,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",calcium channel blockers,antidiabetics,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf OTHER_DRUG (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3816,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",calcium channel blockers,nonsteroidal anti-inflammatory drugs,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf estrogens_bf (n=70)_bf ,_bf salicylate_bf analgesics_bf (n=177)_bf ,_bf antianginals_bf (n=35)_bf ,_bf antihistamines_bf (n=15)_bf ._bf"
3817,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",calcium channel blockers,estrogens,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf OTHER_DRUG (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3818,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",calcium channel blockers,salicylate analgesics,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf estrogens_bf (n=70)_bf ,_bf salicylate_bf analgesics_bf (n=177)_bf ,_bf antianginals_bf (n=35)_bf ,_bf antihistamines_bf (n=15)_bf ._bf"
3819,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",calcium channel blockers,antianginals,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf estrogens_bf (n=70)_bf ,_bf salicylate_bf analgesics_bf (n=177)_bf ,_bf OTHER_DRUG (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3820,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",calcium channel blockers,antihistamines,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf estrogens_bf (n=70)_bf ,_bf salicylate_bf analgesics_bf (n=177)_bf ,_bf antianginals_bf (n=35)_bf ,_bf OTHER_DRUG (n=15)_be ._be"
3821,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antidiabetics,nonsteroidal anti-inflammatory drugs,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf DRUG (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3822,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antidiabetics,estrogens,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf DRUG (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be OTHER_DRUG (n=70)_af ,_af salicylate_af analgesics_af (n=177)_af ,_af antianginals_af (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3823,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antidiabetics,salicylate analgesics,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf DRUG (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3824,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antidiabetics,antianginals,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf DRUG (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be OTHER_DRUG (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3825,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antidiabetics,antihistamines,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf DRUG (n=21)_be ,_be nonsteroidal_be anti-inflammatory_be drugs_be (n=79)_be ,_be estrogens_be (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be OTHER_DRUG (n=15)_af ._af"
3826,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",nonsteroidal anti-inflammatory drugs,estrogens,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf OTHER_DRUG (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3827,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",nonsteroidal anti-inflammatory drugs,salicylate analgesics,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf estrogens_bf (n=70)_bf ,_bf salicylate_bf analgesics_bf (n=177)_bf ,_bf antianginals_bf (n=35)_bf ,_bf antihistamines_bf (n=15)_bf ._bf"
3828,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",nonsteroidal anti-inflammatory drugs,antianginals,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf estrogens_bf (n=70)_bf ,_bf salicylate_bf analgesics_bf (n=177)_bf ,_bf OTHER_DRUG (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3829,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",nonsteroidal anti-inflammatory drugs,antihistamines,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf estrogens_bf (n=70)_bf ,_bf salicylate_bf analgesics_bf (n=177)_bf ,_bf antianginals_bf (n=35)_bf ,_bf OTHER_DRUG (n=15)_be ._be"
3830,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",estrogens,salicylate analgesics,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf DRUG (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3831,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",estrogens,antianginals,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf DRUG (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be OTHER_DRUG (n=35)_af ,_af antihistamines_af (n=15)_af ._af"
3832,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",estrogens,antihistamines,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf DRUG (n=70)_be ,_be salicylate_be analgesics_be (n=177)_be ,_be antianginals_be (n=35)_be ,_be OTHER_DRUG (n=15)_af ._af"
3833,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",salicylate analgesics,antianginals,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf estrogens_bf (n=70)_bf ,_bf salicylate_bf analgesics_bf (n=177)_bf ,_bf OTHER_DRUG (n=35)_be ,_be antihistamines_be (n=15)_be ._be"
3834,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",salicylate analgesics,antihistamines,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf estrogens_bf (n=70)_bf ,_bf salicylate_bf analgesics_bf (n=177)_bf ,_bf antianginals_bf (n=35)_bf ,_bf OTHER_DRUG (n=15)_be ._be"
3835,"Population PK analysis with a database of 625 patients showed that the pharmacokinetics of rivastigmine were not influenced by commonly prescribed medications such as antacids (n=77), antihypertensives (n=72), calcium channel blockers (n=75), antidiabetics (n=21), nonsteroidal anti-inflammatory drugs (n=79), estrogens (n=70), salicylate analgesics (n=177), antianginals (n=35), and antihistamines (n=15). ",antianginals,antihistamines,No interaction,"Population_bf PK_bf analysis_bf database_bf 625_bf patients_bf showed_bf pharmacokinetics_bf rivastigmine_bf influenced_bf commonly_bf prescribed_bf medications_bf antacids_bf (n=77)_bf ,_bf antihypertensives_bf (n=72)_bf ,_bf calcium_bf channel_bf blockers_bf (n=75)_bf ,_bf antidiabetics_bf (n=21)_bf ,_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf (n=79)_bf ,_bf estrogens_bf (n=70)_bf ,_bf salicylate_bf analgesics_bf (n=177)_bf ,_bf DRUG (n=35)_be ,_be OTHER_DRUG (n=15)_af ._af"
3836,"Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. ",Anticholinergics,cholinesterase inhibitors,No interaction,"Use_bf Anticholinergics:_bf Because_bf mechanism_bf action_bf ,_bf cholinesterase_bf inhibitors_bf potential_bf interfere_bf activity_bf anticholinergic_bf medications_bf ._bf"
3837,"Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. ",Anticholinergics,anticholinergic medications,No interaction,"Use_bf Anticholinergics:_bf Because_bf mechanism_bf action_bf ,_bf cholinesterase_bf inhibitors_bf potential_bf interfere_bf activity_bf anticholinergic_bf medications_bf ._bf"
3838,"Use with Anticholinergics: Because of their mechanism of action, cholinesterase inhibitors have the potential to interfere with the activity of anticholinergic medications. ",cholinesterase inhibitors,anticholinergic medications,int,"Use_bf Anticholinergics:_bf Because_bf mechanism_bf action_bf ,_bf cholinesterase_bf inhibitors_bf potential_bf interfere_bf activity_bf anticholinergic_bf medications_bf ._bf"
3839,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",Cholinomimetics,Cholinesterase Inhibitors,No interaction,"Use_bf DRUG Other_be Cholinesterase_be Inhibitors:_be A_be synergistic_be effect_be may_be expected_be cholinesterase_be inhibitors_be given_be concurrently_be succinylcholine_be ,_be similar_be neuromuscular_be blocking_be agents_be cholinergic_be agonists_be bethanechol_be ._be"
3840,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",Cholinomimetics,cholinesterase inhibitors,No interaction,"Use_bf DRUG Other_be Cholinesterase_be Inhibitors:_be A_be synergistic_be effect_be may_be expected_be cholinesterase_be inhibitors_be given_be concurrently_be succinylcholine_be ,_be similar_be neuromuscular_be blocking_be agents_be cholinergic_be agonists_be bethanechol_be ._be"
3841,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",Cholinomimetics,succinylcholine,No interaction,"Use_bf DRUG Other_be Cholinesterase_be Inhibitors:_be A_be synergistic_be effect_be may_be expected_be cholinesterase_be inhibitors_be given_be concurrently_be OTHER_DRUG ,_af similar_af neuromuscular_af blocking_af agents_af cholinergic_af agonists_af bethanechol_af ._af"
3842,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",Cholinomimetics,neuromuscular blocking agents,No interaction,"Use_bf DRUG Other_be Cholinesterase_be Inhibitors:_be A_be synergistic_be effect_be may_be expected_be cholinesterase_be inhibitors_be given_be concurrently_be succinylcholine_be ,_be similar_be neuromuscular_be blocking_be agents_be cholinergic_be agonists_be bethanechol_be ._be"
3843,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",Cholinomimetics,cholinergic agonists,No interaction,"Use_bf DRUG Other_be Cholinesterase_be Inhibitors:_be A_be synergistic_be effect_be may_be expected_be cholinesterase_be inhibitors_be given_be concurrently_be succinylcholine_be ,_be similar_be neuromuscular_be blocking_be agents_be cholinergic_be agonists_be bethanechol_be ._be"
3844,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",Cholinomimetics,bethanechol,No interaction,"Use_bf DRUG Other_be Cholinesterase_be Inhibitors:_be A_be synergistic_be effect_be may_be expected_be cholinesterase_be inhibitors_be given_be concurrently_be succinylcholine_be ,_be similar_be neuromuscular_be blocking_be agents_be cholinergic_be agonists_be OTHER_DRUG ._af"
3845,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",Cholinesterase Inhibitors,cholinesterase inhibitors,No interaction,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf bethanechol_bf ._bf"
3846,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",Cholinesterase Inhibitors,succinylcholine,No interaction,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf OTHER_DRUG ,_be similar_be neuromuscular_be blocking_be agents_be cholinergic_be agonists_be bethanechol_be ._be"
3847,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",Cholinesterase Inhibitors,neuromuscular blocking agents,No interaction,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf bethanechol_bf ._bf"
3848,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",Cholinesterase Inhibitors,cholinergic agonists,No interaction,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf bethanechol_bf ._bf"
3849,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",Cholinesterase Inhibitors,bethanechol,No interaction,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf OTHER_DRUG ._be"
3850,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,succinylcholine,effect,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf OTHER_DRUG ,_be similar_be neuromuscular_be blocking_be agents_be cholinergic_be agonists_be bethanechol_be ._be"
3851,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,neuromuscular blocking agents,effect,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf bethanechol_bf ._bf"
3852,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,cholinergic agonists,effect,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf bethanechol_bf ._bf"
3853,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinesterase inhibitors,bethanechol,effect,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf OTHER_DRUG ._be"
3854,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",succinylcholine,neuromuscular blocking agents,No interaction,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf DRUG ,_be similar_be neuromuscular_be blocking_be agents_be cholinergic_be agonists_be bethanechol_be ._be"
3855,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",succinylcholine,cholinergic agonists,No interaction,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf DRUG ,_be similar_be neuromuscular_be blocking_be agents_be cholinergic_be agonists_be bethanechol_be ._be"
3856,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",succinylcholine,bethanechol,No interaction,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf DRUG ,_be similar_be neuromuscular_be blocking_be agents_be cholinergic_be agonists_be OTHER_DRUG ._af"
3857,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",neuromuscular blocking agents,cholinergic agonists,No interaction,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf bethanechol_bf ._bf"
3858,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",neuromuscular blocking agents,bethanechol,No interaction,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf OTHER_DRUG ._be"
3859,"Use with Cholinomimetics and Other Cholinesterase Inhibitors: A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents or cholinergic agonists such as bethanechol.",cholinergic agonists,bethanechol,No interaction,"Use_bf Cholinomimetics_bf Other_bf Cholinesterase_bf Inhibitors:_bf A_bf synergistic_bf effect_bf may_bf expected_bf cholinesterase_bf inhibitors_bf given_bf concurrently_bf succinylcholine_bf ,_bf similar_bf neuromuscular_bf blocking_bf agents_bf cholinergic_bf agonists_bf OTHER_DRUG ._be"
3860,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",ZEMURON,rocuronium bromide,No interaction,"Drug_bf Interactions:_bf The_bf use_bf DRUG (rocuronium_be bromide)_be Injection_be succinylcholine_be ,_be purpose_be attenuating_be side_be effects_be succinylcholine_be ,_be studied_be ._be"
3861,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",ZEMURON,succinylcholine,No interaction,"Drug_bf Interactions:_bf The_bf use_bf DRUG (rocuronium_be bromide)_be Injection_be OTHER_DRUG ,_af purpose_af attenuating_af side_af effects_af OTHER_DRUG ,_af studied_af ._af"
3862,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",ZEMURON,succinylcholine,No interaction,"Drug_bf Interactions:_bf The_bf use_bf DRUG (rocuronium_be bromide)_be Injection_be OTHER_DRUG ,_af purpose_af attenuating_af side_af effects_af OTHER_DRUG ,_af studied_af ._af"
3863,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",rocuronium bromide,succinylcholine,No interaction,"Drug_bf Interactions:_bf The_bf use_bf ZEMURON_bf (rocuronium_bf bromide)_bf Injection_bf OTHER_DRUG ,_be purpose_be attenuating_be side_be effects_be OTHER_DRUG ,_af studied_af ._af"
3864,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",rocuronium bromide,succinylcholine,No interaction,"Drug_bf Interactions:_bf The_bf use_bf ZEMURON_bf (rocuronium_bf bromide)_bf Injection_bf OTHER_DRUG ,_be purpose_be attenuating_be side_be effects_be OTHER_DRUG ,_af studied_af ._af"
3865,"Drug Interactions: The use of ZEMURON    (rocuronium bromide) Injection before succinylcholine, for the purpose of attenuating some of the side effects of succinylcholine, has not been studied. ",succinylcholine,succinylcholine,No interaction,"Drug_bf Interactions:_bf The_bf use_bf ZEMURON_bf (rocuronium_bf bromide)_bf Injection_bf DRUG ,_be purpose_be attenuating_be side_be effects_be DRUG ,_af studied_af ._af"
3866,"If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ",ZEMURON,succinylcholine,advise,"If_bf DRUG administered_be following_be administration_be OTHER_DRUG ,_af given_af recovery_af OTHER_DRUG observed_af ._af"
3867,"If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ",ZEMURON,succinylcholine,No interaction,"If_bf DRUG administered_be following_be administration_be OTHER_DRUG ,_af given_af recovery_af OTHER_DRUG observed_af ._af"
3868,"If ZEMURON    is administered following administration of succinylcholine, it should not be given until recovery from succinylcholine has been observed. ",succinylcholine,succinylcholine,No interaction,"If_bf ZEMURON_bf administered_bf following_bf administration_bf DRUG ,_be given_be recovery_be DRUG observed_af ._af"
3869,"The median duration of action of ZEMURON    0.6 mg/kg administered after a 1 mg/kg dose of succinylcholine when T 1 returned to 75% of control was 36 minutes (range 14-57, n=12) vs. ",ZEMURON,succinylcholine,No interaction,"The_bf median_bf duration_bf action_bf DRUG 0_be ._be 6_be mg/kg_be administered_be 1_be mg/kg_be dose_be OTHER_DRUG T_af 1_af returned_af 75%_af control_af 36_af minutes_af (range_af 14-57_af ,_af n=12)_af vs_af ._af"
3870,There are no controlled studies documenting the use of ZEMURON    before or after other nondepolarizing muscle relaxants. ,ZEMURON,nondepolarizing muscle relaxants,No interaction,There_bf controlled_bf studies_bf documenting_bf use_bf DRUG nondepolarizing_be muscle_be relaxants_be ._be
3871,"Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ",Ropivacaine,anesthetics,advise,"DRUG used_be caution_be patients_be receiving_be local_be OTHER_DRUG agents_af structurally_af related_af amide-type_af local_af OTHER_DRUG ,_af since_af toxic_af effects_af drugs_af additive_af ._af"
3872,"Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ",Ropivacaine,amide-type local anesthetics,No interaction,"DRUG used_be caution_be patients_be receiving_be local_be anesthetics_be agents_be structurally_be related_be amide-type_be local_be anesthetics_be ,_be since_be toxic_be effects_be drugs_be additive_be ._be"
3873,"Ropivacaine should be used with caution in patients receiving other local anesthetics or agents structurally related to amide-type local anesthetics, since the toxic effects of these drugs are additive. ",anesthetics,amide-type local anesthetics,No interaction,"Ropivacaine_bf used_bf caution_bf patients_bf receiving_bf local_bf DRUG agents_be structurally_be related_be amide-type_be local_be DRUG ,_af since_af toxic_af effects_af drugs_af additive_af ._af"
3874,"In vivo, the plasma clearance of ropivacaine was reduced by 70% during coadministration of fluvoxamine (25 mg bid for 2 days), a selective and potent CYP1A2 inhibitor. ",ropivacaine,fluvoxamine,mechanism,"In_bf vivo_bf ,_bf plasma_bf clearance_bf DRUG reduced_be 70%_be coadministration_be OTHER_DRUG (25_af mg_af bid_af 2_af days)_af ,_af selective_af potent_af CYP1A2_af inhibitor_af ._af"
3875,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",fluvoxamine,Ropivacaine,int,"Thus_bf strong_bf inhibitors_bf cytochrome_bf P4501A2_bf ,_bf DRUG ,_be given_be concomitantly_be administration_be OTHER_DRUG ,_af interact_af OTHER_DRUG leading_af increased_af OTHER_DRUG plasma_af levels_af ._af"
3876,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",fluvoxamine,Ropivacaine,No interaction,"Thus_bf strong_bf inhibitors_bf cytochrome_bf P4501A2_bf ,_bf DRUG ,_be given_be concomitantly_be administration_be OTHER_DRUG ,_af interact_af OTHER_DRUG leading_af increased_af OTHER_DRUG plasma_af levels_af ._af"
3877,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",fluvoxamine,ropivacaine,No interaction,"Thus_bf strong_bf inhibitors_bf cytochrome_bf P4501A2_bf ,_bf DRUG ,_be given_be concomitantly_be administration_be OTHER_DRUG ,_af interact_af OTHER_DRUG leading_af increased_af OTHER_DRUG plasma_af levels_af ._af"
3878,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",Ropivacaine,Ropivacaine,No interaction,"Thus_bf strong_bf inhibitors_bf cytochrome_bf P4501A2_bf ,_bf fluvoxamine_bf ,_bf given_bf concomitantly_bf administration_bf DRUG ,_be interact_be DRUG leading_af increased_af DRUG plasma_af levels_af ._af"
3879,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",Ropivacaine,ropivacaine,No interaction,"Thus_bf strong_bf inhibitors_bf cytochrome_bf P4501A2_bf ,_bf fluvoxamine_bf ,_bf given_bf concomitantly_bf administration_bf DRUG ,_be interact_be DRUG leading_af increased_af DRUG plasma_af levels_af ._af"
3880,"Thus strong inhibitors of cytochrome P4501A2, such as fluvoxamine, given concomitantly during administration of Ropivacaine, can interact with Ropivacaine leading to increased ropivacaine plasma levels. ",Ropivacaine,ropivacaine,No interaction,"Thus_bf strong_bf inhibitors_bf cytochrome_bf P4501A2_bf ,_bf fluvoxamine_bf ,_bf given_bf concomitantly_bf administration_bf DRUG ,_be interact_be DRUG leading_af increased_af DRUG plasma_af levels_af ._af"
3881,Possible interactions with drugs known to be metabolized by CYP1A2 via competitive inhibition such as theophylline and imipramine may also occur. ,theophylline,imipramine,No interaction,Possible_bf interactions_bf drugs_bf known_bf metabolized_bf CYP1A2_bf via_bf competitive_bf inhibition_bf DRUG OTHER_DRUG may_af also_af occur_af ._af
3882,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",ketoconazole,ropivacaine,No interaction,"Coadministration_bf selective_bf potent_bf inhibitor_bf CYP3A4_bf ,_bf DRUG (100_be mg_be bid_be 2_be days_be OTHER_DRUG infusion_af administered_af 1_af hour_af ketoconazole)_af caused_af 15%_af reduction_af in-vivo_af plasma_af clearance_af OTHER_DRUG ._af"
3883,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",ketoconazole,ketoconazole,No interaction,"Coadministration_bf selective_bf potent_bf inhibitor_bf CYP3A4_bf ,_bf DRUG (100_be mg_be bid_be 2_be days_be ropivacaine_be infusion_be administered_be 1_be hour_be ketoconazole)_be caused_be 15%_be reduction_be in-vivo_be plasma_be clearance_be ropivacaine_be ._be"
3884,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",ketoconazole,ropivacaine,mechanism,"Coadministration_bf selective_bf potent_bf inhibitor_bf CYP3A4_bf ,_bf DRUG (100_be mg_be bid_be 2_be days_be OTHER_DRUG infusion_af administered_af 1_af hour_af ketoconazole)_af caused_af 15%_af reduction_af in-vivo_af plasma_af clearance_af OTHER_DRUG ._af"
3885,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",ropivacaine,ketoconazole,No interaction,"Coadministration_bf selective_bf potent_bf inhibitor_bf CYP3A4_bf ,_bf OTHER_DRUG (100_be mg_be bid_be 2_be days_be DRUG infusion_af administered_af 1_af hour_af ketoconazole)_af caused_af 15%_af reduction_af in-vivo_af plasma_af clearance_af DRUG ._af"
3886,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",ropivacaine,ropivacaine,No interaction,"Coadministration_bf selective_bf potent_bf inhibitor_bf CYP3A4_bf ,_bf ketoconazole_bf (100_bf mg_bf bid_bf 2_bf days_bf DRUG infusion_be administered_be 1_be hour_be ketoconazole)_be caused_be 15%_be reduction_be in-vivo_be plasma_be clearance_be DRUG ._af"
3887,"Coadministration of a selective and potent inhibitor of CYP3A4, ketoconazole (100 mg bid for 2 days with ropivacaine infusion administered 1 hour after ketoconazole) caused a 15% reduction in in-vivo plasma clearance of ropivacaine.",ketoconazole,ropivacaine,No interaction,"Coadministration_bf selective_bf potent_bf inhibitor_bf CYP3A4_bf ,_bf DRUG (100_be mg_be bid_be 2_be days_be OTHER_DRUG infusion_af administered_af 1_af hour_af ketoconazole)_af caused_af 15%_af reduction_af in-vivo_af plasma_af clearance_af OTHER_DRUG ._af"
3888,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,gemfibrozil,rosiglitazone,mechanism,An_bf inhibitor_bf CYP2C8_bf (such_bf gemfibrozil)_bf may_bf increase_bf AUC_bf OTHER_DRUG inducer_be CYP2C8_be (such_be rifampin)_be may_be decrease_be AUC_be OTHER_DRUG ._af
3889,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,gemfibrozil,rifampin,No interaction,An_bf inhibitor_bf CYP2C8_bf (such_bf gemfibrozil)_bf may_bf increase_bf AUC_bf rosiglitazone_bf inducer_bf CYP2C8_bf (such_bf rifampin)_bf may_bf decrease_bf AUC_bf rosiglitazone_bf ._bf
3890,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,gemfibrozil,rosiglitazone,No interaction,An_bf inhibitor_bf CYP2C8_bf (such_bf gemfibrozil)_bf may_bf increase_bf AUC_bf OTHER_DRUG inducer_be CYP2C8_be (such_be rifampin)_be may_be decrease_be AUC_be OTHER_DRUG ._af
3891,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,rosiglitazone,rifampin,No interaction,An_bf inhibitor_bf CYP2C8_bf (such_bf gemfibrozil)_bf may_bf increase_bf AUC_bf DRUG inducer_be CYP2C8_be (such_be rifampin)_be may_be decrease_be AUC_be DRUG ._af
3892,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,rosiglitazone,rosiglitazone,No interaction,An_bf inhibitor_bf CYP2C8_bf (such_bf gemfibrozil)_bf may_bf increase_bf AUC_bf DRUG inducer_be CYP2C8_be (such_be rifampin)_be may_be decrease_be AUC_be DRUG ._af
3893,An inhibitor of CYP2C8 (such as gemfibrozil) may increase the AUC of rosiglitazone and an inducer of CYP2C8 (such as rifampin) may decrease the AUC of rosiglitazone. ,rifampin,rosiglitazone,mechanism,An_bf inhibitor_bf CYP2C8_bf (such_bf gemfibrozil)_bf may_bf increase_bf AUC_bf OTHER_DRUG inducer_be CYP2C8_be (such_be rifampin)_be may_be decrease_be AUC_be OTHER_DRUG ._af
3894,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,Terfenadine,astemizole,No interaction,Concomitant_bf administrations_bf recommended:_bf -_bf DRUG astemizole:_be Certain_be macrolides_be interact_be DRUG OTHER_DRUG leading_af increased_af serum_af concentrations_af latter_af ._af
3895,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,Terfenadine,macrolides,No interaction,Concomitant_bf administrations_bf recommended:_bf -_bf DRUG astemizole:_be Certain_be OTHER_DRUG interact_af DRUG astemizole_af leading_af increased_af serum_af concentrations_af latter_af ._af
3896,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,Terfenadine,terfenadine,No interaction,Concomitant_bf administrations_bf recommended:_bf -_bf DRUG astemizole:_be Certain_be macrolides_be interact_be DRUG astemizole_af leading_af increased_af serum_af concentrations_af latter_af ._af
3897,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,Terfenadine,astemizole,No interaction,Concomitant_bf administrations_bf recommended:_bf -_bf DRUG astemizole:_be Certain_be macrolides_be interact_be DRUG OTHER_DRUG leading_af increased_af serum_af concentrations_af latter_af ._af
3898,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,astemizole,macrolides,No interaction,Concomitant_bf administrations_bf recommended:_bf -_bf Terfenadine_bf astemizole:_bf Certain_bf OTHER_DRUG interact_be terfenadine_be DRUG leading_af increased_af serum_af concentrations_af latter_af ._af
3899,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,astemizole,terfenadine,No interaction,Concomitant_bf administrations_bf recommended:_bf -_bf OTHER_DRUG astemizole:_be Certain_be macrolides_be interact_be OTHER_DRUG DRUG leading_af increased_af serum_af concentrations_af latter_af ._af
3900,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,astemizole,astemizole,No interaction,Concomitant_bf administrations_bf recommended:_bf -_bf Terfenadine_bf astemizole:_bf Certain_bf macrolides_bf interact_bf terfenadine_bf DRUG leading_be increased_be serum_be concentrations_be latter_be ._be
3901,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,macrolides,terfenadine,int,Concomitant_bf administrations_bf recommended:_bf -_bf OTHER_DRUG astemizole:_be Certain_be DRUG interact_af OTHER_DRUG astemizole_af leading_af increased_af serum_af concentrations_af latter_af ._af
3902,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,macrolides,astemizole,int,Concomitant_bf administrations_bf recommended:_bf -_bf Terfenadine_bf astemizole:_bf Certain_bf DRUG interact_be terfenadine_be OTHER_DRUG leading_af increased_af serum_af concentrations_af latter_af ._af
3903,Concomitant administrations not recommended:  - Terfenadine and astemizole: Certain macrolides interact with terfenadine and astemizole leading to increased serum concentrations of the latter. ,terfenadine,astemizole,No interaction,Concomitant_bf administrations_bf recommended:_bf -_bf DRUG astemizole:_be Certain_be macrolides_be interact_be DRUG OTHER_DRUG leading_af increased_af serum_af concentrations_af latter_af ._af
3904,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,roxithromycin,No interaction,"Although_bf reaction_bf demonstrated_bf DRUG ,_be concomitant_be administration_be DRUG terfenadine_af astemizole_af recommended_af ._af"
3905,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,terfenadine,No interaction,"Although_bf reaction_bf demonstrated_bf DRUG ,_be concomitant_be administration_be DRUG OTHER_DRUG astemizole_af recommended_af ._af"
3906,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,astemizole,No interaction,"Although_bf reaction_bf demonstrated_bf DRUG ,_be concomitant_be administration_be DRUG terfenadine_af OTHER_DRUG recommended_af ._af"
3907,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,terfenadine,advise,"Although_bf reaction_bf demonstrated_bf DRUG ,_be concomitant_be administration_be DRUG OTHER_DRUG astemizole_af recommended_af ._af"
3908,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",roxithromycin,astemizole,advise,"Although_bf reaction_bf demonstrated_bf DRUG ,_be concomitant_be administration_be DRUG terfenadine_af OTHER_DRUG recommended_af ._af"
3909,"Although such a reaction has not been demonstrated with roxithromycin, concomitant administration of roxithromycin with terfenadine or astemizole is not recommended. ",terfenadine,astemizole,No interaction,"Although_bf reaction_bf demonstrated_bf roxithromycin_bf ,_bf concomitant_bf administration_bf roxithromycin_bf DRUG OTHER_DRUG recommended_af ._af"
3910,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",Cisapride,pimozide,No interaction,"-_bf DRUG ,_be pimozide:_be Other_be drugs_be DRUG OTHER_DRUG ,_af metabolised_af hepatic_af CYP3A_af isozymes_af associated_af QT_af interval_af prolongation_af and/or_af cardiac_af arrythmias_af (typically_af torsades_af de_af pointe)_af result_af increase_af serum_af level_af subsequent_af interaction_af significant_af inhibitors_af isozyme_af ,_af including_af macrolide_af antibacterials_af ._af"
3911,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",Cisapride,cisapride,No interaction,"-_bf DRUG ,_be pimozide:_be Other_be drugs_be DRUG pimozide_af ,_af metabolised_af hepatic_af CYP3A_af isozymes_af associated_af QT_af interval_af prolongation_af and/or_af cardiac_af arrythmias_af (typically_af torsades_af de_af pointe)_af result_af increase_af serum_af level_af subsequent_af interaction_af significant_af inhibitors_af isozyme_af ,_af including_af macrolide_af antibacterials_af ._af"
3912,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",Cisapride,pimozide,No interaction,"-_bf DRUG ,_be pimozide:_be Other_be drugs_be DRUG OTHER_DRUG ,_af metabolised_af hepatic_af CYP3A_af isozymes_af associated_af QT_af interval_af prolongation_af and/or_af cardiac_af arrythmias_af (typically_af torsades_af de_af pointe)_af result_af increase_af serum_af level_af subsequent_af interaction_af significant_af inhibitors_af isozyme_af ,_af including_af macrolide_af antibacterials_af ._af"
3913,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",Cisapride,macrolide antibacterials,No interaction,"-_bf DRUG ,_be pimozide:_be Other_be drugs_be DRUG pimozide_af ,_af metabolised_af hepatic_af CYP3A_af isozymes_af associated_af QT_af interval_af prolongation_af and/or_af cardiac_af arrythmias_af (typically_af torsades_af de_af pointe)_af result_af increase_af serum_af level_af subsequent_af interaction_af significant_af inhibitors_af isozyme_af ,_af including_af macrolide_af antibacterials_af ._af"
3914,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",pimozide,cisapride,No interaction,"-_bf OTHER_DRUG ,_be pimozide:_be Other_be drugs_be OTHER_DRUG DRUG ,_af metabolised_af hepatic_af CYP3A_af isozymes_af associated_af QT_af interval_af prolongation_af and/or_af cardiac_af arrythmias_af (typically_af torsades_af de_af pointe)_af result_af increase_af serum_af level_af subsequent_af interaction_af significant_af inhibitors_af isozyme_af ,_af including_af macrolide_af antibacterials_af ._af"
3915,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",pimozide,pimozide,No interaction,"-_bf Cisapride_bf ,_bf pimozide:_bf Other_bf drugs_bf cisapride_bf DRUG ,_be metabolised_be hepatic_be CYP3A_be isozymes_be associated_be QT_be interval_be prolongation_be and/or_be cardiac_be arrythmias_be (typically_be torsades_be de_be pointe)_be result_be increase_be serum_be level_be subsequent_be interaction_be significant_be inhibitors_be isozyme_be ,_be including_be macrolide_be antibacterials_be ._be"
3916,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",pimozide,macrolide antibacterials,mechanism,"-_bf Cisapride_bf ,_bf pimozide:_bf Other_bf drugs_bf cisapride_bf DRUG ,_be metabolised_be hepatic_be CYP3A_be isozymes_be associated_be QT_be interval_be prolongation_be and/or_be cardiac_be arrythmias_be (typically_be torsades_be de_be pointe)_be result_be increase_be serum_be level_be subsequent_be interaction_be significant_be inhibitors_be isozyme_be ,_be including_be macrolide_be antibacterials_be ._be"
3917,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",cisapride,pimozide,No interaction,"-_bf DRUG ,_be pimozide:_be Other_be drugs_be DRUG OTHER_DRUG ,_af metabolised_af hepatic_af CYP3A_af isozymes_af associated_af QT_af interval_af prolongation_af and/or_af cardiac_af arrythmias_af (typically_af torsades_af de_af pointe)_af result_af increase_af serum_af level_af subsequent_af interaction_af significant_af inhibitors_af isozyme_af ,_af including_af macrolide_af antibacterials_af ._af"
3918,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",cisapride,macrolide antibacterials,mechanism,"-_bf DRUG ,_be pimozide:_be Other_be drugs_be DRUG pimozide_af ,_af metabolised_af hepatic_af CYP3A_af isozymes_af associated_af QT_af interval_af prolongation_af and/or_af cardiac_af arrythmias_af (typically_af torsades_af de_af pointe)_af result_af increase_af serum_af level_af subsequent_af interaction_af significant_af inhibitors_af isozyme_af ,_af including_af macrolide_af antibacterials_af ._af"
3919,"- Cisapride, pimozide: Other drugs such as cisapride or pimozide, which are metabolised by hepatic CYP3A isozymes have been associated with QT interval prolongation and/or cardiac arrythmias (typically torsades de pointe) as a result of increase in their serum level subsequent to interaction with significant inhibitors of the isozyme, including some macrolide antibacterials. ",pimozide,macrolide antibacterials,No interaction,"-_bf Cisapride_bf ,_bf pimozide:_bf Other_bf drugs_bf cisapride_bf DRUG ,_be metabolised_be hepatic_be CYP3A_be isozymes_be associated_be QT_be interval_be prolongation_be and/or_be cardiac_be arrythmias_be (typically_be torsades_be de_be pointe)_be result_be increase_be serum_be level_be subsequent_be interaction_be significant_be inhibitors_be isozyme_be ,_be including_be macrolide_be antibacterials_be ._be"
3920,"Although such a risk is not verified for roxithromycin, combination of roxithromycin with such drugs is not recommended.",roxithromycin,roxithromycin,No interaction,"Although_bf risk_bf verified_bf DRUG ,_be combination_be DRUG drugs_af recommended_af ._af"
3921,"however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Calcitonin (salmon) nasal spray.",diphosphonate,Calcitonin (salmon),effect,"however_bf ,_bf patients_bf Paget's_bf Disease_bf prior_bf DRUG use_be appears_be reduce_be anti-resorptive_be response_be Calcitonin_be (salmon)_be nasal_be spray_be ._be"
3922,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,ASPIRIN,SALICYLATE DRUGS,No interaction,DRUG AND_be OTHER_be SALICYLATE_be DRUGS_be WILL_be BE_be ADDITIVE_be TO_be DISALCID_be AND_be MAY_be INCREASE_be PLASMA_be CONCENTRATIONS_be OF_be SALICYLIC_be ACID_be TO_be TOXIC_be LEVELS_be ._be
3923,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,ASPIRIN,DISALCID,effect,DRUG AND_be OTHER_be SALICYLATE_be DRUGS_be WILL_be BE_be ADDITIVE_be TO_be OTHER_DRUG AND_af MAY_af INCREASE_af PLASMA_af CONCENTRATIONS_af OF_af SALICYLIC_af ACID_af TO_af TOXIC_af LEVELS_af ._af
3924,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,ASPIRIN,SALICYLIC ACID,No interaction,DRUG AND_be OTHER_be SALICYLATE_be DRUGS_be WILL_be BE_be ADDITIVE_be TO_be DISALCID_be AND_be MAY_be INCREASE_be PLASMA_be CONCENTRATIONS_be OF_be SALICYLIC_be ACID_be TO_be TOXIC_be LEVELS_be ._be
3925,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,SALICYLATE DRUGS,DISALCID,effect,ASPIRIN_bf AND_bf OTHER_bf SALICYLATE_bf DRUGS_bf WILL_bf BE_bf ADDITIVE_bf TO_bf OTHER_DRUG AND_be MAY_be INCREASE_be PLASMA_be CONCENTRATIONS_be OF_be SALICYLIC_be ACID_be TO_be TOXIC_be LEVELS_be ._be
3926,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,SALICYLATE DRUGS,SALICYLIC ACID,No interaction,ASPIRIN_bf AND_bf OTHER_bf SALICYLATE_bf DRUGS_bf WILL_bf BE_bf ADDITIVE_bf TO_bf DISALCID_bf AND_bf MAY_bf INCREASE_bf PLASMA_bf CONCENTRATIONS_bf OF_bf SALICYLIC_bf ACID_bf TO_bf TOXIC_bf LEVELS_bf ._bf
3927,ASPIRIN AND OTHER SALICYLATE DRUGS WILL BE ADDITIVE TO DISALCID AND MAY INCREASE PLASMA CONCENTRATIONS OF SALICYLIC ACID TO TOXIC LEVELS. ,DISALCID,SALICYLIC ACID,No interaction,ASPIRIN_bf AND_bf OTHER_bf SALICYLATE_bf DRUGS_bf WILL_bf BE_bf ADDITIVE_bf TO_bf DRUG AND_be MAY_be INCREASE_be PLASMA_be CONCENTRATIONS_be OF_be SALICYLIC_be ACID_be TO_be TOXIC_be LEVELS_be ._be
3928,Salicylates given concomitantly with anticoagulant drugs may predispose to systemic bleeding. ,Salicylates,anticoagulant drugs,effect,DRUG given_be concomitantly_be anticoagulant_be drugs_be may_be predispose_be systemic_be bleeding_be ._be
3929,Salicylates may enhance the hypoglycemic effect of oral antidiabetic drugs of the sulfonylurea class. ,Salicylates,antidiabetic drugs,effect,DRUG may_be enhance_be hypoglycemic_be effect_be oral_be antidiabetic_be drugs_be sulfonylurea_be class_be ._be
3930,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,penicillin,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be OTHER_DRUG ,_af thiopental_af ,_af thyroxine_af ,_af triiodothyronine_af ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3931,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,thiopental,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be OTHER_DRUG ,_af thyroxine_af ,_af triiodothyronine_af ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3932,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,thyroxine,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be OTHER_DRUG ,_af triiodothyronine_af ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3933,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,triiodothyronine,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3934,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,phenytoin,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be OTHER_DRUG ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3935,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,sulfinpyrazone,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3936,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,naproxen,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be OTHER_DRUG ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3937,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,warfarin,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be OTHER_DRUG ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3938,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,methotrexate,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be OTHER_DRUG ,_af possibly_af corticosteroids_af ._af"
3939,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",Salicylate,corticosteroids,mechanism,"DRUG competes_be number_be drugs_be protein_be binding_be sites_be ,_be notably_be penicillin_be ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be methotrexate_be ,_be possibly_be OTHER_DRUG ._af"
3940,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",penicillin,thiopental,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf DRUG ,_be OTHER_DRUG ,_af thyroxine_af ,_af triiodothyronine_af ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3941,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",penicillin,thyroxine,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf DRUG ,_be thiopental_be ,_be OTHER_DRUG ,_af triiodothyronine_af ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3942,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",penicillin,triiodothyronine,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf DRUG ,_be thiopental_be ,_be thyroxine_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3943,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",penicillin,phenytoin,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf DRUG ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be OTHER_DRUG ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3944,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",penicillin,sulfinpyrazone,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf DRUG ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3945,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",penicillin,naproxen,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf DRUG ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be OTHER_DRUG ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3946,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",penicillin,warfarin,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf DRUG ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be OTHER_DRUG ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3947,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",penicillin,methotrexate,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf DRUG ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be OTHER_DRUG ,_af possibly_af corticosteroids_af ._af"
3948,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",penicillin,corticosteroids,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf DRUG ,_be thiopental_be ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be methotrexate_be ,_be possibly_be OTHER_DRUG ._af"
3949,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thiopental,thyroxine,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af triiodothyronine_af ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3950,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thiopental,triiodothyronine,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf DRUG ,_be thyroxine_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3951,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thiopental,phenytoin,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf DRUG ,_be thyroxine_be ,_be triiodothyronine_be ,_be OTHER_DRUG ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3952,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thiopental,sulfinpyrazone,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf DRUG ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3953,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thiopental,naproxen,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf DRUG ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be OTHER_DRUG ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3954,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thiopental,warfarin,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf DRUG ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be OTHER_DRUG ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3955,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thiopental,methotrexate,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf DRUG ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be OTHER_DRUG ,_af possibly_af corticosteroids_af ._af"
3956,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thiopental,corticosteroids,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf DRUG ,_be thyroxine_be ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be methotrexate_be ,_be possibly_be OTHER_DRUG ._af"
3957,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thyroxine,triiodothyronine,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf DRUG ,_be OTHER_DRUG ,_af phenytoin_af ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3958,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thyroxine,phenytoin,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf DRUG ,_be triiodothyronine_be ,_be OTHER_DRUG ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3959,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thyroxine,sulfinpyrazone,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf DRUG ,_be triiodothyronine_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3960,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thyroxine,naproxen,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf DRUG ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be OTHER_DRUG ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3961,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thyroxine,warfarin,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf DRUG ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be OTHER_DRUG ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3962,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thyroxine,methotrexate,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf DRUG ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be OTHER_DRUG ,_af possibly_af corticosteroids_af ._af"
3963,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",thyroxine,corticosteroids,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf DRUG ,_be triiodothyronine_be ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be methotrexate_be ,_be possibly_be OTHER_DRUG ._af"
3964,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",triiodothyronine,phenytoin,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af sulfinpyrazone_af ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3965,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",triiodothyronine,sulfinpyrazone,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf DRUG ,_be phenytoin_be ,_be OTHER_DRUG ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3966,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",triiodothyronine,naproxen,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf DRUG ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be OTHER_DRUG ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3967,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",triiodothyronine,warfarin,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf DRUG ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be OTHER_DRUG ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3968,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",triiodothyronine,methotrexate,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf DRUG ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be OTHER_DRUG ,_af possibly_af corticosteroids_af ._af"
3969,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",triiodothyronine,corticosteroids,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf DRUG ,_be phenytoin_be ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be methotrexate_be ,_be possibly_be OTHER_DRUG ._af"
3970,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",phenytoin,sulfinpyrazone,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf DRUG ,_be OTHER_DRUG ,_af naproxen_af ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3971,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",phenytoin,naproxen,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf DRUG ,_be sulfinpyrazone_be ,_be OTHER_DRUG ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3972,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",phenytoin,warfarin,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf DRUG ,_be sulfinpyrazone_be ,_be naproxen_be ,_be OTHER_DRUG ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3973,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",phenytoin,methotrexate,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf DRUG ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be OTHER_DRUG ,_af possibly_af corticosteroids_af ._af"
3974,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",phenytoin,corticosteroids,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf DRUG ,_be sulfinpyrazone_be ,_be naproxen_be ,_be warfarin_be ,_be methotrexate_be ,_be possibly_be OTHER_DRUG ._af"
3975,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",sulfinpyrazone,naproxen,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf phenytoin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af warfarin_af ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3976,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",sulfinpyrazone,warfarin,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf phenytoin_bf ,_bf DRUG ,_be naproxen_be ,_be OTHER_DRUG ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3977,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",sulfinpyrazone,methotrexate,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf phenytoin_bf ,_bf DRUG ,_be naproxen_be ,_be warfarin_be ,_be OTHER_DRUG ,_af possibly_af corticosteroids_af ._af"
3978,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",sulfinpyrazone,corticosteroids,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf phenytoin_bf ,_bf DRUG ,_be naproxen_be ,_be warfarin_be ,_be methotrexate_be ,_be possibly_be OTHER_DRUG ._af"
3979,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",naproxen,warfarin,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf phenytoin_bf ,_bf sulfinpyrazone_bf ,_bf DRUG ,_be OTHER_DRUG ,_af methotrexate_af ,_af possibly_af corticosteroids_af ._af"
3980,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",naproxen,methotrexate,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf phenytoin_bf ,_bf sulfinpyrazone_bf ,_bf DRUG ,_be warfarin_be ,_be OTHER_DRUG ,_af possibly_af corticosteroids_af ._af"
3981,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",naproxen,corticosteroids,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf phenytoin_bf ,_bf sulfinpyrazone_bf ,_bf DRUG ,_be warfarin_be ,_be methotrexate_be ,_be possibly_be OTHER_DRUG ._af"
3982,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",warfarin,methotrexate,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf phenytoin_bf ,_bf sulfinpyrazone_bf ,_bf naproxen_bf ,_bf DRUG ,_be OTHER_DRUG ,_af possibly_af corticosteroids_af ._af"
3983,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",warfarin,corticosteroids,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf phenytoin_bf ,_bf sulfinpyrazone_bf ,_bf naproxen_bf ,_bf DRUG ,_be methotrexate_be ,_be possibly_be OTHER_DRUG ._af"
3984,"Salicylate competes with a number of drugs for protein binding sites, notably penicillin, thiopental, thyroxine, triiodothyronine, phenytoin, sulfinpyrazone, naproxen, warfarin, methotrexate, and possibly corticosteroids. ",methotrexate,corticosteroids,No interaction,"Salicylate_bf competes_bf number_bf drugs_bf protein_bf binding_bf sites_bf ,_bf notably_bf penicillin_bf ,_bf thiopental_bf ,_bf thyroxine_bf ,_bf triiodothyronine_bf ,_bf phenytoin_bf ,_bf sulfinpyrazone_bf ,_bf naproxen_bf ,_bf warfarin_bf ,_bf DRUG ,_be possibly_be OTHER_DRUG ._af"
3985,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",Leukine,lithium,effect,"Drugs_bf may_bf potentiate_bf myeloproliferative_bf effects_bf DRUG ,_be OTHER_DRUG corticosteroids_af ,_af used_af caution_af ._af"
3986,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",Leukine,corticosteroids,effect,"Drugs_bf may_bf potentiate_bf myeloproliferative_bf effects_bf DRUG ,_be lithium_be OTHER_DRUG ,_af used_af caution_af ._af"
3987,"Drugs which may potentiate the myeloproliferative effects of Leukine, such as lithium and corticosteroids, should be used with caution.",lithium,corticosteroids,No interaction,"Drugs_bf may_bf potentiate_bf myeloproliferative_bf effects_bf Leukine_bf ,_bf DRUG OTHER_DRUG ,_af used_af caution_af ._af"
3988,"Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. ",Digoxin,digoxin,No interaction,"Digoxin:_bf There_bf slight_bf increase_bf area_bf curve_bf (AUC_bf ,_bf 11%)_bf mean_bf peak_bf drug_bf concentration_bf (Cmax_bf ,_bf 18%)_bf DRUG co-administration_be 100_be mg_be sitagliptin_be 10_be days_be ._be"
3989,"Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. ",Digoxin,sitagliptin,No interaction,"Digoxin:_bf There_bf slight_bf increase_bf area_bf curve_bf (AUC_bf ,_bf 11%)_bf mean_bf peak_bf drug_bf concentration_bf (Cmax_bf ,_bf 18%)_bf DRUG co-administration_be 100_be mg_be OTHER_DRUG 10_af days_af ._af"
3990,"Digoxin: There was a slight increase in the area under the curve (AUC, 11%) and mean peak drug concentration (Cmax, 18%) of digoxin with the co-administration of 100 mg sitagliptin for 10 days. ",digoxin,sitagliptin,mechanism,"Digoxin:_bf There_bf slight_bf increase_bf area_bf curve_bf (AUC_bf ,_bf 11%)_bf mean_bf peak_bf drug_bf concentration_bf (Cmax_bf ,_bf 18%)_bf DRUG co-administration_be 100_be mg_be OTHER_DRUG 10_af days_af ._af"
3991,No dosage adjustment of digoxin or JANUVIA is recommended.,digoxin,JANUVIA,No interaction,No_bf dosage_bf adjustment_bf DRUG OTHER_DRUG recommended_af ._af
3992,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,norepinephrine,dobutamine,No interaction,DRUG OTHER_DRUG incompatible_af sodium_af bicarbonate_af solution_af ._af
3993,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,norepinephrine,sodium bicarbonate,int,DRUG dobutamine_be incompatible_be sodium_be bicarbonate_be solution_be ._be
3994,norepinephrine and dobutamine are incompatible with sodium bicarbonate solution. ,dobutamine,sodium bicarbonate,int,norepinephrine_bf DRUG incompatible_be sodium_be bicarbonate_be solution_be ._be
3995,"The addition of sodium bicarbonate to parenteral solutions containing calcium should be avoided, except where compatibility has been previously established. ",sodium bicarbonate,calcium,No interaction,"The_bf addition_bf sodium_bf bicarbonate_bf parenteral_bf solutions_bf containing_bf OTHER_DRUG avoided_be ,_be except_be compatibility_be previously_be established_be ._be"
3996,Do not exceed a 5 mg daily dose of VESIcare when administered with therapeutic doses of ketoconazole or other potent CYP3A4 inhibitors. ,VESIcare,ketoconazole,advise,Do_bf exceed_bf 5_bf mg_bf daily_bf dose_bf DRUG administered_be therapeutic_be doses_be OTHER_DRUG potent_af CYP3A4_af inhibitors_af ._af
3997,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",solifenacin,solifenacin,No interaction,"Patients_bf Congenital_bf Acquired_bf QT_bf Prolongation_bf In_bf study_bf effect_bf DRUG QT_be interval_be 76_be healthy_be women_be ,_be QT_be prolonging_be effect_be appeared_be less_be DRUG 10_af mg_af 30_af mg_af (three_af times_af maximum_af recommended_af dose)_af ,_af effect_af DRUG 30_af mg_af appear_af large_af positive_af control_af moxifloxacin_af therapeutic_af dose_af ._af"
3998,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",solifenacin,solifenacin,No interaction,"Patients_bf Congenital_bf Acquired_bf QT_bf Prolongation_bf In_bf study_bf effect_bf DRUG QT_be interval_be 76_be healthy_be women_be ,_be QT_be prolonging_be effect_be appeared_be less_be DRUG 10_af mg_af 30_af mg_af (three_af times_af maximum_af recommended_af dose)_af ,_af effect_af DRUG 30_af mg_af appear_af large_af positive_af control_af moxifloxacin_af therapeutic_af dose_af ._af"
3999,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",solifenacin,moxifloxacin,No interaction,"Patients_bf Congenital_bf Acquired_bf QT_bf Prolongation_bf In_bf study_bf effect_bf DRUG QT_be interval_be 76_be healthy_be women_be ,_be QT_be prolonging_be effect_be appeared_be less_be DRUG 10_af mg_af 30_af mg_af (three_af times_af maximum_af recommended_af dose)_af ,_af effect_af DRUG 30_af mg_af appear_af large_af positive_af control_af OTHER_DRUG therapeutic_af dose_af ._af"
4000,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",solifenacin,solifenacin,No interaction,"Patients_bf Congenital_bf Acquired_bf QT_bf Prolongation_bf In_bf study_bf effect_bf DRUG QT_be interval_be 76_be healthy_be women_be ,_be QT_be prolonging_be effect_be appeared_be less_be DRUG 10_af mg_af 30_af mg_af (three_af times_af maximum_af recommended_af dose)_af ,_af effect_af DRUG 30_af mg_af appear_af large_af positive_af control_af moxifloxacin_af therapeutic_af dose_af ._af"
4001,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",solifenacin,moxifloxacin,No interaction,"Patients_bf Congenital_bf Acquired_bf QT_bf Prolongation_bf In_bf study_bf effect_bf DRUG QT_be interval_be 76_be healthy_be women_be ,_be QT_be prolonging_be effect_be appeared_be less_be DRUG 10_af mg_af 30_af mg_af (three_af times_af maximum_af recommended_af dose)_af ,_af effect_af DRUG 30_af mg_af appear_af large_af positive_af control_af OTHER_DRUG therapeutic_af dose_af ._af"
4002,"Patients with Congenital or Acquired QT Prolongation In a study of the effect of solifenacin on the QT interval in 76 healthy women, the QT prolonging effect appeared less with solifenacin 10 mg than with 30 mg (three times the maximum recommended dose), and the effect of solifenacin 30 mg did not appear as large as that of the positive control moxifloxacin at its therapeutic dose. ",solifenacin,moxifloxacin,No interaction,"Patients_bf Congenital_bf Acquired_bf QT_bf Prolongation_bf In_bf study_bf effect_bf DRUG QT_be interval_be 76_be healthy_be women_be ,_be QT_be prolonging_be effect_be appeared_be less_be DRUG 10_af mg_af 30_af mg_af (three_af times_af maximum_af recommended_af dose)_af ,_af effect_af DRUG 30_af mg_af appear_af large_af positive_af control_af OTHER_DRUG therapeutic_af dose_af ._af"
4003,"If glucocorticoid replacement is required, the glucocorticoid dose should be carefully adjusted. ",glucocorticoid,glucocorticoid,No interaction,"If_bf DRUG replacement_be required_be ,_be DRUG dose_af carefully_af adjusted_af ._af"
4004,Limited published data indicate that GH treatment increases cytochrome P450 (CP450) mediated antipyrine clearance in man. ,GH,antipyrine,mechanism,Limited_bf published_bf data_bf indicate_bf DRUG treatment_be increases_be cytochrome_be P450_be (CP450)_be mediated_be OTHER_DRUG clearance_af man_af ._af
4005,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,corticosteroids,mechanism,"These_bf data_bf suggest_bf DRUG administration_be may_be alter_be clearance_be compounds_be known_be metabolized_be CP450_be liver_be enzymes_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af sex_af steroids_af ,_af anticonvulsants_af ,_af cyclosporin)_af ._af"
4006,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,sex steroids,mechanism,"These_bf data_bf suggest_bf DRUG administration_be may_be alter_be clearance_be compounds_be known_be metabolized_be CP450_be liver_be enzymes_be (e_be ._be g_be ._be ,_be corticosteroids_be ,_be sex_be steroids_be ,_be anticonvulsants_be ,_be cyclosporin)_be ._be"
4007,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,anticonvulsants,mechanism,"These_bf data_bf suggest_bf DRUG administration_be may_be alter_be clearance_be compounds_be known_be metabolized_be CP450_be liver_be enzymes_be (e_be ._be g_be ._be ,_be corticosteroids_be ,_be sex_be steroids_be ,_be OTHER_DRUG ,_af cyclosporin)_af ._af"
4008,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",GH,cyclosporin,mechanism,"These_bf data_bf suggest_bf DRUG administration_be may_be alter_be clearance_be compounds_be known_be metabolized_be CP450_be liver_be enzymes_be (e_be ._be g_be ._be ,_be corticosteroids_be ,_be sex_be steroids_be ,_be anticonvulsants_be ,_be cyclosporin)_be ._be"
4009,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",corticosteroids,sex steroids,No interaction,"These_bf data_bf suggest_bf GH_bf administration_bf may_bf alter_bf clearance_bf compounds_bf known_bf metabolized_bf CP450_bf liver_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be sex_be steroids_be ,_be anticonvulsants_be ,_be cyclosporin)_be ._be"
4010,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",corticosteroids,anticonvulsants,No interaction,"These_bf data_bf suggest_bf GH_bf administration_bf may_bf alter_bf clearance_bf compounds_bf known_bf metabolized_bf CP450_bf liver_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be sex_be steroids_be ,_be OTHER_DRUG ,_af cyclosporin)_af ._af"
4011,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",corticosteroids,cyclosporin,No interaction,"These_bf data_bf suggest_bf GH_bf administration_bf may_bf alter_bf clearance_bf compounds_bf known_bf metabolized_bf CP450_bf liver_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be sex_be steroids_be ,_be anticonvulsants_be ,_be cyclosporin)_be ._be"
4012,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",sex steroids,anticonvulsants,No interaction,"These_bf data_bf suggest_bf GH_bf administration_bf may_bf alter_bf clearance_bf compounds_bf known_bf metabolized_bf CP450_bf liver_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf corticosteroids_bf ,_bf sex_bf steroids_bf ,_bf OTHER_DRUG ,_be cyclosporin)_be ._be"
4013,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",sex steroids,cyclosporin,No interaction,"These_bf data_bf suggest_bf GH_bf administration_bf may_bf alter_bf clearance_bf compounds_bf known_bf metabolized_bf CP450_bf liver_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf corticosteroids_bf ,_bf sex_bf steroids_bf ,_bf anticonvulsants_bf ,_bf cyclosporin)_bf ._bf"
4014,"These data suggest that GH administration may alter the clearance of compounds known to be metabolized by CP450 liver enzymes (e.g., corticosteroids, sex steroids, anticonvulsants, cyclosporin). ",anticonvulsants,cyclosporin,No interaction,"These_bf data_bf suggest_bf GH_bf administration_bf may_bf alter_bf clearance_bf compounds_bf known_bf metabolized_bf CP450_bf liver_bf enzymes_bf (e_bf ._bf g_bf ._bf ,_bf corticosteroids_bf ,_bf sex_bf steroids_bf ,_bf DRUG ,_be cyclosporin)_be ._be"
4015,Caution is recommended when administering NEXAVAR with compounds that are metabolized/eliminated predominantly by the UGT1A1 pathway (e.g. irinotecan). ,NEXAVAR,irinotecan,advise,Caution_bf recommended_bf administering_bf DRUG compounds_be metabolized/eliminated_be predominantly_be UGT1A1_be pathway_be (e_be ._be g_be ._be irinotecan)_be ._be
4016,Concomitant treatment with NEXAVAR resulted in a 21% increase in the AUC of doxorubicin. ,NEXAVAR,doxorubicin,mechanism,Concomitant_bf treatment_bf DRUG resulted_be 21%_be increase_be AUC_be OTHER_DRUG ._af
4017,Caution is recommended when administering doxorubicin with NEXAVAR. ,doxorubicin,NEXAVAR,advise,Caution_bf recommended_bf administering_bf DRUG OTHER_DRUG ._af
4018,Zidovudine competitively inhibits the intracellular phosphorylation of stavudine. ,Zidovudine,stavudine,effect,DRUG competitively_be inhibits_be intracellular_be phosphorylation_be OTHER_DRUG ._af
4019,"Therefore, use of zidovudine in combination with ZERIT should be avoided. ",zidovudine,ZERIT,advise,"Therefore_bf ,_bf use_bf DRUG combination_be OTHER_DRUG avoided_af ._af"
4020,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,stavudine,doxorubicin,effect,In_bf vitro_bf data_bf indicate_bf phosphorylation_bf DRUG also_be inhibited_be relevant_be concentrations_be OTHER_DRUG ribavirin_af ._af
4021,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,stavudine,ribavirin,effect,In_bf vitro_bf data_bf indicate_bf phosphorylation_bf DRUG also_be inhibited_be relevant_be concentrations_be doxorubicin_be OTHER_DRUG ._af
4022,In vitro data indicate that the phosphorylation of stavudine is also inhibited at relevant concentrations by doxorubicin and ribavirin. ,doxorubicin,ribavirin,No interaction,In_bf vitro_bf data_bf indicate_bf phosphorylation_bf stavudine_bf also_bf inhibited_bf relevant_bf concentrations_bf DRUG OTHER_DRUG ._af
4023,"The interaction of Streptase, Streptokinase, with other drugs has not been well studied. ",Streptase,Streptokinase,No interaction,"The_bf interaction_bf DRUG ,_be OTHER_DRUG ,_af drugs_af well_af studied_af ._af"
4024,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Anticoagulants,Antiplatelet Agents,No interaction,"Use_bf DRUG Antiplatelet_be Agents_be --_be Streptase_be ,_be Streptokinase_be ,_be alone_be combination_be antiplatelet_be agents_be DRUG ,_af may_af cause_af bleeding_af complications_af ._af"
4025,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Anticoagulants,Streptase,No interaction,"Use_bf DRUG Antiplatelet_be Agents_be --_be OTHER_DRUG ,_af Streptokinase_af ,_af alone_af combination_af antiplatelet_af agents_af DRUG ,_af may_af cause_af bleeding_af complications_af ._af"
4026,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Anticoagulants,Streptokinase,No interaction,"Use_bf DRUG Antiplatelet_be Agents_be --_be Streptase_be ,_be OTHER_DRUG ,_af alone_af combination_af antiplatelet_af agents_af DRUG ,_af may_af cause_af bleeding_af complications_af ._af"
4027,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Anticoagulants,antiplatelet agents,No interaction,"Use_bf DRUG Antiplatelet_be Agents_be --_be Streptase_be ,_be Streptokinase_be ,_be alone_be combination_be antiplatelet_be agents_be DRUG ,_af may_af cause_af bleeding_af complications_af ._af"
4028,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Anticoagulants,anticoagulants,No interaction,"Use_bf DRUG Antiplatelet_be Agents_be --_be Streptase_be ,_be Streptokinase_be ,_be alone_be combination_be antiplatelet_be agents_be DRUG ,_af may_af cause_af bleeding_af complications_af ._af"
4029,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Antiplatelet Agents,Streptase,No interaction,"Use_bf Anticoagulants_bf Antiplatelet_bf Agents_bf --_bf OTHER_DRUG ,_be Streptokinase_be ,_be alone_be combination_be antiplatelet_be agents_be anticoagulants_be ,_be may_be cause_be bleeding_be complications_be ._be"
4030,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Antiplatelet Agents,Streptokinase,No interaction,"Use_bf Anticoagulants_bf Antiplatelet_bf Agents_bf --_bf Streptase_bf ,_bf OTHER_DRUG ,_be alone_be combination_be antiplatelet_be agents_be anticoagulants_be ,_be may_be cause_be bleeding_be complications_be ._be"
4031,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Antiplatelet Agents,antiplatelet agents,No interaction,"Use_bf Anticoagulants_bf Antiplatelet_bf Agents_bf --_bf Streptase_bf ,_bf Streptokinase_bf ,_bf alone_bf combination_bf antiplatelet_bf agents_bf anticoagulants_bf ,_bf may_bf cause_bf bleeding_bf complications_bf ._bf"
4032,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Antiplatelet Agents,anticoagulants,No interaction,"Use_bf OTHER_DRUG Antiplatelet_be Agents_be --_be Streptase_be ,_be Streptokinase_be ,_be alone_be combination_be antiplatelet_be agents_be OTHER_DRUG ,_af may_af cause_af bleeding_af complications_af ._af"
4033,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptase,Streptokinase,No interaction,"Use_bf Anticoagulants_bf Antiplatelet_bf Agents_bf --_bf DRUG ,_be OTHER_DRUG ,_af alone_af combination_af antiplatelet_af agents_af anticoagulants_af ,_af may_af cause_af bleeding_af complications_af ._af"
4034,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptase,antiplatelet agents,effect,"Use_bf Anticoagulants_bf Antiplatelet_bf Agents_bf --_bf DRUG ,_be Streptokinase_be ,_be alone_be combination_be antiplatelet_be agents_be anticoagulants_be ,_be may_be cause_be bleeding_be complications_be ._be"
4035,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptase,anticoagulants,effect,"Use_bf OTHER_DRUG Antiplatelet_be Agents_be --_be DRUG ,_af Streptokinase_af ,_af alone_af combination_af antiplatelet_af agents_af OTHER_DRUG ,_af may_af cause_af bleeding_af complications_af ._af"
4036,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptokinase,antiplatelet agents,effect,"Use_bf Anticoagulants_bf Antiplatelet_bf Agents_bf --_bf Streptase_bf ,_bf DRUG ,_be alone_be combination_be antiplatelet_be agents_be anticoagulants_be ,_be may_be cause_be bleeding_be complications_be ._be"
4037,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",Streptokinase,anticoagulants,effect,"Use_bf OTHER_DRUG Antiplatelet_be Agents_be --_be Streptase_be ,_be DRUG ,_af alone_af combination_af antiplatelet_af agents_af OTHER_DRUG ,_af may_af cause_af bleeding_af complications_af ._af"
4038,"Use of Anticoagulants and Antiplatelet Agents -- Streptase, Streptokinase, alone or in combination with antiplatelet agents and anticoagulants, may cause bleeding complications. ",antiplatelet agents,anticoagulants,No interaction,"Use_bf OTHER_DRUG Antiplatelet_be Agents_be --_be Streptase_be ,_be Streptokinase_be ,_be alone_be combination_be antiplatelet_be agents_be OTHER_DRUG ,_af may_af cause_af bleeding_af complications_af ._af"
4039,"In the treatment of acute MI, aspirin, when not otherwise contraindicated, should be administered with Streptokinase ( see below ). ",aspirin,Streptokinase,No interaction,"In_bf treatment_bf acute_bf MI_bf ,_bf DRUG ,_be otherwise_be contraindicated_be ,_be administered_be OTHER_DRUG (_af see_af )_af ._af"
4040,"Anticoagulation and Antiplatelets After Treatment for Myocardial Infarction -- In the treatment of acute myocardial infarction, the use of aspirin has been shown to reduce the incidence of reinfarction and stroke. ",Antiplatelets,aspirin,No interaction,"Anticoagulation_bf DRUG After_be Treatment_be Myocardial_be Infarction_be --_be In_be treatment_be acute_be myocardial_be infarction_be ,_be use_be OTHER_DRUG shown_af reduce_af incidence_af reinfarction_af stroke_af ._af"
4041,"The addition of aspirin to Streptokinase causes a minimal increase in the risk of minor bleeding (3.9% vs. 3.1%), but does not appear to increase the incidence of major bleeding (see",aspirin,Streptokinase,effect,"The_bf addition_bf DRUG OTHER_DRUG causes_af minimal_af increase_af risk_af minor_af bleeding_af (3_af ._af 9%_af vs_af ._af 3_af ._af 1%)_af ,_af appear_af increase_af incidence_af major_af bleeding_af (see_af"
4042,Streptozocin has been reported to prolong the elimination half-life of doxorubicin and may lead to severe bone marrow suppression; ,Streptozocin,doxorubicin,mechanism,DRUG reported_be prolong_be elimination_be half-life_be OTHER_DRUG may_af lead_af severe_af bone_af marrow_af suppression;_af
4043,a reduction of the doxorubicin dosage should be considered in patients receiving ZANOSAR concurrently. ,doxorubicin,ZANOSAR,advise,reduction_bf DRUG dosage_be considered_be patients_be receiving_be OTHER_DRUG concurrently_af ._af
4044,The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    ,streptozocin,phenytoin,effect,The_bf concurrent_bf use_bf DRUG OTHER_DRUG reported_af one_af case_af result_af reduced_af DRUG cytotoxicity_af ._af
4045,The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    ,streptozocin,streptozocin,No interaction,The_bf concurrent_bf use_bf DRUG phenytoin_be reported_be one_be case_be result_be reduced_be DRUG cytotoxicity_af ._af
4046,The concurrent use of streptozocin and phenytoin has been reported in one case to result in reduced streptozocin cytotoxicity.    ,phenytoin,streptozocin,No interaction,The_bf concurrent_bf use_bf OTHER_DRUG DRUG reported_af one_af case_af result_af reduced_af OTHER_DRUG cytotoxicity_af ._af
4047,CHEMET is not known to interact with other drugs including iron supplements; ,CHEMET,iron,No interaction,DRUG known_be interact_be drugs_be including_be OTHER_DRUG supplements;_af
4048,"Concomitant administration of CHEMET with other chelation therapy, such as CaNa 2 EDTA is not recommended. ",CHEMET,CaNa 2 EDTA,advise,"Concomitant_bf administration_bf DRUG chelation_be therapy_be ,_be CaNa_be 2_be EDTA_be recommended_be ._be"
4049,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,barbiturates,effect,"DRUG may_be increase_be effects_be OTHER_DRUG ,_af tolbutamide_af ,_af uricosurics_af ._af"
4050,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,tolbutamide,effect,"DRUG may_be increase_be effects_be barbiturates_be ,_be OTHER_DRUG ,_af uricosurics_af ._af"
4051,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfamethizole,uricosurics,effect,"DRUG may_be increase_be effects_be barbiturates_be ,_be tolbutamide_be ,_be OTHER_DRUG ._af"
4052,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",barbiturates,tolbutamide,No interaction,"Sulfamethizole_bf may_bf increase_bf effects_bf DRUG ,_be OTHER_DRUG ,_af uricosurics_af ._af"
4053,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",barbiturates,uricosurics,No interaction,"Sulfamethizole_bf may_bf increase_bf effects_bf DRUG ,_be tolbutamide_be ,_be OTHER_DRUG ._af"
4054,"Sulfamethizole may increase the effects of barbiturates, tolbutamide, and uricosurics. ",tolbutamide,uricosurics,No interaction,"Sulfamethizole_bf may_bf increase_bf effects_bf barbiturates_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
4055,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,cyclosporine,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be OTHER_DRUG (increased_af nephrotoxicity)_af ,_af sulfonylurea_af agents_af (increased_af hypoglycemic_af response)_af ,_af warfarin_af (increased_af anticoagulant_af effect)_af ,_af methotrexate_af (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4056,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,sulfonylurea agents,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4057,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,warfarin,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be OTHER_DRUG (increased_af anticoagulant_af effect)_af ,_af methotrexate_af (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4058,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4059,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4060,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4061,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4062,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,sulfonylurea agents,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4063,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,warfarin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be OTHER_DRUG (increased_af anticoagulant_af effect)_af ,_af methotrexate_af (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4064,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4065,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4066,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4067,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4068,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",sulfonylurea agents,warfarin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf OTHER_DRUG (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4069,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",sulfonylurea agents,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf OTHER_DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4070,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",sulfonylurea agents,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf OTHER_DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4071,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",sulfonylurea agents,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf methotrexate_bf (decreased_bf renal_bf excretion_bf methotrexate)_bf ,_bf OTHER_DRUG (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4072,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",sulfonylurea agents,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf methotrexate_bf (decreased_bf renal_bf excretion_bf methotrexate)_bf ,_bf OTHER_DRUG (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4073,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",warfarin,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf DRUG (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4074,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",warfarin,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf DRUG (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4075,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",warfarin,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf DRUG (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4076,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",warfarin,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf DRUG (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4077,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",methotrexate,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4078,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",methotrexate,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4079,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",methotrexate,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4080,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",methotrexate,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4081,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",methotrexate,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4082,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",phenytoin,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf methotrexate_bf (decreased_bf renal_bf excretion_bf methotrexate)_bf ,_bf DRUG (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4083,"In elderly patients concurrently receiving certain diuretics, primarily thiazides, an increased incidence of thrombopenia with purpura has been reported. ",diuretics,thiazides,No interaction,"In_bf elderly_bf patients_bf concurrently_bf receiving_bf certain_bf DRUG ,_be primarily_be OTHER_DRUG ,_af increased_af incidence_af thrombopenia_af purpura_af reported_af ._af"
4084,It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ,sulfamethoxazole,anticoagulant,No interaction,It_bf reported_bf DRUG may_be prolong_be prothrombin_be time_be patients_be receiving_be OTHER_DRUG warfarin_af ._af
4085,It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ,sulfamethoxazole,warfarin,effect,It_bf reported_bf DRUG may_be prolong_be prothrombin_be time_be patients_be receiving_be anticoagulant_be OTHER_DRUG ._af
4086,It has been reported that sulfamethoxazole may prolong the prothrombin time in patients who are receiving the anticoagulant warfarin. ,anticoagulant,warfarin,No interaction,It_bf reported_bf sulfamethoxazole_bf may_bf prolong_bf prothrombin_bf time_bf patients_bf receiving_bf DRUG OTHER_DRUG ._af
4087,Sulfamethoxazole may inhibit the hepatic metabolism of phenytoin. ,Sulfamethoxazole,phenytoin,mechanism,DRUG may_be inhibit_be hepatic_be metabolism_be OTHER_DRUG ._af
4088,"At a 1.6-g dose, sulfamethoxazole produced a slight but significant increase in the half-life of phenytoin but did not produce a corresponding decrease in the metabolic clearance rate. ",sulfamethoxazole,phenytoin,mechanism,"At_bf 1_bf ._bf 6-g_bf dose_bf ,_bf DRUG produced_be slight_be significant_be increase_be half-life_be OTHER_DRUG produce_af corresponding_af decrease_af metabolic_af clearance_af rate_af ._af"
4089,"Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. ",Sulfonamides,methotrexate,mechanism,"DRUG also_be displace_be OTHER_DRUG plasma_af protein-binding_af sites_af ,_af thus_af increasing_af free_af OTHER_DRUG concentrations_af ._af"
4090,"Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. ",Sulfonamides,methotrexate,No interaction,"DRUG also_be displace_be OTHER_DRUG plasma_af protein-binding_af sites_af ,_af thus_af increasing_af free_af OTHER_DRUG concentrations_af ._af"
4091,"Sulfonamides can also displace methotrexate from plasma protein-binding sites, thus increasing free methotrexate concentrations. ",methotrexate,methotrexate,No interaction,"Sulfonamides_bf also_bf displace_bf DRUG plasma_be protein-binding_be sites_be ,_be thus_be increasing_be free_be DRUG concentrations_af ._af"
4092,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,barbiturates,effect,"DRUG may_be increase_be effects_be OTHER_DRUG ,_af tolbutamide_af ,_af uricosurics_af ._af"
4093,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,tolbutamide,effect,"DRUG may_be increase_be effects_be barbiturates_be ,_be OTHER_DRUG ,_af uricosurics_af ._af"
4094,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",Sulfoxone,uricosurics,effect,"DRUG may_be increase_be effects_be barbiturates_be ,_be tolbutamide_be ,_be OTHER_DRUG ._af"
4095,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",barbiturates,tolbutamide,No interaction,"Sulfoxone_bf may_bf increase_bf effects_bf DRUG ,_be OTHER_DRUG ,_af uricosurics_af ._af"
4096,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",barbiturates,uricosurics,No interaction,"Sulfoxone_bf may_bf increase_bf effects_bf DRUG ,_be tolbutamide_be ,_be OTHER_DRUG ._af"
4097,"Sulfoxone may increase the effects of barbiturates, tolbutamide, and uricosurics. ",tolbutamide,uricosurics,No interaction,"Sulfoxone_bf may_bf increase_bf effects_bf barbiturates_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
4098,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,cyclosporine,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be OTHER_DRUG (increased_af nephrotoxicity)_af ,_af sulfonylurea_af agents_af (increased_af hypoglycemic_af response)_af ,_af warfarin_af (increased_af anticoagulant_af effect)_af ,_af methotrexate_af (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4099,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,sulfonylurea agents,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4100,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,warfarin,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be OTHER_DRUG (increased_af anticoagulant_af effect)_af ,_af methotrexate_af (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4101,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4102,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4103,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4104,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",thiazides,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf DRUG (increased_be thrombocytopenia)_be ,_be cyclosporine_be (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4105,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,sulfonylurea agents,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4106,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,warfarin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be OTHER_DRUG (increased_af anticoagulant_af effect)_af ,_af methotrexate_af (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4107,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4108,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4109,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4110,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",cyclosporine,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf DRUG (increased_be nephrotoxicity)_be ,_be sulfonylurea_be agents_be (increased_be hypoglycemic_be response)_be ,_be warfarin_be (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4111,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",sulfonylurea agents,warfarin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf OTHER_DRUG (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4112,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",sulfonylurea agents,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf OTHER_DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4113,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",sulfonylurea agents,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf OTHER_DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4114,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",sulfonylurea agents,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf methotrexate_bf (decreased_bf renal_bf excretion_bf methotrexate)_bf ,_bf OTHER_DRUG (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4115,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",sulfonylurea agents,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf methotrexate_bf (decreased_bf renal_bf excretion_bf methotrexate)_bf ,_bf OTHER_DRUG (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4116,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",warfarin,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf DRUG (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4117,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",warfarin,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf DRUG (increased_be anticoagulant_be effect)_be ,_be OTHER_DRUG (decreased_af renal_af excretion_af methotrexate)_af ,_af phenytoin_af (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4118,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",warfarin,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf DRUG (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4119,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",warfarin,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf DRUG (increased_be anticoagulant_be effect)_be ,_be methotrexate_be (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4120,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",methotrexate,methotrexate,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be phenytoin_be (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4121,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",methotrexate,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4122,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",methotrexate,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4123,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",methotrexate,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4124,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",methotrexate,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf DRUG (decreased_be renal_be excretion_be methotrexate)_be ,_be OTHER_DRUG (decreased_af hepatic_af clearance_af phenytoin)_af ._af"
4125,"It may also interact with thiazides (increased thrombocytopenia), cyclosporine (increased nephrotoxicity), sulfonylurea agents (increased hypoglycemic response), warfarin (increased anticoagulant effect), methotrexate (decreased renal excretion of methotrexate), phenytoin (decreased hepatic clearance of phenytoin).",phenytoin,phenytoin,No interaction,"It_bf may_bf also_bf interact_bf thiazides_bf (increased_bf thrombocytopenia)_bf ,_bf cyclosporine_bf (increased_bf nephrotoxicity)_bf ,_bf sulfonylurea_bf agents_bf (increased_bf hypoglycemic_bf response)_bf ,_bf warfarin_bf (increased_bf anticoagulant_bf effect)_bf ,_bf methotrexate_bf (decreased_bf renal_bf excretion_bf methotrexate)_bf ,_bf DRUG (decreased_be hepatic_be clearance_be phenytoin)_be ._be"
4126,Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between FLOMAX capsules and other alpha-adrenergic blocking agents have not been determined. ,FLOMAX,alpha-adrenergic blocking agents,No interaction,Drug-Drug_bf Interactions:_bf The_bf pharmacokinetic_bf pharmacodynamic_bf interactions_bf DRUG capsules_be alpha-adrenergic_be blocking_be agents_be determined_be ._be
4127,"However, interactions may be expected and FLOMAX capsules should NOT be used in combination with other alpha-adrenergic blocking agents. ",FLOMAX,alpha-adrenergic blocking agents,advise,"However_bf ,_bf interactions_bf may_bf expected_bf DRUG capsules_be NOT_be used_be combination_be alpha-adrenergic_be blocking_be agents_be ._be"
4128,The pharmacokinetic interaction between cimetidine and FLOMAX capsules was investigated. ,cimetidine,FLOMAX,No interaction,The_bf pharmacokinetic_bf interaction_bf DRUG OTHER_DRUG capsules_af investigated_af ._af
4129,"Therefore, FLOMAX capsules should be used with caution in combination with cimetidine, particularly at doses higher than 0.4 mg. ",FLOMAX,cimetidine,advise,"Therefore_bf ,_bf DRUG capsules_be used_be caution_be combination_be OTHER_DRUG ,_af particularly_af doses_af higher_af 0_af ._af 4_af mg_af ._af"
4130,Results from limited in vitro and in vivo drug-drug interaction studies between tamsulosin HCI and warfarin are inconclusive. ,tamsulosin HCI,warfarin,No interaction,Results_bf limited_bf vitro_bf vivo_bf drug-drug_bf interaction_bf studies_bf tamsulosin_bf HCI_bf OTHER_DRUG inconclusive_be ._be
4131,"Therefore, caution should be exercised with concomitant administration of warfarin and FLOMAX capsules.        ",warfarin,FLOMAX,advise,"Therefore_bf ,_bf caution_bf exercised_bf concomitant_bf administration_bf DRUG OTHER_DRUG capsules_af ._af"
4132,Administration of valproic acid decreases oral clearance of temozolomide by about 5%. ,valproic acid,temozolomide,mechanism,Administration_bf valproic_bf acid_bf decreases_bf oral_bf clearance_bf OTHER_DRUG 5%_be ._be
4133,Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. ,TNKase,heparin,No interaction,Patients_bf studied_bf clinical_bf trials_bf DRUG routinely_be treated_be OTHER_DRUG aspirin_af ._af
4134,Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. ,TNKase,aspirin,No interaction,Patients_bf studied_bf clinical_bf trials_bf DRUG routinely_be treated_be heparin_be OTHER_DRUG ._af
4135,Patients studied in clinical trials of TNKase were routinely treated with heparin and aspirin. ,heparin,aspirin,No interaction,Patients_bf studied_bf clinical_bf trials_bf TNKase_bf routinely_bf treated_bf DRUG OTHER_DRUG ._af
4136,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",Anticoagulants,heparin,No interaction,"DRUG (such_be OTHER_DRUG vitamin_af K_af antagonists)_af drugs_af alter_af platelet_af function_af (such_af acetylsalicylic_af acid_af ,_af dipyridamole_af ,_af GP_af IIb/IIIa_af inhibitors)_af may_af increase_af risk_af bleeding_af administered_af prior_af ,_af ,_af TNKase_af therapy_af ._af"
4137,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",Anticoagulants,vitamin K antagonists,No interaction,"DRUG (such_be heparin_be vitamin_be K_be antagonists)_be drugs_be alter_be platelet_be function_be (such_be acetylsalicylic_be acid_be ,_be dipyridamole_be ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be TNKase_be therapy_be ._be"
4138,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",Anticoagulants,acetylsalicylic acid,No interaction,"DRUG (such_be heparin_be vitamin_be K_be antagonists)_be drugs_be alter_be platelet_be function_be (such_be acetylsalicylic_be acid_be ,_be dipyridamole_be ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be TNKase_be therapy_be ._be"
4139,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",Anticoagulants,dipyridamole,No interaction,"DRUG (such_be heparin_be vitamin_be K_be antagonists)_be drugs_be alter_be platelet_be function_be (such_be acetylsalicylic_be acid_be ,_be OTHER_DRUG ,_af GP_af IIb/IIIa_af inhibitors)_af may_af increase_af risk_af bleeding_af administered_af prior_af ,_af ,_af TNKase_af therapy_af ._af"
4140,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",Anticoagulants,TNKase,effect,"DRUG (such_be heparin_be vitamin_be K_be antagonists)_be drugs_be alter_be platelet_be function_be (such_be acetylsalicylic_be acid_be ,_be dipyridamole_be ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be OTHER_DRUG therapy_af ._af"
4141,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",heparin,vitamin K antagonists,No interaction,"Anticoagulants_bf (such_bf DRUG vitamin_be K_be antagonists)_be drugs_be alter_be platelet_be function_be (such_be acetylsalicylic_be acid_be ,_be dipyridamole_be ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be TNKase_be therapy_be ._be"
4142,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",heparin,acetylsalicylic acid,No interaction,"Anticoagulants_bf (such_bf DRUG vitamin_be K_be antagonists)_be drugs_be alter_be platelet_be function_be (such_be acetylsalicylic_be acid_be ,_be dipyridamole_be ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be TNKase_be therapy_be ._be"
4143,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",heparin,dipyridamole,No interaction,"Anticoagulants_bf (such_bf DRUG vitamin_be K_be antagonists)_be drugs_be alter_be platelet_be function_be (such_be acetylsalicylic_be acid_be ,_be OTHER_DRUG ,_af GP_af IIb/IIIa_af inhibitors)_af may_af increase_af risk_af bleeding_af administered_af prior_af ,_af ,_af TNKase_af therapy_af ._af"
4144,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",heparin,TNKase,effect,"Anticoagulants_bf (such_bf DRUG vitamin_be K_be antagonists)_be drugs_be alter_be platelet_be function_be (such_be acetylsalicylic_be acid_be ,_be dipyridamole_be ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be OTHER_DRUG therapy_af ._af"
4145,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",vitamin K antagonists,acetylsalicylic acid,No interaction,"Anticoagulants_bf (such_bf heparin_bf vitamin_bf K_bf antagonists)_bf drugs_bf alter_bf platelet_bf function_bf (such_bf acetylsalicylic_bf acid_bf ,_bf dipyridamole_bf ,_bf GP_bf IIb/IIIa_bf inhibitors)_bf may_bf increase_bf risk_bf bleeding_bf administered_bf prior_bf ,_bf ,_bf TNKase_bf therapy_bf ._bf"
4146,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",vitamin K antagonists,dipyridamole,No interaction,"Anticoagulants_bf (such_bf heparin_bf vitamin_bf K_bf antagonists)_bf drugs_bf alter_bf platelet_bf function_bf (such_bf acetylsalicylic_bf acid_bf ,_bf OTHER_DRUG ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be TNKase_be therapy_be ._be"
4147,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",vitamin K antagonists,TNKase,effect,"Anticoagulants_bf (such_bf heparin_bf vitamin_bf K_bf antagonists)_bf drugs_bf alter_bf platelet_bf function_bf (such_bf acetylsalicylic_bf acid_bf ,_bf dipyridamole_bf ,_bf GP_bf IIb/IIIa_bf inhibitors)_bf may_bf increase_bf risk_bf bleeding_bf administered_bf prior_bf ,_bf ,_bf OTHER_DRUG therapy_be ._be"
4148,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",acetylsalicylic acid,dipyridamole,No interaction,"Anticoagulants_bf (such_bf heparin_bf vitamin_bf K_bf antagonists)_bf drugs_bf alter_bf platelet_bf function_bf (such_bf acetylsalicylic_bf acid_bf ,_bf OTHER_DRUG ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be TNKase_be therapy_be ._be"
4149,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",acetylsalicylic acid,TNKase,effect,"Anticoagulants_bf (such_bf heparin_bf vitamin_bf K_bf antagonists)_bf drugs_bf alter_bf platelet_bf function_bf (such_bf acetylsalicylic_bf acid_bf ,_bf dipyridamole_bf ,_bf GP_bf IIb/IIIa_bf inhibitors)_bf may_bf increase_bf risk_bf bleeding_bf administered_bf prior_bf ,_bf ,_bf OTHER_DRUG therapy_be ._be"
4150,"Anticoagulants (such as heparin and vitamin K antagonists) and drugs that alter platelet function (such as acetylsalicylic acid, dipyridamole, and GP IIb/IIIa inhibitors) may increase the risk of bleeding if administered prior to, during, or after TNKase therapy. ",dipyridamole,TNKase,effect,"Anticoagulants_bf (such_bf heparin_bf vitamin_bf K_bf antagonists)_bf drugs_bf alter_bf platelet_bf function_bf (such_bf acetylsalicylic_bf acid_bf ,_bf DRUG ,_be GP_be IIb/IIIa_be inhibitors)_be may_be increase_be risk_be bleeding_be administered_be prior_be ,_be ,_be OTHER_DRUG therapy_af ._af"
4151,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",tolbutamide,sodium salicylate,No interaction,"In_bf study_bf 34_bf different_bf drugs_bf tested_bf ,_bf therapeutically_bf relevant_bf concentrations_bf DRUG ,_be sodium_be salicylate_be sulfamethizole_be displaced_be protein-bound_be teniposide_be fresh_be human_be serum_be small_be significant_be extent_be ._be"
4152,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",tolbutamide,sulfamethizole,No interaction,"In_bf study_bf 34_bf different_bf drugs_bf tested_bf ,_bf therapeutically_bf relevant_bf concentrations_bf DRUG ,_be sodium_be salicylate_be OTHER_DRUG displaced_af protein-bound_af teniposide_af fresh_af human_af serum_af small_af significant_af extent_af ._af"
4153,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",tolbutamide,teniposide,mechanism,"In_bf study_bf 34_bf different_bf drugs_bf tested_bf ,_bf therapeutically_bf relevant_bf concentrations_bf DRUG ,_be sodium_be salicylate_be sulfamethizole_be displaced_be protein-bound_be OTHER_DRUG fresh_af human_af serum_af small_af significant_af extent_af ._af"
4154,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",sodium salicylate,sulfamethizole,No interaction,"In_bf study_bf 34_bf different_bf drugs_bf tested_bf ,_bf therapeutically_bf relevant_bf concentrations_bf tolbutamide_bf ,_bf sodium_bf salicylate_bf OTHER_DRUG displaced_be protein-bound_be teniposide_be fresh_be human_be serum_be small_be significant_be extent_be ._be"
4155,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",sodium salicylate,teniposide,mechanism,"In_bf study_bf 34_bf different_bf drugs_bf tested_bf ,_bf therapeutically_bf relevant_bf concentrations_bf tolbutamide_bf ,_bf sodium_bf salicylate_bf sulfamethizole_bf displaced_bf protein-bound_bf OTHER_DRUG fresh_be human_be serum_be small_be significant_be extent_be ._be"
4156,"In a study in which 34 different drugs were tested, therapeutically relevant concentrations of tolbutamide, sodium salicylate and sulfamethizole displaced protein-bound teniposide in fresh human serum to a small but significant extent. ",sulfamethizole,teniposide,mechanism,"In_bf study_bf 34_bf different_bf drugs_bf tested_bf ,_bf therapeutically_bf relevant_bf concentrations_bf tolbutamide_bf ,_bf sodium_bf salicylate_bf DRUG displaced_be protein-bound_be OTHER_DRUG fresh_af human_af serum_af small_af significant_af extent_af ._af"
4157,"Therefore, caution should be used in administering VUMON (teniposide injection) to patients receiving these other agents. ",VUMON,teniposide,No interaction,"Therefore_bf ,_bf caution_bf used_bf administering_bf DRUG (teniposide_be injection)_be patients_be receiving_be agents_be ._be"
4158,There was no change in the plasma kinetics of teniposide when coadministered with methotrexate. ,teniposide,methotrexate,No interaction,There_bf change_bf plasma_bf kinetics_bf DRUG coadministered_be OTHER_DRUG ._af
4159,An increase in intracellular levels of methotrexate was observed in vitro in the presence of teniposide.,methotrexate,teniposide,mechanism,An_bf increase_bf intracellular_bf levels_bf DRUG observed_be vitro_be presence_be OTHER_DRUG ._af
4160,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",terbinafine,tolbutamide,No interaction,"In_bf vitro_bf studies_bf human_bf liver_bf microsomes_bf showed_bf DRUG inhibit_be metabolism_be OTHER_DRUG ,_af ethinylestradiol_af ,_af ethoxycoumarin_af ,_af cyclosporine_af ._af"
4161,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",terbinafine,ethinylestradiol,No interaction,"In_bf vitro_bf studies_bf human_bf liver_bf microsomes_bf showed_bf DRUG inhibit_be metabolism_be tolbutamide_be ,_be OTHER_DRUG ,_af ethoxycoumarin_af ,_af cyclosporine_af ._af"
4162,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",terbinafine,ethoxycoumarin,No interaction,"In_bf vitro_bf studies_bf human_bf liver_bf microsomes_bf showed_bf DRUG inhibit_be metabolism_be tolbutamide_be ,_be ethinylestradiol_be ,_be OTHER_DRUG ,_af cyclosporine_af ._af"
4163,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",terbinafine,cyclosporine,No interaction,"In_bf vitro_bf studies_bf human_bf liver_bf microsomes_bf showed_bf DRUG inhibit_be metabolism_be tolbutamide_be ,_be ethinylestradiol_be ,_be ethoxycoumarin_be ,_be OTHER_DRUG ._af"
4164,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",tolbutamide,ethinylestradiol,No interaction,"In_bf vitro_bf studies_bf human_bf liver_bf microsomes_bf showed_bf terbinafine_bf inhibit_bf metabolism_bf DRUG ,_be OTHER_DRUG ,_af ethoxycoumarin_af ,_af cyclosporine_af ._af"
4165,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",tolbutamide,ethoxycoumarin,No interaction,"In_bf vitro_bf studies_bf human_bf liver_bf microsomes_bf showed_bf terbinafine_bf inhibit_bf metabolism_bf DRUG ,_be ethinylestradiol_be ,_be OTHER_DRUG ,_af cyclosporine_af ._af"
4166,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",tolbutamide,cyclosporine,No interaction,"In_bf vitro_bf studies_bf human_bf liver_bf microsomes_bf showed_bf terbinafine_bf inhibit_bf metabolism_bf DRUG ,_be ethinylestradiol_be ,_be ethoxycoumarin_be ,_be OTHER_DRUG ._af"
4167,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",ethinylestradiol,ethoxycoumarin,No interaction,"In_bf vitro_bf studies_bf human_bf liver_bf microsomes_bf showed_bf terbinafine_bf inhibit_bf metabolism_bf tolbutamide_bf ,_bf DRUG ,_be OTHER_DRUG ,_af cyclosporine_af ._af"
4168,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",ethinylestradiol,cyclosporine,No interaction,"In_bf vitro_bf studies_bf human_bf liver_bf microsomes_bf showed_bf terbinafine_bf inhibit_bf metabolism_bf tolbutamide_bf ,_bf DRUG ,_be ethoxycoumarin_be ,_be OTHER_DRUG ._af"
4169,"In vitro studies with human liver microsomes showed that terbinafine does not inhibit the metabolism of tolbutamide, ethinylestradiol, ethoxycoumarin, and cyclosporine. ",ethoxycoumarin,cyclosporine,No interaction,"In_bf vitro_bf studies_bf human_bf liver_bf microsomes_bf showed_bf terbinafine_bf inhibit_bf metabolism_bf tolbutamide_bf ,_bf ethinylestradiol_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
4170,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",tricyclic antidepressants,selective serotonin reuptake inhibitors,No interaction,"This_bf may_bf clinical_bf relevance_bf compounds_bf predominantly_bf metabolized_bf enzyme_bf ,_bf tricyclic_bf antidepressants_bf ,_bf -blockers_bf ,_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf (MAO-Is)_bf Type_bf B_bf ,_bf narrow_bf therapeutic_bf window_bf ._bf"
4171,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",tricyclic antidepressants,SSRIs,No interaction,"This_bf may_bf clinical_bf relevance_bf compounds_bf predominantly_bf metabolized_bf enzyme_bf ,_bf tricyclic_bf antidepressants_bf ,_bf -blockers_bf ,_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf (MAO-Is)_bf Type_bf B_bf ,_bf narrow_bf therapeutic_bf window_bf ._bf"
4172,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",tricyclic antidepressants,monoamine oxidase inhibitors (MAO-Is) Type B,No interaction,"This_bf may_bf clinical_bf relevance_bf compounds_bf predominantly_bf metabolized_bf enzyme_bf ,_bf tricyclic_bf antidepressants_bf ,_bf -blockers_bf ,_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf (MAO-Is)_bf Type_bf B_bf ,_bf narrow_bf therapeutic_bf window_bf ._bf"
4173,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",selective serotonin reuptake inhibitors,SSRIs,No interaction,"This_bf may_bf clinical_bf relevance_bf compounds_bf predominantly_bf metabolized_bf enzyme_bf ,_bf tricyclic_bf antidepressants_bf ,_bf -blockers_bf ,_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf (MAO-Is)_bf Type_bf B_bf ,_bf narrow_bf therapeutic_bf window_bf ._bf"
4174,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",selective serotonin reuptake inhibitors,monoamine oxidase inhibitors (MAO-Is) Type B,No interaction,"This_bf may_bf clinical_bf relevance_bf compounds_bf predominantly_bf metabolized_bf enzyme_bf ,_bf tricyclic_bf antidepressants_bf ,_bf -blockers_bf ,_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf (MAO-Is)_bf Type_bf B_bf ,_bf narrow_bf therapeutic_bf window_bf ._bf"
4175,"This may be of clinical relevance for compounds predominantly metabolized by this enzyme, such as tricyclic antidepressants,    -blockers, selective serotonin reuptake inhibitors (SSRIs), and monoamine oxidase inhibitors (MAO-Is) Type B, if they have a narrow therapeutic window. ",SSRIs,monoamine oxidase inhibitors (MAO-Is) Type B,No interaction,"This_bf may_bf clinical_bf relevance_bf compounds_bf predominantly_bf metabolized_bf enzyme_bf ,_bf tricyclic_bf antidepressants_bf ,_bf -blockers_bf ,_bf selective_bf serotonin_bf reuptake_bf inhibitors_bf (SSRIs)_bf ,_bf monoamine_bf oxidase_bf inhibitors_bf (MAO-Is)_bf Type_bf B_bf ,_bf narrow_bf therapeutic_bf window_bf ._bf"
4176,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. ,terbinafine,antipyrine,No interaction,In_bf vivo_bf drug-drug_bf interaction_bf studies_bf conducted_bf normal_bf volunteer_bf subjects_bf showed_bf DRUG affect_be clearance_be OTHER_DRUG digoxin_af ._af
4177,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. ,terbinafine,digoxin,No interaction,In_bf vivo_bf drug-drug_bf interaction_bf studies_bf conducted_bf normal_bf volunteer_bf subjects_bf showed_bf DRUG affect_be clearance_be antipyrine_be OTHER_DRUG ._af
4178,In vivo drug-drug interaction studies conducted in normal volunteer subjects showed that terbinafine does not affect the clearance of antipyrine or digoxin. ,antipyrine,digoxin,No interaction,In_bf vivo_bf drug-drug_bf interaction_bf studies_bf conducted_bf normal_bf volunteer_bf subjects_bf showed_bf terbinafine_bf affect_bf clearance_bf DRUG OTHER_DRUG ._af
4179,Terbinafine decreases the clearance of caffeine by 19%. ,Terbinafine,caffeine,mechanism,DRUG decreases_be clearance_be OTHER_DRUG 19%_af ._af
4180,Terbinafine increases the clearance of cyclosporine by 15%. ,Terbinafine,cyclosporine,mechanism,DRUG increases_be clearance_be OTHER_DRUG 15%_af ._af
4181,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ",terbinafine,warfarin,effect,"There_bf spontaneous_bf reports_bf increase_bf decrease_bf prothrombin_bf times_bf patients_bf concomitantly_bf taking_bf oral_bf DRUG OTHER_DRUG ,_af however_af ,_af causal_af relationship_af LAMISIL_af Tablets_af changes_af established_af ._af"
4182,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ",terbinafine,LAMISIL,No interaction,"There_bf spontaneous_bf reports_bf increase_bf decrease_bf prothrombin_bf times_bf patients_bf concomitantly_bf taking_bf oral_bf DRUG warfarin_be ,_be however_be ,_be causal_be relationship_be OTHER_DRUG Tablets_af changes_af established_af ._af"
4183,"There have been spontaneous reports of increase or decrease in prothrombin times in patients concomitantly taking oral terbinafine and warfarin, however, a causal relationship between LAMISIL    Tablets and these changes has not been established. ",warfarin,LAMISIL,No interaction,"There_bf spontaneous_bf reports_bf increase_bf decrease_bf prothrombin_bf times_bf patients_bf concomitantly_bf taking_bf oral_bf terbinafine_bf DRUG ,_be however_be ,_be causal_be relationship_be OTHER_DRUG Tablets_af changes_af established_af ._af"
4184,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",Terbinafine,rifampin,mechanism,"DRUG clearance_be increased_be 100%_be OTHER_DRUG ,_af CyP450_af enzyme_af inducer_af ,_af decreased_af 33%_af cimetidine_af ,_af CyP450_af enzyme_af inhibitor_af ._af"
4185,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",Terbinafine,cimetidine,mechanism,"DRUG clearance_be increased_be 100%_be rifampin_be ,_be CyP450_be enzyme_be inducer_be ,_be decreased_be 33%_be OTHER_DRUG ,_af CyP450_af enzyme_af inhibitor_af ._af"
4186,"Terbinafine clearance is increased 100% by rifampin, a CyP450 enzyme inducer, and decreased 33% by cimetidine, a CyP450 enzyme inhibitor. ",rifampin,cimetidine,No interaction,"Terbinafine_bf clearance_bf increased_bf 100%_bf DRUG ,_be CyP450_be enzyme_be inducer_be ,_be decreased_be 33%_be OTHER_DRUG ,_af CyP450_af enzyme_af inhibitor_af ._af"
4187,Terbinafine clearance is unaffected by cyclosporine. ,Terbinafine,cyclosporine,No interaction,DRUG clearance_be unaffected_be OTHER_DRUG ._af
4188,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",contraceptives,hypoglycemics,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf DRUG ,_be hormone_be replacement_be therapies_be ,_be OTHER_DRUG ,_af theophyllines_af ,_af phenytoins_af ,_af thiazide_af diuretics_af ,_af beta_af blockers_af ,_af calcium_af channel_af blockers_af ._af"
4189,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",contraceptives,theophyllines,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf DRUG ,_be hormone_be replacement_be therapies_be ,_be hypoglycemics_be ,_be OTHER_DRUG ,_af phenytoins_af ,_af thiazide_af diuretics_af ,_af beta_af blockers_af ,_af calcium_af channel_af blockers_af ._af"
4190,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",contraceptives,phenytoins,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf DRUG ,_be hormone_be replacement_be therapies_be ,_be hypoglycemics_be ,_be theophyllines_be ,_be OTHER_DRUG ,_af thiazide_af diuretics_af ,_af beta_af blockers_af ,_af calcium_af channel_af blockers_af ._af"
4191,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",contraceptives,thiazide diuretics,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf DRUG ,_be hormone_be replacement_be therapies_be ,_be hypoglycemics_be ,_be theophyllines_be ,_be phenytoins_be ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4192,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",contraceptives,beta blockers,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf DRUG ,_be hormone_be replacement_be therapies_be ,_be hypoglycemics_be ,_be theophyllines_be ,_be phenytoins_be ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4193,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",contraceptives,calcium channel blockers,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf DRUG ,_be hormone_be replacement_be therapies_be ,_be hypoglycemics_be ,_be theophyllines_be ,_be phenytoins_be ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4194,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",hypoglycemics,theophyllines,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf DRUG ,_be OTHER_DRUG ,_af phenytoins_af ,_af thiazide_af diuretics_af ,_af beta_af blockers_af ,_af calcium_af channel_af blockers_af ._af"
4195,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",hypoglycemics,phenytoins,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf DRUG ,_be theophyllines_be ,_be OTHER_DRUG ,_af thiazide_af diuretics_af ,_af beta_af blockers_af ,_af calcium_af channel_af blockers_af ._af"
4196,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",hypoglycemics,thiazide diuretics,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf DRUG ,_be theophyllines_be ,_be phenytoins_be ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4197,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",hypoglycemics,beta blockers,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf DRUG ,_be theophyllines_be ,_be phenytoins_be ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4198,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",hypoglycemics,calcium channel blockers,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf DRUG ,_be theophyllines_be ,_be phenytoins_be ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4199,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",theophyllines,phenytoins,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf hypoglycemics_bf ,_bf DRUG ,_be OTHER_DRUG ,_af thiazide_af diuretics_af ,_af beta_af blockers_af ,_af calcium_af channel_af blockers_af ._af"
4200,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",theophyllines,thiazide diuretics,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf hypoglycemics_bf ,_bf DRUG ,_be phenytoins_be ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4201,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",theophyllines,beta blockers,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf hypoglycemics_bf ,_bf DRUG ,_be phenytoins_be ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4202,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",theophyllines,calcium channel blockers,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf hypoglycemics_bf ,_bf DRUG ,_be phenytoins_be ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4203,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",phenytoins,thiazide diuretics,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf hypoglycemics_bf ,_bf theophyllines_bf ,_bf DRUG ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4204,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",phenytoins,beta blockers,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf hypoglycemics_bf ,_bf theophyllines_bf ,_bf DRUG ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4205,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",phenytoins,calcium channel blockers,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf hypoglycemics_bf ,_bf theophyllines_bf ,_bf DRUG ,_be thiazide_be diuretics_be ,_be beta_be blockers_be ,_be calcium_be channel_be blockers_be ._be"
4206,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",thiazide diuretics,beta blockers,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf hypoglycemics_bf ,_bf theophyllines_bf ,_bf phenytoins_bf ,_bf thiazide_bf diuretics_bf ,_bf beta_bf blockers_bf ,_bf calcium_bf channel_bf blockers_bf ._bf"
4207,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",thiazide diuretics,calcium channel blockers,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf hypoglycemics_bf ,_bf theophyllines_bf ,_bf phenytoins_bf ,_bf thiazide_bf diuretics_bf ,_bf beta_bf blockers_bf ,_bf calcium_bf channel_bf blockers_bf ._bf"
4208,"There is no information available from adequate drug-drug interaction studies with the following classes of drugs: oral contraceptives, hormone replacement therapies, hypoglycemics, theophyllines, phenytoins, thiazide diuretics, beta blockers, and calcium channel blockers.",beta blockers,calcium channel blockers,No interaction,"There_bf information_bf available_bf adequate_bf drug-drug_bf interaction_bf studies_bf following_bf classes_bf drugs:_bf oral_bf contraceptives_bf ,_bf hormone_bf replacement_bf therapies_bf ,_bf hypoglycemics_bf ,_bf theophyllines_bf ,_bf phenytoins_bf ,_bf thiazide_bf diuretics_bf ,_bf beta_bf blockers_bf ,_bf calcium_bf channel_bf blockers_bf ._bf"
4209,"Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",Ketoconazole,ketoconazole,No interaction,"Ketoconazole:_bf Spontaneous_bf adverse_bf reaction_bf reports_bf patients_bf taking_bf concomitant_bf DRUG recommended_be doses_be terfenadine_be demonstrate_be QT_be interval_be prolongation_be rare_be serious_be cardiac_be events_be ,_be ._be g_be ._be"
4210,"Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",Ketoconazole,terfenadine,No interaction,"Ketoconazole:_bf Spontaneous_bf adverse_bf reaction_bf reports_bf patients_bf taking_bf concomitant_bf DRUG recommended_be doses_be OTHER_DRUG demonstrate_af QT_af interval_af prolongation_af rare_af serious_af cardiac_af events_af ,_af ._af g_af ._af"
4211,"Ketoconazole: Spontaneous adverse reaction reports of patients taking concomitant ketoconazole with recommended doses of terfenadine demonstrate QT interval prolongation and rare serious cardiac events, e.g. ",ketoconazole,terfenadine,effect,"Ketoconazole:_bf Spontaneous_bf adverse_bf reaction_bf reports_bf patients_bf taking_bf concomitant_bf DRUG recommended_be doses_be OTHER_DRUG demonstrate_af QT_af interval_af prolongation_af rare_af serious_af cardiac_af events_af ,_af ._af g_af ._af"
4212,"Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ",ketoconazole,terfenadine,mechanism,"Pharmacokinetic_bf data_bf indicate_bf DRUG markedly_be inhibits_be metabolism_be OTHER_DRUG ,_af resulting_af elevated_af plasma_af OTHER_DRUG levels_af ._af"
4213,"Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ",ketoconazole,terfenadine,No interaction,"Pharmacokinetic_bf data_bf indicate_bf DRUG markedly_be inhibits_be metabolism_be OTHER_DRUG ,_af resulting_af elevated_af plasma_af OTHER_DRUG levels_af ._af"
4214,"Pharmacokinetic data indicate that ketoconazole markedly inhibits the metabolism of terfenadine, resulting in elevated plasma terfenadine levels. ",terfenadine,terfenadine,No interaction,"Pharmacokinetic_bf data_bf indicate_bf ketoconazole_bf markedly_bf inhibits_bf metabolism_bf DRUG ,_be resulting_be elevated_be plasma_be DRUG levels_af ._af"
4215,Concomitant administration of ketoconazole and terfenadine is contraindicated. ,ketoconazole,terfenadine,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
4216,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,Itraconazole,terfenadine,No interaction,Itraconazole:_bf Torsades_bf de_bf pointes_bf elevated_bf parent_bf OTHER_DRUG levels_be reported_be concomitant_be use_be OTHER_DRUG DRUG clinical_af trials_af DRUG foreign_af post-marketing_af sources_af ._af
4217,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,Itraconazole,terfenadine,No interaction,Itraconazole:_bf Torsades_bf de_bf pointes_bf elevated_bf parent_bf OTHER_DRUG levels_be reported_be concomitant_be use_be OTHER_DRUG DRUG clinical_af trials_af DRUG foreign_af post-marketing_af sources_af ._af
4218,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,Itraconazole,itraconazole,No interaction,Itraconazole:_bf Torsades_bf de_bf pointes_bf elevated_bf parent_bf terfenadine_bf levels_bf reported_bf concomitant_bf use_bf terfenadine_bf DRUG clinical_be trials_be DRUG foreign_af post-marketing_af sources_af ._af
4219,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,Itraconazole,itraconazole,No interaction,Itraconazole:_bf Torsades_bf de_bf pointes_bf elevated_bf parent_bf terfenadine_bf levels_bf reported_bf concomitant_bf use_bf terfenadine_bf DRUG clinical_be trials_be DRUG foreign_af post-marketing_af sources_af ._af
4220,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,terfenadine,terfenadine,No interaction,Itraconazole:_bf Torsades_bf de_bf pointes_bf elevated_bf parent_bf DRUG levels_be reported_be concomitant_be use_be DRUG itraconazole_af clinical_af trials_af itraconazole_af foreign_af post-marketing_af sources_af ._af
4221,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,terfenadine,itraconazole,No interaction,Itraconazole:_bf Torsades_bf de_bf pointes_bf elevated_bf parent_bf DRUG levels_be reported_be concomitant_be use_be DRUG OTHER_DRUG clinical_af trials_af OTHER_DRUG foreign_af post-marketing_af sources_af ._af
4222,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,terfenadine,itraconazole,No interaction,Itraconazole:_bf Torsades_bf de_bf pointes_bf elevated_bf parent_bf DRUG levels_be reported_be concomitant_be use_be DRUG OTHER_DRUG clinical_af trials_af OTHER_DRUG foreign_af post-marketing_af sources_af ._af
4223,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,terfenadine,itraconazole,mechanism,Itraconazole:_bf Torsades_bf de_bf pointes_bf elevated_bf parent_bf DRUG levels_be reported_be concomitant_be use_be DRUG OTHER_DRUG clinical_af trials_af OTHER_DRUG foreign_af post-marketing_af sources_af ._af
4224,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,terfenadine,itraconazole,No interaction,Itraconazole:_bf Torsades_bf de_bf pointes_bf elevated_bf parent_bf DRUG levels_be reported_be concomitant_be use_be DRUG OTHER_DRUG clinical_af trials_af OTHER_DRUG foreign_af post-marketing_af sources_af ._af
4225,Itraconazole: Torsades de pointes and elevated parent terfenadine levels have been reported during concomitant use of terfenadine and itraconazole in clinical trials of itraconazole and from foreign post-marketing sources. ,itraconazole,itraconazole,No interaction,Itraconazole:_bf Torsades_bf de_bf pointes_bf elevated_bf parent_bf terfenadine_bf levels_bf reported_bf concomitant_bf use_bf terfenadine_bf DRUG clinical_be trials_be DRUG foreign_af post-marketing_af sources_af ._af
4226,Concomitant administration of itraconazole and terfenadine is contraindicated. ,itraconazole,terfenadine,advise,Concomitant_bf administration_bf DRUG OTHER_DRUG contraindicated_af ._af
4227,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",azole-type antifungal agents,fluconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf OTHER_DRUG ,_be metronidazole_be ,_be miconazole)_be ketoconazole_be ,_be itraconazole_be ,_be concomitant_be use_be products_be terfenadine_be recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4228,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",azole-type antifungal agents,metronidazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf OTHER_DRUG ,_be miconazole)_be ketoconazole_be ,_be itraconazole_be ,_be concomitant_be use_be products_be terfenadine_be recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4229,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",azole-type antifungal agents,miconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf concomitant_bf use_bf products_bf terfenadine_bf recommended_bf pending_bf full_bf examination_bf potential_bf interactions_bf ._bf"
4230,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",azole-type antifungal agents,ketoconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf OTHER_DRUG ,_be itraconazole_be ,_be concomitant_be use_be products_be terfenadine_be recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4231,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",azole-type antifungal agents,itraconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf ketoconazole_bf ,_bf OTHER_DRUG ,_be concomitant_be use_be products_be terfenadine_be recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4232,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",azole-type antifungal agents,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf concomitant_bf use_bf products_bf OTHER_DRUG recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4233,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",fluconazole,metronidazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf DRUG ,_be OTHER_DRUG ,_af miconazole)_af ketoconazole_af ,_af itraconazole_af ,_af concomitant_af use_af products_af terfenadine_af recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4234,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",fluconazole,miconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf DRUG ,_be metronidazole_be ,_be miconazole)_be ketoconazole_be ,_be itraconazole_be ,_be concomitant_be use_be products_be terfenadine_be recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4235,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",fluconazole,ketoconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf DRUG ,_be metronidazole_be ,_be miconazole)_be OTHER_DRUG ,_af itraconazole_af ,_af concomitant_af use_af products_af terfenadine_af recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4236,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",fluconazole,itraconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf DRUG ,_be metronidazole_be ,_be miconazole)_be ketoconazole_be ,_be OTHER_DRUG ,_af concomitant_af use_af products_af terfenadine_af recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4237,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",fluconazole,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf DRUG ,_be metronidazole_be ,_be miconazole)_be ketoconazole_be ,_be itraconazole_be ,_be concomitant_be use_be products_be OTHER_DRUG recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4238,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",metronidazole,miconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf DRUG ,_be miconazole)_be ketoconazole_be ,_be itraconazole_be ,_be concomitant_be use_be products_be terfenadine_be recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4239,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",metronidazole,ketoconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf DRUG ,_be miconazole)_be OTHER_DRUG ,_af itraconazole_af ,_af concomitant_af use_af products_af terfenadine_af recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4240,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",metronidazole,itraconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf DRUG ,_be miconazole)_be ketoconazole_be ,_be OTHER_DRUG ,_af concomitant_af use_af products_af terfenadine_af recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4241,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",metronidazole,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf DRUG ,_be miconazole)_be ketoconazole_be ,_be itraconazole_be ,_be concomitant_be use_be products_be OTHER_DRUG recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4242,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",miconazole,ketoconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf OTHER_DRUG ,_be itraconazole_be ,_be concomitant_be use_be products_be terfenadine_be recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4243,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",miconazole,itraconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf ketoconazole_bf ,_bf OTHER_DRUG ,_be concomitant_be use_be products_be terfenadine_be recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4244,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",miconazole,terfenadine,advise,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf ketoconazole_bf ,_bf itraconazole_bf ,_bf concomitant_bf use_bf products_bf OTHER_DRUG recommended_be pending_be full_be examination_be potential_be interactions_be ._be"
4245,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",ketoconazole,itraconazole,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf DRUG ,_be OTHER_DRUG ,_af concomitant_af use_af products_af terfenadine_af recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4246,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",ketoconazole,terfenadine,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf DRUG ,_be itraconazole_be ,_be concomitant_be use_be products_be OTHER_DRUG recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4247,"Due to the chemical similarity of other azole-type antifungal agents (including fluconazole, metronidazole, and miconazole) to ketoconazole, and itraconazole, concomitant use of these products with terfenadine is not recommended pending full examination of potential interactions. ",itraconazole,terfenadine,No interaction,"Due_bf chemical_bf similarity_bf azole-type_bf antifungal_bf agents_bf (including_bf fluconazole_bf ,_bf metronidazole_bf ,_bf miconazole)_bf ketoconazole_bf ,_bf DRUG ,_be concomitant_be use_be products_be OTHER_DRUG recommended_af pending_af full_af examination_af potential_af interactions_af ._af"
4248,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",Macrolides,erythromycin,No interaction,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf OTHER_DRUG clarithromycin_be exert_be effect_be terfenadine_be metabolism_be mechanism_be may_be similar_be ketoconazole_be ,_be lesser_be extent_be ._be"
4249,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",Macrolides,clarithromycin,No interaction,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf erythromycin_bf OTHER_DRUG exert_be effect_be terfenadine_be metabolism_be mechanism_be may_be similar_be ketoconazole_be ,_be lesser_be extent_be ._be"
4250,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",Macrolides,terfenadine,No interaction,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf erythromycin_bf clarithromycin_bf exert_bf effect_bf OTHER_DRUG metabolism_be mechanism_be may_be similar_be ketoconazole_be ,_be lesser_be extent_be ._be"
4251,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",Macrolides,ketoconazole,No interaction,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf erythromycin_bf clarithromycin_bf exert_bf effect_bf terfenadine_bf metabolism_bf mechanism_bf may_bf similar_bf OTHER_DRUG ,_be lesser_be extent_be ._be"
4252,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",erythromycin,clarithromycin,No interaction,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf DRUG OTHER_DRUG exert_af effect_af terfenadine_af metabolism_af mechanism_af may_af similar_af ketoconazole_af ,_af lesser_af extent_af ._af"
4253,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",erythromycin,terfenadine,mechanism,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf DRUG clarithromycin_be exert_be effect_be OTHER_DRUG metabolism_af mechanism_af may_af similar_af ketoconazole_af ,_af lesser_af extent_af ._af"
4254,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",erythromycin,ketoconazole,No interaction,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf DRUG clarithromycin_be exert_be effect_be terfenadine_be metabolism_be mechanism_be may_be similar_be OTHER_DRUG ,_af lesser_af extent_af ._af"
4255,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",clarithromycin,terfenadine,mechanism,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf erythromycin_bf DRUG exert_be effect_be OTHER_DRUG metabolism_af mechanism_af may_af similar_af ketoconazole_af ,_af lesser_af extent_af ._af"
4256,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",clarithromycin,ketoconazole,No interaction,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf erythromycin_bf DRUG exert_be effect_be terfenadine_be metabolism_be mechanism_be may_be similar_be OTHER_DRUG ,_af lesser_af extent_af ._af"
4257,"Macrolides: Clinical drug interaction studies indicate that erythromycin and clarithromycin can exert an effect on terfenadine metabolism by a mechanism which may be similar to that of ketoconazole, but to a lesser extent. ",terfenadine,ketoconazole,No interaction,"Macrolides:_bf Clinical_bf drug_bf interaction_bf studies_bf indicate_bf erythromycin_bf clarithromycin_bf exert_bf effect_bf DRUG metabolism_be mechanism_be may_be similar_be OTHER_DRUG ,_af lesser_af extent_af ._af"
4258,"A few spontaneous accounts of QT interval prolongation with ventricular arrhythmia including torsades de pointes, have been reported in patients receiving erythromycin or troleandomycin. ",erythromycin,troleandomycin,No interaction,"A_bf spontaneous_bf accounts_bf QT_bf interval_bf prolongation_bf ventricular_bf arrhythmia_bf including_bf torsades_bf de_bf pointes_bf ,_bf reported_bf patients_bf receiving_bf DRUG OTHER_DRUG ._af"
4259,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,clarithromycin,advise,"Concomitant_bf administration_bf DRUG OTHER_DRUG ,_af erythromycin_af ,_af troleandomycin_af contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4260,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,erythromycin,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be OTHER_DRUG ,_af troleandomycin_af contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4261,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,troleandomycin,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be OTHER_DRUG contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4262,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,terfenadine,No interaction,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4263,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,macrolide antibiotics,No interaction,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4264,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,azithromycin,No interaction,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be DRUG macrolide_af antibiotics_af ,_af including_af OTHER_DRUG ,_af recommended_af ._af"
4265,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",clarithromycin,erythromycin,No interaction,"Concomitant_bf administration_bf terfenadine_bf DRUG ,_be OTHER_DRUG ,_af troleandomycin_af contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af terfenadine_af macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4266,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",clarithromycin,troleandomycin,No interaction,"Concomitant_bf administration_bf terfenadine_bf DRUG ,_be erythromycin_be ,_be OTHER_DRUG contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af terfenadine_af macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4267,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",clarithromycin,terfenadine,No interaction,"Concomitant_bf administration_bf OTHER_DRUG DRUG ,_af erythromycin_af ,_af troleandomycin_af contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af OTHER_DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4268,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",clarithromycin,macrolide antibiotics,No interaction,"Concomitant_bf administration_bf terfenadine_bf DRUG ,_be erythromycin_be ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be terfenadine_be macrolide_be antibiotics_be ,_be including_be azithromycin_be ,_be recommended_be ._be"
4269,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",clarithromycin,azithromycin,No interaction,"Concomitant_bf administration_bf terfenadine_bf DRUG ,_be erythromycin_be ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be terfenadine_be macrolide_be antibiotics_be ,_be including_be OTHER_DRUG ,_af recommended_af ._af"
4270,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",erythromycin,troleandomycin,No interaction,"Concomitant_bf administration_bf terfenadine_bf clarithromycin_bf ,_bf DRUG ,_be OTHER_DRUG contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af terfenadine_af macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4271,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",erythromycin,terfenadine,No interaction,"Concomitant_bf administration_bf OTHER_DRUG clarithromycin_be ,_be DRUG ,_af troleandomycin_af contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af OTHER_DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4272,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",erythromycin,macrolide antibiotics,No interaction,"Concomitant_bf administration_bf terfenadine_bf clarithromycin_bf ,_bf DRUG ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be terfenadine_be macrolide_be antibiotics_be ,_be including_be azithromycin_be ,_be recommended_be ._be"
4273,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",erythromycin,azithromycin,No interaction,"Concomitant_bf administration_bf terfenadine_bf clarithromycin_bf ,_bf DRUG ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be terfenadine_be macrolide_be antibiotics_be ,_be including_be OTHER_DRUG ,_af recommended_af ._af"
4274,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",troleandomycin,terfenadine,No interaction,"Concomitant_bf administration_bf OTHER_DRUG clarithromycin_be ,_be erythromycin_be ,_be DRUG contraindicated:_af Pending_af full_af characterization_af potential_af interactions_af ,_af concomitant_af administration_af OTHER_DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4275,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",troleandomycin,macrolide antibiotics,No interaction,"Concomitant_bf administration_bf terfenadine_bf clarithromycin_bf ,_bf erythromycin_bf ,_bf DRUG contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be terfenadine_be macrolide_be antibiotics_be ,_be including_be azithromycin_be ,_be recommended_be ._be"
4276,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",troleandomycin,azithromycin,No interaction,"Concomitant_bf administration_bf terfenadine_bf clarithromycin_bf ,_bf erythromycin_bf ,_bf DRUG contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be terfenadine_be macrolide_be antibiotics_be ,_be including_be OTHER_DRUG ,_af recommended_af ._af"
4277,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,macrolide antibiotics,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be DRUG macrolide_af antibiotics_af ,_af including_af azithromycin_af ,_af recommended_af ._af"
4278,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",terfenadine,azithromycin,advise,"Concomitant_bf administration_bf DRUG clarithromycin_be ,_be erythromycin_be ,_be troleandomycin_be contraindicated:_be Pending_be full_be characterization_be potential_be interactions_be ,_be concomitant_be administration_be DRUG macrolide_af antibiotics_af ,_af including_af OTHER_DRUG ,_af recommended_af ._af"
4279,"Concomitant administration of terfenadine with clarithromycin, erythromycin, or troleandomycin is contraindicated: Pending full characterization of potential interactions, concomitant administration of terfenadine with other macrolide antibiotics, including azithromycin, is not recommended. ",macrolide antibiotics,azithromycin,No interaction,"Concomitant_bf administration_bf terfenadine_bf clarithromycin_bf ,_bf erythromycin_bf ,_bf troleandomycin_bf contraindicated:_bf Pending_bf full_bf characterization_bf potential_bf interactions_bf ,_bf concomitant_bf administration_bf terfenadine_bf macrolide_bf antibiotics_bf ,_bf including_bf OTHER_DRUG ,_be recommended_be ._be"
4280,Studies to evaluate potential interactions of terfenadine with azithromycin are in progress.,terfenadine,azithromycin,No interaction,Studies_bf evaluate_bf potential_bf interactions_bf DRUG OTHER_DRUG progress_af ._af
4281,"When administered concurrently, testolactone may increase the effects of oral anticoagulants; ",testolactone,anticoagulants,effect,"When_bf administered_bf concurrently_bf ,_bf DRUG may_be increase_be effects_be oral_be anticoagulants;_be"
4282,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",Thalidomide,barbiturates,effect,"DRUG reported_be enhance_be sedative_be activity_be OTHER_DRUG ,_af alcohol_af ,_af chlorpromazine_af ,_af reserpine_af ._af"
4283,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",Thalidomide,alcohol,No interaction,"DRUG reported_be enhance_be sedative_be activity_be barbiturates_be ,_be OTHER_DRUG ,_af chlorpromazine_af ,_af reserpine_af ._af"
4284,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",Thalidomide,chlorpromazine,No interaction,"DRUG reported_be enhance_be sedative_be activity_be barbiturates_be ,_be alcohol_be ,_be OTHER_DRUG ,_af reserpine_af ._af"
4285,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",Thalidomide,reserpine,No interaction,"DRUG reported_be enhance_be sedative_be activity_be barbiturates_be ,_be alcohol_be ,_be chlorpromazine_be ,_be OTHER_DRUG ._af"
4286,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",barbiturates,alcohol,No interaction,"Thalidomide_bf reported_bf enhance_bf sedative_bf activity_bf DRUG ,_be OTHER_DRUG ,_af chlorpromazine_af ,_af reserpine_af ._af"
4287,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",barbiturates,chlorpromazine,No interaction,"Thalidomide_bf reported_bf enhance_bf sedative_bf activity_bf DRUG ,_be alcohol_be ,_be OTHER_DRUG ,_af reserpine_af ._af"
4288,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",barbiturates,reserpine,No interaction,"Thalidomide_bf reported_bf enhance_bf sedative_bf activity_bf DRUG ,_be alcohol_be ,_be chlorpromazine_be ,_be OTHER_DRUG ._af"
4289,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",alcohol,chlorpromazine,No interaction,"Thalidomide_bf reported_bf enhance_bf sedative_bf activity_bf barbiturates_bf ,_bf DRUG ,_be OTHER_DRUG ,_af reserpine_af ._af"
4290,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",alcohol,reserpine,No interaction,"Thalidomide_bf reported_bf enhance_bf sedative_bf activity_bf barbiturates_bf ,_bf DRUG ,_be chlorpromazine_be ,_be OTHER_DRUG ._af"
4291,"Thalidomide has been reported to enhance the sedative activity of barbiturates, alcohol, chlorpromazine, and reserpine. ",chlorpromazine,reserpine,No interaction,"Thalidomide_bf reported_bf enhance_bf sedative_bf activity_bf barbiturates_bf ,_bf alcohol_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
4292,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",Contraceptives,norethindrone,No interaction,"Oral_bf Contraceptives:_bf In_bf 10_bf healthy_bf women_bf ,_bf pharmacokinetic_bf profiles_bf OTHER_DRUG ethinyl_be estradiol_be following_be administration_be single_be dose_be containing_be 1_be ._be 0_be mg_be OTHER_DRUG acetate_af 75_af g_af ethinyl_af estradiol_af studied_af ._af"
4293,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",Contraceptives,ethinyl estradiol,No interaction,"Oral_bf Contraceptives:_bf In_bf 10_bf healthy_bf women_bf ,_bf pharmacokinetic_bf profiles_bf norethindrone_bf ethinyl_bf estradiol_bf following_bf administration_bf single_bf dose_bf containing_bf 1_bf ._bf 0_bf mg_bf norethindrone_bf acetate_bf 75_bf g_bf ethinyl_bf estradiol_bf studied_bf ._bf"
4294,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",Contraceptives,norethindrone acetate,No interaction,"Oral_bf Contraceptives:_bf In_bf 10_bf healthy_bf women_bf ,_bf pharmacokinetic_bf profiles_bf norethindrone_bf ethinyl_bf estradiol_bf following_bf administration_bf single_bf dose_bf containing_bf 1_bf ._bf 0_bf mg_bf norethindrone_bf acetate_bf 75_bf g_bf ethinyl_bf estradiol_bf studied_bf ._bf"
4295,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",Contraceptives,ethinyl estradiol,No interaction,"Oral_bf Contraceptives:_bf In_bf 10_bf healthy_bf women_bf ,_bf pharmacokinetic_bf profiles_bf norethindrone_bf ethinyl_bf estradiol_bf following_bf administration_bf single_bf dose_bf containing_bf 1_bf ._bf 0_bf mg_bf norethindrone_bf acetate_bf 75_bf g_bf ethinyl_bf estradiol_bf studied_bf ._bf"
4296,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",norethindrone,ethinyl estradiol,No interaction,"Oral_bf Contraceptives:_bf In_bf 10_bf healthy_bf women_bf ,_bf pharmacokinetic_bf profiles_bf DRUG ethinyl_be estradiol_be following_be administration_be single_be dose_be containing_be 1_be ._be 0_be mg_be DRUG acetate_af 75_af g_af ethinyl_af estradiol_af studied_af ._af"
4297,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",norethindrone,norethindrone acetate,No interaction,"Oral_bf Contraceptives:_bf In_bf 10_bf healthy_bf women_bf ,_bf pharmacokinetic_bf profiles_bf DRUG ethinyl_be estradiol_be following_be administration_be single_be dose_be containing_be 1_be ._be 0_be mg_be DRUG acetate_af 75_af g_af ethinyl_af estradiol_af studied_af ._af"
4298,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",norethindrone,ethinyl estradiol,No interaction,"Oral_bf Contraceptives:_bf In_bf 10_bf healthy_bf women_bf ,_bf pharmacokinetic_bf profiles_bf DRUG ethinyl_be estradiol_be following_be administration_be single_be dose_be containing_be 1_be ._be 0_be mg_be DRUG acetate_af 75_af g_af ethinyl_af estradiol_af studied_af ._af"
4299,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",ethinyl estradiol,norethindrone acetate,No interaction,"Oral_bf Contraceptives:_bf In_bf 10_bf healthy_bf women_bf ,_bf pharmacokinetic_bf profiles_bf norethindrone_bf ethinyl_bf estradiol_bf following_bf administration_bf single_bf dose_bf containing_bf 1_bf ._bf 0_bf mg_bf norethindrone_bf acetate_bf 75_bf g_bf ethinyl_bf estradiol_bf studied_bf ._bf"
4300,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",ethinyl estradiol,ethinyl estradiol,No interaction,"Oral_bf Contraceptives:_bf In_bf 10_bf healthy_bf women_bf ,_bf pharmacokinetic_bf profiles_bf norethindrone_bf ethinyl_bf estradiol_bf following_bf administration_bf single_bf dose_bf containing_bf 1_bf ._bf 0_bf mg_bf norethindrone_bf acetate_bf 75_bf g_bf ethinyl_bf estradiol_bf studied_bf ._bf"
4301,"Oral Contraceptives: In 10 healthy women, the pharmacokinetic profiles of norethindrone and ethinyl estradiol following administration of a single dose containing 1.0 mg of norethindrone acetate and 75    g of ethinyl estradiol were studied. ",norethindrone acetate,ethinyl estradiol,No interaction,"Oral_bf Contraceptives:_bf In_bf 10_bf healthy_bf women_bf ,_bf pharmacokinetic_bf profiles_bf norethindrone_bf ethinyl_bf estradiol_bf following_bf administration_bf single_bf dose_bf containing_bf 1_bf ._bf 0_bf mg_bf norethindrone_bf acetate_bf 75_bf g_bf ethinyl_bf estradiol_bf studied_bf ._bf"
4302,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Thalidomide,Hormonal Contraceptives,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf rifabutin_bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf certain_bf herbal_bf supplements_bf St_bf ._bf"
4303,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Thalidomide,HIV-protease inhibitors,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf rifabutin_bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf certain_bf herbal_bf supplements_bf St_bf ._bf"
4304,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Thalidomide,griseofulvin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf OTHER_DRUG ,_be modafinil_be ,_be penicillins_be ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4305,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Thalidomide,modafinil,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf OTHER_DRUG ,_be penicillins_be ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4306,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Thalidomide,penicillins,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf OTHER_DRUG ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4307,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Thalidomide,rifampin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf OTHER_DRUG ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4308,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Thalidomide,rifabutin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf OTHER_DRUG ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4309,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Thalidomide,phenytoin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf rifabutin_bf ,_bf OTHER_DRUG ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4310,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Thalidomide,carbamazepine,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf rifabutin_bf ,_bf phenytoin_bf ,_bf OTHER_DRUG ,_be certain_be herbal_be supplements_be St_be ._be"
4311,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Hormonal Contraceptives,HIV-protease inhibitors,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf rifabutin_bf ,_bf phenytoin_bf ,_bf carbamazepine_bf ,_bf certain_bf herbal_bf supplements_bf St_bf ._bf"
4312,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Hormonal Contraceptives,griseofulvin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf OTHER_DRUG ,_be modafinil_be ,_be penicillins_be ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4313,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Hormonal Contraceptives,modafinil,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf OTHER_DRUG ,_be penicillins_be ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4314,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Hormonal Contraceptives,penicillins,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf OTHER_DRUG ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4315,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Hormonal Contraceptives,rifampin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf OTHER_DRUG ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4316,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Hormonal Contraceptives,rifabutin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf OTHER_DRUG ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4317,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Hormonal Contraceptives,phenytoin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf rifabutin_bf ,_bf OTHER_DRUG ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4318,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",Hormonal Contraceptives,carbamazepine,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf rifabutin_bf ,_bf phenytoin_bf ,_bf OTHER_DRUG ,_be certain_be herbal_be supplements_be St_be ._be"
4319,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",HIV-protease inhibitors,griseofulvin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf OTHER_DRUG ,_be modafinil_be ,_be penicillins_be ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4320,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",HIV-protease inhibitors,modafinil,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf OTHER_DRUG ,_be penicillins_be ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4321,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",HIV-protease inhibitors,penicillins,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf OTHER_DRUG ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4322,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",HIV-protease inhibitors,rifampin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf OTHER_DRUG ,_be rifabutin_be ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4323,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",HIV-protease inhibitors,rifabutin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf OTHER_DRUG ,_be phenytoin_be ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4324,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",HIV-protease inhibitors,phenytoin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf rifabutin_bf ,_bf OTHER_DRUG ,_be carbamazepine_be ,_be certain_be herbal_be supplements_be St_be ._be"
4325,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",HIV-protease inhibitors,carbamazepine,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf rifabutin_bf ,_bf phenytoin_bf ,_bf OTHER_DRUG ,_be certain_be herbal_be supplements_be St_be ._be"
4326,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",griseofulvin,modafinil,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf DRUG ,_be OTHER_DRUG ,_af penicillins_af ,_af rifampin_af ,_af rifabutin_af ,_af phenytoin_af ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4327,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",griseofulvin,penicillins,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf DRUG ,_be modafinil_be ,_be OTHER_DRUG ,_af rifampin_af ,_af rifabutin_af ,_af phenytoin_af ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4328,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",griseofulvin,rifampin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf DRUG ,_be modafinil_be ,_be penicillins_be ,_be OTHER_DRUG ,_af rifabutin_af ,_af phenytoin_af ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4329,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",griseofulvin,rifabutin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf DRUG ,_be modafinil_be ,_be penicillins_be ,_be rifampin_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4330,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",griseofulvin,phenytoin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf DRUG ,_be modafinil_be ,_be penicillins_be ,_be rifampin_be ,_be rifabutin_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4331,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",griseofulvin,carbamazepine,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf DRUG ,_be modafinil_be ,_be penicillins_be ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af certain_af herbal_af supplements_af St_af ._af"
4332,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",modafinil,penicillins,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af rifampin_af ,_af rifabutin_af ,_af phenytoin_af ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4333,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",modafinil,rifampin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf DRUG ,_be penicillins_be ,_be OTHER_DRUG ,_af rifabutin_af ,_af phenytoin_af ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4334,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",modafinil,rifabutin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf DRUG ,_be penicillins_be ,_be rifampin_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4335,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",modafinil,phenytoin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf DRUG ,_be penicillins_be ,_be rifampin_be ,_be rifabutin_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4336,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",modafinil,carbamazepine,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf DRUG ,_be penicillins_be ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af certain_af herbal_af supplements_af St_af ._af"
4337,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",penicillins,rifampin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf DRUG ,_be OTHER_DRUG ,_af rifabutin_af ,_af phenytoin_af ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4338,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",penicillins,rifabutin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf DRUG ,_be rifampin_be ,_be OTHER_DRUG ,_af phenytoin_af ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4339,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",penicillins,phenytoin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf DRUG ,_be rifampin_be ,_be rifabutin_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4340,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",penicillins,carbamazepine,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf DRUG ,_be rifampin_be ,_be rifabutin_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af certain_af herbal_af supplements_af St_af ._af"
4341,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",rifampin,rifabutin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf DRUG ,_be OTHER_DRUG ,_af phenytoin_af ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4342,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",rifampin,phenytoin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf DRUG ,_be rifabutin_be ,_be OTHER_DRUG ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4343,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",rifampin,carbamazepine,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf DRUG ,_be rifabutin_be ,_be phenytoin_be ,_be OTHER_DRUG ,_af certain_af herbal_af supplements_af St_af ._af"
4344,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",rifabutin,phenytoin,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af carbamazepine_af ,_af certain_af herbal_af supplements_af St_af ._af"
4345,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",rifabutin,carbamazepine,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf DRUG ,_be phenytoin_be ,_be OTHER_DRUG ,_af certain_af herbal_af supplements_af St_af ._af"
4346,"Important Non-Thalidomide Drug Interactions Drugs That Interfere with Hormonal Contraceptives: Concomitant use of HIV-protease inhibitors, griseofulvin, modafinil, penicillins, rifampin, rifabutin, phenytoin, carbamazepine, or certain herbal supplements such as St. ",phenytoin,carbamazepine,No interaction,"Important_bf Non-Thalidomide_bf Drug_bf Interactions_bf Drugs_bf That_bf Interfere_bf Hormonal_bf Contraceptives:_bf Concomitant_bf use_bf HIV-protease_bf inhibitors_bf ,_bf griseofulvin_bf ,_bf modafinil_bf ,_bf penicillins_bf ,_bf rifampin_bf ,_bf rifabutin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af certain_af herbal_af supplements_af St_af ._af"
4347,John's Wort with hormonal contraceptive agents may reduce the effectiveness of the contraception and up to one month after discontinuation of these concomitant therapies. ,John's Wort,hormonal contraceptive agents,effect,John's_bf Wort_bf hormonal_bf contraceptive_bf agents_bf may_bf reduce_bf effectiveness_bf contraception_bf one_bf month_bf discontinuation_bf concomitant_bf therapies_bf ._bf
4348,"Thiabendazole may compete with other drugs, such as theophylline, for sites of metabolism in the liver, thus elevating the serum levels of such compounds to potentially toxic levels. ",Thiabendazole,theophylline,mechanism,"DRUG may_be compete_be drugs_be ,_be OTHER_DRUG ,_af sites_af metabolism_af liver_af ,_af thus_af elevating_af serum_af levels_af compounds_af potentially_af toxic_af levels_af ._af"
4349,"Therefore, when concomitant use of thiabendazole and xanthine derivatives is anticipated, it may be necessary to monitor blood levels and/or reduce the dosage of such compounds. ",thiabendazole,xanthine derivatives,advise,"Therefore_bf ,_bf concomitant_bf use_bf DRUG xanthine_be derivatives_be anticipated_be ,_be may_be necessary_be monitor_be blood_be levels_be and/or_be reduce_be dosage_be compounds_be ._be"
4350,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Thiamine,No interaction,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf Stavudine_bf ,_bf Tricyclic_bf Antidepressants_bf"
4351,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Loop Diuretics,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf Stavudine_bf ,_bf Tricyclic_bf Antidepressants_bf"
4352,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Contraceptives,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf OTHER_DRUG ,_be Stavudine_be ,_be Tricyclic_be Antidepressants_be"
4353,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Stavudine,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf OTHER_DRUG ,_be Tricyclic_be Antidepressants_be"
4354,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Vitamin B1,Tricyclic Antidepressants,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf Stavudine_bf ,_bf Tricyclic_bf Antidepressants_bf"
4355,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Loop Diuretics,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf Stavudine_bf ,_bf Tricyclic_bf Antidepressants_bf"
4356,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Contraceptives,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf OTHER_DRUG ,_be Stavudine_be ,_be Tricyclic_be Antidepressants_be"
4357,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Stavudine,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf OTHER_DRUG ,_be Tricyclic_be Antidepressants_be"
4358,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Thiamine,Tricyclic Antidepressants,int,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf Stavudine_bf ,_bf Tricyclic_bf Antidepressants_bf"
4359,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Loop Diuretics,Contraceptives,No interaction,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf OTHER_DRUG ,_be Stavudine_be ,_be Tricyclic_be Antidepressants_be"
4360,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Loop Diuretics,Stavudine,No interaction,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf OTHER_DRUG ,_be Tricyclic_be Antidepressants_be"
4361,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Loop Diuretics,Tricyclic Antidepressants,No interaction,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf Stavudine_bf ,_bf Tricyclic_bf Antidepressants_bf"
4362,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Contraceptives,Stavudine,No interaction,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf DRUG ,_be OTHER_DRUG ,_af Tricyclic_af Antidepressants_af"
4363,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Contraceptives,Tricyclic Antidepressants,No interaction,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf DRUG ,_be Stavudine_be ,_be Tricyclic_be Antidepressants_be"
4364,"Interactions for Vitamin B1 (Thiamine):  Loop Diuretics, Oral Contraceptives, Stavudine, Tricyclic Antidepressants",Stavudine,Tricyclic Antidepressants,No interaction,"Interactions_bf Vitamin_bf B1_bf (Thiamine):_bf Loop_bf Diuretics_bf ,_bf Oral_bf Contraceptives_bf ,_bf DRUG ,_be Tricyclic_be Antidepressants_be"
4365,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,CNS depressants,effect,"DRUG capable_be potentiating_be CNS_be depressants_be (e_be ._be g_be ._be ,_be barbiturates_be ,_be anesthetics_be ,_be opiates_be ,_be alcohol_be ,_be etc_be ._be )_be"
4366,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,barbiturates,effect,"DRUG capable_be potentiating_be CNS_be depressants_be (e_be ._be g_be ._be ,_be OTHER_DRUG ,_af anesthetics_af ,_af opiates_af ,_af alcohol_af ,_af etc_af ._af )_af"
4367,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,anesthetics,effect,"DRUG capable_be potentiating_be CNS_be depressants_be (e_be ._be g_be ._be ,_be barbiturates_be ,_be OTHER_DRUG ,_af opiates_af ,_af alcohol_af ,_af etc_af ._af )_af"
4368,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,opiates,effect,"DRUG capable_be potentiating_be CNS_be depressants_be (e_be ._be g_be ._be ,_be barbiturates_be ,_be anesthetics_be ,_be OTHER_DRUG ,_af alcohol_af ,_af etc_af ._af )_af"
4369,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",Phenothiazines,alcohol,effect,"DRUG capable_be potentiating_be CNS_be depressants_be (e_be ._be g_be ._be ,_be barbiturates_be ,_be anesthetics_be ,_be opiates_be ,_be OTHER_DRUG ,_af etc_af ._af )_af"
4370,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",CNS depressants,barbiturates,No interaction,"Phenothiazines_bf capable_bf potentiating_bf CNS_bf depressants_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be anesthetics_be ,_be opiates_be ,_be alcohol_be ,_be etc_be ._be )_be"
4371,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",CNS depressants,anesthetics,No interaction,"Phenothiazines_bf capable_bf potentiating_bf CNS_bf depressants_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf OTHER_DRUG ,_be opiates_be ,_be alcohol_be ,_be etc_be ._be )_be"
4372,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",CNS depressants,opiates,No interaction,"Phenothiazines_bf capable_bf potentiating_bf CNS_bf depressants_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf anesthetics_bf ,_bf OTHER_DRUG ,_be alcohol_be ,_be etc_be ._be )_be"
4373,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",CNS depressants,alcohol,No interaction,"Phenothiazines_bf capable_bf potentiating_bf CNS_bf depressants_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf anesthetics_bf ,_bf opiates_bf ,_bf OTHER_DRUG ,_be etc_be ._be )_be"
4374,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",barbiturates,anesthetics,No interaction,"Phenothiazines_bf capable_bf potentiating_bf CNS_bf depressants_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af opiates_af ,_af alcohol_af ,_af etc_af ._af )_af"
4375,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",barbiturates,opiates,No interaction,"Phenothiazines_bf capable_bf potentiating_bf CNS_bf depressants_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be anesthetics_be ,_be OTHER_DRUG ,_af alcohol_af ,_af etc_af ._af )_af"
4376,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",barbiturates,alcohol,No interaction,"Phenothiazines_bf capable_bf potentiating_bf CNS_bf depressants_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be anesthetics_be ,_be opiates_be ,_be OTHER_DRUG ,_af etc_af ._af )_af"
4377,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",anesthetics,opiates,No interaction,"Phenothiazines_bf capable_bf potentiating_bf CNS_bf depressants_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf DRUG ,_be OTHER_DRUG ,_af alcohol_af ,_af etc_af ._af )_af"
4378,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",anesthetics,alcohol,No interaction,"Phenothiazines_bf capable_bf potentiating_bf CNS_bf depressants_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf DRUG ,_be opiates_be ,_be OTHER_DRUG ,_af etc_af ._af )_af"
4379,"Phenothiazines are capable of potentiating CNS depressants (e.g., barbiturates, anesthetics, opiates, alcohol, etc.) ",opiates,alcohol,No interaction,"Phenothiazines_bf capable_bf potentiating_bf CNS_bf depressants_bf (e_bf ._bf g_bf ._bf ,_bf barbiturates_bf ,_bf anesthetics_bf ,_bf DRUG ,_be OTHER_DRUG ,_af etc_af ._af )_af"
4380,as well as atropine and phosphorous insecticides.,atropine,phosphorous insecticides,No interaction,well_bf DRUG phosphorous_be insecticides_be ._be
4381,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,PURINETHOL,mercaptopurine,No interaction,There_bf usually_bf complete_bf cross-resistance_bf DRUG (mercaptopurine)_be TABLOID_be brand_be Thioguanine_be ._be
4382,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,PURINETHOL,TABLOID,effect,There_bf usually_bf complete_bf cross-resistance_bf DRUG (mercaptopurine)_be OTHER_DRUG brand_af Thioguanine_af ._af
4383,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,PURINETHOL,Thioguanine,effect,There_bf usually_bf complete_bf cross-resistance_bf DRUG (mercaptopurine)_be TABLOID_be brand_be OTHER_DRUG ._af
4384,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,mercaptopurine,TABLOID,effect,There_bf usually_bf complete_bf cross-resistance_bf PURINETHOL_bf (mercaptopurine)_bf OTHER_DRUG brand_be Thioguanine_be ._be
4385,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,mercaptopurine,Thioguanine,effect,There_bf usually_bf complete_bf cross-resistance_bf PURINETHOL_bf (mercaptopurine)_bf TABLOID_bf brand_bf OTHER_DRUG ._be
4386,There is usually complete cross-resistance between PURINETHOL (mercaptopurine) and TABLOID brand Thioguanine. ,TABLOID,Thioguanine,No interaction,There_bf usually_bf complete_bf cross-resistance_bf PURINETHOL_bf (mercaptopurine)_bf DRUG brand_be OTHER_DRUG ._af
4387,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",aminosalicylate derivatives,olsalazine,No interaction,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf OTHER_DRUG ,_be mesalazine_be ,_be sulphasalazine)_be inhibit_be TPMT_be enzyme_be ,_be administered_be caution_be patients_be receiving_be concurrent_be thioguanine_be therapy_be ._be"
4388,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",aminosalicylate derivatives,mesalazine,No interaction,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf olsalazine_bf ,_bf OTHER_DRUG ,_be sulphasalazine)_be inhibit_be TPMT_be enzyme_be ,_be administered_be caution_be patients_be receiving_be concurrent_be thioguanine_be therapy_be ._be"
4389,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",aminosalicylate derivatives,sulphasalazine,No interaction,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf olsalazine_bf ,_bf mesalazine_bf ,_bf sulphasalazine)_bf inhibit_bf TPMT_bf enzyme_bf ,_bf administered_bf caution_bf patients_bf receiving_bf concurrent_bf thioguanine_bf therapy_bf ._bf"
4390,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",aminosalicylate derivatives,thioguanine,mechanism,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf olsalazine_bf ,_bf mesalazine_bf ,_bf sulphasalazine)_bf inhibit_bf TPMT_bf enzyme_bf ,_bf administered_bf caution_bf patients_bf receiving_bf concurrent_bf OTHER_DRUG therapy_be ._be"
4391,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",olsalazine,mesalazine,No interaction,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be OTHER_DRUG ,_af sulphasalazine)_af inhibit_af TPMT_af enzyme_af ,_af administered_af caution_af patients_af receiving_af concurrent_af thioguanine_af therapy_af ._af"
4392,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",olsalazine,sulphasalazine,No interaction,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be mesalazine_be ,_be sulphasalazine)_be inhibit_be TPMT_be enzyme_be ,_be administered_be caution_be patients_be receiving_be concurrent_be thioguanine_be therapy_be ._be"
4393,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",olsalazine,thioguanine,mechanism,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf DRUG ,_be mesalazine_be ,_be sulphasalazine)_be inhibit_be TPMT_be enzyme_be ,_be administered_be caution_be patients_be receiving_be concurrent_be OTHER_DRUG therapy_af ._af"
4394,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",mesalazine,sulphasalazine,No interaction,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf olsalazine_bf ,_bf DRUG ,_be sulphasalazine)_be inhibit_be TPMT_be enzyme_be ,_be administered_be caution_be patients_be receiving_be concurrent_be thioguanine_be therapy_be ._be"
4395,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",mesalazine,thioguanine,mechanism,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf olsalazine_bf ,_bf DRUG ,_be sulphasalazine)_be inhibit_be TPMT_be enzyme_be ,_be administered_be caution_be patients_be receiving_be concurrent_be OTHER_DRUG therapy_af ._af"
4396,"As there is in vitro evidence that aminosalicylate derivatives (e.g., olsalazine, mesalazine, or sulphasalazine) inhibit the TPMT enzyme, they should be administered with caution to patients receiving concurrent thioguanine therapy.    ",sulphasalazine,thioguanine,mechanism,"As_bf vitro_bf evidence_bf aminosalicylate_bf derivatives_bf (e_bf ._bf g_bf ._bf ,_bf olsalazine_bf ,_bf mesalazine_bf ,_bf sulphasalazine)_bf inhibit_bf TPMT_bf enzyme_bf ,_bf administered_bf caution_bf patients_bf receiving_bf concurrent_bf OTHER_DRUG therapy_be ._be"
4397,Caution should be exercised when administering ZADAXIN therapy in combination with other immunomodulating drugs. ,ZADAXIN,immunomodulating drugs,advise,Caution_bf exercised_bf administering_bf DRUG therapy_be combination_be immunomodulating_be drugs_be ._be
4398,Prothrombin time or other suitable anticoagulation test should be monitored if tigecycline is administered with warfarin.   ,tigecycline,warfarin,advise,Prothrombin_bf time_bf suitable_bf anticoagulation_bf test_bf monitored_bf DRUG administered_be OTHER_DRUG ._af
4399,Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  ,antibacterial drugs,contraceptives,effect,Concurrent_bf use_bf antibacterial_bf drugs_bf oral_bf OTHER_DRUG may_be render_be oral_be OTHER_DRUG less_af effective_af ._af
4400,Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  ,antibacterial drugs,contraceptives,No interaction,Concurrent_bf use_bf antibacterial_bf drugs_bf oral_bf OTHER_DRUG may_be render_be oral_be OTHER_DRUG less_af effective_af ._af
4401,Concurrent use of antibacterial drugs with oral contraceptives may render oral contraceptives less effective.  ,contraceptives,contraceptives,No interaction,Concurrent_bf use_bf antibacterial_bf drugs_bf oral_bf DRUG may_be render_be oral_be DRUG less_af effective_af ._af
4402,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,calcium,mechanism,"The_bf bioavailability_bf DRUG decreased_be 80%_be OTHER_DRUG ,_af OTHER_DRUG DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af DRUG ._af"
4403,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,calcium,No interaction,"The_bf bioavailability_bf DRUG decreased_be 80%_be OTHER_DRUG ,_af OTHER_DRUG DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af DRUG ._af"
4404,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,SKELID,No interaction,"The_bf bioavailability_bf DRUG decreased_be 80%_be calcium_be ,_be calcium_be DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af DRUG ._af"
4405,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,aluminum,No interaction,"The_bf bioavailability_bf DRUG decreased_be 80%_be calcium_be ,_be calcium_be DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af DRUG ._af"
4406,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,magnesium,No interaction,"The_bf bioavailability_bf DRUG decreased_be 80%_be calcium_be ,_be calcium_be DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af DRUG ._af"
4407,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,antacids,No interaction,"The_bf bioavailability_bf DRUG decreased_be 80%_be calcium_be ,_be calcium_be DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af OTHER_DRUG ,_af administered_af 1_af hour_af DRUG ._af"
4408,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,SKELID,No interaction,"The_bf bioavailability_bf DRUG decreased_be 80%_be calcium_be ,_be calcium_be DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af DRUG ._af"
4409,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",calcium,calcium,No interaction,"The_bf bioavailability_bf SKELID_bf decreased_bf 80%_bf DRUG ,_be DRUG SKELID_af administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af SKELID_af ._af"
4410,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",calcium,SKELID,No interaction,"The_bf bioavailability_bf OTHER_DRUG decreased_be 80%_be DRUG ,_af DRUG OTHER_DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af OTHER_DRUG ._af"
4411,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",calcium,aluminum,No interaction,"The_bf bioavailability_bf SKELID_bf decreased_bf 80%_bf DRUG ,_be DRUG SKELID_af administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af SKELID_af ._af"
4412,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",calcium,magnesium,No interaction,"The_bf bioavailability_bf SKELID_bf decreased_bf 80%_bf DRUG ,_be DRUG SKELID_af administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af SKELID_af ._af"
4413,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",calcium,antacids,No interaction,"The_bf bioavailability_bf SKELID_bf decreased_bf 80%_bf DRUG ,_be DRUG SKELID_af administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af OTHER_DRUG ,_af administered_af 1_af hour_af SKELID_af ._af"
4414,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",calcium,SKELID,No interaction,"The_bf bioavailability_bf OTHER_DRUG decreased_be 80%_be DRUG ,_af DRUG OTHER_DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af OTHER_DRUG ._af"
4415,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",calcium,SKELID,No interaction,"The_bf bioavailability_bf OTHER_DRUG decreased_be 80%_be DRUG ,_af DRUG OTHER_DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af OTHER_DRUG ._af"
4416,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",calcium,aluminum,No interaction,"The_bf bioavailability_bf SKELID_bf decreased_bf 80%_bf DRUG ,_be DRUG SKELID_af administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af SKELID_af ._af"
4417,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",calcium,magnesium,No interaction,"The_bf bioavailability_bf SKELID_bf decreased_bf 80%_bf DRUG ,_be DRUG SKELID_af administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af SKELID_af ._af"
4418,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",calcium,antacids,No interaction,"The_bf bioavailability_bf SKELID_bf decreased_bf 80%_bf DRUG ,_be DRUG SKELID_af administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af OTHER_DRUG ,_af administered_af 1_af hour_af SKELID_af ._af"
4419,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",calcium,SKELID,No interaction,"The_bf bioavailability_bf OTHER_DRUG decreased_be 80%_be DRUG ,_af DRUG OTHER_DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af OTHER_DRUG ._af"
4420,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,aluminum,No interaction,"The_bf bioavailability_bf DRUG decreased_be 80%_be calcium_be ,_be calcium_be DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af DRUG ._af"
4421,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,magnesium,No interaction,"The_bf bioavailability_bf DRUG decreased_be 80%_be calcium_be ,_be calcium_be DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af DRUG ._af"
4422,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,antacids,No interaction,"The_bf bioavailability_bf DRUG decreased_be 80%_be calcium_be ,_be calcium_be DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af OTHER_DRUG ,_af administered_af 1_af hour_af DRUG ._af"
4423,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",SKELID,SKELID,No interaction,"The_bf bioavailability_bf DRUG decreased_be 80%_be calcium_be ,_be calcium_be DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af DRUG ._af"
4424,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",aluminum,magnesium,No interaction,"The_bf bioavailability_bf SKELID_bf decreased_bf 80%_bf calcium_bf ,_bf calcium_bf SKELID_bf administered_bf time_bf ,_bf 60%_bf aluminum-_bf magnesium-containing_bf antacids_bf ,_bf administered_bf 1_bf hour_bf SKELID_bf ._bf"
4425,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",aluminum,antacids,No interaction,"The_bf bioavailability_bf SKELID_bf decreased_bf 80%_bf calcium_bf ,_bf calcium_bf SKELID_bf administered_bf time_bf ,_bf 60%_bf aluminum-_bf magnesium-containing_bf OTHER_DRUG ,_be administered_be 1_be hour_be SKELID_be ._be"
4426,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",aluminum,SKELID,mechanism,"The_bf bioavailability_bf OTHER_DRUG decreased_be 80%_be calcium_be ,_be calcium_be OTHER_DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af OTHER_DRUG ._af"
4427,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",magnesium,antacids,No interaction,"The_bf bioavailability_bf SKELID_bf decreased_bf 80%_bf calcium_bf ,_bf calcium_bf SKELID_bf administered_bf time_bf ,_bf 60%_bf aluminum-_bf magnesium-containing_bf OTHER_DRUG ,_be administered_be 1_be hour_be SKELID_be ._be"
4428,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",magnesium,SKELID,mechanism,"The_bf bioavailability_bf OTHER_DRUG decreased_be 80%_be calcium_be ,_be calcium_be OTHER_DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af antacids_af ,_af administered_af 1_af hour_af OTHER_DRUG ._af"
4429,"The bioavailability of SKELID is decreased 80% by calcium, when calcium and SKELID are administered at the same time, and 60% by some aluminum- or magnesium-containing antacids, when administered 1 hour before SKELID. ",antacids,SKELID,No interaction,"The_bf bioavailability_bf OTHER_DRUG decreased_be 80%_be calcium_be ,_be calcium_be OTHER_DRUG administered_af time_af ,_af 60%_af aluminum-_af magnesium-containing_af DRUG ,_af administered_af 1_af hour_af OTHER_DRUG ._af"
4430,Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. ,Aspirin,SKELID,mechanism,DRUG may_be decrease_be bioavailability_be OTHER_DRUG 50%_af taken_af 2_af hours_af OTHER_DRUG ._af
4431,Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. ,Aspirin,SKELID,No interaction,DRUG may_be decrease_be bioavailability_be OTHER_DRUG 50%_af taken_af 2_af hours_af OTHER_DRUG ._af
4432,Aspirin may decrease bioavailability of SKELID by up to 50% when taken 2 hours after SKELID. ,SKELID,SKELID,No interaction,Aspirin_bf may_bf decrease_bf bioavailability_bf DRUG 50%_be taken_be 2_be hours_be DRUG ._af
4433,The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. ,SKELID,indomethacin,mechanism,The_bf bioavailability_bf DRUG increased_be 2-4_be fold_be OTHER_DRUG significantly_af altered_af coadministration_af diclofenac_af ._af
4434,The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. ,SKELID,diclofenac,No interaction,The_bf bioavailability_bf DRUG increased_be 2-4_be fold_be indomethacin_be significantly_be altered_be coadministration_be OTHER_DRUG ._af
4435,The bioavailability of SKELID is increased 2-4 fold by indomethacin but is not significantly altered by coadministration of diclofenac. ,indomethacin,diclofenac,No interaction,The_bf bioavailability_bf SKELID_bf increased_bf 2-4_bf fold_bf DRUG significantly_be altered_be coadministration_be OTHER_DRUG ._af
4436,The pharmacokinetic parameters of digoxin are not significantly modified by SKELID coadministration. ,digoxin,SKELID,No interaction,The_bf pharmacokinetic_bf parameters_bf DRUG significantly_be modified_be OTHER_DRUG coadministration_af ._af
4437,In vitro studies show that tiludronate does not displace warfarin from its binding site on protein.,tiludronate,warfarin,No interaction,In_bf vitro_bf studies_bf show_bf DRUG displace_be OTHER_DRUG binding_af site_af protein_af ._af
4438,"These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids. ",sympathomimetic bronchodilators,methylxanthines,No interaction,"These_bf include_bf sympathomimetic_bf bronchodilators_bf ,_bf OTHER_DRUG ,_be oral_be inhaled_be steroids_be ._be"
4439,"These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids. ",sympathomimetic bronchodilators,steroids,No interaction,"These_bf include_bf sympathomimetic_bf bronchodilators_bf ,_bf methylxanthines_bf ,_bf oral_bf inhaled_bf OTHER_DRUG ._be"
4440,"These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids. ",methylxanthines,steroids,No interaction,"These_bf include_bf sympathomimetic_bf bronchodilators_bf ,_bf DRUG ,_be oral_be inhaled_be OTHER_DRUG ._af"
4441,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",SPIRIVA,anticholinergic,advise,"However_bf ,_bf co_bf administration_bf DRUG OTHER_DRUG containing_af drugs_af (e_af ._af g_af ._af ,_af ipratropium)_af studied_af therefore_af recommended_af ._af"
4442,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",SPIRIVA,ipratropium,advise,"However_bf ,_bf co_bf administration_bf DRUG anticholinergic_be containing_be drugs_be (e_be ._be g_be ._be ,_be ipratropium)_be studied_be therefore_be recommended_be ._be"
4443,"However, the co   administration of SPIRIVA with other anticholinergic   containing drugs (e.g., ipratropium) has not been studied and is therefore not recommended.",anticholinergic,ipratropium,No interaction,"However_bf ,_bf co_bf administration_bf SPIRIVA_bf DRUG containing_be drugs_be (e_be ._be g_be ._be ,_be ipratropium)_be studied_be therefore_be recommended_be ._be"
4444,AGGRASTAT has been studied on a background of aspirin and heparin. ,AGGRASTAT,aspirin,No interaction,DRUG studied_be background_be OTHER_DRUG heparin_af ._af
4445,AGGRASTAT has been studied on a background of aspirin and heparin. ,AGGRASTAT,heparin,No interaction,DRUG studied_be background_be aspirin_be OTHER_DRUG ._af
4446,AGGRASTAT has been studied on a background of aspirin and heparin. ,aspirin,heparin,No interaction,AGGRASTAT_bf studied_bf background_bf DRUG OTHER_DRUG ._af
4447,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",AGGRASTAT,heparin,effect,"The_bf use_bf DRUG ,_be combination_be OTHER_DRUG aspirin_af ,_af associated_af increase_af bleeding_af compared_af OTHER_DRUG aspirin_af alone_af (see_af"
4448,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",AGGRASTAT,aspirin,effect,"The_bf use_bf DRUG ,_be combination_be heparin_be OTHER_DRUG ,_af associated_af increase_af bleeding_af compared_af heparin_af OTHER_DRUG alone_af (see_af"
4449,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",AGGRASTAT,heparin,No interaction,"The_bf use_bf DRUG ,_be combination_be OTHER_DRUG aspirin_af ,_af associated_af increase_af bleeding_af compared_af OTHER_DRUG aspirin_af alone_af (see_af"
4450,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",AGGRASTAT,aspirin,No interaction,"The_bf use_bf DRUG ,_be combination_be heparin_be OTHER_DRUG ,_af associated_af increase_af bleeding_af compared_af heparin_af OTHER_DRUG alone_af (see_af"
4451,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",heparin,aspirin,No interaction,"The_bf use_bf AGGRASTAT_bf ,_bf combination_bf DRUG OTHER_DRUG ,_af associated_af increase_af bleeding_af compared_af DRUG OTHER_DRUG alone_af (see_af"
4452,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",heparin,heparin,No interaction,"The_bf use_bf AGGRASTAT_bf ,_bf combination_bf DRUG aspirin_be ,_be associated_be increase_be bleeding_be compared_be DRUG aspirin_af alone_af (see_af"
4453,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",heparin,aspirin,No interaction,"The_bf use_bf AGGRASTAT_bf ,_bf combination_bf DRUG OTHER_DRUG ,_af associated_af increase_af bleeding_af compared_af DRUG OTHER_DRUG alone_af (see_af"
4454,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",aspirin,heparin,No interaction,"The_bf use_bf AGGRASTAT_bf ,_bf combination_bf OTHER_DRUG DRUG ,_af associated_af increase_af bleeding_af compared_af OTHER_DRUG DRUG alone_af (see_af"
4455,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",aspirin,aspirin,No interaction,"The_bf use_bf AGGRASTAT_bf ,_bf combination_bf heparin_bf DRUG ,_be associated_be increase_be bleeding_be compared_be heparin_be DRUG alone_af (see_af"
4456,"The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone (see",heparin,aspirin,No interaction,"The_bf use_bf AGGRASTAT_bf ,_bf combination_bf DRUG OTHER_DRUG ,_af associated_af increase_af bleeding_af compared_af DRUG OTHER_DRUG alone_af (see_af"
4457,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,TOBI,No interaction,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4458,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,dornase alfa,No interaction,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4459,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,PULMOZYME,No interaction,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4460,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,(beta)-agonists,No interaction,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af OTHER_DRUG ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4461,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,corticosteroids,No interaction,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af OTHER_DRUG ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4462,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,anti-pseudomonal antibiotics,No interaction,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4463,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,aminoglycosides,No interaction,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af OTHER_DRUG demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4464,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,dornase alfa,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4465,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,PULMOZYME,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4466,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,(beta)-agonists,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af OTHER_DRUG ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4467,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,corticosteroids,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af OTHER_DRUG ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4468,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,anti-pseudomonal antibiotics,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4469,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",TOBI,aminoglycosides,effect,"In_bf clinical_bf studies_bf DRUG ,_be patients_be taking_be DRUG concomitantly_af dornase_af alfa_af (PULMOZYME_af ,_af Genentech)_af ,_af (beta)-agonists_af ,_af inhaled_af corticosteroids_af ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af OTHER_DRUG demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4470,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",dornase alfa,PULMOZYME,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf (beta)-agonists_bf ,_bf inhaled_bf corticosteroids_bf ,_bf anti-pseudomonal_bf antibiotics_bf ,_bf parenteral_bf aminoglycosides_bf demonstrated_bf adverse_bf experience_bf profiles_bf similar_bf study_bf population_bf whole_bf ._bf"
4471,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",dornase alfa,(beta)-agonists,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf OTHER_DRUG ,_be inhaled_be corticosteroids_be ,_be anti-pseudomonal_be antibiotics_be ,_be parenteral_be aminoglycosides_be demonstrated_be adverse_be experience_be profiles_be similar_be study_be population_be whole_be ._be"
4472,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",dornase alfa,corticosteroids,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf (beta)-agonists_bf ,_bf inhaled_bf OTHER_DRUG ,_be anti-pseudomonal_be antibiotics_be ,_be parenteral_be aminoglycosides_be demonstrated_be adverse_be experience_be profiles_be similar_be study_be population_be whole_be ._be"
4473,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",dornase alfa,anti-pseudomonal antibiotics,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf (beta)-agonists_bf ,_bf inhaled_bf corticosteroids_bf ,_bf anti-pseudomonal_bf antibiotics_bf ,_bf parenteral_bf aminoglycosides_bf demonstrated_bf adverse_bf experience_bf profiles_bf similar_bf study_bf population_bf whole_bf ._bf"
4474,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",dornase alfa,aminoglycosides,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf (beta)-agonists_bf ,_bf inhaled_bf corticosteroids_bf ,_bf anti-pseudomonal_bf antibiotics_bf ,_bf parenteral_bf OTHER_DRUG demonstrated_be adverse_be experience_be profiles_be similar_be study_be population_be whole_be ._be"
4475,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",PULMOZYME,(beta)-agonists,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf OTHER_DRUG ,_be inhaled_be corticosteroids_be ,_be anti-pseudomonal_be antibiotics_be ,_be parenteral_be aminoglycosides_be demonstrated_be adverse_be experience_be profiles_be similar_be study_be population_be whole_be ._be"
4476,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",PULMOZYME,corticosteroids,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf (beta)-agonists_bf ,_bf inhaled_bf OTHER_DRUG ,_be anti-pseudomonal_be antibiotics_be ,_be parenteral_be aminoglycosides_be demonstrated_be adverse_be experience_be profiles_be similar_be study_be population_be whole_be ._be"
4477,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",PULMOZYME,anti-pseudomonal antibiotics,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf (beta)-agonists_bf ,_bf inhaled_bf corticosteroids_bf ,_bf anti-pseudomonal_bf antibiotics_bf ,_bf parenteral_bf aminoglycosides_bf demonstrated_bf adverse_bf experience_bf profiles_bf similar_bf study_bf population_bf whole_bf ._bf"
4478,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",PULMOZYME,aminoglycosides,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf (beta)-agonists_bf ,_bf inhaled_bf corticosteroids_bf ,_bf anti-pseudomonal_bf antibiotics_bf ,_bf parenteral_bf OTHER_DRUG demonstrated_be adverse_be experience_be profiles_be similar_be study_be population_be whole_be ._be"
4479,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",(beta)-agonists,corticosteroids,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf DRUG ,_be inhaled_be OTHER_DRUG ,_af anti-pseudomonal_af antibiotics_af ,_af parenteral_af aminoglycosides_af demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4480,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",(beta)-agonists,anti-pseudomonal antibiotics,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf DRUG ,_be inhaled_be corticosteroids_be ,_be anti-pseudomonal_be antibiotics_be ,_be parenteral_be aminoglycosides_be demonstrated_be adverse_be experience_be profiles_be similar_be study_be population_be whole_be ._be"
4481,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",(beta)-agonists,aminoglycosides,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf DRUG ,_be inhaled_be corticosteroids_be ,_be anti-pseudomonal_be antibiotics_be ,_be parenteral_be OTHER_DRUG demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4482,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",corticosteroids,anti-pseudomonal antibiotics,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf (beta)-agonists_bf ,_bf inhaled_bf DRUG ,_be anti-pseudomonal_be antibiotics_be ,_be parenteral_be aminoglycosides_be demonstrated_be adverse_be experience_be profiles_be similar_be study_be population_be whole_be ._be"
4483,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",corticosteroids,aminoglycosides,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf (beta)-agonists_bf ,_bf inhaled_bf DRUG ,_be anti-pseudomonal_be antibiotics_be ,_be parenteral_be OTHER_DRUG demonstrated_af adverse_af experience_af profiles_af similar_af study_af population_af whole_af ._af"
4484,"In clinical studies of TOBI, patients taking TOBI concomitantly with dornase alfa (PULMOZYME   , Genentech), (beta)-agonists, inhaled corticosteroids, other anti-pseudomonal antibiotics, or parenteral aminoglycosides demonstrated adverse experience profiles similar to the study population as a whole. ",anti-pseudomonal antibiotics,aminoglycosides,No interaction,"In_bf clinical_bf studies_bf TOBI_bf ,_bf patients_bf taking_bf TOBI_bf concomitantly_bf dornase_bf alfa_bf (PULMOZYME_bf ,_bf Genentech)_bf ,_bf (beta)-agonists_bf ,_bf inhaled_bf corticosteroids_bf ,_bf anti-pseudomonal_bf antibiotics_bf ,_bf parenteral_bf OTHER_DRUG demonstrated_be adverse_be experience_be profiles_be similar_be study_be population_be whole_be ._be"
4485,Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ,diuretics,aminoglycoside,effect,Some_bf DRUG enhance_be OTHER_DRUG toxicity_af altering_af antibiotic_af concentrations_af serum_af tissue_af ._af
4486,Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ,diuretics,antibiotic,No interaction,Some_bf DRUG enhance_be aminoglycoside_be toxicity_be altering_be OTHER_DRUG concentrations_af serum_af tissue_af ._af
4487,Some diuretics can enhance aminoglycoside toxicity by altering antibiotic concentrations in serum and tissue. ,aminoglycoside,antibiotic,No interaction,Some_bf diuretics_bf enhance_bf DRUG toxicity_be altering_be OTHER_DRUG concentrations_af serum_af tissue_af ._af
4488,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,ethacrynic acid,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be furosemide_be ,_be urea_be ,_be mannitol_be ._be"
4489,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,furosemide,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be OTHER_DRUG ,_af urea_af ,_af mannitol_af ._af"
4490,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,urea,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be furosemide_be ,_be OTHER_DRUG ,_af mannitol_af ._af"
4491,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",TOBI,mannitol,advise,"DRUG administered_be concomitantly_be ethacrynic_be acid_be ,_be furosemide_be ,_be urea_be ,_be OTHER_DRUG ._af"
4492,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",ethacrynic acid,furosemide,No interaction,"TOBI_bf administered_bf concomitantly_bf ethacrynic_bf acid_bf ,_bf OTHER_DRUG ,_be urea_be ,_be mannitol_be ._be"
4493,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",ethacrynic acid,urea,No interaction,"TOBI_bf administered_bf concomitantly_bf ethacrynic_bf acid_bf ,_bf furosemide_bf ,_bf OTHER_DRUG ,_be mannitol_be ._be"
4494,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",ethacrynic acid,mannitol,No interaction,"TOBI_bf administered_bf concomitantly_bf ethacrynic_bf acid_bf ,_bf furosemide_bf ,_bf urea_bf ,_bf OTHER_DRUG ._be"
4495,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",furosemide,urea,No interaction,"TOBI_bf administered_bf concomitantly_bf ethacrynic_bf acid_bf ,_bf DRUG ,_be OTHER_DRUG ,_af mannitol_af ._af"
4496,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",furosemide,mannitol,No interaction,"TOBI_bf administered_bf concomitantly_bf ethacrynic_bf acid_bf ,_bf DRUG ,_be urea_be ,_be OTHER_DRUG ._af"
4497,"TOBI should not be administered concomitantly with ethacrynic acid, furosemide, urea, or mannitol.",urea,mannitol,No interaction,"TOBI_bf administered_bf concomitantly_bf ethacrynic_bf acid_bf ,_bf furosemide_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
4498,"The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. ",warfarin,tolmetin,No interaction,"The_bf vitro_bf binding_bf DRUG human_be plasma_be proteins_be unaffected_be OTHER_DRUG ,_af OTHER_DRUG alter_af prothrombin_af time_af normal_af volunteers_af ._af"
4499,"The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. ",warfarin,tolmetin,No interaction,"The_bf vitro_bf binding_bf DRUG human_be plasma_be proteins_be unaffected_be OTHER_DRUG ,_af OTHER_DRUG alter_af prothrombin_af time_af normal_af volunteers_af ._af"
4500,"The in vitro binding of warfarin to human plasma proteins is unaffected by tolmetin, and tolmetin does not alter the prothrombin time of normal volunteers. ",tolmetin,tolmetin,No interaction,"The_bf vitro_bf binding_bf warfarin_bf human_bf plasma_bf proteins_bf unaffected_bf DRUG ,_be DRUG alter_af prothrombin_af time_af normal_af volunteers_af ._af"
4501,"However, increased prothrombin time and bleeding have been reported in patients on concomitant TOLECTIN and warfarin therapy. ",TOLECTIN,warfarin,effect,"However_bf ,_bf increased_bf prothrombin_bf time_bf bleeding_bf reported_bf patients_bf concomitant_bf DRUG OTHER_DRUG therapy_af ._af"
4502,"Therefore, caution should be exercised when administering TOLECTIN to patients on anticoagulants. ",TOLECTIN,anticoagulants,advise,"Therefore_bf ,_bf caution_bf exercised_bf administering_bf DRUG patients_be OTHER_DRUG ._af"
4503,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,sulfonylureas,insulin,No interaction,In_bf adult_bf diabetic_bf patients_bf treatment_bf either_bf DRUG OTHER_DRUG change_af clinical_af effects_af either_af TOLECTIN_af hypoglycemic_af agents_af ._af
4504,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,sulfonylureas,TOLECTIN,No interaction,In_bf adult_bf diabetic_bf patients_bf treatment_bf either_bf DRUG insulin_be change_be clinical_be effects_be either_be OTHER_DRUG hypoglycemic_af agents_af ._af
4505,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,sulfonylureas,hypoglycemic agents,No interaction,In_bf adult_bf diabetic_bf patients_bf treatment_bf either_bf DRUG insulin_be change_be clinical_be effects_be either_be TOLECTIN_be hypoglycemic_be agents_be ._be
4506,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,insulin,TOLECTIN,No interaction,In_bf adult_bf diabetic_bf patients_bf treatment_bf either_bf sulfonylureas_bf DRUG change_be clinical_be effects_be either_be OTHER_DRUG hypoglycemic_af agents_af ._af
4507,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,insulin,hypoglycemic agents,No interaction,In_bf adult_bf diabetic_bf patients_bf treatment_bf either_bf sulfonylureas_bf DRUG change_be clinical_be effects_be either_be TOLECTIN_be hypoglycemic_be agents_be ._be
4508,In adult diabetic patients under treatment with either sulfonylureas or insulin there is no change in the clinical effects of either TOLECTIN or the hypoglycemic agents. ,TOLECTIN,hypoglycemic agents,No interaction,In_bf adult_bf diabetic_bf patients_bf treatment_bf either_bf sulfonylureas_bf insulin_bf change_bf clinical_bf effects_bf either_bf DRUG hypoglycemic_be agents_be ._be
4509,Caution should be used if TOLECTIN is administered concomitantly with methotrexate. ,TOLECTIN,methotrexate,advise,Caution_bf used_bf DRUG administered_be concomitantly_be OTHER_DRUG ._af
4510,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",TOLECTIN,nonsteroidal anti-inflammatory drugs,No interaction,"DRUG nonsteroidal_be anti-inflammatory_be drugs_be reported_be reduce_be tubular_be secretion_be methotrexate_be animal_be model_be ,_be possibly_be enhancing_be toxicity_be methotrexate_be ._be"
4511,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",TOLECTIN,methotrexate,mechanism,"DRUG nonsteroidal_be anti-inflammatory_be drugs_be reported_be reduce_be tubular_be secretion_be OTHER_DRUG animal_af model_af ,_af possibly_af enhancing_af toxicity_af OTHER_DRUG ._af"
4512,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",TOLECTIN,methotrexate,No interaction,"DRUG nonsteroidal_be anti-inflammatory_be drugs_be reported_be reduce_be tubular_be secretion_be OTHER_DRUG animal_af model_af ,_af possibly_af enhancing_af toxicity_af OTHER_DRUG ._af"
4513,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",nonsteroidal anti-inflammatory drugs,methotrexate,mechanism,"TOLECTIN_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf reported_bf reduce_bf tubular_bf secretion_bf OTHER_DRUG animal_be model_be ,_be possibly_be enhancing_be toxicity_be OTHER_DRUG ._af"
4514,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",nonsteroidal anti-inflammatory drugs,methotrexate,No interaction,"TOLECTIN_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf reported_bf reduce_bf tubular_bf secretion_bf OTHER_DRUG animal_be model_be ,_be possibly_be enhancing_be toxicity_be OTHER_DRUG ._af"
4515,"TOLECTIN and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model, possibly enhancing the toxicity of methotrexate. ",methotrexate,methotrexate,No interaction,"TOLECTIN_bf nonsteroidal_bf anti-inflammatory_bf drugs_bf reported_bf reduce_bf tubular_bf secretion_bf DRUG animal_be model_be ,_be possibly_be enhancing_be toxicity_be DRUG ._af"
4516,"CYP3A4 Inhibitors: Ketoconazole, an inhibitor of the drug metabolizing enzyme CYP3A4, significantly increased plasma concentrations of tolterodine when coadministered to subjects who were poor metabolizers (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions). ",Ketoconazole,tolterodine,mechanism,"CYP3A4_bf Inhibitors:_bf DRUG ,_be inhibitor_be drug_be metabolizing_be enzyme_be CYP3A4_be ,_be significantly_be increased_be plasma_be concentrations_be OTHER_DRUG coadministered_af subjects_af poor_af metabolizers_af (see_af CLINICAL_af PHARMACOLOGY_af ,_af Variability_af Metabolism_af Drug-Drug_af Interactions)_af ._af"
4517,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,azole antifungals,No interaction,"For_bf patients_bf receiving_bf DRUG potent_be CYP3A4_be inhibitors_be azole_be antifungals_be (eg_be ,_be itraconazole_be ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4518,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,itraconazole,No interaction,"For_bf patients_bf receiving_bf DRUG potent_be CYP3A4_be inhibitors_be azole_be antifungals_be (eg_be ,_be OTHER_DRUG ,_af miconazole)_af macrolide_af antibiotics_af (eg_af ,_af erythromycin_af ,_af clarithromycin)_af cyclosporine_af vinblastine_af ,_af recommended_af dose_af DETROL_af LA_af 2_af mg_af daily_af ._af"
4519,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,miconazole,No interaction,"For_bf patients_bf receiving_bf DRUG potent_be CYP3A4_be inhibitors_be azole_be antifungals_be (eg_be ,_be itraconazole_be ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4520,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,macrolide antibiotics,No interaction,"For_bf patients_bf receiving_bf DRUG potent_be CYP3A4_be inhibitors_be azole_be antifungals_be (eg_be ,_be itraconazole_be ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4521,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,erythromycin,No interaction,"For_bf patients_bf receiving_bf DRUG potent_be CYP3A4_be inhibitors_be azole_be antifungals_be (eg_be ,_be itraconazole_be ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be OTHER_DRUG ,_af clarithromycin)_af cyclosporine_af vinblastine_af ,_af recommended_af dose_af DETROL_af LA_af 2_af mg_af daily_af ._af"
4522,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,clarithromycin,No interaction,"For_bf patients_bf receiving_bf DRUG potent_be CYP3A4_be inhibitors_be azole_be antifungals_be (eg_be ,_be itraconazole_be ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4523,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,cyclosporine,No interaction,"For_bf patients_bf receiving_bf DRUG potent_be CYP3A4_be inhibitors_be azole_be antifungals_be (eg_be ,_be itraconazole_be ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be OTHER_DRUG vinblastine_af ,_af recommended_af dose_af DETROL_af LA_af 2_af mg_af daily_af ._af"
4524,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,vinblastine,No interaction,"For_bf patients_bf receiving_bf DRUG potent_be CYP3A4_be inhibitors_be azole_be antifungals_be (eg_be ,_be itraconazole_be ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be OTHER_DRUG ,_af recommended_af dose_af DETROL_af LA_af 2_af mg_af daily_af ._af"
4525,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",ketoconazole,DETROL LA,advise,"For_bf patients_bf receiving_bf DRUG potent_be CYP3A4_be inhibitors_be azole_be antifungals_be (eg_be ,_be itraconazole_be ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4526,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,itraconazole,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf OTHER_DRUG ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4527,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,miconazole,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4528,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,macrolide antibiotics,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4529,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,erythromycin,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf OTHER_DRUG ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4530,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,clarithromycin,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4531,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,cyclosporine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf OTHER_DRUG vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4532,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,vinblastine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf OTHER_DRUG ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4533,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",azole antifungals,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4534,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",itraconazole,miconazole,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf DRUG ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4535,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",itraconazole,macrolide antibiotics,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf DRUG ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4536,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",itraconazole,erythromycin,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf DRUG ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be OTHER_DRUG ,_af clarithromycin)_af cyclosporine_af vinblastine_af ,_af recommended_af dose_af DETROL_af LA_af 2_af mg_af daily_af ._af"
4537,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",itraconazole,clarithromycin,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf DRUG ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4538,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",itraconazole,cyclosporine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf DRUG ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be OTHER_DRUG vinblastine_af ,_af recommended_af dose_af DETROL_af LA_af 2_af mg_af daily_af ._af"
4539,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",itraconazole,vinblastine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf DRUG ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be OTHER_DRUG ,_af recommended_af dose_af DETROL_af LA_af 2_af mg_af daily_af ._af"
4540,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",itraconazole,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf DRUG ,_be miconazole)_be macrolide_be antibiotics_be (eg_be ,_be erythromycin_be ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4541,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",miconazole,macrolide antibiotics,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4542,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",miconazole,erythromycin,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf OTHER_DRUG ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4543,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",miconazole,clarithromycin,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4544,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",miconazole,cyclosporine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf OTHER_DRUG vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4545,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",miconazole,vinblastine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf OTHER_DRUG ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4546,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",miconazole,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4547,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",macrolide antibiotics,erythromycin,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf OTHER_DRUG ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4548,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",macrolide antibiotics,clarithromycin,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4549,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",macrolide antibiotics,cyclosporine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf OTHER_DRUG vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4550,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",macrolide antibiotics,vinblastine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf OTHER_DRUG ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4551,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",macrolide antibiotics,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4552,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",erythromycin,clarithromycin,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf DRUG ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4553,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",erythromycin,cyclosporine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf DRUG ,_be clarithromycin)_be OTHER_DRUG vinblastine_af ,_af recommended_af dose_af DETROL_af LA_af 2_af mg_af daily_af ._af"
4554,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",erythromycin,vinblastine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf DRUG ,_be clarithromycin)_be cyclosporine_be OTHER_DRUG ,_af recommended_af dose_af DETROL_af LA_af 2_af mg_af daily_af ._af"
4555,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",erythromycin,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf DRUG ,_be clarithromycin)_be cyclosporine_be vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4556,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",clarithromycin,cyclosporine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf OTHER_DRUG vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4557,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",clarithromycin,vinblastine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf OTHER_DRUG ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4558,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",clarithromycin,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf vinblastine_bf ,_bf recommended_bf dose_bf DETROL_bf LA_bf 2_bf mg_bf daily_bf ._bf"
4559,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",cyclosporine,vinblastine,No interaction,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf DRUG OTHER_DRUG ,_af recommended_af dose_af DETROL_af LA_af 2_af mg_af daily_af ._af"
4560,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",cyclosporine,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf DRUG vinblastine_be ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4561,"For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. ",vinblastine,DETROL LA,advise,"For_bf patients_bf receiving_bf ketoconazole_bf potent_bf CYP3A4_bf inhibitors_bf azole_bf antifungals_bf (eg_bf ,_bf itraconazole_bf ,_bf miconazole)_bf macrolide_bf antibiotics_bf (eg_bf ,_bf erythromycin_bf ,_bf clarithromycin)_bf cyclosporine_bf DRUG ,_be recommended_be dose_be DETROL_be LA_be 2_be mg_be daily_be ._be"
4562,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,paclitaxel,HERCEPTIN,mechanism,Administration_bf DRUG combination_be OTHER_DRUG resulted_af two-fold_af decrease_af OTHER_DRUG clearance_af non-human_af primate_af study_af 1_af ._af 5-fold_af increase_af OTHER_DRUG serum_af levels_af clinical_af studies_af ._af
4563,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,paclitaxel,HERCEPTIN,No interaction,Administration_bf DRUG combination_be OTHER_DRUG resulted_af two-fold_af decrease_af OTHER_DRUG clearance_af non-human_af primate_af study_af 1_af ._af 5-fold_af increase_af OTHER_DRUG serum_af levels_af clinical_af studies_af ._af
4564,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,paclitaxel,HERCEPTIN,No interaction,Administration_bf DRUG combination_be OTHER_DRUG resulted_af two-fold_af decrease_af OTHER_DRUG clearance_af non-human_af primate_af study_af 1_af ._af 5-fold_af increase_af OTHER_DRUG serum_af levels_af clinical_af studies_af ._af
4565,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,HERCEPTIN,HERCEPTIN,No interaction,Administration_bf paclitaxel_bf combination_bf DRUG resulted_be two-fold_be decrease_be DRUG clearance_af non-human_af primate_af study_af 1_af ._af 5-fold_af increase_af DRUG serum_af levels_af clinical_af studies_af ._af
4566,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,HERCEPTIN,HERCEPTIN,No interaction,Administration_bf paclitaxel_bf combination_bf DRUG resulted_be two-fold_be decrease_be DRUG clearance_af non-human_af primate_af study_af 1_af ._af 5-fold_af increase_af DRUG serum_af levels_af clinical_af studies_af ._af
4567,Administration of paclitaxel in combination with HERCEPTIN resulted in a two-fold decrease in HERCEPTIN clearance in a non-human primate study and in a 1.5-fold increase in HERCEPTIN serum levels in clinical studies.,HERCEPTIN,HERCEPTIN,No interaction,Administration_bf paclitaxel_bf combination_bf DRUG resulted_be two-fold_be decrease_be DRUG clearance_af non-human_af primate_af study_af 1_af ._af 5-fold_af increase_af DRUG serum_af levels_af clinical_af studies_af ._af
4568,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,Trilostane,aminoglutethimide,int,DRUG may_be interact_be OTHER_DRUG mitotane_af (causing_af great_af decrease_af adrenal_af function)_af ._af
4569,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,Trilostane,mitotane,int,DRUG may_be interact_be aminoglutethimide_be OTHER_DRUG (causing_af great_af decrease_af adrenal_af function)_af ._af
4570,Trilostane may interact with aminoglutethimide or mitotane (causing too great a decrease in adrenal function).,aminoglutethimide,mitotane,No interaction,Trilostane_bf may_bf interact_bf DRUG OTHER_DRUG (causing_af great_af decrease_af adrenal_af function)_af ._af
4571,Trimethoprim may inhibit the hepatic metabolism of phenytoin. ,Trimethoprim,phenytoin,mechanism,DRUG may_be inhibit_be hepatic_be metabolism_be OTHER_DRUG ._af
4572,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",Trimethoprim,phenytoin,mechanism,"DRUG ,_be given_be common_be clinical_be dosage_be ,_be increased_be OTHER_DRUG half-life_af 51%_af decreased_af OTHER_DRUG metabolic_af clearance_af rate_af 30%_af ._af"
4573,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",Trimethoprim,phenytoin,mechanism,"DRUG ,_be given_be common_be clinical_be dosage_be ,_be increased_be OTHER_DRUG half-life_af 51%_af decreased_af OTHER_DRUG metabolic_af clearance_af rate_af 30%_af ._af"
4574,"Trimethoprim, given at a common clinical dosage, increased the phenytoin half-life by 51% and decreased the phenytoin metabolic clearance rate by 30%. ",phenytoin,phenytoin,No interaction,"Trimethoprim_bf ,_bf given_bf common_bf clinical_bf dosage_bf ,_bf increased_bf DRUG half-life_be 51%_be decreased_be DRUG metabolic_af clearance_af rate_af 30%_af ._af"
4575,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,central nervous system depressants,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be tranquillisers_be ._be"
4576,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,alcohol,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be OTHER_DRUG ,_af barbiturates_af ,_af hypnotics_af ,_af narcotic_af analgesics_af ,_af sedatives_af ,_af tranquillisers_af ._af"
4577,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,barbiturates,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be OTHER_DRUG ,_af hypnotics_af ,_af narcotic_af analgesics_af ,_af sedatives_af ,_af tranquillisers_af ._af"
4578,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,hypnotics,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be barbiturates_be ,_be OTHER_DRUG ,_af narcotic_af analgesics_af ,_af sedatives_af ,_af tranquillisers_af ._af"
4579,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,narcotic analgesics,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be tranquillisers_be ._be"
4580,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,sedatives,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be OTHER_DRUG ,_af tranquillisers_af ._af"
4581,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",Triprolidine,tranquillisers,effect,"DRUG may_be enhance_be sedative_be effects_be central_be nervous_be system_be depressants_be including_be alcohol_be ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be OTHER_DRUG ._af"
4582,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",central nervous system depressants,alcohol,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf OTHER_DRUG ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be tranquillisers_be ._be"
4583,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",central nervous system depressants,barbiturates,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf OTHER_DRUG ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be tranquillisers_be ._be"
4584,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",central nervous system depressants,hypnotics,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf barbiturates_bf ,_bf OTHER_DRUG ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be tranquillisers_be ._be"
4585,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",central nervous system depressants,narcotic analgesics,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf barbiturates_bf ,_bf hypnotics_bf ,_bf narcotic_bf analgesics_bf ,_bf sedatives_bf ,_bf tranquillisers_bf ._bf"
4586,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",central nervous system depressants,sedatives,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf barbiturates_bf ,_bf hypnotics_bf ,_bf narcotic_bf analgesics_bf ,_bf OTHER_DRUG ,_be tranquillisers_be ._be"
4587,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",central nervous system depressants,tranquillisers,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf barbiturates_bf ,_bf hypnotics_bf ,_bf narcotic_bf analgesics_bf ,_bf sedatives_bf ,_bf OTHER_DRUG ._be"
4588,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",alcohol,barbiturates,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf DRUG ,_be OTHER_DRUG ,_af hypnotics_af ,_af narcotic_af analgesics_af ,_af sedatives_af ,_af tranquillisers_af ._af"
4589,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",alcohol,hypnotics,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf DRUG ,_be barbiturates_be ,_be OTHER_DRUG ,_af narcotic_af analgesics_af ,_af sedatives_af ,_af tranquillisers_af ._af"
4590,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",alcohol,narcotic analgesics,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf DRUG ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be tranquillisers_be ._be"
4591,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",alcohol,sedatives,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf DRUG ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be OTHER_DRUG ,_af tranquillisers_af ._af"
4592,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",alcohol,tranquillisers,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf DRUG ,_be barbiturates_be ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be OTHER_DRUG ._af"
4593,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",barbiturates,hypnotics,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf DRUG ,_be OTHER_DRUG ,_af narcotic_af analgesics_af ,_af sedatives_af ,_af tranquillisers_af ._af"
4594,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",barbiturates,narcotic analgesics,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf DRUG ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be tranquillisers_be ._be"
4595,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",barbiturates,sedatives,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf DRUG ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be OTHER_DRUG ,_af tranquillisers_af ._af"
4596,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",barbiturates,tranquillisers,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf DRUG ,_be hypnotics_be ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be OTHER_DRUG ._af"
4597,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",hypnotics,narcotic analgesics,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf barbiturates_bf ,_bf DRUG ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be tranquillisers_be ._be"
4598,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",hypnotics,sedatives,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf barbiturates_bf ,_bf DRUG ,_be narcotic_be analgesics_be ,_be OTHER_DRUG ,_af tranquillisers_af ._af"
4599,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",hypnotics,tranquillisers,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf barbiturates_bf ,_bf DRUG ,_be narcotic_be analgesics_be ,_be sedatives_be ,_be OTHER_DRUG ._af"
4600,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",narcotic analgesics,sedatives,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf barbiturates_bf ,_bf hypnotics_bf ,_bf narcotic_bf analgesics_bf ,_bf OTHER_DRUG ,_be tranquillisers_be ._be"
4601,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",narcotic analgesics,tranquillisers,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf barbiturates_bf ,_bf hypnotics_bf ,_bf narcotic_bf analgesics_bf ,_bf sedatives_bf ,_bf OTHER_DRUG ._be"
4602,"Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers. ",sedatives,tranquillisers,No interaction,"Triprolidine_bf may_bf enhance_bf sedative_bf effects_bf central_bf nervous_bf system_bf depressants_bf including_bf alcohol_bf ,_bf barbiturates_bf ,_bf hypnotics_bf ,_bf narcotic_bf analgesics_bf ,_bf DRUG ,_be OTHER_DRUG ._af"
4603,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",anticholinergic drugs,atropine,No interaction,"The_bf effects_bf anticholinergic_bf drugs_bf ,_bf OTHER_DRUG tricyclic_be antidepressants_be may_be enhanced_be concomitant_be administration_be triprolidine_be ._be"
4604,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",anticholinergic drugs,tricyclic antidepressants,No interaction,"The_bf effects_bf anticholinergic_bf drugs_bf ,_bf atropine_bf tricyclic_bf antidepressants_bf may_bf enhanced_bf concomitant_bf administration_bf triprolidine_bf ._bf"
4605,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",anticholinergic drugs,triprolidine,effect,"The_bf effects_bf anticholinergic_bf drugs_bf ,_bf atropine_bf tricyclic_bf antidepressants_bf may_bf enhanced_bf concomitant_bf administration_bf OTHER_DRUG ._be"
4606,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",atropine,tricyclic antidepressants,No interaction,"The_bf effects_bf anticholinergic_bf drugs_bf ,_bf DRUG tricyclic_be antidepressants_be may_be enhanced_be concomitant_be administration_be triprolidine_be ._be"
4607,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",atropine,triprolidine,effect,"The_bf effects_bf anticholinergic_bf drugs_bf ,_bf DRUG tricyclic_be antidepressants_be may_be enhanced_be concomitant_be administration_be OTHER_DRUG ._af"
4608,"The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be enhanced by the concomitant administration of triprolidine. ",tricyclic antidepressants,triprolidine,effect,"The_bf effects_bf anticholinergic_bf drugs_bf ,_bf atropine_bf tricyclic_bf antidepressants_bf may_bf enhanced_bf concomitant_bf administration_bf OTHER_DRUG ._be"
4609,"The concomitant use of Sanctura with other anticholinergic agents that produce dry mouth, constipation, and other anticholinergic pharmacological effects may increase the frequency and/or severity of such effects. ",Sanctura,anticholinergic agents,effect,"The_bf concomitant_bf use_bf DRUG anticholinergic_be agents_be produce_be dry_be mouth_be ,_be constipation_be ,_be anticholinergic_be pharmacological_be effects_be may_be increase_be frequency_be and/or_be severity_be effects_be ._be"
4610,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,Sanctura,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4611,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,digoxin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af OTHER_DRUG ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4612,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,procainamide,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af OTHER_DRUG ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4613,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,pancuronium,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af OTHER_DRUG ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4614,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,morphine,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af OTHER_DRUG ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4615,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,vancomycin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af OTHER_DRUG ,_af metformin_af tenofovir)_af ._af"
4616,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,metformin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af OTHER_DRUG tenofovir)_af ._af"
4617,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,tenofovir,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4618,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,digoxin,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af OTHER_DRUG ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4619,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,procainamide,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af OTHER_DRUG ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4620,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,pancuronium,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af OTHER_DRUG ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4621,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,morphine,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af OTHER_DRUG ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4622,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,vancomycin,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af OTHER_DRUG ,_af metformin_af tenofovir)_af ._af"
4623,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,metformin,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af OTHER_DRUG tenofovir)_af ._af"
4624,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",Sanctura,tenofovir,mechanism,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf DRUG conducted_be ,_be DRUG potential_af pharmacokinetic_af interactions_af drugs_af eliminated_af active_af tubular_af secretion_af (e_af ._af g_af ._af digoxin_af ,_af procainamide_af ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4625,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",digoxin,procainamide,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf DRUG ,_be OTHER_DRUG ,_af pancuronium_af ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4626,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",digoxin,pancuronium,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf DRUG ,_be procainamide_be ,_be OTHER_DRUG ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4627,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",digoxin,morphine,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf DRUG ,_be procainamide_be ,_be pancuronium_be ,_be OTHER_DRUG ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4628,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",digoxin,vancomycin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf DRUG ,_be procainamide_be ,_be pancuronium_be ,_be morphine_be ,_be OTHER_DRUG ,_af metformin_af tenofovir)_af ._af"
4629,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",digoxin,metformin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf DRUG ,_be procainamide_be ,_be pancuronium_be ,_be morphine_be ,_be vancomycin_be ,_be OTHER_DRUG tenofovir)_af ._af"
4630,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",digoxin,tenofovir,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf DRUG ,_be procainamide_be ,_be pancuronium_be ,_be morphine_be ,_be vancomycin_be ,_be metformin_be tenofovir)_be ._be"
4631,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",procainamide,pancuronium,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af morphine_af ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4632,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",procainamide,morphine,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf DRUG ,_be pancuronium_be ,_be OTHER_DRUG ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4633,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",procainamide,vancomycin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf DRUG ,_be pancuronium_be ,_be morphine_be ,_be OTHER_DRUG ,_af metformin_af tenofovir)_af ._af"
4634,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",procainamide,metformin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf DRUG ,_be pancuronium_be ,_be morphine_be ,_be vancomycin_be ,_be OTHER_DRUG tenofovir)_af ._af"
4635,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",procainamide,tenofovir,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf DRUG ,_be pancuronium_be ,_be morphine_be ,_be vancomycin_be ,_be metformin_be tenofovir)_be ._be"
4636,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",pancuronium,morphine,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf procainamide_bf ,_bf DRUG ,_be OTHER_DRUG ,_af vancomycin_af ,_af metformin_af tenofovir)_af ._af"
4637,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",pancuronium,vancomycin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf procainamide_bf ,_bf DRUG ,_be morphine_be ,_be OTHER_DRUG ,_af metformin_af tenofovir)_af ._af"
4638,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",pancuronium,metformin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf procainamide_bf ,_bf DRUG ,_be morphine_be ,_be vancomycin_be ,_be OTHER_DRUG tenofovir)_af ._af"
4639,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",pancuronium,tenofovir,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf procainamide_bf ,_bf DRUG ,_be morphine_be ,_be vancomycin_be ,_be metformin_be tenofovir)_be ._be"
4640,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",morphine,vancomycin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf procainamide_bf ,_bf pancuronium_bf ,_bf DRUG ,_be OTHER_DRUG ,_af metformin_af tenofovir)_af ._af"
4641,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",morphine,metformin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf procainamide_bf ,_bf pancuronium_bf ,_bf DRUG ,_be vancomycin_be ,_be OTHER_DRUG tenofovir)_af ._af"
4642,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",morphine,tenofovir,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf procainamide_bf ,_bf pancuronium_bf ,_bf DRUG ,_be vancomycin_be ,_be metformin_be tenofovir)_be ._be"
4643,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",vancomycin,metformin,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf procainamide_bf ,_bf pancuronium_bf ,_bf morphine_bf ,_bf DRUG ,_be OTHER_DRUG tenofovir)_af ._af"
4644,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",vancomycin,tenofovir,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf procainamide_bf ,_bf pancuronium_bf ,_bf morphine_bf ,_bf DRUG ,_be metformin_be tenofovir)_be ._be"
4645,"Drugs Eliminated by Active Tubular Secretion: Although studies to assess drug-drug interactions with Sanctura have not been conducted, Sanctura has the potential for pharmacokinetic interactions with other drugs that are eliminated by active tubular secretion (e.g. digoxin, procainamide, pancuronium, morphine, vancomycin, metformin and tenofovir). ",metformin,tenofovir,No interaction,"Drugs_bf Eliminated_bf Active_bf Tubular_bf Secretion:_bf Although_bf studies_bf assess_bf drug-drug_bf interactions_bf Sanctura_bf conducted_bf ,_bf Sanctura_bf potential_bf pharmacokinetic_bf interactions_bf drugs_bf eliminated_bf active_bf tubular_bf secretion_bf (e_bf ._bf g_bf ._bf digoxin_bf ,_bf procainamide_bf ,_bf pancuronium_bf ,_bf morphine_bf ,_bf vancomycin_bf ,_bf DRUG tenofovir)_be ._be"
4646,Coadministration of Sanctura with drugs that are eliminated by active renal tubular secretion may increase the serum concentration of Sanctura and/or the coadministered drug due to competition for this elimination pathway. ,Sanctura,Sanctura,No interaction,Coadministration_bf DRUG drugs_be eliminated_be active_be renal_be tubular_be secretion_be may_be increase_be serum_be concentration_be DRUG and/or_af coadministered_af drug_af due_af competition_af elimination_af pathway_af ._af
4647,Concomitant administration of vancomycin and anesthetic agents has been associated with erythema and histamine-like flushing and anaphylactoid reactions. ,vancomycin,anesthetic agents,effect,Concomitant_bf administration_bf DRUG anesthetic_be agents_be associated_be erythema_be histamine-like_be flushing_be anaphylactoid_be reactions_be ._be
4648,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",amphotericin B,aminoglycosides,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf OTHER_DRUG ,_be bacitracin_be ,_be polymyxin_be B_be ,_be colistin_be ,_be viomycin_be ,_be cisplatin_be ,_be indicated_be ,_be requires_be careful_be monitoring_be ._be"
4649,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",amphotericin B,bacitracin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf OTHER_DRUG ,_be polymyxin_be B_be ,_be colistin_be ,_be viomycin_be ,_be cisplatin_be ,_be indicated_be ,_be requires_be careful_be monitoring_be ._be"
4650,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",amphotericin B,polymyxin B,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf bacitracin_bf ,_bf polymyxin_bf B_bf ,_bf colistin_bf ,_bf viomycin_bf ,_bf cisplatin_bf ,_bf indicated_bf ,_bf requires_bf careful_bf monitoring_bf ._bf"
4651,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",amphotericin B,colistin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf bacitracin_bf ,_bf polymyxin_bf B_bf ,_bf OTHER_DRUG ,_be viomycin_be ,_be cisplatin_be ,_be indicated_be ,_be requires_be careful_be monitoring_be ._be"
4652,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",amphotericin B,viomycin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf bacitracin_bf ,_bf polymyxin_bf B_bf ,_bf colistin_bf ,_bf OTHER_DRUG ,_be cisplatin_be ,_be indicated_be ,_be requires_be careful_be monitoring_be ._be"
4653,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",amphotericin B,cisplatin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf bacitracin_bf ,_bf polymyxin_bf B_bf ,_bf colistin_bf ,_bf viomycin_bf ,_bf OTHER_DRUG ,_be indicated_be ,_be requires_be careful_be monitoring_be ._be"
4654,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",aminoglycosides,bacitracin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf DRUG ,_be OTHER_DRUG ,_af polymyxin_af B_af ,_af colistin_af ,_af viomycin_af ,_af cisplatin_af ,_af indicated_af ,_af requires_af careful_af monitoring_af ._af"
4655,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",aminoglycosides,polymyxin B,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxin_be B_be ,_be colistin_be ,_be viomycin_be ,_be cisplatin_be ,_be indicated_be ,_be requires_be careful_be monitoring_be ._be"
4656,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",aminoglycosides,colistin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxin_be B_be ,_be OTHER_DRUG ,_af viomycin_af ,_af cisplatin_af ,_af indicated_af ,_af requires_af careful_af monitoring_af ._af"
4657,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",aminoglycosides,viomycin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxin_be B_be ,_be colistin_be ,_be OTHER_DRUG ,_af cisplatin_af ,_af indicated_af ,_af requires_af careful_af monitoring_af ._af"
4658,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",aminoglycosides,cisplatin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf DRUG ,_be bacitracin_be ,_be polymyxin_be B_be ,_be colistin_be ,_be viomycin_be ,_be OTHER_DRUG ,_af indicated_af ,_af requires_af careful_af monitoring_af ._af"
4659,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",bacitracin,polymyxin B,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be polymyxin_be B_be ,_be colistin_be ,_be viomycin_be ,_be cisplatin_be ,_be indicated_be ,_be requires_be careful_be monitoring_be ._be"
4660,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",bacitracin,colistin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be polymyxin_be B_be ,_be OTHER_DRUG ,_af viomycin_af ,_af cisplatin_af ,_af indicated_af ,_af requires_af careful_af monitoring_af ._af"
4661,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",bacitracin,viomycin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be polymyxin_be B_be ,_be colistin_be ,_be OTHER_DRUG ,_af cisplatin_af ,_af indicated_af ,_af requires_af careful_af monitoring_af ._af"
4662,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",bacitracin,cisplatin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf DRUG ,_be polymyxin_be B_be ,_be colistin_be ,_be viomycin_be ,_be OTHER_DRUG ,_af indicated_af ,_af requires_af careful_af monitoring_af ._af"
4663,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",polymyxin B,colistin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf bacitracin_bf ,_bf polymyxin_bf B_bf ,_bf OTHER_DRUG ,_be viomycin_be ,_be cisplatin_be ,_be indicated_be ,_be requires_be careful_be monitoring_be ._be"
4664,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",polymyxin B,viomycin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf bacitracin_bf ,_bf polymyxin_bf B_bf ,_bf colistin_bf ,_bf OTHER_DRUG ,_be cisplatin_be ,_be indicated_be ,_be requires_be careful_be monitoring_be ._be"
4665,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",polymyxin B,cisplatin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf bacitracin_bf ,_bf polymyxin_bf B_bf ,_bf colistin_bf ,_bf viomycin_bf ,_bf OTHER_DRUG ,_be indicated_be ,_be requires_be careful_be monitoring_be ._be"
4666,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",colistin,viomycin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf bacitracin_bf ,_bf polymyxin_bf B_bf ,_bf DRUG ,_be OTHER_DRUG ,_af cisplatin_af ,_af indicated_af ,_af requires_af careful_af monitoring_af ._af"
4667,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",colistin,cisplatin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf bacitracin_bf ,_bf polymyxin_bf B_bf ,_bf DRUG ,_be viomycin_be ,_be OTHER_DRUG ,_af indicated_af ,_af requires_af careful_af monitoring_af ._af"
4668,"Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.",viomycin,cisplatin,No interaction,"Concurrent_bf and/or_bf sequential_bf systemic_bf topical_bf use_bf potentially_bf neurotoxic_bf and/or_bf nephrotoxic_bf drugs_bf ,_bf amphotericin_bf B_bf ,_bf aminoglycosides_bf ,_bf bacitracin_bf ,_bf polymyxin_bf B_bf ,_bf colistin_bf ,_bf DRUG ,_be OTHER_DRUG ,_af indicated_af ,_af requires_af careful_af monitoring_af ._af"
4669,A study published in 2002 found that vigabatrin causes a statistically significant increase in plasma clearance of carbamazepine. ,vigabatrin,carbamazepine,mechanism,A_bf study_bf published_bf 2002_bf found_bf DRUG causes_be statistically_be significant_be increase_be plasma_be clearance_be OTHER_DRUG ._af
4670,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ",vigabatrin,phenytoin,mechanism,"In_bf 1984_bf ,_bf Drs_bf Rimmer_bf Richens_bf University_bf Wales_bf reported_bf administering_bf DRUG OTHER_DRUG lowered_af serum_af OTHER_DRUG concentration_af patients_af treatment-resistant_af epilepsy_af ._af"
4671,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ",vigabatrin,phenytoin,No interaction,"In_bf 1984_bf ,_bf Drs_bf Rimmer_bf Richens_bf University_bf Wales_bf reported_bf administering_bf DRUG OTHER_DRUG lowered_af serum_af OTHER_DRUG concentration_af patients_af treatment-resistant_af epilepsy_af ._af"
4672,"In 1984, Drs Rimmer and Richens at the University of Wales reported that administering vigabatrin with phenytoin lowered the serum phenytoin concentration in patients with treatment-resistant epilepsy. ",phenytoin,phenytoin,No interaction,"In_bf 1984_bf ,_bf Drs_bf Rimmer_bf Richens_bf University_bf Wales_bf reported_bf administering_bf vigabatrin_bf DRUG lowered_be serum_be DRUG concentration_af patients_af treatment-resistant_af epilepsy_af ._af"
4673,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Phenytoin,int,"DRUG interact_be drugs_be following_be categories:_be -_be Blood_be dyscrasia:_be cause_be unpredictable_be myelotoxicity_be -_be Bone_be marrow_be depressants:_be cause_be predictable_be dose-related_be myelotoxicity_be -_be Radiation_be therapy:_be may_be cause_be marrow_be depression_be -_be Neurotoxic_be medications:_be cause_be neurologic_be toxicity_be -_be Phenytoin:_be increase_be seizure_be activity_be -_be Live_be virus_be vaccines:_be may_be potentiate_be replication_be vaccine_be virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be vaccine_be -_be Mitomycin-C:_be may_be cause_be shortness_be breath_be bronchospasm_be -_be Killed_be virus_be vaccines:_be may_be decrease_be patient's_be response_be vaccine_be"
4674,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Live virus vaccines,int,"DRUG interact_be drugs_be following_be categories:_be -_be Blood_be dyscrasia:_be cause_be unpredictable_be myelotoxicity_be -_be Bone_be marrow_be depressants:_be cause_be predictable_be dose-related_be myelotoxicity_be -_be Radiation_be therapy:_be may_be cause_be marrow_be depression_be -_be Neurotoxic_be medications:_be cause_be neurologic_be toxicity_be -_be Phenytoin:_be increase_be seizure_be activity_be -_be Live_be virus_be vaccines:_be may_be potentiate_be replication_be vaccine_be virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be vaccine_be -_be Mitomycin-C:_be may_be cause_be shortness_be breath_be bronchospasm_be -_be Killed_be virus_be vaccines:_be may_be decrease_be patient's_be response_be vaccine_be"
4675,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,vaccine,No interaction,"DRUG interact_be drugs_be following_be categories:_be -_be Blood_be dyscrasia:_be cause_be unpredictable_be myelotoxicity_be -_be Bone_be marrow_be depressants:_be cause_be predictable_be dose-related_be myelotoxicity_be -_be Radiation_be therapy:_be may_be cause_be marrow_be depression_be -_be Neurotoxic_be medications:_be cause_be neurologic_be toxicity_be -_be Phenytoin:_be increase_be seizure_be activity_be -_be Live_be virus_be vaccines:_be may_be potentiate_be replication_be OTHER_DRUG virus_af ,_af may_af increase_af side_af effects_af vaccination_af ,_af decrease_af patient's_af response_af OTHER_DRUG -_af Mitomycin-C:_af may_af cause_af shortness_af breath_af bronchospasm_af -_af Killed_af virus_af vaccines:_af may_af decrease_af patient's_af response_af OTHER_DRUG"
4676,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Mitomycin-C,int,"DRUG interact_be drugs_be following_be categories:_be -_be Blood_be dyscrasia:_be cause_be unpredictable_be myelotoxicity_be -_be Bone_be marrow_be depressants:_be cause_be predictable_be dose-related_be myelotoxicity_be -_be Radiation_be therapy:_be may_be cause_be marrow_be depression_be -_be Neurotoxic_be medications:_be cause_be neurologic_be toxicity_be -_be Phenytoin:_be increase_be seizure_be activity_be -_be Live_be virus_be vaccines:_be may_be potentiate_be replication_be vaccine_be virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be vaccine_be -_be Mitomycin-C:_be may_be cause_be shortness_be breath_be bronchospasm_be -_be Killed_be virus_be vaccines:_be may_be decrease_be patient's_be response_be vaccine_be"
4677,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,Killed virus vaccines,int,"DRUG interact_be drugs_be following_be categories:_be -_be Blood_be dyscrasia:_be cause_be unpredictable_be myelotoxicity_be -_be Bone_be marrow_be depressants:_be cause_be predictable_be dose-related_be myelotoxicity_be -_be Radiation_be therapy:_be may_be cause_be marrow_be depression_be -_be Neurotoxic_be medications:_be cause_be neurologic_be toxicity_be -_be Phenytoin:_be increase_be seizure_be activity_be -_be Live_be virus_be vaccines:_be may_be potentiate_be replication_be vaccine_be virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be vaccine_be -_be Mitomycin-C:_be may_be cause_be shortness_be breath_be bronchospasm_be -_be Killed_be virus_be vaccines:_be may_be decrease_be patient's_be response_be vaccine_be"
4678,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Vindesine,vaccine,No interaction,"DRUG interact_be drugs_be following_be categories:_be -_be Blood_be dyscrasia:_be cause_be unpredictable_be myelotoxicity_be -_be Bone_be marrow_be depressants:_be cause_be predictable_be dose-related_be myelotoxicity_be -_be Radiation_be therapy:_be may_be cause_be marrow_be depression_be -_be Neurotoxic_be medications:_be cause_be neurologic_be toxicity_be -_be Phenytoin:_be increase_be seizure_be activity_be -_be Live_be virus_be vaccines:_be may_be potentiate_be replication_be OTHER_DRUG virus_af ,_af may_af increase_af side_af effects_af vaccination_af ,_af decrease_af patient's_af response_af OTHER_DRUG -_af Mitomycin-C:_af may_af cause_af shortness_af breath_af bronchospasm_af -_af Killed_af virus_af vaccines:_af may_af decrease_af patient's_af response_af OTHER_DRUG"
4679,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Phenytoin,Live virus vaccines,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf vaccine_bf virus_bf ,_bf may_bf increase_bf side_bf effects_bf vaccination_bf ,_bf decrease_bf patient's_bf response_bf vaccine_bf -_bf Mitomycin-C:_bf may_bf cause_bf shortness_bf breath_bf bronchospasm_bf -_bf Killed_bf virus_bf vaccines:_bf may_bf decrease_bf patient's_bf response_bf vaccine_bf"
4680,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Phenytoin,vaccine,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf OTHER_DRUG virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be OTHER_DRUG -_af Mitomycin-C:_af may_af cause_af shortness_af breath_af bronchospasm_af -_af Killed_af virus_af vaccines:_af may_af decrease_af patient's_af response_af OTHER_DRUG"
4681,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Phenytoin,Mitomycin-C,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf vaccine_bf virus_bf ,_bf may_bf increase_bf side_bf effects_bf vaccination_bf ,_bf decrease_bf patient's_bf response_bf vaccine_bf -_bf Mitomycin-C:_bf may_bf cause_bf shortness_bf breath_bf bronchospasm_bf -_bf Killed_bf virus_bf vaccines:_bf may_bf decrease_bf patient's_bf response_bf vaccine_bf"
4682,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Phenytoin,Killed virus vaccines,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf vaccine_bf virus_bf ,_bf may_bf increase_bf side_bf effects_bf vaccination_bf ,_bf decrease_bf patient's_bf response_bf vaccine_bf -_bf Mitomycin-C:_bf may_bf cause_bf shortness_bf breath_bf bronchospasm_bf -_bf Killed_bf virus_bf vaccines:_bf may_bf decrease_bf patient's_bf response_bf vaccine_bf"
4683,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Phenytoin,vaccine,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf OTHER_DRUG virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be OTHER_DRUG -_af Mitomycin-C:_af may_af cause_af shortness_af breath_af bronchospasm_af -_af Killed_af virus_af vaccines:_af may_af decrease_af patient's_af response_af OTHER_DRUG"
4684,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Live virus vaccines,vaccine,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf OTHER_DRUG virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be OTHER_DRUG -_af Mitomycin-C:_af may_af cause_af shortness_af breath_af bronchospasm_af -_af Killed_af virus_af vaccines:_af may_af decrease_af patient's_af response_af OTHER_DRUG"
4685,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Live virus vaccines,Mitomycin-C,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf vaccine_bf virus_bf ,_bf may_bf increase_bf side_bf effects_bf vaccination_bf ,_bf decrease_bf patient's_bf response_bf vaccine_bf -_bf Mitomycin-C:_bf may_bf cause_bf shortness_bf breath_bf bronchospasm_bf -_bf Killed_bf virus_bf vaccines:_bf may_bf decrease_bf patient's_bf response_bf vaccine_bf"
4686,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Live virus vaccines,Killed virus vaccines,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf vaccine_bf virus_bf ,_bf may_bf increase_bf side_bf effects_bf vaccination_bf ,_bf decrease_bf patient's_bf response_bf vaccine_bf -_bf Mitomycin-C:_bf may_bf cause_bf shortness_bf breath_bf bronchospasm_bf -_bf Killed_bf virus_bf vaccines:_bf may_bf decrease_bf patient's_bf response_bf vaccine_bf"
4687,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Live virus vaccines,vaccine,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf OTHER_DRUG virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be OTHER_DRUG -_af Mitomycin-C:_af may_af cause_af shortness_af breath_af bronchospasm_af -_af Killed_af virus_af vaccines:_af may_af decrease_af patient's_af response_af OTHER_DRUG"
4688,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",vaccine,Mitomycin-C,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf DRUG virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be DRUG -_af Mitomycin-C:_af may_af cause_af shortness_af breath_af bronchospasm_af -_af Killed_af virus_af vaccines:_af may_af decrease_af patient's_af response_af DRUG"
4689,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",vaccine,Killed virus vaccines,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf DRUG virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be DRUG -_af Mitomycin-C:_af may_af cause_af shortness_af breath_af bronchospasm_af -_af Killed_af virus_af vaccines:_af may_af decrease_af patient's_af response_af DRUG"
4690,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",vaccine,vaccine,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf DRUG virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be DRUG -_af Mitomycin-C:_af may_af cause_af shortness_af breath_af bronchospasm_af -_af Killed_af virus_af vaccines:_af may_af decrease_af patient's_af response_af DRUG"
4691,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Mitomycin-C,Killed virus vaccines,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf vaccine_bf virus_bf ,_bf may_bf increase_bf side_bf effects_bf vaccination_bf ,_bf decrease_bf patient's_bf response_bf vaccine_bf -_bf Mitomycin-C:_bf may_bf cause_bf shortness_bf breath_bf bronchospasm_bf -_bf Killed_bf virus_bf vaccines:_bf may_bf decrease_bf patient's_bf response_bf vaccine_bf"
4692,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Mitomycin-C,vaccine,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf OTHER_DRUG virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be OTHER_DRUG -_af Mitomycin-C:_af may_af cause_af shortness_af breath_af bronchospasm_af -_af Killed_af virus_af vaccines:_af may_af decrease_af patient's_af response_af OTHER_DRUG"
4693,"Vindesine can interact with the drugs of the following categories:  - Blood dyscrasia: can cause unpredictable myelotoxicity - Bone marrow depressants: can cause a predictable dose-related myelotoxicity - Radiation therapy: may cause marrow depression - Neurotoxic medications: can cause neurologic toxicity - Phenytoin: can increase seizure activity - Live virus vaccines: may potentiate the replication of the vaccine virus, may increase the side effects of the vaccination, and decrease patient's response to the vaccine - Mitomycin-C: may cause shortness of breath and bronchospasm - Killed virus vaccines: may decrease patient's response to the vaccine",Killed virus vaccines,vaccine,No interaction,"Vindesine_bf interact_bf drugs_bf following_bf categories:_bf -_bf Blood_bf dyscrasia:_bf cause_bf unpredictable_bf myelotoxicity_bf -_bf Bone_bf marrow_bf depressants:_bf cause_bf predictable_bf dose-related_bf myelotoxicity_bf -_bf Radiation_bf therapy:_bf may_bf cause_bf marrow_bf depression_bf -_bf Neurotoxic_bf medications:_bf cause_bf neurologic_bf toxicity_bf -_bf Phenytoin:_bf increase_bf seizure_bf activity_bf -_bf Live_bf virus_bf vaccines:_bf may_bf potentiate_bf replication_bf OTHER_DRUG virus_be ,_be may_be increase_be side_be effects_be vaccination_be ,_be decrease_be patient's_be response_be OTHER_DRUG -_af Mitomycin-C:_af may_af cause_af shortness_af breath_af bronchospasm_af -_af Killed_af virus_af vaccines:_af may_af decrease_af patient's_af response_af OTHER_DRUG"
4694,Drug Interactions: Women on oral contraceptives have shown a significant increase in plasma vitamin A levels.,contraceptives,vitamin A,mechanism,Drug_bf Interactions:_bf Women_bf oral_bf DRUG shown_be significant_be increase_be plasma_be vitamin_be A_be levels_be ._be
4695,Limited evidence suggests that ascorbic acid may influence the intensity and duration of action of bishydroxycoumarin.,ascorbic acid,bishydroxycoumarin,mechanism,Limited_bf evidence_bf suggests_bf ascorbic_bf acid_bf may_bf influence_bf intensity_bf duration_bf action_bf OTHER_DRUG ._be
